

112



San Francisco Public Library

GOVERNMENT INFORMATION CENTER SAN FRANCISCO PUBLIC LIBRARY

REFERENCE BOOK

Not to be taken from the Library

Digitized by the Internet Archive in 2012 with funding from California State Library Califa/LSTA Grant

SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH AIDS OFFICE

HIV SEROPREVALENCE REPORT

Volumes 1 – 7 (1990 – 1996)

(Published at irregular intervals)

HIV SEROPREVALENCE REPORT DOCUMENTS DEP

San Francisco Department of Public Health AIDS Office January 1990 Vol. 1 No. 1

SAN FRANCISCO

PHREIC TIRDARY

TABLE 1: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY GENDER, TRANSMISSION CATEGORY AND SURVEY TYPE, SAN FRANCISCO, FEBRUARY 1 - NOVEMBER 30, 1989

798

		BLINDED	SURVEY (1)		NON-BLINDED SURVEY (2)				
GENDER AND TRANSMISSION CATEGORY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO~ PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	
MALE									
Homosexual/Bisexual	442	224	50.7	45.9 - 55.4	100	36	36.0	26.8 - 46.3	
Homosexual/Bisexual, IVDU	117	80	68.4	59.0 - 76.5	22	10	45.5	25.1 - 67.3	
Heterosexual IVDU	99	12	12.1	6.7 - 20.6	25	0	0.0	0.0 - 16.6	
Sex Partner of a Person at F	R1sk 72	3	4.2	1.1 - 12.5	44	1	2.3	0.1 - 13.5	
Blood Recipient (5)	23	1	4.3	0.2 - 24.0	3	0	0.0	0.0 - 69.0	
Heterosexual (6)	1020	15	1.5	0.9 - 2.5	172	1	0.6	0.0 - 3.7	
Unknown Risk	3	0	0.0	0.0 - 69.0	0	0	***	N/A	
SUB-TOTAL MALE	1776	335	18.9	17.1 - 20.8	366	48	13.1	9.9 - 17.1	
FEMALE									
Heterosexual IVDU	55	5	9.1	3.4 - 20.7	14	2	14.3	2.5 - 43.8	
Sex Partner of a Person at 8	R1sk 57	1	1.8	0.1 - 10.6	41	0	0.0	0.0 - 10.7	
Blood Recipient (5)	11	1	9.1	0.5 - 42.9	3	0	0.0	0.0 - 69.0	
Heterosexual (6)	378	3	0.8	0.2 - 2.5	82	0	0.0	0.0 - 5.6	
Unknown Risk	0	0		N/A	1	0	0.0	0.0 - 94.5	
SUB-TOTAL FEMALE	501	10	2.0	1.0 - 3.8	141	2	1.4	0.2 - 5.6	
TOTAL	2277	345	15.2	13.7 - 16.7	507	50	9.9	7.5 - 12.9	

⁽¹⁾ Blinded survey refers to the testing of blood specimens that were drawn for other purposes after all personal identifiers have been removed; (2) Non-blinded survey refers to voluntary testing of clinic patients after informed consent is obtained. All participants were interviewed for risk behaviors using a standardized questionnaire. Participants are provided test results upon a return appointment; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA, 83% of the IFA positive specimens were also confirmed by a Western Blot assay; (4) 95% Confidence Intervals; (5) Includes persons with a history of blood transfusion(s) between January 1977 - March 1985; (6) Self-identified heterosexuals with no identified risk.

TABLE 2: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP AND SURVEY TYPE, SAN FRANCISCO, FEBRUARY 1 - NOVEMBER 30, 1989

		BLINDED	SURVEY (1)			NON-BLIN	DED SURVEY (2)
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4
19 AND UNDER	219	3	1.4	0.4 - 4.3	33	1	3.0	0.2 - 17.5
20 - 24	524	35	6.7	4.8 - 9.3	114	8	7.0	3.3 - 13.8
25 - 29	548	93	17.0	14.0 - 20.4	119	8	6.7	3.2 - 13.2
30 - 34	401	87	21.7	17.8 - 26.1	96	11	11.5	6.1 - 20.0
35 - 39	281	72	25.6	20.7 - 31.2	69	11	15.9	8.6 - 27.2
40 - 44	156	27	17.3	11.9 - 24.4	39	6	15.4	6.4 - 31.2
45 AND OVER	148	28	18.9	13.1 - 26.4	35	3	8.6	2.2 - 24.2
UNKNOWN	0	0		N/A	2	2	100.0	19.8 -100.0
TOTAL	2277	345	15.2	13.7 - 16.7	507	50	9.9	7.5 - 12.9

TABLE 3: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY AND SURVEY TYPE, SAN FRANCISCO, FEBRUARY 1 - NOVEMBER 30, 1989

		BLINDED	SURVEY (1)		NON-BLINDED SURVEY (2)			
RACE/ETHNICITY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)
WHITE	909	206	22.7	20.0 - 25.6	213	30	14.1	9.8 - 19.7
BLACK	818	77	9.4	7.5 - 11.7	160	8	5.0	2.3 - 10.0
LATINO	368	51	13.9	10.6 - 17.9	84	9	10.7	5.3 - 19.8
ASIAN/PACIFIC ISLANDER	138	6	4.3	1.8 - 9.6	33	2	6.1	1.1 - 21.6
NONE OF THE ABOVE (5)	44	5	11.4	4.3 - 25.4	17	1	5.9	0.3 - 30.8
TOTAL	2277	345	15.2	13.7 - 16.7	507	50	9.9	7.5 - 12.9

⁽¹⁾ Blinded survey refers to the testing of blood specimens that were drawn for other purposes after all personal identifiers have been removed; (2) Non-blinded survey refers to voluntary testing of clinic patients after informed consent is obtained. All participants were interviewed for risk behaviors using a standardized questionnaire. Participants are provided test results upon a return appointment; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA, 83% of the IFA positive specimens were also confirmed using a Western Blot assay; (4) 95% Confidence Intervals; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 4: HIV SEROPREVALENCE FOR WOMEN ATTENDING FAMILY PLANNING CLINICS BY TRANSMISSION CATEGORY AND SURVEY TYPE,
SAN FRANCISCO, FEBRUARY 1 - NOVEMBER 30, 1989

BLINDED SURVEY (1)						NON-BLINDED SURVEY (2)				
TRANSMISSION CATEGORY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)		
Heterosexual IVDU	0	0		N/A	21	2	9.5	1.7 - 31.B		
Sex Partner of a Person at	Risk 0	0		N/A	85	1	1.2	0.1 - 7.3		
Blood Recipient (5)	0	0		N/A	43	0	0.0	0.0 - 10.2		
Heterosexual (6)	0	0		N/A	1123	1	0.1	0.0 - 0.6		
Unknown Risk (7)	1264	4	0.3	0.1 - 0.9	_1	0	0.0	0.0 - 94.5		
TOTAL	1264	4	0.3	0.1 - 0.9	1273	4	0.3	0.1 - 0.9		

⁽¹⁾ Blinded survey refers to the testing of blood specimens that were drawn for other purposes after all personal identifiers have been removed; (2) Non-blinded survey refers to voluntary testing of clinic patients after informed consent is obtained. All participants were interviewed for risk behaviors using a standardized questionnaire. Participants are provided test results upon a return appointment; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and Western Blot assay; (4) 95% Confidence Intervals;

⁽⁵⁾ Includes persons with a history of blood transfusion(s) between January 1977 - March 1985;

⁽⁶⁾ Self-identified heterosexuals with no identified risk; (7) Blinded survey did not

collect risk information.

TABLE 5: HIV SEROPREVALENCE FOR WOMEN ATTENDING FAMILY PLANNING CLINICS BY AGE-GROUP AND SURVEY TYPE,
SAN FRANCISCO, FEBRUARY 1 - NOVEMBER 30, 1989

		BLINDED	SURVEY (1)		NON-BLINDED SURVEY (2)				
AGE-GROUP (YEARS)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4	
19 ANO UNDER	73	0	0.0	0.0 - 6.2	93	0	0.0	0.0 - 4.9	
20 - 24	419	1	0.2	0.0 - 1.5	420	2	0.5	0.1 - 1.9	
25 - 29	414	1	0.2	0.0 - 1.6	403	1	0.2	0.0 - 1.6	
30 - 34	226	2	0.9	0.2 - 3.5	214	1	0.5	0.0 - 3.0	
35 - 39	104	0	0.0	0.0 - 4.4	98	0	0.0	0.0 - 4.7	
40 - 44	18	0	0.0	0.0 - 21.9	22	0	0.0	0.0 - 18.5	
45 AND OVER	7	0	0.0	0.0 - 43.9	10	0	0.0	0.0 - 34.5	
UNKNOWN	3	0	0.0	0.0 - 69.0	13	0	0.0	0.0 - 28.3	
TOTAL	1264	4	0.3	0.1 - 0.9	1273	4	0.3	0.1 - 0.9	

TABLE 6: HIV SEROPREVALENCE FOR WOMEN ATTENDING FAMILY PLANNING CLINICS BY RACE/ETHNICITY AND SURVEY TYPE, SAN FRANCISCO, FEBRUARY 1 - NOVEMBER 30, 1989

		BLINDE	SURVEY (1)		NON-BLINDED SURVEY (2)			
RACE/ETHNICITY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (*)	(95% C.I.)(4)
WHITE	121	1	0.8	0.0 - 5.2	144	0	0.0	0.0 - 3.2
BLACK	154	1	0.6	0.0 - 4.1	219	1	0.5	0.0 - 2.9
LATINA	810	2	0.2	0.0 - 1.0	791	3	0.4	0.1 - 1.2
ASIAN/PACIFIC ISLANDER	148	0	0.0	0.0 - 3.2	106	0	0.0	0.0 - 4.4
NONE OF THE ABOVE (5)	31	0	0.0	0.0 - 13.7	13	0	0.0	0.0 - 28.3
TOTAL	1264	4	0.3	0.1 - 0.9	1273	4	0.3	0.1 - 0.9

⁽¹⁾ Blinded survey refers to the testing of blood specimens that were drawn for other purposes after all personal identifiers have been removed; (2) Non-blinded survey refers to voluntary testing of clinic patients after informed consent is obtained. All participants were interviewed for risk behaviors using a standardized questionnaire. Participants are provided test results upon a return appointment; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and Western Blot assay; (4) 95% Confidence Intervals;

⁽⁵⁾ Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 7: HIV SEROPREVALENCE FOR CIVILIAN MILITARY RECRUIT APPLICANTS FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENDER AND YEAR (1)(2)

		1985			1986			1987			1988			1989	
GENDER	N(3)	HIV+(4) %(5)	N	HIV+	*	N	HIV+	*	N	HIV+	*	N	HIV+	4:
MALE FEMALE	213 45	0	0.0	941 183	9	1.0	869 143	5	0.5	761 179	2	0.3	351 62	2	0.6
TOTAL	258	0	0.0	1124	10	0.9	1012	5	0.5	940	2	0.2	413	3	0.7

		TOTAL	
GENDER	N	HIV+	*
MALE FEMALE	3135 612	18 2	0.6
TOTAL	3747	20	0.5

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC); (2) Data collected between October 1985 and June 1989; (3) Number tested; (4) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western Blot assay; (5) Seroprevalence rate (%).

TABLE 8: HIV SEROPREVALENCE FOR CIVILIAN MILITARY RECRUIT APPLICANTS FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENDER AND AGE GROUP (1)(2)

		MA	LE		FEMALE			
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)
19 AND UNDER	1289	2	0.2	0.0 - 0.6	216	0	0.0	0.0 - 2.2
20 - 24	989	4	0.4	0.1 - 1.1	187	1	0.5	0.0 - 3.4
25 - 29	505	5	1.0	0.4 - 2.4	103	1	1.0	0.1 - 6.1
30 AND OVER	352	7	2.0	0.9 - 4.2	106	0	0.0	0.0 - 4.4
TOTAL	3135	18	0.6	0.4 - 0.9	612	2	0.3	0.1 - 1.3

TABLE 9: HIV SEROPREVALENCE FOR CIVILIAN MILITARY RECRUIT APPLICANTS FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENDER AND RACE/ETHNICITY (1)(2)

		MA	LE		FEMALE			
RACE/ETHNICITY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)
WHITE	1102	9	0.8	0.4 - 1.5	234	2	0.9	0.1 - 3.4
BLACK	628	7	1.1	0.5 - 2.2	154	0	0.0	0.0 - 3.0
LATINO	30B	1	0.3	0.0 - 1.8	51	0	0.0	0.0 - 8.7
ASIAN/PACIFIC ISLANDER	970	0	0.0	0.0 - 0.4	151	0	0.0	0.0 - 3.1
NONE OF THE ABOVE(5)	127	1	0.8	0.0 - 4.2	22	0	0.0	0.0 - 18.5
TOTAL	3135	18	0.6	0.4 - 0.9	612	2	0.3	0.1 - 1.3

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC); (2) Data collected between October 1985 and June 1989; (3) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western Blot assay; (4) 95% Confidence Intervals; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 10: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY YEAR OF DONATION, MARCH 1985 - AUGUST 1989 (1)

YEAR OF DONATION	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
1985	72,204	80	0.111	0.088 - 0.139
1986	86,168	40	0.046	0.034 - 0.064
1987	91,396	30	0.033	0.023 - 0.047
1988	90,192	23	0.026	0.017 - 0.039
1989	51,873	6	0.012	0.005 - 0.027
TOTAL	391,833	179	0.046	0.039 - 0.053

TABLE 11: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA
BY DONATION STATUS AND GENDER, JULY 1, 1988 - AUGUST 31, 1989 (1)

DONATION STATUS	GENDER	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
FIRST-TIME DONORS	Male Female	11,425 12,166	7 1	0.061 0.008	0.027 - 0.132 0.000 - 0.053
REPEAT DONORS	Male Female	39,535 32,610	1 3	0.003 0.009	0.000 - 0.016 0.002 - 0.029
TOTAL		95,736	12	0.013	0.007 - 0.023

⁽¹⁾ Data were provided courtesy of the Irwin Memorial Blood Centers, San Francisco, Ca.;

⁽²⁾ Positive specimens were repeatedly reactive by ELISA and confirmed by a Western Blot assay;

^{(3) 95%} Confidence Intervals.

TABLE 12: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY RACE/ETHNICITY, JULY 1, 1988 - AUGUST 31, 1989 (1)

RACE/ETHNICITY	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
WHITE	81,731	5	0.006	0.002 - 0.015
BLACK	4,220	4	0.095	0.030 - 0.260
LATINO	4,983	3	0.060	0.016 - 0.19
NONE OF THE ABOVE(4)	4,802	0	0.000	0.000 - 0.10
TOTAL	95,736	12	0.013	0.007 - 0.02

TABLE 13: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY AGE-GROUP, JULY 1, 1988 - AUGUST 31, 1989 (1)

AGE-GROUP (YEARS)	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
19 AND UNDER	6,261	0	0.000	0.000 - 0.076
20 - 29	18,995	3	0.016	0.004 - 0.050
30 - 39	28,298	6	0.021	0.009 - 0.049
40 AND OVER	42,182	3	0.007	0.002 - 0.023
TOTAL	95,736	12	0.013	0.007 - 0.023

⁽¹⁾ Data were provided courtesy of the Irwin Memorial Blood Centers, San Francisco, Ca.;

⁽²⁾ Positive specimens were repeatedly reactive by ELISA and confirmed by a Western Blot assay:

^{(3) 95%} Confidence Intervals; (4) Includes Asian/Pacific Islanders, American Indians, Alaskan Natives, other race, and unknown race.

City and County of San Francisco

Department of Public Health



DOCUMENTS DEPT.

APR 9 1990

SAN FRANCISCO

April 2, 1990

Dear Colleague:

Enclosed with this month's AIDS statistics is the second issue of our Quarterly HIV Seroprevalence Report. New to this report are preliminary data from surveys of intravenous drug users (IVDU's) in San Francisco.

To assess the scope of HIV/AIDS among IV drug users, the San Francisco Department of Public Health, in collaboration with the University of California, San Francisco, and community-based drug treatment centers, has been conducting HIV seroprevalence surveys of persons entering methadone treatment programs in San Francisco. These seroprevalence surveys are part of a nationwide sentinel surveillance project funded by the Centers for Disease Control (CDC). This project is designed to estimate HIV infection in various clinic populations, and to monitor trends over time.

The preliminary results of these surveys show an overall HIV infection rate of 9.9% for IVDUs entering methadone treatment programs in San Francisco. A significantly higher seroprevalence rate was found among African American IVDUs as compared to Whites. Latinos also have a higher HIV seroprevalence rate than Whites, but since the confidence intervals overlap, the difference is not statistically significant.

If you have questions regarding the content of this report, please call Tim Kellogg at (415) 554-9050.

Sincerely,

George F. Lemp, Dr.P.H. Chief, Surveillance Branch

AIDS Office

Sandra R. Hernandez, M.D. Director, AIDS Office



HIV SEROPREVALENCE REPORT

San Francisco Department of Public Health AIDS Office April 1990 Vol. 1 No. 2

TABLE 1: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY GENDER, TRANSMISSION CATEGORY AND SURVEY TYPE, SAN FRANCISCO, FEBRUARY 1 - NOVEMBER 30, 1989

		BLINDED	SURVEY (1)			NON-BLIN	IDED SURVEY (2)
GENDER AND TRANSMISSION CATEGORY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)
MALE								
Homosexua 1/Bisexua 1	442	224	50.7	45.9 - 55.4	100	36	36.0	26.8 - 46.3
Homosexual/Bisexual, IVDU	117	80	68.4	59.0 - 76.5	22	10	45.5	25.1 - 67.3
Heterosexual IVDU	99	12	12.1	6.7 - 20.6	25	0	0.0	0.0 - 16.6
Sex Partner of a Person at F	Risk 72	3	4.2	1.1 - 12.5	44	1	2.3	0.1 - 13.5
Blood Recipient (5)	23	1	4.3	0.2 - 24.0	3	0	0.0	0.0 - 69.0
Heterosexual (6)	1020	15	1.5	0.9 - 2.5	172	1	0.6	0.0 - 3.7
Unknown Risk	3	0	0.0	0.0 - 69.0	0	0		N/A
SUB-TOTAL MALE	1776	335	18.9	17.1 - 20.8	366	48	13.1	9.9 - 17.1
FEMALE								
Heterosexual IVDU	55	5	9.1	3.4 - 20.7	14	2	14.3	2.5 - 43.8
Sex Partner of a Person at 8	Risk 57	1	1.8	0.1 - 10.6	41	0	0.0	0.0 - 10.7
Blood Recipient (5)	11	1	9.1	0.5 - 42.9	3	0	0.0	0.0 - 69.0
Heterosexual (6)	378	3	0.8	0.2 - 2.5	82	0	0.0	0.0 - 5.6
Unknown Risk	0	0		N/A	1	0	0.0	0.0 - 94.5
SUB-TOTAL FEMALE	501	10	2.0	1.0 - 3.8	141	2	1.4	0.2 - 5.6
TOTAL	2277	345	15.2	13.7 - 16.7	507	50	9.9	7.5 - 12.9

(1) Blinded survey refers to the testing of blood specimens that were drawn for other purposes after all personal identifiers have been removed; (2) Non-blinded survey refers to voluntary testing of clinic patients after informed consent is obtained. All participants were interviewed for risk behaviors using a standardized questionnaire. Participants are provided test results upon a return appointment; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA, 83% of the IFA positive specimens were also confirmed by a Western Blot assay; (4) 95% Confidence Intervals; (5) Includes persons with a history of blood transfusion(s) between January 1977 - March 1985; (6) Self-identified heterosexuals with no identified risk.

DOCUMENTS DEPT.

APR 9 1990

SAN FRANCISCO



TABLE 2: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP AND SURVEY TYPE,
SAN FRANCISCO, FEBRUARY 1 - NOVEMBER 30, 1989

		BLINDED	SURVEY (1)		NON-BLINDED SURVEY (2)				
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	
19 AND UNDER	219	3	1.4	0.4 - 4.3	33	1	3.0	0.2 - 17.5	
20 - 24	524	35	6.7	4.8 - 9.3	114	8	7.0	3.3 - 13.8	
25 - 29	548	93	17.0	14.0 - 20.4	119	8	6.7	3.2 - 13.2	
30 - 34	401	87	21.7	17.8 - 26.1	96	11	11.5	6.1 - 20.0	
35 - 39	281	72	25.6	20.7 - 31.2	69	11	15.9	8.6 - 27.2	
40 - 44	156	27	17.3	11.9 - 24.4	39	6	15.4	6.4 - 31.2	
45 AND OVER	148	28	18.9	13.1 - 26.4	35	3	8.6	2.2 - 24.2	
UNKNOWN	0	0		N/A	2	2	100.0	19.8 -100.0	
TOTAL	2277	345	15.2	13.7 - 16.7	507	50	9.9	7.5 - 12.9	

TABLE 3: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY AND SURVEY TYPE, SAN FRANCISCO, FEBRUARY 1 - NOVEMBER 30, 1989

		8L I NDEC	SURVEY (1)		NON-BLINDED SURVEY (2)				
RACE/ETHNICITY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4	
WHITE	909	206	22.7	20.0 - 25.6	213	30	14.1	9.8 - 19.7	
BLACK	818	77	9.4	7.5 - 11.7	160	8	5.0	2.3 - 10.0	
LATINO	368	51	13.9	10.6 - 17.9	84	9	10.7	5.3 - 19.8	
ASIAN/PACIFIC ISLANDER	138	6	4.3	1.8 - 9.6	33	2	6.1	1.1 - 21.6	
NONE OF THE ABOVE (5)	44	5	11.4	4.3 - 25.4	17	1	5.9	0.3 - 30.8	
TOTAL	2277	345	15.2	13.7 - 16.7	507	50	9.9	7.5 - 12.9	

⁽¹⁾ Blinded survey refers to the testing of blood specimens that were drawn for other purposes after all personal identifiers have been removed; (2) Non-blinded survey refers to voluntary testing of clinic patients after informed consent is obtained. All participants were interviewed for risk behaviors using a standardized questionnaire. Participants are provided test results upon a return appointment; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA, 83% of the IFA positive specimens were also confirmed using a Western Blot assay; (4) 95% Confidence Intervals; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.



TABLE 4: HIV SEROPREVALENCE FOR WOMEN ATTENDING FAMILY PLANNING CLINICS BY TRANSMISSION CATEGORY AND SURVEY TYPE,
SAN FRANCISCO, FEBRUARY 1 - NOVEMBER 30, 1989

		BLINDED	SURVEY (1)		NON-BLINDED SURVEY (2)					
TRANSMISSION CATEGORY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)		
Heterosexual IVDU	0	0		N/A	21	2	9.5	1.7 - 31.8		
Sex Partner of a Person at	Risk 0	0		N/A	85	1	1.2	0.1 - 7.3		
Blood Recipient (5)	0	0		N/A	43	0	0.0	0.0 - 10.2		
Heterosexual (6)	0	0		N/A	1123	1	0.1	0.0 - 0.6		
Unknown Risk (7)	1264	4	0.3	0.1 - 0.9	1	0	0.0	0.0 - 94.5		
TOTAL	1264	4	0.3	0.1 - 0.9	1273	4	0.3	0.1 - 0.9		

⁽¹⁾ Blinded survey refers to the testing of blood specimens that were drawn for other purposes after all personal identifiers have been removed; (2) Non-blinded survey refers to voluntary testing of clinic patients after informed consent is obtained. All participants were interviewed for risk behaviors using a standardized questionnaire. Participants are provided test results upon a return appointment; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and Western Blot assay; (4) 95% Confidence Intervals;

⁽⁵⁾ Includes persons with a history of blood transfusion(s) between January 1977 - March 1985;

⁽⁶⁾ Self-identified heterosexuals with no identified risk; (7) Blinded survey did not collect risk information.



TABLE 5: HIV SEROPREVALENCE FOR WOMEN ATTENDING FAMILY PLANNING CLINICS BY AGE-GROUP AND SURVEY TYPE, SAN FRANCISCO, FEBRUARY 1 - NOVEMBER 30, 1989

		BLINDED	SURVEY (1)		NON-BLINDED SURVEY (2)				
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4	
19 AND UNDER	73	0	0.0	0.0 - 6.2	93	0	0.0	0.0 - 4.9	
20 - 24	419	1	0.2	0.0 - 1.5	420	2	0.5	0.1 - 1.9	
25 - 29	414	1	0.2	0.0 - 1.6	403	1	0.2	0.0 - 1.6	
30 - 34	226	2	0.9	0.2 - 3.5	214	1	0.5	0.0 - 3.0	
35 - 39	104	0	0.0	0.0 - 4.4	98	0	0.0	0.0 - 4.7	
40 - 44	18	0	0.0	0.0 - 21.9	22	0	0.0	0.0 - 18.5	
45 AND OVER	7	0	0.0	0.0 - 43.9	10	0	0.0	0.0 - 34.5	
UNKNOWN	3	0	0.0	0.0 - 69.0	13	0	0.0	0.0 - 28.3	
TOTAL	1264	4	0.3	0.1 - 0.9	1273	4	0.3	0.1 - 0.9	

TABLE 6: HIV SEROPREVALENCE FOR WOMEN ATTENDING FAMILY PLANNING CLINICS BY RACE/ETHNICITY AND SURVEY TYPE, SAN FRANCISCO, FEBRUARY 1 - NOVEMBER 30, 1989

		BLINDEC	SURVEY (1)		NON-BLINDED SURVEY (2)				
RACE/ETHNICITY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	
WHITE	121	1	0.8	0.0 - 5.2	144	0	0.0	0.0 - 3.2	
BLACK	154	1	0.6	0.0 - 4.1	219	1	0.5	0.0 - 2.9	
LATINA	810	2	0.2	0.0 - 1.0	791	3	0.4	0.1 - 1.2	
ASIAN/PACIFIC ISLANDER	148	0	0.0	0.0 - 3.2	106	0	0.0	0.0 - 4.4	
NONE OF THE ABOVE (5)	31	0	0.0	0.0 - 13.7	13	0	0.0	0.0 - 28.3	
TOTAL	1264	4	0.3	0.1 - 0.9	1273	4	0.3	0.1 - 0.9	

⁽¹⁾ Blinded survey refers to the testing of blood specimens that were drawn for other purposes after all personal identifiers have been removed; (2) Non-blinded survey refers to voluntary testing of clinic patients after informed consent is obtained. All participants were interviewed for risk behaviors using a standardized questionnaire. Participants are provided test results upon a return appointment; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and Western Blot assay; (4) 95% Confidence Intervals;

⁽⁵⁾ Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.




TABLE 7: HIV SEROPREVALENCE FOR CIVILIAN MILITARY RECRUIT APPLICANTS FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENDER AND YEAR (1)(2)

		1985			1986			1987			1988			1989	
GENDER	N(3)	HIV+(4) %(5)	N	HIV+	*	N	HIV+	*	N	HIV+	4	N	HIV+	*
MALE FEMALE	213 45	0	0.0	941 183	9	1.0	869 143	5	0.5	761 179	2	0.3	351 62	2	0.6
TOTAL	258	0	0.0	1124	10	0.9	1012	5	0.5	940	2	0.2	413	3	0.7

		TOTAL	
GENDER	N	HIV+	*
MALE FEMALE	3135 612	18 2	0.6
TOTAL	3747	20	0.5

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC); (2) Data collected between October 1985 and June 1989; (3) Number tested; (4) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western Blot assay; (5) Seroprevalence rate (%).



TABLE 8: HIV SEROPREVALENCE FOR CIVILIAN MILITARY RECRUIT APPLICANTS FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENDER AND AGE GROUP (1)(2)

		MA	NLE		FEMALE				
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	
19 AND UNDER	1289	2	0.2	0.0 - 0.6	216	0	0.0	0.0 - 2.2	
20 - 24	989	4	0.4	0.1 - 1.1	187	1	0.5	0.0 - 3.4	
25 - 29	505	5	1.0	0.4 - 2.4	103	1	1.0	0.1 - 6.1	
30 AND OVER	352	7	2.0	0.9 - 4.2	106	0	0.0	0.0 - 4.4	
TOTAL	3135	18	0.6	0.4 - 0.9	612	2	0.3	0.1 - 1.3	

TABLE 9: HIV SEROPREVALENCE FOR CIVILIAN MILITARY RECRUIT APPLICANTS FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENDER AND RACE/ETHNICITY (1)(2)

		MA	LE		FEMALE				
RACE/ETHNICITY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	
WHITE	1102	9	0.8	0.4 - 1.5	234	2	0.9	0.1 - 3.4	
BLACK	628	7	1.1	0.5 - 2.2	154	0	0.0	0.0 - 3.0	
LATINO	308	1	0.3	0.0 - 1.8	51	0	0.0	0.0 - 8.7	
ASIAN/PACIFIC ISLANDER	970	0	0.0	0.0 - 0.4	151	0	0.0	0.0 - 3.1	
NONE OF THE ABOVE(5)	127	1	0.8	0.0 - 4.2	22	0	0.0	0.0 - 18.5	
TOTAL	3135	18	0.6	0.4 - 0.9	612	2	0.3	0.1 - 1.3	

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC); (2) Data collected between October 1985 and June 1989; (3) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western Blot assay; (4) 95% Confidence Intervals; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.



TABLE 10: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY YEAR OF DONATION, MARCH 1985 - AUGUST 1989 (1)

YEAR OF DONATION	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
1985	72,204	80	0.111	0.088 - 0.139
1986	86,168	40	0.046	0.034 - 0.064
1987	91.396	30	0.033	0.023 - 0.047
1988	90.192	23	0.026	0.017 - 0.039
1989	51,873	6	0.012	0.005 - 0.027
TOTAL	391,833	179	0.046	0.039 - 0.053

TABLE 11: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY DONATION STATUS AND GENDER, JULY 1, 1988 - AUGUST 31, 1989 (1)

DONATION STATUS	GENDER	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
FIRST-TIME	Male	11.425	7	0.061	0.027 - 0.132
DONORS	Female	12,166	1	0.008	0.000 - 0.053
REPEAT	Male	39,535	1	0.003	0.000 - 0.016
DONORS	Female	32,610	3	0.009	0.002 - 0.029
TOTAL		95,736	12	0.013	0.007 - 0.023

⁽¹⁾ Data were provided courtesy of the Irwin Memorial Blood Centers, San Francisco, Ca.; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western Blot assay;

^{(3) 95%} Confidence Intervals.



TABLE 12: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY RACE/ETHNICITY, JULY 1, 1988 - AUGUST 31, 1989 (1)

RACE/ETHNICITY	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
NACE/ETRICITY		FOSTITVE	MAIL (3)	(939 (.1.)(3)
WHITE	81,731	5	0.006	0.002 - 0.01
BLACK	4,220	4	0.095	0.030 - 0.26
LATINO	4,983	3	0.060	0.016 - 0.19
NONE OF THE ABOVE(4)	4,802	0	0.000	0.000 - 0.10
TOTAL	95,736	12	0.013	0.007 - 0.02

TABLE 13: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY AGE-GROUP, JULY 1, 1988 - AUGUST 31, 1989 (1)

AGE-GROUP (YEARS)	TOTAL OONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
19 ANO UNOER	6,261	0	0.000	0.000 - 0.076
20 - 29	18,995	3	0.016	0.004 - 0.050
30 - 39	28,298	6	0.021	0.009 - 0.049
40 AND OVER	42,182	3	0.007	0.002 - 0.023
TOTAL	95,736	12	0.013	0.007 - 0.023

⁽¹⁾ Oata were provided courtesy of the Irwin Memorial Blood Centers, San Francisco, Ca.; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western Blot assay;

^{(3) 95%} Confidence Intervals; (4) Includes Asian/Pacific Islanders, American Indians, Alaskan Natives, other race, and unknown race.




TABLE 14: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY AGE-GROUP (1)

AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
19 AND UNDER	3	0	0.0	0.0 - 69.0
20 - 24	34	1	2.9	0.2 - 17.1
25 - 29	60	6	10.0	4.1 - 21.2
30 - 34	102	9	8.8	4.4 - 16.5
35 - 39	147	17	11.6	7.1 - 18.1
40 - 44	90	11	12.2	6.6 - 21.2
45 AND OVER	59	6	10.2	4.2 - 21.5
MISSING	12	0	0.0	0.0 - 30.1
TCTAL	507	50	9.9	7.5 - 12.9

TABLE 15: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY RACE/ETHNICITY (1)

RACE/ETHNICITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	
	123120	10311142	10112 (4)	(934 0.1.)(3)	
WHITE	317	13	4.1	2.3 - 7.1	
BLACK	121	28	23.1	16.2 - 31.9	
LATINO	53	7	13.2	5.9 - 26.0	
ASIAN/PACIFIC ISLANDER	10	1	10.0	0.5 - 45.9	
NONE OF THE ABOVE (4)	6	1	16.7	0.9 - 63.5	
TOTAL	507	50	9.9	7.5 - 12.9	

Data collected during the 4th quarter of 1989 and the 1st quarter of 1990;
 Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and/or Western Blot assay;
 Includes persons of American Indian and Alaskan Native ancestry, other race, unknown race, and missing race.




TABLE 16: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE
TREATMENT PROGRAMS IN SAN FRANCISCO BY GENDER AND SEXUAL ORIENTATION (1)

			SERO-	
GENOER ANO	NUMBER	NUMBER(2)	PREVALENCE	
SEXUAL ORIENTATION	TESTEO	POSITIVE	RATE (%)	(95% C.I.)(3)
MALE				
Homosexual/Bisexual	15	6	40.0	17.5 - 67.1
Heterosexual	310	27	8.7	5.9 - 12.6
SUB-TOTAL: MALE	325	33	10.2	7.2 - 14.1
FEMALE				
Lesbian/Bisexual	8	2	25.0	4.5 - 64.4
Heterosexual	156	14	9.0	5.2 - 14.9
SUB-TOTAL: FEMALE	164	16	9.8	5.9 - 15.6
MISSING GENOER ANO/OR	18	1	5.6	0.3 - 29.4
SEXUAL ORIENTATION				
TOTAL	507	50	9.9	7.5 - 12.9

TABLE 17: HIV SEROPREVALENCE FOR INTRAVENOUS ORUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY TREATMENT MODALITY (1)

TREATMENT MODALITY	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
OETOXIFICATION	454	44	9.7	7.2 - 12.9
MAINTENANCE	48	6	12.5	5.2 - 25.9
MISSING	5	0	0.0	0.0 - 53.7
TOTAL	507	50	9.9	7.5 - 12.9

⁽¹⁾ Data collected during the 4th quarter of 1989 and the 1st quarter of 1990; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and/or Western Blot assay; (3) 95% Confidence Intervals.



HIV SEROPREVALENCE REPORT DOCUMENTS DEPT

San Francisco Department of Public Health AIDS Office JUL 10 1990 July 1990 __ Vol. 1 No. 3

SAN FRANCISCO WINLIC LIRRARY

TABLE 1: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY GENDER, TRANSMISSION CATEGORY AND SURVEY TYPE, SAN FRANCISCO, FEBRUARY 1 - DECEMBER 31, 1989

		BLINDED	SURVEY (1)		NON-BLINDED SURVEY (2)					
GENDER AND TRANSMISSION CATEGORY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4		
MALE		***						-		
Homosexual/Bisexual	446	226	50.7	45.9 - 55.4	109	38	34.9	26.2 - 44.7		
Homosexual/Bisexual, IVDU	119	82	68.9	59.7 - 76.9	28	13	46.4	28.0 - 65.8		
Heterosexual IVDU	100	12	12.0	6.6 - 20.4	26	0	0.0	0.0 - 16.0		
Sex Partner of a Person at R	isk 73	3	4.1	1.1 - 12.3	49	1	2.0	0.1 - 12.2		
Blood Recipient (5)	23	1	4.3	0.2 - 24.0	3	0	0.0	0.0 - 69.0		
Heterosexual (6)	1020	14	1.4	0.8 - 2.4	200	2	1.0	0.2 - 3.9		
Unknown Risk	8	0	0.0	0.0 - 40.2	0	0		N/A		
SUB-TOTAL MALE	1789	338	18.9	17.1 - 20.8	415	54	13.0	10.0 - 16.7		
FEMALE										
Heterosexual IVDU	55	5	9.1	3.4 - 20.7	18	2	11.1	1.9 - 36.1		
Sex Partner of a Person at R	isk 58	1	1.7	0.1 - 10.5	46	0	0.0	0.0 - 9.6		
Blood Recipient (5)	11	1	9.1	0.5 - 42.9	3	0	0.0	0.0 - 69.0		
Heterosexual (6)	380	3	0.8	0.2 - 2.5	95	0	0.0	0.0 - 4.8		
Unknown Risk	5	0	0.0	0.0 - 53.7	1	0	0.0	0.0 - 94.5		
SUB-TOTAL FEMALE	509	10	2.0	1.0 - 3.7	163	2	1.2	0.2 - 4.8		

⁽¹⁾ Blinded survey refers to the testing of blood specimens that were drawn for other purposes after all personal identifiers have been removed; (2) Non-blinded survey refers to voluntary testing of clinic patients after informed consent is obtained. All participants were interviewed for risk behaviors using a standardized questionnaire. Participants are provided test results upon a return appointment; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western Blot assay; (4) 95% Confidence Intervals, normal approximation; (5) Includes persons with a history of blood transfusion(s) between January 1977 - March 1985; (6) Self-identified heterosexuals with no identified risk.

TABLE 2: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP AND SURVEY TYPE.

SAN FRANCISCO, FEBRUARY 1 - DECEMBER 31, 1989

		BLINDED	SURVEY (1)		NON-BLINDED SURVEY (2)				
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4	
19 AND UNDER	223	3	1.3	0.3 - 4.2	39	1	2.6	0.1 - 15.1	
20 - 24	526	35	6.7	4.7 - 9.2	134	9	6.7	3.3 - 12.7	
25 - 29	550	93	16.9	13.9 - 20.4	135	9	6.7	3.3 - 12.6	
30 - 34	403	88	21.8	18.0 - 26.3	109	12	11.0	6.1 - 18.8	
35 - 39	284	73	25.7	20.8 - 31.3	78	14	17.9	10.5 - 28.6	
40 - 44	158	27	17.1	11.8 - 24.1	44	6	13.6	5.7 - 28.0	
45 AND OVER	154	29	18.8	13.2 - 26.1	37	3	8.1	2.1 - 23.0	
UNKNOWN	0	0		N/A	2	2	100.0	19.8 -100.0	
TOTAL	2298	348	15.1	13.7 - 16.7	578	56	9.7	7.5 - 12.5	

TABLE 3: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY AND SURVEY TYPE, SAN FRANCISCO, FEBRUARY 1 - DECEMBER 31, 1989

		BLINDED	SURVEY (1)		NON-BLINDED SURVEY (2)					
RACE/ETHNICITY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)		
WHITE	916	209	22.8	20.2 - 25.7	243	33	13.6	9.7 - 18.7		
BLACK	829	76	9.2	7.3 - 11.4	182	8	4.4	2.1 - 8.8		
LATINO	371	52	14.0	10.7 - 18.1	95	11	11.6	6.2 - 20.2		
ASIAN/PACIFIC ISLANDER	138	6	4.3	1.8 - 9.6	37	3	8.1	2.1 - 23.0		
NONE OF THE ABOVE (5)	44	5	11.4	4.3 - 25.4	21	1	4.8	0.2 - 25.9		
TOTAL	2298	348	15.1	13.7 - 16.7	578	56	9.7	7.5 - 12.5		

⁽¹⁾ Blinded survey refers to the testing of blood specimens that were drawn for other purposes after all personal identifiers have been removed; (2) Non-blinded survey refers to voluntary testing of clinic patients after informed consent is obtained. All participants were interviewed for risk behaviors using a standardized questionnaire.

Participants are provided test results upon a return appointment; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA amd a Western Blot assay; (4) 95% Confidence Intervals, normal approximation; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 4: HIV SEROPREVALENCE FOR HOMOSEXUAL AND BISEXUAL MEN ATTENDING A
SEXUALLY TRANSMITTED DISEASE CLINIC IN SAN FRANCISCO BY AGE-GROUP (1)

	NUMBER	NUMBER(2)	SERO- PREVALENCE	
AGE-GROUP (YEARS)	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3)
19 AND UNDER	2	0	0.0	0.0 - 80.2
20 - 24	59	24	40.7	28.3 - 54.2
25 - 29	135	82	60.7	51.9 - 68.9
30 - 34	125	72	57.6	48.4 - 66.3
35 - 39	107	63	58.9	48.9 - 68.2
40 - 44	57	25	43.9	31.0 - 57.6
45 AND OVER	59	26	44.1	31.4 - 57.5
TOTAL	544	292	53.7	49.4 - 57.9

TABLE 5: HIV SEROPREVALENCE FOR HOMOSEXUAL AND BISEXUAL MEN ATTENDING A
SEXUALLY TRANSMITTED DISEASE CLINIC IN SAN FRANCISCO BY RACE/ETHNICITY (1)

			SERO-	
	NUMBER	NUMBER(2)	PREVALENCE	
RACE/ETHNICITY	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3)
WHITE	366	186	50.8	45.6 - 56.0
BLACK	81	51	63.0	51.5 - 73.2
LATINO	76	46	60.5	48.6 - 71.3
ASIAN/PACIFIC ISLANDER	14	4	28.6	9.6 - 58.0
NONE OF THE ABOVE (4)	7	5	71.4	30.3 - 94.9
TOTAL	544	292	53.7	49.4 - 57.9

⁽¹⁾ Data collected from a 1989 blinded survey of STD clients at a sexually transmitted disease clinic. These data were presented at the VI International Conference on AIDS, San Francisco, Ca., June 20 - 24, 1990; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western Blot assay; (3) 95% Confidence Intervals, normal approximation; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, unknown race, and missing race.

TABLE 6: HIV SEROPREVALENCE FOR WOMEN ATTENDING FAMILY PLANNING CLINICS BY TRANSMISSION CATEGORY AND SURVEY TYPE, SAN FRANCISCO, FEBRUARY 1 - DECEMBER 31, 1989

		BLINDED	SURVEY (1)		NON-BLINDED SURVEY (2)				
TRANSMISSION CATEGORY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	
Heterosexual IVDU	0	0		N/A	22	2	9.1	1.6 - 30.6	
Sex Partner of a Person at R	isk 0	0		N/A	86	1	1.2	0.1 - 7.2	
Blood Recipient (5)	0	0		N/A	43	0	0.0	0.0 - 10.2	
Heterosexual (6)	0	0		N/A	1134	1	0.1	0.0 - 0.6	
Unknown Risk (7)	1264	4	0.3	0.1 - 0.9	1	0	0.0	0.0 - 94.5.	
TOTAL	1264	4	0.3	0.1 - 0.9	1286	4	0.3	0.1 - 0.9	

⁽¹⁾ Blinded survey refers to the testing of blood specimens that were drawn for other purposes after all personal identifiers have been removed; (2) Non-blinded survey refers to voluntary testing of clinic patients after informed consent is obtained. All participants were interviewed for risk behaviors using a standardized questionnaire. Participants are provided test results upon a return appointment; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western Blot assay; (4) 95% Confidence Intervals, normal approximation; (5) Includes persons with a history of blood transfusion(s) between January 1977 - March 1985; (6) Self-identified heterosexuals with no identified risk;

TABLE 7: HIV SEROPREVALENCE FOR WOMEN ATTENDING FAMILY PLANNING CLINICS BY AGE-GROUP AND SURVEY TYPE,
SAN FRANCISCO, FEBRUARY 1 - DECEMBER 31, 1989

		BLINDED	SURVEY (1)		NON-BLINDED SURVEY (2)					
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)		
						•				
19 AND UNDER	73	0	0.0	0.0 - 6.2	93	0	0.0	0.0 - 4.9		
20 - 24	419	1	0.2	0.0 - 1.5	428	2	0.5	0.1 - 1.9		
25 - 29	414	1	0.2	0.0 - 1.6	407	1	0.2	0.0 - 1.6		
30 - 34	226	2	0.9	0.2 - 3.5	215	1	0.5	0.0 - 3.0		
35 - 39	104	0	0.0	0.0 - 4.4	97	0	0.0	0.0 - 4.7		
40 - 44	18	0	0.0	0.0 - 21.9	22	0	0.0	0.0 - 18.5		
45 AND OVER	7	0	0.0	0.0 - 43.9	10	0	0.0	0.0 - 34.5		
UNKNOWN	3	0	0.0	0.0 - 69.0	14	0	0.0	0.0 - 26.8		
TOTAL	1264	4	0.3	0.1 - 0.9	1286	4	0.3	0.1 - 0.9		

TABLE 8: HIV SEROPREVALENCE FOR WOMEN ATTENDING FAMILY PLANNING CLINICS BY RACE/ETHNICITY AND SURVEY TYPE, SAN FRANCISCO, FEBRUARY 1 - DECEMBER 31, 1989

		BLINDED	SURVEY (1)		NON-BLINDED SURVEY (2)					
RACE/ETHNICITY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)		
WHITE	121	1	0.8	0.0 - 5.2	144	0	0.0	0.0 - 3.2		
BLACK	154	1	0.6	0.0 - 4.1	219	1	0.5	0.0 - 2.9		
LATINA	810	2	0.2	0.0 - 1.0	791	3	0.4	0.1 - 1.2		
ASIAN/PACIFIC ISLANDER	148	0	0.0	0.0 - 3.2	106	0	0.0	0.0 - 4.4		
NONE OF THE ABOVE (5)	31	0	0.0	0.0 - 13.7	13	0	0.0	0.0 - 28.3		
TOTAL	1264	4	0.3	0.1 - 0.9	1273	4	0.3	0.1 - 0.9		

⁽¹⁾ Blinded survey refers to the testing of blood specimens that were drawn for other purposes after all personal identifiers have been removed; (2) Non-blinded survey refers to voluntary testing of clinic patients after informed consent is obtained. All participants were interviewed for risk behaviors using a standardized questionnaire. Participants are provided test results upon a return appointment; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western Blot assay; (4) 95% Confidence Intervals, normal approximation; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 9: HIV SEROPREVALENCE FOR CIVILIAN MILITARY RECRUIT APPLICANTS FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENOER AND YEAR (1)(2)

		1985			1986			1987			1988			1989	
GENOER	N(3) I	HIV+(4) %(5)	N	HIV+	*	N	HIV+	*	N	HIV+	*	N	HIV+	8
MALE FEMALE	213 45	0	0.0	941 183	9	1.0	869 143	5 0	0.5	761 179	2	0.3	351 62	2	0.6
TOTAL	258	0	0.0	1124	10	0.9	1012	5	0.5	940	2	0.2	413	3	0.7

		TOTAL	
GENOER	N	HIV+	*
MALE FEMALE	3135 612	18 2	0.6
TOTAL	3747	20	0.5

⁽¹⁾ Data provided by the U.S. Department of Oefense, and the Centers for Oisease Control (COC); (2) Data collected between October 1985 and June 1989; (3) Number tested; (4) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western Blot assay; (5) Seroprevalence rate (%).

TABLE 10: HIV SEROPREVALENCE FOR CIVILIAN MILITARY RECRUIT APPLICANTS FROM THE CITY AND COUNTY OF SAN FRANCISCO
BY GENDER AND AGE GROUP (1)(2)

		MA	NLE		FEMALE				
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	
19 AND UNDER	1289	2	0.2	0.0 - 0.6	216	0	0.0	0.0 - 2.2	
20 - 24	989	4	0.4	0.1 - 1.1	187	1	0.5	0.0 - 3.4	
25 - 29	505	5	1.0	0.4 - 2.4	103	1	1.0	0.1 - 6.1	
30 AND OVER	352	7	2.0	0.9 - 4.2	106	0	0.0	0.0 - 4.4	
TOTAL	3135	18	0.6	0.4 - 0.9	612	2	0.3	0.1 - 1.3	

TABLE 11: HIV SEROPREVALENCE FOR CIVILIAN MILITARY RECRUIT APPLICANTS FROM THE CITY AND COUNTY OF SAN FRANCISCO
BY GENDER AND RACE/ETHNICITY (1)(2)

		MA	LE		FEMALE			
RACE/ETHNICITY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4
WHITE	1102	9	0.8	0.4 - 1.5	234	2	0.9	0.1 - 3.4
BLACK	628	7	1.1	0.5 - 2.2	154	0	0.0	0.0 - 3.0
LATINO	308	1	0.3	0.0 - 1.8	51	0	0.0	0.0 - 8.7
ASIAN/PACIFIC ISLANDER	970	0	0.0	0.0 - 0.4	151	0	0.0	0.0 - 3.1
NONE OF THE ABOVE(5)	127	1	0.8	0.0 - 4.2	22	0	0.0	0.0 - 18.5
TOTAL	3135	18	0.6	0.4 - 0.9	612	2	0.3	0.1 - 1.3

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC); (2) Data collected between October 1985 and June 1989; (3) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western Blot assay; (4) 95% Confidence Intervals, normal approximation; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 12: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY YEAR OF DONATION, MARCH 1985 - AUGUST 1989 (1)

YEAR OF	TOTAL	NUMBER(2)	SERO- PREVALENCE	
DONATION	DONATIONS	POSITIVE	RATE (%)	(95% C.I.)(3)
1985	72,204	80	0,111	0.088 - 0.13
1986	86,168	40	0.046	0.034 - 0.00
1987	91,396	30	0.033	0.023 - 0.04
1988	90,192	23	0.026	0.017 - 0.03
1989	51,873	6	0.012	0.005 - 0.00
TOTAL	391,833	179	0.046	0.039 - 0.0

TABLE 13: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY DONATION STATUS AND GENDER, JULY 1, 1988 - AUGUST 31, 1989 (1)

DONATION STATUS	GENDER	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
FIRST-TIME DONORS	Male Female	11,425 12,166	7 1	0.061 0.008	0.027 - 0.132 0.000 - 0.053
REPEAT DONORS	Male Female	39,535 32,610	1 3	0.003 0.009	0.000 - 0.016 0.002 - 0.029
TOTAL		95,736	12	0.013	0.007 - 0.023

⁽¹⁾ Data were provided courtesy of the Irwin Memorial Blood Centers, San Francisco, Ca.;

⁽²⁾ Positive specimens were repeatedly reactive by ELISA and confirmed by a Western Blot assay;

^{(3) 95%} Confidence Intervals, normal approximation.

TABLE 14: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY RACE/ETHNICITY, JULY 1, 1988 - AUGUST 31, 1989 (1)

,731 5	0.006	0.002 - 0.015
,220 4	0.095	0.030 - 0.260
,983 3	0.060	0.016 - 0.192
,802 0	0.000	0.000 - 0.100
.736 12	0.013	0.007 - 0.023
	,220 4 ,983 3 ,802 0	,220 4 0.095 ,983 3 0.060 ,802 0 0.000

TABLE 15: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY AGE-GROUP, JULY 1, 1988 - AUGUST 31, 1989 (1)

AGE-GROUP (YEARS)	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
19 AND UNDER	6,261	0	0.000	0.000 - 0.076
20 - 29	18,995	3	0.016	0.004 - 0.050
30 - 39	28,29B	6	0.021	0.009 - 0.049
40 AND OVER	42,182	3	0.007	0.002 - 0.023
TOTAL	95.736	12	0.013	0.007 - 0.02

⁽¹⁾ Data were provided courtesy of the Irwin Memorial Blood Centers, San Francisco, Ca.; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western Blot assay; (3) 95% Confidence Intervals, normal approximation; (4) Includes Asian/Pacific Islanders, American Indians, Alaskan Natives, other race, and unknown race.

TABLE 16: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY AGE-GROUP (1)

	NUMBER	NUMBER(2)	SERO- PREVALENCE	
AGE-GROUP (YEARS)	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3)
19 AND UNDER	3	0	0.0	0.0 - 69.0
20 - 24	42	1	2.4	0.1 - 14.1
25 - 29	82	10	12.2	6.3 - 21.7
30 - 34	135	9	6.7	3.3 - 12.6
35 - 39	194	23	11.9	7.8 - 17.5
40 - 44	132	15	11.4	6.7 - 18.3
45 AND OVER	80	10	12.5	6.5 - 22.2
MISSING	14	0	0.0	0.0 - 26.8
TOTAL	682	68	10.0	7.9 - 12.5

TABLE 17: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY RACE/ETHNICITY (1)

RACE/ETHNICITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
WHITE	429	20	4.7	2.9 - 7.2
BLACK	156	39	25.0	18.6 - 32.7
LATINO	74	7	9.5	4.2 - 19.1
ASIAN/PACIFIC ISLANDER	13	1	7.7	0.4 - 37.9
NONE OF THE ABOVE (4)	10	1	10.0	0.5 - 45.9
TOTAL	682	68	10.0	7.9 - 12.5

⁽¹⁾ Data collected between the 4th quarter of 1989 and the 2nd quarter of 1990; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western Blot assay; (3) 95% Confidence Intervals, normal approximation; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, unknown race, and missing race.

TABLE 18: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE
TREATMENT PROGRAMS IN SAN FRANCISCO BY GENDER AND SEXUAL ORIENTATION (1)

			SERO-	
GENDER AND	NUMBER	NUMBER(2)	PREVALENCE	
SEXUAL ORIENTATION	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3)
MALE				
Homosexual/Bisexual	19	8	42.1	21.1 - 66.0
Heterosexual	417	39	9.4	6.8 - 12.7
SUB-TOTAL: MALE	436	47	10.8	8.1 - 14.2
FEMALE				
Lesbian/Bisexual	11	2	18.2	3.2 - 52.2
Heterosexual	210	18	8.6	5.3 - 13.4
SUB-TOTAL: FEMALE	221	20	9.0	5.8 - 13.8
MISSING GENDER AND/OR	25	1	4.0	0.2 - 22.3
SEXUAL ORIENTATION				
TOTAL	682	68	10.0	7.9 - 12.5
TOTAL	002	00	10.0	7.9 - 12.3

TABLE 19: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY TREATMENT MODALITY (1)

TREATMENT MODALITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
DETOXIFICATION	597	56	9.4	7.2 - 12.1
MAINTENANCE	79	12	15.2	8.4 - 25.4
MISSING	6	0	0.0	0.0 - 48.3
TOTAL	682	68	10.0	7.9 - 12.5

⁽¹⁾ Data collected between the 4th quarter of 1989 and the 2nd quarter of 1990; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western Blot assay; (3) 95% Confidence Intervals, normal approximation.

TABLE 20: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB)

AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY GENDER AND

TRANSMISSION CATEGORY (1)

			SERO-	
GENDER AND	NUMBER	NUMBER(2)	PREVALENCE	
TRANSMISSION CATEGORY	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3)
MALE				
Homosexual/Bisexual	18	13	72.2	46.4 - 89.3
Homosexual/Bisexual, IVDU	7	5	71.4	30.3 - 94.9
Heterosexual IVDU	10	2	20.0	3.5 - 55.8
Heterosexual (4)	76	1	1.3	0.1 - 8.1
Unknown Risk	9	0	0.0	0.0 - 37.1
SUB-TOTAL MALE	120	21	17.5	11.4 - 25.7
FEMALE				
LENALE				
Heterosexual IVDU	3	0	0.0	0.0 - 69.0
Heterosexual (4)	40	0	0.0	0.0 - 10.9
Unknown Risk	8	0	0.0	0.0 - 40.2
SUB-TOTAL FEMALE	51	0	0.0	0.0 - 8.7
TOTAL	171	01	10.2	7.0 10.4
TOTAL	171	21	12.3	7.9 - 18.4

TABLE 21: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT
A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY ORIGIN OF BIRTH (1)

0 19.2 - 43.4
7 0.7 - 8.3
7

 ⁽¹⁾ Data collected between January 1989 and June 1990;
 (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western Blot assay;
 (3) 95% Confidence Intervals, normal approximation;
 (4) Includes self-identified heterosexuals with no identified risk, persons with a history of blood transfusion(s) or with a bleeding disorder, and persons with a sexual partner(s) at risk for HIV/AIDS.

TABLE 22: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB)

AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY AGE-GROUP (1)

	MUMBED	NUMBER (0)	SERO-	
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	PREVALENCE RATE (%)	(95% C.I.)(3
19 AND UNDER	41	4	9.8	3.2 - 24.1
20 - 24	46	8	17.4	8.3 - 32.0
25 - 29	30	8	26.7	13.0 - 46.2
30 - 34	25	1	4.0	0.2 - 22.3
35 - 39	22	0	0.0	0.0 - 18.5
40 - 44	5	0	0.0	0.0 - 53.7
45 AND OVER	2	0	0.0	0.0 - 80.2
TOTAL	171	21	12.3	7.9 - 18.4

TABLE 23: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB)
AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY RACE/ETHNICITY (1)

	NUMBER	NUMBER(2)	SERO- PREVALENCE	
RACE/ETHNICITY	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3)
WHITE	30	11	36.7	20.5 - 56.1
BLACK	27	5	18.5	7.0 - 38.7
LATINO	29	3	10.3	2.7 - 28.5
ASIAN/PACIFIC ISLANDER	81	1	1.2	0.1 - 7.6
NONE OF THE ABOVE (4)	4	1	25.0	1.3 - 78.1
TOTAL	171	21	12.3	7.9 - 18.4

⁽¹⁾ Data collected between January 1989 and June 1990; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western Blot assay; (3) 95% Confidence Intervals, normal approximation;

⁽⁴⁾ Includes American Indian and Alaskan Native ancestry, other race, unknown race, and missing race.



P70 #58

HIV SEROPREVALENCE REPORT

San Francisco Department of Public Health AIDS Office
October 1990 Vol. 1 No. 4

TABLE 1: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY GENDER, TRANSMISSION CATEGORY
AND SURVEY TYPE, SAN FRANCISCO, FEBRUARY 1, 1989 - AUGUST 31, 1990

		BLINDED	SURVEY (1)			NON-BLIN	IDED SURVEY (2)
GENDER AND TRANSMISSION CATEGORY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)
MALE								
Homosexua 1/Bisexual	526	258	49.0	44.7 - 53.4	184	63	34.2	27.5 - 41.6
Homosexual/Bisexual, IVDU	129	88	68.2	59.4 - 76.0	51	27	52.9	38.6 - 66.8
Heterosexual IVDU	111	15	13.5	8.0 - 21.6	40	1	2.5	0.1 - 14.7
Sex Partner of a Person at I	Risk 82	4	4.9	1.6 - 12.7	79	1	1.3	0.1 - 7.8
Blood Recipient (5)	26	1	3.8	0.2 - 21.6	3	0	0.0	0.0 - 69.0
Heterosexual (6)	1209	14	1.2	0.7 - 2.0	308	3	1.0	0.3 - 3.1
Unknown Risk	83	12	14.5	8.0 - 24.3	1	0	0.0	0.0 - 94.5
SUB-TOTAL MALE	2166	392	18.1	16.5 - 19.8	666	95	14.3	11.7 - 17.2
FEMALE								
Heterosexual IVDU	64	6	9.4	3.9 - 19.9	27	4	14.8	4.9 - 34.6
Sex Partner of a Person at I	Risk 63	1	1.6	0.1 - 9.7	59	0	0.0	0.0 - 7.6
Blood Recipient (5)	13	1	7.7	0.4 - 37.9	3	0	0.0	0.0 - 69.0
Heterosexual (6)	437	4	0.9	0.3 - 2.5	122	0	0.0	0.0 - 3.8
Unknown Risk	30	0	0.0	0.0 - 14.1	6	0	0.0	0.0 - 48.3
SUB-TOTAL FEMALE	607	12	2.0	1.1 - 3.5	217	4	1.8	0.6 - 5.0
TOTAL	2773	404	14.6	13.3 - 15.9	883	99	11.2	9.2 - 13.5

⁽¹⁾ Blinded survey refers to the testing of blood specimens that were drawn for other purposes after all personal identifiers have been removed; (2) Non-blinded survey refers to voluntary testing of clinic patients after informed consent is obtained. All participants were interviewed for risk behaviors using a standardized questionnaire. Participants are provided test results upon a return appointment; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western Blot assay; (4) 95% Confidence Intervals, normal approximation; (5) Includes persons with a history of blood transfusion(s) between January 1977 - March 1985; (6) Self-identified heterosexuals with no identified risk.

Don't have been

TABLE 2: HIV SERDPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP AND SURVEY TYPE, SAN FRANCISCO, FEBRUARY 1, 1989 - AUGUST 31, 1990

		BLINDED	SURVEY (1)		NON-BLINDED SURVEY (2)				
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(3) PDSITIVE	SERD- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERD- PREVALENCE RATE (%)	(95% C.I.)(4)	
19 AND UNDER	266	3	1.1	D.3 - 3.5	63	3	4.8	1.2 - 14.2	
20 - 24	618	39	6.3	4.6 - 8.6	205	11	5.4	2.8 - 9.7	
25 - 29	654	108	16.5	13.8 - 19.6	215	25	11.6	7.8 - 16.9	
3D - 34	488	1D0	20.5	17.1 - 24.4	162	20	12.3	7.9 - 18.7	
35 - 39	340	89	26.2	21.7 - 31.3	115	24	20.9	14.1 - 29.7	
40 - 44	188	29	15.4	10.7 - 21.6	68	11	16.2	8.7 - 27.5	
45 AND DVER	191	32	16.8	11.9 - 23.0	55	5	9.1	3.4 - 20.7	
UNKNOWN	28	4	14.3	4.7 - 33.6	0	0		N/A	
TOTAL	2773	404	14.6	13.3 - 15.9	883	99	11.2	9.2 - 13.5	

TABLE 3: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY AND SURVEY TYPE, SAN FRANCISCO, FEBRUARY 1, 1989 - AUGUST 31, 1990

		BLINDED	SURVEY (1)		NON-BLINDED SURVEY (2)				
RACE/ETHNICITY	NUMBER TESTED	NUMBER(3) POSITIVE	SERD- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	
WHITE	1D97	236	21.5	19.1 - 24.1	393	61	15.5	12.2 - 19.6	
BLACK	993	9D	9.1	7.4 - 11.1	260	13	5.0	2.8 - 8.6	
LATINO	454	59	13.0	10.1 - 16.5	155	21	13.5	8.8 - 2D.2	
ASIAN/PACIFIC ISLANDER	159	9	5.7	2.8 - 10.8	53	3	5.7	1.5 - 16.6	
NONE OF THE ABOVE (5)	70	10	14.3	7.4 - 25.2	22	1	4.5	0.2 - 24.9	
TOTAL	2773	404	14.6	13.3 - 15.9	883	99	11.2	9.2 - 13.5	

⁽¹⁾ Blinded survey refers to the testing of blood specimens that were drawn for other purposes after all personal identifiers have been removed; (2) Non-blinded survey refers to voluntary testing of clinic patients after informed consent is obtained. All participants were interviewed for risk behaviors using a standardized questionnaire. Participants are provided test results upon a return appointment; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA amd a Western Blot assay; (4) 95% Confidence Intervals, normal approximation; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 4: HIV SEROPREVALENCE FOR HOMOSEXUAL AND BISEXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC IN SAN FRANCISCO BY AGE-GROUP (1)

AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
				
19 AND UNDER	2	0	0.0	0.0 - 80.2
20 - 24	70	30	42.9	31.3 - 55.2
25 - 29	162	95	58.6	50.6 - 66.2
30 - 34	150	86	57.3	49.0 - 65.3
35 - 39	12B	76	59.4	50.3 - 67.9
40 - 44	65	27	41.5	29.7 - 54.4
45 AND OVER	72	29	40.3	29.1 - 52.5
UNKNOWN	6	3	50.0	13.9 - 86.1
	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2			
TOTAL	655	346	52.8	48.9 - 56.7

TABLE 5: HIV SEROPREVALENCE FOR HOMOSEXUAL AND BISEXUAL MEN ATTENDING A
SEXUALLY TRANSMITED DISEASE CLINIC IN SAN FRANCISCO BY RACE/ETHNICITY (1)

RACE/ETHNICITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
WHITE	439	215	49.0	44.2 - 53.8
BLACK	97	65	67.0	56.6 - 76.0
LATINO	90	53	58.9	48.0 - 69.0
ASIAN/PACIFIC ISLANDER	18	5	27.8	10.7 - 53.6
NONE OF THE ABOVE (4)	11	8	72.7	39.3 - 92.7
TOTAL	655	346	52.8	48.9 - 56.7

⁽¹⁾ Data collected from 1989 and 1990 blinded surveys of STD clients at a sexually transmitted disease clinic; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western Blot assay;

^{(3) 95%} Confidence Intervals, normal approximation; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, unknown race, and missing race.

TABLE 6: HIV SEROPREVALENCE FOR WOMEN ATTENDING FAMILY PLANNING CLINICS BY TRANSMISSION CATEGORY AND SURVEY TYPE, SAN FRANCISCO, FEBRUARY 1, 1989 - AUGUST 31, 1990

		BLINDED	SURVEY (1)		NON-BLINDED SURVEY (2)				
TRANSMISSION CATEGORY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	SERO- NUMBER(3) PREVALEN POSITIVE RATE (4			
Heterosexual IVDU	13	0	0.0	0.0 - 28.3	37	3 8.1	2.1 - 23.0		
Sex Partner of a Person at Ri		0	0.0	0.0 - 34.5	128	1 0.8	0.0 - 4.9		
Blood Recipient (5)	5	0	0.0	0.0 - 53.7	71	0 0.0	0.0 - 6.4		
Heterosexual (6)	504	0	0.0	0.0 - 0.9	1866	3 0.2	0.0 - 0.5		
Unknown Risk (7)	1274	4	0.3	0.1 - 0.9	20	0 0.0	0.0 - 20.0		
TOTAL	1806	4	0.2	0.1 - 0.9	2122	7 0.3	0.1 - 0.7		

⁽¹⁾ Blinded survey refers to the testing of blood specimens that were drawn for other purposes after all personal identifiers have been removed; (2) Non-blinded survey refers to voluntary testing of clinic patients after informed consent is obtained. All participants were interviewed for risk behaviors using a standardized questionnaire. Participants are provided test results upon a return appointment; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western Blot assay; (4) 95% Confidence Intervals, normal approximation; (5) Includes persons with a history of blood transfusion(s) between January 1977 - March 1985; (6) Self-identified heterosexuals with no identified risk; (7) 1989 blinded survey did not collect risk information.

TABLE 7: HIV SEROPREVALENCE FOR WOMEN ATTENDING FAMILY PLANNING CLINICS BY AGE-GROUP AND SURVEY TYPE, SAN FRANCISCO, FEBRUARY 1, 1989 - AUGUST 31, 1990

		BLINDED	SURVEY (1)		NON-BLINDED SURVEY (2)			
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)
19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN	106 605 583 311 139 34 10	0 1 1 2 0 0 0	0.0 0.2 0.2 0.6 0.0 0.0	0.0 - 4.4 0.0 - 1.1 0.0 - 1.1 0.1 - 2.6 0.0 - 3.4 0.0 - 12.6 0.0 - 34.5 0.0 - 21.9	199 688 635 359 170 4B 23	0 2 1 2 2 2 0 0	0.0 0.3 0.2 0.6 1.2 0.0	0.0 - 2.4 0.1 - 1.2 0.0 - 1.0 0.1 - 2.2 0.2 - 4.6 0.0 - 9.2 0.0 - 17.8 N/A
TOTAL	1806	4	0.2	0.1 - 0.6	2122	7	0.3	0.1 - 0.7

TABLE 8: HIV SEROPREVALENCE FOR WOMEN ATTENDING FAMILY PLANNING CLINICS BY RACE/ETHNICITY AND SURVEY TYPE, SAN FRANCISCO, FEBRUARY 1, 1989 - AUGUST 31, 1990

		BLINDEC	SURVEY (1)		NON-BLINDED SURVEY (2)				
RACE/ETHNICITY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	
WHITE	168	1	0.6	0.0 - 3.8	226	0	0.0	0.0 - 2.1	
BLACK	212	1	0.5	0.0 - 3.0	410	2	0.5	0.1 - 1.9	
LATINA	1168	2	0.2	0.0 - 0.7	1273	4	0.3	0.1 - 0.9	
ASIAN/PACIFIC ISLANDER	217	0	0.0	0.0 - 2.2	185	1	0.5	0.0 - 3.4	
NONE OF THE ABOVE (5)	41	0	0.0	0.0 - 10.7	28	0	0.0	0.0 - 15.0	
TOTAL	1806	4	0.2	0.1 - 0.6	2122	7	0.3	0.1 - 0.7	

⁽¹⁾ Blinded survey refers to the testing of blood specimens that were drawn for other purposes after all personal identifiers have been removed; (2) Non-blinded survey refers to voluntary testing of clinic patients after informed consent is obtained. All participants were interviewed for risk behaviors using a standardized questionnaire. Participants are provided test results upon a return appointment; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western Blot assay; (4) 95% Confidence Intervals, normal approximation; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 9: HIV SEROPREVALENCE FOR CIVILIAN MILITARY RECRUIT APPLICANTS FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENDER AND YEAR (1)(2)

	1985		1986		1987		1988			1989					
GENDER	N(3)	HIV+(4) %(5)	N	HIV+	*	N	HIV+	4	N	HIV+	*	N	HIV+	8
MALE FEMALE	213 45	0	0.0	941 183	9	1.0 0.5	869 143	5 0	0.5	759 178	2	0.3	709 124	2	0.3
TOTAL	258	0	0.0	1124	10	0.9	1012	5	0.5	937	2	0.2	833	3	0.4

		1990			TOTAL	
GENOER	N	HIV+	*	N	HIV+	*
MALE FEMALE	144 34	0	0.0	3635 707	18 2	0.5
TOTAL	178	0	0.0	4342	20	0.5

⁽¹⁾ Oata provided by the U.S. Oepartment of Oefense, and the Centers for Disease Control (CDC); (2) Oata collected between October 1985 and March 1990; (3) Number tested; (4) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western Blot assay; (5) Seroprevalence rate (%).

TABLE 10: HIV SEROPREVALENCE FOR CIVILIAN MILITARY RECRUIT APPLICANTS FROM THE CITY AND COUNTY OF SAN FRANCISCO
BY GENDER AND AGE GROUP (1)(2)

		M	ALE		FEMALE				
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	
40 440 44050	1400			0.0.0.5	050				
19 AND UNDER	1486	2	0.1	0.0 - 0.5	253	0	0.0	0.0 - 1.9	
20 - 24	1165	4	0.3	0.1 - 0.9	220	1	0.5	0.0 - 2.9	
25 - 29	587	5	0.9	0.3 - 2.1	119	1	0.8	0.0 - 5.3	
30 AND OVER	397	7	1.8	0.8 - 3.8	115	0	0.0	0.0 - 4.0	
TOTAL	3635	18	0.5	0.3 - 0.8	707	2	0.3	0.0 - 1.1	

TABLE 11: HIV SEROPREVALENCE FOR CIVILIAN MILITARY RECRUIT APPLICANTS FROM THE CITY AND COUNTY OF SAN FRANCISCO
BY GENDER AND RACE/ETHNICITY (1)(2)

-		MA	LE		FEMALE				
RACE/ETHNICITY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	
WHITE	1266	9	0.7	0.3 - 1.3	264	2	0.8	0.1 - 3.0	
BLACK	729	7	1.0	0.4 - 1.9	178	0	0.0	0.0 - 2.6	
LATINO	370	1	0.3	0.0 - 1.5	62	0	0.0	0.0 - 7.3	
ASIAN/PACIFIC ISLANDER	1131	0	0.0	0.0 - 0.3	177	0	0.0	0.0 - 2.6	
NONE OF THE ABOVE(5)	139	1	0.7	0.0 - 3.8	26	0	0.0	0.0 - 16.0	
TOTAL	3635	18	0.5	0.3 - 0.8	707	2	0.3	0.0 - 1.1	

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC); (2) Data collected between October 1985 and March 1990; (3) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western Blot assay; (4) 95% Confidence Intervals, normal approximation; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 12: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY YEAR OF DONATION, MARCH 1985 - AUGUST 1989 (1)

YEAR OF DONATION	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
1985 1986 1987 1988 1989	72,204 86,168 91,396 90,192 51,873	80 40 30 23 6	0.111 0.046 0.033 0.026 0.012	0.088 - 0.139 0.034 - 0.064 0.023 - 0.047 0.017 - 0.039 0.005 - 0.027
TOTAL	391,833	179	0.046	0.039 - 0.053

TABLE 13: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY DONATION STATUS AND GENDER, JULY 1, 1988 - AUGUST 31, 1989 (1)

DONATION STATUS	GENDER	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
FIRST-TIME	Male	11.425	7	0.061	0.027 - 0.132
DONORS	Female	12,166	1	0.008	0.000 - 0.053
REPEAT	Male	39,535	1	0.003	0.000 - 0.01
DONORS	Female	32,610	3	0.009	0.002 - 0.029

⁽¹⁾ Data were provided courtesy of the Irwin Memorial Blood Centers, San Francisco, Ca.;

⁽²⁾ Positive specimens were repeatedly reactive by ELISA and confirmed by a Western Blot assay;

^{(3) 95%} Confidence Intervals, normal approximation.

TABLE 14: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY RACE/ETHNICITY, JULY 1, 1988 - AUGUST 31, 1989 (1)

RACE/ETHNICITY	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
WHITE	81,731	5	0,006	0.002 - 0.015
BLACK	4,220	4	0.095	0.030 - 0.260
LATINO	4,983	3	0.060	0.016 - 0.192
NONE OF THE ABOVE(4) 4,802	0	0.000	0.000 - 0.100
TOTAL	95,736	12	0.013	0.007 - 0.02

TABLE 15: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY AGE-GROUP, JULY 1, 1988 - AUGUST 31, 1989 (1)

AGE-GROUP (YEARS)	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
19 AND UNDER	6,261	0	0.000	0.000 - 0.076
20 - 29	18,995	3	0.016	0.004 - 0.050
30 - 39	28,298	6	0.021	0.009 - 0.049
40 AND OVER	42,182	3	0.007	0.002 - 0.023
TOTAL	95,736	12	0.013	0.007 - 0.023

⁽¹⁾ Data were provided courtesy of the Irwin Memorial Blood Centers, San Francisco, Ca.; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western Blot assay; (3) 95% Confidence Intervals, normal approximation; (4) Includes Asian/Pacific Islanders, American Indians, Alaskan Natives, other race, and unknown race.

TABLE 16: HIV SEROPREVALENCE FOR INTRAVENOUS ORUG USERS ENTERING METHADONE
TREATMENT PROGRAMS IN SAN FRANCISCO BY AGE-GROUP (1)

	SERO-				
AGE-GROUP (YEARS)	NUMBER TESTEO	NUMBER(2) POSITIVE	PREVALENCE RATE (%)	(95% C.I.)(3)	
19 ANO UNOER	3	0	0.0	0.0 - 69.0	
20 - 24	68	1	1.5	0.1 - 9.0	
25 - 29	123	8	6.5	3.1 - 12.8	
30 - 34	182	11	6.0	3.2 - 10.8	
35 - 39	259	26	10.0	6.8 - 14.5	
40 - 44	182	20	11.0	7.0 - 16.7	
45 ANO OVER	131	17	13.0	8.0 - 20.2	
MISSING	18	1	5.6	0.3 - 29.4	
TOTAL	966	84	8.7	7.0 - 10.7	

TABLE 17: HIV SEROPREVALENCE FOR INTRAVENOUS ORUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY RACE/ETHNICITY (1)

	SERO- NUMBER NUMBER(2) PREVALENCE					
RACE/ETHNICITY	TESTEO	NUMBER(2) POSITIVE	RATE (%)	(95% C.I.)(3)		
WHITE	596	21	3.5	2.2 - 5.4		
BLACK	229	51	22.3	17.2 - 28.3		
LATINO	108	9	8.3	4.1 - 15.6		
ASIAN/PACIFIC ISLANDER	21	2	9.5	1.7 - 31.8		
NONE OF THE ABOVE (4)	12	1	8.3	0.4 - 40.2		
TOTAL	966	84	8.7	7.0 - 10.7		

⁽¹⁾ Oata collected between the 4th quarter of 1989 and the 3rd quarter of 1990; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western Blot assay; (3) 95% Confidence Intervals, normal approximation; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, unknown race, and missing race.

TABLE 18: HIV SEROPREVALENCE FOR INTRAVENOUS ORUG USERS ENTERING METHADONE
TREATMENT PROGRAMS IN SAN FRANCISCO BY GENOER AND SEXUAL ORIENTATION (1)

			SERO-	
GENOER AND	NUMBER	NUMBER(2)	PREVALENCE	
SEXUAL ORIENTATION	TESTEO	POSITIVE	RATE (%)	(95% C.I.)(3)
MALE				
Homosexual/Bisexual	24	8	33.3	16.4 - 55.3
Heterosexual	598	51	8.5	6.5 - 11.1
SUB-TOTAL: MALE	622	59	9.5	7.4 - 12.1
FEMALE				
Lesbian/Bisexual	17	2	11.8	2.1 - 37.7
Heterosexual	296	21	7.1	4.6 - 10.8
SUB-TOTAL: FEMALE	313	23	7.3	4.8 - 11.0
MISSING GENOER ANO/OR SEXUAL ORIENTATION	31	2	6.5	1.1 - 22.8
TOTAL	966	84	8.7	7.0 - 10.7

TABLE 19: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY TREATMENT MODALITY (1)

TREATMENT MOOALITY	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
OETOXIFICATION	836	72	8.6	6.8 - 10.8
MAINTENANCE	124	12	9.7	5.3 - 16.6
MISSING	6	0	0.0	0.0 - 48.3

TOTAL	966	84	8.7	7.0 - 10.7

⁽¹⁾ Data collected between the 4th quarter of 1989 and the 3rd quarter of 1990; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western Blot assay; (3) 95% Confidence Intervals, normal approximation.

TABLE 20: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB)
AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY GENDER AND
TRANSMISSION CATEGORY (1)

GENOFR ANO	NUMBER	NUMBER(2)	SERO- PREVALENCE	
	TESTE0	POSITIVE	RATE (%)	(95% C.I.)(3)
MALE				
Homosexual/Bisexual	22	16	72.7	49.6 - 88.4
Homosexual/Bisexual, IVOU	8	6	75.0	35.6 - 95.5
Heterosexual/Bisexual, IVOU	11	2	18.2	3.2 - 52.2
			4.1	
Heterosexual (4)	98	4		1.3 - 10.7
Unknown Risk	9	0	0.0	0.0 - 37.1
SUB-TOTAL MALE	148	28	18.9	13.1 - 26.4
FEMALE				
Heterosexual IVDU	5	1	20.0	1.0 - 70.1
Heterosexual (4)	44	0	0.0	0.0 - 10.0
Unknown Risk	9	0	0.0	0.0 - 37.1
SUB-TOTAL FEMALE	58	1	1.7	0.1 - 10.5
TOTAL	206	29	14.1	9.8 - 19.8

TABLE 21: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY ORIGIN OF BIRTH (1)

ORIGIN OF BIRTH	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
BORN IN USA BORN OUTSIDE USA	78 128	24 5	30.8 3.9	21.1 - 42.4 1.4 - 9.3
TOTAL	206	29	14.1	9.8 - 19.8

 ⁽¹⁾ Oata collected between January 1989 and August 1990;
 (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western Blot assay;
 (3) 95% Confidence Intervals, normal approximation;
 (4) Includes self-identified heterosexuals with no identified risk, persons with a history of blood transfusion(s) or with a bleeding disorder, and persons with a sexual partner(s) at risk for HIV/AIOS.

TABLE 22: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB)
AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY AGE-GROUP (1)

	NUMBER	NUMBER(2)	SERO- PREVALENCE	/ \/
AGE-GROUP (YEARS)	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3)
19 ANO UNOER	6	0	0.0	0.0 - 48.3
20 - 24	9	1	11.1	0.6 - 49.3
25 - 29	29	3	10.3	2.7 - 28.5
30 - 34	33	4	12.1	4.0 - 29.1
35 - 39	23	6	26.1	11.1 - 48.7
40 - 44	24	8	33.3	16.4 - 55.3
45 AND OVER	82	7	8.5	3.8 - 17.3
TOTAL	206	29	14.1	9.8 - 19.8

TABLE 23: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB)
AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY RACE/ETHNICITY (1)

	NUMBER	NUMBER(2)	SERO- PREVALENCE	
RACE/ETHNICITY	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3)
WHITE	35	12	34.3	19.7 - 52.3
BLACK	37	9	24.3	12.4 - 41.6
LATINO	36	6	16.7	7.0 - 33.5
ASIAN/PACIFIC ISLANOER	93	1	1.1	0.1 - 6.7
NONE OF THE ABOVE (4)	5	1	20.0	1.0 - 70.1
TOTAL	206	29	14.1	9.8 - 19.8

⁽¹⁾ Data collected between January 1989 and August 1990; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western Blot assay; (3) 95% Confidence Intervals, normal approximation.





AIDS MONTHLY GRAND ROUNDS

Dear Colleague,

The Department of Public Health will be holding another in its series of monthly AIDS Grand Rounds on the clinical, epidemiologic, social, and public health aspects of the AIDS epidemic in San Francisco. The next session will be held on Wednesday, October 24, 1990, at 101 Grove Street, Room 300, from 3:30 to 5:00 PM. The program on October 24 will cover these selected topics from the American Public Health Association meeting.

Gay and Bisexual Men: Risk Factors for Recent Seroconversion

HIV Infection in Women:
Program Design and Ethical Issues

Crack Use and Risk for Heterosexual Transmission

Survival Trends in Gay/Bisexual Men with AIDS Michael Samuels, MPH Univ. California, Berkeley

Gerry Oliva, MD, MPH S.F. Dept. Public Health

Eve Golden, MS Univ. California, Berkeley

Anne Hirozawa, MPH S.F. Dept. Public Health

I encourage you to participate in what promises to be an informative session.

Sincerely,


Sandra R. Hernandez, M.D. Director, AIDS Office

NEW - CM.D.

**Physicians and nurses may receive Category 1 continuing education credits for attending these Grand Rounds, as described below. Attendance records must be kept by the Department of Public Health, and participants must sign the attendance sheet in order to receive credit. No certificates of participation will be preparted; participants should keep track of their own hours of attendance.

"As an organization accredited for continuing medical education, Extended Programs in Medical Education of the University of California School of Medicine in San Francisco verifies that continuing medical education activities designated Category I meet the criteria for Category I on an hour-for-hour basis for the Physician's Recognition Award of the California Medical Association."

Members of the Press: These Grand Rounds are for general informational purposes only. If you are interested in obtaining further information or in arranging interviews, please contact Beverly Hayon at 554-2550.



SF P70 #58 1/91

HIV SEROPREVALENCE REPORT

San Francisco Department of Public Health AIDS Office
January 1991
Vol. 2 No. 1

DOCUMENTS DEPT

JAN 2 2 1991

TABLE 1: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY GENDER, TRANSMISSION CATEGORY
AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (1)

PUBLIC LIBRARY

		198	39 SURVEY			19	990 SURVEY		COMPARISON OF 1989 AND 1990 PROPORTIONS
			SERO-				SERO-		
GENDER AND	NUMBER	NUMBER(2)	PREVALENCE		NUMBER	NUMBER(2)	PREVALENCE		
TRANSMISSION CATEGORY	TESTED	POSITIVE	RATE (%)	(95% C.1.)(3)	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3)	P-VALUE (4)
HALE									
Homosexual/8isexual	446	226	50.7	45.9 - 55.4	293	122	41.6	36.0 - 47.5	< .05
Homosexual/Bisexual, IVDU	119	82	68.9	59.7 - 76.9	38	26	68.4	51.2 - 82.0	N.S.
Heterosexual IVDU	99	12	12.1	6.7 - 20.6	55	7	12.7	5.7 - 25.1	N.S.
Sex Partner at Risk for HIV	73	3	4.1	1.1 - 12.3	47	4	8.5	2.8 - 21.3	N.S.
81ood Recipient (5)	23	1	4.3	0.2 - 24.0	7	0	0.0	0.0 - 37.2	N.S.
Heterosexual (6)	1020	14	1.4	0.8 - 2.4	661	10	1.5	0.8 ~ 2.9	N.S.
Unknown Risk	8	0	0.0	0.0 - 33.7	155	24	15.5	10.4 - 22.4	*
SUB-TOTAL MALE	1788	338	18.9	17.1 - 20.8	1256	193	15.4	13.4 - 17.5	< .05
FEMALE									
Heterosexual IVDU	55	5	9.1	3.4 - 20.7	26	2	7.7	1.3 - 26.6	N.S.
Sex Partner at Risk for HIV	58	1	1.7	0.1 - 10.5	24	0	0.0	0.0 - 13.6	N.S.
81ood Recipient (5)	11	1	9.1	0.5 - 42.9	4	0	0.0	0.0 - 53.5	N.S.
Heterosexual (6)	380	3	0.8	0.2 - 2.5	235	6	2.6	1.0 - 5.7	N.S.
Unknown Risk	5	0	0.0	0.0 - 46.7	_60	0	0.0	0.0 - 5.8	*
SUB-TOTAL FEMALE	509	10	2.0	1.0 - 3.7	349	8	2.3	1.1 - 4.6	N.S.
TOTAL	2297	348	15.2	13.7 - 16.7	1605	201	12.5	11.0 - 14.3	⟨ .05

⁽¹⁾ The 1989 and 1990 unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Based on the Z-statistic for testing the significance of the difference in the 1990 and 1989 seroprevalence rates. P-values are 2-tailed. N.S. = not significant; (5) Includes persons with a history of blood transfusion(s) between January 1977 - March 1985; (6) Self-identified heterosexuals with no identified risk.

^{*} Collection of risk information for the 1990 survey is still in progress.

TABLE 2: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (1)

AGE-GROUP (YEARS)		198	39 SURVEY			1989 AND 1990 PROPORTIONS			
	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	P-VALUE (4)
19 AND UNDER	223	3	1.3	0.3 - 4.2	150	3	2.0	0.5 - 6.2	N.S.
20 - 24	526	35	6.7	4.7 - 9.2	332	14	4.2	2.4 - 7.1	N.S.
25 - 29	550	93	16.9	13.9 - 20.4	399	56	14.0	10.9 - 17.9	N.S.
30 - 34	403	88	21.8	18.0 - 26.3	280	49	17.5	13.3 - 22.6	N.S.
35 - 39	284	73	25.7	20.8 - 31.3	201	50	24.9	19.2 - 31.5	N.S.
40 - 44	158	27	17.1	11.8 - 24.1	104	15	14.4	8.6 - 23.0	N.S.
45 AND OVER	153	29	19.0	13.3 - 26.3	119	12	10.1	5.6 - 17.3	N.S.
UNKNOWN	0	0		N/A	20	2	10.0	1.8 - 33.1	
TOTAL	2297	348	15.2	13.7 - 16.7	1605	201	12.5	11.0 - 14.3	< .05

TABLE 3: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (1)

-RACE/ETHNICITY		198	9 SURVEY			COMPARISON OF 1989 AND 1990 PROPORTIONS			
	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	P-VALUE (4)
WHITE	916	209	22.8	20.2 - 25.7	595	103	17.3	14.4 - 20.6	< .01
BLACK	828	76	9.2	7.3 - 11.4	589	58	9.8	7.6 - 12.6	N.S.
LATINO	371	52	14.0	10.7 - 18.1	296	30	10.1	7.1 - 14.3	N.S.
ASIAN/PACIFIC ISLANDER	138	6	4.3	1.8 - 9.6	98	6	6.1	2.5 - 13.4	N.S.
NONE OF THE ABOVE (5)	44	5	11.4	4.3 - 25.4	27	4	14.8	4.9 - 34.6	N.S.
TÓTAL	2297	348	15.2	13.7 - 16.7	1605	201	12.5	11.0 - 14.3	< .05

⁽¹⁾ The 1989 and 1990 unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examiniation, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Based on the Z-statistic for testing the significance of the difference in the 1990 and 1989 seroprevalence rates. P-values are 2-tailed. N.S. = not significant; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 4: HIV SEROPREVALENCE FOR HOMOSEXUAL AND BISEXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC 8Y AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (1)

		1989	SURVEY			COMPARISON OF 1989 AND 1990 PROPORTIONS			
AGE-GROUP (YEARS)	NUMBER Tested	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	P-VALUE (4)
19 AND UNDER	2	0	0.0	0.0 - 75.2	6	1	16.7	0.9 - 63.5	N.S.
20 - 24	62	26	41.9	29.8 - 55.1	29	12	41.4	24.1 - 60.9	N.S.
25 - 29	138	85	61.6	52.9 - 69.6	91	42	46.2	35.8 - 56.9	< .05
30 - 34	132	77	58.3	49.4 - 66.7	74	35	47.3	35.7 - 59.2	N.S.
35 - 39	113	68	60.2	50.5 - 69.1	58	36	62.1	48.3 - 74.2	N.S.
40 - 44	57	25	43.9	31.0 - 57.6	26	10	38.5	20.9 - 59.3	N.S.
45 AND OVER	61	27	44.3	31.8 - 57.5	46	12	26.1	14.8 - 41.4	N.S.
UNKNOWN	0	0		N/A	1	0	0.0	0.0 - 94.5	
TOTAL	565	308	54.5	50.3 - 58.7	331	148	44.7	39.3 - 50.2	< .01

TABLE 5: HIV SEROPREVALENCE FOR HOMOSEXUAL AND BISEXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989-1990 (1)

		1989	SURVEY			COMPARISON OF 1989 AND 1990 PROPORTIONS			
RACE/ETHNICITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (\$)	(95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (\$)	(95% C.I.)(3)	P-VALUE (4)
WHITE	379	195	51.5	46.3 - 56.6	214	84	39.3	32.7 - 46.2	< .01
BLACK LATINO	87 78	56 48	64.4 61.5	53.3 - 74.1 49.8 - 72.1	54	37 22	68.5 47.8	54.3 - 80.1 33.1 - 62.9	N.S. N.S.
ASIAN/PACIFIC ISLANDER	14	4	28.6	9.6 - 58.0	14	3	21.4	5.7 - 51.2	N.S.
NONE OF THE ABOVE (5)	7	5	71.4	30.3 - 94.9	3	2	66.7	12.5 - 98.2	N.S.
TOTAL	565	308	54.5	50.3 - 58.7	331	148	44.7	39.3 - 50.2	< .01

⁽¹⁾ The 1989 and 1990 unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examiniation, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Based on the Z-statistic for testing the significance of the difference in the 1990 and 1989 seroprevalence rates. P-values are 2-tailed. N.S. = not significant; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 6: HIV SEROPREVALENCE FOR HETEROSEXUAL MALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (2)

		1989	SURVEY			COMPARISON OF 1989 AND 1990 PROPORTIONS			
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (*)	(95% C.I.)(4)	P-VALUE (5)
19 AND UNDER 20 - 24	127 316	1 3	0.8	0.0 - 5.0 0.2 - 3.0	77 175	1	1.3	0.1 - 8.0 0.0 - 3.6	N.S. N.S.
25 - 29 30 - 34	271 183	1	0.4	0.0 - 2.4	179	5	2.8	1.0 - 6.7	N.S.
35 - 39	96	8	3.1	0.8 - 9.5	82	2	2.4	0.4 - 9.3	N.S.
40 - 44 45 AND OVER	62 61	0 2	0.0 3.3	0.0 - 5.6 0.6 - 12.4	41 46	0	4.9 0.0	0.8 - 17.8 0.0 - 7.5	N.S. N.S.
UNKNOWN	0	0		N/A	7	0	0.0	0.0 - 37.2	
TOTAL	1116	18	1.6	1.0 - 2.6	715	14	2.0	1.1 - 3.3	N.S.

TABLE 7: HIV SEROPREVALENCE FOR HETEROSEXUAL MALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (2)

		1989	SURVEY			COMPARISON OF 1989 AND 1990 PROPORTIONS			
RACE/ETHNICITY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	P-VALUE (5)
WHITE	323	5	1.5	0.6 - 3.8	193	4	2.1	0.7 - 5.6	N.S.
BLACK	482	10	2.1	1.1 - 3.9	324	7	2.2	1.0 - 4.6	N.S.
LATINO	213	2	0.9	0.2 - 3.7	147	3	2.0	0.5 - 6.3	N.S.
ASIAN/PACIFIC ISLANDER	79	1	1.3	0.1 - 7.8	41	0	0.0	0.0 - 8.3	N.S.
NONE OF THE ABOVE (6)	19	0	0.0	0.0 - 16.7	10	0	0.0	0.0 - 28.5	N.S.
***************************************	::::::::::::::::::::::::::::::::::::::								
TOTAL	1116	18	1.6	1.0 - 2.6	715	14	2.0	1.1 - 3.3	N.S.

⁽¹⁾ Includes heterosexuals with a sex partner(s) at risk for HIV, heterosexuals with a history of blood transfusion(s), and heterosexuals with no identified risk; (2) The 1989 and 1990 unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA amd a Western blot assay; (4) 95% Confidence Intervals, normal approximation method; (5) Based on the Z-statistic for testing the significance of the difference in the 1990 and 1989 seroprevalence rates. P-values are 2-tailed. N.S. = not significant; (6) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE B: HIV SEROPREVALENCE FOR HETEROSEXUAL FEMALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (2)

		1989	SURVEY			COMPARISON OF 1989 AND 1990 PROPORTIONS			
AGE-GROUP (YEARS)	NUMBER Tested	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	P-VALUE (5)
19 AND UNDER	87	2	2.3	0.4 - 8.8	44	1	2.3	0.1 - 13.5	N.S.
20 - 24	123	2	1.6	0.3 - 6.3	76	1	1.3	0.1 - 8.1	N.S.
25 - 29	101	1	1.0	0.1 - 6.2	68	1	1.5	0.1 - 9.0	N.S.
30 - 34	53	0	0.0	0.0 - 6.5	33	1	3.0	0.2 - 17.5	N.S.
35 - 39	42	0	0.0	0.0 - 8.1	18	1	5.6	0.3 - 29.4	N.S.
40 - 44	22	0	0.0	0.0 - 14.7	10	1	10.0	0.5 - 45.9	N.S.
45 AND OVER	21	0	0.0	0.0 - 15.3	11	0	0.0	0.0 - 26.4	N.S.
UNKNOHN	0	0		N/A	3	0	0.0	0.0 - 62.6	
TOTAL	449	5	1.1	0.4 - 2.7	263	6	2.3	0.9 - 5.1	N.S.

TABLE 9: HIV SEROPREVALENCE FOR HETEROSEXUAL FEMALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (2)

RACE/ETHNICITY		1989	SURVEY			COMPARISON OF 1989 AND 1990 PROPORTIONS			
	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	P-VALUE (5)
WHITE	148	2	1.4	0.2 - 5.3	76	1	1.3	0.1 - 8.1	N.S.
8LACK	191	3	1.6	0.4 - 4.9	109	4	3.7	1.2 - 9.7	N.S.
LATINO	61	0	0.0	0.0 - 5.7	50	1	2.0	0.1 - 12.0	N.S.
ASIAN/PACIFIC ISLANDER	40	0	0.0	0.0 - 8.5	26	0	0.0	0.0 - 12.6	N.S.
NONE OF THE ABOVE (5)	9	0	0.0	0.0 - 30.9	2	0	0.0	0.0 - 75.2	N.S.
TOTAL	449	5	1.1	0.4 - 2.7	263	6	2.3	0.9 - 5.1	N.S.

⁽¹⁾ Includes heterosexuals with a sex partner(s) at risk for HIV, heterosexuals with a history of blood transfusion(s), and heterosexuals with no identified risk; (2) The 1989 and 1990 unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (4) 95% Confidence Intervals, normal approximation method; (5) Based on the Z-statistic for testing the significance of the difference in the 1990 and 1989 seroprevalence rates. P-values are 2-tailed. N.S. = not significant; (6) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 10: HIV SEROPREVALENCE FOR MOMEN ATTENDING A FAMILY PLANNING CLINIC BY TRANSMISSION CATEGORY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (1)

		198	9 SURVEY		1990 SURVEY				
TRANSMISSION CATEGORY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	
Heterosexual IVDU	0	0		N/A	20	1	5.0	0.3 - 26.9	
Sex Partner at Risk for HIV	0	0		N/A	23	0	0.0	0.0 - 14.1	
Blood Recipient (4)	0	0		N/A	11	0	0.0	0.0 - 26.4	
Heterosexual (5)	0	0		N/A	1153	1	0.1	0.0 - 0.6	
Unknown Risk (6)	1265	4	0.3	0.1 - 0.9	8	0	0.0	0.0 - 33.7	
TOTAL	1265	4	0.3	0.1 - 0.9	1215	2	0.2	0.0 - 0.7	

⁽¹⁾ The 1989 and 1990 unlinked (blinded) surveys were drawn from women seeking family planning services. Specimens were collected from inital and annual visits, and tested for HIV after all personal identifiers had been removed;

⁽²⁾ All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western Blot assay;

^{(3) 95%} Confidence Intervals, normal approximation; (4) Includes persons with a history of blood transfusion(s) between January 1977 - March 1985; (5) Self-identified heterosexuals with no identified risk;

^{(6) 1989} survey did not collect risk information.

TABLE 11: HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (1)

		198	9 SURVEY			19	90 SURVEY	
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3
19 AND UNDER	73	0	0.0	0.0 - 4.8	79	0	0.0	0.0 - 4.4
20 - 24	419	1	0.2	0.0 - 1.5	420	0	0.0	0.0 - 0.9
25 - 29	414	1	0.2	0.0 - 1.6	363	0	0.0	0.0 - 1.0
30 - 34	226	2	0.9	0.2 - 3.5	211	1	0.5	0.0 - 3.0
35 - 39	105	0	0.0	0.0 - 3.4	81	0	0.0	0.0 - 4.3
40 - 44	18	0	0.0	0.0 - 17.5	32	1	3.1	0.2 - 18.0
45 AND OVER	7	0	0.0	0.0 - 37.2	5	0	0.0	0.0 - 46.7
UNKNOWN	3	0	0.0	0.0 - 62.6	24	0	0.0	0.0 - 13.6
TOTAL	1265	4	0.3	0.1 - 0.9	1215	2	0.2	0.0 - 0.7

TABLE 12: HIV SEROPREVALENCE FOR WOMEN ATTENDING FAMILY PLANNING CLINICS BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (1)

		198	9 SURVEY		1990 SURVEY				
- RACE/ETHNICITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95 % C.I.)(3)	
WHITE	122	1	0.8	0.0 - 5.2	114	1	0.9	0.0 - 5.5	
8LACK	154	1	0.6	0.0 - 4.1	128	0	0.0	0.0 - 2.8	
LATINA	809	2	0.2	0.0 - 1.0	801	0	0.0	0.0 - 0.5	
ASIAN/PACIFIC ISLANDER	149	0	0.0	0.0 - 2.4	150	1	0.7	0.0 - 4.2	
NONE OF THE ABOVE (4)	31	0	0.0	0.0 - 10.8	22	0	0.0	0.0 - 14.7	
TOTAL	1265	4	0.3	0.1 - 0.9	1215	ż	0.2	0.0 - 0.7	

⁽¹⁾ The 1989 and 1990 unlinked (blinded) surveys were drawn from women seeking family planning services. Specimens were collected from all initial and annual visits and tested for HIV after all personal identifiers had been removed;

⁽²⁾ All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western Blot assay;

^{(3) 95%} Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 13: HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENDER AND YEAR (1)(2)

		1985			1986			1987			1988			1989	
GENDER	N(3)	HIV+(4	i) *(5)	N	HIV+	t	N	HIV+	ŧ	N	HIV+	t	N	HIV+	ŧ
MALE FEMALE	213 45	0	0.0 0.0	941 183	9 1	1.0 0.5	869 143	5 0	0.5 0.0	759 178	2	0.3	711 124	2	0.3 0.8
TOTAL	258	0	0.0	1124	10	0.9	1012	5	0.5	937	2	0.2	835	3	0.4

		1990		TOTAL		
GENDER	N	HIV+	¥	N	HIV+	*
MALE FEMALE	411 87	0	0.0	3904 760	18 2	0.5 0.3
TOTAL	498	0	0.0	4664	20	0.4

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC); (2) Data collected between October 1985 and September 1990; (3) Number tested; (4) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (5) Seroprevalence rate (1).

TABLE 14: HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENDER AND AGE GROUP (1)(2)

		H	LE		FEMALE			
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (\$)	(95% C.I.)(4)
19 AND UNDER	1615	2	0.1	0.0 - 0.5	268	0	0.0	0.0 - 1.3
20 - 24	1237	4	0.3	0.1 - 0.9	243	1	0.4	0.0 - 2.6
25 - 29	629	5	0.8	0.3 - 2.0	128	1	0.8	0.0 - 4.9
30 AND OVER	423	7	1.7	0.7 - 3.5	121	0	0.0	0.0 - 2.9
TOTAL	3904	18	0.5	0.3 - 0.7	760	2	0.3	0.0 - 1.1

TABLE 15: HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENDER AND RACE/ETHNICITY (1)(2)

SERC NUMBER(3) PREVAIL POSITIVE RATE 9 0.7 7 0.9 1 0.2	LENCE (%) (95% C.I.)(4	4) TESTED PO 280	UMBER(3) OSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)
7 0.9			_		
7 0.9			0	0.0	0.0 1.0
1 0.5			U	0.0	0.0 - 1.9
1 0.4	2 0.0 - 1.6	71	0	0.0	0.0 - 4.9
0 0.0	0.0 - 0.3	194	0	0.0	0.0 - 1.8
1 0.7	7 0.0 - 4.4	27	0	0.0	0.0 - 12.2
		7/0		0.7	0.0 - 1.1
=	************	***************************************			

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC); (2) Data collected between October 1985 and September 1990; (3) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (4) 95% Confidence Intervals, normal approximation method; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 16: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY YEAR OF DONATION, MARCH 1985 - SEPTEMBER 1990 (1)

YEAR OF DONATION	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
1985	72,204	80	0.111	0.088 - 0.139
1986	86,168	40	0.046	0.034 - 0.064
1987	91,396	30	0.033	0.023 - 0.047
1988	90,192	23	0.026	0.017 - 0.039
1989	72,892	10	0.014	0.007 - 0.026
1990	56,408	6	0.011	0.004 - 0.024
TOTAL	469,260	189	0.040	0.035 - 0.047

TABLE 17: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO 8AY AREA 8Y DONATION STATUS AND GENDER, OCTOBER 1, 1989 - SEPTEMBER 30, 1990 (1)

DONATION STATUS	GENDER	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
FIRST-TIME	Male	9,616	4	0.042	0.013 - 0.114
DONORS	Female	9,673	1	0.010	0.001 - 0.067
REPEAT	Male	31,004	3	0.010	0.002 - 0.031
DONORS	Female	27,165	2	0.007	0.001 - 0.030
TOTAL		77,458	10	0.013	0.007 - 0.025

⁽¹⁾ Data were provided courtesy of the Irwin Memorial Blood Centers, San Francisco, Ca.;

⁽²⁾ Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay;

^{(3) 95%} Confidence Intervals, normal approximation method.

TABLE 18: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY RACE/ETHNICITY, OCTOBER 1, 1989 - SEPTEMBER 30, 1990 (1)

	TOTAL	NUMBER(2)	SERO- PREVALENCE	
RACE/ETHNICITY	DONATIONS	POSITIVE	RATE (%)	(95% C.I.)(3)
WHITE	65,535	5	0.008	0.003 - 0.01
BLACK	3,215	2	0.062	0.011 - 0.25
LATINO	3,732	3	0.080	0.021 - 0.25
NONE OF THE ABOVE	(4) 4,976	0	0.000	0.000 - 0.07
TOTAL	77,458	10	0.013	0.007 - 0.02

TABLE 19: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY AGE-GROUP, OCTOBER 1, 1989 - SEPTEMBER 30, 1990 (1)

AGE-GROUP (YEARS)	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
19 AND UNDER	5,50B	0	0.000	0.000 - 0.066
20 - 29	15,234	1	0.007	0.000 - 0.043
30 - 39	22,264	7	0.031	0.014 - 0.06B
40 AND OVER	34,452	2	0.006	0.001 - 0.023
TOTAL	77,458	10	0.013	0.007 - 0.025

⁽¹⁾ Data were provided courtesy of the Irwin Memorial Blood Centers, San Francisco, Ca.; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes Asian/Pacific Islanders, American Indians, Alaskan Natives, other race, and unknown race.

TABLE 20: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY AGE-GROUP (1)

	NUM8ER	NUMBER(2)	SERO- PREVALENCE	
AGE-GROUP (YEARS)	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3
19 AND UNDER	6	0	0.0	0.0 - 41.4
20 - 24	89	3	3.4	0.9 - 10.2
25 - 29	167	9	5.4	2.7 - 10.3
30 - 34	251	16	6.4	3.8 - 10.3
35 - 39	354	33	9.3	6.6 - 13.0
40 - 44	252	26	10.3	7.0 - 14.9
45 AND OVER	181	23	12.7	8.4 - 18.7
MISSING	18	1	5.6	0.3 - 29.4
TOTAL	1318	111	8.4	7.0 - 10.1

TABLE 21: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY RACE/ETHNICITY (1)

RACE/ETHNICITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
WHITE	815	28	3.4	2.3 - 5.0
BLACK	307	67	21.8	17.4 - 26.9
LATINO	148	11	7.4	4.0 - 13.2
ASIAN/PACIFIC ISLANDER	31	4	12.9	4.2 - 30.8
NONE OF THE ABOVE (4)	17	1	5.9	0.3 - 30.8
			: :::::: :::	
TOTAL	1318	111	8.4	7.0 - 10.1

⁽¹⁾ Data collected between the 4th quarter of 1989 and the 4th quarter of 1990; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Mestern blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, unknown race, and missing race.

TABLE 22: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE
TREATMENT PROGRAMS IN SAN FRANCISCO BY GENDER AND SEXUAL ORIENTATION (1)

			SE RO-	
GENDER AND	NUMBER	NUMBER(2)		
SEXUAL ORIENTATION	TESTED	. ,		(95% C.I.)(3)
				(/37 0.1.)(0)
MALE				
Homosexual/Bisexual	30	9	30.0	15.4 - 49.6
Heterosexual	_B15	68	8.3	6.6 - 10.5
SU8-TOTAL: MALE	845	17	9.1	7.3 - 11.3
FEHALE				
Lesbian/Bisexual	23	3	13.0	3.4 - 34.7
Heterosexual	417	29	7.0	4.8 - 9.9
SUB-TOTAL: FEMALE	440	32	7.3	5.1 - 10.2
MISSING GENDER AND/OR	33	2	6.1	1.1 - 21.6
SEXUAL ORIENTATION				
TOTAL	1318	111	8.4	7.0 - 10.1

TABLE 23: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY TREATMENT MODALITY (1)

TREATMENT MODALITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
DETOXIFICATION	1134	95	8.4	6.9 - 10.2
HAINTENANCE	177	16	9.0	5.4 - 14.5
MISSING	7	0	0.0	0.0 - 37.2
TOTAL	1318	111	8.4	7.0 - 10.1

⁽¹⁾ Data collected between the 4th quarter of 1989 and the 4th quarter of 1990; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method.

S.F. Department of Public Health AIDS Office--Surveillance Branch 25 Van Ness Avenue, 5th Floor 5an Francisco, CA 94102

SAN ERANCISCO, CA 94103 DOCUMENTS MCALLISTER S.F. PUBLIC LIBRARY MURIEL DOBBIN

P70 P59

HIV SEROPREVALENCE REPORT

San Francisco Department of Public Health AIDS Office

April 1991

Vol. 2 No. 2

DOCUMENTS DEPT.

Contents

BURL EHANGIDES

TABLE 1: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY GENDER AND TRANSMISSION CATEGORY, SAN FRANCISCO, 1989 - 1990Page 1
TABLE 2: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP, SAN FRANCISCO, 1989 - 1990
TABLE 3: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY, SAN FRANCISCO, 1989 - 1990Page 2
TABLE 4: HIV SEROPREVALENCE FOR HOMOSEXUAL AND BISEXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP, SAN FRANCISCO, 1989 - 1990Page 3
TABLE 5: HIV SEROPREVALENCE FOR HOMOSEXUAL AND BISEXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY, SAN FRANCISCO, 1989 - 1990Page 3
TABLE 6: HIV SEROPREVALENCE FOR HETEROSEXUAL MALES ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP, SAN FRANCISCO, 1989 - 1990Page 4
TABLE 7: HIV SEROPREVALENCE FOR HETEROSEXUAL MALES ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY, SAN FRANCISCO, 1989 - 1990Page 4
TABLE 8: HIV SEROPREVALENCE FOR HETEROSEXUAL FEMALES ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP, SAN FRANCISCO, 1989 - 1990Page 5
TABLE 9: HIV SEROPREVALENCE FOR HETEROSEXUAL FEMALES ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY, SAN FRANCISCO, 1989 - 1990Page 5
TABLE 10: HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY TRANSMISSION CATEGORY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990Page 6
TABLE 11: HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990Page 7
TABLE 12: HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990Page 7
TABLE 13: HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY TRANSMISSION CATEGORY, SAN FRANCISCO, 1990
TABLE 14: HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY AGE - GROUP, SAN FRANCISCO, 1990
TABLE 15: HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC

TABLE 16: HIV SEROPREVALENCE FOR NEWBORN INFANTS AND THEIR MOTHERS FROM THE CITY AND COUNTY OF SAN FRANCISCO, 1988 - 1989
TABLE 17: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE TREATMENT IN SAN FRANCISCO BY AGE-GROUP, 1989 - 1991
TABLE 18: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE TREATMENT IN SAN FRANCISCO BY RACE/ETHNICITY, 1989 - 1991
TABLE 19: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE TREATMENT IN SAN FRANCISCO BY GENDER AND SEXUAL ORIENTATION, 1989 - 1991
TABLE 20: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE TREATMENT IN SAN FRANCISCO BY TREATMENT MODALITY, 1989 - 1991Page 12
TABLE 21: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) IN SAN FRANCISCO BY GENDER AND TRANSMISSION CATEGORY, 1990 - 1991
TABLE 22: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) IN SAN FRANCISCO BY ORIGIN OF BIRTH, 1990 - 1991
TABLE 23: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) IN SAN FRANCISCO BY AGE-GROUP, 1990 - 1991
TABLE 24: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) IN SAN FRANCISCO BY RACE/ETHNICITY, 1990 - 1991
TABLE 25: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY YEAR OF DONATION, MARCH 1985 - SEPTEMBER 1990
TABLE 26: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY DONATION STATUS AND GENDER, OCTOBER 1989 - SEPTEMBER 1990Page 15
TABLE 27: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY RACE/ETHNICITY, OCTOBER 1989 - SEPTEMBER 1990Page 16
TABLE 28: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY AGE-GROUP, OCTOBER 1989 - SEPTEMBER 1990
TABLE 29: HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM SAN FRANCISCO BY GENDER AND YEAR, 1985 - 1990
TABLE 30: HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM SAN FRANCISCO BY GENDER AND AGE-GROUP, 1985 - 1990
TABLE 31: HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM SAN FRANCISCO BY GENDER AND RACE/ETHNICITY, 1985 - 1990

TABLE 1: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY GENDER, TRANSMISSION CATEGORY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (1)

	1989 SURVEY					1990 SURVEY			
GENDER AND TRANSMISSION CATEGORY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	
MALE									
Homosexual/Bisexual	446	226	50.7	45.9 - 55.4	623	269	43.2	39.3 - 47.2	
Homosexual/Bisexual, IVOU	119	82	68.9	59.7 - 76.9	89	55	61.8	50.9 - 71.7	
Heterosexual IVOU	99	12	12.1	6.7 - 20.6	101	8	7.9	3.7 - 15.5	
Sex Partner at Risk for HIV	73	3	4.1	1.1 - 12.3	103	9	8.7	4.3 - 16.4	
Blood Recipient (4)	23	1	4.3	0.2 - 24.0	9	1	11.1	0.6 - 49.3	
Heterosexual (5)	1020	14	1.4	0.8 - 2.4	1372	29	2.1	1.4 - 3.1	
Unknown Risk	8	0	0.0	0.0 - 33.7	184	24	13.0	8.7 - 19.0	
SUB-TOTAL MALE	1788	338	18.9	17.1 - 20.8	2481	395	15.9	14.5 - 17.4	
FEMALE									
Heterosexual IVOU	55	5	9.1	3.4 - 20.7	59	5	8.5	3.2 - 19.4	
Sex Partner at Risk for HIV	58	1	1.7	0.1 - 10.5	55	1	1.8	0.1 - 11.0	
Blood Recipient (4)	11	1	9.1	0.5 - 42.9	6	1	16.7	0.9 - 63.5	
Heterosexual (5)	380	3	0.8	0.2 - 2.5	538	13	2.4	1.3 - 4.2	
Unknown Risk	5	0	0.0	0.0 - 46.7	21	0	0.0	0.0 - 15.3	
SUB-TOTAL FEMALE	509	10	2.0	1.0 - 3.7	679	20	2.9	1.9 - 4.6	

TOTAL	2297	348	15.2	13.7 - 16.7	3160	415	13.1	12.0 - 14.4	

⁽¹⁾ The 1989 and 1990 unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STO episode Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons with a history of blood transfusion(s) between January 1977 - March 1985; (5) Self-identified heterosexuals with no identified risk.

TABLE 2: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP AND YEAR OF SURVEY.

SAN FRANCISCO, 1989 - 1990 (1)

		198	89 SURVEY			1990 SURVEY			
AGE-GROUP (YEARS)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUM8ER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(
19 ANO UNOER	223	3	1.3	0.3 - 4.2	272	6	2.2	0.9 - 5.0	
20 - 24	526	35	6.7	4.7 - 9.2	704	34	4.8	3.4 - 6.8	
25 - 29	550	93	16.9	13.9 - 20.4	781	104	13.3	11.1 - 15.9	
30 - 34	403	88	21.8	18.0 - 26.3	566	113	20.0	16.8 - 23.5	
35 - 39	284	73	25.7	20.8 - 31.3	379	89	23.5	19.4 - 28.	
40 - 44	158	27	17.1	11.8 - 24.1	222	38	17.1	12.5 - 22.	
45 ANO OVER	153	29	19.0	13.3 - 26.3	226	31	13.7	9.6 - 19.	
UNKNOWN	0	0			10	0	0.0	0.0 - 28.	
	***************************************		•••		 				
TOTAL	2297	348	15.2	13.7 - 16.7	3160	415	13.1	12.0 - 14	

TABLE 3: HIV SEROPREVALENCE FOR CLIENTS ATTENOING A SEXUALLY TRANSMITTEO DISEASE CLINIC 8Y RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (1)

		198	89 SURVEY		1990 SURVEY			
RACE/ETHNICITY	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3
WHITE	916	209	22.8	20.2 - 25.7	1204	218	18.1	16.0 - 20.4
AFRICAN AMERICAN	828	76	9.2	7.3 - 11.4	1172	110	9.4	7.8 - 11.2
LATINO	371	52	14.0	10.7 - 18.1	560	68	12.1	9.6 - 15.2
ASIAN/PACIFIC ISLANOER	138	6	4.3	1.8 - 9.6	181	13	7.2	4.0 - 12.2
NONE OF THE ABOVE (4)	44	5	11.4	4.3 - 25.4	43	6	14.0	5.8 - 28.6
TOTAL	2297	348	15.2	13.7 - 16.7	3160	415	13.1	12.0 - 14.4

⁽¹⁾ The 1989 and 1990 unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STO episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 4: HIV SEROPREVALENCE FOR HOMOSEXUAL AND 815EXUAL MEN ATTENDING A SEXUALLY TRANSMITTED 015EASE CLINIC BY AGE-GROUP AND YEAR OF SURVEY, 5AN FRANCISCO, 1989 - 1990 (1)

	1989 SURVEY					1990 SURVEY			
AGE-GROUP (YEAR5)	NUMBER TESTEO	NUM8ER(2) PO5ITIVE	5ERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	5ERO- PREVALENCE RATE (%)	(95% C.I.)(3)	
19 ANO UNDER	2	0	0.0	0.0 - 75.2	14	2	14.3	2.5 - 43.8	
20 - 24	62	26	41.9	29.8 - 55.1	80	27	33.8	23.8 - 45.3	
25 - 29	138	85	61.6	52.9 - 69.6	174	80	46.0	38.5 - 53.7	
30 - 34	132	77	58.3	49.4 - 66.7	167	87	52.1	44.3 - 59.8	
35 - 39	113	68	60.2	50.5 - 69.1	128	69	53.9	44.9 - 62.7	
40 - 44	57	25	43.9	31.0 - 57.6	61	30	49.2	36.3 - 62.2	
45 ANO OVER	61	27	44.3	31.8 - 57.5	87	29	33.3	23.8 - 44.3	
UNKNOWN	0	0			1	0	0.0	0.0 - 92.7	
***************************************			***********						
TOTAL	565	308	54.5	50.3 - 58.7	712	324	45.5	41.8 - 49.2	

TABLE 5: HIV SEROPREVALENCE FOR HOMOSEXUAL AND 815EXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC 8Y RACE/ETHNICITY, SAN FRANCISCO, 1989 - 1990 (1)

		1989 SURVEY			1990 SURVEY				
RACE/ETHNICITY	NUM8ER TE5TE0	NUMBER(2) POSITIVE	5ERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUM8ER TESTEO	NUM8ER(2) POSITIVE	5ERO- PREVALENCE RATE (%)	(95% C.I.)(3)	
WHITE AFRICAN AMERICAN LATINO A5IAN/PACIFIC ISLANOER	379 87 78 14	195 56 48	51.5 64.4 61.5 28.6	46.3 - 56.6 53.3 - 74.1 49.8 - 72.1 9.6 - 58.0	453 117 106 28	188 74 50	41.5 63.2 47.2 28.6	36.9 - 46.2 53.8 - 71.8 37.5 - 57.1 14.0 - 48.9	
NONE OF THE ABOVE (4)	7	5	71.4	30.3 - 94.9	8	4	50.0	17.5 - 82.5	
TOTAL	565	308	54.5	50.3 - 58.7	712	324	45.5	41.8 - 49.2	

⁽¹⁾ The 1989 and 1990 unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW 5TO episode 5pecimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (2) All positive specimens were repeatedly reactive by ELI5A and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 6: HIV SEROPREVALENCE FOR HETEROSEXUAL MALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (2)

AGE-GROUP (YEARS)		198			1990 SURVEY			
	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	: (95% C.I.)(
19 ANO UNOER	127	1	0.8	0.0 - 5.0	155	2	1.3	0.2 - 5.1
20 - 24	316	3	0.9	0.2 - 3.0	358	4	1.1	0.4 - 3.0
25 - 29	271	1	0.4	0.0 - 2.4	389	10	2.6	1.3 - 4.8
30 - 34	183	8	4.4	2.0 - 8.7	230	11	4.8	2.5 - 8.6
35 - 39	96	3	3.1	0.8 - 9.5	159	8	5.0	2.4 - 10.0
40 - 44	62	0	0.0	0.0 - 5.6	98	3	3.1	0.8 - 9.3
45 AND OVER	61	2	3.3	0.6 - 12.4	91	1	1.1	0.1 - 6.8
UNKNOWN	0	0			4	0	0.0	0.0 - 53.
TOTAL	1116	18	1.6	1.0 - 2.6	1484	39	2.6	1.9 -

TABLE 7: HIV SEROPREVALENCE FOR HETEROSEXUAL MALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY, SAN FRANCISCO, 1989 - 1990 (2)

		198	39 SURVEY		1990 SURVEY			
RACE/ETHNICITY	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(
WHITE	323	5	1.5	0.6 - 3.8	413	11	2.7	1.4 - 4.9
AFRICAN AMERICAN	482	10	2.1	1.1 - 3.9	684	17	2.5	1.5 - 4.0
LATINO	213	2	0.9	0.2 - 3.7	286	9	3.1	1.5 - 6.1
ASIAN/PACIFIC ISLANDER	79	1	1.3	0.1 - 7.8	82	1	1.2	0.1 - 7.5
NONE OF THE ABOVE (5)	19	0	0.0	0.0 - 16.7	19	1	5.3	0.3 - 28.1
TOTAL	1116	18	1.6	1.0 - 2.6	1484	39	2.6	1.9 - 3.6

⁽¹⁾ Includes heterosexuals with a sex partner(s) at risk for HIV, heterosexuals with a history of blood transfusion(s), and heterosexuals with no identified risk; (2) The 1989 and 1990 unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA amd a Western blot assay; (4) 95% Confidence Intervals, normal approximation method; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 8: HIV SEROPREVALENCE FOR HETEROSEXUAL FEMALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO. 1989 - 1990 (2)

	1989 SURVEY					1990 SURVEY			
AGE-GROUP (YEARS)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	
19 ANO UNOER	87	2	2.3	0.4 - 8.8	88	2	2.3	0.4 - 8.7	
20 - 24	123	2	1.6	0.3 - 6.3	195	1	0.5	0.0 - 3.3	
25 - 29	101	1	1.0	0.1 - 6.2	139	4	2.9	0.9 - 7.7	
30 - 34	53	0	0.0	0.0 - 6.5	В0	4	5.0	1.6 - 13.0	
35 - 39	42	0	0.0	0.0 - 8.1	43	3	7.0	1.8 - 20.1	
40 - 44	22	0	0.0	0.0 - 14.7	28	1	3.6	0.2 - 20.2	
45 AND OVER	21	0	0.0	0.0 - 15.3	22	0	0.0	0.0 - 14.7	
UNKNOWN	0	0			4	0	0.0	0.0 - 53.5	
			**********	***************			=========		
TOTAL	449	5	1.1	0.4 - 2.7	599	15	2.5	1.5 - 4.2	

TABLE 9: HIV SEROPREVALENCE FOR HETEROSEXUAL FEMALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY, SAN FRANCISCO. 1989 - 1990 (2)

	1989 SURVEY					1990 SURVEY			
RACE/ETHNICITY	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	
WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANOER NONE OF THE ABOVE (5)	148 191 61 40 9	2 3 0 0	1.4 1.6 0.0 0.0	0.2 - 5.3 0.4 - 4.9 0.0 - 5.7 0.0 - 8.5 0.0 - 30.9	175 264 100 53 7	4 9 1 1 0	2.3 3.4 1.0 1.9 0.0	0.7 - 6.1 1.7 - 6.6 0.1 - 6.2 0.1 - 11.4 0.0 - 37.2	
TOTAL	449	5	1.1	0.4 - 2.7	599	15	2.5	1.5 - 4.2	

⁽¹⁾ Includes heterosexuals with a sex partner(s) at risk for HIV, heterosexuals with a history of blood transfusion(s), and heterosexuals with no identified risk; (2) The 1989 and 1990 unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STO episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA amd a Western blot assay; (4) 95% Confidence Intervals, normal approximation method; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 10: HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY TRANSMISSION CATEGORY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (1)

		198	9 SURVEY		1990 SURVEY			
TRANSMISSION CATEGORY	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3
Heterosexual IVOU	0	0			20	1	5.0	0.3 - 26.9
Sex Partner at Risk for HIV	0	0			24	0	0.0	0.0 - 13.6
Blood Recipient (4)	0	0			11	0	0.0	0.0 - 26.4
Heterosexual (5)	0	0			1313	1	0.1	0.0 - 0.5
Unknown Risk (6)	1266	4	0.3	0.1 - 0.9	8	0	0.0	0.0 - 33.7
TOTAL	1266	4	0.3	0.1 - 0.9	1376	2	0.1	0.0 - 0.6

⁽¹⁾ The 1989 and 1990 unlinked (blinded) surveys were drawn from women seeking family planning services. Specimens were collected from inital and annual visits, and tested for HIV after all personal identifiers had been removed;

⁽²⁾ All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay;

^{(3) 95%} Confidence Intervals, normal approximation; (4) Includes persons with a history of blood transfusion(s) between January 1977 - March 1985; (5) Self-identified heterosexuals with no identified risk;

^{(6) 1989} unlinked survey did not collect risk information.

TABLE 11: HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY AGE-GROUP AND YEAR OF SURVEY.

SAN FRANCISCO. 1989 - 1990 (1)

		198	39 SURVEY		1990 SURVEY			
AGE-GROUP (YEARS)	NUM8ER) TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
19 ANO UNOER	73	0	0.0	0.0 - 4.B	93	0	0.0	0.0 - 3.B
20 - 24	420	1	0.2	0.0 - 4.8	474	0	0.0	0.0 - 3.B
25 - 29	414	1	0.2	0.0 - 1.6	401	0	0.0	0.0 - 0.9
30 - 34	226	2	0.9	0.2 - 3.5	243	1	0.4	0.0 - 2.6
35 - 39	105	0	0.0	0.0 - 3.4	97	0	0.0	0.0 - 3.6
40 - 44	18	0	0.0	0.0 - 17.5	34	1	2.9	0.2 - 17.1
45 ANO OVER	7	0	0.0	0.0 - 37.2	8	0	0.0	0.0 - 33.7
UNKNOWN	3	0	0.0	0.0 - 62.6	26	0	0.0	0.0 - 12.6
TOTAL	1266	4	0.3	0.1 - 0.9	1376	2	0.1	0.0 - 0.6

TABLE 12: HIV SEROPREVALENCE FOR WOMEN ATTENOING FAMILY PLANNING CLINICS BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (1)

		19B9 SURVEY			1990 SURVEY			
RACE/ETHNICITY	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
WHITE	122	1	0.8	0.0 - 5.2	126	1	0.8	0.0 - 5.0
AFRICAN AMERICAN LATINA	154 810	1 2	0.6 0.2	0.0 - 4.1 0.0 - 1.0	145 90B	0	0.0	0.0 - 2.5 0.0 - 0.4
ASIAN/PACIFIC ISLANDER	149	0	0.0	0.0 - 2.4	166	1	0.6	0.0 - 3.8
NONE OF THE ABOVE (4)	31	0	0.0	0.0 - 10.B	31	0	0.0	0.0 - 10.8
TOTAL	1266	4	0.3	0.1 - 0.9	1376	2	0.1	0.0 - 0.6

⁽¹⁾ The 1989 and 1990 unlinked (blinded) surveys were drawn from women seeking family planning services. Specimens were collected from all initial and annual visits and tested for HIV after all personal identifiers had been removed;

⁽²⁾ All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay;

^{(3) 95%} Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and

TABLE 13: HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY TRANSMISSION CATEGORY, SAN FRANCISCO, 1990 (1)

NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
8	1	12.5	0.7 - 53.3
3	0	0.0	0.0 - 62.6
419	2	0.5	0.1 - 1.9
1	0	0.0	0.0 - 92.7
431	3	0.7	0.2 - 2.2
	8 3 419 1	### RESTED POSITIVE R	NUMBER NUMBER(2) PREVALENCE TESTED POSITIVE RATE (%) 8 1 12.5 3 0 0.0 419 2 0.5 1 0 0.0

⁽¹⁾ This 1990 unlinked (blinded) survey was drawn from routine blood specimens from women seeking abortions. Survey specimens were tested for HIV after all personal identifiers had been removed; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation; (4) Includes persons with

a history of blood transfusion(s) between January 1977 - March 1985;

⁽⁵⁾ Self-identified heterosexuals with no identified risk.

TABLE 14: HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY AGE-GROUP, SAN FRANCISCO, 1990 (1)

AGE-GROUP (YEARS)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
19 AND UNDER	68	0	0.0	0.0 - 5.1
20 - 24	139	1	0.7	0.0 - 4.5
25 - 29	106	0	0.0	0.0 - 3.3
30 - 34	80	2	2.5	0.4 - 9.6
35 - 39	26	0	0.0	0.0 - 12.6
40 - 44	8	0	0.0	0.0 - 33.7
45 AND OVER	0	0		
UNKNOWN	4	0	0.0	0.0 - 53.5
TOTAL	431	3	0.7	0.2 - 2.2

TABLE 15: HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY RACE/ETHNICITY, SAN FRANCISCO, 1990 (1)

	NUMBER	NUMBER(2)	SERO- PREVALENCE	
RACE/ETHNICITY	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3)
WHITE	50	1	2.0	0.1 - 12.0
AFRICAN AMERICAN	106	2	1.9	0.3 - 7.3
LATINA	223	0	0.0	0.0 - 1.6
ASIAN/PACIFIC ISLANDER	45	0	0.0	0.0 - 7.6
NONE OF THE ABOVE (4)	7	0	0.0	0.0 - 37.2
				==========
TOTAL	431	3	0.7	0.2 - 2.2

⁽¹⁾ This 1990 unlinked (blinded) survey was drawn from routine blood specimens from women seeking abortions. Survey specimens were tested for HIV after all personal identifiers had been removed; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 16: HIV SEROPREVALENCE FOR NEWBORN INFANTS AND THEIR MOTHERS, SAN FRANCISCO, 1988 - 1989 (1)

	1988 SURVEY					19	989 SURVEY (2)
	NUMBER TESTEO	NUM8ER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(
AGE-GROUP (YEARS)								
20 - 24	274	1	0.363	0.019 - 2.017				
30 - 34	433	1	0.231	0.121 - 1.486				
OVER 35	269	1	0.372	0.194 - 2.379				
UNKNOWN	990	2	0.202	0.035 - 0.811				;-
RACE/ETHNICITY								
BLACK	241	2	0.830	0.144 - 3.289				
HISPANIC	414	3	0.725	0.187 - 2.285				
TOTAL - SAN FRANCISCO	2,565	5	0.195	0.072 - 0.483	2,547	4	0.157	0.050 - 0.
TOTAL - BAY AREA (5)	20,977	27	0.129	0.087 - 0.190	21,217	25	0.118	0.078 - 0.
TOTAL - STATEWIOE	135,762	101	0.074	0.061 - 0.091	144,284	92	0.064	0.052 - 0.

⁽¹⁾ Data courtesy of the California Department of Health Services Office of AIDS. Specimens for this survey of newborn infants (women giving birth) are drawn from the genetic diseases screening program. Antibodies in a newborn reflect the infection status of the mother and not necessarily of the child. (2) Demographic breakdown of the 1989 survey is not available; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (4) 95% Confidence Intervals, normal approximation; (5) Includes Alameda, Contra Costa, Marin, San Francisco, San Mateo and Santa Clara counties.

TABLE 17: HIV SEROPREVALENCE FOR INTRAVENOUS ORUG USERS ENTERING METHAOONE TREATMENT PROGRAMS IN SAN FRANCISCO BY AGE-GROUP (1)

	NUMBER	NUMBER(2)	SERO- PREVALENCE	
AGE-GROUP (YEARS)	TESTEO	POSITIVE	RATE (%)	(95% C.I.)(3)
19 ANO UNOER	12	1	8.3	0.4 - 40.2
20 - 24	106	3	2.8	0.7 - 8.7
25 - 29	230	14	6.1	3.5 - 10.2
30 - 34	330	22	6.7	4.3 - 10.1
35 - 39	489	51	10.4	7.9 - 13.6
40 - 44	363	36	9.9	7.1 - 13.6
45 AND OVER	251	27	10.8	7.3 - 15.4
MISSING	31	2	6.5	1.1 - 22.8
TOTAL	1812	156	8.6	7.4 - 10.0

TABLE 18: HIV SEROPREVALENCE FOR INTRAVENOUS ORUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY RACE/ETHNICITY (1)

			SERO-	
	NUMBER	NUMBER(2)	PREVALENCE	
RACE/ETHNICITY	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3)
WHITE	1111	38	3.4	2.5 - 4.7
AFRICAN AMERICAN	426	96	22.5	18.7 - 26.9
LATINO	210	17	8.1	4.9 - 12.9
ASIAN/PACIFIC ISLANOER	42	4	9.5	3.1 - 23.5
NONE OF THE ABOVE (4)	23	1	4.3	0.2 - 24.0
TOTAL	1812	156	8.6	7.4 - 10.0

⁽¹⁾ Oata collected between the 4th quarter of 1989 and the 1st quarter of 1991; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, unknown race, and missing race.

TABLE 19: HIV SEROPREVALENCE FOR INTRAVENOUS ORUG USERS ENTERING METHADONE
TREATMENT PROGRAMS IN SAN FRANCISCO BY GENOER AND SEXUAL ORIENTATION (1)

		~~~~		
			SERO-	
GENOER ANO	NUMBER	NUMBER(2)	PREVALENCE	
SEXUAL ORIENTATION	TESTEO	POSITIVE	RATE (%)	(95% C.I.)(3)
MALE				
Homosexual/Bisexual	42	13	31.0	18.1 - 47.2
Heterosexual	1119	94	8.4	6.9 - 10.2
SUB-TOTAL: MALE	1161	107	9.2	7.6 - 11.1
FEMALE				
Lesbian/Bisexual	30	4	13.3	4.4 - 31.6
Heterosexual	581	43	7.4	5.5 - 9.9
SUB-TOTAL: FEMALE	611	47	7.7	5.8 - 10.2
MISSING GENOER ANO/OR SEXUAL ORIENTATION	40	2	5.0	0.9 - 18.2
TOTAL	1812	156	8.6	7.4 - 10.0

TABLE 20: HIV SEROPREVALENCE FOR INTRAVENOUS ORUG USERS ENTERING METHAOONE TREATMENT PROGRAMS IN SAN FRANCISCO BY TREATMENT MODALITY (1)

TREATMENT MODALITY	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
OETOXIFICATION	1545	130	8.4	7.1 - 9.9
MAINTENANCE	261	26	10.0	6.7 - 14.4
MISSING	6	0	0.0	0.0 - 41.4
***************************************				
TOTAL	1812	156	8.6	7.4 - 10.0

⁽¹⁾ Oata collected between the 4th quarter of 1989 and the 1st quarter of 1991; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method.

TABLE 21: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB)
AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY GENDER AND
TRANSMISSION CATEGORY (1)

			SERO-	
GENOER ANO	NUMBER	NUMBER(2)	PREVALENCE	
TRANSMISSION CATEGORY	TESTEO	POSITIVE	RATE (%)	(95% C.I.)(3)
MALE				
Homosexual/Bisexual	2B	21	75.0	54.B - 8B.6
Homosexual/Bisexual, IVOU	13	10	76.9	46.0 - 93.B
Heterosexual IVOU	12	2	16.7	2.9 - 49.1
Heterosexual (4)	115	6	5.2	2.1 - 11.5
Unknown Risk	10	0	0.0	0.0 - 28.5
SUB-TOTAL MALE	17B	39	21.9	16.2 - 2B.B
FEMALE				
Heterosexual IVOU	5	1	20.0	1.1 - 70.1
Heterosexual (4)	49	0	0.0	0.0 - 7.0
Unknown Risk	10	0	0.0	0.0 - 2B.5
SUB-TOTAL FEMALE	64	1	1.6	0.1 - 9.5
***************************************	******			
TOTAL	242	40	16.5	12.2 - 21.9

TABLE 22: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB)
AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY ORIGIN OF BIRTH (1)

ORIGIN OF BIRTH	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
BORN IN USA	99	33	33.3	24.4 - 43.6
BORN OUTSIDE USA	143	7	4.9	2.2 - 10.2
			***********	
TOTAL	242	40	16.5	12.2 - 21.9

⁽¹⁾ Oata collected between the 1st quarter of 1990 to the 1st quarter 1991;

⁽²⁾ Positive specimens were repeatedly reactive by ELISA and confirmed by an

IFA and a Western blot assay: (3) 95% Confidence Intervals, normal approximation:

⁽⁴⁾ Includes self-identified heterosexuals with no identified risk, persons with a history of blood transfusion(s) or with a bleeding disorder, and persons with a sexual partner(s) at risk for HIV/AIOS.

TABLE 23: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB)
AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY AGE-GROUP (1)

	NUMBER	NUMBER(2)	SERO- PREVALENCE	
AGE-GROUP (YEARS)	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3)
19 AND UNDER	7	0	0.0	0.0 - 37.2
20 - 24	11	2	1B.2	3.2 - 52.2
25 - 29	35	6	17.1	7.2 - 34.3
30 - 34	38	7	1B.4	8.3 - 34.9
35 - 39	26	8	30.B	15.1 - 51.9
40 - 44	30	9	30.0	15.4 - 49.6
45 AND OVER	95	8	B.4	4.0 - 16.4
			*********	
TOTAL	242	40	16.5	12.2 - 21.9

TABLE 24: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB)
AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY RACE/ETHNICITY (1)

	NUMBER	NUMBER(2)	SERO- PREVALENCE	
RACE/ETHNICITY	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3)
WHITE	46	17	37.0	23.6 - 52.5
AFRICAN AMERICAN	44	12	27.3	15.5 - 43.0
LATINO	42	В	19.0	9.1 - 34.6
ASIAN/PACIFIC ISLANDER	103	1	1.0	0.1 - 6.1
NONE OF THE ABOVE (4)	7	2	28.6	5.1 - 69.7
				**********
TOTAL	242	40	16.5	12.2 - 21.9

⁽¹⁾ Data collected between the 1st quarter 1990 to the 1st quarter 1991;

⁽²⁾ Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation.

TABLE 25: HIV SEROPREVALENCE FOR 8LOOD ODNORS FROM THE SAN FRANCISCO BAY AREA BY YEAR OF ODNATION, MARCH 1985 - SEPTEMBER 1990 (1)

YEAR OF OONATION	TOTAL OONATIONS	NUM8ER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
1985	72,204	80	0.111	0.088 - 0.13
1986	86,168	40	0.046	0.034 - 0.06
1987	91,396	30	0.033	0.023 - 0.04
1988	90,192	23	0.026	0.017 - 0.03
1989	72,892	10	0.014	0.007 - 0.02
1990	56,408	6	0.011	0.004 - 0.02
TOTAL	469,260	189	0.040	0.035 - 0.04

TABLE 26: HIV SEROPREVALENCE FOR BLOOD ODNORS FROM THE SAN FRANCISCO BAY AREA 8Y ODNATION STATUS AND GENDER, OCTOBER 1, 1989 - SEPTEMBER 30, 1990 (1)

OONATION		TOTAL	SERO- TOTAL NUMBER(2) PREVALENCE						
STATUS	GENOER	OONATIONS	POSITIVE	RATE (%)	(95% C.I.)(3)				
FIRST-TIME	Male	9,616	4	0.042	0.013 - 0.114				
OONORS	Female	9,673	1	0.010	0.001 - 0.067				
REPEAT	Male	31,004	3	0.010	0.002 - 0.031				
OONORS	Female	27,165	2	0.007	0.001 - 0.030				
				*******					
TOTAL		77,458	10	0.013	0.007 - 0.025				

⁽¹⁾ Oata were provided courtesy of the Irwin Memorial 8lood Centers, San Francisco, Calif.;

⁽²⁾ Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (3) 95% Confidence Intervals, normal approximation method.

TABLE 27: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA
BY RACE/ETHNICITY, OCTOBER 1, 1989 - SEPTEMBER 30, 1990 (1)

RACE/ETHNICITY (	TOTAL CONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
WHITE	65,535	5	0.008	0.003 - 0.019
BLACK	3,215	2	0.062	0.011 - 0.251
LATINO	3,732	3	0.080	0.021 - 0.256
NONE OF THE ABOVE(4)	4,976	0	0.000	0.000 - 0.073
				:::::::::::::::::::::::::::::::::::::::
TOTAL	77,458	10	0.013	0.007 - 0.025

TABLE 28: HIV SEROPREVALENCE FOR BLOOO CONORS FROM THE SAN FRANCISCO BAY AREA BY AGE-GROUP, OCTOBER 1, 1989 - SEPTEMBER 30, 1990 (1)

AGE-GROUP (YEARS)			SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
19 AND UNOER	5,508	0	0.000	0.000 - 0.066
20 - 29	15,234	1	0.007	0.000 - 0.043
30 - 39	22,264	7	0.031	0.014 - 0.068
40 ANO OVER	34,452	2	0.006	0.001 - 0.023
*********	*********			
TOTAL	77,458	10	0.013	0.007 - 0.025

⁽¹⁾ Oata were provided courtesy of the Irwin Memorial Blood Centers, San Francisco, Ca.; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes Asian/Pacific Islanders, American Indians, Alaskan Natives, other race, and unknown race.

TABLE 29: HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENDER AND YEAR (1)(2)

		1985			1986			1987			1988			1989	
GENDER	N(3)	HIV+(4	) %(5)	N	HIV+	*	N	HIV+	×	N	HIV+	×	N	HIV+	*
MALE FEMALE	213 45	0	0.0	941 183	9	1.0	869 143	5 0	0.5	759 178	2	0.3	711 124	2	0.3
TOTAL	258	0	0.0	1124	10	0.9	1012	5	0.5	937	2	0.2	835	3	0.4

		1990		TOTAL				
GENDER	N	HIV+	*	N	HIV+	*		
MALE FEMALE	518 105	0	0.0	4011 778	18 2	0.4		
TOTAL	623	0	0.0	4789	20	0.4		

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC); (2) Data collected between October 1985 and December 1990; (3) Number tested; (4) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (5) Seroprevalence rate (%).

TABLE 30: HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENOER AND AGE GROUP (1)(2)

		MAL	.E		FEMALE			
AGE-GROUP (YEARS)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4
19 ANO UNOER 20 - 24 25 - 29 30 ANO OVER	1667 1261 650 433	2 4 5 7	0.1 0.3 0.B 1.6	0.0 - 0.5 0.1 - 0.9 0.3 - 1.9 0.7 - 3.5	279 248 130 121	0 1 1 0	0.0 0.4 0.8 0.0	0.0 - 0.5 0.1 - 0.9 0.3 - 1.9 0.7 - 3.5
TOTAL	4011	18	0.4	0.3 - 0.7	778	2	0.3	0.3 - 0.7

TABLE 31: HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO
BY GENOER AND RACE/ETHNICITY (1)(2)

	MALE					FEMALE			
RACE/ETHNICITY	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4	
WHITE	1391	9	0.6	0.3 - 1.3	287	2	0.7	0.1 - 2.8	
BLACK	773	7	0.9	0.4 - 1.9	188	0	0.0	0.0 - 1.9	
LATINO	415	1	0.2	0.0 - 1.5	72	0	0.0	0.0 - 4.9	
ASIAN/PACIFIC ISLANDER	1287	0	0.0	0.0 - 0.3	201	0	0.0	0.0 - 1.8	
NONE OF THE ABOVE(5)	145	1	0.7	0.0 - 4.4	30	0	0.0	0.0 - 11.1	
TOTAL	4011	18	0.4	0.3 - 0.7	778	2	0.3	0.0 - 1.0	

⁽¹⁾ Oata provided by the U.S. Oepartment of Oefense, and the Centers for Oisease Control (COC); (2) Data collected between October 1985 and Oecember 1990; (3) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (4) 95% Confidence Intervals, normal approximation method; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

SF P70 #58 7/91

## HIV SEROPREVALENCE REPORT

San Francisco Department of Public Health AIDS Office

July 1991

Vol. 2 No. 3

DOCUMENTS DEPT.

JUL 1 6 1991

S..., MALCISCO FUELIC LIBRARY

Contents

#### SPECIAL REPORT: FINDINGS FROM THE YOUNG MEN'S SURVEY (YMS)

HIV SEROPREVALENCE FOR PARTICIPANTS OF THE YOUNG MEN'S SURVEY
BY AGE GROUP AND RACE/ETHNICITY, SAN FRANCISCO, 1991 ......Page 1

#### CLINIC-BASED AND SCREENING SURVEYS

TABLE 1: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY GENDER AND TRANSMISSION CATEGORY, SAN FRANCISCO, 1989 - 1990Page 2
TABLE 2: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP, SAN FRANCISCO, 1989 - 1990
TABLE 3: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY, SAN FRANCISCO, 1989 - 1990
TABLE 4: HIV SEROPREVALENCE FOR HOMOSEXUAL AND BISEXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP, SAN FRANCISCO, 1989 - 1990Page 4
TABLE 5: HIV SEROPREVALENCE FOR HOMOSEXUAL AND BISEXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY, SAN FRANCISCO, 1989 - 1990Page 4
TABLE 6: HIV SEROPREVALENCE FOR HETEROSEXUAL MALES ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP, SAN FRANCISCO, 1989 - 1990Page 5
TABLE 7: HIV SEROPREVALENCE FOR HETEROSEXUAL MALES ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY, SAN FRANCISCO, 1989 - 1990Page 5
TABLE 8: HIV SEROPREVALENCE FOR HETEROSEXUAL FEMALES ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP, SAN FRANCISCO, 1989 - 1990Page 6
TABLE 9: HIV SEROPREVALENCE FOR HETEROSEXUAL FEMALES ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY, SAN FRANCISCO, 1989 - 1990Page 6
TABLE 10: HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY TRANSMISSION CATEGORY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990Page 7
TABLE 11: HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990Page 8
TABLE 12: HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990

BY TRANSMISSION CATEGORY, SAN FRANCISCO, 1990 - 1991
TABLE 14: HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY AGE - GROUP, SAN FRANCISCO, 1990 - 1991
TABLE 15: HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY RACE/ETHNICITY, SAN FRANCISCO, 1990 - 1991Page 10
TABLE 16: HIV SEROPREVALENCE FOR NEWBORN INFANTS AND THEIR MOTHERS FROM THE CITY AND COUNTY OF SAN FRANCISCO, 1988 - 1989
TABLE 17: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE TREATMENT IN SAN FRANCISCO BY AGE-GROUP, 1989 - 1991Page 12
TABLE 18: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE TREATMENT IN SAN FRANCISCO BY RACE/ETHNICITY, 1989 - 1991Page 12
TABLE 19: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE TREATMENT IN SAN FRANCISCO BY GENDER AND SEXUAL ORIENTATION, 1989 - 1991Page 13
TABLE 20: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE TREATMENT IN SAN FRANCISCO BY TREATMENT MODALITY, 1989 - 1991Page 13
TABLE 21: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) IN SAN FRANCISCO BY GENDER AND TRANSMISSION CATEGORY, 1990 - 1991Page 14
TABLE 22: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) IN SAN FRANCISCO BY ORIGIN OF BIRTH, 1990 - 1991
TABLE 23: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) IN SAN FRANCISCO BY AGE-GROUP, 1990 - 1991
TABLE 24: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) IN SAN FRANCISCO BY RACE/ETHNICITY, 1990 - 1991
TABLE 25: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY YEAR OF DONATION, MARCH 1985 - SEPTEMBER 1990Page 16
TABLE 26: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY DONATION STATUS AND GENDER, OCTOBER 1989 - SEPTEMBER 1990Page 16
TABLE 27: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY RACE/ETHNICITY, OCTOBER 1989 - SEPTEMBER 1990Page 17
TABLE 28: HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY AGE-GROUP, OCTOBER 1989 - SEPTEMBER 1990
TABLE 29: HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM SAN FRANCISCO BY GENDER AND YEAR, 1985 - 1990
TABLE 30: HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM SAN FRANCISCO BY GENDER AND AGE-GROUP, 1985 - 1990
TABLE 31: HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM SAN FRANCISCO BY GENDER AND RACE/ETHNICITY, 1985 - 1990Page 19
HIV SEROPREVALENCE REPORT is released on a quarterly basis by the San Francisco Department of Public Health AIDS Office, Surveillance

HIV SEROPREVALENCE REPORT is released on a quarterly basis by the San Francisco Department of Public Health AIDS Office, Surveillance Branch, 25 Van Ness Avenue, Suite 500, San Francisco, CA. 94102-6033, Phone (415) 554-9050. AIDS Office Director: Sandra R Hernandez, MD; AIDS Surveillance Branch Chief: George F Lemp, DrPH. Funding and technical support is provided by the Division of HIV/AIDS, Centers for Disease Control. Additional support is provided by the California Department of Health Services Office of AIDS.

HIV SEROPREVALENCE FOR PARTICIPANTS OF THE YOUNG MEN'S SURVEY BY AGE-GROUP, SAN FRANCISCO. 1991 (1)

AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
17 - 19 20 - 22 23 - 25	21 93 144	3 13 15	14.3 14.0 10.4	3.B - 37.4 7.9 - 23.1 6.1 - 16.9
TOTAL	25B	31	12.0	8.4 - 16.B

HIV SEROPREVALENCE FOR PARTICIPANTS OF THE YOUNG MEN'S SURVEY, BY RACE/ETHNICITY, SAN FRANCISCO, 1991 (1)

RACE/ETHNICITY	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
WHITE	13B	15	10.9	6.4 - 17.6
AFRICAN AMERICAN	35	В	22.9	11.0 - 40.6
LATINO	49	7	14.3	6.4 - 27.9
ASIAN/PACIFIC ISLANDER	33	0	0.0	0.0 - 10.2
NONE OF THE ABOVE (4)	3	1	33.3	1.B - B7.5
	-========	========		==========
TOTAL	258	31	12.0	8.4 - 16.B

(1) The Young Men's Survey (YMS) was a collaborative effort of the San Francisco Department of Public Health and the California Department of Health Services. The survey was conducted during the Spring of 1991 at seven gay identified dance clubs and bars in San Francisco. All male patrons were screened upon entry to the club and recruited if they identified themselves as San Francisco residents and under 25 years of age. A total of 501 men were eligible, of which 258 (51%) agreed to participate. Structured interviews were conducted and blood specimens were drawn on site. Specimens were tested for HIV and markers to Hepatitis B (HBsAG and HBcAB) and syphilis (VORL and MHA-TP); (2) All HIV positive specimens were repeatedly reactive by ELISA and confirmed by an IFA. Indeterminate HIV results were tested by a Western blot assay; (3) 95% Confidence Intervals. normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, or unknown race.

TABLE 1: HIV SEROPREVALENCE FOR CLIENTS ATTENOING A SEXUALLY TRANSMITTED DISEASE CLINIC BY GENOER, TRANSMISSION CATEGORY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (1)

GENOER ANO TRANSMISSION CATEGORY		198	9 SURVEY		1990 SURVEY				
	NUMBER TESTEO	NUM8ER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	
MALE									
Homosexual/8isexual	446	226	50.7	45.9 - 55.4	623	269	43.2	39.3 - 47.2	
Homosexual/Bisexual, IVOU	119	82	68.9	59.7 - 76.9	89	55	61.8	50.9 - 71.7	
Heterosexual IVOU	99	12	12.1	6.7 - 20.6	101	8	7.9	3.7 - 15.5	
Sex Partner at Risk for HIV	73	3	4.1	1.1 - 12.3	103	. 9	8.7	4.3 - 16.4	
Blood Recipient (4)	23	1	4.3	0.2 - 24.0	9	1	11.1	0.6 - 49.3	
Heterosexual (5)	1020	14	1.4	0.8 - 2.4	1372	29	2.1	1.4 - 3.1	
Unknown Risk	8	0	0.0	0.0 - 33.7	184	24	13.0	8.7 - 19.0	
SU8-TOTAL MALE	1788	338	18.9	17.1 - 20.8	2481	395	15.9	14.5 - 17.4	
FEMALE									
Heterosexual IVOU	55	5	9.1	3.4 - 20.7	59	5	8.5	3.2 - 19.4	
Sex Partner at Risk for HIV	58	1	1.7	0.1 - 10.5	55	1	1.8	0.1 - 11.0	
8lood Recipient (4)	11	1	9.1	0.5 - 42.9	6	1	16.7	0.9 - 63.5	
Heterosexual (5)	380	3	0.8	0.2 - 2.5	538	13	2.4	1.3 - 4.2	
Unknown Risk	5	0	0.0	0.0 - 46.7	21	0	0.0	0.0 - 15.3	
SUB-TOTAL FEMALE	509	10	2.0	1.0 - 3.7	679	20	2.9	1.9 - 4.6	
			**********			415	13.1	12.0 - 14.4	

⁽¹⁾ The 1989 and 1990 unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons with a history of blood transfusion(s) between

January 1977 - March 1985; (5) Self-identified heterosexuals with no identified risk.

TABLE 2: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP AND YEAR OF SURVEY.

SAN FRANCISCO, 1989 - 1990 (1)

		198	9 SURVEY		1990 SURVEY			
AGE-GROUP (YEARS)	NUMBER TESTEO	NUMBER(2) POS1TIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
10 AND HNOED	202	_	1.2	0.3.4.0	0.70		2.0	0.0 5.0
19 ANO UNOER 20 - 24	223	3	1.3	0.3 - 4.2	272	6	2.2	0.9 - 5.0
	526	35	6.7	4.7 - 9.2	704	34	4.8	3.4 - 6.8
25 - 29	550	93	16.9	13.9 - 20.4	781	104	13.3	11.1 - 15.9
30 - 34	403	88	21.8	18.0 - 26.3	566	113	20.0	16.8 - 23.5
35 - 39	284	73	25.7	20.8 - 31.3	379	89	23.5	19.4 - 28.1
40 - 44	158	27	17.1	11.8 - 24.1	222	38	17.1	12.5 - 22.9
45 ANO OVER	153	29	19.0	13.3 - 26.3	226	31	13.7	9.6 - 19.1
UNKNOWN	0	0			10	0	0.0	0.0 - 28.5
	=======		=======================================					=======================================
TOTAL	2297	348	15.2	13.7 - 16.7	3160	415	13.1	12.0 - 14.4

TABLE 3: HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (1)

	1989 SURVEY					1990 SURVEY			
RACE/ETHNICITY	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	
WHITE	916	209	22.8	20.2 - 25.7	1204	218	18.1	16.0 - 20.4	
AFRICAN AMERICAN	828	76	9.2	7.3 - 11.4	1172	110	9.4	7.8 - 11.2	
LATINO	371	52	14.0	10.7 - 18.1	560	68	12.1	9.6 - 15.2	
ASIAN/PACIFIC ISLANDER	138	6	4.3	1.8 - 9.6	181	13	7.2	4.0 - 12.2	
NONE OF THE ABOVE (4)	44	5	11.4	4.3 - 25.4	43	6	14.0	5.8 - 28.6	
*	========							=======================================	
TOTAL	2297	348	15.2	13.7 - 16.7	3160	415	13.1	12.0 - 14.4	

⁽¹⁾ The 1989 and 1990 unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STO episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 4: HIV SEROPREVALENCE FOR HOMOSEXUAL AND 8ISEXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC 8Y AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (1)

	1989 SUR <b>V</b> EY					1990 SURVEY			
AGE-GROUP (YEARS)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUM8ER TESTEO	NUM8ER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	
19 ANO UNOER	2	0	0.0	0.0 - 75.2	14	2	14.3	2.5 - 43.8	
20 - 24	62	26	41.9	29.8 - 55.1	80	27	33.8	23.8 - 45.3	
25 - 29	138	85	61.6	52.9 - 69.6	174	80	46.0	38.5 - 53.7	
30 - 34	132	77	58.3	49.4 - 66.7	167	87	52.1	44.3 - 59.8	
35 - 39	113	68	60.2	50.5 - 69.1	128	69	53.9	44.9 - 62.7	
40 - 44	57	25	43.9	31.0 - 57.6	61	30	49.2	36.3 - 62.2	
45 ANO OVER	61	27	44.3	31.8 - 57.5	87	29	33.3	23.8 - 44.3	
UNKNOWN	0	0			1	0	0.0	0.0 - 92.7	
TOTAL	 565	308	54.5	50.3 - 58.7	712	324	45.5	41.8 - 49.2	

TABLE 5: HIV SEROPREVALENCE FOR HOMOSEXUAL AND BISEXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC 8Y RACE/ETHNICITY, SAN FRANCISCO, 1989 - 1990 (1)

		198	89 SURVEY		1990 SURVEY			
	NUM8ER	NUM8ER(2)	SERO- PREVALENCE		NUM8ER	NUM8ER(2)	SERO- PREVALENCE	
RACE/ETHNICITY	TESTE0	POSITIVE	RATE (%)	(95% C.I.)(3)	TESTEO	POSITIVE	RATE (%)	(95% C.I.)(3)
WHITE	379	195	51.5	46.3 - 56.6	453	188	41.5	36.9 - 46.2
AFRICAN AMERICAN	87	56	64.4	53.3 - 74.1	117	74	63.2	53.8 - 71.8
LATINO	78	48	61.5	49.8 - 72.1	106	50	47.2	37.5 - 57.1
ASIAN/PACIFIC ISLANOER	14	4	28.6	9.6 - 58.0	28	8	28.6	14.0 - 48.9
NONE OF THE ABOVE (4)	7	5	71.4	30.3 - 94.9	8	4	50.0	17.5 - 82.5
					<b>.</b>			
TOTAL	565	308	54.5	50.3 - 58.7	712	324	45.5	41.8 - 49.2

⁽¹⁾ The 1989 and 1990 unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STO episode Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 6: HIV SEROPREVALENCE FOR HETEROSEXUAL MALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (2)

	1989 SURVEY							1990 SURVEY .			
AGE-GROUP (YEARS)	NUMBER TESTEO	NUM8ER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)			
19 ANO UNOER	127	1	0.B	0.0 - 5.0	155	2	1.3	0.2 - 5.1			
20 - 24	316	3	0.9	0.2 - 3.0	35B	4	1.1	0.4 - 3.0			
25 - 29	271	1	0.4	0.0 - 2.4	3B9	10	2.6	1.3 - 4.B			
30 - 34	1B3	8	4.4	2.0 - 8.7	230	11	4.B	2.5 - B.6			
35 - 39	96	3	3.1	0.8 - 9.5	159	8	5.0	2.4 - 10.0			
40 - 44	62	0	0.0	0.0 - 5.6	9B	3	3.1	0.B - 9.3			
45 ANO OVER	61	2	3.3	0.6 - 12.4	91	1	1.1	0.1 - 6.B			
UNKNOWN	0	0			4	0	0.0	0.0 - 53.5			
					[						
TOTAL	1116	18	1.6	1.0 - 2.6	1484	39	2.6	1.9 - 3.6			

TABLE 7: HIV SEROPREVALENCE FOR HETEROSEXUAL MALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY, SAN FRANCISCO, 1989 - 1990 (2)

		198	B9 SURVEY			1990 SURVEY			
RACE/ETHNICITY	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	
WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANOER NONE OF THE ABOVE (5)	323 482 213 79 19	5 10 2 1	1.5 2.1 0.9 1.3 0.0	0.6 - 3.8 1.1 - 3.9 0.2 - 3.7 0.1 - 7.8 0.0 - 16.7	413 684 286 82 19	11 17 9 1	2.7 2.5 3.1 1.2 5.3	1.4 - 4.9 1.5 - 4.0 1.5 - 6.1 0.1 - 7.5 0.3 - 2B.1	
TOTAL	1116	1B	1.6	1.0 - 2.6	1484	39	2.6	1.9 - 3.6	

⁽¹⁾ Includes heterosexuals with a sex partner(s) at risk for HIV, heterosexuals with a history of blood transfusion(s), and heterosexuals with no identified risk; (2) The 1989 and 1990 unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STO episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (4) 95% Confidence Intervals, normal approximation method; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 8: HIV SEROPREVALENCE FOR HETEROSEXUAL FEMALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC 8Y AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (2)

AGE-GROUP (YEARS)		198	89 SURVEY			1990 SURVEY			
	NUM8ER TESTEO	NUM8ER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	
I9 ANO UNOER	87	2	2.3	0.4 - 8.8	88	2	2.3	0.4 - 8.7	
20 - 24	123	2	1.6	0.3 - 6.3	195	1	0.5	0.0 - 3.3	
25 - 29	101	1	1.0	0.1 - 6.2	139	4	2.9	0.9 - 7.7	
30 - 34	53	0	0.0	0.0 - 6.5	80	4	5.0	1.6 - 13.0	
35 - 39	42	0	0.0	0.0 - 8.1	43	3	7.0	1.8 - 20.1	
40 - 44	22	0	0.0	0.0 - 14.7	28	1	3.6	0.2 - 20.2	
45 ANO OVER	21	0	0.0	0.0 - 15.3	22	. 0	0.0	0.0 - 14.7	
UNKNOWN	0	0			4	0	0.0	0.0 - 53.5	
TOTAL	449	5	1.1	0.4 - 2.7	599	15	2.5	1.5 - 4.2	

TABLE 9: HIV SEROPREVALENCE FOR HETEROSEXUAL FEMALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC 8Y RACE/ETHNICITY, SAN FRANCISCO, 1989 - 1990 (2)

SERO- ER(3) PREVALENI TIVE RATE (%			NUM8ER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)
0 1.4	02 - 53	175	_		
2 1.4		3   175	4	2.3	0.7 - 6.1
3 1.6	0.4 - 4.9	264	9	3.4	1.7 - 6.6
0 0.0	0.0 - 5.7	7   100	1	1.0	0.1 - 6.2
0 0.0	0.0 - 8.5	5 53	1	1.9	0.1 - II.4
0.0	0.0 - 30.9	7	0	0.0	0.0 - 37.2
					1.5 - 4.2
	5 1.1	5 1.1 0.4 - 2.7	5 1.1 0.4 - 2.7 599	5 1.1 0.4 - 2.7 599 15	5 1.1 0.4 - 2.7 599 15 2.5

⁽¹⁾ Includes heterosexuals with a sex partner(s) at risk for HIV, heterosexuals with a history of blood transfusion(s), and heterosexuals with no identified risk; (2) The 1989 and 1990 unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STO episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (4) 95% Confidence Intervals, normal approximation method; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 10: HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY TRANSMISSION CATEGORY AND YEAR OF SURVEY. SAN FRANCISCO, 1989 - 1990 (1)

		198	9 SURVEY			19	90 SURVEY	
TRANSMISSION CATEGORY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
Heterosexual IVDU Sex Partner at Risk for HIV Blood Recipient (4)	0 0 0	0 0 0			20 24 11	1 0 0	5.0 0.0 0.0	0.3 - 26.9 0.0 - 13.6 0.0 - 26.4
Heterosexual (5) Unknown Risk (6)	0 1266	0 4	0.3	0.1 - 0.9	1313 B	1 0	0.1	0.0 - 0.5 0.0 - 33.7
TOTAL	1266	4	0.3	0.1 - 0.9	1376	2	0.1	0.0 - 0.6

⁽¹⁾ The 1989 and 1990 unlinked (blinded) surveys were drawn from women seeking family planning services. Specimens were collected from inital and annual visits, and tested for HIV after all personal identifiers had been removed;

⁽²⁾ All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay;

^{(3) 95%} Confidence Intervals, normal approximation; (4) Includes persons with a history of blood transfusion(s) between January 1977 - March 1985; (5) Self-identified heterosexuals with no identified risk;

^{(6) 1989} unlinked survey did not collect risk information.

TABLE 11: HIV SEROPREVALENCE FOR WOMEN ATTENOING A FAMILY PLANNING CLINIC 8Y AGE-GROUP AND YEAR OF SURVEY.

SAN FRANCISCO, 1989 - 1990 (1)

		1989 SURVEY				1990 SURVEY			
AGE-GROUP (YEARS)	NUMBER TESTED	NUM8ER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTEO	NUM8ER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	
19 AND UNOER	73	0	0.0	0.0 - 4.8	93	0	0.0	0.0 - 3.8	
20 - 24	420	1	0.2	0.0 - 1.5	474	0	0.0	0.0 - 0.8	
25 - 29	414	1	0.2	0.0 - 1.6	401	0	0.0	0.0 - 0.9	
30 - 34	226	2	0.9	0.2 - 3.5	243	1	0.4	0.0 - 2.6	
35 - 39	105	0	0.0	0.0 - 3.4	97	0	0.0	0.0 - 3.6	
40 - 44	18	0	0.0	0.0 - 17.5	34 .	. 1	2.9	0.2 - 17.1	
45 AND OVER	7	0	0.0	0.0 - 37.2	8	0	0.0	0.0 - 33.7	
UNKNOWN	3	0	0.0	0.0 - 62.6	26	0	0.0	0.0 - 12.6	
TOTAL	1266	4	0.3	0.1 - 0.9	1376		0.1	0.0 - 0.6	

TABLE 12: HIV SEROPREVALENCE FOR WOMEN ATTENOING FAMILY PLANNING CLINICS BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1990 (1)

		198	39 SURVEY		1990 SURVEY			
RACE/ETHNICITY	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUM8ER TESTED	NUM8ER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
WHITE	122	1	0.8	0.0 - 5.2	126	1	0.8	0.0 - 5.0
AFRICAN AMERICAN	154	1	0.6	0.0 - 4.1	145	0	0.0	0.0 - 2.5
LATINA	810	2	0.2	0.0 - 1.0	908	0	0.0	0.0 - 0.4
ASIAN/PACIFIC ISLANOER	149	0	0.0	0.0 - 2.4	166	1	0.6	0.0 - 3.8
NONE OF THE ABOVE (4)	31	0	0.0	0.0 - 10.8	31	0	0.0	0.0 - 10.8
TOTAL	1266	4	0.3	0.1 - 0.9	1376	2	0.1	0.0 - 0.6

⁽¹⁾ The 1989 and 1990 unlinked (blinded) surveys were drawn from women seeking family planning services. Specimens were collected from all initial and annual visits and tested for HIV after all personal identifiers had been removed;

⁽²⁾ All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay;

^{(3) 95%} Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 13: HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ASORTION CLINIC BY TRANSMISSION CATEGORY, SAN FRANCISCO, 1990-1991 (1)

TRANSMISSION CATEGORY	NUM8ER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
Heterosexual IVDU	13	3	23.1	6.2 - 54.0
Sex Partner at Risk for HIV	7	0	0.0	0.0 - 37.2
Heterosexual (5)	746	3	0.4	0.1 - 1.3
Unknown Risk	9	0	0.0	0.0 - 30.9
TOTAL	775	6	0.8	0.3 - 1.8

⁽¹⁾ This 1990-91 unlinked (blinded) survey was drawn from routine blood specimens from women seeking abortions. Survey specimens were tested for HIV after all personal identifiers had been removed; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay;

^{(3) 95%} Confidence Intervals, normal approximation; (4) Includes persons with a history of blood transfusion(s) between January 1977 - March 1985;

⁽⁵⁾ Self-identified heterosexuals with no identified risk.

TABLE 14: HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY AGE-GROUP, SAN FRANCISCO, 1990-1991 (1)

AGE-GROUP (YEARS)	NUM8ER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
19 AND UNDER	125	0	0.0	0.0 - 2.8
20 - 24	238	1	0.4	0.0 - 2.7
25 - 29	197	2	1.0	0.2 - 4.0
30 - 34	122	2	1.6	0.3 - 6.4
35 - 39	65	1	1.5	0.1 - 9.4
40 - 44	19	0	0.0	0.0 - 16.7
45 AND OVER	0	0		·
UNKNOWN	9	0	0.0	0.0 - 30.9
TOTAL	775	6	0.8	0.3 - 1.8

TABLE 15: HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY RACE/ETHNICITY, SAN FRANCISCO, 1990-1991 (1)

73 195	1 3	1.4	0.1 - 8.4
	_		
195	3	1 5	0.4.4.0
		1.5	0.4 - 4.8
404	2	0.5	0.1 - 2.0
88	0	0.0	0.0 - 4.0
15	0	0.0	0.0 - 20.5
775	6	0.8	0.3 - 1.8

⁽¹⁾ This 1990-91 unlinked (blinded) survey was drawn from routine blood specimens from women seeking abortions. Survey specimens were tested for HIV after all personal identifiers had been removed; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TABLE 16: HIV SEROPREVALENCE FOR NEWBORN INFANTS AND THEIR MOTHERS, SAN FRANCISCO, 1988 - 1989 (1)

			198	8 SURVEY		1989 SURVEY (2)			
	(	NUM8ER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUM8ER TESTEO	NUM8ER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)
AGE-GROUP(YEARS)									
20 - 24		274	1	0.363	0.019 - 2.017				
30 - 34		433	1	0.231	0.121 - 1.486				
OVER 35		269	1	0.372	0.194 - 2.379				
UNKNOWN		990	2	0.202	0.035 - 0.811				
RACE/ETHNICITY									
8LACK		241	2	0.830	0.144 - 3.289				
HISPANIC		414	3	0.725	0.187 - 2.285				
TOTAL - SAN FRANC	CISCO	2,565	5	0.195	0.072 - 0.483	2,547	4	0.157	0.050 - 0.431
TOTAL - 8AY AREA	(5)	20,977	27	0.129	0.087 - 0.190	21,217	25	0.118	0.078 - 0.177
TOTAL - STATEWIDE	E	135,762	101	0.074	0.061 - 0.091	144,284	92	0.064	0.052 - 0.079

⁽I) Data courtesy of the California Department of Health Services Office of AIOS. Specimens for this survey of newborn infants (women giving birth) are drawn from the genetic diseases screening program. Antibodies in a newborn reflect the infection status of the mother and not necessarily of the child. (2) Demographic breakdown of the 1989 survey is not available; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (4) 95% Confidence Intervals, normal approximation; (5) Includes Alameda, Contra Costa, Marin, San Francisco, San Mateo and Santa Clara counties.

TABLE 17: HIV SEROPREVALENCE FOR INTRAVENOUS ORUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY AGE-GROUP (1)

			SERO-	
	NUMBER	NUMBER(2)	PREVALENCE	
AGE-GROUP (YEARS)	TESTEO	POSITIVE	RATE (%)	(95% C.I.)(3)
19 AND UNDER	14	1	7.1	0.4 - 35.8
20 - 24	120	3	2.5	0.6 - 7.7
25 - 29	256	15	5.9	3.4 - 9.7
30 - 34	359	26	7.2	4.9 - 10.6
35 - 39	550	57	10.4	8.0 - 13.3
40 - 44	423	40	9.5	6.9 - 12.8
45 ANO OVER	283	30	10.6	7.4 - 14.9
MISSING	34	3	8.8	2.3 - 24.8
TOTAL	2039	175	8.6	7.4 - 9.9

TABLE 18: HIV SEROPREVALENCE FOR INTRAVENOUS DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY RACE/ETHNICITY (1)

			CEDO	
	NUMBER	NUMBER(2)	SERO- PREVALENCE	
RACE/ETHNICITY	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3)
WHITE	1235	44	3.6	2.6 - 4.8
AFRICAN AMERICAN	502	108	21.5	18.1 - 25.4
LATINO	233	18	7.7	4.8 - 12.1
ASIAN/PACIFIC ISLANDER	45	4	8.9	2.9 - 22.1
NONE OF THE ABOVE (4)	24	1	4.2	0.2 - 23.1
TOTAL	2039	175	8.6	7.4 - 9.9

⁽¹⁾ Data collected between the 4th quarter of 1989 and the 2nd quarter of 1991; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, unknown race, and missing race.

TABLE 19: HIV SEROPREVALENCE FOR INTRAVENOUS ORUG USERS ENTERING METHAOONE
TREATMENT PROGRAMS IN SAN FRANCISCO BY GENDER AND SEXUAL ORIENTATION (1)

			SERO-	
GENDER ANO	NUMBER	NUMBER(2)	PREVALENCE	
SEXUAL ORIENTATION	TESTE0	POSITIVE	RATE (%)	(95% C.1.)(3)
MALE				
Homosexual/Bisexual	47	15	31.9	19.5 - 47.3
Heterosexual	1263	106	8.4	7.0 - 10.1
SUB-TOTAL: MALE	1310	121	9.2	7.8 - 11.0
FEMALE				
Lesbian/Bisexual	33	4	12.1	4.0 - 29.1
Heterosexual	655	47	7.2	5.4 - 9.5
SUB-TOTAL: FEMALE	688	51	7.4	5.6 - 9.7
MISSING GENDER ANO/OR	41	3	7.3	1.9 - 21.0
SEXUAL ORIENTATION				
=======================================				
TOTAL	2039	175	8.6	7.4 - 9.9

TABLE 20: HIV SEROPREVALENCE FOR INTRAVENOUS ORUG USERS ENTERING METHADONE
TREATMENT PROGRAMS IN SAN FRANCISCO BY TREATMENT MODALITY (1)

TREATMENT MODALITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
OETOXIF1CAT1ON	1710	140	8.2	7.0 - 9.6
MA1NTENANCE	322	35	10.9	7.8 - 14.9
M1SS1NG	7	0	0.0	0.0 - 37.2
TOTAL	2039	175	8.6	7.4 - 9.9

⁽¹⁾ Data collected between the 4th quarter of 1989 and the 2nd quarter of 1991; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method.

TABLE 21: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB)
AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY GENDER AND
TRANSMISSION CATEGORY (1)

	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
MALE				
Homosexual/Bisexual	33	26	7B.B	60.6 - 90.4
Homosexual/Bisexual, IVOU	16	13	B1.2	53.7 - 95.0
Heterosexual IVOU	17	3	17.6	4.7 - 44.2
Heterosexual (4)	123	7	5.7	2.5 - 11.B
Unknown Risk	12	0	0.0	0.0 - 24.6
SUB-TOTAL MALE	201	49	24.4	18.7 - 31.0
FEMALE				
Heterosexual IVOU	5	1	20.0	1.1 - 70.1
Heterosexual (4)	52	0	0.0	0.0 - 6.6
Unknown Risk	10	0	0.0	0.0 - 2B.5
SUB-TOTAL FEMALE	67	1	1.5	0.1 - 9.1
TOTAL	26B	50	1B.7	14.3 - 24.0

TABLE 22: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB)
AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY ORIGIN OF BIRTH (1)

	NUMBER	NUMBER(2)	SERO- PREVALENCE	
ORIGIN OF BIRTH	TESTEO	POSITIVE	RATE (%)	(95% C.I.)(3)
BORN IN USA	115	43	37.4	2B.7 - 46.9
BORN OUTSIOE USA	153	7	4.6	2.0 - 9.6
			.======================================	
TOTAL	26B	50	18.7	14.3 - 24.0

⁽¹⁾ Survey of Risk Behaviors (SRB). Oata collected between the 1st quarter of 1990 to the 2nd quarter 1991; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes self-identified heterosexuals with no identified risk, persons with a history of blood transfusion(s) or with a bleeding disorder, and persons with a sexual partner(s) at risk for HIV/AIDS.

TABLE 23: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB)
AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY AGE-GROUP (1)

	NUMBER	NUMBER(2)	SERO- PREVALENCE	
AGE-GROUP (YEARS)	TESTEO	POSITIVE	RATE (%)	(95% C.I.)(3)
19 ANO UNOER	7	0	0.0	0.0 - 37.2
20 - 24	14	3	21.4	5.7 - 51.2
25 - 29	37	8	21.6	10.4 - 38.7
30 - 34	43	В	18.6	B.9 - 33.9
35 - 39	32	11	34.4	19.2 - 53.2
40 - 44	35	12	34.3	19.7 - 52.3
45 AND OVER	100	8	B.0	3.8 - 15.6
TOTAL	26B	50	18.7	14.3 - 24.0

TABLE 24: HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB)
AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY RACE/ETHNICITY (1)

			SERO-		
RACE/ETHNICITY	NUMBER TESTEO	NUMBER(2) POSITIVE	PREVALENCE RATE (%)	(95% C.I.)(3)	
WHITE	51	21	41.2	27.9 - 55.8	
AFRICAN AMERICAN	52	17	32.7	20.7 - 47.2	
LATINO	51	9	17.6	B.9 - 31.4	
ASIAN/PACIFIC ISLANOER	107	1	0.9	0.0 - 5.B	
NONE OF THE ABOVE (4)	7	2	28.6	5.1 - 69.7	
			=======================================		
TOTAL	26B	50	1B.7	14.3 - 24.0	

⁽¹⁾ Survey of Risk Behaviors (SRB). Oata collected between the 1st quarter of 1990 and the 2nd quarter 1991; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method.

TABLE 25: HIV SEROPREVALENCE FOR BLOOO OONORS FROM THE SAN FRANCISCO BAY AREA BY YEAR OF OONATION, MARCH 1985 - SEPTEMBER 1990 (1)

			SERO-	
YEAR OF	TOTAL	NUMBER(2)	PREVALENCE	
OONATION	OONATIONS	POSITIVE	RATE (%)	(95% C.I.)(3)
19B5	72,204	80	0.111	0.0BB - 0.13
19B6	86,16B	40	0.046	0.034 - 0.06
19B7	91,396	30	0.033	0.023 - 0.04
19BB	90,192	23	0.026	0.017 - 0.03
19B9	72,B92	10	0.014	0.007 - 0.02
1990	56,408	6	0.011	0.004 - 0.02
	=======================================			
TOTAL	469,260	189	0.040	0.035 - 0.04

TABLE 26: HIV SEROPREVALENCE FOR BLOOO OONORS FROM THE SAN FRANCISCO BAY AREA
BY OONATION STATUS ANO GENOER, OCTOBER 1, 1989 - SEPTEMBER 30, 1990 (1)

OONATION STATUS	GENOER	TOTAL OONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
FIRST-TIME	Male	9,616	4	0.042	0.013 - 0.114
OONORS	Female	9,673	1	0.010	0.001 - 0.067
REPEAT	Male	31,004	3	0.010	0.002 - 0.031
OONORS	Female	27,165	2	0.007	0.001 - 0.030
					*************
TOTAL		77,458	10	0.013	0.007 - 0.025

⁽¹⁾ Oata were provided courtesy of the Irwin Memorial Blood Centers, San Francisco, Calif.;

⁽²⁾ Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (3) 95% Confidence Intervals, normal approximation method.

TABLE 27: HIV SEROPREVALENCE FOR BLOOD ODNORS FROM THE SAN FRANCISCO BAY AREA BY RACE/ETHNICITY, OCTOBER 1, 1989 - SEPTEMBER 30, 1990 (1)

			SERO-		
	TOTAL	NUMBER(2)	PREVALENCE		
RACE/ETHNICITY	OONATIONS	POSITIVE	RATE (%)	(95% C.I.)(3)	
WHITE	65,535	5	0.008	0.003 - 0.019	
BLACK	3,215	2	0.062	0.011 - 0.25	
LATINO	3,732	3	0.080	0.021 - 0.250	
NONE OF THE ABOVE (4	4,976	0	0.000	0.000 - 0.073	
=======================================				*******	
TOTAL	77,458	10	0.013	0.007 - 0.02	

TABLE 28: HIV SEROPREVALENCE FOR BLOOD ODNORS FROM THE SAN FRANCISCO BAY AREA BY AGE-GROUP, OCTOBER 1, 1989 - SEPTEMBER 30, 1990 (1)

			SERO-	
AGE-GROUP	TOTAL	NUMBER(2)	PREVALENCE	
(YEARS)	OONATIONS	POSITIVE	RATE (%)	(95% C.I.)(3)
<del></del>				
19 ANO UNOER	5,508	0	0.000	0.000 - 0.066
20 - 29	15,234	1	0.007	0.000 - 0.043
30 - 39	22,264	7	0.031	0.014 - 0.068
40 ANO OVER	34,452	2	0.006	0.001 - 0.023
		=======================================		
TOTAL	77,458	10	0.013	0.007 - 0.025

⁽¹⁾ Oata were provided courtesy of the Irwin Memorial Blood Centers, San Francisco, Ca.; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes Asian/Pacific Islanders, American Indians, Alaskan Natives, other race, and unknown race.

TABLE 29: HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENOER AND YEAR (1)(2)

		1985			1986			1987			1988			1989	
GENDER	N(3)	HIV+(4	4) %(5)	N	HIV+	%									
MALE FEMALE	213 45	0	0.0	941 183	9	1.0	869 143	5	0.5	759 178	2	0.3	711 124	2	0.3
TOTAL	258	0	0.0	1124	10	0.9	1012	5	0.5	937	. 2	0.2	835	3	0.4

	1990			1991			TOTAL		
GENOER	N	HIV+	%	N	HIV+	%	N	HIV+	%
MALE FEMALE	521 105	0	0.0	100 16	0	0.0	4114 794	18 2	0.4
TOTAL	626	0	0.0	116	0	0.0	4908	20	0.4

⁽¹⁾ Oata provided by the U.S. Oepartment of Oefense, and the Centers for Oisease Control (COC); (2) Data collected between October 1985 and March 1991; (3) Number tested; (4) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (5) Seroprevalence rate (%).

TABLE 30: HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENOER AND AGE GROUP (1)(2)

		MAL	.E		FEMALE				
AGE-GROUP (YEARS)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	
19 ANO UNOER	1700	2	0.1	0.0 - 0.5	2B6	0	0.0	0.0 - 0.5	
20 - 24	1296	4	0.3	0.1 - 0.8	254	1	0.4	0.1 - 0.8	
25 - 29	661	5	0.B	0.3 - 1.9	131	1	0.B	0.3 - 1.9	
30 ANO OVER	457	7	1.5	0.7 - 3.3	123	0	0.0	0.7 - 3.3	
				<b>= 2 2 3 3 3 3 3 3 3 3 3 3</b>					
TOTAL	4114	18	0.4	0.3 - 0.7	794	2	0.3	0.3 - 0.7	

TABLE 31: HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENORR AND RACE/ETHNICITY (1)(2)

		MAL	.E		FEMALE			
RACE/ETHNICITY	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)
WHITE	1433	9	0.6	0.3 - 1.2	291	2	0.7	0.1 - 2.7
BLACK	7B5	7	0.9	0.4 - 1.9	190	0	0.0	0.0 - 1.9
LATINO	429	1	0.2	0.0 - 1.5	73	0	0.0	0.0 - 4.B
ASIAN/PACIFIC ISLANDER	1315	0	0.0	0.0 - 0.3	20B	0	0.0	0.0 - 1.7
NONE OF THE ABOVE(5)	152	1	0.7	0.0 - 4.2	32	0	0.0	0.0 - 10.5
	===========	=========	=======================================	=======================================				
TOTAL	4114	18	0.4	0.3 - 0.7	794	2	0.3	0.0 - 1.0

⁽¹⁾ Oata provided by the U.S. Oepartment of Oefense, and the Centers for Oisease Control (COC); (2) Oata collected between October 1985 and Oecember 1990; (3) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (4) 95% Confidence Intervals, normal approximation method; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

5. F. DEPARTMENT OF PUBLIC HEALTH AIDS OFFICE-BURVEILLANCE BRANCH 25 VAN NESS AVENUE, 8TH FLOOR SAN FRANCISCO, CA 94102

# P70 #53 10/91

## HIV SEROPREVALENCE REPORT

### San Francisco Department of Public Health AIDS Office

October 1991

Vol. 2 No. 4

#### Contents

DOCUMENTS DEPT.

### FINDINGS FROM THE YOUNG MEN'S SURVEY (YMS)

NOV 1 8 1991

HIV SEROPREVALENCE FOR PARTICIPANTS BY AGE-GROUP AND RACE/ETHNICITY SAM TRANSISCO HIV SEROPREVALENCE FOR PARTICIPANTS BY NUMBER AND GENDER OF SEXUAL PARTICES	Page 1
HIV SEROPREVALENCE FOR PARTICIPANTS BY NUMBER AND GENDER OF SEXUAL PARTNERS	Page 2
HIV SEROPREVALENCE FOR PARTICIPANTS BY HISTORY OF RECEPTIVE ANAL INTERCOURSE	Page 3
HIV SEROPREVALENCE FOR PARTICIPANTS BY HISTORY OF INSERTIVE ANAL INTERCOURSE	Page 4

#### SURVEY OF CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC: 1989 - 1991

SEROPREVALENCE FOR CLIENTS ATTENDING AN STD CLINIC BY GENDER AND TRANSMISSION CATEGORY Page 5
SEROPREVALENCE FOR CLIENTS ATTENDING AN STD CLINIC BY AGE-GROUP
SEROPREVALENCE FOR CLIENTS ATTENDING AN STD CLINIC BY RACE/ETHNICITY
SEROPREVALENCE FOR HOMOSEXUAL AND BISEXUAL MEN ATTENDING AN STD CLINIC BY AGE-GROUP
SEROPREVALENCE FOR HOMOSEXUAL AND BISEXUAL MEN ATTENDING AN STD CLINIC BY RACE/ETHNICITY Page 9
SEROPREVALENCE FOR HETEROSEXUAL MALES ATTENDING AN STD CLINIC BY AGE-GROUP
SEROPREVALENCE FOR HETEROSEXUAL MALES ATTENDING AN STD CLINIC BY RACE/ETHNICITY
SEROPREVALENCE FOR HETEROSEXUAL FEMALES ATTENDING AN STD CLINIC BY AGE-GROUP
SEROPREVALENCE FOR HETEROSEXUAL FEMALES ATTENDING AN STD CLINIC BY RACE/ETHNICITY

#### SURVEYS OF WOMEN OF REPRODUCTIVE AGE: FAMILY PLANNING AND ABORTION CLINIC CLIENTS

HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY TRANSMISSION CATEGORY	Page	14
HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY AGE-GROUP	Page	15
HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY RACE/ETHNICITY	Page	16
HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY TRANSMISSION CATEGORY	Page	17
HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY AGE-GROUP	Page	18
HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY RACE/ETHNICITY	Page	18

#### SURVEY OF CHILDBEARING WOMEN IN SAN FRANCISCO, 1989 - 1990

HIV SEROPREVALENCE FOR NEWBORN INFANTS AND THEIR MOTHERS BY AGE - GROUP AND RACE/ETHNICITY ..... Page 19

#### SURVEY OF INJECTION DRUG USERS (IDUs) ENTERING METHADONE TREATMENT PROGRAMS

HIV SEROPREVALENCE FOR IDUS ENTERING METHADONE TREATMENT BY AGE-GROUP AND RACE/ETHNICITY	Page	20
HIV SEROPREVALENCE FOR IDUS ENTERING METHADONE TREATMENT BY GENDER AND SEXUAL ORIENTATION	. Page	2
HIV SEROPREVALENCE FOR IDUS ENTERING METHADONE TREATMENT BY TREATMENT MODALITY	Page	21
HIV SEROPREVALENCE FOR IDUS ENTERING METHADONE TREATMENT BY OUARTER AND YEAR OF ENTRY	Page	22

# 

HIV SEROPREVALENCE REPORT is released on a quarterly basis by the San Francisco Department of Public Health AIDS Office, Surveillance Branch, 25 Van Ness Avenue, Suite 500, San Francisco, CA 94102-6033, Phone (415) 554-9050. AIDS Office Director: Sandra R Hernandez, MD, AIDS Surveillance Branch Chief: George F Lemp, DrPH; Program Coordinator: Nellie Rose; Epidemiologist/Data Manager: Tim Kellogg, Funding and technical support is provided by the Division of HIV/AIDS, Centers for Disease Control. Additional support is provided by the California Department of Health Services Office of AIDS.

HIV SEROPREVALENCE FOR PARTICIPANTS OF THE YOUNG MEN'S SURVEY BY AGE-GROUP, SAN FRANCISCO, 1991 (1)

AGE-GROUP (YEARS)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
17 - 19	21	3	14.3	3.8 - 37.4
20 - 22	93	13	14.0	7.9 - 23.1
23 - 25	144	15	10.4	6.1 - 16.9
TOTAL	258	31.	12.0	8.4 - 16.8

HIV SEROPREVALENCE FOR PARTICIPANTS OF THE YOUNG MEN'S SURVEY, BY RACE/ETHNICITY, SAN FRANCISCO, 1991 (1)

RACE/ETHNICITY	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
WHITE	138	15	10.9	6.4 - 17.6
AFRICAN AMERICAN	35	8	22.9	11.0 - 40.6
LATINO	49	7	14.3	6.4 - 27.9
ASIAN/PACIFIC ISLANOER	33	0	0.0	0.0 - 10.2
NONE OF THE ABOVE (4)	3	I	33.3	1.8 - 87.5
TOTAL	258	31	12.0	8.4 - 16.8

(1) The Young Men's Survey (YMS) was a collaborative effort of the San Francisco Oepartment of Public Health and the California Oepartment of Health Services. The survey was conducted during the Spring of 1991 at seven gay-identified dance clubs and bars in San Francisco. All male patrons were screened upon entry to the club and recruited if they identified themselves as San Francisco residents and under 25 years of age. A total of 501 men were eligible, of which 258 (51%) agreed to participate. Structured interviews were conducted and blood specimens were drawn on site. Specimens were tested for HIV and markers to Hepatitis B (HBsAG and HBcAB) and syphilis (VORL and MHA-TP); (2) All HIV positive specimens were repeatedly reactive by ELISA and confirmed by an IFA. Indeterminate HIV results were tested by a Western blot assay; (3) 95% Confidence Intervals. normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, or unknown race.

HIV SEROPREVALENCE FOR PARTICIPANTS OF THE YOUNG MEN'S SURVEY BY GENOER OF SEXUAL PARTNERS, SAN FRANCISCO, 1991 (1)

GENOER OF PARTNERS (2)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)
ONLY MEN	99	9	9.1	4.5 - 17.0
MOSTLY MEN, SOME WOMEN	126	20	15.9	10.2 - 23.7
EQUALLY WITH MEN AND WOMEN	13	2	15.4	2.7 - 46.3
MOSTLY WOMEN, SOME MEN	16	0	0.0	0.0 - 19.4

HIV SEROPREVALENCE FOR PARTICIPANTS OF THE YOUNG MEN'S SURVEY BY NUMBER OF LIFETIME MALE PARTNERS, SAN FRANCISCO, 1991 (1)

NUMBER OF PARTNERS (2)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)
ONE PARTNER	В	0	0.0	0.0 - 33.7
2 - 9 PARTNERS	81	7	8.6	3.B - 17.5
10 - 24 PARTNERS	73	6	B.2	3.4 - 17.6
25 - 49 PARTNERS	36	4	11.1	3.6 - 27.0
50 OR MORE PARTNERS	49	14	2B.6	17.0 - 43.5

⁽¹⁾ The Young Men's Survey (YMS) was a collaborative effort of the San Francisco Oepartment of Public Health and the California Oepartment of Health Services. The survey was conducted during the Spring of 1991 at seven gay-identified dance clubs and bars in San Francisco. All male patrons were screened upon entry to the club and recruited if they identified themselves as San Francisco residents and under 25 years of age. A total of 501 men were eligible, of which 25B (51%) agreed to participate. Structured interviews were conducted and blood specimens were drawn on site. Specimens were tested for HIV and markers to Hepatitis B (HBsAG and HBcAB) and syphilis (VORL and MHA-TP); (2) This analysis was limited to participants who admitted to at least one male sexual partner during their lifetime. (3) All HIV positive specimens were repeatedly reactive by ELISA and confirmed by an IFA. Indeterminate HIV results were tested by a Western blot assay; (4) 95% Confidence Intervals, normal approximation method.

HIV SEROPREVALENCE FOR PARTICIPANTS OF THE YOUNG MEN'S SURVEY BY HISTORY OF RECEPTIVE ANAL INTERCOURSE, SAN FRANCISCO, 1991 (1)

			SERO-	
	NUMBER	NUMBER(2)	PREVALENCE	
	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3
RECEPTIVE ANAL SEX 6-MONTHS				
PRIOR TO INTERVIEW? (4)				
Yes	143	23	16.1	10.7 - 23.4
No	85	6	7.1	2.9 - 15.3
IF YES, DID PARTNER(S)				
WEAR A CONDOM?				
Always	82	12	14.6	8.1 - 24.6
Sometimes	37	7	18.9	8.6 - 35.7
Never	23	4	17.4	5.7 - 39.5
WHEN A CONDOM WAS NOT USED,				
DID YOUR PARTNER(S) EJACULATE				
IN YOUR RECTUM?				
Always	9	1	11.1	0.6 - 49.3
Sometimes	22	6	27.3	11.6 - 50.4
Never	29	4	13.8	4.5 - 32.6

⁽¹⁾ The Young Men's Survey (YMS) was a collaborative effort of the San Francisco Department of Public Health and the California Department of Health Services. The survey was conducted during the Spring of 1991 at seven gay-identified dance clubs and bars in San Francisco. All male patrons were screened upon entry to the club and recruited if they identified themselves as San Francisco residents and under 25 years of age. A total of 501 men were eligible, of which 258 (51%) agreed to participate. Structured interviews were conducted and blood specimens were drawn on site. Specimens were tested for HIV and markers to Hepatitis B (HBsAG and HBcAB) and syphilis (VDRL and MHA-TP); (2) All HIV positive specimens were repeatedly reactive by ELISA and confirmed by an IFA. Indeterminate HIV results were tested by a Western blot assay; (3) 95% Confidence Intervals, normal approximation method. (4) This analysis was limited to participants who admitted to at least one male sexual partner during their lifetime.

HIV SEROPREVALENCE FOR PARTICIPANTS OF THE YOUNG MEN'S SURVEY BY HISTORY OF INSERTIVE ANAL INTERCOURSE, SAN FRANCISCO, 1991 (1)

	NUMBER	NUMBER(2)	SERO- PREVALENCE	
	TESTEO	POSITIVE	RATE (%)	(95% C.I.)(3)
INSERTIVE ANAL SEX 6-MONTHS				
PRIOR TO INTERVIEW? (4)				
Yes	152	21	13.8	8.9 - 20.6
No	76	8	10.5	5.0 - 20.2
IF YES, OIO YOU				
WEAR A CONDOM?				
Always	85	14	16.5	9.6 - 26.4
Sometimes	44	5	11.4	4.3 - 25.4
Never	22	2	9.1	1.6 - 30.6
WHEN A CONDOM WAS NOT USED,				
DIO YOU EJACULATE IN YOUR				
PARTNER(S) RECTUM?				
Always	6	0	0.0	0.0 - 41.4
Sometimes	31	3	9.7	2.5 - 26.9
Never	28	4	14.3	4.7 - 33.6

⁽¹⁾ The Young Men's Survey (YMS) was a collaborative effort of the San Francisco Department of Public Health and the California Oepartment of Health Services.

The survey was conducted during the Spring of 1991 at seven gay-identified dance clubs and bars in San Francisco. All male patrons were screened upon entry to the club and recruited if they identified themselves as San Francisco residents and under 25 years of age. A total of 501 men were eligible, of which 258 (51%) agreed to participate. Structured interviews were conducted and blood specimens were drawn on site. Specimens were tested for HIV and markers to Hepatitis B (HBsAG and HBcAB) and syphilis (VORL and MHA-TP); (2) All HIV positive specimens were repeatedly reactive by ELISA and confirmed by an IFA. Indeterminate HIV results were tested by a Western blot assay; (3) 95% Confidence Intervals, normal approximation method. (4) This analysis was limited to participants who admitted to at least one male sexual partner during their lifetime.

HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTEO DISEASE CLINIC BY GENOER AND TRANSMISSION CATEGORY. AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (1)

		198	1989 SURVEY			1990	1990 SURVEY			199	1991 SURVEY	
GENDER AND TRANSMISSION CATEGORY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
MALE												
Homosexual/Bisexual	446	226	50.7	45.9 - 55.4	929	269	43.0	39.1 - 47.0	90	30	33.3	24.0 - 44.1
Homosexual/Bisexual, IOU	119	82	6.89	59.7 - 76.9	90	55	61.1	50.2 - 71.0	7	4	57.1	20.2 - 88.2
Heterosexual 10U	66	12	12.1	6.7 - 20.6	101	ω	7.9	3.7 - 15.5	18	0	0.0	0.0 - 17.5
Sex Partner at Risk for HIV	73	က	4.1	1.1 - 12.3	103	6	8.7	4.3 - 16.4	14	0	0.0	0.0 - 21.7
Blood Recipient (4)	23	1	4.3	0.2 - 24.0	6	1	11.1	0.6 - 49.3	0	0	1	ŀ
Heterosexual (5)	1020	14	1.4	0.8 - 2.4	1378	59	2.1	1.4 - 3.0	223	4	1.8	0.6 - 4.8
Unknown Risk	80	٩	0.0	0.0 - 33.7	781	25	13.4	9.0 - 19.3	80	7	12.5	0.7 - 53.3
												,
SUB-TOTAL MALE	1788	338	18.9	17.1 - 20.8	2494	396	15.9	14.5 - 17.4	360	38	10.8	7.9 - 14.6
FEMALE												,
Heterosexual 10U	55	'n	9.1	3.4 - 20.7	09	Ŋ	8.3	3.1 - 19.1	14	1	7.1	0.4 - 35.8
Sex Partner at Risk for HIV	28	1	1.7	0.1 - 10.5	55	1	1.8	0.1 - 11.0	2	0	0.0	0.0 - 46.7
Blood Recipient (4)	11	-1	9.1	0.5 - 42.9	9	1	16.7	0.9 - 63.5	0	0	1	:
Heterosexual (5)	380	m	0.8	0.2 - 2.5	541	13	2.4	1.3 - 4.2	98	-1	1.2	0.1 - 7.2
Unknown Risk	2	9	0.0	0.0 - 46.7	61	٩	0.0	0.0 - 16.7	7	7	14.3	0.8 - 58.0
SUB-TOTAL FEMALE	509	10	2.0	1.0 - 3.7	681	20	2.9		112	ന	2.7	0.7 - 8.2
				7 1 2 1 2 1	2175	716		1 2 0 0 1 1 2 2	472	42	σ	472 42 8 9 6.6 - 11.9
IDIAL	1677	040	13.2	13.7 - 10.7	2113	410	13.1	12.0 - 14.3	7/4	7		

⁽¹⁾ These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STO episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen. (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons with a history of blood transfusion(s) between January 1977 - March 1985; (5) Self-identified heterosexuals with no other identified risks. The 1991 survey is still in progress: (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay;

AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (1) ITV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC 8Y AGE-GROUP

		198	1989 SURVEY			199	1990 SURVEY			199	1991 SURVEY	
AGE-GROUP (YEARS)	NUMBER TESTEO	NUMBER NUMBER(2)	SERO- NUMBER(2) PREVALENCE POSITIVE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)
19 ANO UNDER	223	ω	1.3	0.3 - 4.2	274	6	2.2	0.9 - 4.9	40	0	0.0	0.0 - 8.5
20 - 24	526	35	. 6.7	4.7 - 9.2	707	34	4.8	3.4 - 6.7	127	ω	2.4	0.6 - 7.3
25 - 29	550	93	16.9	13.9 - 20.4	785	104	13.2	11.0 - 15.9	96	œ	8.3	3.9 - 16.2
30 - 34	403	88	21.8	18.0 - 26.3	568	113	19.9	16.7 - 23.5	90	20	22.2	14.4 - 32.4
35 - 39	284	73	25.7	20.8 - 31.3	382	90	23.6	19.5 - 28.2	49	10	20.4	10.7 - 34.8
40 - 44	158	27	17.1	11.8 - 24.1	223	38	17.0	12.5 - 22.8	30	_	ω ω	0.2 - 19.1
45 ANO OVER	153	29	19.0	13.3 - 26.3	226	31	13.7	9.6 - 19.1	38	0	0.0	0.0 - 8.9
UNKNOWN	0	ల	1	1	10	0	0.0	0.0 - 28.5		0	0.0	2 0 0.0 0.0 - 75.2
TOTAL 2297 348 15.2 13.7 - 16.7 3175 416 13.1 12.0 - 14.3	2297	348	15.2	13.7 - 16.7	3175	416	13.1	12.0 - 14.3		42	8.9	6.6 - 11.9

The 1991 survey is still in progress: (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay: ind/or treatment for a NEW STO episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen. 3) 95% Confidence Intervals, normal approximation method. 1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination.

HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (1)

		196	1989 SURVEY			199	1990 SURVEY			199	1991 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	-	SERO- REVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE		SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	L	SERO- REVALENCE RATE (%) (95% C.I.)(3)
WHITE	916	209	22.8	20.2 - 25.7	1209	219	18.1	16.0 - 20.4	190	27	14.2	9.7 - 20.2
AFRICAN AMERICAN	828	76	9.2	7.3 - 11.4	1176	111	9.4	7.9 - 11.3	159	7	4.4	1.9 - 9.2
LATINO	371	52	14.0	10.7 - 18.1	564	89	12.1	9.5 - 15.1	84	7	8.3	3.7 - 17.0
ASIAN/PACIFIC ISLANDER	138	9	4.3	1.8 - 9.6	183	13	7.1	4.0 - 12.1	31	-	3.2	0.2 - 18.5
NONE OF THE ABOVE (4)	44	2	11.4	4.3 - 25.4	43	ιΩ	11.6	4.4 - 25.9	ω	0	0.0	0.0 - 33.7
		=======================================					:: :: :: :: :: :: :: :: :: :: :: :: ::		10 10 10 10 10 10 10 10 10 10 10 10 10 1			
_ T0TAL	2297	348	15.2	13.7 - 16.7	3175	416	13.1	12.0 - 14.3	472	42	8.9	6.6 - 11.9

and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen. (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race. (1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination. The 1991 survey is still in progress; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay;

HIV SEROPREVALENCE FOR HOMOSEXUAL AND BISEXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY AGE-GROUP AND YEAR OF SURVEY. SAN FRANCISCO. 1989 - 1991 (1)

		198	1989 SURVEY			190	1990 SURVEY			199	1991 SURVEY	
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE		SERO- PREVALENCE RATE (%) (95% C.I.)(3)
19 AND UNDER	2	0	0.0	0.0 - 75.2	14	2	14.3	2.5 - 43.8	ω	0	0.0	0.0 - 62.6
20 - 24	62	26	41.9	29.8 - 55.1	81	27	33.3	23.5 - 44.B	11	2	18.2	3.2 - 52.2
25 - 29	138	85	61.6	52.9 - 69.6	174	80	46.0	38.5 - 53.7	22	00	36.4	18.0 - 59.2
30 - 34	132	77	58.3	49.4 - 66.7	168	87	51.8	44.0 - 59.5	28	14	50.0	31.1 - 68.9
35 - 39	113	68	60.2	50.5 - 69.1	129	69	53.5	44.5 - 62.2	17	9	52.9	28.5 - 76.1
40 - 44	57	25	43.9	31.0 - 57.6	62	30	48.4	35.7 - 61.3	9	-	11.1	0,6 - 49.3
45 AND OVER	61	27	44.3	31.8 - 57.5	87	29	33.3	23.8 - 44.3	7	0	0.0	0.0 - 37.2
UNKNOWN	0	0	;	1	1	0	0.0	0.0 - 92.7	0	0	;	;
	***************************************			=======================================								
TOTAL	565	308	54.5	50.3 - 58.7	716	324	45.3	41.6 - 49.0	97	34	35.1	25.8 - 45.5
(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen. The 1991 survey is still in progress; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay:	surveys wer TD episode. progress; (2	e drawn fro Specimens ) All posit	m blood spe were collec ive specime	cimens collected ted consecutivel	for routiry and teste	ne syphilis ad after all	screening of personal in	on individuals see dentifiers had be	eking evalu een removed Western b	uation, exan d from the s blot assay;	nination. specimen.	Ш

^{(3) 95%} Confidence Intervals, normal approximation method.

HIV SEROPREVALENCE FOR HOMOSEXUAL AND BISEXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (1)

		198	1989 SURVEY			198	1990 SURVEY			198	1991 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	_	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3
TT THE	370	195	7.	46 3 - 56 6	456	188	41.2	36.7 - 45.9	7.1	24	33.8	23.3 - 46.1
WHITE	87	56	64.4	53.3 - 74.1	117	74	63.2	53.8 - 71.8		က	33.3	9.0 - 69.1
LATINO	78	48	61.5	49.8 - 72.1	107	20	46.7	37.1 - 56.6	14	9	42.9	18.8 - 70.4
ASIAN/PACIFIC ISLANDER	14	4	28.6	9.6 - 58.0	28	œ	28.6	14.0 - 48.9	*	*	1	1
NONE OF THE ABOVE (4)	7	r2	71.4	30.3 - 94.9	80	4	50.0	17.5 - 82.5	m		33.3	1.8 - 87.5
												01 31 11 11 11 11 11 11 11 11 11 11 11 11
TOTAL	565	308	54.5	50.3 - 58.7	716	324	45.3	41.6 - 49.0	26	34	35.1	25.8 - 45.5

⁽¹⁾ These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race. and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen. The 1991 survey is still in progress; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay;

^{*} This subgroup combined with 'None of the Above' due to a small sample size.

TOTAL 1116 18 1.6 1.0 - 2.6 1490 39 2.6 1.9 - 3.6	UNKNOWN	45 AND OVER	40 - 44	35 - 39	30 - 34	25 - 29	20 - 24	19 AND UNDER	AGE-GROUP (YEARS)	
1116	0	61	62	96	183	271	316	127	NUMBER TESTEO	
18	0	2	0	ω	œ	1	ω	-	NUMBER(3) POSITIVE	198
1.6	;	3.3	0.0	3.1	4.4	0.4	0.9	0.8	SERO- NUMBER(3) PREVALENCE POSITIVE RATE (%)	1989 SURVEY
1.0 - 2.6		0.6 - 12.4	0.0 - 5.6	0.8 - 9.5	2.0 - 8.7	0.0 - 2.4	0.2 - 3.0	0.0 - 5.0	SERO- PREVALENCE RATE (%) (95% C.I.)(4)	
1490	4	91	98	159	230	392	359	157	NUM8ER TESTEO	
39	0	1	ω	œ	11	10	4	2	NUMBER(3) POSITIVE	199
2.6	0.0	1.1	3.1	5.0	4.8	2.6	1.1	1.3	SERO- PREVALENCE RATE (%)	1990 SURVEY
1.9 - 3.6	0.0 - 53.5	0.1 - 6.8	0.8 - 9.3	2.4 - 10.0	2.5 - 8.6	1.3 - 4.8	0.4 - 3.0	0.2 - 5.0	SERO- PREVALENCE RATE (%) (95% C.I.)(4)	
237		20	12	18	42	51	71	22	NUMBER TESTEO	
4	C	0	0	0	4	0	0	0	NUMBER(3) POSITIVE	199
1.7	0.0	0.0	0.0	0.0	9.5	0.0	0.0	0.0	SERO- PREVALENCE RATE (%)	1991 SURVEY
0.5 - 4.6	0.0 0.0 92.7	0.0 - 16.0	0.0 - 24.6	0.0 - 17.5	3.1 - 23.5	0.0 - 6.8	0.0 - 4.9	0.0 - 14.7	SERO- PREVALENCE RATE (%) (95% C.I.)(4)	

and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen. (1) Includes heterosexuals with a sex partner(s) at risk for HIV, heterosexuals with a history of blood transfusion(s), and heterosexuals with no identified risk; The 1991 survey is still in progress; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Mestern blot assay; (2) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination,

(4) 95% Confidence Intervals, normal approximation method.

HIV SEROPREVALENCE FOR HETEROSEXUAL MALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (2)

		1986	1989 SURVEY			199	1990 SURVEY			199	1991 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(4)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(4)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(4
WHITE	323	Ŋ	1.5	0.6 - 3.8	414	11	2.7	1.4 - 4.8	64	2	3.1	0.5 - 11.8
AFRICAN AMERICAN	482	10	2.1	1.1 - 3.9	989	18	2.6	1.6 - 4.2	103	1	1.0	0.1 - 6.1
LATINO	213	2	6.0	0.2 - 3.7	288	6	3.1	1.5 - 6.1	20	1	2.0	0.1 - 12.0
ASIAN/PACIFIC ISLANDER	79	1	1.3	0.1 - 7.8	84	1	1.2	0.1 - 7.4	19	0	0.0	0.0 - 16.7
NONE OF THE ABOVE (5)	19	0	0.0	0.0 - 16.7	18	0	0.0	0.0 - 17.5	-	0	0.0	0.0 - 92.7
			### ### ### ##########################							***		
TOTAL	1116	18	1.6	1.0 - 2.6	1490	39	2.6	1.9 - 3.6	237	4	1.7	0.5 - 4.6

⁽¹⁾ Includes heterosexuals with a sex partner(s) at risk for HIV, heterosexuals with a history of blood transfusion(s), and heterosexuals with no identified risk; (2) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation. examination. 4) 95% Confidence Intervals, normal approximation method; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race. and/or treatment for a NEW STO episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen. The 1991 survey is still in progress; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay;

		198	1989 SURVEY			199	1990 SURVEY			199	1991 SURVEY	
AGE-GROUP (YEARS)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- NUMBER(2) PREVALENCE POSITIVE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)
						,			;	,		
19 ANO UNOER	87	2	2.3	- 1	. 88	. 2	2.3	0.4 - 8.7	13	0	0.0	- 1
20 - 24	123	2	1.6	0.3 - 6.3	195	-	0.5	0.0 - 3.3	37	0	0.0	0.0 - 9.1
25 - 29	101	1	1.0	0.1 - 6.2	139	4	2.9	- 1	18	. 0	0.0	- 1
30 - 34	53	0	0.0	0.0 - 6.5	80	4	5.0	1.6 - 13.0	6	-	16.7	0.9 - 63.5
35 - 39	42	0	0.0	0.0 - 8.1	44	ω	6.8	1.8 - 19.7	4	0	0.0	0.0 - 53.5
40 - 44	22	0	0.0	0.0 - 14.7	28	-	3.6	0.2 - 20.2	6	0	0.0	0.0 - 41.4
45 ANO OVER	21	0	0.0	0.0 - 15.3	24	0	0.0	0.0 - 13.6	6	0	0.0	0.0 - 41.4
UNKNOWN	0	0	1	1	4	0	0.0	0.0 - 53.5	ь	0	0.0	0.0 - 92.7
TOTAL	449	رب د	1.1	1.1 0.4 - 2.7 602 15 2.5 1.5 - 4.2	602	15	2.5	1.5 - 4.2	91	ь	1.1	1 1.1 0.1 - 6.8
<ol> <li>Includes heterosexuals with a sex partner(s) at risk for HIV, heterosexuals with a history of blood transfusion(s), and heterosexuals with no identified risk;</li> <li>These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STO episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen.</li> <li>The 1991 survey is still in progress; (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay;</li> </ol>	th a sex pa surveys wer O episode.	rtner(s) at e drawn fro Specimens ) All posit	t risk for I	HIV, heterosexual ecimens collected consecutivel ens were repeated	s with a hi for routir y and teste	story of blue syphilis and after all	ood transfu screening c personal i	usion(s), and heton individuals send the dentifiers had bend by an IFA and .	erosexuals eking eval een remove a Western l	s with no identified luation, examination, red from the specimen blot assay;	ntified ris nination,	<i>.</i> ?
ine 1991 Survey is still in progress; (3) All positive sp	rogress; (3	) All position	Tive specim	ens were repeated	ly reductive	י של ברוסא פ	and contribute	a by all Ira allu		Jiot assay,		

^{(4) 95%} Confidence Intervals, normal approximation method.

HIV SEROPREVALENCE FOR HETEROSEXUAL FEMALES (1) ATTENDING A SEXUALLY TRANSMITTEO DISEASE CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (1)

		198	1989 SURVEY			199	1990 SURVEY			199	1991 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	_	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- NUMBER(2) PREVALENCE POSITIVE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)
TTHO	148	,	4 -	0.2 - 5.3	176	4	2.3	0.7 - 6.1	30	0	0.0	0.0 - 11.1
AFRICAN AMERICAN	191	ı m	1.6	0.4 - 4.9	264	6	3.4	1.7 - 6.6	34	-	2.9	0.2 - 17.1
LATINA	61	0	0.0	0.0 - 5.7	101	1	1.0	0.1 - 6.2	15	0	0.0	0.0 - 20.5
ASIAN/PACIFIC ISLANDER	40	0	0.0	0.0 - 8.5	53	1	1.9	0.1 - 11.4	თ	0	0.0	0.0 - 30.9
NONE OF THE ABOVE (4)	6	0	0.0	0.0 - 30.9	œ	0	0.0	0.0 - 33.7	က	0	0.0	0.0 - 62.6
TOTAL	449	2	1.1	0.4 - 2.7	602	15	2.5	1.5 - 4.2	91		1.1	0.1 - 6.8

⁽¹⁾ Includes heterosexuals with a sex partner(s) at risk for HIV, heterosexuals with a history of blood transfusion(s), and heterosexuals with no identified risk; (2) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, (4) 95% Confidence Intervals, normal approximation method; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race. and/or treatment for a NEW STO episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen. The 1991 survey is still in progress: (3) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay:

		198	1989 SURVEY			199	1990 SURVEY			199	1991 SURVEY	
TRANSMISSION CATEGORY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- NUMBER(2) PREVALENCE POSITIVE RATE (%)	SERO- NUMBER NUMBER(2) PREVALENCE TESTED POSITIVE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER NUMBER(2) TESTED POSITIVE	SERO- NUMBER(2) PREVALENCE POSITIVE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUM8ER TESTED	NUMBER(2) POSITIVE	SERO- NUMBER(2) PREVALENCE POSITIVE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
Heterosexual IOU	0	0	;	:	20	-	5.0	0.3 - 26.9	7	_	14.3	0.8 - 58.0
Sex Partner at Risk for HIV	0	0	:	;	24	0	0.0	0.0 - 13.6	10	0	0.0	0.0 - 28.5
8lood Recipient (4)	0	0	1	1	=	0	0.0	0.0 - 26.4	4	0	0.0	0.0 - 53.5
Heterosexual (5)	0	0	1	;	1313	-	0.1	0.0 - 0.5	1246	2	0.2	0.0 - 0.6
Unknown Risk (6)	1266	4	0.3	0.1 - 0.9	8	0	0.0	0.0 - 33.7	7	0	0.0	0.0 - 37.2
TOTAL	1266	4	0.3	0.1 - 0.9	1376	2	0.1	1266 4 0.3 0.1 - 0.9 1376 2 0.1 0.0 - 0.6 1274 3 0.2 0.1 - 0.7	1274	ω	0.2	0.1 - 0.7
(1) These unlinked (blinded) surveys were drawn from women seeking family planning services. Specimens were collected from inital and annual visits.	urveys wer	e drawn fro	m women see	sking family plar	ning servic	ces. Specime	ens were col	lected from inita	and confi	al visits,	150	
and a Western blot assay; (3) 95% Confidence Intervals, normal approximation; (4) Includes persons with a history of blood transfusion(s) between lanuary 1977 - March 1985; (5) Self-identified heterosexuals with no other identified risks; (6) The 1989 unlinked survey did not collect risk information.	95% Confic	dence Interv	als, normal	approximation;	(4) Include	es persons wasks: (6) The	with a histo	ry of blood trans	fusion(s)	between risk inform	ation.	
January 1977 - March 1985; (5)	Selt-ider	itified hete	rosexuals w	vith no other ide	intified ris	sks; (b) Ine	utiun 686T a	ked survey did no	1 collect	risk inform	lation.	

		198	1989 SURVEY			199	1990 SURVEY			199	1991 SURVEY	
AGE-GROUP (YEARS)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)
19 AND UNDER	73	0	0.0	0.0 - 4.8	93	0	0.0	0.0 - 3.8	81	0	0.0	0.0 - 4.3
20 - 24	420	1	0.2	0.0 - 1.5	474	0	0.0	0.0 - 0.8	400	0	0.0	0.0 - 0.9
25 - 29	414	1	0.2	0.0 - 1.6	401	0	0.0	0.0 - 0.9	427	2	0.5	0.1 - 1.9
30 - 34	226	2	0.9	0.2 - 3.5	243	1	0.4	0.0 - 2.6	220	0	0.0	0.0 - 1.6
35 - 39	105	0	0.0	0.0 - 3.4	97	0	0.0	0.0 - 3.6	112	1	6.0	0.0 - 5.6
40 - 44	18	0	0.0	0.0 - 17.5	34	1	5.9	0.2 - 17.1	92	0	0.0	0.0 - 12.6
45 AND OVER	7	0	0.0	0.0 - 37.2	80	0	0.0	0.0 - 33.7	4	0	0.0	0.0 - 53.5
UNKNOWN	m	0	0.0	0.0 - 62.6	56	0	0.0	0.0 - 12.6	4	0	0.0	0.0 - 53.5
										ii ii ii ii ii ii ii ii ii ii		
TOTAL	1266	4	0.3	0.1 - 0.9	1376	2	0.1	0.0 - 0.6	1274	က	0.2	0.1 - 0.7

and tested for HIV after all personal identifiers had been removed; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA (1) These unlinked (blinded) surveys were drawn from women seeking family planning services. Specimens were collected from inital and annual visits, and a Western blot assay; (3) 95% Confidence Intervals, normal approximation.

HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (1)

		19	1989 SURVEY			199	1990 SURVEY			199	1991 SURVEY	
RACE/ETHNICITY	NUM8ER TESTED	NUMBER NUMBER(2)	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER NUMBER(2) TESTED POSITIVE	SERO- NUMBER(2) PREVALENCE POSITIVE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUM8ER TESTED	NUMBER(2) POSITIVE	SERO- NUMBER(2) PREVALENCE POSITIVE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
WHITE	122	-	0.8	0.0 - 5.2	126	_	0.8	0.0 - 5.0	92	0	0.0	0.0 - 3.8
AFRICAN AMERICAN	154	<b>.</b>	0.6	0.0 - 4.1	145	0	0.0	0.0 - 2.5	92	↦	1.1	0.1 - 6.8
LATINA	810	2	0.2	0.0 - 1.0	908	0	0.0	0.0 - 0.4	936	2	0.2	0.0 - 0.9
ASIAN/PACIFIC ISLANDER	149	0	0.0	0.0 - 2.4	166	₽	0.6	0.0 - 3.8	125	0	0.0	0.0 - 2.8
NONE OF THE ABOVE (4)	31	0	0.0	0.0 - 10.8	31	0	0.0	0.0 - 10.8	29	0	0.0	0.0 - 11.5
TOTAL 1266 4 0.3 0.1 - 0.9 1376 2	1266	4	0.3	0.1 - 0.9	1376	2	0.1	0.1 0.0 - 0.6 1274 3 0.2 0.1 - 0.7	1274	ω	0.2	0.1 - 0.7
(1) These unlinked (blinded) surveys were drawn from women seeking family planning services. Specimens were collected from all initial	surveys wer	e drawn fr	om women se	eking family plar	ming servi	ces. Specim	ens were col	family planning services. Specimens were collected from all initial and annual visits		and annual visits	its IEA	,

and tested for HIV after all personal identifiers had been removed; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry. other race, and unknown race.

#### V SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY TRANSMISSION CATEGORY, SAN FRANCISCO, 1990-1991 (1)

		199	O SURVEY			199	1 SURVEY	
TRANSMISSION CATEGORY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
Heterosexual IDU	8	1	12.5	0.7 - 53.3	7	4	57.1	20.2 - 88.2
Sex Partner at Risk for HIV	3	0	0.0	0.0 - 62.6	6	0	0.0	0.0 - 41.4
Heterosexual (4)	419	2	0.5	0.1 - 1.9	483	3	0.6	0.2 - 2.0
Unknown Risk	1	0	0.0	0.0 - 92.7	8	0	0.0	0.0 - 33.7
TOTAL	431	3	0.7	0.2 - 2.2	504	7	1.4	0.6 - 3.0

⁾ The 1990 and 1991 unlinked (blinded) surveys were drawn from routine blood specimens from women seeking abortions. rvey specimens were tested for HIV after all personal identifiers had been removed; (2) All positive specimens re repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, rmal approximation method; (4) Self-identified heterosexuals with no other identified risks.

		199	0 SURVEY			199	1 SURVEY	
AGE-GROUP (YEARS)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
19 AND UNDER	68	0	0.0	0.0 - 5.1	B4	0	0.0	0.0 - 4.2
20 - 24	139	1	0.7	0.0 - 4.5	141	2	1.4	0.2 - 5.6
25 - 29	106	0	0.0	0.0 - 3.3	127	3	2.4	0.6 - 7.3
30 - 34	В0	2	2.5	0.4 - 9.6	78	1	1.3	0.1 - 7.9
35 - 39	26	0	0.0	0.0 - 12.6	53	1	1.9	0.1 - 11.4
40 - 44	В	0	0.0	0.0 - 33.7	15	0	0.0	0.0 - 20.5
45 AND OVER	0	0			0	0		
JNKNOWN	4	0	0.0	0.0 - 53.5	6	0	0.0	0.0 - 41.4
	*******							
rotal .	431	3	0.7	0.2 - 2.2	504	7	1.4	0.6 - 3.0

HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY RACE/ETHNICITY, SAN FRANCISCO, 1990-1991 (1)

		199	O SURVEY			199	1 SURVEY	
RACE/ETHNICITY	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
WHITE	50	1	2.0	0.1 - 12.0	3В	2	5.3	0.9 - 19.I
AFRICAN AMERICAN	106	2	1.9	0.3 - 7.3	122	2	I.6	0.3 - 6.4
LATINA	223	0	0.0	0.0 - 1.6	269	3	1.1	0.3 - 3.5
ASIAN/PACIFIC ISLANOER	45	0	0.0	0.0 - 7.6	65	0	0.0	0.0 - 5.4
NONE OF THE ABOVE (4)	7	0	0.0	0.0 - 37.2	10	0	0.0	0.0 - 2B.5
 TOTAL	431	3	0.7	0.2 - 2.2	504	7	1.4	0.6 - 3.0

⁽¹⁾ The 1990 and 1991 unlinked (blinded) surveys were drawn from routine blood specimens from women seeking abortions. Survey specimens were tested for HIV after all personal identifiers had been removed; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

HIV SEROPREVALENCE FOR NEWBORN INFANTS AND THEIR MOTHERS. SAN FRANCISCO. 1989 - 1990 (1)

	1989 SURVEY				1990 SURVEY			
	NUM8ER TESTED	NUM8ER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUM8ER TESTED	NUM8ER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
AGE-GROUP(YEARS)								
UNDER 20	219	1	0.457	0.024 - 2.912	181	0	0.000	0.000 - 1.979
20 - 24	442	2	0.452	0.078 - 1.808	446	0	0.000	0.000 - 0.810
25 - 29	638	0	0.000	0.000 - 0.568	618	1	0.162	0.008 - 1.044
30 - 34	625	0	0.000	0.000 - 0.579	625	1	0.160	0.008 - 1.033
35 AND OVER	485	0	0.000	0.000 - 0.746	451	0	0.000	0.000 - 0.802
UNKNOWN	138	1	0.725	0.038 - 4.572	117	0	0.000	0.000 - 3.037
RACE/ETHNICITY								
WHITE	679	0	0.000	0.000 - 0.533	663	1	0.151	0.008 - 0.975
AFRICAN AMERICAN	334	1	0.299	0.016 - 1.921	324	0	0.000	0.000 - 1.113
LATINO	564	1	0.177	0.009 - 1.143	608	1	0.165	0.009 - 1.061
ASIAN/PACIFIC IS.	636	0	0.000	0.000 - 0.569	633	0	0.000	0.000 - 0.572
OTHER	206	1	0.485	0.025 - 3.092	115	0	0.000	0.000 - 3.088
UNKNOWN	128	1	0.781	0.041 - 4.918	95	0	0.000	0.000 - 3.720
TOTAL - SAN FRANCISCO	2,547	4	0.157	0.050 - 0.431	2,438	2	0.082	0.014 - 0.330
TOTAL - 8AY AREA (4)	21,217	25	0.118	0.078 - 0.118	21,397	23	0.108	0.070 - 0.164
TOTAL - STATEWIDE	144,284	92	0.064	0.052 - 0.079	150,494	106	0.070	0.058 - 0.086

⁽¹⁾ Data courtesy of the California Department of Health Services Office of AIDS. Specimens for this survey of newborn infants (and women giving birth to) are drawn from the genetic diseases screening program. Antibodies in a newborn reflect the infection status of the mother and not necessarily of the child. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay: (3) 95% Confidence Intervals.

HIV SEROPREVALENCE FOR INJECTION ORUG USERS ENTERING METHAOONE TREATMENT PROGRAMS IN SAN FRANCISCO 8Y AGE-GROUP (1)

	NUMBER	NUMBER(2)	SERO- PREVALENCE	
AGE-GROUP (YEARS)	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3)
		·		
19 AND UNDER	15	1	6.7	0.3 - 34.0
20 - 24	126	3	2.4	0.6 - 7.3
25 - 29	268	13	4.9	2.7 - 8.3
30 - 34	374	27	7.2	4.9 - 10.5
35 - 39	557	56	10.1	7.7 - 12.9
40 - 44	450	45	10.0	7.5 - 13.2
45 ANO OVER	287	30	10.5	7.3 - 14.7
MISSING	46	3	6.5	1.7 - 18.9
				==========
TOTAL	2123	178	8.4	7.3 - 9.7

HIV SEROPREVALENCE FOR INJECTION ORUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY RACE/ETHNICITY (1)

	SERO- NUMBER NUMBER(2) PREVALENCE					
RACE/ETHNICITY	TESTE0	POSITIVE	RATE (%)	(95% C.I.)(3		
WHITE	1283	46	3.6	2.7 - 4.8		
AFRICAN AMERICAN	518	109	21.0	17.7 - 24.9		
LATINO	233	18	7.7	4.8 - 12.1		
ASIAN/PACIFIC ISLANOER	47	4	8.5	2.8 - 21.3		
NONE OF THE ABOVE (4)	42	1	2.4	0.1 - 14.1		
============				=========		
TOTAL	2123	178	8.4	7.3 - 9.7		
TOTAL	2123	170	0.4	7.5		

⁽¹⁾ Oata collected between the 4th quarter of 1989 and the 3rd quarter of 1991;

⁽²⁾ Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method;

⁽⁴⁾ Includes persons of American Indian and Alaskan Native ancestry, other race, unknown race, and missing race.

HIV SEROPREVALENCE FOR INJECTION ORUG USERS ENTERING METHAOONE TREATMENT PROGRAMS IN SAN FRANCISCO BY GENOER AND SEXUAL ORIENTATION (1)

			SERO-	
GENOER ANO	NUM8ER	NUM8ER(2)	PREVALENCE	
SEXUAL ORIENTATION	TESTEO	POSITIVE	RATE (%)	(95% C.I.)(3)
MALE				
Homosexual/8isexual	47	15	31.9	19.5 - 47.3
Heterosexual	1288	106	8.2	6.8 - 9.9
Unknown Orientation	14	2	14.3	2.5 - 43.8
SU8-TOTAL: MALE	1349	123	9.1	7.7 - 10.8
FEMALE				
Lesbian/8isexual	34	3	8.8	2.3 - 24.8
Heterosexual	700	51	7.3	5.5 - 9.5
Unknown Orientation	3	0	0.0	0.0 - 62.6
SU8-TOTAL: FEMALE	737	54	7.3	5.6 - 9.5
MISSING GENOER	37	1	2.7	0.1 - 15.8
TOTAL	2123	178	8.4	7.3 - 9.7

HIV SEROPREVALENCE FOR INJECTION ORUG USERS ENTERING METHAOONE TREATMENT PROGRAMS IN SAN FRANCISCO BY TREATMENT MODALITY (1)

TREATMENT MODALITY	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
OETOXIFICATION	1720	140	8.1	6.9 - 9.6
MAINTENANCE	378	38	10.1	7.3 - 13.6
MISSING	25	0	0.0	0.0 - 13.1
TOTAL	2123	178	8.4	7.3 - 9.7

⁽¹⁾ Oata collected between the 1st quarter of 1989 and the 3rd quarter of 1991;

⁽²⁾ Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method.

HIV SEROPREVALENCE FOR INJECTION ORUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY QUARTER AND YEAR OF ENTRY, SAN FRANCISCO (1)

	4TH	i QTR/1989	15	T QTR/I	1990	200	QTR/1	1990	3R(	QTR/1	.990	4Tł	I QTR/1	1990
GENOER	N(2)	HIV+(3) %(4	) N	HIV+	%	N	HIV+	%	N	HIV+	%	N	HIV+	%
MALE FEMALE	152 81	16 10.5 10 12.3	203 100	19 6	9.4 6.0	149 82	15 5	10.1	247 110	18 6	7.3 5.5	I 54 I 09	16 9	10.4
TOTAL	233	26 11.2	303	25	8.3	231	20	8.7	357	24	6.7	263	25	9.5

	15	r QTR/I	991	200	QTR/1	991	3R0	QTR/	1991		TOTAL	
GENDER	N	HIV+	%	N	HIV+	%	N	HIV+	%	N	HIV+	%
MALE FEMALE	208 118	18 8	8.7 6.8	200 113	17 8	8.5 7.1	36 24	4 2	11.1	1349 737	123 54	9.1
TOTAL	326	26	8.0	313	25	8.0	60	6	10.0	2086	177	8.5

⁽I) Oata collected between the 4th quarter of 1989 and the 3rd quarter of 1991. This table excludes records with missing gender; (2) Number tested; (3) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (4) Seroprevalence rate (%).

TIV SEROPREVALENCE FOR INJECTION ORUG USERS (IOUS) AND NON-INJECTION ORUG USERS (NON-IOUS) ENTERING A METHADONE-FREE DETOXIFICATION PROGRAM BY AGE-GROUP, SAN FRANCISCO. 1990-1991 (1)

			IDUs			NO	N-IOUs	
			SERO-				SERO-	
	NUMBER	NUMBER(2)	PREVALENCE		NUMBER	NUMBER(2)	PREVALENCE	
AGE-GROUP (YEARS)	TESTEO	POSITIVE	RATE (%)	(95% C.I.)(3)	TESTE0	POSITIVE	RATE (%)	(95% C.I.)(3)
			_					
19 ANO UNOER	4	1	25.0	1.3 - 78.1	4	0	0.0	0.0 - 53.5
20 - 24	32	3	9.4	2.5 - 26.2	23	1	4.3	0.2 - 24.0
25 - 29	4B	5	10.4	3.9 - 23.4	75	6	8.0	3.3 - 17.2
30 - 34	41	5	12.2	4.6 - 27.0	48	5	10.4	3.9 - 23.4
35 - 39	49	3	6.1	1.6 - 17.9	51	4	7.B	2.5 - 19.7
40 - 44	35	4	11.4	3.7 - 27.7	31	2	6.5	1.1 - 22.8
45 ANO OVER	13	1	7.7	0.4 - 37.9	15	0	0.0	0.0 - 20.5
MISSING	0	0			0	0		
TOTAL	222	22	9.9	6.5 <b>-</b> 14.8	247	18	7.3	4.5 - 11.5

V SEROPREVALENCE FOR INJECTION ORUG USERS (IOUs) AND NON-INJECTION ORUG USERS (NON-IOUs) ENTERING A THAOONE-FREE DETOXIFICATION PROGRAM BY RACE/ETHNIC GROUP, SAN FRANCISCO, 1990-1991 (1)

	NUMBER	NUMBER(2)	SERO- PREVALENCE		NUMBER	NUMBER(2)	SERO- PREVALENCE	
RACE/ETHNICITY	TESTEO	POSITIVE	RATE (%)	(95% C.I.)(3)	TESTEO	POSITIVE	RATE (%)	(95% C.I.)(3)
VHITE	150	19	12.7	8.0 - 19.3	100	10	10.0	5.2 - 18.0
AFRICAN AMERICAN	27	1	3.7	0.2 - 20.9	106	8	7.5	3.6 - 14.B
ATINO	22	0	0.0	0.0 - 14.7	24	0	0.0	0.0 - 13.6
SIAN/PACIFIC ISLANDER	14	2	14.3	2.5 - 43.B	13	0	0.0	0.0 - 23.1
ONE OF THE ABOVE (4)	9	0	0.0	0.0 - 62.6	4	0	0.0	0.0 - 53.5
·	========						=======	==== <b>==</b> ======
TOTAL	222	22	9.9	6.5 - 14.B	247	18	7.3	4.5 - 11.5

⁾ Oata collected between the 4th quarter of 1990 and the 3rd quarter of 1991; (2) Positive specimens were peatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, rmal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, known race, and missing race.

HIV SEROPREVALENCE FOR INJECTION ORUG USERS (IOUs) AND NON-INJECTION ORUG USERS (NON-IOUs) ENTERING A METHADONE-FREE OETOXIFICATION PROGRAM 8Y GENOER AND SEXUAL ORIENTATION, SAN FRANCISCO, 1990-1991 (1)

			IOUs		NON-IOUs				
GENOER ANO	NUM8ER	NUM8ER(2)	SERO- PREVALENCE		NUMBER	NUM8ER(2)	SERO- PREVALENCE		
SEXUAL ORIENTATION	TESTEO	POSITIVE		(95% C.I.)(3)	NUMBER TESTEO	POSITIVE	RATE (%)		C.I.)(3)
MALE									
Homosexual/8isexual	29	11	37.9	21.3 - 57.6	12	8	66.7	25 /	- 88.7
Heterosexual			7.0	3.3 - 13.7		_	4.2		- 9.2
	115	<u>8</u> 			144	<u>6</u> 14	9.0		
SU8-TOTAL: MALE	144	19	13.2	8.3 - 20.1	156	14	9.0	5.2	- 14.9
FEMALE									
Lesbian/Bisexual	5	0	0.0	0.0 - 46.7	8	0	0.0	0.0	- 33.7
Heterosexual	63	1	1.6	0.I - 9.7	66	1	1.5		- 9.3
SU8-TOTAL: FEMALE	68		1.5	0.1 - 9.0	74	<del>-</del>	1.4		- 8.3
SUO-TUTAL: FEMALE	00	1	1.5	0.1 - 9.0	/4	1	1.4	0.1	- 0.3
MISSING GENOER ANO/OR	10	2	20.0	3.5 - 55.8	17	3	17.6	1.7	- 44.2
SEXUAL ORIENTATION	10	2	20.0	3.3 - 33.6	1'	3	17.0	4.7	- 44.2
SEXUAL UNITATION									
					+				======
TOTAL	222	22	9.9	6.5 - I4.8	247	18	7.3	4.5	- 11.5

HIV SEROPREVALENCE FOR INJECTION ORUG USERS (IOUs) AND NON-INJECTION ORUG USERS (NON-IOUs) ENTERING A METHADONE-FREE OETOXIFICATION PROGRAM 8Y ORUG PREFERENCE, SAN FRANCISCO, 1990-1991 (1)

	IOUs					NON-IOUs				
PRIMARY ORUG	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUM8ER TESTEO	NUM8ER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)		
HEROIN COCAINE/CRACK AMPHETAMINES/SPEEO OTHER OR UNSPECIFIEO ORUGS	154 13 50 5	10 0 12 0	6.5 0.0 24.0 0.0	3.3 - 11.9 0.0 - 23.1 13.5 - 38.5 0.0 - 46.7	11 146 10 80	1 9 4 4	9.1 6.2 40.0 5.0	0.5 - 42.9 3.0 - 11.7 13.7 - 72.6 1.6 - 13.0		
TOTAL	222	22	9.9	6.5 - 14.B	247	18	7.3	4.5 - 11.5		

⁽¹⁾ Oata collected between the 4th quarter of 1990 and the 3rd quarter of 1991; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, unknown race, and missing race.

HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY GENDER AND TRANSMISSION CATEGORY (I)

		•	SER0~	
GENOER AND	NUM8ER	NUMBER(2)	PREVALENCE	
TRANSMISSION CATEGORY	TESTE0	POSITIVE	RATE (%)	(95% C.I.)(3)
MALE				
Homosexual/8isexual	35	28	80.0	62.5 - 90.9
Homosexual/8isexual, IOU	17	13	76.5	49.8 - 92.2
Heterosexual IOU	17	3	17.6	4.7 - 44.2
Heterosexual (4)	135	7	5.2	2.3 - 10.8
Unknown Risk	13	0	0.0	0.0 - 23.I
SU8-TOTAL MALE	217	51	23.5	18.1 - 29.8
FEMALE				
Heterosexual IOU	5	1	20.0	1.1 - 70.I
Heterosexual (4)	55	0	0.0	0.0 - 6.3
Unknown Risk	10	0	0.0	0.0 - 28.5
SU8-TOTAL FEMALE	70	1	1.4	0.1 - 8.8
TOTAL	287	52	18.1	13.9 - 23.2

HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (T8) AT A MUNICIPAL T8 CLINIC IN SAN FRANCISCO BY ORIGIN OF BIRTH (1)

ORIGIN OF BIRTH	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
80RN IN USA 80RN OUTSIDE USA	124 163	45 7	36.3 4.3	28.0 - 45.5 1.9 - 9.0
TOTAL	287	52	18.1	13.9 - 23.2

⁽I) Survey of Risk Behaviors (SR8). Oata collected between the Ist quarter of 1990 to the 3rd quarter 1991; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes self-identified heterosexuals with no identified risk, persons with a history of blood transfusion(s) or with a bleeding disorder, and persons with a sexual partner(s) at risk for HIV/AIDS.

HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY AGE-GROUP (1)

			SERO-	
	NUM8ER	NUM8ER(2)	PREVALENCE	
AGE-GROUP (YEARS)	TESTEO	POSITIVE	RATE (%)	(95% C.I.)(3)
	_	_		
19 ANO UNDER	8	0	0.0	0.0 - 33.7
20 - 24	15	3	20.0	5.3 - 48.6
25 - 29	38	8	21.1	10.1 - 37.8
30 - 34	46	8	17.4	8.3 - 32.0
35 - 39	35	13	37.1	22.0 - 55.1
40 - 44	37	12	32.4	18.6 - 49.9
45 AND OVER	108	8	7.4	3.5 - 14.5
TOTAL	287	52	18.1	13.9 - 23.2

HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY RACE/ETHNICITY (1)

			SERO-	
	NUM8ER	NUMBER(2)	PREVALENCE	
RACE/ETHNICITY	TESTEO	POSITIVE	RATE (%)	(95% C.I.)(3)
HILTE	50	00		00.4 55.0
WHITE	56	23	41.1	28.4 - 55.0
AFRICAN AMERICAN	56	17	30.4	19.2 - 44.3
LATINO	57	9	15.8	7.9 - 28.4
ASIAN/PACIFIC ISLANDER	111	1	0.9	0.0 - 5.6
NONE OF THE ABOVE (4)	7	2	28.6	5.1 - 69.7
TOTAL	287	52	18.1	13.9 - 23.2

⁽¹⁾ Survey of Risk 8ehaviors (SR8). Oata collected between the 1st quarter of 1990 and the 3rd quarter 1991; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

11V SEROPREVALENCE FOR HIGH-RISK ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER AND HOMELESS YOUTH CENTERS BY GENDER AND TRANSMISSION CATEGORY, SAN FRANCISCO, 1990-1991 (1)

NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)		NUMBER TESTED	NUMBER(2) POSITIVE		(95% C.I.)(3
4	1	25.0	1.3 - 78.1	46	21	45.7	31.2 - 60.8
7	0	0.0	0.0 - 37.2	22	0	0.0	0.0 - 14.7
460	3	0.7	0.2 - 2.1	90	0	0.0	0.0 - 3.9
3	0	0.0	0.0 - 62.6	3	0	0.0	0.0 - 62.6
474	4	0.8	0.3 - 2.3	161	21	13.0	8.4 - 19.5
4	0	0.0	0.0 - 53.5	30	1	3.3	0.2 - 19.1
148	0	0.0	0.0 - 2.4	218	3	1.4	0.4 - 4.3
2	0	0.0	0.0 - 75.2	9	0	0.0	0.0 - 30.9
154	0	0.0	0.0 - 2.3	257	4	1.6	0.5 - 4.2
2	0	0.0	0.0 - 75.2	3	0	0.0	0.0 - 62.6
	4 7 460 3 474 4 148 2 2 154	TESTED POSITIVE  4 1 7 0 460 3 3 0 474 4  4 0 148 0 2 0 154 0	TESTED POSITIVE RATE (%)  4 1 25.0 7 0 0.0 460 3 0.7 3 0 0.0 474 4 0.8  4 0 0.8  4 0 0.0 148 0 0.0 2 0 0.0 154 0 0.0	TESTED POSITIVE RATE (%) (95% C.I.)(3)  4	TESTED POSITIVE RATE (%) (95% C.I.)(3) TESTED  4 1 25.0 1.3 - 78.1 46 7 0 0.0 0.0 - 37.2 22 460 3 0.7 0.2 - 2.1 90 3 0.0 0.0 - 62.6 3  474 4 0.8 0.3 - 2.3 161  4 0 0.0 0.0 - 53.5 30 148 0 0.0 0.0 - 2.4 218 2 0 0.0 0.0 - 75.2 9  154 0 0.0 0.0 - 2.3 257	TESTED POSITIVE RATE (%) (95% C.I.)(3) TESTED POSITIVE  4 1 25.0 1.3 - 78.1 46 21 7 0 0.0 0.0 - 37.2 22 0 460 3 0.7 0.2 - 2.1 90 0 3 0 0.0 0.0 - 62.6 3 0 474 4 0.8 0.3 - 2.3 161 21  4 0 0.0 0.0 - 53.5 30 1 148 0 0.0 0.0 - 2.4 218 3 2 0 0.0 0.0 - 75.2 9 0 154 0 0.0 0.0 - 2.3 257 4	TESTED         POSITIVE         RATE (%)         (95% C.I.)(3)         TESTED         POSITIVE         RATE (%)           4         1         25.0         1.3 - 78.1         46         21         45.7           7         0         0.0         0.0 - 37.2         22         0         0.0           460         3         0.7         0.2 - 2.1         90         0         0.0           3         0         0.0         0.0 - 62.6         3         0         0.0           474         4         0.8         0.3 - 2.3         161         21         13.0           4         0         0.0         0.0 - 53.5         30         1         3.3           148         0         0.0         0.0 - 2.4         218         3         1.4           2         0         0.0         0.0 - 75.2         9         0         0.0           154         0         0.0         0.0 - 2.3         257         4         1.6

⁾ These surveys of high-risk adolescents are unlinked (blinded) surveys. Blood specimens are drawn for syphilis screening individuals as part of the routine intake process or initial entrance evaluation. Specimens were collected consecutively did tested after all personal identifiers had been removed from the specimen; (2) All positive specimens were speatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, simmal approximation method; (4) Self-identified heterosexuals with no other identified risks.

HIV SEROPREVALENCE FOR HIGH-RISK ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER AND HOMELESS YOUTH CENTERS 8Y AGE-GROUP, SAN FRANCISCO, 1990-1991 (1)

		JUVENILE OETENTION CENTER					HOMELESS YOUTH CENTERS			
AGE-GROUP (YEARS)	NUM8ER TESTEO	NUM8ER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUM8ER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)			
UNOER 15 15 - 19 20 - 24 MISSING	107 503 3 17	0 4 0	0.0 0.8 0.0 0.0	0.0 - 3.3 0.3 - 2.2 0.0 - 62.6 0.0 - 18.4	56 329 32 4	0 14 10 1	0.0 4.3 31.2 25.0	0.0 - 6.2 2.4 - 7.2 16.8 - 50.1 1.3 - 78.1		
TOTAL	630	4	0.6	0.2 - 1.7	421	25	5.9	4.0 - 8.8		

HIV SEROPREVALENCE FOR HIGH-RISK ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER AND HOMELESS YOUTH CENTERS BY RACE/ETHNICITY, SAN FRANCISCO, 1990-1991 (1)

		JUVENILE	OETENTION (	CENTER	HOMELESS YOUTH CENTERS				
RACE/ETHNICITY	NUM8ER TESTEO	NUM8ER(2) POSITIVE	SERO- PREVALENCE RATE (%)		NUMBER TESTED	NUM8ER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	
WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	59 381 119 60 11	0 3 1 0	0.0 0.8 0.8 0.0	0.0 - 5.9 0.2 - 2.5 0.0 - 5.3 0.0 - 5.8 0.0 - 26.4	184 101 91 35 10	12 5 3 3 2	6.5 5.0 3.3 8.6 20.0	3.6 - 11.4 1.8 - 11.7 0.9 - 10.0 2.2 - 24.2 3.5 - 55.8	
TOTAL	630	4	0.6	0.2 - 1.7	421	25	5.9	4.0 ~ 8.8	

⁽¹⁾ These surveys of high-risk adolescents are unlinked (blinded) surveys. 8lood specimens are drawn for syphilis screening on individuals as part of the routine intake process or initial entrance evaluation. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, unknown race, and missing race.

HIV SEROPREVALENCE FOR 8L000 00NORS FROM THE SAN FRANCISCO 8AY AREA 8Y YEAR OF OONATION, MARCH 1985 - JUNE 1991 (1)

			SERO-	
YEAR OF	TOTAL	NUM8ER(2)	PREVALENCE	
OONATION	OONATIONS	POSITIVE	RATE (%)	(95% C.I.)(3)
1985	72,204	80	0.111	0.088 - 0.13
1986	88,168	40	0.045	0.033 - 0.06
1987	91,396	30	0.033	0.023 - 0.04
1988	90,192	23	0.026	0.017 - 0.03
1989	87,320	10	0.011	0.006 - 0.02
1990	84,578	11	0.013	0.007 - 0.02
1991	44.300	2	0.005	0.001 - 0.01
		=======		
TOTAL	558,158	196	0.035	0.030 - 0.04

HIV SEROPREVALENCE FOR 8LOOD ODNORS FROM THE SAN FRANCISCO 8AY AREA 8Y ODNATION STATUS AND GENOER, JANUARY 1, 1989 - JUNE 1, 1991 (1)

OONATION STATUS	GENOER	TOTAL OONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
FIRST-TIME	Male	26,558	14	0.053	0.030 - 0.091
OONORS	Female	27,239	2	0.007	0.001 - 0.030
REPEAT	Male	85,546	5	0.006	0.002 - 0.014
OONORS	Female	72,731	5	0.007	0.003 - 0.017
	••••				
TOTAL		212,074	26	0.012	0.008 - 0.018

⁽¹⁾ Oata were provided courtesy of the Irwin Memorial 8lood Centers, San Francisco, CA.; Oata for 1991 are still incomplete; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (3) 95% Confidence Intervals, normal approximation method.

HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY RACE/ETHNICITY, JANUARY 1, 1989 - JUNE 1, 1991 (1)

	TOTAL	NUMBER(2)	SERO- PREVALENCE	
RACE/ETHNICITY	DONATIONS	POSITIVE	RATE (%)	(95% C.I.)(3)
			•	
WHITE	179,527	11	0.006	0.003 - 0.01
BLACK	9,119	7	0.077	0.034 - 0.16
LATINO	7,960	8	0.101	0.047 - 0.20
NONE OF THE ABOVE	(4) 15,468	0	0.000	0.000 - 0.02
	==========	********		
TOTAL	212,074	26	0.012	0.008 - 0.01

HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY AGE-GROUP, JANUARY 1, 1989 - JUNE 1, 1991 (1)

AGE-GROUP (YEARS)	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
19 AND UNDER	15,016	0	0.000	0.000 - 0.024
20 - 29	41,801	6	0.014	0.006 - 0.033
30 - 39	61,180	14	0.023	0.013 - 0.039
40 AND OVER	94,076	6	0.006	0.003 - 0.015
TOTAL	212,073	26	0.012	0.008 - 0.018

⁽¹⁾ Data were provided courtesy of the Irwin Memorial Blood Centers,
San Francisco, Ca.; (2) Positive specimens were repeatedly reactive
by ELISA and confirmed by a Western blot assay; (3) 95% Confidence Intervals,
normal approximation method; (4) Includes Asian/Pacific Islanders,
American Indians, Alaskan Natives, other race, and unknown race.

HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENOER AND YEAR (1)(2)

	1985			1986		1987		1988			1989				
GENOER	N(3)	HIV+(4	1) %(5)	N	HIV+	%	N	HIV+	%	N	HIV+	%	N	HIV+	%
MALE FEMALE	213 45	0	0.0	941 183	9 1	1.0	869 143	5	0.5	759 178	2	0.3	711 124	2	0.3
TOTAL	258	0	0.0	1124	10	0.9	1012	5	0.5	937	2	0.2	835	3	0.4

	1990				1991		TOTAL		
GENOER	N	HIV+	%	N	HIV+	%	N	HIV+	%
MALE FEMALE	522 105	0	0.0	202	1 0	0.5	4217 811	19	0.5
TOTAL	627	0	0.0	235	1	0.4	5028	21	0.4

⁽¹⁾ Oata provided by the U.S. Oepartment of Defense, and the Centers for Oisease Control (COC); (2) Oata collected between October 1985 and June 1991; (3) Number tested; (4) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (5) Seroprevalence rate (%).

HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENOER AND AGE GROUP (1)(2)

		MAL	.E		FEMALE				
AGE-GROUP (YEARS)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	
	1740	2	0.1	2.0 0.5	001	0	0.0	2.0 0.5	
19 ANO UNOER	1742	2	0.1	0.0 - 0.5	291	0	0.0	0.0 - 0.5	
20 - 24	1331	4	0.3	0.1 - 0.8	262	1	0.4	0.1 - 0.8	
25 - 29	678	6	0.9	0.4 - 2.0	134	1	0.7	0.4 - 2.0	
30 ANO OVER	466	7	1.5	0.7 - 3.2	124	0	0.0	0.7 - 3.2	
TOTAL	4217	19	0.5	0.3 - 0.7	811	2	0.2	0.3 - 0.7	

HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENOER AND RACE/ETHNICITY (1)(2)

		MAL	LE			FEMALE			
RACE/ETHNICITY	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	
WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE(5)	1470 799 446 1346 156	10 7 1 0	0.7 0.9 0.2 0.0 0.6	0.3 - 1.3 0.4 - 1.9 0.0 - 1.4 0.0 - 0.3 0.0 - 4.1	300 192 74 213 32	2 0 0 0	0.7 0.0 0.0 0.0 0.0	0.1 - 2.7 0.0 - 1.9 0.0 - 4.7 0.0 - 1.7 0.0 - 10.5	
TOTAL	4217	19	0.5	0.3 - 0.7	811	2	0.2	0.0 - 1.0	

⁽¹⁾ Oata provided by the U.S. Department of Oefense, and the Centers for Oisease Control (COC); (2) Oata collected between October 1985 and June 1991; (3) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (4) 95% Confidence Intervals, normal approximation method; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

## 57 P70 #58 4/92

## HIV SEROPREVALENCE REPORT

San Francisco Department of Public Health AIDS Office

April 1992 Vol. 3 Nos. 1 & 2

CONTENTS

DOCUMENTS DEPT.

23

23

	-
SPECIAL PEROPT	Page
SPECIAL REPORT Summary of Conclusions from the HIV Concensus Meeting SAN FRANCISCO	
Estimated HIV Incidence & Prevalence in San Francisco in 1992 LIBRARY	1
SURVEY FINDINGS FROM THE YOUNG MEN'S SURVEY (YMS)	
HIV Seroprevalence for Participants by Age Group and Race/Ethnicity	2
HIV Seroprevalence for Participants by Gender of Sexual Partners & No. of Lifetime Male Partners	3
SURVEY OF CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLIN	IC: 1989-1991
HIV Seroprevalence for Clients Attending an STD Clinic by Gender and Transmission Category	4
HIV Seroprevalence for Clients Attending an STD Clinic by Age Group	5
HIV Seroprevalence for Clients Attending an STD Clinic by Race/Ethnicity	6
HIV Seroprevalence for Homosexual & Bisexual Men Attending an STD Clinic by Age Group	7
HIV Seroprevalence for Homosexual & Bisexual Men Attending an STD Clinic by Race/Ethnicity	8
HIV Seroprevalence for Heterosexual Males Attending an STD Clinic by Age Group	9
HIV Seroprevalence for Heterosexual Males Attending an STD Clinic by Race/Ethnicity	10
HIV Seroprevalence for Heterosexual Females Attending an STD Clinic by Age Group	11
HIV Seroprevalence for Heterosexual Females Attending an STD Clinic by Race/Ethnicity	12
SURVEYS OF WOMEN OF REPRODUCTIVE AGE: FAMILY PLANNING & ABORTON CL CLIENTS	INIC
HIV Seroprevalence for Women Attending a Family Planning Clinic by Transmission Category	13
HIV Seroprevalence for Women Attending a Family Planning Clinic by Age Group	14
HIV Seroprevalence for Women Attending a Family Planning Clinic by Race/Ethnicity	15
HIV Seroprevalence for Women Attending an Abortion Clinic by Transmission Category	16
HIV Seroprevalence for Women Attending an Abortion Clinic by Age Group	17
HIV Seroprevalence for Women Attending an Abortion Clinic by Race/Ethnicity	17
SURVEY OF CHILDBEARING WOMEN IN SAN FRANCISCO, 1989-90	
HIV Seroprevalence for Newborn Infants and their Mothers by Age Group and Race/Ethnicity	18
SURVEY OF INJECTION DRUG USERS (IDUs) ENTERING METHADONE TREATMENT P	ROGRAMS
HIV Seroprevalence for IDUs Entering Methadone Treatment by Age Group and Race/Ethnicity	19
HIV Seroprevalence for IDUs Entering Methadone Treatment by Gender & Sexual Orientation	20
HIV Seroprevalence for IDUs Entering Methadone Treatment by Treatment Modality	20
HIV Seroprevalence for IDUs Entering Methadone Treatment by Quarter and Year of Entry	21
SURVEY OF DRUG USERS (IDUs & NON-IDUs) ENTERING A METHADONE-FREE DETO	X PROGRAM
HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Age Group	22
HIV Seroprevalence for Clients Entering a Drug-Eree Detox Program by Race/Ethnicity	22

HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Sexual Orientation

HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Drug Use Preference

## SURVEY OF PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A TB CLINIC

HIV Scroprevalence for TB Patients by Age Group and Race/Ethnicity	25
SURVEY OF ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER & HOMEI CENTERS	LESS YOUTH
HIV Seroprevalence for High-Risk Adolescents by Age Group and Race/Ethnicity	26
HIV Seroprevalence for High-Risk Adolescents by Gender and Transmission Category	27
RESULTS OF HIV SCREENING OF BLOOD DONORS FROM THE SAN FRANCISCO BAY 1991	Y AREA: 1985-
HIV Seroprevalence for Blood Donors by Year of Donation, Donation Status, and Gender	28
HIV Seroprevalence for Blood Donors by Age Group and Race/Ethnicity	29
RESULTS OF HIV SCREENING OF CIVILIAN APPLICANTS FOR MILITARY SERVICE:	1985-1991
HIV Seroprevalence for Civilian Applicants for Military Service by Gender and Year	30
HIV Seroprevalence for Civilian Applicants for Military Service by Gender and Age Group	31
HIV Seroprevalence for Civilian Applicants for Military Service by Gender and Race/Ethnicity	31

HIV SEROPREVALENCE REPORT is released on a quarterly basis by the San Francisco Department of Public Health AIDS Office Surveillance Branch, 25 Van Ness Avenue, Suite 500, San Francisco, CA 94102-6033. Phone (415) 554-9050. AIDS Office Director, Sandra R. Hernandez, MD. AIDS Surveillance Branch Chief, George F. Lemp, DrPH. Program Coordinator, Sean Nguyen. Epidemiologist/Data Manager, Tim Kellogg. Funding and technical support is provided by the Division of HIV/AIDS, Centers for Disease Control. Additional support is provided by the California Department of Health Services Office of AIDS.

ESTIMATED HIV INCIDENCE AND PREVALENCE IN SAN FRANCISCO IN 1992, SUMMARY OF CONCLUSIONS FROM THE HIV CONSENSUS MEETING (1)

	POPULATION	UTV DE	TVALENCE	ANN	
RISK GROUP	SIZE(2)	N(3)	PERCENT PERCENT	N(4)	PERCENT PERCENT
Gay/Bisexual Men:					
Non-IDUs					
Young (17-25 years)	5,000	600	12	200	4.0
Older (26+ years)	50,000	22,500	45	415	1.5
IDUs	3,000	1,900	63	35	3.5
Subtotal	58,000	25,000	43	650	2.0
Injection Drug Users					
Heterosexual Men	8,500	1,200	14	150	2.0
Women	4,500	500	11	80	2.0
Subtotal	13,000	1,700	13	230	2.0
Other Adults/Adolescents					
Heterosexual Men	253,000	250	0.1	50	0.02
Women	315,000	630	0.2	100	0.03
Subtota1	568,000	880	0.15	150	0.025
Infants and Children	85,000	85	0.1	5	0.03 (of birt
TOTAL	724,000	27,665	4	1,035	0.15

⁽¹⁾ The HIV Consensus Meeting was coordinated by the San Francisco Department of Public Health AIDS Office and was held on September 11th, 1991. The purpose of this meeting was to provide a forum where researchers could discuss their data and generate best estimates on the direction of the HIV/AIDS epidemic in San Francisco. The results of this meeting were intended to guide prevention efforts in the fight against HIV infection. The goals of this meeting were: 1) to assemble together AIDS researchers and epidemiologists to present their data on HIV infection among various risk populations in San Francisco, and 2) for these researchers to provide their scientific opinions on the direction of the epidemic so as to arrive at a consensus on the best estimate of HIV prevalence and incidence in San Francisco. Requests for the HIV Consensus Meeting Summary Report can be made to: San Francisco Department of Public Health AIDS Office, Surveillance Branch, 25 Van Ness Avenue 5th Floor, San Francisco, CA 94102 Phone (415) 554-9050. (2) Population estimates were based on a randomized telephone survey of gay/bisexual men conducted in 1989, a survey of gay and bisexual men of color conducted in 1990, population-based (household) risk behavior surveys of African-Americans, Latinos, Filipinos, Japanese, Chinese, and Southeast Asians, treatment data from Community Substance Abuse Services of the San Francisco Department of Public Health, 1991 street-based surveys conducted by the Urban Health Study, a household survey of AIDS in multi-ethnic neighborhoods (AMEN Cohort) conducted by the University of California, San Francisco, and the 1990 census. (3) Total number of persons living with HIV infection. (4) Number of new infections per year.

HIV SEROPREVALENCE FOR PARTICIPANTS OF THE YOUNG MEN'S SURVEY BY AGE-GROUP, SAN FRANCISCO, 1991 (1)

AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
17 - 19	21	3	14.3	3.8 - 37.4
20 - 22	93	13	14.0	7.9 - 23.1
23 - 25	144	15	10.4	6.1 - 16.9
TOTAL	258	31	12.0	8.4 - 16.8

HIV SEROPREVALENCE FOR PARTICIPANTS OF THE YOUNG MEN'S SURVEY, BY RACE/ETHNICITY, SAN FRANCISCO, 1991 (1)

RACE/ETHNICITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
WHITE	138	15	10.9	6.4 - 17.6
AFRICAN AMERICAN	35	8	22.9	11.0 - 40.6
LATINO	49	7	14.3	6.4 - 27.9
ASIAN/PACIFIC ISLANDER	33	0	0.0	0.0 - 10.2
NONE OF THE ABOVE (4)	3	1	33.3	1.8 - 87.5
TOTAL	258	31	12.0	8.4 - 16.8

⁽¹⁾ The Young Men's Survey (YMS) was a collaborative effort of the San Francisco Department of Public Health and the California Department of Health Services. The survey was conducted during the Spring of 1991 at seven gay-identified dance clubs and bars in San Francisco. All male patrons were screened upon entry to the club and recruited if they identified themselves as San Francisco residents and under 25 years of age. A total of 501 men were eligible, of which 258 (51%) agreed to participate. Structured interviews were conducted and blood specimens were drawn on site. Specimens were tested for HIV and markers to Hepatitis B (HBsAG and HBcAB) and syphilis (VDRL and MHA-TP); (2) All HIV positive specimens were repeatedly reactive by ELISA and confirmed by an IFA. Indeterminate HIV results were tested by a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, or unknown race.

HIV SEROPREVALENCE FOR PARTICIPANTS OF THE YOUNG MEN'S SURVEY BY GENDER OF SEXUAL PARTNERS, SAN FRANCISCO, 1991 (1)

GENDER OF PARTNERS (2)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)
ONLY MEN	99	9	9.1	4.5 - 17.0
MOSTLY MEN, SOME WOMEN	126	20	15.9	10.2 - 23.7
EQUALLY WITH MEN AND WOMEN	13	2	15.4	2.7 - 46.3
MOSTLY WOMEN, SOME MEN	16	0	0.0	0.0 - 19.4

HIV SEROPREVALENCE FOR PARTICIPANTS OF THE YOUNG MEN'S SURVEY BY NUMBER OF LIFETIME MALE PARTNERS, SAN FRANCISCO, 1991 (1)

NUMBER OF PARTNERS (2)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)
ONE PARTNER	8	0	0.0	0.0 - 33.7
2 - 9 PARTNERS	81	7	8.6	3.8 - 17.5
10 - 24 PARTNERS	73	6	8.2	3.4 - 17.6
25 - 49 PARTNERS	36	4	11.1	3.6 - 27.0
50 OR MORE PARTNERS	49	14	28.6	17.0 - 43.5

(1) The Young Men's Survey (YMS) was a collaborative effort of the San Francisco Department of Public Health and the California Department of Health Services. The survey was conducted during the Spring of 1991 at seven gay-identified dance clubs and bars in San Francisco. All male patrons were screened upon entry to the club and recruited if they identified themselves as San Francisco residents and under 25 years of age. A total of 501 men were eligible, of which 258 (51%) agreed to participate. Structured interviews were conducted and blood specimens were drawn on site. Specimens were tested for HIV and markers to Hepatitis B (HBsAG and HBcAB) and syphilis (VDRL and MHA-TP); (2) This analysis was limited to participants who admitted to at least one male sexual partner during their lifetime. (3) All HIV positive specimens were repeatedly reactive by ELISA and confirmed by an IFA. Indeterminate HIV results were tested by a Western blot assay; (4) 95% Confidence Intervals, normal approximation method.

HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTEO DISEASE CLINIC BY GENOER AND TRANSMISSION CATEGORY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (1)

		198	1989 SURVEY			1991	1990 SURVEY			1991	1991 SURVEY	
GENOER AND TRANSMISSION CATEGORY	NUMBER TESTED	NUMBER(2) POSITIVE	SERU- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERU- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERU- PREVALENCE RATE (%)	(95% C.1.)(3)
MALE												
Homosexual/Bisexual Homosexual/Bisexual, IOU	119	226 82	50.7	1.1	626 90	269 55	43.0	1.1	674 80	383	37.5 47.5	33.9 - 41.3 36.3 - 58.9
Heterosexual IDU Sex Partner at Risk for HIV	823	52.	L.2.	1.1	<u>5</u>	<b>დ</b> თ .	7.9 8.7	1.1	8 ₁ 2,	04	3.3	3.8 - 14.4 1.1 - 8.7
Blood Recipient (4) Heterosexual (5) Unknown Risk	202 8	-40	40 2.40	0.2 - 24.0 0.8 - 2.4 0.0 - 33.7	1381	- 62 S	2.1 13.4	0.6 - 49.3 1.4 - 3.0 9.0 - 19.3	1663	15	2.5 26.8	1.8 - 3.4 16.2 - 40.5
SUB-TOTAL MALE	1788	338	18.9	17.1 - 20.8	2497	396	15.9	14.5 - 17.4	2713	360	13.3	12.0 - 14.6
FEMALE												
Heterosexual IDU Sex Partner at Risk for HIV Blood Recipient (4) Heterosexual (5) Unknown Risk	88188	880	    	3.4 - 20.7 0.1 - 10.5 0.5 - 42.9 0.2 - 2.5 0.0 - 46.7	088 o 24 e	2	8.1 7.5 7.0 0.0	3.1 - 19.1 0.1 - 11.0 0.9 - 63.5 1.3 - 4.2 0.0 - 16.7	25 68 29 29	mm0@-	3.20 3.20 4.20	1.3 - 15.1 1.1 - 12.5 0.0 - 62.6 0.5 - 2.4 0.2 - 19.6
SUB-TOTAL FEMALE	209	0.	2.0	1.0 - 3.7	189	50	5.9	1.9 - 4.6	849	15	1.8	1.0 - 3.0
TOTAL 2297	2297	348	15.2	13.7 – 16.7	3178	416	13.1	11.9 - 14.3	3562	375	10.5	10.5 9.5 - 11.6

(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STO episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (3) 45% Confidence Intervals, normal approximation method; (4) Includes persons with a history of blood transfusion(s) between January 1977 - March 1985; (5) The Ludes persons with a history of blood transfusion(s) between January 1977 - March 1985;

		198	1989 SURVEY			199	1990 SURVEY			1991	1 SURVEY	
AGE-GROUP (YEARS)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERU- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERU- PREVALENCE RATE (%)	(95 <b>%</b> C.1.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN	223 526 526 550 403 188 153 153	35 33 35 27 23 38 88 88 39 50 50 50 50 50 50 50 50 50 50 50 50 50	1.3 6.7 16.9 21.8 25.7 17.1 19.0	0.3 - 4.2 4.7 - 9.2 18.9 - 20.4 18.0 - 31.3 20.8 - 31.3 11.8 - 24.1	274 708 785 785 382 382 223 226 10	9 \$ 401 E C C C C C C C C C C C C C C C C C C	2.2 13.2 13.8 17.0 13.7 0.0	0.9 4.9 3.4 6.7 16.7 - 15.9 10.5 - 28.2 12.5 - 22.8 0.0 - 19.1	290 834 834 607 391 262 265 17	25 88 103 75 75 49 49	0.3 10.6 17.0 18.7 7.21 5.9	0.0 - 2.2 1.9 - 4.2 18.6 - 12.9 18.1 - 23.2 18.3 - 24.1 18.3 - 24.1 0.3 - 30.8
T0TAL 2297	2297	348	15.2	13.7 - 16.7	3178	416	13.1	11.9 - 14.3	3562	375	10.5	9.5 - 11.6

HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (1)

		1989 8	9 SURVEY			199	1990 SURVEY			1991	1 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	SERU- PREVALENCE RATE (%)	SERU- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERU- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERU- PREVALENCE RATE (%) (95% C.I.)(3)
WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	916 828 371 138 44	209 76 52 5	22.8 9.2 14.0 4.3	20.2 - 25.7 7.3 - 11.4 10.7 - 18.1 1.8 - 9.6 4.3 - 25.4	1210 1178 564 183 43	219 111 68 13	18.1 9.4 12.1 7.1	16.0 - 20.4 7.8 - 11.3 9.5 - 15.1 4.0 - 12.1 4.4 - 25.9	1428 1167 675 233 59	209 78 67 14	14.6 6.7 9.9 6.0 11.9	12.9 - 16.6 5.3 - 8.3 7.8 - 12.5 3.5 - 10.1 5.3 - 23.5
T0TAL 2297	2297	348	15.2	13.7 - 16.7	3178	416	13.1	11.9 - 14.3	3562	375	10.5	9.5 - 11.6
						- 1. 14 1			1.4			

⁽¹⁾ These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; 62 All postitive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Mestern blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Mative ancestry, other race, and unknown race.

		1988	1989 SURVEY			199	1990 SURVEY			199	1991 SURVEY	
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERU- PREVALENCE RATE (%)	SERU- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERU- PREVALENCE RATE (%) (95% C.1.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERU- PREVALENCE RATE (%)	SERU- PREVALENCE RATE (%) (95% C.I.)(3)
19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER UNKNOMN		26 26 27 27 27 0	0.0 41.9 58.3 60.2 43.9 44.3	0.0 - 75.2 29.8 - 55.1 52.9 - 69.6 49.4 - 69.1 50.5 - 69.1 31.0 - 57.6 31.8 - 57.5		27 27 80 87 87 87 00 0	14.3 33.3 53.5 53.5 0.0	14 2 14.3 2.5 - 43.8 81 27 33.3 23.5 - 44.8 174 80 46.0 38.5 - 53.7 168 87 51.8 44.0 - 62.2 129 69 53.5 44.5 - 62.2 62 30 48.4 35.7 - 61.3 87 29 33.3 23.8 - 44.3 1 0 0.0 9.0 - 92.7	01 86 120 120 120 80 80 1	16 17 17 18 18 18 18 18 18 18 18 18 18 18 18 18	10.0 18.6 38.3 47.4 46.7 41.9 30.0	10.0 0.5 - 45.9 18.6 11.3 - 28.8 38.3 31.5 - 45.5 47.4 39.9 - 55.1 46.7 37.6 - 56.0 30.0 20.5 - 41.4 0.0 0.0 - 92.7
TOTAL S65	F1	308	54.5	308 54.5 50.3 - 58.7		324	45.3	41.6 - 49.0	754	291	38.6	35.1 - 42.2
(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested after all personal (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Mestern blot assay; (3) 95% Confidence Intervals, normal approximation method.	urveys wer episode. e repeated normal app	e drawn from Specimens Ily reactive proximation n	n blood spectors collection by ELISA armethod.	re drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; dly reactive by ELISA and confirmed by an IFA and a Mestern blot assay; proximation method.	for routing y and teste an IFA and	ne syphilis ad after all a Western b	screening of personal in lot assay;	n individuals se dentifiers had b	eking evalu sen removed	ation, exam from the s	ination, pecimen;	

HIV SEROPREVALENCE FOR HOMOSEXUAL AND BISEXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (1)

		1985	1989 SURVEY			1990	1990 SURVEY			199	1991 SURVEY	
RACE/ETHNICITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERU- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERU- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERU- PREVALENCE RATE (%)	SERU- PREVALENCE RATE (%) (95% C.I.)(3)
WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	379 87 78 14	195 56 4 4 5	51.5 64.4 61.5 28.6 71.4	46.3 - 56.6 53.3 - 74.1 49.8 - 72.1 9.6 - 58.0 30.3 - 94.9	456 117 107 28 8	188 74 50 8 8	41.2 63.2 46.7 28.6 50.0	41.2 36.7 - 45.9 63.2 53.8 - 71.8 46.7 37.1 - 56.6 28.6 14.0 - 48.9 50.0 17.5 - 82.5	526 84 105 11	181 4 4 4 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6	34.4 52.4 45.7 42.9 54.5	30.4 - 38.7 41.3 - 63.3 36.1 - 55.7 25.0 - 62.6 24.6 - 81.9
TOTAL	565	308	54.5	50.3 - 58.7	91.2	324	45.3	41.6 - 49.D	754	291	38.6	35.1 - 42.2
(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.	episode. repeated:	e drawn from Specimens v ly reactive s persons of	n blood spec were collect by ELISA an f American I	thens collected sed consecutivel d confirmed by ndian and Alask	for routin y and teste an IFA and an Native a	e syphilis d d after all a Western b ncestry, otl	screening o personal i lot assay; her race, a	n individuals ser dentifiers had by (3) 95% Confiden nd unknown race.	eking evalu een removec ce Interval	nation, exam I from the s S,	ination, pecimen.	

		1989	υ,			199	1990 SURVEY			1991	0)		
AGE-GROUP (YEARS)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	SERU- PREVALENCE RATE (%) (95% C.I.)(4)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%) (	(95% C.I.)(4)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERU- PREVALENCE RATE (%)	(95% C.I.)(4)	(4)
19 AND UNGER 20 - 24 25 - 29 30 - 34 35 - 34 40 - 44 45 AND OVER UNKNOWN	127 316 271 183 96 62 61		00.04.00.0. 8044-00.1	0.0000000000000000000000000000000000000	157 360 392 232 159 159 4	04 <u>5</u> E&&-0		0.22 - 5.0 1.34 - 3.0 2.35 - 4.8 2.45 - 4.8 2.46 - 10.0 0.0 - 9.3 0.1 - 9.3 0.1 - 5.8 0.1 - 5.8	158 498 424 286 175 133 8	040050	0.00%	0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01	2.2 2.2 2.2 5.0 5.5 5.3 5.3 3.3
TOTAL	1116	18	1.6	1.0 - 2.6	1493	39	2.6	1.9 - 3.6	1785	45	2.5	1.9 - 3.4	3.4
(1) Includes betanneasuals with a sex nartheor(s) at risk for HIV betanneasuals with a history of blood transfusion(s), and betanneasuals with no identified risk:	h a cex oa	introprise) at	rick for Hi	TV. heterosexu	ale with a hi	istory of bl	and transfus	ston(s), and he	terosexuals	with no ide	ntified ris		

(1) Includes betrosexular virt a sex partner(2) at risk for HIV, beterosexular with a history of blood traintisor(8), and neterosexular with no identified to individuals seeking evaluation, examination, and/our treatment for a NEW STO episode. Specimens were collected for routine syphilis screening on individuals seeking evaluation, examination, and/our treatment for a NEW STO episode. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (3) AIT positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay;

		198	1989 SURVEY			19	1990 SURVEY			199.	1991 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(3) POSITIVE	SERU- PREVALENCE RATE (%)	SERU- PREVALENCE RATE (%) (95% C.I.)(4)	(4) NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	SERU- PREVALENCE RATE (%) (95% C.I.)(4)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	SERU- PREVALENCE RATE (%) (95% C.I.)(4)
WHITE AFRICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (5)	323 482 213 79 19	≈ 0 c c c c c c c c c c c c c c c c c c	2.1 0.0 0.0	0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0	415 9 688 7 7 288 8 8 84 7 18	<u> </u>	2.7 3.3.1 0.0	1.4 - 4.8 1.6 - 4.2 1.5 - 6.1 0.1 - 7.4 0.0 - 17.5	497 743 398 122 25	5500	4.2.6. 0.1.0.0 0.0.0	2.4 2.6 2.6 3.0 1.6 1.6 0.0 0.0 1.6 0.0 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6
T0TAL 1116	1116	18	1.6	1.0 - 2.6	6 1493	39	2.6	1.9 - 3.6	1785	45	2.5	1.9 - 3.4
(1) Includes heterosexuals with a sex partner(s) at risk for HIV, heterosexuals with a history of blood transfusion(s), and het (2) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals as and/or treatment for a NEW SID epistode. Specimens were collected consecutively and tested after all personal identifiers had it positives specimens were repeatedly reactive by ELISA and confrimed by an IFA and a Mestern blot assay; (4) 95% Confider (3) All positives specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Mestern blot assay; (4) 95% Confider (5) And a proveniation method; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.	h a sex paurveys were episode. e repeated	urtner(s) at e drawn fro Specimens Ny reactive	risk for Hi m blood spec were collect by ELISA ar	IV, heterose cimens collected consecution and confirmed Indian and	exuals with a sected for routinely and tell by an IFA a laskan Nativ	history of b tine syphilis sted after al nd a Western e ancestry, o	lood transfus screening on 1 personal id olot assay; ther race, an	partner(s) at risk for HIV, heterosexuals with a history of blood transfusion(s), and heterosexuals with no identified risk; were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, e. Specimens were oflected consecutivity and tested after all personal identifiers had been removed from the specimen, tedly reactive by ELISA and confirmed by an IFA and a Hestern blot assay; (4) 95% Confidence Intervals, udes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.	eterosexuals seeking eval been remove ence Interva	with no ide uation, exam d from the s ls,	ntified risk ination, pecimen.	•

	SERU- PREVALENCE RATE (%) (95% C.I.)(3)	0.0 - 3.0 0.3 - 3.6 0.0 - 2.2 0.9 - 10.2 0.8 - 16.4 0.2 - 18.0 0.0 - 53.5	0.8 - 2.7	
1991 SURVEY	SERU- PREVALENCE RATE (%)	0.1.0.8.4.4.8.0. 0.1.0.4.4.0.0.	1.4	ntified risk; ination,
199	NUMBER(2) POSITIVE	0-00000-0	11	with no ide ation, exam
	NUMBER TESTEO	117 264 160 89 45 50 32	761	erosexuals eking evalu
	SERU- PREVALENCE RATE (%) (95% C.I.)(3)	0.4 - 8.7 0.0 - 3.3 0.9 - 7.7 1.6 - 13.0 1.8 - 19.7 0.2 - 20.2 0.0 - 13.6	2.5 1.5 - 4.2	ion(s), and het individuals se
1990 SURVEY	SERO- PREVALENCE RATE (%)	.00.00.00.00 .00.00.00	2.5	ood transfus screening on
199	NUMBER(2) POSITIVE	N−44m-00	15	story of blue syphilis
	NUMBER TESTED	198 195 133 133 14 24 4 4	602	s with a hi for routin
	SERU- PREVALENCE RATE (%) (95% C.I.)(3)	0.4 - 8.8 0.3 - 6.2 0.0 - 6.2 0.0 - 8.5 0.0 - 14.7 0.0 - 15.3	5 1.1 0.4 - 2.7	partnar(s) at risk for HIV, heterosexuals with a history of blood transfusion(s), and heterosexuals with no identified risk; were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination,
1989 SURVEY	SERO- PREVALENCE RATE (%)	2.1.0.0000 0.00000	1.1	risk for HI m blood spec
198	NUMBER(2) POSITIVE	NN-00000	5	irtner(s) at
	NUMBER TESTEO	123 101 53 53 22 22 0	449	
	AGE-GROUP (YEARS)	19 ANO UNOER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 ANO OVER UNKNOWN	TOTAL 449	(1) Includes heterosexuals with a sex (2) These unlinked (blinded) surveys

LY TRANSMITTED DISEASE CLINIC BY RACE/ETHNICITY	
SEASE (	
TRANSMITTED DI	
₹	
TEROSEXUAL FEMALES (1) ATTENDING A SEXU	£
(E)	1991
FEMALE	1989 - 1
	EAR OF SURVEY, SAN FRANCISCO, 1989
E FOR HE	×, يې
SEROPREVALENC	YEAR OF SURVE
HIV	AND

1991 SURVEY

1990 SURVEY

1989 SURVEY

					-							
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE		SERU- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERU- PREVALENCE RATE (%)	SERU- NUMBER(2) PREVALENCE POSITIVE RATE (%) (95% C.I.)(3)
WHITE AFRICAN AMERICAN LATINA ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	148 191 9 9	NM000	4.6.000	0.2 - 5.3 0.4 - 5.3 0.0 - 5.7 0.0 - 8.5 0.0 - 30.9	176 264 101 53 8	460	2.5. 0.0 0.0	0.7 - 6.1 1.7 - 6.6 0.1 - 6.2 0.1 - 11.4 0.0 - 33.7	266 269 136 74 16	88-00	0.0 0.0 0.0	0.7 - 4.6 0.7 - 4.5 0.0 - 4.5 0.0 - 4.7 0.0 - 19.4
TOTAL 449	449	5	1.1	0.4 - 2.7	602	15	2.5	1.5 - 4.2	761	11	1.4	0.8 - 2.7
(1) Includes heterosexuals with a sex (2) These unlinked (blinded) surveys w and/or treatment for a NEW STD episode (3) All positive specimens were repeat on mathem (4) All positive mathem (4) Incline mathem (5) Incline	th a sex particular s	urtner(s) at e drawn fro Specimens Ily reactive	risk for HI m blood spec were collect by ELISA an	V, heterosexua timens collected ed consecutive id confirmed by	Is with a hi I for routin Iy and teste an IFA and	istory of blue syphilis of after all a Western bundestry, of	lood transfus screening or personal ic plot assay; (	partner(s) at risk for HIV, heterosexuals with a history of blood transfusion(s), and heterosexuals with no identified risk; were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, e. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen. Additionable by ELISA and confirmed by an IFA and a Nestern blot assay; (4) 95% Confidence Intervals, indian and Alaskan Native ancestry, other race, and unknown race.	erosexuals eking evalu een removed ce Interval	with no ider ation, exam from the s	ntified risk ination, pecimen.	

		198	1989 SURVEY			199	1990 SURVEY			199.	1991 SURVEY	
TRANSMISSION CATEGORY	NUMBER	NUMBER(2) POSITIVE	SERU- PREVALENCE RATE (%)	SERU- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (X)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERU- PREVALENCE RATE (X)	SERU- PREVALENCE RATE (%) (95% C.I.)(3)
Heterosexual IDU Sex Partner at Risk for HIV Blood Recipient (4) Heterosexual (5) Unknown Risk (6)	0 0 0 0 1266	00004	0.3	0 24 0.0 0 24 0 0.0 0 1313 1 0 0.0 4 0.3 0.1 - 0.9	20 24 11 1313 8	-00-0	1	0.3 - 26.9 0.0 - 13.6 0.0 - 26.4 0.0 - 26.4 0.0 - 33.7 8	9 11 1925 8			1 11.1 0.6 - 49.3 0 0.0 0.0 - 26.4 2 0.1 0.0 - 53.5 0 0.0 0.0 - 33.7 0 0.0 - 33.7
TOTAL 1266	1266	4	0.3	0.1 - 0.9	1376	2		0.0 - 0.6	1957		0.2	0.0 - 0.5
(1) These unlinked (blinded) surveys were drawn from women seeking family planning services. Specimens were collected from inital and annual visit and tested for HIV after all personal identifiers had been removed; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by and a Western blot assay; (3) 95. Confidence Intervals, normal approximation; (4) Includes persons with a history of blood transfusion(s) between January 1977 - March 1985; (5) Self-identified heterosexuals with no other identified risks; (6) The 1989 unlinked survey did not collect risk info	urveys wer ersonal 10 95% Conf10 Self-1der	e drawn fro lentifiers h lence Intervitified heter	m women see ad been rem als, normal rosexuals w	ere drawn from women seeking family planning services. Specimens were collected from inital and annual visits, identifiers had been removed; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA idence Intervals, normal approximation; (4) Includes persons with a history of blood transfusion(s) between entified history of blood transfusion(s) between entified prisks; (6) The 1999 unlinked survey did not collect risk information.	ning servic sitive spec (4) Include ntified ris	ces. Specime cimens were as persons w sks; (6) The	ns were coll repeatedly r ith a histor 1989 unlink	ected from inita eactive by ELISA y of blood trans ed survey did no	il and annu and confi fusion(s)	al visits, rmed by an between risk inform	IFA ation.	

1989 SURVEY

					-				_			
AGE-GROUP (YEARS)	NUMBER	NUMBER(2) POSITIVE	SERU- PREVALENCE RATE (X)	SERU- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERU- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (X)	SERU- PREVALENCE RATE (%) (95% C.I.)(3)
19 ANO UNDER 20 – 24 25 – 29 35 – 34 35 – 39 40 – 44 45 ANO OVER UNKNOWN	73 420 414 226 105 18 3	040000	00000000	0.0 - 1.8 0.0 - 1.5 0.0 - 1.5 0.0 - 3.5 0.0 - 3.5 0.0 - 3.5	93 474 401 243 97 34 8	000-0-00	00000000	0.0 - 3.8 0.0 - 0.9 0.0 - 2.6 0.0 - 3.6 0.0 - 3.6 0.0 - 17.1 0.0 - 12.1	107 636 646 334 175 42 6	0000-000	00,000000	0.0 - 3.3 0.0 - 0.6 0.1 - 1.2 0.0 - 3.6 0.0 - 3.6 0.0 - 8.1 0.0 - 26.4
TOTAL 1266	1266	4	0.3	0.1 - 0.9	1376	2	١.0	0.0 - 0.6	1957	ю	0.2	0.0 - 0.5
(1) These unlinked (blinded) surveys wind tested for HIV after all personal	rveys were	e drawn from entifiers ha	n women seek ad been remo	ing family pla ved; (2) All p	nning servic	es. Speciment	repeatedly r	were drawn from women seeking family planning services. Specimens were collected from inital and annual visits, identifiers had been removed; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA	al and annu	al visits, rmed by an	IFA	

1991 SURVEY

1990 SURVEY

(1) These unlinked (blinded) surveys were drawn from women seeking family plar and tested for HIV after all personal identifiers had been removed; (2) All pot and a Western blot assay; (3) 95% Confidence Intervals, normal approximation.

		198	1989 SURVEY			1990	1990 SURVEY			199	1991 SURVEY	
RACE/ETHNICITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERU- REVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERU- PREVALENCE RATE (%)	SERU- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERU- PREVALENCE RATE (%)	SERU- PREVALENCE RATE (%) (95% C.I.)(3)
WHITE ARRICAN AMERICAN LATINA ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	122 154 810 149 31		00000	0.0 - 5.2 0.0 - 4.1 0.0 - 1.0 0.0 - 2.4 0.0 - 10.8	126 145 908 166 31	-00-0	80000	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	156 141 1441 178 41	0-000	00000	0.00 0.00 - 2.3 0.00 - 0.6 0.00 - 0.6 8.3
1266	1266		0.3	4 0.3 0.1 - 0.9 1376	1376	2	0.1	0.1 0.0 - 0.6	1957	က	0.2	0.0 - 0.5
(1) These unlinked (blinded) surveys were drawn from women seeking family planning services. Specimens were collected from all initial and annual visits and tested for HIV after all personal identifiers had been removed; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Mestern blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.	surveys wer personal 1c 95% Confid	re drawn fro dentifiers h dence Interv	m women seel ad been remx als, normal	king family plan oved; (2) All po approximation m	ning servic sitive spec ethod; (4)	ses. Specimer simens were r Includes per	ns were coll repeatedly r rsons of Ame	lected from a reactive by El prican Indian	ll initial ar ISA and conf and Alaskan	nd annual vis Firmed by an Native ances	its IFA try,	

## HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY TRANSMISSION CATEGORY, SAN FRANCISCO, 1990-1991 (1)

		199	O SURVEY			199	1 SURVEY	
	NUMBER	NUMBER(2)	SERO- PREVALENCE		NUMBER	NUMBER(2)	SERO- PREVALENCE	
TRANSMISSION CATEGORY	TESTED	POSITIVE		(95% C.I.)(3)	TESTED	POSITIVE		(95% C.I.)(3)
Heterosexual IDU	8	1	12.5	0.7 - 53.3	14	5	35.7	14.0 - 64.4
Sex Partner at Risk for HIV	3	0	0.0	0.0 - 62.6	7	0	0.0	0.0 - 37.2
Heterosexual (4)	419	2	0.5	0.1 - 1.9	817	4	0.5	0.2 - 1.3
Unknown Risk	1	0	0.0	0.0 - 92.7	8	0	0.0	0.0 - 33.7
TOTAL	431	3	0.7	0.2 - 2.2	846	9	1.1	0.5 - 2.1

⁽¹⁾ The 1990 and 1991 unlinked (blinded) surveys were drawn from routine blood specimens from women seeking abortions. Survey specimens were tested for HIV after all personal identifiers had been removed; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Self-identified heterosexuals with no other identified risks.

HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY AGE-GROUP, SAN FRANCISCO, 1990-1991 (1)

		199	00 SURVEY			199	1 SURVEY	
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
19 ANO UNOER	68	0	0.0	0.0 - 5.1	133	1	0.8	0.0 - 4.7
20 - 24	139	1	0.7	0.0 - 4.5	253	2	0.8	0.1 - 3.1
25 - 29	106	0	0.0	0.0 - 3.3	223	4	1.8	0.6 - 4.8
30 - 34	80	2	2.5	0.4 - 9.6	118	1	0.8	0.0 - 5.3
35 - 39	26	0	0.0	0.0 - 12.6	86	1	1.2	0.1 - 7.2
40 - 44	8	0	0.0	0.0 - 33.7	27	0	0.0	0.0 - 12.2
45 AND OVER	0	0			0	0		
UNKNOWN	4	0	0.0	0.0 - 53.5	6	0	0.0	0.0 - 41.4
		.=======	.========					
TOTAL	431	3	0.7	0.2 - 2.2	846	9	1.1	0.5 - 2.1

HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY RACE/ETHNICITY, SAN FRANCISCO, 1990-1991 (1)

		199	O SURVEY			199	1 SURVEY	
RACE/ETHNICITY	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
WHITE	50	1	2.0	0.1 - 12.0	71	3	4.2	1.1 - 12.7
AFRICAN AMERICAN	106	2	1.9	0.3 - 7.3	206	3	1.5	0.4 - 4.5
LATINA	223	0	0.0	0.0 - 1.6	437	3	0.7	0.2 - 2.2
ASIAN/PACIFIC ISLANGER	45	0	0.0	0.0 - 7.6	107	0	0.0	0.0 - 3.3
NONE OF THE ABOVE (4)	7	0	0.0	0.0 - 37.2	25	0	0.0	0.0 - 13.1
			*********					
TOTAL	431	3	0.7	0.2 - 2.2	846	9	1.1	0.5 - 2.1

⁽¹⁾ The 1990 and 1991 unlinked (blinded) surveys were drawn from routine blood specimens from women seeking abortions. Survey specimens were tested for HIV after all personal identifiers had been removed; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

HIV SEROPREVALENCE FOR NEWBORN INFANTS AND THEIR MOTHERS, SAN FRANCISCO, 1989 - 1990 (1)

		198	B9 SURVEY			19	990 SURVEY	
	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(
AGE-GROUP(YEARS)								
UNDER 20	219	1	0.457	0.024 - 2.912	181	0	0.000	0.000 - ' 9
20 - 24	442	2	0.452	0.078 - 1.808	446	0	0.000	0.000 - C B
25 - 29	638	0	0.000	0.000 - 0.568	618	1	0.162	0.008 - 1.54
30 - 34	625	0	0.000	0.000 - 0.579	625	1	0.160	0.008 1.0
35 AND OVER	485	0	0.000	0.000 - 0.746	451	0	0.000	0.000 C RK
UNKNOWN	138	1	0.725	0.038 - 4.572	117	0	0.000	0.000 3 0.
RACE/ETHNICITY								
WHITE	679	0	0.000	0.000 - 0.533	663	1	0.151	0.00A 0.9
AFRICAN AMERICAN	334	1	0.299	0.016 - 1.921	324		0.000	0.000 - 1 1
LATINO	564	1	0.177	0.009 - 1.143	608	1	0.165	0.009 - 1 0
ASIAN/PACIFIC IS.	636	o	0.000	0.000 - 0.569	633	0	0.000	0.000 - 0.5
OTHER	206	1	0.485	0.025 - 3.092	115	0	0.000	0.000 - 3.0
UNKNOWN	128	1	0.781	0.041 - 4.918	95	ő	0.000	0.000 - 3.72
TOTAL - SAN FRANCISCO	2,547	4	0.157	0.050 - 0.431	2,438	2	0.082	0.014 - 0.3
TOTAL - SAIT FIGURE2000	2,577		0.137	0.030 = 0.431	2,730	_	0.002	0.014 - 0.3
TOTAL - BAY AREA (4)	21,217	25	0.118	0.078 - 0.118	21,397	23	0.108	0.070 - 0.1
TOTAL - STATEWIDE	144,284	92	0.064	0.052 - 0.079	150,494	106	0.070	0.058 - 0.0

⁽¹⁾ Data courtesy of the California Department of Health Services Office of AIDS. Specimens for this survey of newborn infants (and women giving birth to) are drawn from the genetic diseases screening program. Antibodies in a newborn reflect the infection status of the mother and not necessarily of the child. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (3) 95% Confidence Intervals, normal approximation; (4) Includes Alameda, Contra Costa, Marin, San Francisco, San Mateo and Santa Clara counties.

HIV SEROPREVALENCE FOR INJECTION DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY AGE-GROUP (1)

	NUMBER	All IMPED (2)	SERO- PREVALENCE	
AGE-GROUP (YEARS)	TESTED	NUMBER(2) POSITIVE	RATE (%)	(95% C.I.)(3)
19 AND UNDER	16	1	6.2	0.3 - 32.3
20 - 24	163	3	1.8	0.5 - 5.7
25 - 29	355	20	5.6	3.6 - 8.7
30 - 34	509	32	6.3	4.4 - 8.9
35 - 39	759	74	9.7	7.8 - 12.1
40 - 44	600	55	9.2	7.0 - 11.8
45 AND OVER	390	37	9.5	6.9 - 12.9
MISSING	64	4	6.2	2.0 - 16.0
TOTAL	2856	226	7.9	7.0 - 9.0

HIV SEROPREVALENCE FOR INJECTION DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY RACE/ETHNICITY (1)

	NUMBER	NUMBER(2)	SERO- PREVALENCE	
RACE/ETHNICITY	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3)
WHITE	1741	61	3.5	2.7 - 4.5
AFRICAN AMERICAN	666	138	20.7	17.7 - 24.0
LATINO	328	22	6.7	4.3 - 10.1
ASIAN/PACIFIC ISLANDER	71	4	5.6	1.8 - 14.5
NONE OF THE ABOVE (4)	50	1	2.0	0.1 - 12.0
TOTAL	2856	226	7.9	7.0 - 9.0

⁽¹⁾ Data collected between the 4th quarter of 1989 and the 4th quarter of 1991;

⁽²⁾ Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method;

⁽⁴⁾ Includes persons of American Indian and Alaskan Native ancestry, other race, unknown race, and missing race.

HIV SEROPREVALENCE FOR INJECTION DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY GENDER AND SEXUAL ORIENTATION (1)

			SERO-	
GENDER AND	NUMBER	NUMBER(2)	PREVALENCE	
SEXUAL ORIENTATION	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3
MALE				
Homosexua1/Bisexua1	63	19	30.2	19.6 - 43.2
Heterosexua1	1756	138	7.9	6.7 - 9.2
Unknown Orientation	28	4	14.3	4.7 - 33.6
SUB-TOTAL: MALE	1847	161	8.7	7.5 - 10.1
FEMALE				
Lesbian/Bisexua1	41	4	9.8	3.2 - 24.1
Heterosexua1	917	59	6.4	5.0 - 8.3
Unknown Orientation	3	0	0.0	0.0 - 62.6
SUB-TOTAL: FEMALE	961	63	6.6	5.1 - 8.4
MISSING GENDER	48	2	4.2	0.7 - 15.4
TOTAL	2856	226	7.9	7.0 - 9.0

HIV SEROPREVALENCE FOR INJECTION DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY TREATMENT MODALITY (1)

TREATMENT MODALITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
DETOXIFICATION	2307	178	7.7	6.7 - 8.9
MAINTENANCE MISSING	513 36	48 0	9.4 0.0	7.0 - 12.3 0.0 - 9.4
				******
TOTAL	2856	226	7.9	7.0 - 9.0

⁽¹⁾ Data collected between the 4th quarter of 1989 and the 4th quarter of 1991;

⁽²⁾ Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method.

HIV SEROPREVALENCE FOR INJECTION DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS IN SAN FRANCISCO BY QUARTER AND YEAR OF ENTRY, SAN FRANCISCO (1)

	4TI	H QTR/	1989	15	1ST QTR/1990		2ND QTR/1990		3RD QTR/1990			4TH QTR/1990			
GENDER	N(2)	HIV+(	3) %(4)	N	HIV+	z	N	HIV+	z	N	HIV+	z	N	HIV+	z
MALE FEMALE	162 85	16 10	9.9 11.8	230 109	23 7	10.0	176 93	19 6	10.8 6.5	273 119	20 7	7.3 5.9	171 115	16 10	9.4 8.7
TOTAL	247	26	10.5	339	30	8.8	269	25	9.3	392	27	6.9	286	26	9.1
				,											
	18	T QTR/	1991	2NI	D QTR/	1991	3RI	QTR/	1991	4Th	I QTR/1	1991		TOTAL	
GENDER	N	HIV+	z	N	HIV+	z	N	HIV+	z	N	HIV+	z	N	HIV+	z
MALE	218	18	8.3	219 119	19	8.7	237	18 5	7.6 4.1	161 75	12	7.5 2.7	1847 961	161 63	8.7 6.6
FEMALE	123	8	6.5	113		======									

⁽¹⁾ Data collected between the 4th quarter of 1989 and the 4th quarter of 1991. This table excludes records with missing gender; (2) Number tested; (3) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (4) Seroprevalence rate (%).

HIV SEROPREVALENCE FOR INJECTION DRUG USERS (IDUs) AND NON-INJECTION DRUG USERS (NON-IDUs) ENTERING A METHADONE-FREE DETOXIFICATION PROGRAM BY AGE-GROUP, SAN FRANCISCO, 1990-1992 (1)

			IDUs		NON-IDUs				
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95 <b>%</b> C.I.)(3)	
19 AND UNDER	5	1	20.0	1.1 - 70.1	6	0	0.0	0.0 - 41.4	
20 - 24	55	5	9.1	3.4 - 20.7	51	1	2.0	0.1 - 11.8	
25 - 29	87	7	8.0	3.6 - 16.4	128	9	7.0	3.5 - 13.3	
30 - 34	79	13	16.5	9.4 - 26.9	106	13	12.3	7.0 - 20.4	
35 - 39	91	9	9.9	4.9 - 18.4	93	8	8.6	4.1 - 16.7	
40 - 44	59	6	10.2	4.2 - 21.5	62	3	4.8	1.3 - 14.4	
45 AND OVER	27	5	18.5	7.0 - 38.7	30	3	10.0	2.6 - 27.7	
MISSING	1	0	0.0	0.0 - 92.7	2	0			
TOTAL	404	46	11.4	8.5 - 15.0	478	37	7.7	5.6 - 10.6	

HIV SEROPREVALENCE FOR INJECTION DRUG USERS (IDUs) AND NON-INJECTION DRUG USERS (NON-IDUs) ENTERING A METHADONE-FREE DETOXIFICATION PROGRAM BY RACE/ETHNIC GROUP, SAN FRANCISCO, 1990-1992 (1)

			IDUs		NON-IDUs				
RACE/ETHNICITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	
WHITE	277	34	12.3	8.8 - 16.9	175	19	10.9	6.8 - 16.7	
AFRICAN AMERICAN	49	8	16.3	7.8 - 30.2	217	16	7.4	4.4 - 11.9	
LATINO	39	2	5.1	0.9 - 18.6	47	1	2.1	0.1 - 12.7	
ASIAN/PACIFIC ISLANDER	24	2	8.3	1.5 - 28.5	30	0	0.0	0.0 - 11.1	
NONE OF THE ABOVE (4)	15	0	0.0	0.0 - 33.7	9	1	11.1	0.8 - 58.0	
TOTAL	404	46	11.4	8.5 - 15.0	478	37	7.7	5.6 - 10.6	

⁽¹⁾ Data collected between the 4th quarter of 1990 and the 1st quarter of 1992; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, unknown race, and missing race.

HIV SEROPREVALENCE FOR INJECTION DRUG USERS (IDUS) AND NON-INJECTION DRUG USERS (NON-IDUS) ENTERING A
METHADONE-FREE DETOXIFICATION PROGRAM BY GENDER AND SEXUAL ORIENTATION, SAN FRANCISCO, 1990-1992 (1)

			IDUs			NO	N-IDUs	
GENDER AND SEXUAL ORIENTATION	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
MALE								
Homosexual/Bisexual	59	23	39.0	26.8 - 52.6	37	20	54.1	37.1 - 70.1
Heterosexua1	216	18	8.3	5.2 - 13.1	273	9	3.3	1.6 - 6.4
SUB-TOTAL: MALE	275	41	14.9	11.0 - 19.8	310	29	9.4	6.5 - 13.3
FEMALE					2			
Lesbian/Bisexual	17	0	0.0	0.0 - 18.4	19	0	0.0	0.0 - 16.7
Heterosexual	99	3	3.0	0.8 - 9.2	126	5	4.0	1.5 - 9.5
SUB-TOTAL: FEMALE	116	3	2.6	0.7 - 7.9	145	5	3.4	1.3 - 8.3
MISSING GENDER AND/OR SEXUAL ORIENTATION	13	2	15.4	2.7 - 46.3	23	3	13.0	3.4 - 34 '
TOTAL	404	46	11.4	8.5 - 15.0	478	37	7.7	5.6 - 10.6

IV SEROPREVALENCE FOR INJECTION DRUG USERS (IDUs) AND NON-INJECTION DRUG USERS (NON-IDUs) ENTERING A ETHADONE-FREE DETOXIFICATION PROGRAM BY DRUG PREFERENCE, SAN FRANCISCO, 1990-1992 (1)

		IDUs				NON-IDUs			
PRIMARY DRUG	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	
HEROIN	288	22	7.6	5.0 - 11.5	26	1	3.8	0.2 - 21.6	
COCAINE/CRACK	31	3	9.7	2.5 - 26.9	294	22	7.5	4.9 - 11.3	
MPHETAMINES/SPEED	78	21	26.9	17.8 - 38.4	17	7	41.2	19.4 - 66.5	
OTHER OR UNSPECIFIED DRUGS	7	0	0.0	0.0 - 37.2	141	7	5.0	2.2 - 10.3	
***************************************				**********	********	***********		*************	
TOTAL	404	46	11.4	8.5 - 15.0	478	37	7.7	5.6 - 10.6	

⁾ Data collected between the 4th quarter of 1990 and the 1st quarter of 1992; (2) Positive specimens were peatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, rmal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, known race, and missing race.

Page 23

HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB)
AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY GENDER AND TRANSMISSION CATEGORY (1)

GENDER AND	NUMBER	NUMBER(2)	SERO- PREVALENCE	
TRANSMISSION CATEGORY	TESTED	POSITIVE	RATE (%)	(95% C.I.)(3)
MALE				
Homosexua1/Bisexua1	43	35	81.4	66.1 - 91.1
Homosexua1/Bisexua1, IDU	20	15	75.0	50.6 - 90.4
Heterosexual IDU	19	4	21.1	7.0 - 46.1
Heterosexual (4)	143	7	4.9	2.2 - 10.2
Unknown Risk	12	0	0.0	0.0 - 24.6
SUB-TOTAL MALE	237	61	25.7	20.4 - 31.9
FEMALE				
Heterosexual IDU	6	1	16.7	0.9 - 63.5
Heterosexual (4)	58	0	0.0	0.0 - 6.0
Unknown Risk	14	0	0.0	0.0 - 21.7
SUB-TOTAL FEMALE	78	1	1.3	0.1 - 7.9
			**********	=========
TOTAL	315	62	19.7	15.5 - 24.6

HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY ORIGIN OF BIRTH (1)

ORIGIN OF BIRTH	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
BORN IN USA BORN OUTSIDE USA	140 175	<b>54</b> 8	38.6 4.6	30.6 - 47.2 2.1 - 9.1
TOTAL	315	62	19.7	15.5 - 24.6

⁽¹⁾ Survey of Risk Behaviors (SRB). Data collected between the 1st quarter of 1990 to the 4th quarter 1991; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes self-identified heterosexuals with no identified risk, persons with a history of blood transfusion(s) or with a bleeding disorder, and persons with a sexual partner(s) at risk for HIV/AIDS.

HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY AGE-GROUP (1)

AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
				<u> </u>
19 AND UNDER	9	1	11.1	0.6 - 49.3
20 - 24	16	3	18.8	5.0 - 46.3
25 - 29	43	10	23.3	12.3 - 39.0
30 - 34	53	10	18.9	9.9 - 32.4
35 - 39	38	13	34.2	20.1 - 51.4
40 - 44	44	14	31.8	19.1 - 47.7
45 AND OVER	112	11	9.8	5.2 - 17.3
***************************************				=======================================
TOTAL	315	62	19.7	15.5 - 24.6

HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A MUNICIPAL TB CLINIC IN SAN FRANCISCO BY RACE/ETHNICITY (1)

RACE/ETHNICITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
WHITE	60	27	45.0	32.3 - 58.3
AFRICAN AMERICAN LATINO	65 67	19 13	29.2 19.4	18.9 - 42.0 11.1 - 31.2
ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	116 7	1 2	0.9 28.6	0.0 - 5.4 5.1 - 69.7
			*******	**********
TOTAL	315	62	19.7	15.5 - 24.6

⁽¹⁾ Survey of Risk Behaviors (SRB). Data collected between the 1st quarter of 1990 and the 4th quarter 1991; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

HIV SEROPREVALENCE FOR HIGH-RISK ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER AND HOMELESS YOUTH CENTERS BY AGE-GROUP, SAN FRANCISCO, 1990-1992 (1)

	-	JUVENILE DETENTION CENTER				HOMELESS YOUTH CENTERS			
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	
UNDER 15	171	0	0.0	0.0 - 2.1	93	0	0.0	0.0 - 3.8	
15 - 19	706	4	0.6	0.2 - 1.5	536	17	3.2	1.9 - 5.1	
20 - 24	5	0	0.0	0.0 - 46.7	52	10	19.2	10.1 - 33.0	
MISSING	21	0	0.0	0.0 - 15.3	8	1	12.5	0.7 - 53.3	
======================================	903	4	0.4	0.1 - 1.2	689	28	4.1	2.8 - 5.9	

HIV SEROPREVALENCE FOR HIGH-RISK ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER AND HOMELESS YOUTH CENTERS BY RACE/ETHNICITY, SAN FRANCISCO, 1990-1992 (1)

		JUVENILE DETENTION CENTER				HOMELESS YOUTH CENTERS		
RACE/ETHNICITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
WHITE	87	0	0.0	0.0 - 4.1	305	14	4.6	2.6 - 7.8
AFRICAN AMERICAN	504	3	0.6	0.2 - 1.9	150	5	3.3	1.2 - 8.0
LATINO	188	1	0.5	0.0 - 3.4	158	4	2.5	0.8 - 6.8
ASIAN/PACIFIC ISLANDER	103	0	0.0	0.0 - 3.4	63	3	4.8	1.2 - 14.2
NONE OF THE ABOVE (4)	21	0	0.0	0.0 - 15.3	13	2	15.4	2.7 - 46.3
TOTAL	903	4	0.4	0.1 - 1.2	689	28	4.1	2.8 - 5.9

⁽¹⁾ These surveys of high-risk adolescents are unlinked (blinded) surveys. Blood specimens are drawn for syphilis screening on individuals as part of the routine intake process or initial entrance evaluation. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes persons of American Indian and Alaskan Native ancestry, other race, unknown race, and missing race.

IV SEROPREVALENCE FOR HIGH-RISK ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER AND HOMELESS YOUTH CENTERS BY GENDER AND TRANSMISSION CATEGORY, SAN FRANCISCO, 1990-1992 (1)

		JUVENILE	DETENTION C	ENTER	HOMELESS YOUTH CENTERS			
GENDER AND TRANSMISSION CATEGORY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
MALE								v
MALE								
Homosexual/Bisexual	4	1	25.0	1.3 - 78.1	71	23	32.4	22.0 - 44.7
Heterosexual IOU	9	0	0.0	0.0 - 30.9	31	0	0.0	0.0 - 10.8
Heterosexual (4)	667	3	0.4	0.1 - 1.4	172	1	0.6	0.0 - 3.7
Unknown Risk	4	0	0.0	0.0 - 53.5	4	0	0.0	0.0 - 53.5
SUB-TOTAL MALE	684	4	0.6	0.2 - 1.6	278	24	8.6	5.7 - 12.7
FEMALE					1			
Heterosexual IDU	7	0	0.0	0.0 - 37.2	46	1	2.2	0.1 - 13.0
Heterosexual (4)	208	0	0.0	0.0 - 37.2	349	3	0.9	0.7 - 13.0
Unknown Risk	2	0	0.0	0.0 - 75.2	11	0	0.0	0.0 - 26.4
SUB-TOTAL FEMALE	217	0	0.0	0.0 - 1.7	406	4	1.0	0.3 - 2.7
MISSING GENOER	2	0	0.0	0.0 - 75.2	5	0	0.0	0.0 - 46.7
					İ			
TOTAL	903	4	0.4	0.1 - 1.2	689	28	4.1	2.8 - 5.9
IVIAL	703	-	0.4	0.1 - 1.2	009	20	4.1	2.0 - 3.9

⁽¹⁾ These surveys of high-risk adolescents are unlinked (blinded) surveys. Blood specimens are drawn for syphilis screening on individuals as part of the routine intake process or initial entrance evaluation. Specimens were collected consecutively and tested after all personal identifiers had been removed from the specimen; (2) All positive specimens were repeatedly reactive by ELISA and confirmed by an IFA and a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Self-identified heterosexuals with no other identified risks.

HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY YEAR OF DONATION, MARCH 1985 - DECEMBER 1991 (1)

YEAR OF DONATION	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
1985 1986 1987 1988 1989 1990	72, 204 88, 168 91, 396 90, 192 87, 320 84, 578 77, 273	80 40 30 23 10 11 8	0.111 0.045 0.033 0.026 0.011 0.013	0.088 - 0.139 0.033 - 0.062 0.023 - 0.047 0.017 - 0.039 0.006 - 0.022 0.007 - 0.024 0.005 - 0.021
TOTAL	591,131	202	0.034	0.030 - 0.039

HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY DONATION STATUS AND GENDER, JANUARY 1, 1991 - DECEMBER 31, 1991 (1)

DONATION STATUS	GENDER	TOTAL DONATIONS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
FIRST-TIME	Ma1e	9,456	3	0.032	0.008 - 0.101
DONORS	Fema1e	9,473	2	0.021	0.004 - 0.085
REPEAT	Ma1e	30,886	2	0.006	0.001 - 0.026
DONORS	Fema1e	27,458	1	0.004	0.000 - 0.024
TOTAL		77,273	8	0.010	0.005 - 0.021

⁽¹⁾ Data were provided courtesy of the Irwin Memorial 81ood Centers, San Francisco, CA.;

⁽²⁾ Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay;

^{(3) 95%} Confidence Intervals, normal approximation method.

HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY RACE/ETHNICITY, JANUARY 1, 1991 - DECEMBER 31, 1991 (1)

	TOTAL			
RACE/ETHNICITY	DONATIONS	NUMBER(2) POSITIVE	PREVALENCE RATE (%)	(95% C.I.)(3)
WHITE	64,635	4	0.006	0.002 - 0.01
BLACK	3,249	3	0.092	0.024 - 0.29
ASIAN/PACIFIC ISL NONE OF THE ABOVE	•	0	0.000	0.000 - 0.07
	., ., ., ., .			
TOTAL	77,273	8	0.010	0.005 - 0.02

HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY AGE-GROUP, JANUARY 1, 1991 - DECEMBER 31, 1991 (1)

AGE-GROUP	TOTAL	NUMBER(2)	SERO- PREVALENCE	
(YEARS)	DONATIONS	POSITIVE	RATE (%)	(95% C.I.)(3)
19 AND UNDER	5,434	0	0.000	0.000 - 0.067
20 - 29	14,139	2	0.014	0.002 - 0.057
30 - 39	21,495	6	0.028	0.011 - 0.064
40 AND OVER	36,205	0	0.000	0.000 - 0.010
	*************			
TOTAL	77,273	8	0.010	0.005 - 0.021

⁽¹⁾ Data were provided courtesy of the Irwin Memorial Blood Centers, San Francisco, Ca.; (2) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (3) 95% Confidence Intervals, normal approximation method; (4) Includes Latinos, American Indians, Alaskan Natives, other race, and unknown race.

HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENDER AND YEAR (1)(2)

	ı	1985			1986	1		1987			1988			1989	
GENDER	N(3)	HIV+(4	1) %(5)	N	HIV+	z	N	HIV+	z	N	HIV+	z	N	HIV+	Z
MALE FEMALE	213 45	0	0.0	941 183	9	1.0	869 143	5 0	0.5 0.0	759 178	2	0.3	711 124	2	0.3
TOTAL	258	0	0.0	1124	10	0.9	1012	5	0.5	937	2	0.2	835	3	0.4

	1	1990			1991			TOTAL	
GENDER	N	HIV+	z	N	HIV+	z	N	HIV+	z
MALE FEMALE	520 105	0	0.0	407 76	2	0.5 0.0	4420 854	20 2	0.5
TOTAL	625	0	0.0	483	2	0.4	5274	22	0.4

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC); (2) Data collected between October 1985 and December 1991; (3) Number tested; (4) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (5) Seroprevalence rate (%).

HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENOER AND AGE GROUP (1)(2)

		MAL	.E			FEMAL	.E	
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)
19 ANO UNOER	1842	3	0.2	0.0 - 0.5	317	0	0.0	0.0 - 0.5
20 - 24	1386	4	0.3	0.1 - 0.8	272	1	0.4	0.1 - 0.8
25 - 29	706	6	0.8	0.3 - 1.9	137	1	0.7	0.3 - 1.9
30 ANO OVER	486	7	1.4	0.6 - 3.1	128	0	0.0	0.6 - 3.1
TOTAL	4420	20	0.5	0.3 - 0.7	854	2	0.2	0.3 - 0.7

HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENOER AND RACE/ETHNICITY (1)(2)

		MAL	.E			FEMAL	.E	
RACE/ETHNICITY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)	NUMBER TESTEO	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(4)
WHITE AFRICAN AMERICAN	1534 828	11	0.7	0.4 - 1.3 0.4 - 1.8	307 198	2	0.7	0.1 - 2.6 0.0 - 1.8
LATINO ASIAN/PACIFIC ISLANGER NONE OF THE ABOVE(5)	477 1423 158	1 0 1	0.2 0.0 0.6	0.0 - 1.4 0.0 - 0.3 0.0 - 4.0	80 235 34	0 0 0	0.0 0.0 0.0	0.0 - 4.4 0.0 - 1.5 0.0 - 9.9
TOTAL	4420	20	0.5	0.3 - 0.7	854	2	0.2	0.0 - 0.9

⁽¹⁾ Oata provided by the U.S. Department of Defense, and the Centers for Oisease Control (CDC); (2) Oata collected between October 1985 and December 1991; (3) Positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay; (4) 95% Confidence Intervals, normal approximation method; (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

S. F. DEPARTMENT OF PUBLIC HEALTH AIDS OFFICE-SURVEILLANCE BRANCH 25 VAN NESS AVENUE, 5TH FLOOR SAN FRANCISCO, CA 94102

> MURIEL DOBBIN SAN FRANCISCO FUBLIC LIBRARY DOCUMENTS DEPARTMENT

193 Wel. 4 #/

DOCHMENTS DEPT

FEB 5 1993

SAN FRANCISCO PUBLIC LIBRAR

## HIV SEROPREVALENCE REPORT

San Francisco Department of Public Health AIDS Office

/// January, 1993 Volume 4, No. 1

## **CONTENTS**

	<u> </u>
SURVEY OF CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC: 1989-1991	
HIV Seroprevalence for Clients Attending a STD Clinic by Gender & Transmission Category	1
HIV Seroprevalence for Clients Attending a STD Clinic by Race/Ethnicity	2
HIV Seroprevalence for Clients Attending a STD Clinic by Age-Group	3
HIV Seroprevalence for Gay & Bisexual Men Attending a STD Clinic by Race/Ethnicity	4
HIV Seroprevalence for Gay & Bisexual Men Attending a STD Clinic by Age-Group	5
HIV Seroprevalence for Heterosexual Males Attending a STD Clinic by Race/Ethnicity	6
HIV Seroprevalence for Heterosexual Males Attending a STD Clinic by Age-Group	7
HIV Seroprevalence for Heterosexual Females Attending a STD Clinic by Race/Ethnicity	8
HIV Seroprevalence for Heterosexual Females Attending a STD Clinic by Age-Group	9
SURVEY OF INJECTION DRUG USERS (IDUs) ENTERING METHADONE TREATMENT PROGRAMS	
TRUGRAVIS	
HIV Seroprevalence for IDUs Entering Methadone Treatment by Gender & Sexual Orientation	10
HIV Seroprevalence for IDUs Entering Methadone Treatment by Race/Ethnicity	11
HIV Seroprevalence for IDUs Entering Methadone Treatment by Age-Group	12
SURVEY OF DRUG USERS (IDUs & NON-IDUs) ENTERING A METHADONE-FREE	
DETOX PROGRAM	
HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Gender & Sexual Orientation	13
HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Race/Ethnicity	14
HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Age-Group	15
HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Drug Preference	16
CURLINA OR WOLLD AND REPORT OF THE PARTY OF	
SURVEY OF WOMEN OF REPRODUCTIVE AGE: FAMILY PLANNING & ABORTION CLINIC CLIENTS	
HIV Seroprevalence for Women Attending a Family Planning Clinic by Transmission Category	17
HIV Seroprevalence for Women Attending a Family Planning Clinic by Race/Ethnicity	18
HIV Seroprevalence for Women Attending a Family Planning Clinic by Age-Group	19
HIV Seroprevalence for Women Attending an Abortion Clinic by Transmission Category	20
HIV Seroprevalence for Women Attending an Abortion Clinic by Race/Ethnicity	21
HIV Seroprevalence for Women Attending an Abortion Clinic by Age-Group	22
CURLINA OR CAME DRIVE BY A REAL PROPERTY OF CAME AND A SECOND OF CAME A	
SURVEY OF CHILDBEARING WOMEN IN SAN FRANCISCO: 1989-91	
HIV Seroprevalence for Newborn Infants and their Mothers by Age-Group & Race/Ethnicity	23

## SURVEY OF PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A TB CLINIC

HIV Seroprevalence for TB Patients by Gender & Transmission Category HIV Seroprevalence for TB Patients by Origin of Birth HIV Seroprevalence for TB Patients by Race/Ethnicity	24 25 26
HIV Scroprevalence for TB Patients by Age-Group	27
SURVEY OF ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER (JDC) & HOMELESS YOUTH CENTERS (HYCs)	
HIV Seroprevalence for Adolescents Entering a JDC by Gender & Transmission Category	28
HIV Seroprevalence for Adolescents Entering a JDC by Race/Ethnicity	29
HIV Scroprevalence for Adolescents Entering a JDC by Age-Group	30
HIV Seroprevalence for Adolescents Entering HYCs by Gender & Transmission Category	31
HIV Seroprevalence for Adolescents Entering HYCs by Race/Ethnicity	32
HIV Seroprevalence for Adolescents Entering HYCs by Age-Group	33
RESULTS OF HIV SCREENING OF CIVILIAN APPLICANTS FOR MILITARY SERVICE: 1985-1991	
HIV Seroprevalence for Civilian Applicants for Military Service by Gender & Year	34
HIV Seroprevalence for Civilian Applicants for Military Service by Race/Ethnicity & Year	35
HIV Seroprevalence for Civilian Applicants for Military Service by Age-Group & Year	36
RESULTS OF HIV SCREENING OF BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA: 1985-1991	
HIV Seroprevalence for Blood Donors by Year of Donation	37
HIV Seroprevalence for Blood Donors by Donation Status & Gender	38
HIV Seroprevalence for Blood Donors by Race/Ethnicity	39
HIV Seroprevalence for Blood Donors by Age-Group	40

HIV SEROPREVALENCE REPORT is released on a quarterly basis by the San Francisco Department of Public Health AIDS Office, Surveillance Branch, 25 Van Ness Avenue, Suite 500, San Francisco, CA 94102-6033. Phone (415) 554-9050. AIDS Office Director Mitch Katz, M.D. AIDS Surveillance Branch Chief, George F. Lemp, Dr.P.H. Program Coordinator, Sean Nguyen. Epidemiologist/Data Manager, Tim Kellogg. Funding and technical support is provided by the Division of HIV/AIDS, Centers for Disease Control Additional support is provided by the California Department of Health Services Office of AIDS.

HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY GENOER AND TRANSMISSION CATEGORY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (1)

	(95% C.I.)(3)	33.5 - 41.6 33.5 - 14.0 33.5 - 14.0 33.5 - 14.0 1.0 - 12.0 1.0 - 10.9 1.0 - 10.9 1.0 - 10.9 1.0 - 10.9 1.0 - 2.3	9.5 - 11.6
SURVEY	SERO- PREVALENCE RATE (%) (99	37.8 46.8 37.6 37.6 33.3 13.3 13.3 10.0 10.0 10.0 10.0 10.0	10.5
1991	NUMBER(2) POSITIVE	255 377 380 380 380 1   151 1   151	375
	NUMBER TESTED	672 178 120 160 160 271 271 271 28 68 15 15	3561
	(95% C.I.)(3)	39.1 - 47.0 50.3 - 71.2 3.5 - 15.0 1.4 - 3.0 8.8 - 19.1 14.4 - 17.4 0.0 - 9.7 1.3 - 4.1 1.3 - 4.1	11.9 - 14.3
0 SURVEY	SERO- PREVALENCE RATE (%)	6.1.2.8.3.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0	13.1
1990	NUMBER(2) POSITIVE	20   0   0   0   0   0   0   0   0   0	416
	NUMBER TESTEO	626 90 101 103 103 138 187 187 2497 2497 19 60 60 55 55 60 19 19 19 19 19 19 19 19 19 19 19 19 19	3178
	(95% C.I.)(3)	46.1 - 55.7 61.8 - 20.2 6.8 - 20.4 6.9 - 12.0 0.1 - 21.9 0.8 - 2.3 17.1 - 20.8 17.1 - 20.0 0.0 - 9.2 0.2 - 2.3 0.2 - 2.3	13.7 - 16.7
9 SURVEY	SERO- PREVALENCE RATE (%)	2.02 1.17 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.1.4 1.4	15.2
1989	NUMBER(2) POSITIVE	222 881 133 133 100 100 100 100	348
	NUMBER TESTEO	440 1044 1047 1023 1023 1023 1038 85 85 85 85 86 10 10 10 10 10 10 10 10 10 10 10 10 10	2297
	GENDER AND TRANSMISSION CATEGORY	MALE Gay/Bisexual 1 DU (4) Gay/Bisexual 1 DU (4) Everosexual 1 DU (4) Sx Partner at Risk for HIV Blood Recipient (5) Unknown Risk SUB-TOTAL MALE FEMALE  IDU (4) Sx Partner at Risk for HIV Blood Recipient (5) Heerosexual (6) Unknown Risk SUB-TOTAL RALE  SW Partner at Risk for HIV Blood Recipient (5) Heerosexual (7) Blood Recipient (5) Heerosexual (6) Unknown Risk	TOTAL

These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, and/or treathent for a MEW STO episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.

By Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. Includes persons with a history of injection drug use (IUU) since January 1978 and March 1985.

Self-identified heterosexuals with no other identified risks.

Includes women who have sex with women and women who have sex with both men and women. Lesbian or bisexual women who have all history of injection drug use (IUU) since 1978 are included in the IOU category. Collection of female sexual orientation began in 1991.

³⁶⁹⁶⁶⁶ 

HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTEO DISEASE (STD) CLINIC BY RACE/ETHNICITY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (1)

1991 SURVEY

1990 SURVEY

1989 SURVEY

SERO- PREVALENCE RATE (%) (95% C.I.)(3)	12.9 - 16.6 5.3 - 8.3 7.8 - 12.4 3.0 - 9.4 4.9 - 22.9	9.5 - 11.6	
)- ENCE (\$) (95%			
	14.7 6.7 9.9 5.6 11.9	10.5	
NUMBER(2) POSITIVE	210 78 67 67 13	375	
NUMBER	1429 1165 675 233 59	3561	
.1.)(3)	- 20.4 - 11.2 - 15.0 - 11.8 - 25.1	11.9 - 14.3	iduals
. (95% C.		11.9	on indivitively
SERO- PREVALENCE RATE (%) (95% C.I.)(3)	18.1 9.4 7.1	13.1	are drawn from blood specimens collected for routine syphilis screening on individua ind/or treatment for a NEW STO episode. Specimens were collected consecutively nal identifiers were removed. edly reactive by ELISA and confirmed by a Western blot assay. nomial. Confidence Intervals not calculated for sample sizes under 20 observations, n and Alaskan Native ancestry, other race, and unknown race.
NUMBER(2) POSITIVE	219 111 68 13	416	ne syphilis were collect olot assay. ample sizes
NUMBER TESTEO	1210 1178 564 183 43	3178	for routin Specimens v a Western B ated for sa
2.1.)(3)	- 25.7 - 11.4 - 18.0 - 9.2 - 24.6	13.7 - 16.7	collected apisode. firmed by not calcul other rac
E (95% (	20.1	13.7	ecimens EW STO moved. and confervals recestry.
SERO- PREVALENCE RATE (\$) (95% C.I.)(3)	22.8 9.2 14.0 11.4	15.2	om blood spent for a Ners were respectively. Fidence Into Native an
NUMBER(2) POSITIVE	209 76 52 5 6	348	ere drawn from blood specimens collected for routine syphilis nd/or treatment for a NEW STO episode. Specimens were collected identifiers were removed. edly reactive by ELISA and confirmed by a Western blot assay, nomial. Confidence Intervals not calculated for sample sizes on and Alaskan Native ancestry, other race, and unknown race.
NUMBER TESTEO	916 828 371 138 44	2297	surveys wer ination, and all persond re repeater exact bind
RACE/ETHNICITY	WHITE AFICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL	<ol> <li>These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STO episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.</li> <li>All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.</li> <li>SpSE Confidence Intervals, exact binomals. Confidence Intervals not calculated for sample sizes under 20 observations.</li> <li>Jobs SpSE Confidence Intervals, exact binomals. Confidence Intervals not calculated for sample sizes under 20 observations.</li> <li>Jobs SpSE Confidence Intervals.</li> </ol>

AGE-GROUP (YEARS)	NUMBER TESTEO	1989 NUMBER(2) F POSITIVE	SURVEY SERO- REVALENCE RATE (X)	95% C.1		<b>~</b> 0	1990	1 8 2 1	(95% C. I	.)(3)	NUMBER TESTEO	1991 NUMBER(2) F POSITIVE	SERO-PREVALENCE RATE (X)	SURVEY SERO- PREVALENCE RATE (\$) (95% C.I.)(3)
19 ANO UNDER 20 - 24 25 - 29 35 - 34 35 - 39 40 - 44 45 ANO OVER UNKNOWN	223 526 526 284 158 0	0 29 27 29 0	1.3 16.9 16.9 21.8 25.7 17.1	0.3 - 13.9 - 2 17.9 - 2 20.7 - 3 11.6 - 2 13.1 - 2	3.9 20.3 26.2 23.9 26.1	274 708 785 785 382 223 10	9 ¥ \$ 5 E C C S S E C C	2.2 13.2 13.2 23.6 17.0 0.0	10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10.0.0 10	4.7 6.6 7.3 22.8 18.9 .9	288 897 893 390 263 265 17	1 25 103 25 50 1 23 33	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0.0 - 1.9 8.5 - 4.1 14.0 - 20.2 15.4 - 23.5 14.5 - 24.3 14.5 - 17.0
TOTAL	2297	348	15.2	13.7 - 16.7		3178	416	13.1	11.9 - 14.3	14.3	3561	375	10.5	9.5 - 11.6

⁽¹⁾ These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEM STO episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

OPREVALENCE FOR GAY AND BISEXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY RACE/ETHNICITY, IR OF SURVEY, SAN FRANCISCO, 1989 – 1991 (1)
EN ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY 1991 (1)
EN ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) C 1991 (1)
EN ATTENDING A SEXUALLY TRANSMITTED DISEASE 1991 (1)
EN ATTENDING A SEXUALLY TRANSMITTED (
EN ATTENDING A SEXUALLY 1991 (1)
EN ATTENDING A
AY AND BISEXUAL ME FRANCISCO, 1989 -
OR GAY SAN FRA
HIV SEROPREVALENCE FOR GAY AND BISEXUAL MEN ATTENDIN AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (1)

1991 SURVEY

1990 SURVEY

1989 SURVEY

95% C.1.)(3)	29.5 - 37.6 40.1 - 62.1 34.9 - 54.3 21.5 - 59.4	34.0 - 41.0	
SERO- PREVALENCE RATE (%) (95% C.I.)(3)	33.5 51.2 84.4 54.5	37.5	
NUMBER(2) POSITIVE	182 44 48 11 6	291	
NUMBER TESTED	544 86 108 11	ררר	
SERO- PREVALENCE RATE (%) (95% C.I.)(3)	36.7 - 45.9 53.8 - 72.0 37.0 - 56.6 13.2 - 48.7	41.6 - 49.0	individuals ely rvations.
SERO- PREVALENCE RATE (%) (	41.2 63.2 46.7 28.6 50.0	45.3	creening on d consecutiv nder 20 obse
NUMBER(2) POSITIVE	188 74 50 8 8	324	e syphilis s ere collecte lot assay. mple sizes u own race.
NUMBER	456 117 107 28 8	716	for routin specimens w twestern b ted for sa
SERO- PREVALENCE RATE (%) (95% C.I.)(3)	46.9 - 57.3 53.1 - 74.4 49.8 - 72.3	50.8 - 59.3	were drawn from blood specimens collected for routine syphilis screening on individuals and/or treatment for a NEW SID episode. Specimens were collected consecutively sonal identifiers were removed.  ated by reactive by ELISA and confirmed by a Western blot assay.  binomial. Confidence Intervals not calculated for sample sizes under 20 observations. ian and Alaskan Native ancestry, other race, and unknown race.
SERO- PREVALENCE RATE (%)	52.2 64.3 61.5 28.6 83.3	55.1	n blood spec nt for a NEW rs were remo by ELISA an idence Inter Native ance
NUMBER(2) POSITIVE	194 54 48 4 5	305	e drawn from (/or treatment) i identifie ily reactive mial. Conf
NUMBER	372 84 78 14	554	surveys wer nation, and all persona re repeated exact bind
RACE/ETHNICITY	WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL	(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

		1989	9 SURVEY			1990	0 SURVEY			1991	1 SURVEY	
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
19 AND UNDER 20 - 24 25 - 29 35 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN	2 61 134 129 112 55 61	25 25 27 27 0	0.0 41.0 62.7 58.9 50.7 45.3 44.3	28.6 - 54.3 53.9 - 70.9 49.9 - 67.5 51.0 - 69.8 32.0 - 59.4 31.5 - 57.6	14 174 174 168 129 62 87	22 23 36 0 0	14.3 33.3 46.0 53.5 53.5 0.0	23. 2 - 44. 7 38.4 - 53. 7 44. 0 - 59. 5 44. 5 - 61. 3 35. 5 - 61. 4 23. 6 - 44. 3	10 96 204 177 120 120 88 80	1 16 74 83 83 37 24 0	10.0 16.7 36.3 46.9 46.7 46.7 30.0	9.8 - 25.6 229.7 - 43.3 39.4 - 54.5 31.5 - 55.0 20.3 - 41.3
TOTAL	554	305	55.1	50.8 - 59.3	91.2	324	45.3	41.6 - 49.0	רנר	291	37.5	34.0 - 41.0
(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals sekting evaluation, examination, and for treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.  (2) All containes constraint and account operations to be IIXA and confirmed to a tacker what accounts accounts to the consecutive to the second consecutive to the co	surveys wer nation, and all persona	e drawn fro 1/or treatme 1 1 1dentifie	m blood spec nt for a NEI rs were rem	timens collected STD episode.	d for routin Specimens v	e syphilis ere collect	screening or ed consecuti	n individuals ively				

		1989	9 SURVEY				1990	1990 SURVEY			199	1991 SURVEY		
RACE/ETHNICITY	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%) (95% C.I.)(4)	(95% C.1	.)(4)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%) (	SERO- REVALENCE RATE (X) (95X C.1.)(4)	NUMBER	NUMBER(3) POSITIVE	SERO- NUMBER(3) PREVALENCE POSITIVE RATE (%) (95% C.I.)(4)	(95 <b>%</b> C. I.	)(4)
WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (5)	316 471 209 78 19	0-1295	0.0	0.00	7.8.9.9.0 6.9	413 683 286 84 18	118810	7.2.2. 0.0.88.66.7	1.3 - 4.7 1.6 - 4.1 1.2 - 5.4 0.0 - 6.5	497 741 399 122 122 25	12 12 12 0	2.6 3.0 1.6 0.0		7.2 7.3 1.3
TOTAL	1093	11	1.6	0.9 - 2.5	2.5	1484	38	2.6	1.8 - 3.5	1784	45	2.5	1.8 - 3.4	3.4
(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks. (2) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. (3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (4) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.	h a sex pa urveys wer ation, and 11 persona e repeated exact bind	inther at risk for HIV and heterosexuals with no other identified risks, e drawn from blood specimens collected for routine syphilis screening of for treatment for a NEW STD episode. Specimens were collected consecut il identifiers were removed.  In the state of th	sk for HIV am blood spent for a NEI rs were remained by ELISA and theme Inter Native and	and heter cimens co N STD epi ved. nd confir vals not	osexuals illected i sode. Sp med by a calculation race.	with no of for routing becimens we Western bi ted for sar	ther identii e syphilis s ere collecte lot assay. mple sizes u	ied risks. screening on consecuti inder 20 obs	individuals vely ervations.					

HIV SEROPREVALENCE FOR HETEROSEXUAL MALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY RACE/ETHNICITY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (2)

1991 SURVEY	SERO- NUMBER NUMBER(3) PREVALENCE FESTED POSITIVE RATE (2) 4952 C 1 7/4)
1990 SURVEY	SERO- NUMBER NUMBER(3) PREVALENCE TESTED POSITIVE RATE (\$) (952 C.1.)(4)
1989 SURVEY	SERO- NUMBER NUMBER(3) PREVALENCE TESTED POSITIVE BATE (2) (95g. C. 1.)(4)
	AGE-GPOID (VEARS)

1.9 2.0 4.0 13.5 7.5

11111 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.

0460074

157 497 424 287 287 103 133 8

4.5 7.9 7.9 6.7

3.4

.8

2.5

45

1784

3.5

iduals

2.1.2.1.2.2.1.2.2.2.2.2.2.2.2.2.2.2.2.2	1.8 -	andivic
	2.6	ted risks.
24008£-0	88	her identif syphilis s
157 360 389 229 158 98 89	1484	with no oth or routine secimens wer
2.8 1.1 12.3	2.5	osexuals llected f
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.	0.9 - 2.5	and heter cimens co W STO epi
0.0.4.8.0.8. 0.0.4.5.0.8. 0.0.4.5.0.8.	1.6	k for HIV blood spe t for a NE
-8088000	71	ner at ris drawn from
126 312 265 265 181 181 93 60 60 56	1093	with a sex part ) surveys were mination, and/o
19 AND UNDER 20 – 24 25 – 29 30 – 34 35 – 39 40 – 44 45 AND OVER UNKNOMN	TOTAL	(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks. (2) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis creaming on individual seek in examination, and/or treatment for a MR/ ID enisode. Specimens were collected consecutively

ting evaluation, examination, any or creatment for a firm of or process. Specimens were conference consecutively tested for this After all personal identifiers were removed. positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. Confidence Intervals to exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. and All 95%

£3

SMITTEO OISEASE (STD) CLINIC BY RACE/ETHNICITY,
EASE (
SIO O
TRANSMITTE
, SEXUALLY
FEMALES (1) ATTENOING A SEXUALLY TRANS 989 – 1991 (2)
£ 6
FEMALES 1989 - 19
LENCE FOR HETEROSEXUAL URVEY, SAN FRANCISCO, 1
∺Y. G.v.
SEROPREVALENC YEAR OF SURVE
ANO

4	se-o.	9	
c. I. )(		, - 2.	
(95%	9900	0.7	
	0.00 0.00 0.00	1.5	
NUMBER(3) POSITIVE	ww-00	11	
NUMBER	257 266 133 74 16	746	
)(4)	0.5.4	3.9	181 .
(95% C. I.	4.0.00	1.3 -	n individu ively servations
SERO- PREVALENCE RATE (%)	1.8 1.0 0.0 0.0	2.3	fled risks. screening o ed consecut under 20 ob
NUMBER(3) POSITIVE	800	14	other identi me syphilis were collect olot assay. umple sizes nown race.
NUMBER TESTEO	171 263 101 53 8	296	with no c for routing specimens w Western it ited for sa
)(4)	3.8 7.2 7.2	2.3	sexuals lected code. S wed by a calcula
(95% C. I.	0.00	0.2 -	and heterc cimens co' A STD epis oved. nd confirm rvals not estry, oth
SERO- PREVALENCE RATE (%)	0.0	6.0	artner at risk for HIV and heterosexuals with no other identified risks. Here drawn from blood specimens collected for routine syphilis screening on individual d/or treatment for a NEW 7ID episode. Specimens were collected consecutively all identifiers were removed. Adjy reactive by ELISA and confirmed by a Mestern blot assay. comfail. Confidence Intervals not calculated for sample sizes under 20 observations. I and Alaskan Native ancestry, other race, and unknown race.
NUMBER(3) POSITIVE		4	irtner at ri ve drawn fro Nor treatme il identifie Ily reactive mial. Conf and Alaskan
NUMBER TESTEO	145 184 61 40 8	438	th a sex pa surveys wer ination, and all persons ere repeated exact bind
RACE/ETHNICITY	MHITE AFRICAN AMERICAN LATINO ASTAN/PACIFIC ISLANGER NONE OF THE ABOVE (5)	TOTAL	(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.  (2) These unlinded (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seking exaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.  (3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (4) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.  (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.
	SERO- NUMBER(3) PREVALENCE TESTED POSITIVE RATE (\$) (95% C.I.)(4)  SERO- NUMBER(3) PREVALENCE TESTED POSITIVE RATE (\$) (95% C.I.)(4)	NUMBER (3) PREVALENCE TESTED POSITIVE RATE (\$\frac{x}{3}\) PREVALENCE TESTED POSITIVE RATE (\$\frac{x}{3}\) FREVALENCE TESTED POSITIVE TESTED P	NUMBER (3) PREVALENCE TESTED POSITIVE RATE (\$\frac{7}{8}\) PREVALENCE RATE (\$\frac{7}{8}\) PRE

	.1.)(4)	2.8. 2.9.0 2.9.0 2.9.0 2.9.0 2.9.0	- 2.6	
	(95% C.	0.000000	0.7 -	
1991 SURVEY	SERO- PREVALENCE RATE (%) (95% C.I.)(4)	0 - 0 4 4 0 0 0 0 8 5 1 - 0	1.5	
1961	NUMBER(3) POSITIVE	080800-0	Ε	
	NUMBER	116 258 160 86 42 48 32	746	
	.)(4)	8.0 - 2.8 - 2.8 - 12.5 - 19.0 - 11.7	3.9	uals s.
	(95% C. I	0.3 - 8.0 0.5 - 6.8 0.5 - 6.3 1.4 - 12.5 1.5 - 19.1 0.0 - 11.7	1.3 - 3.9	individ vely ervation
1990 SURVEY	SERO- PREVALENCE RATE (%) (95% C.I.)(4)	20.02 2.02.2.2.0 2.00.00	2.3	fied risks. screening on ed consecuti
199	NUMBER(3) POSITIVE	0-₩4₩-00	14	other identifies a syphilis are collectional assay. Imple sizes town race.
	NUMBER	194 137 137 27 24 4	296	with no of for routing pecimens with western by the for sain and unknish
	.)(4)	13.9 13.9 13.9	2.3	osexuals ollected sode. S med by a calcula
	(95% C.1	moooooo .	0.2 - 2.3	nd heter Imens cc STD epi ved. d confir vals not stry, ot
1989 SURVEY	SERO- PREVALENCE RATE (%) (95% C.I.)(4)	%0-0000 %800000	0.9	urtner at risk for HIV and heterosexuals with no other ider de drawn from blood specimens collected for routine syphilite treatment for a NEW SID episode. Specimens were collision in identifiers were removed. If y reactive by ELISA and confirmed by a Mestern blot assay and all confidence Intervals not calculated for sample size and Alaskan Native ancestry, other race, and unknown race.
198	NUMBER(3) POSITIVE	N00000	4	irtner at ri e drawn fro //or treatme il identifie ily reactive mial. Conf and Alaskan
	NUMBER	20 20 20 20 00	438	ith a sex pi surveys wen flation, and all persons ere repeated exact bind
	AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 25 - 29 30 - 34 30 - 34 40 - 44 45 AND OVER UNKNOWN	TOTAL	(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.  (2) These unlinked (Innded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.  (3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (4) 55% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.  (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.
	AGE	20 20 30 30 40 40 10 10 10 10 10 10 10 10 10 10 10 10 10	.0L	(5) A A B B B B B B B B B B B B B B B B B

HIV SEROPREVALENCE FOR HETEROSEXUAL FEMALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY AGE-GROUP, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (2)

ORIENTATION,	
AND SEXUAL	
BY GENDER	
PROGRAMS	
TREATMENT	
METHADONE	
ENTERING	
USERS (IDUs) 19 - 1991 (1)	
TION DRUG	
FOR INJECTOR	
HIV SEROPREVALENCE FOR INJECTION DRUG USERS (IDUs) ENTERING METHADONE TREATMENT PROGRAMS BY GENDER AND SEXUAL ORIENTATION AND YEAR OF SURVEY, SAN FRANCISCO, 1989 – 1991 (1)	
AND	

		1989	9 SURVEY			195	1990 SURVEY			199	1991 SURVEY	
GENDER AND SEXUAL ORIENTATION	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95 <b>%</b> C.1.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95 <b>%</b> C.1.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95 <b>%</b> C.1.)(3)
MALE												
Gay/Bisexual Heterosexual Unknown Orientation	143	<b>4</b> 00 €	33.3 9.8 0.0	5.5 - 15.9	25 716 7	8 1 1	32.0 8.0 14.3	14.9 - 53.5 6.1 - 10.2	11888	202	25.0 7.3 18.2	10.7 - 44.9 5.4 - 9.5
SUB-TOTAL MALE	152	º	10.5	6.1 - 16.5	748	8	8.8	6.9 - 11.1	727	S S	8.1	6.2 - 10.3
FEMALE												
Lesbian/Bisexual Heterosexual Unknown Orientation	4 2 1	000	0.00	4.9 - 20.5	376 376 2	~%0	0.0 0.0	1.2 - 31.7 3.7 - 8.7	14 376 0	080	6.1	3.9 - 9.0
SUB-TOTAL FEMALE	182	۱ 📽	10.3	4.5 - 19.2	398	24	6.0	3.9 - 8.8	390	18	5.9	3.8 - 8.7
MISSING GENDER	7	0	0.0	:	5	0	0.0	· :	51	2	13.3	•
TOTAL	237	24	10.1	6.6 - 14.7	1158	06	7.8	6.3 - 9.5	1132	84	7.4	6.0 - 9.1
(1) Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 1978. Excludes persons with a prior admission to treatment during the survey period, and persons who were preferentially admitted to treatment due to HIV/AIDS. Blood specimens were collected for syphilis screening as part of the admission requirements, and tested for HIV after all personal identifiers were removed.  (2) All positive specimens were repeatedly reactive by EIISM and confirmed by a Western blot assay.  (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.	methadone ior admiss treatment equirement e repeated exact bino	treatment w sion to trea t due to HIV ss, and test ily reactive mial. Conf	the have a hittment during /AIDS. Bloc ed for HIV a by ELISA an idence Inter-	a history of injection drug use (IDU) since 1978, uring the survey period, and persons who were Blood specimens were collected for syphilis screening tha feet and identifiers were removed. SA and confirmed by a Mestern blot assay. Intervals not calculated for sample sizes under 20 obs	ion drug us iod, and pe e collected al identifi a Western b	e (IDU) str grsons who v f for syphif ers were re lot assay.	ce 1978. were its screening moved. under 20 obs	servations.				

' RACE/ETHNICITY
PROGRAMS BY
TREATMENT
G METHADONE
JS) ENTERIN
RS (IDU
ION DRUG USERS (I ISCO, 1989 - 1991
INJECTION FRANCISCO
FOR Y, SAN
HIV SEROPREVALENCE FOR INJECTION DRUG USERS (IDUs) ENTERING METHADONE TREATMENT PROGRAMS BY RACE AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (1)
HIV S

		198	1989 SURVEY			1990	) SURVEY			1991	1991 SURVEY		
RACE/ETHNICITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (X) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (\$) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	(95% C. I.	)(3)
WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	142 61 27 5 5	2 1 1 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	3.5 23.0 18.5 0.0	1.2 - 8.0 13.2 - 35.5 6.3 - 38.1 	722 256 135 29 16	24 7 7 1	3.3 21.1 5.2 13.8 6.3	2.1 - 4.9 16.3 - 26.6 2.1 - 10.4 3.9 - 31.7	699 267 118 28 20	24 53 7 0	3.4 19.9 5.9 0.0	2.2 - 5.1 15.2 - 25.1 2.4 - 11.8 0.0 - 10.1 0.0 - 13.9	2,5,5,0 2,0 2,0 2,0 3,0 4,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5
TOTAL	237	24	10.1	6.6 - 14.7	1158	06	7.8	6.3 - 9.5	1132	84	7.4	6.0 - 9.1	9.1
(1) Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 1978. Excludes persons with a prior admission to treatment during the survey period, and persons who were preferentially admitted to treatment due to HIV/AIDS. Blood specimens were collected for syphilis screening as part of the admission requirements, and tested for HIV after all personal identifiers were removed.  (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.  (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.  (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.	methadone for admiss treatment equirement e repeated exact bino an Indian	treatment with the treatment with the to HIV is, and test III reactive mial. Confand Alaskan	ho have a hitment during /AIDS. Blox ed for HIV a by ELISA ar idence Inter Native ance	treatment who have a history of injection drug use (IDU) since 1978. In to treatment during the survey period, and persons who were clue to HIV/AIDS. Blood specimens were collected for syphilis screening is, and tested for HIV after all personal identifiers were removed. Ily reactive by ELISA and confirmed by a Western blot assay. mial. Confidence Intervals not calculated for sample sizes under 20 obs and Alaskan Native ancestry, other race, and unknown race.	ton drug us tod, and pe e collected al identifi a Western b ated for sa	e (IDU) sind rsons who we for syphiliers were red lot assay. mple sizes u	ce 1978. ere is screening noved. under 20 obs	servations.					

		96L	1989 SURVEY			199	1990 SURVEY			T661	1 SURVEY	
AGE-GROUP (YEARS)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
19 AND UNDER 20 - 24 25 - 29 35 - 34 35 - 34 40 - 44 45 AND OVER UNKNOWN	22 17 28 445 444 64 64 6	0-28	0.0 1.7.7 1.2.2 1.4.9 0.0	0.9 - 23.5 10.9 - 23.5 10.9 - 23.5 10.0 - 18.3 10.0 - 10.1	6 73 149 222 306 306 166 124		6 4 6 6. ย. 7 6 6. ย. 7 6 6. ย. 7 6 6. ย. 8 6. ย. 8 6. ย. 8 6. ย. 8 6. ย. 8. в. 8. в. в. 8. в. 8. в. 8. в. 8. в. 8. в. 8. в. в. 8. в. в. 8. в. в. 8. в. в. 8. в. в. 8. в. в. 8. в. в. в. 8. в. в. в. 8. в. в. 8. в. в. в. в. в. 8. в. в. в. в. в. 8. в.		7 183 307 261 155 30	0 0 0 7 2 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00.00 00	0.0 - 5.3 2.1 - 10.5 3.1 - 10.5 5.6 - 11.2 6.0 - 13.4 4.1 - 13.1
TOTAL	237	24	10.1	6.6 - 14.7	8511	06	7.8	6.3 - 9.5	1132	78	7.4	6.0 - 9.1
(1) Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 19 Excludes persons with a prior admission to treatment during the survey period, and persons who were preferentially admitted to treatment due to HIVAIDS. Blood specimens were collected for syphilis so as part of the admission requirements, and tested for HIV After all personal identifiers were removed (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under		treatment was ion to treat the to HIV is, and test illy reactive mial. Conf	who have a highword during //AIDS, Blocked for HIV aby ELISA and idence Inter	treatment who have a history of injection drug use (IDU) since 1978. Sion to treatment during the survey period, and persons who were is due to HIV/AIDs. Blood specimens were collected for syphilis screening is, and tested for HIV after all personal identifiers were removed. If yeactive by ELISA and confirmed by a Mestern blot assay. Sassay, mial. Confidence Intervals not calculated for sample sizes under 20 observations.	ion drug us iod, and pe e collected al identifi a Western b	se (IDU) sin arsons who w 1 for syphil lers were re olot assay.	nce 1978. ere its screening emoved. under 20 obs	ervations.				

HIV SEROPREVALENCE FOR INJECTION DRUG USERS (IDUs) ENTERING METHADONE TREATMENT PROGRAMS BY AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (1)

		IDUs	w			NON-IDUS	IDUs	
GENDER AND SEXUAL ORIENTATION	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
MALE								
Gay/Bisexual Heterosexual Unknown Orientation	42 5 1 6 1 6 1 6 1 6 1 6 1 6 1 6 1 6 1 6 1	1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2	29.6 7.8 20.0	18.0 - 43.6 4.6 - 12.1	71   25	2 2 5 1 A	52.9 2.6 18.2	0.9 - 6.0
FEMALE	3	3	į		2	2	2	
Lesbian/Bisexual Heterosexual Unknown Orientation	86.8	000	0.00 -	0.3 - 7.3	26 5   15	000	0.00 L	0.3 - 7.5
MISSING GENDER	0	1 0	•		0	0 0		
TOTAL	402	37	9.5	6.6 - 12.5	332	18	5.4	3.2 - 8.4

(1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Sample includes both injection drug users (IDUs) who have a history of needle use since 1978, and non-injection drug users who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment. Excludes persons with a prior admission to treatment during the survey period, persons who were preferentially admitted to treatment due to HIV/AIDS, and persons under alcohol treatment only. Blood specimens were collected for syphilis screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed. Bloostive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.

95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. ®®

		IDUs	ø			NON	NON-IDUs	
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (X)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
WHITE ARICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	265 63 40 21 13	26 0 0	9.8 2.5 0.0	6.5 - 14.0 6.7 - 25.4 0.1 - 13.2 0.1 - 23.8	116 153 33 22 8	<b>∞</b> ∞00⊢	7.8 5.2 0.0 0.0	3.6 - 14.2 2.3 - 10.0 0.0 - 8.7 0.0 - 12.7
TOTAL	402	37	9.2	6.6 - 12.5	332	18	5.4	3.2 - 8.4

(1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Sample includes both injection drug users (IDIs) who have a history of needle use since 1978, and non-injection drug users who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment. Excludes persons with a prior admission to treatment during the survey period, persons who were preferentially admitted to treatment due to HIVAIDs. And persons under a lobolo Irreatment only Blood specimens were collected for supplies screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were reseatedly reactive by ELISA and confirmed by a Mestern blot assay.

(2) All positive speciments were reseatedly reactive by ELISA and confirmed by a Mestern blot assay.

(3) 535 Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

		IOUs	s			NON-	NON-IOUs	
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.1.)(3)
19 AND UNDER	4	o	0.0		S	0	0.0	
20 - 24	47	5	4.3	- 1	ਲ	_	2.9	0.1 - 15.3
25 - 29	82	9	7.1	2.6 - 14.7	102	9	5.9	2.2 - 12.4
30 - 34	62	2	12.7	1	75	2	6.7	2.2 - 14.9
35 - 39	46	6	9.6	1	57	က	5,3	1.1 - 14.6
40 - 44	63	9	9.5	1	43	_	2,3	0.1 - 12.3
45 AND OVER	ဓ	4	13.3	1	91	2	12.5	
MISSING	0	0			0	0		
TOTAL	402	37	9.5	6.6 - 12.5	332	18	5.4	3.2 - 8.4

(1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Sample includes both injection drug users (IDUs) who have a history of needle use since 1978, and non-injection drug users who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment. Excludes persons with a prior admission to treatment during the survey period, persons who were preferentially admitted to treatment due to HIV/AIOS, and persons under alcohol treatment only. Blood specimens were collected for syphilis screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

HIV SEROPREVALENCE FOR INJECTION DRUG USERS (IDUs) AND NON-INJECTION DRUG USERS (NON-IDUs) ENTERING A DRUG-FREE DETOXIFICATION PROGRAM BY DRUG PREFERENCE, SAN FRANCISCO, 1990 - 1991 (1)	ON DRUG US AM BY DRUG	ERS (IDUS)	AND NON-INJE	ECTION DRUG US ISCO, 1990 - 1	ERS (NON-IDU	s) ENTERING	ď	
		IDUs	v			NON	NON-IDUS	,
PRIMARY DRUG	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
HEROIN COCAINE/CRACK HEROIN AND COCAINE (SPEEDBALL) AMHETAMINES/SPEED OTHER OR UNSPECIFIED DRUGS	242 26 1) 9 65	4 E O S E B	5.8 11.5 0.0 20.0 12.3	3.2 - 9.5 2.4 - 30.2 10.8 - 32.3 5.5 - 22.8	209 209 0 13 92	1 0 7 1	5.6 4.3 53.8 1.1	2.0 - 8.0
TOTAL	402	37	9.5	6.6 + 12.5	332	18	5.4	3.2 - 8.4

(1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Sample includes both injection drug users (IDIs) who have an history of needle use since 1978, and non-injection drug users who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment, who have serversons with a prior admission to treatment during the survey period, persons who were preferentially admitted to treatment due to HIVALDS, and persons under alcohol treatment only. Blood specimens were collected for syphilis screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeated by reactive by ELISA and confirmed by a Mestern blot assay.

	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	0.01 - 0.37	0.03 - 0.45	
1991 SURVEY		0.00 0.00 0.00 0.00 0.00	0.15	
199	NUMBER(2) POSITIVE	-0070	е	
	NUMBER TESTED	9 11 4 1925 8	1957	
	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	0.13 -24.87 0.00 -11.73 0.00 - 0.42	0.02 - 0.52	cted servations.
1990 SURVEY	SERO- PREVALENCE RATE (%)	00.000000000000000000000000000000000000	0.15	were coller under 20 obs
199	NUMBER(2) POSITIVE	-00-0	2	Specimens e removed. llot assay. ample sizes ch 1985.
	NUMBER TESTED	20 24 11 1313 8	1376	services tifiers wer a Western i ated for sa 1978.
	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	0.09 - 0.81	0.09 - 0.81	drawn from women seeking family planning services. Specimens were collected is tested for HIV after all personal identifiers were removed.  ady reactive by ELISA and confirmed by a Mestern blot assay.  Indiaction drug use (IDV) since January 1978.  Jobod transfusions(s) between January 1977 and March 1985.  no other Identified risks.
1989 SURVEY	SERO- PREVALENCE RATE (X)	0.32	0.32	drawn from women seeking i stested for HIV after all adly reactive by ELISA and nomial. Confidence Interval injection drug use (IDU) s blood transfusions(s) bets no other identified risks.
198	NUMBER(2) POSITIVE	00004	4	frawn from w tested for Ily reactive Minal. Conf Mingection dri Nood transf no other ide
	NUMBER TESTED	0 0 0 1266	1266	urvey was casts, and re repeated exact bincastory of itstory of itstory of buals with reduced on the results with results
	TRANSMISSION CATEGORY	Heterosexual IDU (4) Sex Partner at Risk for HIV Blood Recipient (5) Heterosexual (6) Unknown Risk (7)	TOTAL	(1) This unlinked (blinded) survey was drawn from women seeking family planning services. Specimens were collected from initial and annual visits, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 55% Confidence Intervals, eact bindmial. Confidence Intervals not calculated for sample sizes under 20 observations. (5) Includes persons with a history of injection drug use (IDU) since January 1978. (5) Includes persons with a history of blood transfusions(s) between January 1977 and March 1985. (5) Self-identified heterosexuals with no other identified risks.

HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (1)

		198	1989 SURVEY			1990	0 SURVEY			1991	1 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE		SERO- PREVALENCE RATE (\$) (95% C.I.)(3)	NUMBER TESTEO	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (\$) (95% C.I.)(3)
WHITE AFRICAN AMERICAN LATINA ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	122 154 810 149 31	800	0.00 0.00 0.00	0.02 - 4.48 0.02 - 3.56 0.03 - 3.56 0.00 - 1.99 0.00 - 9.21	126 145 908 166 31	-00-0	0.79 0.00 0.00 0.60 0.00	0.02 - 4.34 0.00 - 2.04 0.00 - 0.33 0.02 - 3.31 0.00 - 9.21	156 141 1441 178 41	0-200	0.00 0.71 0.00 0.00	0.00 - 1.90 0.02 - 3.89 0.02 - 0.50 0.00 - 1.67 0.00 - 7.05
TOTAL	1266	4	0.32	0.09 - 0.81	1376	5	0.15	0.02 - 0.52	1957	в	0.15	0.03 - 0.45
(1) This unlinked (blinded) survey was drawn from women seeking family planning services. Specimens were collected from initial and annual visits, and tested for HIV after all personal identifiers were removed. (2) All positives specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.	urvey was risits, and re repeate exact bin can Indian	drawn from v tested for dly reactive omial. Conf	women seekin HIV after a by ELISA au Fidence Inter	g family plannin 11 personal iden nd confirmed by rvals not calcul sstry, other rac	g services. tifiers wer a Western b ated for sa	Specimens e removed. Slot assay. Imple sizes nown race.	were colle	cted servations.				

HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1991 (1)

		1989	9 SURVEY			199	1990 SURVEY			1991	1 SURVEY	
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
19 AND UNDER 20 - 24 25 - 29 36 - 34 35 - 39 40 - 44 45 AND OVER UNSNOWN	73 420 414 226 105 18 3	080000	0.000000 0.000000000000000000000000000	0.00 - 4.02 0.01 - 1.32 0.01 - 1.34 0.01 - 3.16 0.00 - 2.81	93 474 401 243 97 34 8 8	000-0-00	0.00 0.00 0.00 0.00 0.00 0.00	0.00 - 3.17 0.00 - 0.63 0.00 - 0.74 0.01 - 2.27 0.00 - 3.04 0.07 -15.33	107 636 646 646 334 175 42 6	000-000	0.00 0.31 0.31 0.00 0.00 0.00	0.00 - 2.76 0.00 - 0.47 0.04 - 1.11 0.00 - 0.89 0.00 - 6.88 
TOTAL	1266	4	0.32	0.09 - 0.81	1376	2	0.15	0.02 - 0.52	1957	ю	0.15	0.03 - 0.45
(1) This unlinked (blinded) survey was drawn from women seeking family planning services. Specimens were collected from initial and annual visits, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELSA and confirmed by a Mestern blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.	urvey was d isits, and re repeated exact bino	rawn from w tested for I Ily reactive mial. Conf	omen seekin HIV after a by ELISA ai	drawn from women seeking family planning services. Specimens were collected it tested for HIV after all personal identifiers were ranvoed.  dly reactive by ELISA and confirmed by a Hestern blot assay.  confidence Intervals not calculated for sample sizes under 20 observ	g services. tifiers wer a Western b ated for sa	Specimens e removed. lot assay. mple sizes	were colle	cted servations.				

		199	1990 SURVEY			199	1991 SURVEY	
TRANSMISSION CATEGORY	NUMBER	NUMBER(2) POSITIVE		SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBE	SERO- PREVALENCE RATE (%)	SERO- R(2) PREVALENCE IVE RATE (\$) (95% C.I.)(3)
Heterosexual IDU (4) Sex Partner at Risk for HIV Heterosexual (5) Unknown Risk	8 3 419	0 5 0 0	12.50 0.00 0.48 0.00	 i	14 7 817 8	R040	35.71 0.00 0.49 0.00	 0.13 - 1.25
TOTAL	431	е	0.70	0.14 - 2.02	846	6	ا.06	0.49 - 2.01

(1) This unlinked (blinded) survey was drawn from women seeking induced abortions. Specimens were collected for evaluation purposes, and tested for HIV after all personal identifiers were moved.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons with a history of injection drug use (IDS) since January 1978.

		961	1990 SURVEY			199	1991 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (X)	SERO- PREVALENCE RATE (X) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (X)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
WHITE AFRICAN AMERICAN	03 D 20 C 20 C	- 80	2.00	0.05 -10.65	71 206 437	mmr	4.23 1.46 0.69	0.88 -11.86
ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	45	000	000	0.00 - 6.44	107	000	000	0.00 - 2.76
TOTAL	431	ю	0.70	0.14 - 2.02	846	6	٦.06	0.49 - 2.01

(1) This unlinked (blinded) survey was drawn from women seeking induced abortions. Specimens were collected for evaluation purposes, and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confinmed by a Western blot assay.

(3) 55% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

HIV SEROPREVALENCE FOR MOMEN ATTENDING AN ABORTION CLINIC BY AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1990 - 1991 (1)

		199	1990 SURVEY			199	1991 SURVEY	
AGE-GROUP (YEARS)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
19 AND UNDER 20 - 24 25 - 29 30 - 34 40 - 44 40 - 44 41 AND OVER UNKNOWN	89 106 26 8 8 0 0 0 0 4	0-00000	0.0020000000000000000000000000000000000	0.00 - 4.31 0.02 - 3.94 0.00 - 2.79 0.00 - 10.88 	133 253 223 118 86 27 27	-04000	0.00 0.00 0.00 0.00	0.02 - 4.12 0.10 - 2.83 0.49 - 4.53 0.02 - 4.63 0.00 -10.50
TOTAL	431	9	0.70	0.14 - 2.02	846	6	1.06	0.49 - 2.01
<ol> <li>This unlinked (blinded) survey was drawn from women seeking induced abortions. Specimens were collected for evaluation purposes, and tested for HIV after all personal identifiers were moved.</li> <li>Il positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.</li> <li>55 Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.</li> </ol>	Survey was HIV after are repeated exact bin	drawn from wall personal	omen seeking identifiers by ELISA ar idence Inter	induced abortics were removed.  Induced abortics were removed.  Induced by and calculations.	ons. Speci Western b	mens were color assay.	collected fo	r evaluation servations.

	(95% C.I.)(3)		0.01 - 2.67 0.00 - 0.66 0.17 - 1.56	0.03 - 1.04 0.01 - 1.29 0.04 - 7.50		0.17 - 1.59 0.20 - 2.74 0.00 - 0.83	0.00 - 0.66 0.00 - 0.81 0.03 - 5.67	0.16 - 0.68	0.10 - 0.20	0.07 - 0.10
11 SURVEY	SERO- PREVALENCE RATE (%)		0.00	0.29		0.63 0.95 0.16	0.0. 0.08	0.36	0.14	0.08
1991	NUMBER(2) POSITIVE		-04	2		46-	00-	6	31	124
	NUMBER		206 454 653	695 429 72		640 317 634	454 367 96	2509	22103	154918
	(95% C.I.)(3)		- 0 0	0.00 - 0.89 0.00 - 0.66 0.00 - 2.53		0.00 - 0.84 0.00 - 0.92 0.00 - 0.91	111	0.01 - 0.30	0.07 - 0.16	0.06 - 0.09
SURVEY	SERO- PREVALENCE RATE (\$) (9			0.00		0.15 0.00 0.16 0.16		0.08 0	0.11 0	0.07 0
1990	NUMBER(2) POSITIVE		00-	-00		-0-	000	2	23	106
	NUMBER		181 446 618	625 451 117		663 324 608	633 115 95	2438	21397	150494
	(95% C.I.)(3)		0.01 - 2.52 0.05 - 1.62 0.00 - 0.47	0.00 - 0.48 0.00 - 0.62 0.02 + 3.97	1	0.00 - 0.44 0.01 - 1.66 0.00 - 0.98	0.00 - 0.47 0.01 - 2.67 0.02 - 4.28	0.04 - 0.40	0.08 - 0.17	0.05 - 0.08
9 SURVEY	SERO- PREVALENCE RATE (%)		0.00	0.00		0.00	0.00 0.49 0.78	0.16	0.12	0.06
1989	NUMBER(2) POSITIVE		-80	00-		0	0	4	25	92
	NUMBER		219 442 638	625 485 138		679 334 564	636 206 128	2547	21217	144284
		AGE-GROUP (YEARS)	UNDER 20 20 - 24 25 - 29	30 - 34 35 ANO OVER UNKNOMN	RACE/ETHNICITY	WHITE AFRICAN AMERICAN LATINA	ASIAN/PACIFIC IS. OTHER UNKNOMN	TOTAL - SAN FRANCISCO	TOTAL - BAY AREA (4)	TOTAL - STATEMIOE

⁽¹⁾ Data courtesy of the California Department of Health Services Office of AIDS. Specimens from this survey of newborn infants fand women giving birth) are drawn from the genetic diseases screening program. Antibodies in a newborn infant reflect the infection status of the mother and not necessarily of the child.
(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.
(3) 55% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.
(4) Includes the counties of Alameda, Contra Costa, Marin, San Francisco, San Mateo, and Santa Clara.

S (TB)	(95% C.I.)(3)		66.6 - 91.6 50.9 - 91.3 1.9 - 9.6	19.9 - 31.2		0.0 - 4.7	0.0 - 6.8	15.1 - 24.0
TUBERCULOSI CATEGORY,	SERO- PREVALENCE RATE (%)		81.4 75.0 21.1 4.8 0.0	25.2		7.0.0 0.0	1.3	19.3
RANSMISSION	NUMBER(2) POSITIVE		35 4 7 0	<u>_</u>		-00	-	62
NTS UNDER TR GENDER AND T 1)	NUMBER		43 20 19 147 13	345		62 12 12	8	325
HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A MUNICIPAL TB CLINIC BY GENDER AND TRANSMISSION CATEGORY, SAN FRANCISCO, 1989 – 1991 (1)	GENDER AND TRANSMISSION CATEGORY	MALE	Gay/Bisexual IDU (4) Gay/Bisexual IDU (4) Heterosexual IDU (4) Heterosexual (5) Unknown Risk	SUB-TOTAL MALE	FEMALE	Heterosexual IDU (4) Heterosexual (5) Unknown Risk	SUB-TOTAL FEMALE	TOTAL

(1) This interview-based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3), TB suspects (class 5), contacts to persons with B (class 1 and class 2), and persons with past TB infection (class 4).

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons with a history of injection drig use (IDU) since January 1978.

(5) Includes persons with a sexual partner(s) at risk for HIV, persons with a history of blood transfusion(s) or with hemophilia, and self-identified heterosexuals with no other identified risks.

.)(3)	8.7	24.0
(95% C. I	29.4 - 45.7	15.1 - 24.0
SERO- PREVALENCE RATE (%) (95% C.I.)(3)	37.2 4.5	19.3
NUMBER(2) POSITIVE	22 g	62
NUMBER TESTED	145	322
ORIGIN OF BIRTH	SORN IN USA SORN OUTSIDE USA	TOTAL

(1) This interview based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3), TB suspects (class 5), contacts to persons with TB (class 1 and class 2), and persons with past TB infection (class 4). (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 55% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

	(3)	0,7.5,7.
S (TB) - 1991 (1)	(95% C.1.)(	30.5 - 56.0 18.0 - 40.7 10.6 - 30.5 0.0 - 4.7
1 TUBERCULLOSIS (TB) (NCISCO, 1989 - 1991 (1) SERO- PREVALENCE		28.4 19.1 0.9 28.6
ITY, SAN FRA	- 1	27 85 13 5
RACE/ETHNIC	TESTED	63 67 68 117
AT A MUNICIPAL TB CLINIC BY RACE/ETHNICITY, SAN FRANCISCO, 1989 – 1991 (1)  SERO-SEROPLOSIS (18)  SERO-SERO-SERO-SERO-SERO-SERO-SERO-SERO-	RACE/ETHNICITY	WHITE ARIZAN AMERICAN AJAINO SZIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)

(1) This interview based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3), TB suspects (class 5), contacts to persons with TB (class 1 and class 2), and persons with past TB infection (class 4).

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

15.1 - 24.0

19.3

62

322

TOTAL

SERO- E RATE (\$) (95% C.I.)(3)	12.3 - 34.7 16.2 - 34.4 18.1 - 40.1 1.8 - 12.6	15.1 - 24.0
SERO- PREVALENCE RATE (%)	11.1 22.0 24.5 28.2 5.6	19.3
NUMBER(2) POSITIVE	13 20 20 20 0	62
NUMBER	98 71 89 0	322
AGE-GROUP (YEARS)	19 AND UNDER 20 - 29 30 - 39 40 - 49 50 AND OVER UNKNOWN	TOTAL

(1) This interview based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3), TB suspects (class 5), contacts to persons with B (class 1 and class 2), and persons with past TB infection (class 4). (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 50% Confidence Intervals, exact binomial. Confidence Intervals and calculated for sample sizes under 20 observations.

(95% C.1.)(3)	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	
SERO- PREVALENCE RATE (%) (	25.000.000.000.000.000.000.000.000.000.0	
NUMBER(2) POSITIVE	-owo 4 000 0 0	
NUMBER	628 628 205 205 2	
GENDER AND TRANSAISSION CATEGORY	MALE  Gay/Bisexual  Heterosexual, IDU (4)  Heterosexual  Unknown Risk  SUB-TOTAL MALE  FEMALE  FEMALE  FEMALE  Missing GENDER  Missing GENDER	

(1) This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood specimens were collected for sphils screening on imates as part of the routine intake process. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.
(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.
(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes persons with a history of higection drug use (IDU) since January 1978.

0.1 - 1.2

0.5

835

TOTAL

SERO- 2) PREVALENCE E RATE (%) (95% C.I.)(3)	0.0 - 3.5 0.1 - 1.9 0.0 - 3.3 0.0 - 3.	0.1 - 1.2
SERO- PREVALENCE RATE (%)	0.0000	0.5
NUMBER(2) POSITIVE	08-00	4
NUMBER	83 469 168 96 19	835
RACE/ETHNICITY	WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL

(1) This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood specimens were collected for spyllis screening on inmates as part of the routine intake process. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.

(3) 55% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

N CENTER	SERO- PREVALENCE RATE (\$) (95% C.I.)(3)	0.0 - 2.0 0.2 - 1.5	0.1 - 1.2
ILE DETENTIO	SERO- PREVALENCE RATE (%)	0.000	0.5
ING A JUVEN	NUMBER(2) POSITIVE	0400	4
ADOLESCENTS ENTER	NUMBER TESTED	148 666 3 18	835
HIV SEROPREVALENCE FOR ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER BY AGE-GROUP, SAN FRANCISCO, 1990 – 1991 (1)	AGE-GROUP (YEARS)	UNDER 15 15 – 19 20 – 24 UNKNOMN	TOTAL

(1) This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood specimens were collected for syphilis screening on immates as part of the routine intake process. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed by the specimens were repeated to the reactive by ELISA and confirmed by a Hestern blot assay.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Hestern blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(95% C.1.)(3)	19.9 - 42.7 0.0 - 9.5 0.0 - 3.4 3.4 5.3 - 12.3	0.1 - 12.0 0.2 - 2.7  0.3 - 2.7
SERO- PREVALENCE RATE (%)	00.000 B 40.000 E	2.3 0.0 0.1 1.1
NUMBER(2) POSITIVE	22   0 0 23	L 80 4 L
NUMBER	930 163 266 266	44 319 11 374 6
GENDER AND TRANSMISSION CATEGORY	MALE Gay/Bisexual Heterosexual, IDU (4) Heterosexual (5) Unknown Risk SUB-TOTAL MALE FEMALE	Heterosexual IDU (4) Heterosexual (5) Uhrown Risk SUB-TOTAL FEMALE MISSING GENDER

(1) This unlinked (blinded) survey includes adolescents seeking services at two homeless youth shelters. Blood specimens were collected collected consecutively and tested for HIV after all personal identifiers were removed. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. Western blot assay.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 55% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes persons with a history of injection drug use (IDU) since January 1978.

0.9 2.8 -

27

646

TOTAL

WHITE
AFRICAN AMERICAN
LATINA
ASTAN/PACIFIC ISLANDER
NONE OF THE ABOVE (4)

TOTAL

RACE/ETHNICITY

6.0

(1) This unlinked (blinded) survey includes adolescents seeking services at two homeless youth shelters. Blood specimens were collected for spyllis screening as part of the routine medical evaluation. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.

(3) 55% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

SERO- 2) PREVALENCE E RATE (\$) (95% C.1.)(3)	0.0 - 3.5 1.8 - 5.1 10.5 - 35.0	2.8 - 6.0
SERO- PREVALENCE RATE (%)	0.0 3.2 20.8 0.0	4.2
NUMBER(2) POSITIVE	0550-	27
NUMBER	85 506 48 1	646
(YEARS)		
AGE-GROUP (YEARS)	UNDER 15 15 - 19 20 - 24 25 - 29 UNKNOWN	TOTAL

(1) This unlinked (blinded) survey includes adolescents seeking services at two homeless youth shelters. Blood specimens were collected for syphilis screening as part of the routine medical evaluation. Specimens were collected consecutively and tested for HIV after all personal identifiers were ranoved.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENOER AND YEAR, 1985 - 1991 (1)

	) \$(4)	0.28	0.36					
1989	IV+(3)	75	ო					
	N(2) HIV+(3) \$(4)	711	835					
	7(4)	0.26	0.21					
1988	IV+(3)	00	2					
	N(2) HIV+(3) X(4)	759 178	937					
	五(4)	0.58	0.49		五(4)	0.45	0.42	
1987	۷+(ع)	0.0	w	AL.	۷+(3)	20 2	22	
-	N(2) HIV+(3) %(4)	869 143	1012	 TOTAL	N(2) HIV+(3) %(4)	4420 854	5274	
	ž				ž	4,		
	<b>Z</b> (4)	0.96	0.89		<b>Z</b> (4)	0.00	0.41	
1986	N(2) HIV+(3) %(4)	6-	<u>5</u>	1991	N(2) HIV+(3) X(4)	00	2	
7	(2) HI	941 183	1124	7	(2) HIV	407	483	
	ž		-		ž	,		
	<b>Z</b> (4)	0.00	0.00		<b>Z</b> (4)	0.00	0.00	
1985	N(2) HIV+(3) %(4)	00	0	1990	N(2) HIV+(3) X(4)	00	0	
ř	(2) HIV	213 45	258	-	(2) HI	520 105	625	
	ž				ž	3,2		
	GENDER	MALE FEMALE	TOTAL		GENDER	MALE FEMALE	TOTAL	
	G	Σ'ιι	-		G	Σ.π.	-	

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC). Data Collected between October 1985 and December 1991.
(2) Number of specimens tested.
(3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
(4) Seroprevalence rate (\$\frac{7}{8}\).

**%**(4)

00.000

0.36

N(2) HIV+(3)	286 1 178 1 102 1 253 0 16 0	835 3					
N(2) HIV+(3) X(4)	334 1 0.30 193 1 0.52 115 0 0.00 267 0 0.00 28 0 0.00	937 2 0.21					
N(2) HIV+(3) X(4)	346 2 0.58 212 3 1.42 108 0 0.00 320 0 0.00 26 0 0.00	1012 5 0.49		TOTAL	N(2) HIV+(3) X(4)	1841 13 0,71 1026 7 0,68 557 1 0,18 1658 0 0,00 192 1 0,52	5274 22 0.42
N(2) HIV+(3) X(4)	334 7 1.71 193 2 0.83 115 0 0.00 267 0 0.00 28 1 1.43	937 10 0.89		1991	N(2) HIV+(3) %(4)	162 2 1.23 65 0 0.00 69 0 0.00 172 0 0.00 15 0 0.00	483 2 0.41
RACE/ETHNICITY N(2) HIV+(3) X(4)	HITE 94 0 0.00 HISPANIC 11 0 0.00 ASTAN/P.I. 85 0 0.00 OTHER 17 0 0.00	TOTAL 258 0 0.00		1990	RACE/ETHNICITY N(2) HIV+(3) X(4)	HITE 210 0 0.00 AFRICAN AMERICAN 85 0 0.00 ASIAN/P. 1. 20 0.00 OTHER	T0TAL 625 0 0.00
	N(2) HIV+(3) X(4) N(2) HIV+(3) X(4) N(2) HIV+(3) X(4) N(2) HIV+(3) X(4)	N(2) HIV+(3) X(4) HIV+(3	ERICAN \$1 N(2) HIV+(3) \$\mathbb{X}(4)\$ N(3) HIV+(3) HIV+(3) \$\mathbb{X}(4)\$ N(3) HIV+(3) HIV+(	ERICAN \$1 0 0.00 334 7 1.71 346 2 0.58 334 1 0.30 115 0 0.00 115 0 0.00 28 1 1.43 26 0 0.00 28 0 0.00 28 1 1.43 26 0 0.00 28 0 0.00 28 1 1.43 26 0 0.00 28 0 0.00 28 1 1.43 26 0 0.00 28 0 0.00 28 1 1.43 26 0 0.00 28 0 0.00 28 1 1.43 26 0 0.00 28 0 0.00 28 1 1.43 26 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0 0.00 28 0	ERICAN (2) HIV+(3) X(4) N(2) HIV+(3) X(4) HIV+(3) X(4) N(2) HIV+(3	FRICAN \$\(\frac{94}{51}\) 0 0.00 \\ \frac{334}{51}\) 7 \(\frac{1}{17}\) 1 \(\frac{1}\) 1 \(\frac{1}\) 1 \(\f	FRICAN (2) HIV+(3) X(4) N(2) H

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC). Data Collected between October 1985 and December 1991.
(2) Number of specimens tested.
(3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
(4) Seroprevalence rate (\$\frac{7}{3}\).

HIV SENDREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY AGE-GROUP AND YEAR, 1985 - 1991 (1)

N(2) HIV+(3) X(4) N(2) HIV+(3)	¥:	1985	-3.		1986			1987			1988			1989	
0 0.00 417 1 0.21 448 0 0.00 417 1 0.24 352 0 0.00 0.00 0.00 1236 2 0.70 265 1 0.38 236 0 0.00 211 1 0.24 215 0 0.00 0.00 121 4 2.67 133 3 2.26 121 0 0.00 102 0 0.00 0.00 0.00 121 4 2.67 133 3 2.26 121 0 0.00 0.00 0.00 0.00 0.00 0.00 0.0	N(2) HI	(+(3)	<b>X</b> (4)	N(2) H	IV+(3)	7(4)	N(2)	4IV+(3)	7(4)	N(2)	HIV+(3	) %(4)	N(2)	HIV+(	3) %(4)
0 0.00 937 10 0.89 1012 5 0.49 937 2 0.21 835 3	129 48 45 36 0	00000	9888	417 236 163 121 0	-0E40	0.21 0.70 1.47 2.67	448 265 166 133	0	0.00 2.26	417 236 163 121 0	-0-00	. 0.0.0 9.00 9.00 9.00 9.00 9.00 9.00 9.	352 211 170 102 0	0-700	0.00 0.47 1.18 0.00
The second contract of	258		00.00	937	5	0.89	1012	u,	0.49	937	2	0.21	835		0.36

	N(2) HIV+(3) X(4)	0.13 0.31 0.86 1.05	0.42
TOTAL	IV+(3	64870	23
10	N(2) H	2366 1307 933 668 0	5274
	) ऋ(4)	0.43 0.00 1.35 0.00	0.41
1991	IV+(3)	-0-00	2
	N(2) HIV+(3) X(4)	235 108 74 66 0	483
	) ऋ(4)	8886.	0.00
1990	IV+(3)	00000	0
	N(2) HIV+(3) X(4)	300 154 111 60	625
	AGE-GROUP	19 AND UNDER 20 - 24 25 - 29 30 AND OVER UNKNOWN	TOTAL

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC). Oata Collected between October 1985 and December 1991.
(2) Number of specimens tested.
(3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
(4) Seroprevalence rate (%).

(95% C.I.)(3)	0.088 - 0.139 0.023 - 0.062 0.017 - 0.037 0.006 - 0.022 0.007 - 0.024 0.007 - 0.024	0.030 - 0.039
SERO- PREVALENCE RATE (%)	0.111 0.045 0.033 0.026 0.013 0.013	0.034
NUMBER(2) POSITIVE	80 4 80 11 2 3 3 4 8	202
TOTAL DONATIONS	72204 88168 8136 91396 90192 87320 84578 77273	591131
YEAR OF DONATION	1985 1986 1987 1988 1989 1990	TOTAL

⁽¹⁾ Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 59% Confidence Intervals, normal approximation.

	_			
<b>≪</b>	(95% C.I.)(3)	0.008 - 0.101	0.001 - 0.026 0.000 - 0.024	0.005 - 0.021
NCISCO BAY ARE IER 1991 (1)	SERO- PREVALENCE RATE (%)	0.032	0.006	0.010
OM THE SAN FRA 1991 – DECEMB	NUMBER(2) POSITIVE	23	-12	œ
OOD DONORS FRO NDER, JANUARY	TOTAL	9456 9473	30886 27458	77273
CE FOR BLI US AND GEI	GENDER	Male Female	Male Female	
11V SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA 3Y DONATION STATUS AND GENDER, JANUARY 1991 - DECEMBER 1991 (1)	DONATION	FIRST-TIME DONORS	REPEAT	TOTAL

(1) Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, normal approximation.

(95% C.I.)(3)	0.002 - 0.017 0.024 - 0.294 0.000 - 0.070 0.001 - 0.155	0.005 - 0.021
SERO- PREVALENCE RATE (%)	0.006 0.092 0.000 0.024	0.010
NUMBER(2) POSITIVE	4 E O F	80
TOTAL	64635 3249 3 5199 4 190	81211
RACE/ETHNICITY	HHITE ARICAN AMERICAN ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL

(1) Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, normal approximation. (4) Includes Latinos, American Indians, Alaxan Natives, other race, and unknown race.

£ <b>A</b>	(95 <b>%</b> C.1.)(3)	0.000 - 0.067 0.002 - 0.057 0.011 - 0.064 0.000 - 0.010	0.005 - 0.021
NCISCO BAY ARE	SERO- PREVALENCE RATE (%)	0.000 0.014 0.028 0.000	0.010
OM THE SAN FRA	NUMBER(2) POSITIVE	0890	60
OOD DONORS FRO	TOTAL	5434 14139 21495 36205	81211
HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY AGE-GROUP, JANUARY 1991 - DECEMBER 1991 (1)	AGE-GROUP (YEARS)	19 AND UNDER 20 – 29 30 – 39 40 AND OVER	TOTAL

(1) Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay. (3) 95% Confidence Intervals, normal approximation.

**HIV Seroprevalence Report** 

San Francisco Department of Public Health AIDS Office July, 1994 Volume 5, No. 1 AUG 2 2 1994

SAN FRANCISCO
PUBLIC LIBRARY

## Contents

	<u>Page</u>
SURVEY OF CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC: 1989-93	
HIV Seroprevalence for Clients Attending a STD Clinic by Gender and Transmission Category	1
HIV Seroprevalence for Clients Attending a STD Clinic by Gender and Transmission Category	3
HIV Seroprevalence for Clients Attending a STD Clinic by Age Group	4
HIV Seroprevalence for Gay & Bisexual Men Attending a STD Clinic by Race/Ethnicity	5
HIV Seroprevalence for Gay & Bisexual Men Attending a STD Clinic by Age Group	6
HIV Seroprevalence for Heterosexual Males Attending a STD Clinic by Race/Ethnicity	7
HIV Seroprevalence for Heterosexual Males Attending a STD Clinic by Age Group	8
HIV Seroprevalence for Heterosexual Females Attending a STD Clinic by Race/Ethnicity	9
HIV Seroprevalence for Heterosexual Females Attending a STD Clinic by Age Group	10
SURVEY OF INJECTION DRUG USERS (IDUs) ENTERING METHADONE TREATMENT PROGRAMS	
HIV Seroprevalence for IDUs Entering Methadone Treatment by Gender & Sexual Orientation	11
HIV Seroprevalence for IDUs Entering Methadone Treatment by Race/Ethnicity	13
HIV Seroprevalence for IDUs Entering Methadone Treatment by Age Group	14
SURVEY OF DRUG USERS (IDUs) & NON-IDUs ENTERING A METHADONE-FREE DETOX PROGRAM	
HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Gender & Sexual Orientation	15
HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Race/Ethnicity	16
HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Age Group	17
HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Primary Drug	18
SURVEY OF WOMEN OF REPRODUCTIVE AGE: FAMILY PLANNING & ABORTION CLINIC CLIENTS	
HIV Seroprevalence for Women Attending a Family Planning Clinic by Transmission Category	19
HIV Seroprevalence for Women Attending a Family Planning Clinic by Race/Ethnicity	20
HIV Seroprevalence for Women Attending a Family Planning Clinic by Age Group	21
HIV Seroprevalence for Women Attending an Abortion Clinic by Transmission Category	22
HIV Seroprevalence for Women Attending an Abortion Clinic by Race/Ethnicity	23
HIV Seroprevalence for Women Attending an Abortion Clinic by Age Group	24
SURVEY OF CHILDBEARING WOMEN IN SAN FRANCISCO: 1989-92	
HIV Seroprevalence for Newborn Infants and Their Mothers by Age Group and Ethnicity	25
SURVEY OF PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A TB CLINIC	
HIV Seroprevalence for TB Patients by Gender and Transmission Category	27
HIV Seroprevalence for TB Patients by Origin of Birth	28
HIV Seroprevalence for TB Patients by Race/Ethnicity	29
HIV Seroprevalence for TB Patients by Age Group	30

## SURVEY OF ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER (JDC) AND HOMELESS YOUTH CENTERS (HYCs)

HIV Seroprevalence for Adolescents Entering a JDC by Gender & Transmission Category	31
HIV Seroprevalence for Adolescents Entering a JDC by Race/Ethnicity	32
HIV Seroprevalence for Adolescents Entering a JDC by Age Group	33
HIV Seroprevalence for Adolescents Entering HYCs by Gender & Transmission Category	34
HIV Seroprevalence for Adolescents Entering HYCs by Race/Ethnicity	35
HIV Seroprevalence for Adolescents Entering HYCs by Age Group	36
RESULTS OF HIV SCREENING OF CIVILIAN APPLICANTS FOR MILITARY SERVICE: 1985-1992	
HIV Seroprevalence for Civilian Applicants for Military Service by Gender & Year	37
HIV Seroprevalence for Civilian Applicants for Military Service by Race/Ethnicity & Year	38
HIV Seroprevalence for Civilian Applicants for Military Service by Age Group & Year	39
The Selephevalence for Civilian Applicants for Military Selvice by Age Group & Year	33
RESULTS OF HIV SCREENING OF BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA: 1985-19	200
RESULTS OF HIV SCREENING OF BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA: 1985-1	993
HIV Seroprevalence for Blood Donors by Year of Donation	40
HIV Seroprevalence for Blood Donors by Donation Status & Gender	41
HIV Seroprevalence for Blood Donors by Race/Ethnicity	42
HIV Seroprevalence for Blood Donors by Age Group	43

HIV SEROPREVALENCE REPORT is released on a semi-annual basis by the San Francisco Department of Public Health, AIDS Office, Seroepidemiology and Surveillance Branch, 25 Van Ness Avenue, Suite 500, San Francisco, CA 94102-6033. Phone (415) 554-9050. AIDS Office Director, Mitch Katz, M.D. Seroepidemiology and Surveillance Branch Chief, George F. Lemp, Dr. P.H. Program Coordinator, Sean Nguyen. Epidemiologist/Data Manager, Tim Kellogg. Funding and technical support is provided by the Division of HIV/AIDS, Centers for Disease Control and Prevention. Additional support is provided by the California Department of Health Services, Office of AIDS.

HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY GENDER AND TRANSMISSION CATEGORY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (1)	
HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY GENDER AND TRANSMISSION AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (1)	CATEGORY,
HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY GENDER AND AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (1)	TRANSMISSION
HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY GENDER. AND YEAR OF SURVEY, SAN FRANCISCO, 1989 – 1993 (1)	AND
HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (1)	GENDER
HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (1)	B
HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (1)	CLINIC
HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (1)	(STD)
HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (1)	DISEASE
HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSM AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (1)	IITED
HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (1)	TRANSM
HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXU. AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 .	(1)
HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SAND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1	SEXU/
HIV SEROPREVALENCE FOR CLIENTS ATTENDING AND YEAR OF SURVEY, SAN FRANCISCO, 1989	4 .
HIV SEROPREVALENCE FOR CLIENTS AT AND YEAR OF SURVEY, SAN FRANCISCO	TENDING , 1989
HIV SEROPREVALENCE FOR CLIENT AND YEAR OF SURVEY, SAN FRANC	S AT ISCO
HIV SEROPREVALENCE FOR AND YEAR OF SURVEY, SAN	CLIENT
HIV SEROPREVALENCE AND YEAR OF SURVEY,	FOR
HIV SEROPREVAL AND YEAR OF SU	ENCE JRVEY,
HIV SEROPE AND YEAR C	EVAL OF SU
AND	SEROPE YEAR C
	AND

1989 SURVEY 1991 SURVEY	SERO- NUMBER (2) PREVALENCE RY TESTED POSITIVE RATE (%) (95% C.1.)(3) SERO- NUMBER NUMBER(2) PREVALENCE TESTED POSITIVE RATE (%) (95% C.1.)(3)		440 224 50.9 46.1 - 55.7 626 269 43.0 39.1 - 47.0 672 254 37.8 34.1 - 41.6 67.1 14.8 1 71.1 61.8 - 79.2 10.1 15.9 10.1 15.9 12.1 14.0 10.1 12.1 14.1 14.1 14.1 14.1 14.1 14.1 14	1788         338         18.9         17.1 - 20.8         2497         396         15.9         14.4 - 17.4         2712         360         13.3         12.0 - 14.6		for HIV 58 1 1.7 0.0 - 9.2 55 1 1.8 0.0 - 9.7 65 3 4.6 1.0 - 12.9   ) 11 1 9.1 6 1 16.7 6 1.3 2.4 1.3 4.1 681 8 1.2 0.5 - 2.3 5.0 0.0 0.0 - 10.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	509 10 2.0 0.9 3.6 681 20 2.9 1.8 4.5 849 15 1.8 1.0 2.9		2297 348 15.2 13.7 - 16.7 3178 416 13.1 11.9 - 14.3 3561 375 10.5 9.5 - 11.6	mination, and/or treatment for a NEW STD episode. Sprintation, and/or treatment for a NEW STD episode. Sprinter all personal identifiers were removed; sodily reactive by ELISA and confirmed by a Western blot nomial. Confidence Intervals not calculated for samplification drugu use (IDU) since January 1978. blood transfusions(s) between January 1977 and March no other identified risks.	These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STO episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. Specimens were repeatedly reactive by ELISA and confirmed below as Western blot assay.  Standame breams were repeatedly reactive by ELISA and confirmed by Western blot assay.  The Ludes persons with a history of injection drug use (100) since January 1978. The March 1985.  The Cludes persons with a history of blood transfusions(s) between January 1977 and March 1985.  Self-identified heterosexuals with no other identified risks.  The Cludes women who have sex with women and women who have sex with homen and women who have sex with homen and women who have sex with women and women who have sex with women and women who have sex with men and women who have sex with women and women who have sex with men and women who have sex with women and women who have sex with women and women who have sex with women and women who have sex with men and women who have sex with women and women who have sex with men and women who have sex with women and women who have sex w
			440 114 104 70 70 23 1023			55 58 11 380 5				ded) surveys were drawn valuation, examination tied for HIV after all is were repeatedly reac affs, exact binomial.  a history of injection a history of blood trockwals with no other overwals with no other overwals with no other and	ded) surveys were drawn yealuation, examination its dor HIV after all is were repeatedly reaches, exact binomial. The history of injection a history of blood trocescuals with no other yes sex with women and lection drug use (100)
	GENDER AND TRANSMISSION CATEGORY	MALE	Gay/Bisexual Gay/Bisexual, IDU (4) Heterosexual IDU (4) Sex Partner at Risk for HIV Blood Recipient (5) Heterosexual (6) Unknown Risk	SUB-TOTAL MALE	FEMALE	IDU (4) Sex Partner at Risk for HIV Lesbian/Bisexual (7) Blood Recipient (5) Heterosexual (6) Unknown Risk	SUB-TOTAL FEMALE	MISSING GENDER	TOTAL		

HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY GENDER AND TRANSMISSION CATEGORY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (1) (cont'd)

		1992	2 SURVEY			1993	3 SURVEY	
GENDER AND TRANSMISSION CATEGORY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
Gay/Bisexual Gay/Bisexual, IDU (4)	650	226	34.8	31.1 - 38.6 24.7 - 52.8	669	239	34.2	
Heterosexual IDU (4) Sex Partner at Risk for HIV	<b>5</b> %	<b>/</b> 4	6.7	2.7 - 13.4 1.7 - 14.8	K 8:	<b>∞</b> 10·	8.0 6.3	3.0 - 16.6 2.1 - 14.0
Blood Recipient (5) Heterosexual (6) Unknown Risk	1575 43	- 3g o	0.0 16.3 0.5	1.6 - 3.2	1771	- 92	7.7 2.3 18.5	1.6 - 3.1
SUB-TOTAL MALE	2495	562	12.0	10.7 - 13.3	2747	324	11.8	10.6 - 13.1
IDU (4) Sex Partner at Risk for HIV	53.2	m⊷c	0.80	1.5 - 19.1	300	мос	8000	1.4 - 18.7
Blood Recipient (5) Heterosexual (6) Unknown Risk	689	040	9.00		69 ₈ 5	• <b>0 ∞</b> ←	0-4 0-7	
SUB-TOTAL FEMALE	776	∞	1.0	0.4 - 2.0	845	12	1.4	0.7 - 2.5
MISSING GENDER	-	0	0.0	:		0		·
	3272	307	9.4	8.4 - 10.4	3592	336	9.6	8.4 - 10.4

All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
93% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. Includes persons with a history of injection drug use (IDU) since January 1978.
Self-identified heterosexuals with no other identified risks.
Includes persons with homen and women who have sex with women and women who have sex with women and women. Lesbian or bisexual women who have are sex with women and women in 1991.
sexual orientation began in 1991. These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

REVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY RACE/ETHNICITY.	
CLINIC BY	
(STD)	
DISEASE	
TRANSMITTED	
EXUALLY	93 (1)
AS	9
ENDING	1989 -
LIENTS ATT	AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (1)
8	SAN
VALENCE F	SURVEY,
8	ö
80	AR
V SEROP	D YEAR

		1989	9 SURVEY			1990	OO SURVEY			1991	1 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%) (	(95% C.I.)(3)	NUMBER 3) TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% 6.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%) (	(95% C.1.)(3)
WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	916 828 371 138 44	200 76 52 52 54 56	22.8 9.2 14.0 4.3	20.1 - 25.7 7.3 - 11.4 10.6 - 18.0 1.6 - 9.2 3.8 - 24.6	7 1210 4 1178 0 564 2 183 6 43	219 111 68 13 5	18.1 9.4 12.1 7.1 11.6	16.0 - 20.4 7.8 - 11.2 9.5 - 15.0 3.9 - 25.1	1429 1165 675 233 59	210 78 67 67 13	7.7 6.7 9.9 5.6 11.9	12.9 - 16.6 5.3 - 8.3 7.8 - 12.4 3.0 - 22.9
TOTAL	2297	348	15.2	13.7 - 16.7	7 3178	416	13.1	11.9 - 14.3	3561	375	10.5	9.5 - 11.6

		1992	2 SURVEY			1993	3 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%) (	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE		SERO- PREVALENCE RATE (%) (95% C.I.)(3)
WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	1320 1016 683 203 50	163 78 53 9 9	12.3 7.5 7.8 7.4 12.0	10.6 - 14.2 5.9 - 9.3 5.9 - 10.0 2.0 - 24.3	1396 1108 719 292 77	198 66 57 9 6	7.5 6.0 7.9 7.8	12.4 - 16.1 4.6 - 7.5 6.1 - 10.1 1.4 - 5.8 2.9 - 16.2
TOTAL	3272	307	7.6	8.4 - 10.4	3592	336	7.6	8.4 - 10.4

⁽¹⁾ These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifies were removed.

CO All positive specimens were repeatedly reactive by ELISA and confined by a Western blot assay.

CO ALL conficience Intervals, axact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. Includes persons of American Indian and Alaskan Native ancestly, other race, and unknown race.

1001 SHRVEY 1990 SURVEY HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY AGE-GROUP, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (1) 1989 SURVEY

		<u>8</u>	1989 SURVET			•	0661	99U SURVEY		Ī		1991	SURVEY		
AGE-GROUP (YEARS)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	(3)
19 AND UNDER 20 - 24 25 - 29 25 - 34 35 - 34 40 - 44 45 AND OVER UNKNOWN	223 526 530 550 403 158 153	25.73.88.33.33 0.00	1.3 16.7 21.8 25.7 17.1 19.0	13.7.9 - 2.2.1 13.0.2 - 2.2.1 13.1.6 - 2.2.2	26.2 23.5 23.5 23.5 26.1	274 708 708 785 570 382 223 226	0 113 113 113 113 113 113 113 113 113 11	2.2 4.8 13.2 13.6 13.7 0.0	0 x 1 5 6 5 6 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	4.7 4.7 23.3 23.3 18.9	288 897 833 608 390 263 265 17	-8855882 -8858881	2.000000000000000000000000000000000000	0.18.47.48	7.202.2 7.202.2 7.30.2 7.0 7.0
TOTAL	2297	348	15.2	13.7 - 16.7	6.7	3178	416	13.1	11.9 - 14.3	14.3	3561	375	10.5	9.5 - 11.6	11.6
		1992	2 SURVEY				1993	SURVEY		-					
AGE-GROUP (YEARS)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	(2)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	.)(3)					
19 AND UNDER 20 - 24 25 - 29 35 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN	241 776 777 777 821 874 243 20	2 5 5 6 5 6 5 6 5 6 5 6 5 6 6 5 6 6 6 6	8.0 8.6 8.6 6.6 6.9 0.0	12.2.2.1 1.3.2.2.1 1.3.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.	3.0 4.0 110.8 110.8 22.2 22.2 31.7	243 789 883 678 575 304 26	1 0 107 107 45 35 1	0.4 7.7.7 7.5.5 3.8 3.8	0.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.00 × 1.	22.2 21.8 21.3 21.3 17.1 19.6					
TOTAL	3272	307	5.6	8.4 - 10.4	7.0	3592	336	9.6	8.4 - 10.4	10.4					

These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

£

HIV SEROPREVALENCE FOR GAY AND BISEXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY RACE/ETHNICITY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (1)

RACE/ETHNICITY UHITE	NUMBER TESTED	1989 NUMBER(2) PF POSITIVE F	SERO- RATE (%)	SURVEY  SERO- RATE (X) (95% C.I.)(3) 52.2 46.9 - 57.3	32	NUMBER C POSITIV	SERO- SERO- SPREALENCE E RATE (%)		NUMBER TESTED	NUMBER(2) F POSITIVE	~	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4) TOTAL	25.4	305	83.65.53.5 28.5.5.3.5 3.6.5.5.5.5	53.1 - 74.4 49.8 - 72.3	23 1177	324 4 8 8 8 9 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	63.2 66.7 288.6 50.0 50.0 45.3	53.8 - 72.0 37.0 - 56.6 13.2 - 48.7 	155	291	53.0 45.7 46.7 540.7 38.7	35.2 - 42.3

	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	28.9 - 37.4 39.6 - 63.0 29.6 - 47.6 7.5 - 33.5	31.5 - 38.5
3 SURVEY	SERO- PREVALENCE RATE (%)	33.1 38.3 17.9 30.8	34.9
1993	NUMBER(2) POSITIVE	164 39 46 7 7	260
	NUMBER	496 76 120 39 13	772
	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	28.0 - 36.8 35.2 - 55.3 27.9 - 47.1 11.6 - 47.8	31.5 - 38.7
2 SURVEY	SERO- PREVALENCE RATE (%)	32.3 37.1 26.9 50.0	35.0
1992	NUMBER(2) POSITIVE	147 46 39 7 6	245
	NUMBER	455 102 105 26 12	200
	RACE/ETHNICITY	WHITE AREICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL

⁽¹⁾ These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 55% Londidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons of American Indian and Alaskan Native ancestry, other nace, and unknown nace.

	1991 SURVEY	
:ASE (STD) CLINIC BY AGE-GROUP,	1990 SURVEY	
HIV SEROPREVALENCE FOR GAY AND BISEXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY AGE-GROUP, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (1)	1989 SURVEY	Control

		1989	39 SURVEY			1990	0 SURVEY			1991	1 SURVEY		j
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%) (	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%) (	(95% C.1.)(3)	ء ا
19 AND UNDER 20 - 24 35 - 29 35 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN	24 128 128 128 128 128 128 128 128 128 128	0 2 3 2 8 2 2 0	0.0 41.0 62.7 58.9 60.7 45.5 44.3	28.6 - 54.3 53.9 - 67.5 51.0 - 69.8 32.0 - 59.4 31.5 - 57.6	14 174 168 129 62 1	277 887 87 87 87 0	23.3 53.3 54.0 53.3 53.3 0.0	23.2 - 44.7 38.4 - 53.7 44.0 - 59.5 44.5 - 62.3 35.5 - 61.4	01 195 173 178 178 178 178 178	0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	10.0 18.8 37.9 47.5 47.5 42.5 30.0 0.0	11.2 - 28.8 31.1.2 - 45.2 39.8 - 55.1 38.2 - 56.9 32.0 - 53.6	
TOTAL	554	305	55.1	50.8 - 59.3	716	324	45.3	41.6 - 49.0	751	291	38.7	35.2 - 42.3	۱ "

(STD) CLINIC BY A  1990  1990  4 2 2 7  4 2 2 7  4 2 2 7  6 324  6 324
SERO- PREVALENCE RATE (%) 14.3 33.3 46.0 51.8 53.5 48.4 68.4 68.4 68.4 68.4 68.4 68.4 68.4

								,	i
AGE-GROUP (YEARS)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)	i
19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER UNKHOWN	102 162 186 103 103 67 67	252255 13852255 138525 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 13852 1	20.0 37.1.4 47.6 52.2 56.3 16.7	10.3 - 26.7 25.0 - 39.9 37.7 - 46.1 37.6 - 57.6 15.1 - 35.7	2 171 197 120 120 90 90 5	0 9 9 8 8 8 8 6 0	8.5 28.1 28.1 44.2 34.1 20.0	3.2 - 17.5 19.9 - 33.0 37.1 - 51.4 37.5 - 56.0 32.1 - 56.7 24.7 - 45.2	
TOTAL	200	242	35.0	31.5 - 38.7	744	260	34.9	31.5 - 38.5	
) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. Specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  ) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  ) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.	Surveys we lustion, exa for HIV af were repeate s, exact bin	re drawn fromination, arter all pers dly reactive	om blood spend/or treatm ional identi by ELISA an idence Inte	cimens collected ent for a NEW STI fiers were remove nd confirmed by a rvals not calcula	for routir episode. ed. a Western b	e syphilis Specimens olot assay.	syphilis screening on Specimens were collected of assay.	n ted servations.	i

19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN

E

ପ୍ରଚ

SURVEY

41V SEROPREVALENCE FOR HETEROSEXUAL MALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY RACE/ETHNICITY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (2)

SURVEY	SERO- PREVALENCE RATE (%) (95% C.1.)(4)	2.4 1.3 - 4.2 2.6 1.6 - 4.2 3.0 1.6 - 5.2 1.6 0.2 - 5.8 0.0 - 11.3	2.5 1.8 - 3.4					
1991	NUMBER(3) P	55500	45					
	NUMBER	497 741 399 122 25	1784					
	(95% C.1.)(4)	1.3 - 4.7	1.8 - 3.5		(95% C.1.)(4)	2.2 - 5.4 1.3 - 3.8 0.7 - 3.4 0.0 - 3.7 0.1 - 16.7	1.8 - 3.2	ed ervations.
SURVEY	SERO- PREVALENCE RATE (%)	2.6 2.8 0.0 0.0	2.6	SURVEY	SERO- PREVALENCE RATE (%)	3.2	2.4	ied risks. creening or ere collect nder 20 obs
1990	NUMBER(3) POSITIVE	<u> </u>	38	1993	NUMBER(3) POSITIVE	20 16 7	45	ther identife syphilis sopecimens we specimens we contain the system of
	NUMBER	413 683 286 84 18	1484		NUMBER	569 686 416 148 31	1850	with no of for routing episode. d. Western bl ted for sar y, and unkno
	(95% C.1.)(4)	0.5 - 3.7 0.0 - 3.6 0.1 - 5.4 0.0 - 0.0	0.9 - 2.5		(95% C.1.)(4)	0.9 - 3.5 2.1 - 5.0 0.7 - 3.8 0.3 - 7.7	1.7 - 3.3	partner at risk for HIV and heterosexuals with no other identified risks. Here drawn from blood specimens collected for routine syphilis screening of amination, and/ou treatment for a NEW SID episode. Specimens were collected ifter all personal identifiers were removed. Sectimens were collectedly reactive by ELISA and confirmed by a Western blot assay. nomial. Confidence intervals not calculated for sample sizes under 20 ob and Alaskan Native ancestry, other race, and unknown race.
SURVEY	SERO- PREVALENCE RATE (%)	400WO	1.6	SURVEY	SERO- PREVALENCE RATE (%)	0.2283.9	2.4	k for HIV a n blood spec Nor treatme and identif by ELISA an idence inter Native ance
1989	NUMBER(3) POSITIVE	won-0	17	1992	NUMBER(3) POSITIVE	10 21 7 0	07	rther at rise dawn from ination, and er all persoly reactive mial. Confi
	NUMBER	316 471 209 78 19	1093		NUMBER	520 632 379 91	1641	th a sex pa surveys wer ation, exam for HIV aft re repeated exact bino
	RACE/ETHNICITY	WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (5)	TOTAL		RACE/ETHNICITY	WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (5)	TOTAL	(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks. (2) These unkinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers where removed. (3) ALL positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (4) 95% Confidence Intervals, exact binomial. Confidence Intervals, and calculated for sample sizes under 20 observations. (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

SURVEY	SERO- PREVALENCE RATE (%) (95% C.I.)	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	2.5 1.8				
1991	NUMBER(3) P	0400064-	45				
	NUMBER	497 497 287 175 103 133	1784				
	(95% C.1.)(4)	0.2 - 4.5 1.2 - 4.7 2.1 - 7.9 0.6 - 8.7	1.8 - 3.5		(95% C.1.)(4)	0.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00	1.8 - 3.2
O SURVEY	SERO- PREVALENCE RATE (%)		5.6	3 SURVEY	SERO- PREVALENCE RATE (%)	0.5082.00 0.5082.00	2.4 fied risks.
1990	NUMBER(3) POSITIVE	<b>~</b> 400 ≈ ∞ − 0	38	1993	NUMBER(3) POSITIVE	0w5550w0	45 ther identi
	NUMBER	157 360 389 229 229 4 89 89 4	1484		NUMBER	124 454 459 333 182 182 158	1850 with no of for routing
	(95% C.1.)(4)	0.0 - 4.3 0.0 - 1.1 0.0 - 1.1 0.7 - 9.1 0.0 - 4.9	0.9 - 2.5		(95% C.1.)(4)	0.00 1.1.2.1.10 1.1.2.2.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10 1.0.0.10	1.7 - 3.3 nd heterosexuals imens collected
9 SURVEY	SERO- PREVALENCE RATE (%)	8.00.42.00.	1.6	2 SURVEY	SERO- PREVALENCE RATE (%)	00000000000000000000000000000000000000	2.4 Sk for HIV a
1989	NUMBER(3) POSITIVE	-mommono	11	1992	NUMBER(3) POSITIVE	ow5ña4	40 artner at ri
	NUMBER	312 265 265 181 93 60 56	1093		NUMBER	127 441 394 306 159 106 106	1641 Hith a sex pe Surveys wer
	AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 25 - 29 35 - 29 35 - 34 40 - 44 45 AND OVER UNKNOWN	TOTAL		AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN	TOTAL 1641 40 2.4 1.7 - 3.3   1850 45 2.4 1.8 - 3 1.8 - 3 1.8 - 3 1.8 - 3 1.8 - 3 1.8 - 3 1.8 - 3 1.8 - 3 1.8 - 3 1.8 - 3 1.8 - 3 1.8 - 3 1.8 - 3 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8

HIV SEROPREVALENCE FOR HETEROSEXUAL FEMALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY RACE/ETHNICITY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (2)

	SERO- PREVALENCE RATE (%) (95% C.I.)(4)	0.6 - 4.3	0.7 - 2.6		
1 SURVEY	SERO- PREVALENCE RATE (%)	0.000 0.000	1.5		
1991	NUMBER(3) POSITIVE	WW-00	11		
	NUMBER	257 266 133 74 16	972		
	C.1.)(4)	0.4 - 5.0 1.6 - 6.4 0.0 - 5.4 0.0 - 10.1	1.3 - 3.9		
SURVEY	SERO- PREVALENCE RATE (%) (95% C.I.)(4)	1.8 3.4 1.0 0.0 0.0	2.3 1.	\$VEY	
1990 SUF		0 1 1 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	14 2.	1993 SURVEY	
	BER NUMBER(3) TED POSITIVE	171 263 101 53 8	1 965		
	NUMBER	1281	36		
	SERO- PREVALENCE RATE (%) (95% C.I.)(4)	0.0 - 3.8 0.3 - 4.7 0.0 - 4.8 0.0 - 7.2	0.2 - 2.3		
1989 SURVEY		7.000 0.00 0.00	6.0	1992 SURVEY	
198	NUMBER(3) POSITIVE	33 0 0 0 0	7	198	
	NUMBER	145 184 61 40 8	438		
	RACE/ETHNICITY	WHITE AFRICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (5)	TOTAL		

		199	1992 SURVEY			199	1993 SURVEY	
	NUMBER	NUMBER(3)	SERO- NUMBER(3) PREVALENCE					
RACE/ETHNICITY	TESTED	POSITIVE	RATE (%)	RATE (%) (95% C.I.)(4)	TESTED	NUMBER(3) POSITIVE		PREVALENCE RATE (%) (95% C.I.)(4)
1.5	572	c	0 0		21%		7.	
AFRICAN AMERICAN	214	m	1.4	0.3 - 4.0	260	ı —	0.4	0.0 - 2.1
ONI	150	2	1.3		145	~	1.4	
AN/PACIFIC ISLANDER	22	0	0.0		87	-	-:	
IE OF THE ABOVE (5)	14	0	0.0	· :	21	-	8.4	
	,		,			,		
IOIAL	c/ ₉	^	). ()	0.2 - 1.7	121	ю	=	0.5 - 2.2
IIAC	cko	^	0.0		0.2 - 1.4		151	(4)

⁽¹⁾ Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.

(2) These uniciked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NIV SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(4) 55% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

⁶ 

		1989	9 SURVEY			1990	O SURVEY			1991	1 SURVEY		i
AGE-GROUP (YEARS)	NUMBER	NUMBER(3) POSITIVE		SERO- PREVALENCE RATE (%) (95% C.I.)(4)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- NUMBER(3) PREVALENCE POSITIVE RATE (%) (95% C.I.)(4)	NUMBER		SERO- PREVALENCE RATE (%)	SERO- NUMBER(3) PREVALENCE POSITIVE RATE (%) (95% C.I.)(4)	1
19 AND UNDER 20 - 24 25 - 29	87 119 101	Wc	2.3 1.0	0.3 - 8.1 0.0 - 4.6 0.0 - 5.4	88 194 137	% w → w	2002	0.3 - 8.0 0.0 - 2.8 0.5 - 6.3	116 258 160	0 M O M	0.0	0.0 - 2.5	1

		(95% C.1.)(4)	0.0 - 2.5 0.0 - 3.4 0.0 - 3.4 0.7 - 9.9 0.6 - 16.2 0.5 - 14.3	0.7 - 2.6	
	1 SURVEY	SERO- PREVALENCE RATE (%) (	0.00.044.00 0.00.00.000.000000000000000	1.5	
	1991	NUMBER(3) POSITIVE	0M0MNH0	=	
		NUMBER	116 258 160 86 48 43 32 4	97/	
		(95% C.1.)(4)	0.3 - 8.0 0.5 - 6.3 1.4 - 12.5 1.5 - 19.1 0.0 - 11.7	1.3 - 3.9	
AGE-GROUP,	SURVEY	SERO- PREVALENCE RATE (%) (95	00.27.25.3 00.77.00 00.77.00	2.3 1	
D) CLINIC BY	1990 s	NUMBER(3) PRE POSITIVE RA	N-W4W-00	14	
DISEASE (ST		NUMBER NU TESTED PO	194 137 137 227 227 243	965	
UALLY TRANSMITTED		c.1.)(4)	8.4.2.7.2.2. 1.4.4.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.	0.2 - 2.3	-
\ SEXUALLY	د	SERO- REVALENCE RATE (%) (95% C.I.)(4)	0000000		
TENDING A SEX	1989 SURVEY	4	20-0000 #800000	0.9	
ALES (1) AT - 1993 (2)	15	NUMBER(3) POSITIVE	N <del></del> 00000	7	
SEXUAL FEM		NUMBER	202 202 202 202 0	438	
HIV SEROPREVALENCE FOR HETEROSEXUAL FEMALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY AGE-GROUP, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (2)		AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 25 - 29 35 - 34 35 - 39 40 - 44 45 AND OVER UNKNOMN	TOTAL	

		. 199	1992 SURVEY			1993	3 SURVEY	
AGE-GROUP (YEARS)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(4)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.1.)(4)
19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN	188 174 177 77 23 3	00m000	0.000,000	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00	98 212 180 95 60 60 67 74 8	-00mno	0.00-04460	0.0 - 5.6 0.0 - 3.1 0.0 - 5.7 0.0 - 5.7 1.3 - 17.5 0.8 - 22.8
TOTAL	969	5	2.0	0.2 - 1.7	727	80	1:1	0.5 - 2.2
(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.  (2) Includes heterosexuals with a were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.  (3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (4) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.	ith a sex p surveys We lation, exa for HIV af ere repeate exect bin	arther at ri me drawn fro mination, ar ter all pers dly reactive omial. Conf	sk for HIV am blood speamed/or treating conal identification by ELISA an idence Inter	and heterosexual; cimens collected ent for a NEW SIT fiers were remov- nd confirmed by invals not calcul;	s with no of for routing possible.  ed.  ed.  western be a second possible.	other identi se syphilis Specimens olot assay.	fied risks. screening or were collectunder 20 obs	n ted servations.

HIV SEROPREVALENCE FOR INJECTION DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS BY GENDER AND SEXUAL ORIENTATION, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (1)

		1989	19 SURVEY			199	1990 SURVEY			1991	SURVEY	
GENDER AND SEXUAL ORIENTATION	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
MALE												
Gay/Bisexual Heterosexual Unknown Orientation	143	720	33.3 9.8 0.0	5.5 - 15.9	25 716 7	57	32.0 8.0 14.3	14.9 - 53.5 6.1 - 10.2	28 688 11	50 2	25.0 7.3 18.2	10.7 - 44.9 5.4 - 9.5
SUB-TOTAL MALE	152	<b>5</b>	10.5	6.1 - 16.5	748	%	8. 8.	6.9 - 11.1	727	29	1.8	6.2 - 10.3
FEMALE												
Lesbian/Bisexual Heterosexual Unknown Orientation	4 to L	000	0.00	4.9 - 20.5	376	25° 0	0.0 0.0	1.2 - 31.7 3.7 - 8.7	14 376 0	080	0.0	3.9 - 9.0
SUB-TOTAL FEMALE	78	œ	10.3	4.5 - 19.2	398	57	0.9	3.9 - 8.8	390	23	5.9	3.8 - 8.7
MISSING GENDER	7	0	0.0		12	0	0.0	· :	15	2	13.3	· :
TOTAL	237	54	10.1	6.6 - 14.7	1158	06	7.8	6.3 - 9.5	1132	84	7.4	6.0 - 9.1

Includes persons entering methadone treatment who have a history of injection drug use (10U) since 1978.
 Excludes persons with a prior admission to treatment during the survey period, and persons who were preferentially admitted to treatment due to HIV/AIDS. Blood specimens were collected for syphilis screening as part of the admission requirements, and tested for HIV after all personal identifiers were removed.
 AIL positive speciences were repeatedly reactive by ELISA and confinmed by a Western blot assay.
 Opfidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

ORIENTATION,	
SEXUAL OF	
S.	
GENDER	
B	
PROGRAMS	
REATMENT	
THADONE 1	
TERING M	€
SE	1993
G USERS E	- 66
ORUG	, 19
VALENCE FOR INJECTION DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS BY GENDER AND SE	AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993
ä	SAN
ILENCE F	SURVEY,
SEROPREVA	FAR OF
HIV S	AND

		1992	2 SURVEY			199	1993 SURVEY	
GENDER AND SEXUAL ORIENTATION	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
MALE								
Gay/Bisexual Heterosexual Jnknown Orientation	26 849 40	8258	30.8 7.4 7.5	14.3 - 51.8 5.7 - 9.4 1.6 - 20.4	15 262 1	980	40.0 7.6 0.0	4.7 - 11.5
SUB-TOTAL MALE	915	72	8.1	6.4 - 10.0	278	56	4.6	6.2 - 13.4
FEMALE								
Lesbian/Bisexual Heterosexual Jnknown Orientation	21 432 5	282	9.5 0.0	1.2 - 30.4 4.0 - 8.7	143	<u>ν</u> Σ0	9.1	4.9 - 15.0
SUB-TOTAL FEMALE	458	28	6.1	4.1 - 8.7	160	15	9.4	5.3 - 15.0
MISSING GENDER	14	-	7.1	•	-	0	0.0	:
TOTAL	1387	103	7.4	6.1 - 8.9	625	17	9.3	6.8 - 12.5

HIV SEROPREVALENCE FOR INJECTION DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1993 (1)

		1989	9 SURVEY			1990	O SURVEY			1991	1 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	142 61 27 5	ν <b>∡</b> νοο	3.5 23.0 18.5 0.0	1.2 - 8.0 13.2 - 35.5 6.3 - 38.1	722 256 256 135 29 16	24 54 7 1	3.3 21.1 5.2 13.8 6.3	2.1 - 4.9 16.3 - 26.6 2.1 - 10.4 3.9 - 31.7	699 267 118 28 20	24 53 7 0 0	3.4 19.9 5.9 0.0 0.0	2.2 - 5.1 15.2 - 25.1 2.4 - 11.8 0.0 - 13.9
TOTAL	237	54	10.1	6.6 - 14.7	1158	06	7.8	6.3 - 9.5	1132	84	7.4	6.0 - 9.1
		1992	2 SURVEY			1993	3 SURVEY					
RACE/ETHNICITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)				
WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	889 299 139 29 31	35 11 3	3.9 7.9 0.0 9.7	2.8 - 5.4 13.9 - 22.9 4.0 - 13.7 0.0 - 3.8 2.0 - 25.8	289 98 38 10 10	22 0 0 0 0 0	8.0 5.3 0.0 0.0	5.1 - 11.7 9.6 - 25.2 0.6 - 17.7				
TOTAL	1387	103	7.4	6.1 - 8.9	439	41	9.3	6.8 - 12.5				
(1) Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 1978. Excludes persons with a prior admission to treatment during the survey period, and persons who were preferentially admitted to treatment due to HIVANIDS. Blood specimens were collected for syphilis screening as part of the admission requirements, and tested for HIV after all personal identifiers were removed. (2) All lositive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence intervals, and to assay ander 20 observations. (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.	ng methadone prior admis to treatmen n requiremen Were repeate s, exact bin rican Indian	treatment wasion to treat the to HIV ts, and test dly reactive omial. Conf	ho have a hi tment during /AIDS. Bloo ed for HIV & by ELISA ar idence Inter Native ance	a history of injection drug use (1DU) since 1978. uring the survey period, and persons who were Blood specimens were collected for syphilis screening HIV after all personal identifiers were removed. Sha nd confirmed by a Western blot assay. Intervals not calculated for sample sizes under 20 obsancestry, other race, and unknown race.	ion drug us iod, and pe e collecter al identifi a Western k ated for se e, and unkr	se (IDU) sin ersons who w d for syphil iers were re olot assay.	ce 1978. ere is screening moved. under 20 obs	ervations.				

HIV SEROPREVALENCE FOR INJECTION DRUG USERS ENTERING METHADONE TREATMENT PROGRAM

AND YEAR OF SURVEY, SAN FRANCISCO, 1989		1993 (1)										
		1989	SURVEY			1990	SURVEY			1991	1 SURVEY	
AGE-GROUP (YEARS)	NUMBER NU TESTED PO	NUMBER(2) F POSITIVE	SERO- PREVALENCE RATE (%) (	SERO- PREVALENCE RATE (%) (95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%) (	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.1.)(3)
19 AND UNDER 20 - 24 25 - 29 35 - 34 35 - 39 40 - 44 40 - 44 50 - 40 OVER UNKANGAN	455 474 60 60	0-0mtr00	0.0 7.7 7.7 6.7 6.0 0.0	0.9 - 23.5 1.4 - 18.3 8.9 - 28.7 6.2 - 28.3	149 149 306 306 126 126	12233344711 22333344711	6.7 4.7 7.5 7.5 13.3 8.3	0.0 - 7.4 1.9 - 9.4 3.5 - 10.4 4.8 - 11.1 8.5 - 14.0	55 134 183 307 261 155	00758852	0.000.000.000.000.000.0000.0000.0000.0000	0.0 2.1 - 5.3 3.4 - 11.5 5.6 - 12.2 4.1 - 13.4 2.1 - 28.5

	S	
	1990	
MS BY AGE-GROUP		
æ		
S		

	1

1991 SURVEY	SERO- NUMBER NUMBER(2) PREVALENCE TESTED POSITIVE RATE (%) (95% C.I.)(3)	2000 0 2
	)(3)	

1991 SURVEY	SERO- NUMBER(2) PREVALENCE POSITIVE RATE (%)	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	84 7.4	
	UMBER	7 55 134 183 307 261 155	1132	

us 1	PREV RAT	00 00 00 00 00 00 00 00 00 00 00 00 00		
1991	NUMBER(2) POSITIVE	0 0 0 26 26 27 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	84	

9.1

6.0

9.5

6.3

7.8

8

1158

- 14.7

9.9

10.1

24

237

TOTAL

(95% C.1.)(3)

PREVALENCE RATE (%)

NUMBER(2) POSITIVE

NUMBER

SERO-PREVALENCE RATE (%) (95% C.1.)(3)

NUMBER(2) POSITIVE

NUMBER

AGE-GROUP (YEARS)

AND UNDER

SURVEY

1993

SURVEY

992

25.1 21.2 25.7 10.9

2.2

0.07.0.0

0001-51-00

01245882

12.5 10.2 14.3 22.3 22.3

06.5.00

7087680

-28 By B 9 2 0

2357335° 6

19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN

- 12.5

6.8

9.3

41

439

8.9

6.1

7.4

03

1387

TOTAL

Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 1978. Excludes persons with a prior adhission to treatment during the survey period, and persons who were proferentially admitted to treatment due to HIVAIDS. Blood specimens were collected for syphilis screening as part of the admission requirements, and tested for HIV after all personal identifiers were removed. All to ositive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

ରଚ

4 HIV SEROPREVALENCE FOR INJECTION DRUG USERS (IDUS) AND NON-INJECTION DRUG USERS (NON-IDUS) ENTERING DRUG-FREE DETOXIFICATION PROGRAM BY GENDER AND SEXUAL ORIENTATION, SAN FRANCISCO, 1990 - 1993 (1)

	(95x c.1.)(3)		32.4 - 67.6 1.4 - 4.8	7.6 - 9.4		0.0 - 10.5	0.6 - 5.2	:	3.8 - 7.4	
NON-IDUS	SERO- PREVALENCE RATE (%)		50.0 2.7 15.8	6.7		0.0	2.1		5.4	
-NON	NUMBER(2) POSITIVE		71m	<u> </u> Fi		040	, 4	0	35	
	NUMBER		34 407 19	760		27 162 5	194	0	929	
	SERO- PREVALENCE RATE (%) (95% C.I.)(3)		22.5 - 41.3 4.2 - 8.2	7.8 - 12.4		0.0 - 6.6	1.0 - 5.1	:	6.2 - 9.6	
10	SERO- PREVALENCE RATE (%)		31.4 6.0 12.5	6.6		0.0	2.5	•	7.8	
IDUS	NUMBER(2) POSITIVE		2 3 3 3 3	ļ ⁸⁸		070	ļ ^	0	27	
	NUMBER TESTED		102 570 16	889		6 525 50 64	278	0	996	
	GENDER AND SEXUAL ORIENTATION	MALE 	Gay/Bisexual Heterosexual Unknown Orientation	SUB-TOTAL MALE	FEMALE	Lesbian/Bisexual Heterosexual Unknown Orientation	SUB-TOTAL FEMALE	MISSING GENDER	TOTAL	

This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Sample includes both injection drug users (100s) who have a history of needle use since 1978, and non-injection drug users who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment. Excludes persons with a prior admission to treatment during the survey period, persons who were preferentially admitted to treatment due to HIVAIDS, and persons under alcohol treatment only. Blood specimens were collected for syphilis screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed. All positive specimens were repeatedly reactive by ELISA and confrimed by a Western blot assay. E

HIV SEROPREVALENCE FOR INJECTION DRUG USERS (IDUS) AND NON-INJECTION DRUG USERS (NON-IDUS) ENTERING A DRUG-FREE DETOXIFICATION PROGRAM BY RACE/ETHNICITY, SAN FRANCISCO, 1990 - 1993 (1)

		IDUS	s			NON-IDUS	IDUs	
RACE/ETHNICITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- ((2) PREVALENCE IVE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.1.)(3)
WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	601 121 39 25	27 6 7 0 0	5.0 5.0 5.1 0.0	4.8 - 9.0 10.1 - 21.1 1.8 - 10.5 0.0 - 11.3	213 311 70 45 15	581-0-	4.7 7.4 1.4 0.0 6.7	2.3 - 8.5 4.7 - 10.9 0.0 - 7.7 0.0 - 6.4
TOTAL	996	Я	7.8	6.2 - 9.6	654	35	5.4	3.8 - 7.4

(1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Sample includes both injection drug users (IDUs) who have a history of needle use since 1978, and non-injection drug users who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment. Excludes persons with a prior admission to treatment during the survey period, persons who were preferentially admitted to treatment due to HIV/AIDs, and persons under alcohol treatment only. Blood specimens were collected for syphilis screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 55% Confidence Intervals, and Alaskan Walive ancestry, other race, and unknown race.

NON-1DUS	SERO- ) PREVALENCE RATE (%) (95% C.I.)(3)	2.4 0.3 - 8.2 8.2 8.2 8.2 8.3 4.3 - 10.5 8.4 0.9 - 8.4 0.9 - 8.4 0.9 - 8.4 0.9 - 8.4 0.9 - 8.4 0.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9 0.0 - 16.9	5.4 3.8 - 7.4
NO	NUMBER(2) POSITIVE	00004500	35
	NUMBER	7 171 115 119 40 3	929
	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	0.6 - 7.8 2.7 - 10.0 6.0 - 14.8 5.0 - 12.8 4.8 - 14.1 6.4 - 21.3	6.2 - 9.6
s	SERO- PREVALENCE RATE (%)	0.0 7.2.7.7 8.8.3.7.7.0 0.0 0.0	7.8
IDUS	NUMBER(2) POSITIVE	0 x 0 6 x 2 7 1 0	22
	NUMBER	110 173 173 182 183 5	996
	AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 20 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER MISSING	TOTAL

(1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Sample includes both injection drug users (IDUs) who have a history of needle use since 1978, and non-injection drug users sample includes both injection drug users (IDUs) who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment, who have some persons with a prior admission to treatment during the survey period, persons who were preferentially admitted to treatment during the survey period, persons who were preferentially admitted to treatment during the survey period, persons who were preferentially admitted to treatment only. Blood specimens were collected for syphilis screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed. (2) 91 positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

HIV SEROPREVALENCE FOR INJECTION DRUG USERS (IDUS) AND NON-INJECTION DRUG USERS (NON-IDUS) ENTERING A DRUG-FREE DETOXIFICATION PROGRAM BY PRIMARY DRUG, SAN FRANCISCO, 1990 - 1993 (1)

		IDUS	Ø			-NON	NON-IDUS	
PRIMARY DRUG	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
HERDIN COCAINE/CRACK HERDIN AND COCAINE (SPEEDBALL) BARBI TURATES AMPHETAMINES/SPEED OTHER OR UNSPECIFIED DRUGS	639 46 42 103 136	2002	8.7 11.9 19.4 7.7	2.7 - 5.9 2.4 - 20.8 4.0 - 25.6 12.3 - 28.4 9.2 - 21.8	58 411 3 3 21 161	3880088	3.4 5.4 38.1 1.9	3.4 - 8.0 3.4 - 8.0 18.1 - 61.6 0.4 - 5.3
TOTAL	996	K	7.8	6.2 - 9.6	924	35	5.4	3.8 - 7.4

(1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Sample includes both injection drug users (IDUs) who have a history of needle use since 1978, and non-injection drug users who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to reatment. Excludes persons with a prior admission to treatment during the survey period, persons who were preferentially admitted to treatment due to HIV/AIDS, and persons under alcohol treatment only. Blood specimens were collected for syphilis screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

V SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY TRANSMISSION CATEGORY	
TRANSMISS	
CLINIC BY	
PLANNING	3
A FAMILY	9 - 1992
ATTENDING	AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1992 (1)
FOR WOMEN	SAN FRAN
EVALENCE	F SURVEY,
IV SEROPRI	ND YEAR O
I	•

1 SURVEY	SERO- PREVALENCE RATE (%)	1.00000	0.15					
1991	NUMBER(2) POSITIVE	-0070	ю					
	NUMBER	9 11 4 1925 8	1957					
	(95% C.1.)(3)	0.13 -24.87 0.00 -11.73 0.00 - 0.42	0.02 - 0.52					ations.
		0.13 0.00 0.00	9.					Serv
1990 SURVEY	SERO- PREVALENCE RATE (%)	5.00 0.00 0.08 0.00	0.15					were colle
199	NUMBER(2) POSITIVE	-00-0	2					Specimens e removed. olot assay. ample sizes ch 1985.
	NUMBER	20 24 11 1313 8	1376					g services. Liffiers wer a Western bated for se 1978.
	(95% C.1.)(3)		0.09 - 0.81		(95% C.1.)(3)	0.00 - 0.43	0.00 - 0.43	family plannin personal iden confirmed by als not calcul since January ween January 1
9 SURVEY	SERO- PREVALENCE RATE (%) (*		0.32	1992 SURVEY	SERO- PREVALENCE RATE (%) (	0.00	0.08	omen seeking HIV after all by ELISA and idence Interes us use (IDU) usions(s) bett ntified risks
1989	NUMBER(2) POSITIVE	00004	7	199	NUMBER(2) POSITIVE	000-0	1	drawn from w tested for dly reactive injection dr blood transf no other ide
	NUMBER	1266	1266		NUMBER	4 0 1293 0	1297	rvey was sits, and e repeate exact bin story of story of als with
	TRANSMISSION CATEGORY	Heterosexual IDU (4) Sex Partner at Risk for HIV Blood Recipient (5) Heterosexual (6) Unknown Risk (7)	TOTAL		TRANSMISSION CATEGORY	Heterosexual IDU (4) Sex Partner at Risk for HIV Blood Recipient (5) Heterosexual (6) Unknown Risk (7)	TOTAL	(1) This unlinked (blinded) survey was drawn from women seeking family planning services. Specimens were collected from initial and annual visits, and tested for HIV after all personal identifiers were removed.  (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes persons with a history of injection drug use (10) since January 1978.  (5) Includes persons with a history of blood transfusions(s) between January 1977 and March 1985.  (6) Self-identified heterosexuals with no other identified risks.

0.01 - 0.37

0.03 - 0.45

(95% C.1.)(3)

HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1992 (1)

	(95% C.1.)(3)	0.00 - 1.90 0.02 - 3.89 0.02 - 0.50 0.00 - 1.67 0.00 - 7.05	0.03 - 0.45					
1991 SURVEY	SERO- PREVALENCE RATE (%) (	0.00	0.15					
1991	NUMBER(2) POSITIVE	0-700	3					
	NUMBER	156 141 178 178 41	1957					
	(95% C.1.)(3)	0.02 - 4.34 0.00 - 2.04 0.00 - 0.33 0.02 - 3.31 0.00 - 9.21	0.02 - 0.52					ations.
SURVEY	SERO- PREVALENCE RATE (%) (95	0.00	0.15 0.					Specimens were collected removed. It assay. ole sizes under 20 observ. an race.
1990	NUMBER(2) PR POSITIVE R	-00-0	2					Specimens we removed. ot assay. ple sizes unc
	NUMBER	126 145 908 166 31	1376					services. iffiers were Western bluted for sam , and unknot
	(95% C.1.)(3)	0.02 - 4.48 0.02 - 3.56 0.03 - 1.89 0.00 - 9.21	0.09 - 0.81		(95% C.1.)(3)	0.00 - 3.59 0.00 - 2.81 0.00 - 3.14	0.00 - 0.43	is drawn from women seeking family planning services. Specime mot tested for HIV after all personal identifiers were removed mot sective by ELISA and confirmed by a Vestern blot assay sinomial. Confidence Intervals not calculated for sample size an and Alaskan Native ancestry, other race, and unknown race.
9 SURVEY	SERO- PREVALENCE RATE (%)	0.00.00 0.00 0.00 0.00 0.00 0.00 0.00	0.32	2 SURVEY	SERO- PREVALENCE RATE (%)	88288	0.08	omen seeking HIV after al by ELISA ark idence Inter Native ance
1989	NUMBER(2) POSITIVE	000	7	1992	NUMBER(2) POSITIVE	00-00	1	drawn from w tested for ally reactive omial. Conf
	NUMBER	122 154 810 149 31	1266		NUMBER	105 1001 94 15	1297	urvey was crisits, and re repeated exact bincan Indian
	RACE/ETHNICITY	WHITE AFRICAN AMERICAN LATINA ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL		RACE/ETHNICITY	WHITE AFRICAN AMERICAN LATINA ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL	<ol> <li>This unlinked (blinded) survey was drawn from women seeking family planning services. Specimens were collected from initial and annual visits, and tested for HIV after all perabal identifiers were removed.</li> <li>It positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.</li> <li>95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.</li> <li>Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.</li> </ol>

HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1992 (1)	
B√	
CLINIC	
PLANNING 1)	
FAMILY 1992 (	
1989 -	
ATTENI CISCO,	
PRAN	
SAN	
HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLA AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1992 (1)	
PREV OF	
SEROI	
AND	

	(95% C.1.)(3	0.00 - 2.76 0.00 - 0.47 0.00 - 0.10 0.00 - 0.89 0.01 - 3.14 0.00 - 6.88	0.03 - 0.45					
1 SURVEY	SERO- PREVALENCE RATE (%)	0.00 0.03 0.03 0.00 0.00 0.00	0.15					
1991	NUMBER(2) POSITIVE	0000-000	м					
	NUMBER	107 636 646 334 175 42 6	1957					
	(95% C.1.)(3)	0.00 - 3.17 0.00 - 0.63 0.00 - 0.74 0.01 - 2.27 0.00 - 3.04 0.07 -15.33	0.02 - 0.52					ted:
) SURVEY	SERO- PREVALENCE RATE (%)	0.00 0.00 0.04 0.00 0.00 0.00	0.15					were collect
1990	NUMBER(2) POSITIVE	000-0-00	2					Specimens e removed. lot assay. mple sizes
	NUMBER	93 474 401 243 97 97 8 8	1376					services. iffiers wer Western b
	(95% C.1.)(3)	0.00 - 4.02 0.01 - 1.32 0.01 - 1.34 0.01 - 3.16 0.00 - 2.81	0.09 - 0.81		(95% c.1.)(3)	0.00 - 4.87 0.00 - 0.77 0.01 - 1.30 0.00 - 1.33 0.00 - 6.44	0.00 - 0.43	was drawn from women seeking family planning services. Specimens were collected and tested for HIV after all personal identifiers were removed. Peatedly reactive by ELISA and confirmed by a Western blot assay. ELISA and confirmed by a Western blot assay.
SURVEY	SERO- PREVALENCE RATE (%)	0.00 0.24 0.00 0.00 0.00	0.32	SURVEY	SERO- PREVALENCE RATE (%)	000000000000000000000000000000000000000	0.08	omen seeking IIV after al by ELISA arv idence Inter
1989	NUMBER(2) POSITIVE	02000	7	1992	NUMBER(2) POSITIVE	00-0000	-	rawn from we tested for b ly reactive mial. Confi
	NUMBER	73 420 414 226 105 18 7	1266		NUMBER	427 427 427 45 45 6	1297	urvey was drisits, and the repeated exact bino
	AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 25 - 29 25 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN	TOTAL		AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN	TOTAL	(1) This unlinked (blinded) survey if from initial and annual visits, (2) All positive specimens where repo

HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY TRANSMISSION CATEGORY AND YEAR OF SURVEY, SAN FRANCISCO, 1990 - 1992 (1)

	(95% 0.1.)(3)		2.29
	, c	0.22 - 1.59	0.56 - 2.29
	(95	ö	0
SURVEY	RO- C%)	0.0 <b>∞</b> ·	
	SERO- PREVALENCE RATE (%) (	14.29 60.00 0.68	1.21
1992	€8 #8		
	NUMBER(2) POSITIVE	-wwo	^
	NUMBER	730	742
-			
	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	. 25.1	5.0
	6 0.1	0.13 - 1.25	0.49 - 2.01
	(62)	0.1	0.4
VEY	RO- LENCE (%)	-060	,
SURVEY	SE PREVA RATE	35.71 0.00 0.49 0.00	1.06
1991	NUMBER(2) POSITIVE		
	MBER	NO40	٥
	NUMBER	14 7 817 8	846
	)(3)	٢	705
	c.1.	 0.06 - 1.71	0.14 - 2.02
	SERO- PREVALENCE RATE (%) (95% C.1.)(3)	0.0	0.1
ÆΥ	30- ENCE (%)	8888	0.70
SURVE	SEF REVAI	12.50 0.00 0.48 0.00	0.1
1990			
	NUMBER(2) POSITIVE	1020	м
	NUMBER	8 419 1	431
	35	,	
		r HIV	
	GORY	(4) sk fc	
	CATE	IDU at Ri (5)	
	NOIS	xual ner xual Risk	
	TRANSMISSION CATEGORY	Heterosexual IDU (4) Sex Partner at Risk for HIV Heterosexual (5) Unknown Risk	TOTAL
	TRA	Sex Net Het Unk	5

(1) This unlinked (blinded) survey was drawn from women seeking induced abortions. Specimens were collected for evaluation purposes, and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons with a history of injection drug use (IDU) since January 1978.

HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY RACE/ETHNICITY	
B	
CLINIC	
8	2
E	~
ABO	199
A	٠
TEND ING	20. 1990
AT	IS
WOMEN	FRANC
FO.	SAN
ų	`
VALENC	SURVE
RE	9
SEROF	YEAR
2	9
I	A

1990 SURVEY 1992 SURVEY	SERO- NUMBER (2) PREVALENCE SITIVE RATE (2) (95% C.1.)(3)  SERO- NUMBER NUMBER(2) PREVALENCE SITIVE RATE (2) (95% C.1.)(3)  TESTED POSITIVE RATE (2) (95% C.1.)(3)	1 2.00 0.05 -10.65 71 3 4.23 0.88 -11.86 50 2 4.00 0.49 -13.71 7.46 0.30 -4.20 172 6 3.49 1.29 7.44 0.00 0.00 -1.33 437 3 0.69 0.14 - 1.99 393 0 0.00 0.00 -0.74 107 0 0.00 -2.76 108 0 0.00 0.00 -2.74 0.00 0.00 0.00 -1.27 1.29 1.29 1.29 1.29 1.29 1.29 1.29 1.29	3 0.70 0.14 - 2.02 846 9 1.06 0.49 - 2.01 742 9 1.21 0.56 - 2.29	(1) This unlinked (blinded) survey was drawn from women seeking family planning services. Specimens were collected from initial and annual visits, and tested for HIV after all personal identifiers were removed.  (2) All positive specimens were repeatedly reactive by ELISA and confinemed by a Western blot assay.  (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.
URVEY				seeking family planning ser after all personal identific ELISA and confirmed by a We- ce Intervals not calculated
1990 8	NUMBER(2) POSITIVE	- 0000	3	as drawn from womer and tested for HIV stedly reactive by olinomial. Confider
	NUMBER RACE/ETHNICITY TESTED	HHITE AMERICAN 106 LATINA ASSAN/PACIFIC ISLANDER 45 NONE OF THE ABOVE (4)	TOTAL 431	(1) This unlinked (blinded) survey was from initial and annual visits, an (2) All positive specimens were repeat (3) 95% Confidence Intervals, exact bill

HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1990 - 1992 (1)

		1990	o survey			1991	1 SURVEY			1992	2 SURVEY	
AGE-GROUP (YEARS)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
19 AND UNDER 20 - 24 25 - 29 35 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN	68 106 106 80 26 8 8 0	0-00000	0.00	0.00 - 4.31 0.02 - 3.94 0.00 - 2.79 0.30 - 8.74 0.00 - 10.88	133 253 223 118 86 27 0	-04000	0.75 0.79 1.79 0.00 0.00	0.02 - 4.12 0.10 - 2.83 0.49 - 4.53 0.03 - 4.63 0.03 - 6.31	112 189 202 131 131 23	00M-000-	33.33	0.00 - 2.64 0.13 - 3.77 0.013 - 4.28 0.02 - 4.18 0.30 - 8.64 0.00 -12.21
TOTAL .	431	3	0.70	0.14 - 2.02	846	6	1.06	0.49 - 2.01	742	6	1.21	0.56 - 2.29
(1) This unlinked (blinded) survey we from initial and annual visits, (2) All positive specimens were repectable 59 95% Confidence Intervals, exact	survey was or visits, and ere repeated, exact bing	drawn from we tested for I dly reactive omial. Conf	omen seeking HIV after al by ELISA ar idence Inter	was drawn from women seeking family planning services. Specimens were collected and tested for HIV after all personal identifiers were removed. estedly reactive by ELISA and confirmed by a Western blot assay. binomial. Confidence Intervals not calculated for sample sizes under 20 observations.	g services. tifiers wer a Western b	Specimens e removed. Not assay. mple sizes	Were colle	cted servations.				

ILV SEROPREVALENCE FOR NEWBORN INFANTS AND THEIR MOTHERS BY AGE GROUP AND RACE/ETHNICITY, 1989-1992 (1)

		1989	39 SURVEY				1990	O SURVEY			1991	1 SURVEY	
	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	1.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% 6.1.)(3)
AGE-GROUP (YEARS)													
UNDER 20 20 - 24	219		0.46	0.01	2.52	181	00	0.00		206		0.00	1 1
25 - 29 30 - 34	625	000	888	888	0.48	618 625		0.16 0.16	0.00 - 0.90	653	40.	0.61	0.17 - 1.56
JS AND OVER UNKNOWN	138		0.72	0.02	3.97	117	00	88		422		1.39	
RACE/ETHNICITY													
WHITE AFRICAN AMERICAN	679	0-	0.00		0.44	663	-0	0.15		640	4 M	0.63	0.17 - 1.59
LATINO ASIAN/PACIFIC IS.	284	-0-	80.0	000	0.98	633	-00	20.0	0.00 - 0.91	454	-00	0.00	0.00 - 0.88
UNKNOWN	128		0.78		4.28	<u> </u>	00	.00		28		1.04	0.03 - 5.67
TOTAL - SAN FRANCISCO	2547	4	0.16	0.04 - 0.40	0.40	2438	2	0.08	0.01 - 0.30	2509	٥	0.36	0.16 - 0.68
TOTAL - BAY AREA (4)	21217	\$2	0.12	0.08 - 0.17	0.17	21397	23	0.11	0.07 - 0.16	22103	31	0.14	0.10 - 0.20
TOTAL - STATEWIDE	144284	92	90.0	0.05 - 0.08	90.0	150494	106	0.07	60.0 - 90.0	154918	124	0.08	0.07 - 0.10

⁽¹⁾ Data courtesy of the California Department of Health Services Office of AIDS. Specimens from this survey of nebborn infants cand women giving birth) are drawn from the genetic diseases screening program. Antibodies in a newborn infant reflect the infection status of the mother and not necessarily of the child.

2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes the counties of Alameda, Contra Costa, Marin, San Francisco, San Mateo, and Santa Clara.

HIV SEROPREVALENCE FOR NEWBORN INFANTS AND THEIR MOTHERS BY AGE GROUP AND RACE/ETHNICITY, 1989-1992 (1)

		199	1992 SURVEY	
	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
AGE-GROUP (YEARS)				
UNDER 20 20 - 24	165	00	0.00	0.00 - 1.80
25 - 29	639	~ ~	0.31	0.04 - 1.13
35 AND OVER UNKNOWN	136	ı-o	0.00	0.01 - 1.24
RACE/ETHNICITY				
WHITE AFRICAN AMERICAN	312	0100	0.00	
ASIAN/PACIFIC IS. OTHER UNKNOWN	135 735 74	000	8888	0.00 - 0.45 0.00 - 2.19 0.00 - 3.82
TOTAL - SAN FRANCISCO	5445	'n	0.20	0.07 - 0.48
TOTAL - BAY AREA (4)	21565	31	0.14	0.10 - 0.20
TOTAL - STATEWIDE	151033	101	0.07	0.05 - 0.08

(1) Data courtesy of the California Department of Health Services Office of AIDS. Specimens from this survey of newborn infants dand women giving birth) are drawn from the genetic diseases screening program. Antibodies in a newborn infant reflect the infection status of the mother and not necessarily of the child. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Vestern blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes the counties of Alameda, Contra Costa, Marin, San Francisco, San Mateo, and Santa Clara.

(95% 0.1.)(3)	61.5 - 84.5 56.5 - 89.7 9.6 - 41.1 3.2 - 10.5 22.0 - 31.7 0.0 - 6.5
SERO- PREVALENCE RATE (%)	74.2 2.3.6 2.3.6 26.6 26.6 25.0 25.0 4.5
NUMBER(2) POSITIVE	5   6   5   5   5   5   5   5   5   5
NUMBER	62 29 193 194 195 197 197 197 197 197 197 197 197 197 197
GENDER AND TRANSMISSION CATEGORY	HALE  Homosexual/Bisexual Homosexual/Bisexual Heterosexual IDU (4) Heterosexual IDU (5) Unknown Risk SUB-TOTAL MALE FEMALE  Heterosexual IDU (4) Heterosexual (5) Unknown Risk SUB-TOTAL FEMALE

(1) This interview-based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and TB suspects (class 5). Data collected between the 1st quarter of 1992 and TB suspects (class 5). Data collected between the 1st quarter of 1992.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons with a history of injection drug use (IDU) since January 1978.

(5) Includes persons with a sexual partner(s) at risk for HIV, persons with a history of blood transfusion(s) or with a bleeding disorder, and self-identified heterosexuals with no other identified risks.

17.4 - 25.2

21.1

4

944

TOTAL

(TB) - 1992 (1)	
HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A MUNICIPAL TB CLINIC BY ORIGIN OF BIRTH, SAN FRANCISCO, 1989 - 1992 (1)	
FOR PATIENTS UNDER T	
IV SEROPREVALENCE T A MUNICIPAL TB C	

			<ol> <li>This interview-based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and TB suspects (class 5). Data collected between the 1st quarter of 1989 and the 4th quarter of 1992.</li> <li>All positive specimens/were repeatedly reactive by ELISA and confirmed by a Western blot assay.</li> <li>95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.</li> </ol>
SERO- REVALENCE RATE (%) (95% C.I.)(3)	29.6 - 42.4 2.9 - 9.5	21.1 17.4 - 25.2	ons with newly d quarter of 1989 a d confirmed by a vals not calcula:
SERO- PREVALENCE RATE (%)	35.8 5.5	21.1	ncludes pers sen the 1st by ELISA an idence Inter
NUMBER(2) POSITIVE	82 12	76	behaviors ir lected betweelly reactive
NUMBER	229	977	ey of risk - Data col re repeated exact bino
ORIGIN OF BIRTH	BORN IN USA Born Outside Usa	TOTAL	(1) This interview-based surva and TB suspects (class 5). (2) All positive specimenslwer (3) 95% Confidence Intervals,

(3)	ં જંબંજાંબં ·	.2	(1) This interview-based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and TB suspects (class 5). Data collected between the 1st quarter of 1989 and the 4th quarter of 1992. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
(95% с.1.)	31.8 - 52.6 18.9 - 36.0 12.6 - 29.8 0.2 - 5.2	17.4 - 25.2	ons with n quarter of nd confirme vals not c
SERO- PREVALENCE RATE (%) (95% C.I.)(3)	41.9 20.2 1.5 36.4	21.1	ncludes perseen the 1st by ELISA ar
NUMBER(2) POSITIVE	\$26°24	76	behaviors i lected betw Ily reactive
NUMBER	93 112 136 11	977	ey of risk Data col re repeated exact bino
RACE/ETHNIC1TY	WHITE ARICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL	(1) This interview-based survent Base Survent Suspects (class 5) (2) All positive specimens we (3) 95% Confidence Intervals,

HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A MUNICIPAL TB CLINIC BY AGE-GROUP, SAN FRANCISCO, 1989 - 1992 (1)

6.1.)(3)	16.4 - 36.8 18.5 - 34.3 21.2 - 39.3 2.8 - 12.4	17.4 - 25.2
(95%	21.2	17.7
SERO- PREVALENCE RATE (%) (95% C.I.)(3)	255. 295.8 295.8 295.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 305.8 3	21.12
NUMBER(2) POSITIVE	- 83332 0 83333	76
NUMBER	9 78 1128 1123 123	977
AGE-GROUP (YEARS)	19 AND UNDER 20 - 39 40 - 49 50 AND OVER UNKNOWN	TOTAL

(1) This interview-based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and TB suspects (class 5.). Data collected between the 1st quarter of 1989 and the 4th quarter of 1992. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence intervals so the calculated for sample sizes under 20 observations.

		i
ENTER	_	
TENTION C	- 1993 (1	
UVENILE DE	sco, 1990	
TERING A JI	SAN FRANCI	
HIV SEROPREVALENCE FOR ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER	BY GENDER AND TRANSMISSION CATEGORY, SAN FRANCISCO, 1990 - 1993 (1)	
FOR ADOLE	SMISSION	
REVALENCE	AND TRAN	1
HIV SEROP	BY GENDER	

SERO-NUMBER(2) PREVALENCE POSITIVE RATE (%) (95% C.I.)(3)

> NUMBER TESTED

> GENDER AND TRANSMISSION CATEGORY

								(1) This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood specimens were collected for syphilis screening on inmates as part of the routine intake process. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.  (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.  (4) Includes persons with a history of injection drug use (IDU) since January 1978.
	0.1 - 0.7	0.1 - 0.8		0.2 - 2.2	0.1 - 2.1	:	0.2 - 0.8	g a juvenile detent routine intake proc iers were removed. d confirmed by a We vals not calculate since January 1978 s.
	0.00	0.3		0.0	7.0	0.0	0.4	its entering in a first of the sal identify ELISA and sence Interview (IDU)
	-040	, <b>S</b>		0 M O	m	0	8	s adolescer mates as po- all persor reactive t al. Confic ection drug
	17 1414 8	1457		14 403 2	419	2	1881	survey include creening on in for HIV after for HIV after for Expeatedly exact binomi history of inj xuals with no
MALE	Homosexual/Bisexual Heterosexual, IDU (4) Heterosexual (5) Unknown Risk	SUB-TOTAL MALE	FEMALE	Heterosexual IDU (4) Heterosexual (5) Unknown Risk	SUB-TOTAL FEMALE	MISSING GENDER	TOTAL	(1) This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Bloocollected for syphilis screening on immates as part of the routine intake process. Specimens we consecutively and tested for HIV after all personal identifiers were removed.  (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay. Sp. Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes (4) Includes persons with a history of injection drug use (IDU) since January 1978.

CENTER	
DETENTION	
JUVENILE (1)	
4 E	
19 E	
ENTER 1990 -	
ADOLESCENTS FRANCISCO,	
SAN	
HIV SEROPREVALENCE FOR ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER BY RACE/ETHNICITY, SAN FRANCISCO, 1990 - 1993 (1)	
BA	

RACE/ETHNIC1TY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	
WHITE WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	171 988 439 236 47	0.40	0.0000	0.00 - 2.13	
TOTAL	1881	€0	0.4	0.2 - 0.8	
(1) This unlinked (blinded) survey includes adolescents entering a juvenile deter collected for syphilis screening on immates as part of the routine intake proconsecutively and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a w. (3) 59% Confidence Intervals, exact binomial. Confidence intervals and calculate	urvey inclusening on for HIV affice repeated exact bind	rdes adolesc inmates as ter all pers Aly reactive	ents enterir part of the onal identif by ELISA ar	g a juvenile det routine intake p iers were remove d confirmed by a vals not calcula	(1) This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood specimens were collected for syphilis screening on inwates as part of the routine intake process. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. All positives specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (2) ALI positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

ions. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western biot assay.
(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes
(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

SERO- PREVALENCE RATE (%) (95% C.I.)(3)	0.0 - 1.6	0.2 - 0.8
SERO- PREVALENCE RATE (%)	0.0	0.4
NUMBER(2) POSITIVE	1-2000	80
NUMBER	356 1495 4 0 26	1881
(YEARS)		
AGE-GROUP (YEARS)	UNDER 15 15 - 19 20 - 24 25 - 29 UNKNOWN	TOTAL

(1) This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood specimens were collected for syphilis screening on inmates as part of the routine intake process. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

HIV SEROPREVALENCE FOR ADOLESCENTS ENTERING HOMELESS YOUTH CENTERS BY GENDER AND TRANSMISSION CATEGORY, SAN FRANCISCO, 1990 - 1993 (1)
1990 -
HOMELES:
NTERING SAN FR
SCENTS E
SSION C
LENCE FO
HIV SEROPREVALENCE FOR ADOLESCENTS ENTERING HOMELESS YOUTH CENTERS BY GENDER AND TRANSMISSION CATEGORY, SAN FRANCISCO, 1990 - 1993 (1
HIV S BY GE

GENDER AND TRANSMISSION CATEGORY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% c.1.)(3)
MALE .				
Homosexual/Bisexual Heterosexual, IDU (4) Heterosexual (5) Unknown Risk	433 433 33	5 ₆₋₄₀	41.4 1.7 0.0	35.3 - 47.8 0.0 - 9.1 0.3 - 2.3
SUB-TOTAL MALE	736	) <u>6</u>	14.4	12.0 - 17.1
FEMALE -				
Heterosexual IDU (4) Heterosexual (5) Unknown Risk	114 946 22	490	3.5	1.0 - 8.7 0.2 - 1.4 0.0 - 12.7
SUB-TOTAL FEMALE	1082	<u>ا</u> ۾	6.0	0.4 - 1.7
MISSING GENDER	10	8	20.0	:
TOTAL	1848	121	6.5	5.5 - 7.8

SERO- PREVALENCE RATE (%) (95% C.I.)(3)	8.3 - 12.8 1.7 - 5.2 2.9 - 7.1 1.2 - 7.1 1.8 - 15.7	5.5 - 7.8
	10.4 3.1 4.7 3.3 6.5	6.5
NUMBER(2) POSITIVE	77 13 21 6	121
NUMBER	742 419 445 180 62	1848
RACE/ETHNICITY	WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL

(1) This unlinked (blinded) survey includes adolescents seeking services at two homeless youth shelters. Blood specimens were collected for syphilis screening as part of the routine medical evaluation. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.
(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.
(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

HIV SEROPREVALENCE FOR ADOLESCENTS ENTERING HOMELESS YOUTH CENTERS BY AGE-GROUP, SAN FRANCISCO, 1990 - 1993 (1)

(95% C.1.)(3)	0.0 - 2.0 2.7 - 5.2 23.2 - 36.7 3.5 - 7.7
PREVALENCE RATE (%)	0.0 3.8 29.6 0.0
NUMBER(2) POSITIVE	39 56 56 26
NUMBER TESTED	149 1018 189 4 4
AGE-GROUP (YEARS)	UNDER 15 15 - 19 20 - 24 25 - 29 UNKNOWN

(1) This unlinked (blinded) survey includes adolescents seeking services at two homeless youth shelters. Blood specimens were collected for syphilis screening as part of the routine medical evaluation. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

7.8 5.5 -

6.5

121

1848

TOTAL

IV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO Y GENDER AND YEAR, 1985 - 1992 (1)

	ጃ(4)	0.28	0.36	
1989	(8)	1	ю	
	N(2) HIV+(3) X(4)	711	835	
	) 7(4)	0.26	2 0.21	
1988	IV+(3)	0 0	2	
	N(2) HIV+(3) X(4)	759 178	937	
	ኧ(4)	0.58	0.49	
1987	IV+(3)	20	S.	
	N(2) HIV+(3) X(4)	869 143	1012	
	<b>X</b> (4)	0.96	0.89	
1986	10+(3)	9	10	
	N(2) HIV+(3) \$(4)	941 183	1124	
	4)	88	 8	
ю	N(2) HIV+(3) X(4)	0.00	0.00	
1985	HIV+	00		
	N(2)	213	258	
	GENOER	MALE FEMALE	AL	
	GEN	MAL	TOTAL	

			between
五(4)	0.44	0.41	ollected
10+(3)	21 2	23	Oata C
N(2) HIV+(3) X(4)	4733 937	5670	(cpc).
<b>z</b> (4).	0.32	0.25	e Control
.V+(3)	-0	-	)1seas
N(2) HIV+(3) X(4)	313 86	399	ers for (
ጃ( <b>4</b> )	0.49	0.42	d the Cent
(V+(3)	0	2	se, an
N(2) HIV+(3) X(4)	407	480	of Defens
N(2) HIV+(3) X(4)	0.00	00.00	Department
IV+(3	00		u.s.
N(2) H	520 105	625	the St
GENOER	MALE FEMALE	TOTAL	1) Data provided by the U.S. Department of Defense, and the Centers for Oisease Control (CDC). Data Collected between
Ö	3.5	1	=

TOTAL

1992

1991

1990

October 1985 and December 1992. 2) Number of specimens tested. 3) All hostitive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay. 4) Seroprevalence rate (X). =

IV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO PACE AND ETHNICITY AND YEAR, 1985 - 1992 (1)

1989	N(2) HIV+(3) X(4)	286 1 0.35 178 1 0.56 102 1 0.98 253 0 0.00 16 0 0.00	835 3 0.36					between
1988	N(2) HIV+(3) X(4)	334 1 0.30 193 1 0.52 115 0 0.00 267 0 0.00 28 0 0.00	937 2 0.21	TOTAL	N(2) HIV+(3) %(4)	1970 13 0.66 1077 7 0.65 ( 605 2 0.33 1817 0 0.00 201 1 0.50	5670 23 0.41	(CDC). Data Collected between blot assay.
1987	N(2) HIV+(3) X(4)	346 2 0.58 212 3 1.42 108 0 0.00 320 0 0.00 26 0 0.00	1012 5 0.49	1992	N(2) HIV+(3) X(4)	131 0 0.00 53 0 0.00 49 1 2.04 158 0 0.00	399 1 0.25	ters for Disease Control
1986	N(2) HIV+(3) X(4)	334 7 1.71 193 2 0.83 115 0 0.00 267 0 0.00 28 1 1.43	937 10 0.89	1991	N(2) HIV+(3) X(4)	160 2 1.25 63 0 0.00 68 0 0.00 173 0 0.00 16 0 0.00	480 2 0.42	Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC). Da Cycloer 1985 and December 1982. Number of specimens tested. All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. Seroprevalence rate (%).
1985	N(2) HIV+(3) X(4)	94 0 0.00 51 0 0.00 11 0 0.00 85 0 0.00 17 0 0.00	258 0 0.00	1990	N(2) HIV+(3) \$(4)	210 0 0.00 B5 0 0.00 78 0 0.00 232 0 0.00 20 0.00	625 0 0.00	by the U.S. Department and December 1992. Ilmens tested. specimens were repeated
	RACE/ETHNICITY	WHITE BLACK HISPANIC ASIAN/P.I. OTHER	TOTAL		RACE/ETHNICITY	WHITE BLACK LATINO ASIAN/P.I. OTHER	TOTAL	1) Data provided by the U.S. [ October 1985 and December 1 2) Number of specimens tested 3) All positive specimens were 4) Seroprevalence rate (%).

IV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO A AGE-GROUP AND YEAR, 1985 - 1992 (1)

1989	N(2) HIV+(3) X(4)	352 0 0.00 211 1 0.47 170 2 1.18 102 0 0.00 0 0 .	835 3 0.36						between
1988	N(2) HIV+(3) X(4)	417 1 0.24 236 0 0.00 163 1 0.61 121 0 0.00 0 0 .	937 2 0.21	•	TOTAL	N(2) HIV+(3) X(4)	2547 3 0.12 1408 4 0.28 1000 9 0.90 715 7 0.98	5670 23 0.41	l (CDC). Oata Collected blot assay.
1987	N(2) HIV+(3) X(4)	448 0 0.00 265 1 0.38 166 1 0.60 133 3 2.26 0 0	1012 5 0.49		1992	N(2) HIV+(3) X(4)	1899 0 0.00 1000 0 0.00 655 1 1.54 45 0 0.00	399 1 0.25	nters for Oisease Control
1986	N(2) HIV+(3) X(4)	417 1 0.21 236 2 0.70 163 3 1.47 121 4 2.67 0 0	937 10 0.89		1991	N(2) HIV+(3) X(4)	227 1 0.44 109 0 0.00 76 1 1.32 68 0 0.00	480 2 0.42	of Defense, and the Cer ily reactive by ELISA and
1985	N(2) HIV+(3) %(4)	129 0 0.00 48 0 0.00 45 0 0.00 36 0 0.00	258 0 0.00		1990	N(2) HIV+(3) X(4)	300 1154 0 0 0.00 1111 60 0 0.00 0 0 0.00	625 0 0.00	Gata provided by the U.S. Department of Defense, and the Centers for Oisease Control (CDC). Gata Collected between October 1985 and December 1992.  Number of specimens tested.  If Destitive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  Seroprevalence rate (%).
	AGE-GROUP	19 AND UNDER 20 – 24 25 – 29 30 AND OVER UNKNOWN	TOTAL			AGE-GROUP	19 AND UNDER 20 – 24 25 – 29 30 AND OVER UNKKOMN	TOTAL	1) Oata provide October 198 2) Number of si 3) All positive 4) Seroprevale

³⁹ 

HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY YEAR OF DONATION, MARCH 1985 - DECEMBER 1993 (1)

YEAR OF DONATION	TOTAL DONORS	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
1988 1986 1986 1989 1990 1992	72, 204 88, 168 91, 336 97, 320 87, 320 87, 578 77, 578 78, 578 77, 578	838855	0.000 0.003 1.400.000 0.0000 0.0000 0.0000	0.088 - 0.139 0.033 - 0.067 0.013 - 0.067 0.017 - 0.039 0.006 - 0.029 0.007 - 0.024 0.008 - 0.021 0.001 - 0.021
TOTAL	739,773	211	0.029	0.025 - 0.033

(1) Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay. (3) 95% Confidence Intervals, normal approximation.

(95% C.I.)(3)	0.020 - 0.074 0.003 - 0.037	0.001 - 0.010	0.005 - 0.012
SERO- PREVALENCE RATE (%)	0.039	0.003	0.008
NUMBER(2) POSITIVE	10 8	e –	71
TOTAL DONORS	25,753 25,687	93,509 80,966	225,915
GENOER	Male Female	Male Female	
DONATION STATUS	FIRST-TIME DONORS	REPEAT	TOTAL

(1) Gata provided by the Irwin Memorial Blood Centers, San Francisco, Ca. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, normal approximation.

(95% C.I.)(3)	0,003 - 0,010 0,020 - 0,132 0,000 - 0,022 0,003 - 0,061	0.005 - 0.012
SERO- PREVALENCE RATE (%)	0.005 0.053 0.000 0.000	0.008
NUMBER(2) POSITIVE	10 5 0 2	71
TOTAL	186,867 9,420 16,450 13,178	225,915
RACE/ETHNICITY	WHITE AFRIGAN AMERICAN ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL

(1) Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, normal approximation. (4) Includes Latinos, American Indians, Alaskan Natives, other race, and unknown race.

(95% C.I.)(3)	0.000 - 0.024 0.003 - 0.027 0.009 - 0.033 0.000 - 0.007	0.005 - 0.012
SERO- PREVALENCE RATE (%)	0.000 0.010 0.018 0.002	0.008
NUMBER(2) POSITIVE	0 11 2	17
TOTAL DONORS	14,941 40,240 61,325 109,409	225,915
AGE-GROUP (YEARS)	19 AND UNDER 20 – 29 30 – 30 40 AND OVER	TOTAL

(1) Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, normal approximation.

S.F. Dept. of Public Health AIDS Office, Surveillance Branch 25 Van Ness Ave., Suite 500 San Francisco, CA 94102-6033

## **HIV Seroprevalence Report**

San Francisco Department of Public Health AIDS Office

March, 1995 Volume 6, No. 1

APR 3 1995

"ENITS DEFT.

SAN FRANCISCO PUBLIC LIBRARY

## Contents

	Page
SURVEY OF CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC: 1989-94	
HIV Seroprevalence for Clients Attending a STD Clinic by Gender and Transmission Category HIV Seroprevalence for Clients Attending a STD Clinic by Race/Ethnicity HIV Seroprevalence for Clients Attending a STD Clinic by Age Group HIV Seroprevalence for Gay & Bisexual Men Attending a STD Clinic by Race/Ethnicity HIV Seroprevalence for Gay & Bisexual Men Attending a STD Clinic by Age Group HIV Seroprevalence for Heterosexual Males Attending a STD Clinic by Race/Ethnicity HIV Seroprevalence for Heterosexual Males Attending a STD Clinic by Age Group HIV Seroprevalence for Heterosexual Females Attending a STD Clinic by Race/Ethnicity HIV Seroprevalence for Heterosexual Females Attending a STD Clinic by Age Group	1 3 4 5 6 7 8 9
SURVEY OF INJECTION DRUG USERS (IDUs) ENTERING METHADONE TREATMENT PROGRAMS	
HIV Seroprevalence for IDUs Entering Methadone Treatment by Gender & Sexual Orientation HIV Seroprevalence for IDUs Entering Methadone Treatment by Race/Ethnicity HIV Seroprevalence for IDUs Entering Methadone Treatment by Age Group	11 13 14
SURVEY OF DRUG USERS (IDUs & NON-IDUs) ENTERING A METHADONE-FREE DETOX PROGRAM	M
HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Gender & Sexual Orientation HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Race/Ethnicity HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Age Group HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Primary Drug	15 16 17 18
SURVEY OF WOMEN OF REPRODUCTIVE AGE: FAMILY PLANNING & ABORTION CLINIC CLIENTS	
HIV Seroprevalence for Women Attending a Family Planning Clinic by Transmission Category HIV Seroprevalence for Women Attending a Family Planning Clinic by Race/Ethnicity HIV Seroprevalence for Women Attending a Family Planning Clinic by Age Group HIV Seroprevalence for Women Attending an Abortion Clinic by Transmission Category HIV Seroprevalence for Women Attending an Abortion Clinic by Race/Ethnicity HIV Seroprevalence for Women Attending an Abortion Clinic by Age Group	19 20 21 22 23 24
SURVEY OF CHILDBEARING WOMEN IN SAN FRANCISCO: 1989-93	
HIV Seroprevalence for Newborn Infants and Their Mothers by Age Group and Ethnicity	25
SURVEY OF PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A TB CLINIC	
HIV Seroprevalence for TB Patients by Gender and Transmission Category HIV Seroprevalence for TB Patients by Origin of Birth HIV Seroprevalence for TB Patients by Race/Ethnicity HIV Seroprevalence for TB Patients by Age Group	27 28 29 30

## SURVEY OF ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER (JDC) AND HOMELESS YOUTH CENTERS (HYCs)

HIV Seroprevalence for Adolescents Entering a JDC by Race/Ethnicity HIV Seroprevalence for Adolescents Entering a JDC by Age Group HIV Seroprevalence for Adolescents Entering HYCs by Gender & Transmission Category HIV Seroprevalence for Adolescents Entering HYCs by Race/Ethnicity	31 32 33 34 35 36
RESULTS OF HIV SCREENING OF CIVILIAN APPLICANTS FOR MILITARY SERVICE: 1985-1993	
HIV Seroprevalence for Civilian Applicants for Military Service by Race/Ethnicity & Year	37 38 39
RESULTS OF HIV SCREENING OF BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA: 1985-1	993
HIV Seroprevalence for Blood Donors by Donation Status & Gender HIV Seroprevalence for Blood Donors by Race/Ethnicity	40 41 42 43

HIV SEROPREVALENCE REPORT is released on a semi-annual basis by the San Francisco Department of Public Health, AIDS Office, Seroepidemiology and Surveillance Branch, 25 Van Ness Avenue, Suite 500, San Francisco, CA 94102-6033. Phone (415) 554-9050. Director of Epidemiology, Disease Control, and AIDS, Mitch Katz, M.D. Seroepidemiology and Surveillance Branch Chief, George F. Lemp, Dr. P.H. Program Coordinator, Sean Nguyen. Epidemiologist/Data Manager, Tim Kellogg. Funding and technical support is provided by the Division of HIV/AIDS, Centers for Disease Control and Prevention. Additional support is provided by the California Department of Health Services. Office of AIDS.

HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY GENDER AND TRANSMISSION CATEGORY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (1)

		1989	9 SURVEY			1990	0 SURVEY			1991	1 SURVEY	
GENDER AND TRANSMISSION CATEGORY	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)
MALE												
Gay/Bisexual	440	224	50.9	46.1 - 55.7	626	269	43.0	39.1 - 47.0	672	254	37.8	34.1 - 41.6
Gay/Bisexual, IDO (4) Heterosexual IDU (4)		13	12.5		101	n &	7.9	1 1	118	6	7.6	
Sex Partner at Risk for HIV		е .	4.3	1	103	σ,	8.7	4.1 - 15.9	122	4 (	3.3	0.9 - 8.2
Blood Recipient (5) Heterosexual (6)	23	14	4 H	0.1 - 21.9	1381	29	2.1	1.4 - 3.0	1663	41	.5	1.8 - 3.3
Unknown Risk	14	2	14.3		187	. 52	13.4	7	69	15	25.4	1
SUB-TOTAL MALE	1788	338	18.9	17.1 - 20.8	2497	396	15.9	14.4 - 17.4	2713	360	13.3	12.0 - 14.6
PEMALE .												
IDU (4)		ĸ	9.1	- (1	09	S	8.3	7	65	m	5.1	1.1 - 14.1
Sex Partner at Risk for HIV	u,	1	1.7	0.0 - 9.2	55	7	1.8	0.0 - 9.7	9	e ·	4.6	
Lesbian/Bisexual (7) Blood Recipient (5)	0 [[	0 1	9.1		0 6	0 1	16.7		3 26	0 0	0 0	0.0 - 10.9
Heterosexual (6)	380	e	8.0	0.2 - 2.3	541	13	2.4	1.3 - 4.1	681	80	1.2	0.5 - 2.3
Unknown Risk	S	0	0.0		19	0	0.0		15	п	6.7	
SUB-TOTAL FEMALE	509	10	2.0	0.9 - 3.6	681	20	2.9	1.8 - 4.5	849	15	1.8	1.0 - 2.9
MISSING GENDER	0	0		· :	•	0			0	0		
TOTAL	2297	348	15.2	13.7 - 16.7	3178	416	13.1	11.9 - 14.3	3562	375	10.5	9.5 - 11.6

These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening of individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected

consecutively and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95t Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

 ⁽⁴⁾ Includes persons with a history of injection drug use (IDU) since January 1978.
 (5) Includes persons with a history of blood transfusions(s) between January 1977 and March 1985.
 (6) Self-identified heterosexuals with no other identified risks.
 (7) Includes women who have sex with women and women who have sex with both men and women. Lesbian or bisexual women who have a history of injection drug use (IDU) since 1978 are included in the IDU category. Collection of female sexual orientation began in 1991.

HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY GENDER AND TRANSMISSION CATEGORY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (1)

		1992	2 SURVEY			1993	3 SURVEY			1994	4 SURVEY	
GENDER AND TRANSMISSION CATEGORY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (*)	(95% C.I.) (3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)
атум												
Gay/Bisexual	650	226	34.8	31.1 - 38.6	699	239	34.2	30.7 - 37.8	694	200	28.8	25.5 - 32.3
Gay/Bisexual, IDU (4) Heterosexual IDU (4)	104	7	6.7		75	9 9	8.0		105	32	6.7	
Sex Partner at Risk for HIV	99	4.0	6.1	1 1	80	<u>ه</u> دی	6.3	1 1	3 82	mc	3.7	
Blood Kecipient (5) Heterosexual (6)	1575	36	2.3		1771	40	2.3		1752	31	1.8	
Unknown Risk	43	7	16.3	6.8 - 30.7	9	17	18.5	9.9 - 30.0	4	0	0.0	:
SUB-TOTAL MALE	2495	299	12.0	10.7 - 13.3	2749	325	11.8	10.6 - 13.1	2724	273	10.0	8.9 - 11.2
FEMALE												
	:	,	c		;	ſ	(		:	,	,	
IDU (4)	43	m F	0.6	1.5 - 19.1	44	m C	æ c	1.4 - 18.7	55	-1 -	π π α	0.0
Lesbian/Bisexual (7)	31	10	0.0	0.0 - 9.2	. 4	00	0.0		. 84	10	0.0	1
Blood Recipient (5)	0	0		ı	æ (	0 (	0.0		7	<b>0</b> 1	0.0	
Heterosexual (6) Unknown Risk	669	<b>*</b> O	0.0	0.2 - 1.0	23	<b>∞</b> ⊢1	4.1	0.1 - 21.9	7 890	0 0	0.0	
SUB-TOTAL FEMALE	776	ω	1.0	0.4 - 2.0	846	12	1.4	0.7 - 2.5	829	7	8.0	0.3 - 1.7
MISSING GENDER	н	0	0.0		0	0		:	0	0		
TOTAL	3272	307	9.4	8.4 - 10.4	3595	337	9.4	8.4 - 10.4	3553	280	7.9	7.0 - 8.8
(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.  (3) All positive specimens were respeatedly reactive by ELISA and confirmed by a Western blot assay.  (4) Includes persons with a history of injection drug use (IDD) since January 1978.  (5) Includes persons with a history of blood transfusions(s) between January 1977 and March 1985.  (6) Self-identified heterosexuals with no other identified risks.  (7) Includes women who have sex with women and women who have sex with women and women. Lesbian or bisexual women who sexual orientation drug use (IDU) since 1978 are included in the IDU category. Collection of female sexual orientation began in 1991.	irveys we examinate to a steel of the control of th	re drawn from blood specime tion, and/or treatment for all personal identifiers will preactive by ELISA and comial. Confidence Intervalinjection drug use (IDU) s. blood transfusions(s) between and women who have sex men and women who have sex DU) since 1978 are includes	m blood spectors in treatment in the blood spectors in the bloom in th	trion, and/or treatment for a NEW STD episode. Specimens were collected all pand/or treatment for a NEW STD episode. Specimens were collected all personal identifiers were removed. dely reactive by ELISA and confirmed by a Western blot assay. comfal. Confidence Intervals not calculated for sample sizes under 20 cinjection drug use (IDU) since January 1978 and March 1985. no other identified risks in confidence intervals not calculated for sample sizes under 20 confidence intervals not calculated for sample sizes under 20 confident identified risks.	for routin isode. Spe- is Western b ated for san 1978. and women	tine syphilis screening of Specimens were collected or blot assay.  Fample sizes under 20 of March 1985.  March 1985.  The Collection of female or Collection of female	screening on collected under 20 obs	ervations.				

HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY RACE/ETHNICITY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (1)

1989 SURVEY

1991 SURVEY

1990 SURVEY

	(95% C.I.) (3)	12.9 - 16.6 5.3 - 8.3 7.8 - 12.4 3.0 - 9.4 4.8 - 22.6	9.5 - 11.6		(95% C.I.) (3)	9.5 - 12.9 5.8 - 9.1 4.0 - 7.4 0.9 - 4.6 2.5 - 12.3	7.0 - 8.8	
17000	SERO- PREVALENCE RATE (%)	14.7 6.7 9.9 5.6 11.7	10.5	4 SURVEY	SERO- PREVALENCE RATE (%)	11.1 7.3 5.5 2.3 6.2	7.9	
	NUMBER(2) POSITIVE	210 78 67 13	375	1994	NUMBER(2) POSITIVE	147 76 43 7	280	
	NUMBER	1429 1165 675 233 60	3562		NUMBER	1321 1037 775 307 113	3553	
	(95% C.I.) (3)	16.0 - 20.4 7.8 - 11.2 9.5 - 15.0 3.8 - 11.8 3.9 - 25.1	11.9 - 14.3		(95% C.I.) (3)	12.4 - 16.2 4.6 - 7.5 6.1 - 10.1 1.4 - 5.8 2.9 - 16.2	8.4 - 10.4	n servations.
	SERO- PREVALENCE RATE (%)	18.1 9.4 12.1 7.1 11.6	13.1	1993 SURVEY	SERO- PREVALENCE RATE (%)	14.2 6.0 7.9 3.1 7.8	9.4	screening or collected under 20 obs
	NUMBER(2) POSITIVE	219 111 68 13 5	416	199	NUMBER(2) POSITIVE	199 66 57 9	337	e syphilis cimens were lot assay, mple sizes own race.
	NUMBER TESTED	1210 1178 564 183	3178		NUMBER TESTED	1398 1109 719 292 77	3595	for routin laode. Spe western bated for sa
	(95% C.I.) (3)	20.1 - 25.7 7.3 - 11.4 10.6 - 18.0 1.6 - 9.2 3.8 - 24.6	13.7 - 16.7		(95% C.I.) (3)	10.6 - 14.2 5.9 - 9.3 5.9 - 10.0 2.0 - 8.2 4.5 - 24.3	8.4 - 10.4	were drawn from blood specimens collected for routine syphilis screening on mation, and/or treatment for a NEW STD episode. Specimens were collected trail personal identifiers were removed. Itsely reactive by ELISA and confirmed by a Western blot assay. Annotal. Confidence Intervals not calculated for sample sizes under 20 obstant and haakan Native ancestry, other race, and unknown race.
	SERO- PREVALENCE RATE (%)	22.8 9.2 14.0 4.3 11.4	15.2	2 SURVEY	SERO- PREVALENCE RATE (%)	12.3 7.5 7.8 4.4 12.0	9.4	m blood spec treatment f identifiers by ELISA an idence Intex Native ance
	NUMBER(2) POSITIVE	209 76 52 6	348	1992	NUMBER(2) POSITIVE	163 76 53 9	307	e drawn fro ion, and/or iii personal iiy reactive mial. Conf
	NUMBER	916 828 371 138 44	2297		NUMBER	1320 1016 683 203 50	3272	urveys wen v. examinata IV after e e repeated exact bind an Indian
	RACE/ETHNIC1TY	WHITE APRICAN AMERICAN LATINO ASIN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL		RACE/ETHNICITY	WHITE AFRICAN AMERICAN LATINO ASIN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL	(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiars were removed.  (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (3) 554 Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY AGE-GROUD, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (1)

⁽¹⁾ These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by BLISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

HIV SEROPREVALENCE FOR GAY AND BISEXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY RACE/ETHNICITY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (1)

		1989	9 SURVEY			199	1990 SURVEY			1991	1 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95 <b>k</b> C.I.) (3)
WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	372 84 78 14	194 54 48 5	52.2 64.3 61.5 28.6 83.3	46.9 - 57.3 53.1 - 74.4 49.8 - 72.3	456 117 107 28 8	188 74 50 8 8	41.2 63.2 46.7 28.6 50.0	36.7 - 45.9 53.8 - 72.0 37.0 - 56.6 13.2 - 48.7	525 83 105 27 11	182 44 48 11 6	34.7 53.0 45.7 40.7 54.5	30.6 - 38.9 41.7 - 64.1 36.0 - 55.7 22.4 - 61.2
TOTAL	554	305	55.1	50.8 - 59.3	716	324	45.3	41.6 - 49.0	751	291	38.7	35.2 - 42.3
•		1992	2 SURVEY			1993	3 SURVEY			199.	1994 SURVEY	
RACE/ETHNICITY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95k C.I.) (3)
WHITE AFRICAN AMERICAN LATINO ASIN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	455 102 105 26 12	147 46 39 7 6	32.3 45.1 37.1 26.9 50.0	28.0 - 36.8 35.2 - 55.3 27.9 - 47.1 11.6 - 47.8	497 76 120 39	165 39 46 7 4	33.2 51.3 38.3 17.9 30.8	29.1 - 37.5 39.6 - 63.0 29.6 - 47.6 7.5 - 33.5	487 88 114 47 23	135 46 37 7	27.7 52.3 32.5 14.9 30.4	23.8 - 31.9 41.4 - 63.0 24.0 - 41.9 13.2 - 52.9
TOTAL	700	245	35.0	31.5 - 38.7	745	261	35.0	31.6 - 38.6	759	232	30.6	27.3 - 34.0

⁽¹⁾ These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 55% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons of American Indian and Alaskan Native ancestry, other zace, and unknown race.

HIV SEROPREVALENCE FOR GAY AND BISEXUAL MEN ATTENDING A SEXUALLY TRA AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (1)

		1989	9 SURVEY			1990	0 SURVEY			1991	1 SURVEY	
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- ER(2) PREVALENCE TIVE RATE (%) (95% C.I.) (3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- ER(2) PREVALENCE TIVE RATE (\$) (95% C.I.) (3)
19 AND UNDER	2	0	0.0		14	2	14.3	-	10	1	10.0	
20 - 24	61	25	41.0	28.6 - 54.3	81	27	33.3	23.2 - 44.7	85	16	18.8	11.2 - 28.8
25 - 29	134	84	62.7	53.9 - 70.9	174	80	46.0	38.4 - 53.7	195	74	37.9	31.1 - 45.2
30 - 34	129	9/	58.9	49.9 - 67.5	168	87	51.8	44.0 - 59.5	175	83	47.4	39.8 - 55.1
35 - 39	112	89	60.7	51.0 - 69.8	129	69	53,5	44.5 - 62.3	118	26	47.5	38.2 - 56.9
40 - 44	55	25	45.5	32.0 - 59.4	62	30	48.4	35.5 - 61.4	87	37	42.5	32.0 - 53.6
45 AND OVER	61	27	44.3	31.5 - 57.6	87	29	33.3	23.6 - 44.3	80	24	30.0	20.3 - 41.3
UNKNOWN	0	0			7	0	0.0		7	0	0.0	•

		NUMBER	10	82	195	175	118	87	80	-1	751	
		(95% C.I.) (3)		23.2 - 44.7	38.4 - 53.7	44.0 - 59.5	44.5 - 62.3	35.5 - 61.4	23.6 - 44.3		41.6 - 49.0	
AGE-GROUP,	1990 SURVEY	SERO- PREVALENCE RATE (%)	14.3	33.3	46.0	51.8	53,5	48.4	33.3	0.0	45.3	
CLINIC BY	199	NUMBER (2) POSITIVE	7	27	80	87	69	30	29	0	324	
ISEASE (STD		NUMBER	14	81	174	168	129	62	87	-	716	
Y TRANSMITTED DISEASE (STD) CLINIC BY AGE-GROUP,		(95% C.I.) (3)		٠	53.9 - 70.9	•	•		31.5 - 57.6		50.8 - 59.3	

35.2 - 42.3

38.7

291

55.1

305

554

TOTAL

15	

SURVEY

1992

,	
SURVEY	SERO.

93

1

SURVEY

1994

l H
E E
2

贸
į
1 5

5
MBER
5

2
448
1 2

Ś
ER

NUMB
æ

NUM
æ

NUMB
~

NUM
~

Ħ
BER

5N
SER

NUM
æ

NUMBE
~

NUM
~

NUME	POSI
NUMBER	TESTED

_
MBER
Σ

NUMB
~

<u> </u>	5	
~	H	
UMBER	H	
<u> </u>	H	
Σ	S	
	0	

VALENCE TE (%) SERO-

(95% C.I.) (3)

PREVALENCE RATE (%)

NUMBER (2) POSITIVE

NUMBER

(95% C.I.) (3)

RATE (%) PREVALENCE

NUMBER (2) POSITIVE

NUMBER

AGE-GROUP (YEARS)

SERO-

(95% C.I.) (3)

ď	-		
3R (2)	LIVE	0 0 0 0 0 0	

PRE	14444	, m
BER (2)	0 38 65 55 31 0	232

- 28.6 - 27.7 - 43.1 - 49.2 - 52.7

10.3 15.3 28.8 32.1 29.6 21.5

0.00

12 77 77 181 182 136 95 95

17.5 - 33.0 - 51.7 - 56.0 - 56.7 - 45.2

3.2 119.9 37.4 32.1 24.7

0.0 8.5 8.5 26.1 44.4 46.7 34.1

5 1188 1198 1120 68 68 90

- 26.7 - 39.9 - 46.1 - 57.6 - 64.6

10.3 25.0 31.7 37.6 39.7

20.0 17.4 32.1 38.7 47.6 52.2 24.3

10 92 162 1186 67 67

AND UNDER
- 24
- 29
- 34
- 39

19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER

UNKNOMN

- 34.0 27.3

9.0

759

- 38.6

31.6

35.0

261

745

- 38.7

31.5

35.0

245

200

TOTAL

(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were rawoved.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

HIV SEROPREVALENCE FOR HETEROSEXUAL MALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY RACE/ETHNICITY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (2)

1991 SURVEY	SERO- NUMBER NUMBER(3) PREVALENCE TESTED POSITIVE RATE (‡) (95% C.I.)(4)	497 12 2.4 1.3 - 4.2 741 19 2.6 1.6 - 4.0 399 12 3.0 1.6 - 5.2 122 2 1.6 0.2 - 5.8 26 0 0.0 - 10.9	1785 45 2.5 1.8 - 3.4	VENTURE A SET DITTE	SERO- NUMBER (3) PREVALENCE TESTED POSITIVE RATE (*) (95% C.I.) (4)	518 5 1.0 0.3 - 2.2 635 24 - 5.6 471 5 1.1 0.3 - 2.5 159 0 0.0 0.0 - 1.9 51 0 0.0 0.0 - 5.7	1834 34 1.9 1,3 - 2.6	
1990 SURVEY	SERO- NUMBER NUMBER(3) PREVALENCE TESTED POSITIVE RATE (%) (95% C.I.)(4)	413 11 2.7 1.3 - 4.7 683 18 2.6 1.6 - 4.1 286 8 2.8 1.2 - 5.4 84 1 1.2 0.0 - 6.5 18 0 0.0	1484 38 2.6 1.8 - 3.5	VATVOTIS FOOT	SERO- NUMBER NUMBER(3) PREVALENCE TESTED POSITIVE RATE (%) (95% C.I.)(4)	569 20 3.5 2.2 - 5.4 687 16 2.3 1.3 - 3.8 416 7 1.7 0.7 - 3.4 148 1 0.7 0.0 - 3.7 31 1 3.2 0.1 - 16.7	1851 45 2.4 1.8 - 3.2	with no other identified risks. for routine syphilis screening on sode. Specimens were collected Western blot assay. ted for sample sizes under 20 observations. , and unknown race.
1989 SURVEY	SERO- NUMBER (1) PREVALENCE RACE/ETHNICITY TESTED POSITIVE RATE (\$) (95% C.I.) (4)	MHITE ARRICAN AMERICAN ASTRICAN AMERICAN ASTRICAN AMERICAN ASTRICAN AMERICAN ASTAN/PACIPIC ISLANDER ASTAN/PACIPIC ISLANDER 78 1 1.3 0.0 6.9	TOTAL 1093 17 1.6 0.9 - 2.5	AMAGIS COOL	SERO- NUMBER NUMBER(3) PREVALENCE TRSTED POSITIVE RAIE (\$) (95* C.I.) (4)	MHITE ARRICAN AMERICAN 632 21 1.9 0.9-3.5 LATINO 1.9 1.9 0.9-3.5 0.0 1.7 1.8 0.7-3.6 ASTAN/PACIPIC ISLANDER 91 2 2.2 0.3-7.7 NONE OF THE ABOVE (5) 19 0 0.0	TOTAL 1641 40 2.4 1.7 - 3.3	(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.  (2) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NRW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.  (3) All postive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (4) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.  (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

SEROPREVALENCE FOR HETEROSEKUAL MALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEAS HIV SEROPREVALENCE FOR HETEROSEKUAL MALES (1) ATTE AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (2)

		198	1989 SURVEY			1990	SURVEY			1991	1 SURVEY	
AGE-GROUP (YEARS)	NUMBER	NUMBER (3) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.) (4)	NUMBER	NUMBER (3) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- NUMBER(3) PREVALEROE POSITIVE RATE (*) (95% C.I.)(4)	NUMBER	NUMBER (3) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- NUMBER (3) PREVALENCE POSITIVE RATE (\$) (95% C.I.) (4)

	1991	NUMBER NUMBER (3)
SE (STD) CLINIC BY AGE-GROUP,	1990 SURVEY	SERO- RER NUMBER (3) PREVALENCE
SE		3

	1991 SURVEY	-0885
STD) CLINIC BY AGE-GROUP,	1990 SURVEY	-0898

2.4.2 4.5 8.5 7.9 6.7 7.9 6.7 1.9

2621230

E.1.24.8.1.0 6.1.24.1.10

157 360 389 229 229 158 98 89

4.3 9.1 12.3 12.3

0.00

8 0 0 4 6 0 E

H M O B M O R C

126 312 265 265 181 93 60 60 56

19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN

	(95% C.I.) (4)
91 SURVEY	SERO- PREVALENCE RATE (%)

1991 SURVEY	
SERO- NUMBER(3) PREVALENCE POSITIVE RATE (\$)	(95% C.I.) (4)

- 0.0 1.9 0.2 2.0 1.0 4.0 1.7 6.3 2.8 10.3 2.8 13.5 0.8 7.5

3.4

1.8

2.5

45

1.8

2.6

1484

2.5

6.0

17

1093

2.6 1.4 2.5 5.0 9.4 4.7

0.00

0.0122000

0 7 1 1 1 8 5 0 0

1112 496 470 309 204 1117 2

2.4 1.9 1.9 1.8 1.9 1.8 1.8 1.9

0.00.011.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.11.00.1

0.000.7

0 10 10 0

125 454 459 459 333 182 126 126 14

E 0 0 1 0 4 C

0.012110

0.0 0.7 2.5 5.0 3.8 3.8

127 441 394 300 159 106 104

19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER

UNKNOWN

2.6

1.3

1.9

34

1834

3.2

1.8

1851

3.3

1.7

40

1641

TOTAL

consecutively and tested for HIV after all personal identifiers were removed.

(3) All positive specimen were repeatedly reactive by EliSA and confirmed by a Western blot assay.

(4) 95; Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on

(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks. (2) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening of individuals seeking evaluation, examination, and/or terathent for a NTH STD episode. Specimens were collected

(95% C.I.) (4)

PREVALENCE RATE (%)

NUMBER (3) POSITIVE

NUMBER

(95% C.I.) (4)

PREVALENCE RATE (%)

NUMBER (3) POSITIVE

NUMBER

(95% C.I.) (4)

PREVALENCE RATE (%)

NUMBER (3) POSITIVE

NUMBER

AGE-GROUP (YEARS)

SERO-

SERO-

SERO-

SURVEY

1994

SURVEY

1993

SURVEY

SER( PREVALI RATE	
ER (3)	

HIV SEROPREVALENCE FOR HETEROSEKUAL FEMALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY RACE/ETHNICITY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (2)

		1989	SURVEY			199	1990 SURVEY			1991	1 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER (3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)	NUMBER	NUMBER (3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)
WHITE AFRICAN AMERICAN LATINA ASTAN/PACIFIC ISLANDER NONE OF THE ABOVE (5)	145 184 61 40 8	0 0 0 0 0 0	0.7 1.6 0.0 0.0	0.0 - 3.8 0.3 - 4.7 0.0 - 4.8 0.0 - 7.2	171 263 101 53 8	011103	1.8 3.4 1.0 1.9 0.0	0.4 - 5.0 1.6 - 6.4 0.0 - 5.4 0.0 - 10.1	257 266 133 74 16	0 0 1 2 2	1.9 0.8 0.0	0.6 - 4.5 0.6 - 4.3 0.0 - 4.1 0.0 - 4.0
TOTAL	438	4	6.0	0.2 - 2.3	596	14	2.3	1.3 - 3.9	746	11	1.5	0.7 - 2.6
		1992	SURVEY			1993	3 SURVEY			1994	4 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER (3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)
WHITE ARRICAN AMERICAN LATINA ASTAN/PACIFIC ISLANDER NONE OF THE ABOVE (5)	245 214 150 72 14	00000	0.00	0.0 - 1.2 0.3 - 4.0 0.2 - 4.7 0.0 - 4.1	215 260 145 87 21		1.00.0.4.0.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1	0.3 - 4.0 0.0 - 2.1 0.2 - 4.9 0.0 - 6.2 0.1 - 23.8	205 251 153 86 22	m N H O O	1.5 0.0 0.0	0.3 - 4.2 0.1 - 2.8 0.0 - 3.6 0.0 - 3.4 0.0 - 12.7
TOTAL	969	rv.	7.0	0.2 - 1.7	728	ω	1.1	0.5 - 2.2	717	9	8.0	0.3 - 1.8
(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.  (2) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.  (3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (4) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 obsay.  (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.	with a sex pa l) surveys wer thon, examinat rr HIV after a were repeated s, exact bino rican Indian	rtner at risted drawn from the	hk for HIV and blood spectreatment fidentifiers by ELISA and dence Internative ance	at risk for HIV and heterosexuals with no other identified risks.  In from blood specimens collected for routine syphilis screening on mofor treatment for a NDM STD episode. Specimens were collected sonal identifiers were removed.  Cotto by ELISA and confirmed by a Western blot assay.  Confidence intervals not calculated for sample sizes under 20 observations. askan Native ancestry, other race, and unknown race.	s with no c for routir isode. Spe a Western b ated for sa	ther identiane syphilis scimens were lot assay.	fied risks. screening on collected under 20 obs	ervations.				

SEROPREVALENCE FOR HETEROSEXUAL FEWALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC YEAR OF SHRYEY, SAN FRANCISCO, 1989 - 1994 (2)

	1991 SURVEY	SERO- NUMBER NUMBER(3) PREVALENCE TESTED POSITIVE RATE (\$) (95% C.I.) (4)
	1990 SURVEY	SERO- NUMBER NUMBER(3) PREVALENCE TESTED POSITIVE RATE (\$) (95\$ C.I.) (4)
AND IEAN OF SURVEIT, SPA FRANCISCO, 1987 - 1977 (4)	1989 SURVEY	SERO- NUMBER (3) PREVALENCE TESTED POSITIVE RATE (\$) (95% C.I.) (4)

		_
0.		
GROUP,		
G.	-	

SURVEY	
1991	

1989 SURVEY	1990 SURVEY	1991 SURVEY

BY AGE-GR	SURVEY
Д ,	

	1991	1991 SURVEX
9	(c) dumant	SERO-

	SERO- REVALENCE DATE (\$) (06% C T )(4)
1 SURVEY	SERO- PREVALENCE RATE (*)
1991	NUMBER (3)

2.5 3.4 1.9 16.2 14.3

0.10 6.44 6.00

0 1 2 2 2 2 2 2 2

1116 258 258 160 86 42 48 48 32

0.3 - 8.0 0.0 - 2.8 0.5 - 6.3 1.4 - 12.5 1.5 - 19.1 0.1 - 19.0

0.00

2 4 6 6 6 0

88 194 137 79 43 27 27 24

8.1 - 4.6 - 5.4 - 7.4 - 13.9

m 0 0 0 0 0 0

0000000

87 1119 101 52 39 20 20 20

19 AND UNDER 20 - 24 25 - 29 .30 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN

5.6

0.7

1.5

Ħ

746

3.9

1.3

2.3

14

969

2,3

0.2

6.0

4

438

TOTAL

(95% C.I.) (4)

PREVALENCE RATE (%) SERO-

NUMBER (3) POSITIVE

NUMBER

(95% C.I.) (4)

PREVALENCE RATE (%)

NUMBER (3) POSITIVE

NUMBER

(95% C.I.) (4)

PREVALENCE RATE (%)

NUMBER (3) POSITIVE

NUMBER

AGE-GROUP (YEARS)

SERO-

SURVEY

1992

SERO-

SURVEY

1994

SURVEY

1993

6.9

HH00000

98 217 164 92 92 42 46 0

0.0 - 5.6 0.0 - 1.4 0.0 - 3.1 0.0 - 5.7 0.0 - 4.9 1.3 - 17.5 0.8 - 22.8

0.00

----

98 213 180 95 60 60 47 29

0.00 - 3.0 0.00 - 1.3.0 0.00 - 1.3.2 0.00 - 11.0 0.00 - 12.2

0.000.0000

0000000

97 1188 174 91 77 77 42 23

19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER

UNKNOWN

1.8

.

0.3

8.0

9

717

2.5

0.5

1:1

728

1.7

0.2

Ľ

595

TOTAL

(1) Includes heterosexuals with a sex partner at risk for hiv and nevelocexuass with a screening on C2) These untilnked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(4) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

HIV SEROPREVALENCE FOR INJECTION DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS BY GENDER AND SEXUAL ORIENTATION, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (1)

		1989	9 SURVEY			199	1990 SURVEY			1991	1 SURVEY	
GENDER AND SEXUAL ORIENTATION	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)
MALE.												
Gay/Bisexual Heterosexual Unknown Orientation	6 143 3	14 0	33.3 9.8 0.0	5.5 - 15.9	25 716	8 57 1	32.0 8.0 14.3	14.9 - 53.5 6.1 - 10.2	28 688 11	50 2	25.0 7.3 18.2	10.7 - 44.9 5.4 - 9.5
SUB-TOTAL MALE	152	16	10.5	6.1 - 16.5	748	99	8.8	6.9 - 11.1	727	29	8.1	6.2 - 10.3
FEMALE												
Lesbian/Bisexual Heterosexual Unknown Ozientation	73	0 & 0	0.0	4.9 - 20.5	376 2	0 2 2 0	10.0 5.9 0.0	3.7 - 8.7	14 376 0	23	0.0	3.9 - 9.0
SUB-TOTAL FEMALE	78	œ	10.3	4.5 - 19.2	398	24	0.9	3.9 - 8.8	390	23	5.9	3.8 - 8.7
MISSING GENDER	7	0	0.0	:	12	0	0.0	:	15	7	13.3	
TOTAL	237	24	10.1	6.6 - 14.7	1158	06	7.8	6.3 - 9.5	1132	84	7.4	6.0 - 9.1

⁽¹⁾ Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 1978. Excludes persons with a prior admission to treatment during the survey period, and persons who were preferentially admitted to treatment due to HIV/AIDS. Blood specimens were collected for syphilis screening as part of the admission requirements, and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) Sys Confidence Intervals, exact bloomial. Confidence Intervals not calculated for sample alzes under 20 observations.

[.] 

HIV SEROPREVALENCE FOR INVECTION DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS BY GENDER AND SEXUAL ORIENTATION, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (1)

		1992	2 SURVEY			1993	3 SURVEY			1994	4 SURVEY	
GENDER AND SEXUAL ORIENTATION	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER TESTED	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)
MALE												
Gay/Bisexual Heterosexual Unknown Orientation	26 849 40	8 E E	30.8 7.4 7.5	14.3 - 51.8 5.7 - 9.4 1.6 - 20.4	236	4 17 0	44.4	4.3 - 11.3	13 207 0	0 0 0 0	15.4 9.7	6.0 - 14.5
SUB-TOTAL MALE	915	74	8.1	6.4 - 10.0	246	21	8.5	5.4 - 12.8	220	22	10.0	6.4 - 14.7
FEMALE												
Lesbian/Bisexual Heterosexual Unknown Oxientation	21 432 5	0 8 2	6.0	1.2 - 30.4 4.0 - 8.7	130 130	2 111 0	15.4 8.5 0.0	4.3 - 14.6	12 150 0	15 0	16.7	5.7 - 16.0
SUB-TOTAL FEMALE MISSING GENDER	458	1 28	6.1 .	4.1 - 8.7	144	13	. 0.0	4.9 - 14.9	162	17	10.5	6.2 - 16.3
TOTAL	1387	103	7.4	6.1 - 8.9	391	34	8.7	6.1 - 11.9	383	39	10.2	7.3 - 13.7
(1) Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 1978. Excludes persons with a prior admission to treatment during the survey period, and persons who were preferentially admitted to treatment due to HIV/AIDS. Blood specimens were collected for syphilis screening as part of the admission requirements, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample stress under 20		treatment with to treatment to treatment to HIV/AIDMend tested for ly reactive mial. Confi	ho have a hit during the S. Blood sport HIV after by ELISA and dence Inter	treatment who have a history of injection drug use (IDU) since 1978.  To treatment during the survey period, and persons who were use to HIV/AIDS. Blood specimens were collected for syphilis screening and tested for HIV after all personal identifiers were removed.  ELY reactive by ELISA and confirmed by a Western blot assay.  Confidence Intervals not calculated for sample sizes under 20 observations	ion drug us and person llected for dentifiers a Western b	te (IDU) sin is who were syphilis s were remove llot assay.	ce 1978. creening d. under 20 obs	ervations.				

1989 SURVEY

1991 SURVEY

1990 SURVEY

(95% C.I.) (3)	- 5.1 - 25.1 - 11.8 - 10.1	0 - 9.1		(95% C.I.) (3)	3.5 - 10.1 12.7 - 31.5 4.7 - 25.2	7.3 - 13.7	
	2.2 15.2 2.4 0.0	6.0			3.5 12.7 4.7	7.3	
SERO- PREVALENCE RATE (%)	3.4 19.9 5.9 0.0	7.4	4 SURVEY	SERO- PREVALENCE RATE (%)	6.3 21.0 12.5 8.3 0.0	10.2	
NUMBER(2) POSITIVE	5 2 2 4 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	84	1994	NUMBER(2) POSITIVE	15 17 6 1 0	39	
NUMBER	699 267 118 28 20	1132		NUMBER TESTED	240 81 48 12 2	383	
(95% C.I.) (3)	2.1 - 4.9 16.3 - 26.6 2.1 - 10.4 3.9 - 31.7	6.3 - 9.5		(95% C.I.) (3)	5.0 - 11.9 7.2 - 23.5 0.7 - 18.7	6.1 - 11.9	rvations.
SERO- PREVALENCE RATE (%) (	3.3 21.1 5.2 13.8 6.3	7.8	1993 SURVEY	SERO- PREVALENCE RATE (%) (	8.0 13.9 5.6 0.0	8.7	nce 1978. screening ed. under 20 obse
NUMBER(2) POSITIVE	224 7 1	06	199	NUMBER(2) POSITIVE	21 2 0	34	e (IDU) sin s who were syphilis were remov lot assay. mple sizes own race.
NUMBER	722 256 135 29 16	1158		NUMBER	264 79 36 3	391	ion drug us and person llected for dentifiers a Western b ated for sa
(95% C.I.) (3)	1.2 - 8.0 13.2 - 35.5 6.3 - 38.1	6.6 - 14.7		(95% C.I.) (3)	2.8 - 5.4 13.9 - 22.9 4.0 - 13.7 0.0 - 25.8	6.1 - 8.9	treatment who have a history of injection drug use (IDU) since 1978.  to treatment during the survey period, and persons who were e to HIV/AIDS. Blood specimens were collected for syphilis screening and tessed for HIV after all personal identifiers were removed.  dly reactive by ELISA and confirmed by a Western blot assay.  confidence Thervals not calculated for sample sizes under 20 observations. and Alaskan Native ancestry, other race, and unknown race.
SERO- PREVALENCE RATE (%)	3.5 23.0 18.5 0.0	10.1	2 SURVEY	SERO- PREVALENCE RATE (%)	3.9 18.1 7.9 0.0	7.4	ho have a hi t during the S. Blood sp or HIV after by ELISA an idence Inter
NUMBER(2) POSITIVE	1 0 0 0	24	1992	NUMBER(2) POSITIVE	11.00 3.00	103	treatment w to treatmen to treatmen to HIV/AID and tested f illy reactive mial. Conf
NUMBER	142 61 27 5	237		NUMBER TESTED	889 299 139 29 31	1387	g methadone radmission reatment du ulrements, erre repeate, exact bing can Indian
RACE/ETHNICITY	WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL		RACE/ETHNICITY	WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL	(1) Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 1978. Schludes persons with a prior admission to treatment during the survey period, and persons who were preferentially admitted to treatment due to HIV/AIDS. Blood specimens were collected for syphilis screening as part of the admission requirements, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) SP\$ Confidence Intervals, exact binomial. Confidence Intervals are collected by the speciment of the states under 20 (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

	1991 SURVEY	SERO- NUMBER NUMBER(2) PREVALENCE TESTED POSITIVE RAYE (\$) (95% C.I.) (3)
	1990 SURVEY	SERO- NUMBER NUMBER(2) PREVALENCE TESTED POSITIVE RATE (\$) (95% C.I.)(3)
THE TOTAL CONTROL AND THE TOTAL CONTROL OF THE TOTA	1989 SURVEY	SERO- NUMBER (2) PREVALENCE TESTED POSITIVE RATE (\$) (95% C.I.) (3)

EY
SURVEY
SI

1 8	PRE
1991	NUMBER (2)
	NUMBER

- KATE (%) (95% C.1.) (3)
- 55 134 1183 307 261 155 30

- 0.0 5.3 2.11 10.5 3.4 11.2 5.6 12.2 6.0 13.4 7.11 13.1
- CATE (*) (95* C.I.) (3)

- 7.4 - 9.4 - 10.4 - 11.1

0.1.0.0

16.7 1.4 4.7 6.3 7.5 9.4 13.3

1 14 23 23 22 22 22 23

6 73 73 222 222 306 224 166 166

23.5 18.3 28.7 28.3

0.0 5.9 7.1 6.7 17.2

0 1 1 1 3 2 1 0 0

117 117 28 44 64 64 64 64 64

19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER

UNKNOMN

AND UNDER

. . . . . 6.0 4.6.9

- 19.4

- 12.2 - 20.0 - 18.2 - 23.8 - 22.0

3.5

0.0 8.3 7.5 114.1 13.5 0.0

0 0 4 4 11 4 6 0

0 23 23 48 48 78 83 83

- 28.0 - 19.6 - 25.6 - 10.8

1.9 8 0 1 1 . 9 . 9 . 1

0.0 8.7 16.7 5.1 5.6

0 7 7 23 56 96 96 90 2

12.3 12.5 12.5 10.2 11.7 14.3

4.00 23.1

0.0 3.6 6.8 6.8 7.0 10.1

230 28 30 28

6 56 133 175 357 277 22

19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER

UNKNOMN

. .

- 13.7

7.3

10.2

39

383

- 11.9

6.1

8.7

34

391

8.9

6,1

7.4

103

1387

TOTAL

All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

as part of the admission requirements, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repectedly reactive by BLISA and confirmed by a Western blot assay. (3) 95% confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes un

preferentially admitted to treatment due to HIV/AIDS. Blood specimens were collected for syphilis screening

(1) Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 1978. Excludes persons with a prior admission to treatment during the survey period, and persons who were

(95% C.I.) (3)

PREVALENCE RATE (%)

NUMBER (2) POSITIVE

> NUMBER TESTED

> > (95% C.I.) (3)

PREVALENCE RATE (%)

NUMBER (2)

POSITIVE

NUMBER

(95% C.I.) (3)

PREVALENCE RATE (%)

NUMBER (2)

NUMBER TESTED

AGE-GROUP (YEARS)

AND UNDER

POSITIVE

SERO-

SERO-

SERO-

SURVEY

1994

1993 SURVEY

SURVEY

1992

9.1

6.0

7.4

84

1132

9.5

6.3

7.8

90

1158

- 14.7

9.9

10.1

24

237

TOTAL

		IDUs	<b>5</b> 0			NON-	NON-IDUs	
GENDER AND SEXUAL ORIENTATION	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)
MALE								
Gay/Bisexual	118	37	31.4	4	39	20	51.3	,
Heterosexual Unknown Orientation	671 19	38	5.7	4.0 - 7.7	434	3	2.5 15.8	1.3 - 4.5
SUB-TOTAL MALE	808	12	9.5	7.6 - 11.8	492	34	6.9	4.8 - 9.5
FEMALE								
Leabian/Bisexual	9	1	1.7	0.0	31	o	0.0	0.0 - 9.2
Heterosexual	268	7	2.6		180	4	2.2	
Unknown Orientation	6	0	0.0	•	ហ	0	0.0	:
SUB-TOTAL FEMALE	337	60	2.4	1.0 - 4.6	216	4"	1.9	0.5 - 4.7
MISSING GENDER	0	0			0	0		
TOTAL	1145	85	7.4	6.0 - 9.1	708	38	5.4	3.8 - 7.3

Sample includes both injection drug users (IDUs) who have a history of needle use since 1978, and non-injection drug users Excludes persons with a prior admission to treatment during the survey period, persons who were preferentially admitted to treatment due to HIV/AIDS, and persons under alcohol treatment only. Blood specimens were collected for syphilis screenings as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment. (1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program.

HIV SEROPREVALENCE FOR INJECTION DRUG USERS (IDUS) AND NON-INJECTION DRUG USERS (NON-IDUS) ENTERING A DRUG-FREE DETOXIFICATION PROGRAM BY RACE/ETHNICITY, SAN FRANCISCO, 1990 - 1994 (1)

		IDUs	<u>o</u>			-NON	NON-IDUs	
RACE/ETHNICITY	NUMBER TESTED	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.) (3)	NUMBER	NUMBER (2) POSITIVE		SERO- PREVALENCE RATE (%) (95% C.I.)(3)
THE COLUMN	7.34	47	4	4.7 - 8.4	241	17	4	2.3 - 8.0
APRICAN AMERICAN	199	28	14.1	9.6 - 19.7	325	25	7.7	5.0 - 11.1
LATINO	138	9	4.3	1.6 - 9.2	77	-	1.3	0.0 - 7.0
ASIAN/PACIFIC ISLANDER	43	7	4.7	0.6 - 15.8	20	0	0.0	0.0 - 5.8
NONE OF THE ABOVE (4)	31	7	6.5	0.8 - 21.4	15	1	6.7	
					_			
TOTAL	1145	82	7.4	6.0 - 9.1	108	38	5.4	3.8 - 7.3

(1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Stample includes both injection drug users with the previous 12-months prior to admission to treatment. Who have a history of needle use a since 1979, and non-injection drug users who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment. Excludes persons with a prior admission to treatment the previous persons who were preferentially admitted to treatment due to HIV/AIDS, and persons under alcohol treatment only. Blood specimens were collected for syphilis excepting as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western bloc assay.
(3) 954 confidence Intervals not Confidence Intervals not calculated for sample sizes under 20 observations.
(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

		IDUs	o ₃			-NON	NON-IDUS	
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.) (3)	NUMBER	NUMBER(2) POSITIVE		SERO- PREVALENCE RATE (%) (95% C.I.) (3)
19 AND UNDER	17	0	0.0		7	0	0.0	
20 - 24	136	4	2.9	0.8 - 7.4	90	7	2.2	0.3 - 7.8
25 - 29	214	11	5,1	2.6 - 9.0	178	11	6.2	
30 - 34	217	20	9.5		155	13	8.4	4.5 - 13.9
35 - 39	256	18	7.0		134	4	3.0	0.8 - 7.5
40 - 44	195	18	9.5	5.6 - 14.2	97	9	6.2	2.3 - 13.0
45 AND OVER	104	14	13.5		44	7	4.5	0.6 - 15.5
MISSING	9	0	0.0		e.	0	0.0	:
TOTAL	1145	85	7.4	6.0 - 9.1	708	38	5.4	3.8 - 7.3

Sample includes both injection drug users (IDUs) who have a history of needle use since 1978, and non-injection drug users Excludes persons with a prior admission to treatment during the survey period, persons who were preferentially admitted to treatment due to HIV/AIDS, and persons under alcohol treatment only. Blood specimens were collected for syphilis screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed. (3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observation. who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment. (1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program.

HIV SEROPREVALENCE FOR INJECTION DRUG USERS (IDUs) AND NON-INJECTION DRUG USERS (NON-IDUS) ENTERING A DRUG-FREE DETOXIFICATION PROGRAM BY PRIMARY DRUG, SAN FRANCISCO, 1990 - 1994 (1)

		IDUs	o,			NON-	NON-IDUs	
PRIMARY DRUG	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	д	SERO- REVALENCE RATE (%) (95% C.I.)(3)
NIOGEN	782	96	3.7	2.5	79	۳	3.8	7 01 - 8 0
COCATNE/CRACK	47	4	8 .5	2.4 - 20.4	425	23	5.4	3.5 - 8.0
HEROIN AND COCAINE (SPEEDBALL	52	7	13.5	5.6 - 25.8	0	0		
BARBITURATES	0	0			m	0	0.0	
AMPHETAMINES/SPEED	113	24	21.2	14.1 - 29.9	22	80	36.4	17.2 - 59.3
OTHER OR UNSPECIFIED DRUGS	151	21	13.9	8.8 - 20.5	179	4	2.2	0.6 - 5.6
TOTAL.	1145	er er	4.7	6.0 - 9.1	708	. 86	4	7.8 - 7.3
			•			}		

 This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program.
 Sample includes both injection drug users (IDUs) who have a history of needle use since 1978, and non-injection drug users Excludes persons with a prior admission to treatment during the survey period, persons who were preferentially admitted to treatment the to HIV/AIDS, and persons under alcohol treatment only. Blood specimens were collected for syphilis screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment.

		198	1989 SURVEY			199	1990 SURVEY			199	1991 SURVEY	
TRANSMISSION CATEGORY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (*) (95* C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
Heterosexual IDU (4) Sex Partner at Risk for HIV Blood Recibien: (5)	000	000			20 24 11	100	5.00	0.13 -24.87 0.00 -11.73	11	H 0 0	11.11 0.00 0.00	
Heterosexual (6) Unknown Risk (7)	1266	0 4	0.32	0.09 - 0.81	1313	10	0.08	0.00 - 0.42	1925	0 0	0.10	0.01 - 0.37
TOTAL	1266	4	0.32	0.09 - 0.81	1376	2	0.15	0.02 - 0.52	1957	3	0.15	0.03 - 0.45
		00.	Varianto coor									

	SERO- REVALENCE RATE (%) (95% C.I.)(3)	0.00 - 0.43
1992 SURVEY	SERO- PREVALENCE RATE (%)	0.00
199	NUMBER(2) POSITIVE	00000
	NUMBER	4 0 0 1293 0 1297
	TRANSMISSION CATEGORY	Heterosexual IDU (4) Sex Partner at Risk for HIV Blood Recipient (5) Heterosexual (6) Unknown Risk (7) TOTAL

This unlinked (blinded) survey was drawn from women seeking family planning services. Specimens were collected from initial and annual visites, and tested for HIV after all personal identifiers were removed.
 All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 St Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

Includes persons with a history of injection drug use (IDU) since January 1978.

Includes persons with a history of blood transfusions(s) between January 1977 and March 1985.

Self-identified heterosexuals with no other identified risks.

The 1989 unlinked survey did not collect risk information

⁽⁶⁾ 

HIV SEROPREVALENCE FOR MOMEN ATTENDING A FAMILY PLANNING CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1992 (1)

		1989	9 SURVEY			199	1990 SURVEY			1991	1 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.) (3)
WHITE	122	1	0.82	0.02 - 4.48	126	1	0.79	0.02 - 4.34	156	0	00.00	0.00 - 1.90
AFRICAN AMERICAN	154	н	0.65	0.02 - 3.56	145	0	00.00	0.00 - 2.04	141	н	0.71	0.02 - 3.89
LATINA	810	7	0.25	0.03 - 0.89	908	0	00.0	0.00 - 0.33	1441	7	0.14	0.02 - 0.50
ASIAN/PACIFIC ISLANDER	149	0	00.0	0.00 - 1.99	166	-	09.0	0.02 - 3.31	178	0	00.0	0.00 - 1.67
NONE OF THE ABOVE (4)	31	0	00.00	0.00 - 9.21	31	0	00.00	0.00 - 9.21	41	0	0.00	0.00 - 7.05
TOTAL	1266	4	0.32	0.09 - 0.81	1376	2	0.15	0.02 - 0.52	1957	е	0.15	0.03 - 0.45
						•						
					1							

	RACE/ETHNICITY	WHITE ARECAN AMERICAN LATINA ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)
	NUMBER	82 1001 1001 15
. 199	NUMBER(2) POSITIVE	00400
1992 SURVEY	SERO- PREVALENCE RATE (%)	0.00 0.10 0.00 0.00
	(95% C.	000.0

(I.) (3)

3.59 2.81 0.56 3.14

0.00 - 0.43

0.08

ч

1297

TOTAL

This unlinked (blinded) survey was drawn from women seeking family planning services. Specimens were collected from initial and annual visits, and tested for HIV after all personal identifiers were removed.
 All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 S5% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.
 Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

		1989	9 SURVEY			1990	0 SURVEY			1991	1 SURVEY	
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (\$) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (\$) (95% C.I.)(3)
19 AND UNDER	73	0	0.00	0.00 - 4.02	93	0	0.00		107	0	0.00	0.00 - 2.76
20 - 24	420	1	0.24	0.01 - 1.32	474	0	00.00	0.00 - 0.63	636	0	00.0	0.00 - 0.47
25 - 29	414	1	0.24	0.01 - 1.34	401	0	0.00		646	2	0.31	0.04 - 1.11
30 - 34	226	2	0.88	0.11 - 3.16	243	1	0.41		334	0	00.0	0.00 - 0.89
35 - 39	105	0	0.00	0.00 - 2.81	6	0	00.0		175	1	0.57	0.01 - 3.14
40 - 44	18	0	0.00		34	1	2.94	0.07 -15.33	42	0	00.0	0.00 - 6.88
45 AND OVER	7	0	0.00		80	0	00.0		9	0	0.00	
UNKNOWN	м	0	0.00		56	0	0.00	0.00 -10.88	ដ	0	0.00	
TOTAL	1366	4	22	0 0 0	1376		21.0	0 0 - 0 52	1957		21.0	0 03 - 0 45
	2004									,		

	(95% C.I.) (3)		0.00 - 0.77	0.01 - 1.30		0.00 - 2.15	0.00 - 6.44		:		0.00 - 0.43
2 SURVEY	SERO- PREVALENCE RATE (%)	00.00	00.00	0.23	00.00	0.00	0.00	0.00	0.00		0.08
1992	NUMBER(2) POSITIVE	0	0	1	0	0	0	0	0		н
	NUMBER TESTED	09	390	427	223	138	45	00	9		1297
	AGE-GROUP (YEARS)	19 AND UNDER	20 - 24	25 - 29	-1	35 - 39	40 - 44	45 AND OVER	UNKNOWN		TOTAL

⁽¹⁾ This unlinked (blinded) survey was drawn from women seeking family planning services. Specimens were collected from initial and annual visits, and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 55% Confidence Intervals, exact bloomial. Confidence Intervals not calculated for sample sizes under 20 observations.

²¹ 

HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY TRANSMISSION CATEGORY AND YEAR OF SURVEY, SAN FRANCISCO, 1990 - 1992 (1)

	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	0.22 - 1.59	0.56 - 2.29
2 SURVEY	SERO- PREVALENCE RATE (%)	14.29 60.00 0.68	1.21
1992	NUMBER(2) POSITIVE	1 W IG O	n
	NUMBER	7 5 730	742
	SERO- PREVALENCE RAIE (%) (95% C.I.)(3)	0.13 - 1.25	0.49 - 2.01
1 SURVEY	SERO- PREVALENCE RATE (%)	35.71 0.00 0.49 0.00	1.06
1991	NUMBER(2) POSITIVE	rv 🗢 44 🗢	ъ. Г
	NUMBER	14 7 817 8	846
	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	0.06 - 1.71	0.14 - 2.02
1990 SURVEY	SERO- PREVALENCE RATE (%)	12.50 0.00 0.48 0.00	0.70
199	NUMBER (2) POSITIVE	0 0 0 0 1	m
	NUMBER	8 3 419 1	431
	TRANSMISSION CATEGORY	Heterosexual IDU (4) Sex Partner at Risk for HIV Heterosexual (5) Unknown Risk	TOTAL

(1) This unlinked (blinded) survey was drawn from women seeking induced abortions. Specimens were collected for evaluation purposes, and tested for HIV after all presonal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (3) 45% Lichardespersons with a Mischor of injection frug use (IDD) since January 1978.

		1990	O SURVEY			1991	1 SURVEY			1992	2 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (*) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (*) (95* C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.) (3)
WHITE	20	1	2.00	0.05 -10.65	11	м	4.23	0.88 -11.86	20	8	4.00	0.49 -13.71
AFRICAN AMERICAN	106	7	1.89	0.23 - 6.65	206	e	1.46	0.30 - 4.20	172	9	3.49	1.29 - 7.44
LATINA	223	0	00.0	0.00 - 1.33	437	e	69.0	0.14 - 1.99	393	0	00.0	0.00 - 0.76
ASIAN/PACIFIC ISLANDER	45	0	00.0	0.00 - 6.44	107	0	00.00	0.00 - 2.76	108	0	00.0	0.00 - 2.74
NONE OF THE ABOVE (4)		0	00.00		25	0	00.0	0.00 -11.29	19	н	5.26	:
TOTAL	431	E	0.70	0.14 - 2.02	846		1.06	0.49 - 2.01	742	6	1.21	0.56 - 2.29

⁽¹⁾ This unlinked (blinded) survey was drawn from women seeking induced abortions. Specimens were collected for evaluation purposes, and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 55% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1990 - 1992 (1)

		1990	0 SURVEY			1991	1 SURVEY			1992	2 SURVEY	
AGE-GROUP (YEARS)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (*) (95% C.I.) (3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.) (3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.) (3)
19 AND UNDER	89	0	0.00	0.00 - 4.31	133	п	0.75	0.02 - 4.12	112	0	0.00	0.00 - 2.64
20 - 24	139	Н	0.72	0.02 - 3.94	253	7	0.79	0.10 - 2.83	189	7	1.06	0.13 - 3.77
25 - 29	106	0	00.00	0.00 - 2.79	223	4	1.79	0.49 - 4.53	202	m	1.49	0.31 - 4.28
30 - 34	80	7	2.50	0.30 - 8.74	118	-	0.85	0.02 - 4.63	131	-	0.76	0.02 - 4.18
35 - 39	26	0	0.00	0.00 -10.88	98	-	1.16	0.03 - 6.31	81	63	2.47	0.30 - 8.64
40 - 44	8	0	00.00		27	0	0.00	0.00 -10.50	23	0	0.00	0.00 -12.21
45 AND OVER	0	0			•	0	٠		-	0	00.0	
UNKNOWN	4	0	0.00		9	0	00.00		m 	1	33.33	:
TOTAL	431	е	0.70	0.14 - 2.02	846	6	1.06	0.49 - 2.01	742	6	1.21	0.56 - 2.29

(1) This unlinked (blinded) survey was drawn from women seeking induced abortions. Specimens were collected for evaluation purposes, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 55% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

HIV SEROPREVALENCE FOR NEWBORN INFANTS AND THEIR MOTHERS BY AGE GROUP AND RACE/ETHNICITY, 1989-1993 (1)

1991 SURVEY	SERO- NUMBER NUMBER(2) PREVALENCE TESTED POSITIVE RATE (*) (95* C.I.)(3)		1 0.49 0.01 -	- 00.0 0.00 0	4 0.61 0.17 -	2 0.29 0.03 -	429 1 0.23 0.01 - 1.29	1 1.39 0.04 -				- 21 0 63 0 17	217 3 0 95 0 20 218	031.0	- 00.0 9T.0 T	- 00.0 0.00 0	- 00.0 0.00 0	1 1.04 0.03 -		2509 9 0.36 0.16 - 0.68		22103 31 0.14 0.10 - 0.20	154918 124 0.08 0.07 - 0.10		
1	(95% C.I.) (3)		0.00 - 1.64	0.00 - 0.67	0.00 - 0.90	0.00 - 0.89	99.0 - 00.0	0.00 - 2.53	_		_	0000	20:00 - 00:00	10.0	0.00 - 0.91	٠	0.00 - 2.57	0.00 - 3.10	•	0.01 - 0.30	_	0.07 - 0.16	0.06 - 0.09	_	
1990 SURVEY	SERO- PREVALENCE RATE (%)		0.00	00.0	0.16	0.16	00.0	0.00				7			0.10	0.00	0.00	00.00		0.08		0.11	0.07		
199	NUMBER(2) POSITIVE		0	0	7	7	0	0				٢	4 C	,	٠,	0	0	0		7		23	106		
	NUMBER		181	446	618	625	451	117				633	324	1 0	909	633	115	95		2438		21397	150494		
	(95% C.I.) (3)		0.01 - 2.52	٠	•	•	ı	0.02 - 3.97		_		77 0	75.0 - 10.0		•	١	0.01 - 2.67	0.02 - 4.28		0.04 - 0.40	_	0.08 - 0.17	0.05 - 0.08		
SURVEY	SERO- PREVALENCE RATE (%)		0.46	0.45	0.00	0.00	0.00	0.72				0	0.0	000	8T.0	0.00	0.49	0.78		0.16		0.12	90.0		
1989	NUMBER(2) POSITIVE		1	7	0	0	0	-				c	۰,	٠.	٦.	0	-	г		4		25	92		
	NUMBER		219	442	638	625	485	138				923	224	100	264	636	206	128		2547		21217	144284		
		AGE-GROUP (YEARS)	UNDER 20	20 - 24	25 - 29	30 - 34	35 AND OVER	UNKNOWN			RACE/ETHNICITY		APPLOAN AMEDICAN	AFRICAN AMERICAN	LATINO	ASIAN/PACIFIC IS.	OTHER ,	UNKNOWN		TOTAL - SAN FRANCISCO		TOTAL - BAY AREA (4)	TOTAL - STATEWIDE		

⁽¹⁾ Data courtesy of the California Department of Health Services Office of AIDS. Specimens from this survey of meborn infants (and women giving birth) are drawn from the genetic diseases screening program. Antibodies in a newborn infant reflect the infection status of the mother and not necessarily of the child.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Nestern blot assay.

(3) 594 Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes the counties of Alameda, Contra Costa, Marin, San Francisco, San Mateo, and Santa Clara.

²⁵ 

HIV SEROPREVALENCE FOR NEWBORN INFANTS AND THEIR MOTHERS BY AGE GROUP AND RACE/ETHNICITY, 1989-1993(1)

	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)
AGE-GROUP (YEARS)								
UNDER 20	165	0	0.00	0.00 - 1.80	170	1	0.59	- 1
20 - 24	428	0	00.00	0.00 - 0.70	446	0	0.00	0.00 - 0.67
25 - 29	639	7	0.31	0.04 - 1.13	662	-1	0.15	
30 - 34	628	7	0.32	1	677	7	0.30	1
35 AND OVER	446	-	0.22	•	466	п	0.21	
UNKNOWN	136	0	0.00	0.00 - 2.18	14	0	00.0	
RACE/ETHNICITY								
The state of the s	242	ć	6	97 0	717	٠, ,	000	
HILE	010	، د	8.		17.	۷,	0.50	
AFRICAN AMERICAN	312	n c	00.0	0.52 - 3.70	310	7 C	0.32	0.01 - 1.75
ASTAN/PACTETC TS	299		00.00	- 1	199	10	00.00	- 1
OTHER	135	0	0.00	- 1	148	0	0.00	- 1
JINKNOMN	77	0.	00.0	0.00 - 3.82	m	0	00.00	
TOTAL - SAN FRANCISCO	2442	ហ	0.20	0.07 - 0.48	2435	ĸ	0.21	0.07 - 0.48
TOTAL - BAY AREA (4)	21565	31	0.14	0.10 - 0.20	21601	16	0.07	0.04 - 0.12
TOTAL - STATEWIDE	151033	101	0.07	0.05 - 0.08	150598	83	90.0	0.04 - 0.07

Data courtesy of the California Department of Health Services Office of AIDS. Specimens from this survey of
hebborn infants (and women giving birth) are drawn from the genetic diseases screening program. Antibodies
in a newborn infant reflect the infection status of the mother and not necessarily of the child.
 All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 S\$4 Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.
 Includes the counties of Alameda, Contra Costa, Marin, San Francisco, San Mateo, and Santa Clara.

(95% C.I.) (3)		- 1	56.5 - 89.7	- 1		22.0 - 31.7			0.0 - 6.5		1.5 - 10.1	
SERO- PREVALENCE RATE (%)		74.2	75.9	6.1	12.5	26.6		25.0	1.2	0.0	4.5	
NUMBER(2) POSITIVE		46	22	12	7	88		4	7	0	ļ ⁵	
NUMBER		62	29	196	16	334		16	83	13	112	
GENDER AND TRANSMISSION CATEGORY	MALE	Gay/Bisexual	Gay/Bisexual, IDU (4)	Heterosexual (5)		SUB-TOTAL MALE	FEMALE	Heterosexual IDU	Heterosexual (5)	Unknown Risk	SUB-TOTAL FEMALE	

⁽¹⁾ This interview based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and TB suspects (class 5). Bata collected between the late quarter of 1989 and the 4th quarter of 1992.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons with a history of injection drug use (IDU) since January 1978.

(5) Includes persons with a sexual partner(s) at risk for HIV, persons with a history of blood transfusion(s) or with a bleeding disorder, and self-identified heterosexuals with no other identified risks.

17.4 - 25.2

21.1

94

446

TOTAL

HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A MUNICIPAL TB CLINIC BY ORIGIN OF BIRTH, SAN FRANCISCO, 1989 - 1992 (1)

SERO- PREVALENCE RATE (%) (95% C.I.)(3)	29.6 - 42.4 2.9 - 9.5	17.4 - 25.2
SERO- PREVALENCE RATE (%)	35.8 5.5	21.1
NUMBER(2) POSITIVE	82 12	94
NUMBER	229	446
ORIGIN OF BIRTH	BORN IN USA BORN OUTSIDE USA	TOTAL

This interview based survey of risk behaviors includes persons with newly disgnosed tuberculosis (TB) (class 3) and TB suspects (class 5). Data collected between the last quarter of 1989 and the 4th quarter of 1992.
 All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 Seconfidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

RACE/ETHNICITY WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)
-------------------------------------------------------------------------------------------

(1) This interview based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and TB suspects (class 5). Data collected between the 1st quarter of 1989 and the 4th quarter of 1992.

(3) All positive specianes were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 55% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A MUNICIPAL TB CLINIC BY AGE-GROUP, SAN FRANCISCO, 1989 - 1992 (1)

k C.I.) (3)	16.4 - 36.8 18.5 - 34.3 21.2 - 39.2 2.8 - 12.4	17.4 - 25.2
SERO- PREVALENCE RATE (%) (95% C.I.)(3)	11.1 25.6 25.8 29.6 6.5 29.6 6.5	21.1 17.
NUMBER(2) POSITIVE	20 33 32 8 8	94
NUMBER TESTED	9 78 128 108 123	446
AGE-GROUP (YEARS)	19 AND UNDER 20 - 29 30 - 39 40 - 49 50 AND OVER UNKROWN	TOTAL

(1) This interview based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and TB suspects (class 5). Data collected between the 1st quarter of 1989 and the 4th quarter of 1992.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 59% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(95% C.I.) (3)		0.0 - 12.7 0.1 - 0.6	0.1 - 0.6		0.1 - 1.7	0.1 - 1.6		0.1 - 0.7
SERO- PREVALENCE RATE (%)		5.0 0.0	0.0		0.00	9.0	0.0	0.3
NUMBER(2) POSITIVE		404	0   5		0 # 0	m	0	ω
NUMBER		19 22 1812	19		17 507 5	529	v	2407
GENDER AND TRANSMISSION CATEGORY	MALE	Gay/Bisexual Heterosexual, IDU (4) Heterosexual (5)	Unknown Risk SUB-TOTAL MALE	FEMALE	Heterosexual IDU (4) Heterosexual (5) Unknown Risk	SUB-TOTAL FEMALE	MISSING GENDER	TOTAL

⁽¹⁾ This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood specimens were collected for syphilis screening on immetes as part of the routine intake process. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.
(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
(3) 55% Confidence Intervals, exact binomial, Confidence Intervals not calculated for sample sizes under 20 observations.
(4) Includes persons with a history of injection durg use (IDU) since January 1978.

HIV SEROPREVALENCE FOR ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER BY RACE/ETHNICITY, SAN FRANCISCO, 1990 - 1994 (1)

SERO- REVALENCE RATE (%) (95% C.I.)(3)	0.0 - 1.5 0.2 - 1.1 0.0 - 0.9 0.0 - 1.7	0.1 - 0.7
SERO- PREVALENCE RATE (%)	0.000	0.3
NUMBER(2) POSITIVE	0 4 4 0	80
NUMBER TESTED	204 1231 597 319 56	2407
RACE/ETHNICITY	WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL

(1) This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood specimens were collected for spphilists excending on immetes as part of the routine intake process. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.

(3) 595 Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons of American Indian and Alaskan Native ancestry, other zace, and unknown race.

* C.I.) (3)	0.0 - 1.3 0.1 - 0.7 	0.1 - 0.7
SERO- PREVALIGNCE RATE (%) (95% C.I.)(3)	0.00	0.3 0
NUMBER(2) POSITIVE	47000	<b>6</b> 0
NUMBER TESTED	443 1927 4 3 3	2407
AGE-GROUP (YEARS)	UNDER 15 15 - 19 20 - 24 25 - 29 UNKNOWN	TOTAL

(1) This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood specimens were collected for syphils screening on innates as part of the routine intake process. Specimens were collected consecutively and tested for HIV after all personal identifiars were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

HIV SEROPREVALENCE FOR ADOLESCENTS ENTERING HOMELESS YOUTH CENTERS BY GENDER AND TRANSMISSION CATEGORY, SAN FRANCISCO, 1990 - 1994 (1)

GENDER AND TRANSMISSION CATEGORY	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	
MALE					
Gay/Bi sexual	369	165	44.7	39.6 - 49.9	
•	78	8 '	2.6	ı	
Heterosexual (5)	590	۰, م	1.0	0.4 - 2.3	
Unknown Risk	23	ij	£. 4.	ı	
SUB-TOTAL MALE	1060	174	16.4	14.3 - 18.8	
FEMALE					
Heterosexual IDU (4)	170	7	4.1	1.8 - 8.6	
Heterosexual (5)	1320	11	8.0	1	
Unknown Risk	32	0	0.0	0.0 - 10.5	
SUB-TOTAL FEMALE	1522	18	1.2	0.7 - 1.9	
MISSING GENDER	10	7	20.0	3.5 - 55.8	
TOTAL	2592	194	7.5	6.5 - 8.6	

This unlinked (blinded) survey includes adolescents seeking services at two homeless youth shelters. Blood specimens were collected for spythils screening as part of the routine medical evaluation. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed to seek the second of the second secular second secon

	n	
SERO- REVALENCE RATE (*) (95* C.I.)(3)	9.8 - 13.8 2.6 - 6.1 3.6 - 7.3 2.3 - 7.7 2.3 - 12.5	6.5 - 8.6
SERO- PREVALENCE RATE (%)	111.7 4.0 5.2 6.3 5.7	7.5
NUMBER(2) POSITIVE	122 23 32 11 6	194
NUMBER	1044 570 616 257 105	2592
RACE/ETHNICITY	WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL

(1) This unlinked (blinded) survey includes adolescents seeking services at two homeless youth shelters. Blood specimens were collected for sphilis servening as part of the routine medical evaluation. Specimens were collected cor sphilis servening as part of the routine medical evaluation. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

HIV SEROPREVALENCE FOR ADOLESCENTS ENTERING HOMBLESS YOUTH CENTERS BY AGE-GROUP, SAN FRANCISCO, 1990 - 1994 (1)

SERO- REVALENCE RATE (%) (95% C.I.)(3)	0.1 - 2.9 2.4 - 4.1 27.0 - 36.1 1.1 - 70.1 1.3 - 25.8	6.5 - 8.6
SERO- PREVALENCE RATE (%)	0.7 3.1 31.4 20.0 7.4	7.5
NUMBER(2) POSITIVE	2 130 1	194
NUMBER	272 1874 414 5	2592
AGE-GROUP (YEARS)	UNDER 15 15 - 19 20 - 24 25 - 29 UNKNOWN	TOTAL

(1) This unlinked (blinded) survey includes adolescents seeking services at two homeless youth shelters. Blood specimens were collected for syphilis screening as part of the routine medical evaluation. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENDER AND YEAR, 1985 - 1993 (1)

1989	N(2) HIV+(3) %(4)	711 2 0.28 124 1 0.81	835 3 0.36		TOTAL	N(2) HIV+(3) \$ (4)	5054 21 0.42 1010 2 0.20	6064 23 0.38	
1988	N(2) HIV+(3) \$(4)	759 2 0.26 178 0 0.00	937 2 0.21	-	1993	N(2) HIV+(3) %(4)	319 0 0.00 73 0 0.00	392 0 0.00	
1987	N(2) HIV+(3) \$(4)	869 5 0.58 143 0 0.00	1012 5 0.49		1992	N(2) HIV+(3) \$(4)	315 1 0.32 86 0 0.00	401 1 0.25	
1986	N(2) HIV+(3) &(4)	941 9 0.96 183 1 0.55	1124 10 0.89		1991	N(2) HIV+(3) \$ (4)	407 2 0.49 73 0 0.00	480 2 0.42	
1985	N(2) HIV+(3) \$ (4)	213 0 0.00 45 0 0.00	258 0 0.00		1990	N(2) HIV+(3) \$(4)	520 0 0.00 105 0 0.00	625 0 0.00	
	GENDER	MALE FEMALE	TOTAL			GENDER .	MALE FEMALE	TOTAL	

Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC). Data Collected between October 1995 and December 1993.
 Number of specimens tested.
 All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 Seroprevalence rate (%).

HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY RACE AND ETHNICITY AND YEAR, 1985 - 1993 (1)

1989	N(2) HIV+(3) %(4)	286 1 0.35 178 1 0.56 102 1 0.98 253 0 0.00 16 0 0.00	835 3 0.36	TOTAL	N(2) HIV+(3) %(4)	2114 13 0.61 1120 7 0.63 668 2 0.30 1950 0 0.00 212 1 0.47	6064 23 0.38	
1988	N(2) HIV+(3) %(4)	334 1 0.30 193 1 0.52 115 0 0.00 267 0 0.00 28 0 0.00	937 2 0.21	1993	N(2) HIV+(3) %(4)	141 0 0.00 43 0 0.00 63 0 0.00 133 0 0.00 12 0 0.00	392 0 0.00	
1987	N(2) HIV+(3) %(4)	346 2 0.58 212 3 1.42 108 0 0.00 320 0 0.00 26 0 0.00	1012 5 0.49	1992	N(2) HIV+(3) %(4)	134 0 0.00 53 0 0.00 49 1 2.04 158 0 0.00 7 0 0.00	401 1 0.25	
1986	N(2) HIV+(3) %(4)	409 7 1.71 242 2 0.83 74 0 0.00 329 0 0.00 70 1 1.43	1124 10 0.89	1991	N(2) HIV+(3) %(4)	160 2 1.25 63 0 0.00 68 0 0.00 173 0 0.00 16 0 0.00	480 2 0.42	
1985	RACE/ETHNICITY N(2) HIV+(3) %(4)	MHITE 94 0 0.00 BLACK 51 0 0.00 LATINO 11 0 0.00 ASTAN/P.I. 85 0 0.00 OTHER 17 0 0.00	TOTAL 258 0 0.00	1990	RACE/ETHNICITY N(2) HIV+(3) %(4)	MHITE 210 0 0.00 BLACK 85 0 0.00 IATINO 78 0 0.00 ASTAN/P.I. 232 0 0.00 OTHER 20 0.00	TOTAL 625 0 0.00	

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC). Data Collected between October 1985 and December 1993.

(2) Number of specimens tested.

(3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(4) Seroprevalence rate (§).

HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY AGE-GROUP AND YEAR, 1985 - 1993 (1)

	\$ (4)	0.00 0.47 1.18 0.00	0.36		\$ (4)	0.11 0.26 0.84 0.92	0.38	
1989	N(2) HIV+(3) %(4)	00510	е	TOTAL	N(2) HIV+(3) %(4)	W 4 0 1 0	23	
	N(2)	352 211 170 102 0	835		N(2)	2726 1512 1069 757 0	6064	between
	\$ (4)	0.24 0.00 0.61 0.00	0.21		\$ (4)	00.00	0.00	ollected
1988	N(2) HIV+(3) %(4)	10100	8	1993	N(2) HIV+(3) %(4)	00000	0	Data C
	N(2)	417 236 163 121 0	937		N(2)	176 103 69 44 0	392	(cpc)
	\$ (4)	0.00 0.38 0.60 2.26	0.49		\$ (4)	0.00 0.00 1.54 0.00	0.25	e Control
1987	N(2) HIV+(3) %(4)	0 3 1 1 0	ហ	1992	N(2) HIV+(3) %(4)	00100	1	Diseas
	N(2) H	448 265 166 133	1012		N(2) H	192 100 65 44	401	ters for
	\$ (4)	0.21 0.70 1.47 2.67	0.89		\$ (4)	0.44	0.42	d the Cen
1986	N(2) HIV+(3) %(4)	10 6 4 0	10	1991	N(2) HIV+(3) \$ (4)	10100	2	ise, and
	N(2) H	485 285 204 150	1124		N(2) H	227 110 76 67 0	480	of Defer
	\$ (4)	0.00	0.00		\$ (4)	00.00	00.0	partment
1985	N(2) HIV+(3) %(4)	00000	0	1990	N(2) HIV+(3) \$(4)	00000	0	U.S. De
	N(2) H	129 48 45 36	258		N(2) H	300 154 111 60 0	625	by the
	AGE-GROUP	19 AND UNDER 20 - 24 25 - 29 33 AND OVER UNKNOWN	TOTAL		AGE-GROUP	19 AND UNDER 20 - 24 25 - 29 30 AND OVER UNKNOWN	TOTAL	l) Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC). Data Collected between

 ⁽¹⁾ Data provided by the U.S. Department of Defense, and the centers tot busease context (2000) occober 1983 and December 1993.
 (2) Number of specimens tested.
 (3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 (4) Seroprevalence rate (*).

HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY YEAR OF DONATION, MARCH 1985 - DECEMBER 1993 (1)

Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca.
 All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 95% Confidence Intervals, normal approximation.

(95% C.I.) (3)	0.020 - 0.074 0.003 - 0.037	0.001 - 0.010 0.000 - 0.008	0.005 - 0.012
SERO- PREVALENCE RATE (%)	0.039	0.003	0.008
NUMBER(2) POSITIVE	10	вн	17
TOTAL	25753 25687	93509	225915
GENDER	Male Female	Male Female	
DONATION	FIRST-TIME DONORS	REPEAT	TOTAL

(1) Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca.
(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
(3) 95% Confidence Intervals, normal approximation.


HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY RACE/ETHNICITY, JANUARY 1991 - DECEMBER 1993 (1)

RACE/STHNICITY	TOTAL	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)
	730301	5	200	010 0 - 600 0
ARTICAN AMERICAN	9420	, un	0.053	0.020 - 0.132
ASTAN/PACTETC ISLANDER	16450	0	0.000	0.000 - 0.022
NONE OF THE ABOVE (4)	13178	73	0.015	0.003 - 0.061
	225915	17	0.008	0.005 - 0.012

Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca.
 Il positive specimens were repeatedly reactive by BLISA and confirmed by a Western blot assay.
 St Confidence Intervals, normal approximation.
 Includes Latinos, American Indians, Alaskan Natives, other race, and unknown race.

I.) (3)	0.024 0.027 0.033 0.007	0.012
(95% C.I.) (3)	0.000 - 0.024 0.003 - 0.027 0.009 - 0.033 0.000 - 0.007	0.005 - 0.012
SERO- PREVALENCE RATE (%)	0.000 0.010 0.018 0.002	0.008
NUMBER(2) POSITIVE	0 4 111 2	17
TOTAL	14941 40240 61325 109409	225915
AGE-GROUP (YEARS)	19 AND UNDER 20 - 29 30 - 39 40 AND OVER	TOTAL

Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca.
 All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 95% Confidence Intervals, normal approximation.



P70 #58 Nov 1995

Nov 1995

HIV Seroprevalence Report

DOCUMENTS DEPT.

DEC 1 5 1995

SAN FRANCISCO PUBLIC LIBRARY

San Francisco Department of Public Health AIDS Office November, 1995 Volume 6, No. 2

## Contents

	Page
SURVEY OF CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC: 1989-94	
HIV Seroprevalence for Clients Attending a STD Clinic by Gender and Transmission Category HIV Seroprevalence for Clients Attending a STD Clinic by Race/Ethnicity HIV Seroprevalence for Clients Attending a STD Clinic by Age Group HIV Seroprevalence for Gay & Bisexual Men Attending a STD Clinic by Race/Ethnicity HIV Seroprevalence for Gay & Bisexual Men Attending a STD Clinic by Age Group HIV Seroprevalence for Heterosexual Males Attending a STD Clinic by Race/Ethnicity HIV Seroprevalence for Heterosexual Males Attending a STD Clinic by Age Group HIV Seroprevalence for Heterosexual Females Attending a STD Clinic by Race/Ethnicity HIV Seroprevalence for Heterosexual Females Attending a STD Clinic by Race/Ethnicity HIV Seroprevalence for Heterosexual Females Attending a STD Clinic by Age Group	1 3 4 5 6 7 8 9
SURVEY OF INJECTION DRUG USERS (IDUs) ENTERING METHADONE TREATMENT PROGRAMS	
HIV Seroprevalence for IDUs Entering Methadone Treatment by Gender & Sexual Orientation HIV Seroprevalence for IDUs Entering Methadone Treatment by Race/Ethnicity HIV Seroprevalence for IDUs Entering Methadone Treatment by Age Group	11 13 14
SURVEY OF DRUG USERS (IDUs & NON-IDUs) ENTERING A METHADONE-FREE DETOX PROGRAM	ĺ
HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Gender & Sexual Orientati	ion 15
HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Race/Ethnicity HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Age Group HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Primary Drug SURVEY OF WOMEN OF REPRODUCTIVE AGE: FAMILY PLANNING & ABORTION CLINIC CLIENTS	16 17 18
HIV Seroprevalence for Women Attending a Family Planning Clinic by Transmission Category HIV Seroprevalence for Women Attending a Family Planning Clinic by Race/Ethnicity HIV Seroprevalence for Women Attending a Family Planning Clinic by Age Group HIV Seroprevalence for Women Attending an Abortion Clinic by Transmission Category HIV Seroprevalence for Women Attending an Abortion Clinic by Race/Ethnicity HIV Seroprevalence for Women Attending an Abortion Clinic by Age Group	19 20 21 22 23 24
SURVEY OF CHILDBEARING WOMEN IN SAN FRANCISCO: 1989-93	
HIV Seroprevalence for Newborn Infants and Their Mothers by Age Group and Ethnicity	25
SURVEY OF PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A TB CLINIC	
HIV Seroprevalence for TB Patients by Gender and Transmission Category HIV Seroprevalence for TB Patients by Origin of Birth HIV Seroprevalence for TB Patients by Race/Ethnicity	27 28 29
HIV Seroprevalence for TB Patients by Age Group	30

## SURVEY OF ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER (JDC) AND HOMELESS YOUTH CENTERS (HYCs)

HIV Seroprevalence for Adolescents Entering a JDC by Gender & Transmission Category HIV Seroprevalence for Adolescents Entering a JDC by Race/Ethnicity HIV Seroprevalence for Adolescents Entering a JDC by Age Group HIV Seroprevalence for Adolescents Entering HYCs by Gender & Transmission Category HIV Seroprevalence for Adolescents Entering HYCs by Race/Ethnicity HIV Seroprevalence for Adolescents Entering HYCs by Age Group	31 32 33 34 35 36
RESULTS OF HIV SCREENING OF CIVILIAN APPLICANTS FOR MILITARY SERVICE: 1985-1994	
HIV Seroprevalence for Civillan Applicants for Military Service by Gender & Year HIV Seroprevalence for Civillan Applicants for Military Service by Race/Ethnicity & Year HIV Seroprevalence for Civillan Applicants for Military Service by Age Group & Year	37 38 39
RESULTS OF HIV SCREENING OF BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA: 1985-1994	
HIV Seroprevalence for Blood Donors by Year of Donation HIV Seroprevalence for Blood Donors by Donation Status & Gender HIV Seroprevalence for Blood Donors by Race/Ethnicity HIV Seroprevalence for Blood Donors by Age Group	40 41 42 43

HIV SEROPREVALENCE REPORT Is released on a semi-annual basis by the San Francisco Department of Public Health, AIDS Office, SeroepIdemiology and Surveillance Branch, 25 Van Ness Avenue, Sulte 500, San Francisco, CA 94102-6033. Phone (415) 554-9050. Director of Epidemiology, Disease Control, and AIDS, Mitch Katz, M.D. Seroepidemiology and Surveillance Assistant Branch Chief, Giuliano Nieri. Program Coordinator, Sean Nguyen. EpIdemiologist/Data Manager, Tim Kellogg. Funding and technical support is provided by the Division of HIV/AIDS, Centers for Disease Control and Prevention. Additional support is provided by the California Department of Health Services, Office of AIDS.

HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY GENDER AND TRANSMISSION CATEGORY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (1)

				itions.	ed observa	syphilis screening on finens were collected or assay. The sizes under 20 observations to 1985.  Lesbian or bisexual women who ollection of female	Specimens were collected srn blot assay. The sample sizes under 20 of March 1985.  March 1985.  Collection of female synthesis assay.	for routification. Spear western hated for saled for saled for saled for many many many many many many many many	vimens collected or a NEW STD ep were removed, d confirmed by vals not calcul since January tween January 11 s.	m blood spec treatment f identifiers by ELISA an idence Inter ug use (IDU) usions(s) bet ntified risk n who have se 78 are inclu	e drawn fron ion, and/or ill personal lly reactive mial Confi njection dra lood transfi lood transfi loo other ider en and women u) since 197	rveys wer , examinat IV after a s repeated exact bino exact bino exact bino atory of bell with n with wom k with wom k with wom by use (ID en a control of the control of t	(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations (4) Includes persons with a history of injection drug use (IDU) since January 1978. (5) Includes persons with a history of blood transfusions (a) between January 1977 and March 1985. (6) Self-identified heterosexuals with no other identified risks. (7) Includes women who have sex with women and women who have sex with both men and women. Lesbian or bisexual women who have a history of thjection drug use (IDU) since 1978 are included in the IDU category. Collection of female sexual orientation began in 1991.
9.5 - 11.6	10.5	375	3562	9 - 14.3	11.9	13.1	416	3178	13.7 - 16.7	15.2	348	2297	TOTAL
		0	0				0	0			0	0	MISSING GENDER
1.0 - 2.9	1.8	15	849	8 - 4.5	1.8	2.9	20	681	0.9 - 3.6	2.0	10	509	SUB-TOTAL FEMALE
0.5 - 2.3	1.2	1 8	15	3 - 4.1	1.3	0.0	0	541 19	0.2 - 2.3	0.8	0 3	380	Heterosexual (6) Unknown Risk
0.0 - 10.9	0.0	00	26			16.7	1 0	60		9.1	۲ 0	11 0	Lesbian/Bisexual (7) Blood Recipient (5)
1 1	5.1 4.6	ωw	59	.8 - 18.4 .0 - 9.7	2.8 0.0	1.8	<b>1</b> 0	60 55	3.0 - 20.0 0.0 - 9.2	9.1 1.7	1 5	5 5 5	IDU (4) Sex Partner at Risk for HIV
													FEMALE
12.0 - 14.6	13.3	360	2713	4 - 17.4	14.4	15.9	396	2497	17.1 - 20.8	18.9	338	1788	SUB-TOTAL MALE
.8 - 3	25.4	0 41 15	1663	1 1 1	8 8.4.	11.1 2.1 13.4	1 29 25	1381 187	0.1 - 21.9	14.3	14	23 1023 14	Blood Recipient (5) Heterosexual (6) Unknown Risk
34.1 - 41.6 35.5 - 58.4 3.5 - 14.0 0.9 - 8.2	37.8 46.8 7.6	254 3 <b>7</b> 9	672 79 118	1 - 47.0 3 - 71.2 5 - 15.0	39.1 50.3 3.5 4.1	43.0 61.1 7.9	269 55 8	626 90 101	46.1 - 55.7 61.8 - 79.2 6.8 - 20.4 0.9 - 12.0	50.9 71.1 12.5	224 81 13	440 114 104 70	Gay/Bisexual Gay/Bisexual, IDU (4) Heterosexual IDU (4) Sex Partner at Risk for HIV
													MALE
(95% C.I.) (3)	SERO- PREVALENCE RATE (%)	NUMBER (2) POSITIVE	NUMBER TESTED	(95% C.I.) (3)		SERO- PREVALENCE RATE (%)	NUMBER (2)	NUMBER	(95% C.I.) (3)	SERO- PREVALENCE RATE (%)	NUMBER (2) POSITIVE	NUMBER	GENDER AND TRANSMISSION CATEGORY
	1991 SURVEY	199			Y.	1990 SURVEY	15			1989 SURVEY	1989		

7.0	7.9	281	3555	8.4 - 10.4	9.4	337	3595	8.4 - 10.4	9.4	307	3272	TOTAL
		0	0			0	0		0.0	0	1	MISSING GENDER
0.3	0.8	7	830	0.7 - 2.5	1.4	12	846	0.4 - 2.0	1.0	80	776	SUB-TOTAL FEMALE
	0.0	0	N	1	4.3	Ľ	23	1	0.0	0	7	Unknown Risk
0.2	0.8	<b>υ</b> (	661	0.5 - 2.2	1.1	<b>c</b> o c	698	0.2 - 1.5	0.6	<b>.</b>	669	Heterosexual (6)
0.0	0.0	. 0	48	0.0 - 6.7	0.0		. 43	0.0 - 9.2	0.0	. 0	31	Lesbian/Bisexual (7)
0.0	1.8	р р	55	1.4 - 18.7 0.0 - 9.5	. 6.8	ο ω	30	1.5 - 19.1 0.1 - 19.6	7.0 3.8	υω	43 26	IDU (4) Sex Partner at Risk for HIV
												FEMALE
9.0	10.1	274	2725	10.6 - 13.1	11.6	325	2749	10.7 - 13.3	12.0	299	2495	SUB-TOTAL MALE
	0.0	0	4.4	1	18.5	12	65	6.8 - 30.7	16.3	7	43	Unknown Risk
1.2	1.8	31 0	1752	1.6 - 3.1	2.3	40	1771	1.6 - 3.2	2.3	36	1575	Heterosexual (6)
0.8	3.7	<b>ς</b> ω	3 82	2.1 - 14.0	3 . 3 . 3	س د	80	1.7 - 14.8	6.1	4.0	66	Sex Partner at Risk for HIV
2.	6.7	7	105	3.0 - 16.6	8.0	6	75		6.7	7	104	Heterosexual IDU (4)
25.6 36.6	28.9	201 32	695	30.7 - 37.8 32.9 - 63.1	34.2 47.8	239 22	699	31.1 - 38.6 24.7 - 52.8	34.8 38.0	226 19	650 50	Gay/Bisexual Gay/Bisexual, IDU (4)
												MALE
Œ (95 <b>%</b> C.I.) (3)	SERO- PREVALENCE RATE (%)	NUMBER (2) POSITIVE	NUMBER	(95 <b>%</b> C.I.) (3)	SERO- PREVALENCE RATE (%)	NUMBER (2) POSITIVE	NUMBER	(95% C.I.) (3)	SERO- PREVALENCE RATE (%)	NUMBER (2) POSITIVE	NUMBER	GENDER AND TRANSMISSION CATEGORY
	1994 SURVEY	199			3 SURVEY	1993			1992 SURVEY	199		

⁽¹⁾ These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected

consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons with a history of injection drug use (IDM) since January 1978.

(5) Includes persons with a history of blood transfusions(s) between January 1977 and March 1985. Includes persons with a history of injection drug use (IDU) since January 1978. Includes persons with a history of blood transfusions(s) between January 1977 and March 1985.

⁽⁶⁾ Self-identified heterosexuals with no other identilied risks.

(7) Includes women who have sex with women and women who have sex with both men and women. Lesbian or bisexual women who have a history of injection drug use (IDU) since 1978 are included in the IDU category. Collection of female sexual orientation began in 1991.

HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY RACE/ETHNICITY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (1)

1989 SURVEY

1990 SURVEY

1991 SURVEY

				ervations.	screening on collected under 20 obs	utine syphilis screening Specimens were collected rim blot assay. The blot assay ander 20 ounknown race.	for routir isode. Spe a Western b ated for sa	m from blood specimens collected for routine syphilis screening on nal/or treatment for a NEW STD episode. Specimens were collected sonal identifiers were removed. In the collected specimens were collected by ELISA and confirmed by a Western blot assay. Confidence Intervals not calculated for sample sizes under 20 observations askan Native ancestry, other race, and unknown race.	m blood spec treatment f identifiers by ELISA an idence Inter	re drawn fro	surveys weron, examinated the second	(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.  (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 obs  (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.
7.0 - 8.8	7.9	281	3555	8.4 - 10.4	9.4	337	3595	8.4 - 10.4	9.4	307	3272	TOTAL
9.5 - 12.9 5.9 - 9.2 4.0 - 7.4 0.9 - 4.6 2.5 - 12.3	11.1 7.4 5.5 6.2	147 77 43 7	1321 1038 776 307 113	12.4 - 16.2 4.6 - 7.5 6.1 - 10.1 1.4 - 5.8 2.9 - 16.2	14.2 6.0 7.9 3.1	199 66 57 9	1398 1109 719 292 77	10.6 - 14.2 5.9 - 9.3 5.9 - 10.0 2.0 - 8.2 4.5 - 24.3	12.3 7.5 7.8 4.4	163 76 53 9	1320 1016 683 203	WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)
(95% C.I.) (3)	SERO- PREVALENCE RATE (%)	NUMBER (2) POSITIVE	NUMBER	(95% C.I.) (3)	SERO- PREVALENCE RATE (%)	NUMBER (2) POSITIVE	NUMBER	(95% C.I.) (3)	SERO- PREVALENCE RATE (%)	NUMBER (2) POSITIVE	NUMBER	RACE/ETHNICITY
	1994 SURVEY	199			1993 SURVEY	199			1992 SURVEY	199		
9.5 - 11.6	10.5	375	3562	11.9 - 14.3	13.1	416	3178	13.7 - 16.7	15.2	348	2297	TOTAL
12.9 - 16.6 5.3 - 8.3 7.8 - 12.4 3.0 - 9.4 4.8 - 22.6	14.7 6.7 9.9 5.6 11.7	210 78 67 13	1429 1165 675 233	16.0 - 20.4 7.8 - 11.2 9.5 - 15.0 3.8 - 11.8 3.9 - 25.1	18.1 9.4 12.1 7.1 11.6	219 111 68 13	1210 1178 564 183 43	20.1 - 25.7 7.3 - 11.4 10.6 - 18.0 1.6 - 9.2 3.8 - 24.6	22.8 9.2 14.0 4.3 11.4	209 76 52 6	916 828 371 138 44	HHITE AFRICAN AMERICAN LATINO LATINO LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)
(95% C.I.) (3)	SERO- PREVALENCE RATE (%)	NUMBER (2) POSITIVE	NUMBER	(95% C.I.) (3)	SERO- PREVALENCE RATE (%)	NUMBER (2) POSITIVE	NUMBER	(95% C.I.) (3)	SERO- PREVALENCE RATE (%)	NUMBER (2) POSITIVE	NUMBER	RACE/ETHNICITY

TOTAL	19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN	AGE-GROUP (YEARS)	TOTAL	19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN	AGE-GROUP (YEARS)
3272	241 776 775 621 374 243 222 20	NUMBER TESTED	2297	223 526 550 550 403 284 158 153	NUMBER . TESTED
307	2 67 62 41 22 2	19: NUMBER (2) POSITIVE	3 4 8	35 35 35 35 88 88 73 27 0	NUMBER (
9.4	0.8 2.6 8.6 16.6 16.9	1992 SURVEY  SERO- 2) PREVALENCE E RATE (%)	15.2	1.3 6.7 16.9 21.8 25.7 17.1	1989 SURVEY SERO- SPEVALENCE RATE (*)
8.4 - 10.4	0.1 - 3.0 1.6 - 4.0 6.8 - 10.8 12.0 - 17.7 13.0 - 20.7 12.4 - 22.2 6.3 - 14.6 1.2 - 31.7	(95% C.I.) (3)	13.7 - 16.7	0.3 - 3.9 4.7 - 9.1 13.9 - 20.3 17.9 - 26.2 20.7 - 31.2 11.6 - 23.9 13.1 - 26.1	(95% C.I.) (3)
3595	244 790 883 679 394 275 275 276	NUMBER	3178	274 708 785 785 570 570 382 223 223 10	NUMBER
337	1 65 108 69 45 39	NUMBER (2) POSITIVE	416	6 1104 113 90 90 38 31	199 NUMBER (2) POSITIVE
9.4	0.4 1.1 7.4 15.9 17.5 16.4 12.8 3.8	1993 SURVEY  SERO- 2) PREVALENCE E RATE (*)	13.1	2.2 4.8 13.2 19.8 17.0 13.7 0.0	1990 SURVEY SERO- 2) PREVALENCE RATE (*)
8.4 - 10.4	0.0 - 2.3 0.5 - 2.2 5.7 - 9.3 13.2 - 18.9 13.9 - 21.3 12.2 - 21.3 9.3 - 17.1 0.1 - 19.6	(95% C.I.) (3)	11.9 - 14.3	0.8 - 4.7 3.3 - 6.6 11.0 - 15.8 11.6 - 23.3 19.4 - 28.1 12.3 - 22.6 9.5 - 18.9	(95% C.I.) (3)
3555	225 833 826 626 238 294	NUMBER	3562	288 897 833 609 390 263 265	NUMBER TESTED
281	1 17 47 77 70 33 36	NUMBER (2) POSITIVE	375	1 25 87 103 75 50 33	199 NUMBER (2) POSITIVE
7.9	0.4 5.3 12.3 16.0 12.8	1994 SURVEY  SERO- 2) PREVALENCE E RATE (%)	10.5	0.3 2.8 10.4 16.9 19.2 19.2 19.5	1991 SURVEY SERO- 2) PREVALENCE RATE (%)
7.0 - 8.8	0.0 - 2.5 1.2 - 3.2 4.0 - 7.0 9.8 - 15.1 12.7 - 19.5 9.0 - 17.5 8.7 - 16.5	(95* C.I.) (3)	9.5 - 11.6	1.8 4.1 8.5 12.7 14.0 20.1 15.4 23.5 14.5 24.3 8.7 17.0	(95% C.I.) (3)

⁽¹⁾ These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

HIV SEROPREVALENCE FOR GAY AND BISEXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY RACE/ETHNICITY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (1)

		198	1989 SURVEY			199	1990 SURVEY			199	1991 SURVEY	
RACE/ETHNICITY	NUMBER TESTED	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95 <b>%</b> C.I.) (3)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER TESTED	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)
WHITE AFRICAN AMERICAN LATINO ASIAN PACIFIC ISLANDER NONE OF THE ABOVE (4)	372 84 78 14	19 54 48 5	52.2 64.3 61.5 28.6 83.3	46.9 - 57.3 53.1 - 74.4 49.8 - 72.3	456 117 107 28	188 74 50 8	41.2 63.2 46.7 28.6 50.0	36.7 - 45.9 53.8 - 72.0 37.0 - 56.6 13.2 - 48.7	525 83 105 27 11	182 444 111 6	34.7 53.0 45.7 40.7 54.5	30.6 - 38.9 41.7 - 64.1 36.0 - 55.7 22.4 - 61.2
TOTAL	554	305	55.1	50.8 - 59.3	716	324	45.3	41.6 - 49.0	751	291	38.7	35.2 - 42.3
		199	1992 SURVEY			199	1993 SURVEY			199	1994 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER TESTED	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER TESTED	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)
WHITE AFRICAN AMERICAN	455 102	147 46	32.3 45.1	28.0 - 36.8 35.2 - 55.3	497	165 39	33.2 51.3	29.1 - 37.5 39.6 - 63.0	487 89	135 47	27.7 52.8	23.8 - 31.9 41.9 - 63.5
LATIKO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	105 26 12	39	37.1	27.9 - 47.1	120 39 13	46	38.3 17.9 30.8	7.5 - 33.5	114 47 23	37 7 7 7	32.5 14.9 30.4	24.0 - 41.9 6.2 - 28.3 13.2 - 52.9
TOTAL	700	245	35.0	31.5 - 38.7	745	261	35.0	31.6 - 38.6	760	233	30.7	27.4 - 34.1
(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 obs (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.	surveys wern, examinat HIV after are repeated, exact bindian Indian	re drawn fro ion, and/on all personal illy reactive smial. Conf	om blood spectreatment identifies by ELISA a idence Into Native and	n from blood specimens collected for routine syphilis screening on ind/or treatment for a NEW STD episode. Specimens were collected sonal identifiers were temoved. Inctive by ELISA and confirmed by a Western blot assay. Confidence Intervals not calculated for sample sizes under 20 observations.	for routingsode. Special speci	ne syphilis ecimens were blot assay. ample sizes nown race.	screening o collected under 20 ob	n Bervations.				

		198	1989 SURVEY			199	1990 SURVEY			1991	1 SURVEY	
AGE-GROUP (YEARS)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95 <b>%</b> C.I.) (3)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (*)	(95 <b>%</b> C.I.) (3)
19 AND UNDER	2	0	0.0		14	2	14.3	•	10	1	10.0	
20 - 24	61	25	41.0	28.6 - 54.3	81	27	33.3	23.2 - 44.7	85	16	18.8	1
25 - 29	134	84	62.7	53.9 - 70.9	174	80	46.0	38.4 - 53.7	195	74	37.9	
30 - 34	129	76	58.9	- 1	168	87	51.8		175	83	47.4	
35 - 39	112	68	60.7	51.0 - 69.8	129	69	53.5	44.5 - 62.3	118	56	47.5	
40 - 44	55	25	45.5	32.0 - 59.4	62	30	48.4	- 1	87	37	42.5	- 1
45 AND OVER	61	27	44.3	31.5 - 57.6	87	29	33.3	23.6 - 44.3	80	24	30.0	20.3 - 41.3
UNKNOWN	0	0		; ;		0	0.0	:		0	0.0	
TOTAL	554	305	55.1	50.8 - 59.3	716	324	45.3	41.6 - 49.0	751	291	38.7	35.2 - 42.3
		199	1992 SURVEY			199	1993 SURVEY			1994	94 SURVEY	
AGE-GROUP (YEARS)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)
19 AND UNDER	10	N	20.0	· •	и	0	0.0		12	0	0.0	1
20 - 24	92	16	17.4		71	6	8.5	3.2 - 17.5	77	14	18.2	10.3 - 28.6
30 - 34	162	7 52	32.1	25.0 - 39.9	188	2 4 9	26.1	19.9 - 33.0	181	65.00	35.7	28.8 - 43.1
35 - 39	103	49	47.6	37.6 - 57.6	120	56	46.7	37.5 - 56.0	137	56	40.9	
40 - 44	67	35	52.2		68	30	44.1	32.1 - 56.7	76	31	40.8	
	74	18	24.3	15.1 - 35.7	90	31	34.4	24.7 - 45.2	95	29	30.5	
UNKNOWN	6	1	16.7	•	Un Un	1	20.0	•	0	0		
TOTAL	700	245	35.0	31.5 - 38.7	745	261	35.0	31.6 - 38.6	760	233	30.7	27.4 - 34.1
(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on	surveys wer	e drawn fro	m blood spe	cimens collected	for routin	ne syphilis	screening o	B				
Individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens wer consecutively and tested for HIV after all personal identifiers were removed.  (2) All positive specimens were repeatedly reactive by EUISA and confirmed by a Western blot assay.	n, examinat	ion, and/or	identifier by ELISA a	for a NEW STD ep. s were removed. nd confirmed by	isode. Spe a Western l	Specimens were rn blot assay.	collected					
	CARCE DAM	MITGI. COM	Tuerice Tire	continuence intervats not carculated for sailbre sizes mider to observations	ared for se	aufore arges	maer 20 on	SELVACIONS.				

6

HIV SEROPREVALENCE FOR HETEROSEXUAL MALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY RACE/ETHNICITY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (2)

1989 SURVEY

1990 SURVEY

1991 SURVEY

RACE/ETHNICITY	NUMBER	NUMBER (3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)	NUMBER TESTED	NUMBER (3)	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)	NUMBER	NUMBER (3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)
WHITE AFRICAN AMERICAN	316 471	மை	1.6		413	111	2.7	1.3 - 4.7	497	12	2 2 4 6	1.3 - 4.2
LATINO LATINO LATINO	209	- 20	1.0	0.1 - 3.4	286	- 6	2.8		399	, 12 12	3.0	
NONE OF THE ABOVE (5)	19	o +	0.0		18	0 F	0.0		26	0 4	0.0	1 1
TOTAL	1093	17	1.6	0.9 - 2.5	1484	38	2.6	1.8 - 3.5	1785	45	2.5	1.8 - 3.4
		19	1992 SURVEY			19	1993 SURVEY			199	1994 SURVEY	
RACE/ETHNICITY	NUMBER TESTED	NUMBER (3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)	NUMBER TESTED	NUMBER (3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)	NUMBER TESTED	NUMBER (3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)
WHITE AFRICAN AMERICAN	520 632	10 21	1.9 3.3	0.9 - 3.5 2.1 - 5.0	569	20 16	2 3	2.2 - 5.4	518	24	1.0	0.3 - 2.2
LATINO ASIAN/PACIFIC ISLANDER	379 91	2 7	2.2	1	148	1 7	1.7	0.7 - 3.4	159	0 0	0.0	1 1
NONE OF THE ABOVE (5)	19	01	0.0		31	μ,	3.2		51	0 (	0.0	
TOTAL	1641	40	2.4	1.7 - 3.3	1851	4.5	2.4	1.8 - 3.2	1834	34	1.9	1.3 - 2.6
(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks. (2) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. (3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (4) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 obs (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.	surveys weren, examinal of the saminal of the same of the saminal of the same of	artner at r re drawn fr re drawn for tion, and/o all persona dly reactiv omial. Con and Alaska	isk for HIV om blood spe om blood spe r treatment r identifies e by ELISA a e by filence Inte fidence Inte	at risk for HIV and heterosexuals with no other identified risks.  In from blood specimens collected for routine syphilis screening on ad/or treatment for a NEW STD episode. Specimens were collected sonal identifiers were removed.  Contidence Intervals not calculated for sample sizes under 20 observations askan Native ancestry, other race, and unknown race.	ed for rout; episode. Sp  a Mestern pulated for s ace, and unk	other ident ine syphilis pecimens wer blot assay. sample sizes known race.	ified risks. screening c e collected under 20 ob	on servations.				

	0000							
NUMBER (3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)	NUMBER	NUMBER (3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)		NUMBER
-	D	٠	167	J	1 2	'		157
5 ω	1.0	1 1	360	4 6	1.1			497
<b>6</b> 0 (	4.4	1	229	10	4.4			288
ω	3.2	-1	158	00	5.1			175
J C	0.0	•	98	ن د				103
0 1		1 9		0 +	0.0			8
			-					
17	1.6	0.9 - 2.5	1484	38	2.6	1.8 - 3.5		1785
199								
				1993	3 SURVEY			
NUMBER (3) POSITIVE	1	(95% C.I.) (4)	NUMBER	NUMBER (3)	77 76	(95% C.I.) (4)	4	NUMBER
NUMBER (3) POSITIVE	SERO-PREVALENCE (*)	(95 <b>*</b> C.I.) (4)	NUMBER TESTED	19 NUMBER (3) POSITIVE	SERO-PREVALENCE (*)	(95% C.I.) (4)		NUMBER TESTED
NUMBER (3) POSITIVE	SERO- PREVALENCE RATE (*) 0.0 0.7	(95* C.I.) (4) 0.0 - 2.3 0.1 - 2.0	NUMBER TESTED	NUMBER (3) POSITIVE  0 3	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)		NUMBER TESTED
NUMBER (3) POSITIVE 0 3 10	SERO- PREVALENCE RATE (*) 0.0 0.7 2.5	(95* C.I.) (4) 0.0 - 2.3 0.1 - 2.0 1.2 - 4.6	NUMBER TESTED 125	NUMBER (3) POSITIVE  0 3 10	SERO-PREVALENCE RATE (*)	(95% C.I.) (4)		NUMBER TESTED 112 496
NUMBER (3) POSITIVE 0 10 10	SERO- PREVALENCE RATE (*)	(95% C.I.) (4)	NUMBER TESTED	NUMBER (3) POSITIVE  0 0 10	SERO- PREVALENCE RATE (%) 0.0 0.7 2.2 3.0	(95% C.I.) (4)		NUMBER TESTED  112 496 470 309
NUMBER (3) POSITIVE  0 3 10 15	SERO- PREVALENCE RATE (*)	(95% C.I.) (4)	NUMBER TESTED 125 454 459 459 133 333 136	NUMBER (3) POSITIVE  0 0 10 10	SERO-PREVALENCE RATE (*) 0.0 0.7 2.2 3.0 7.1	(95% C.I.) (4)		NUMBER TESTED 112 496 470 309 204 117
NUMBER (3) POSITIVE  0 15 6 4	SERO- PREVALENCE RATE (*) 0.0 0.7 2.5 5.0 3.8	(95% C.I.) (4)	NUMBER TESTED 125 454 454 459 333 182 182 182 182 182 182 182 182 182 182	NUMBER (3) POSITIVE  0 10 10 10 9	33 SURVEY  SERO- PREVALENCE RATE (*)  0.0 0.7 2.2 3.0 5.5	(95% C.I.) (4) 0.0 - 2.4 0.1 - 1.9 1.0 - 4.0 1.4 - 5.5 2.7 - 9.9		NUMBER TESTED 112 496 470 309 204 117
NUMBER (3) POSITIVE  0 3 10 15 6 4 1	SERO- PREVALENCE RATE (*) 0.0 0.7 2.5 5.0 3.8 3.8 1.0	(95% C.I.) (4) 0.0 - 2.3 0.1 - 4.6 1.2 - 4.6 1.4 - 8.1 1.4 - 9.4 0.0 - 5.2	NUMBER TESTED 125 454 459 333 182 126 126 128 128 128 128 128 128 128 128 128 128	NUMBER (3) POSITIVE 0 10 10 10 10 0 0 0 0 0 0 0 0 0 0 0 0	SERO- PREVALENCE RATE (%) 0.0 0.7 2.2 2.2 3.0 5.5 5.1 7.1	0.0 - 2.4 0.0 - 2.4 0.1 - 1.9 1.0 - 4.0 2.7 - 9.9 3.3 - 13.1 0.4 - 5.4		NUMBER TESTED 112 496 470 309 204 117 1124 2
	NUMBER (3) POSITIVE 1 3 3 0 0 2 0 17	92	SERO- PREVALENCE RATE (*) 0.8 1.0 0.0 4.4 3.2 0.0 3.6	SERO- PREVALENCE (*) (95% C.I.) (4) RATE (*) (95% C.I.) (4)  0.8	SERO- PREVALENCE RATE (*) (95% C.I.) (4) TESTED POSITIV  0.8 0.0 - 4.3 157 2 1.0 0.2 - 2.8 360 4 0.0 0.0 - 1.1 399 10 4.4 1.9 - 8.5 229 10 3.2 0.7 - 9.1 158 8 0.0 - 4.9 98 3 3.6 0.4 - 12.3 89 1 3.6 0.4 - 12.3 89 1 3.6 0.9 - 2.5 1484 38	SERO- PREVALENCE  RATE (*) (95 C.I.) (4) TESTED POSITIVE  0.8 0.0 - 4.3 157 2 1.0 0.2 - 2.8 360 4 0.0 0.0 - 1.1 389 10 4.4 1.9 - 8.5 329 10 3.2 0.7 - 9.1 158 3 0.0 0.4 - 12.3 89 1 3.6 0.4 - 12.3 89 1 3.6 0.4 - 12.3 89 1 1.6 0.9 - 2.5 1484 38	SERO- PREVALENCE RATE (*) (95% C.I.) (4) TESTED POSITIVE RATE (*)  0.8 0.0 - 4.3 157 2 1.3  1.0 0.2 - 2.8 360 4 1.1  0.0 0.0 - 1.1 389 10 4.4  1.9 - 8.5 229 10 4.4  3.2 0.7 - 9.1 158 8 5.1  0.0 0.4 - 12.3 89 1 1.1  1.6 0.9 - 2.5 1484 38 2.6	SERO- PREVALENCE RATE (*) (95* C.I.) (4)  157  0.8  0.0 - 4.3  1.0  0.2 - 2.8  0.0 - 1.1  360  4.4  1.9 - 8.5  2.9  3.2  0.7 - 9.1  3.6  0.0 - 0.4 - 12.3  89  1.6  0.9 - 2.5  1.6  0.9 - 2.5  1.8 - 3.5  1.6  0.9 - 2.5  1484  38  28  28  28  28  28  28  28  38  38

8

HIV SEROPREVALENCE FOR HETEROSEXUAL FEMALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY RACE/ETHNICITY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (2)

		rvations.	ified risks. screening on collected under 20 obse	other identine syphilis ecimens were blot assay. ample sizes nown race.	s with no for routi isode. Sp a Western lated for sa e, and unk	at risk for HIV and heterosexuals with no other identified risks.  I from blood specimens collected for routine syphilis screening on nd/or treatment for a NEW STD episode. Specimens were collected sonal identifiers were removed.  Sonal identifiers were removed.  Cotive by ELISA and confirmed by a Western blot assay.  Confidence Intervals not calculated for sample sizes under 20 observations.  Confidence Intervals not calculated for sample sizes.	m blood spec treatment f identifiers by ELISA and idence Inter	arther at ri re drawn fro tion, and/or tion and/or tion and/or tion and/or mial. Conf and Alaskan	with a sex party serveys well surveys well cion, examinal or HIV after a were repeated by, exact bind exican Indian	(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks. (2) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. (3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (4) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 obs (5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.
6 0.8 0.3 - 1.8	718	0.5 - 2.2	1.1	œ	728	0.2 - 1.7	0.7	v	695	TOTAL
3 1.5 0.3 - 4.2 2 0.8 0.1 - 2.8 1 0.6 0.0 - 3.6 0 0.0 0.0 - 3.4 0 0.0 0.0 - 12.7	205 251 251 154 86 22	0.3 - 4.0 0.0 - 2.1 0.2 - 4.9 0.0 - 6.2 0.1 - 23.8	1.4 4.1.4 81.4	פרמיים	215 260 145 87 21	0.0 - 1.2 0.3 - 4.0 0.2 - 4.7 0.0 - 4.1	0.0 1.4 0.0 0.0	00000	245 214 150 72 14	WHITE AFRICAN AMERICAN LATINA ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (5)
SERO- NUMBER(3) PREVALENCE POSITIVE RATE (*) (95* C.I.)(4)	NUMBER NUM	(95% C.I.) (4)	SERO- PREVALENCE RATE (%)	NUMBER (3) POSITIVE	NUMBER TESTED	(95% C.I.) (4)	SERO- PREVALENCE RATE (%)	NUMBER (3) POSITIVE	NUMBER TESTED	RACE/ETHNICITY
1994 SURVEY			1993 SURVEY	195			1992 SURVEY	199		
11 1.5 0.7 - 2.6	746	1.3 - 3.9	2.3	14	596	0.2 - 2.3	0.9	4.	438	TOTAL
5 1.9 0.6 - 4.5 5 1.9 0.6 - 4.3 1 0.8 0.0 - 4.1 0 0.0 0.0 - 4.0 0 0.0 0.0 - 4.0	257 266 133 74 16	0.4 - 5.0 1.6 - 6.4 0.0 - 5.4 0.0 - 10.1	1.8 3.4 1.0 1.9	0 1 1 2 3	171 263 101 53	0.0 - 3.8 0.3 - 4.7 0.0 - 4.8 0.0 - 7.2	0.7 1.6 0.0 0.0	0 0 0 0 1	145 184 61 40 8	WHITE AFRICAN AMERICAN LATINA ASSAN/PACIFIC ISLANDER NONE OF THE ABOVE (5)
SERO- NUMBER(3) PREVALENCE POSITIVE RATE (%) (95% C.I.)(4)	NUMBER NUM	(95% C.I.) (4)	SERO- PREVALENCE RATE (%)	NUMBER (3) POSITIVE	NUMBER	(95% C.I.) (4)	SERO- PREVALENCE RATE (%)	NUMBER (3) POSITIVE	NUMBER TESTED	RACE/ETHNICITY
1991 SURVEY			90 SURVEY	1990			39 SURVEY	1989		
								- 1994 (2)	ANCISCO, 1989	AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (2)

		191	1989 SURVEY			199	1990 SURVEY			1991	91 SURVEY
AGE-GROUP (YEARS)	NUMBER	NUMBER (3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)	NUMBER	NUMBER (3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)	NUMBER TESTED	NUMBER (3) POSITIVE	SERO- PREVALENCE RATE (%)
19 AND UNDER	87	2	2.3	•	88	N	2.3	•	116	0	
20 - 24	119	יי	0.8	ı.	194	_	0.5	0.0 - 2.8	258	w	
25 - 29	101		1.0		137	س	2.2	•	160	0	
30 - 34	52	۱ د	0.0	0.0 - 5.6	79	، 4	J :		8 6	ω <b>(</b>	
30 - 34		, ,		•		, ,	) i	10.0		, .	
35 - 39	39	0	0.0	1	43	w	7.0	1.5 - 19.1	42	N	
40 - 44	20	0	0.0	1	27	<b>–</b>	3.7	0.1 - 19.0	48	N	
45 AND OVER	20	0	0.0	t	24	0	0.0	0.0 - 11.7	32	_	
INDIVIDUAL		۰ د							<u>.</u>	۱ د	
CNANOWN	c	c				c				c	
					-						
TOTAL	438	4.	0.9	0.2 - 2.3	596	14	2.3	1.3 - 3.9	746	11	
		199	1992 SURVEY			19:	1993 SURVEY			19	1994 SURVEY
AGE-GROUP (YEARS)	NUMBER	NUMBER (3)	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)	NUMBER	NUMBER (3)	SERO- PREVALENCE RATE (%)	(95% C.I.) (4)	NUMBER	NUMBER (3) POSITIVE	SERO- PREVALENCE RATE (%)
19 AND UNDER	97	٥	0 0	1	98	1	1 0	٠	98	1	
20 - 24	188	р,	0.5	•	213	0	0.0	•	217	1	
25 - 29	174	ч	0.6	0.0 - 3.2	180	р.	0.6	0.0 - 3.1	164	N	
30 - 34	91	0	0.0	•	95	Ь	1.1	r	93	N	
35 - 39	77	ω	3.9	ı	60	0	0.0	•	58	0	
40 - 44	42	0 (	0.0		47	w e	6.4	•	42	0	
45 AND OVER	23	0	0.0		29	N	6.9	•	46	0	
UNKNOWN	ω	0	0.0	ı	6	0	0.0	1	0	0	
TOTAL	695	σ	0.7	0.2 - 1.7	728	œ	1.1	0.5 - 2.2	718	σ	

⁽¹⁾ Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.
(2) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NBW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.
(3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
(4) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

¹⁰ 

10.7 - 44.9 5.4 - 9.5

6.2 - 10.3

6.0 - 9.1

(95% C.I.) (3)

,

		199	1992 SURVEY			19:	1993 SURVEY			199	1994 SURVEY	
GENDER AND SEXUAL ORIENTATION	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER TESTED	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
MALE												
Gay/Bisexual	26	) æ	30.8	14.3 - 51.8	336	1,4	44.4		207	ນຸ້ນ	15.4	60 - 14.5
Unknown Orientation	40	u c	7.5	1.6 - 20.4	1	0	0.0	11.3	0	0 0		
SUB-TOTAL MALE	915	74	8.1	6.4 - 10.0	246	21	8.5	5.4 - 12.8	220	22	10.0	6.4 - 14.7
FEMALE												
Lesbian/Bisexual	21	2 2	n 19	1.2 - 30.4	130	1 2	15.4	4.3 - 14.6	12	15	16.7	5.7 - 16.0
Unknown Orientation	ហ	0	0.0			0	0.0		0	0	•	
SUB-TOTAL FEMALE	458	28	6.1	4.1 - 8.7	144	13	9.0	4.9 - 14.9	162	17	10.5	6.2 - 16.3
MISSING GENDER	14	1	7.1		1	0	0.0		P	0	0.0	
TOTAL	1387	103	7.4	6.1 - 8.9	391	34	8.7	6.1 - 11.9	383	39	10.2	7.3 - 13.7
(1) Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 1978. Excludes persons with a prior admission to treatment during the survey period, and persons who were preferentially admitted to treatment due to HIV/AIDS. Blood specimens were collected for sphilis screening as part of the admission requirements, and tested for HIV after all personal identifiers were removed.	y methadone r admission reatment due	treatment w to treatmen to HIV/AII	ho have a hot during the S. Blood sor HIV afte	istory of inject e survey period, pecimens were co	ion drug umand person dected for dentifiers	se (IDU) si ns who were r syphilis : were remov	nce 1978. screening					

as part of the admission requirements, and tested for Hiv after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

HIV SEROPREVALENCE FOR INJECTION DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (1)

		198	1989 SURVEY			199	1990 SURVEY			199	1991 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER	NUMBER (2)	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)
WHITE WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	142 61 27 5	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	3.5 23.0 18.5 0.0	1.2 - 8.0 13.2 - 35.5 6.3 - 38.1	722 256 135 29 16	55 2 7 4 4 1 4 7	3.3 21.1 5.2 13.8 6.3	2.1 - 4.9 16.3 - 26.6 2.1 - 10.4 3.9 - 31.7	699 267 118 28 20	224 533 7 0	19.9 5.9 0.0	2.2 - 5.1 15.2 - 25.1 2.4 - 11.8 0.0 - 10.1 0.0 - 13.9
TOTAL	237	24	10.1	6.6 - 14.7	1158	90	7.8	6.3 - 9.5	1132	60 44	7.4	6.0 - 9.1
		199	1992 SURVEY			199	1993 SURVEY			1994	4 SURVEY	
RACE/ETHNICITY	NUMBER TESTED	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER TESTED	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER TESTED	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95 <b>%</b> C.I.) (3)
WHITE AFRICAN AMERICAN LATINO	889 299	35 54	3.9 18.1 7.9	2.8 - 5.4 13.9 - 22.9 4.0 - 13.7	264 79 36	21 11 2	13.9 5.6	5.0 - 11.9 7.2 - 23.5 0.7 - 18.7	240 81 48	15 17	6.3 21.0 12.5	3.5 - 10.1 12.7 - 31.5 4.7 - 25.2
ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	29 31	3	0.0 9.7	0.0 - 9.8 2.0 - 25.8	3 9	00	0.0		12	01	0.0	::
TOTAL	1387	103	7.4	6.1 - 8.9	391	34	8.7	6.1 - 11.9	383	99	10.2	7.3 - 13.7
(1) Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 1978. Excludes persons with a prior admission to treatment during the survey period, and persons who were preferentially admitted to treatment due to HIV/AIDS. Blood specimens were collected for sphills screening as part of the admission requirements, and tested for HIV after all personal identifiers were removed.  (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.  (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.	y methadone r admission reatment due uirements, a ere repeated, exact bincian Indian	treatment w to treatmen to HIV/AII nd tested f lly reactive mial. Conf	who have a late during the during the S. Blood soor HIV after the ELISA at idence Internative and	nistory of inject ne survey period, specimens were co ar all personal i and confirmed by preals not calcul	ion drug us and persos llected for dentifiers a Western lated for seated and unknown.	se (IDU) sin ns who were r syphilis s were remove blot assay. ample sizes nown race.	creening d.	servations.				

PRE POSITIVE RAP 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	, CB	95% C.I.) (3)	NUMBE: TESTE: 6 6 73 149 222 304 166	O R	NUMBER ( POSITIV  1 1 7 7 14 23 23 22 1	NUMBER ( POSITIV 7 7 7 14 23 22 2 2 1	1990 NUMBER(2) POSITIVE  1 1 7 14 23 23 21 22	1990 SURVEY  SERO- NUMBER (2) PREVALENCE POSITIVE RATE (*)  1 16.7 1 1.4 7 4.7 4 6.3 23 7.5 23 7.5 21 9.4 22 13.3 1 8.3	1990 SURVEY  SERO- NUMBER(2) PREVALENCE  POSITIVE RATE (*) (95% C.I.)(3)  1 16.7 0.0 - 7.4  1 1.4 0.0 - 7.4  1 4.7 1.9 - 9.4  14 6.3 3.5 - 19.4  121 9.4 5.9 - 14.0  22 13.3 8.5 - 19.4  1 8.3 19.4
24 1	10.1	6.6 - 14.7	1158		90	90 7.8		7.8 6.3 -	7.8 6.3 - 9.5
				1 1					
1992 SURVEY									
	SURVEY				199	1993 SURVEY	1993 SURVEY	1993 SURVEY	1993 SURVEY 1994
NUMBER(2) PRE POSITIVE RA	O.C.	(95% C.I.) (3)	NUMBER TESTED		NUMBER (2) POSITIVE	1993 SURVEY  SERO- NUMBER (2) PREVALENCE POSITIVE RATE (%)	93	SERO-PREVALENCE	SERO- PREVALENCE PREVALENCE RATE (*) (95% C.I.)(3) TESTED POSITIV
	, č	95% C.I.) (3)	NUMBER TESTED 0 7		NUMBER (2) POSITIVE  0 0 0 2	93	SERO-PREVALENCE RATE (*) 0.0 8.7	SERO- PREVALENCE RATE (*) (95% C.I.) (3)	SERO-   SERO-   PREVALENCE   NUMBER   NUMBER     RATE (*)   (95% C.I.) (3)   TESTED   POSITIV   C.   C.   C.   C.   C.   C.   C.   C.
	, G	95% C.I.) (3)	NUMBER TESTED 0 0 7 7 23 56 96		NUMBER (2) POSITIVE 0 0 2 5 16	93	SERO-PREVALENCE RATE (%)  0.0 8.7 8.7 8.9 16.7	SERO- PREVALENCE PREVALENCE (*) (95% C.I.) (3) 0.0 0.0 0.1 0.0 8.7 1.1 - 28.0 8.9 3.0 - 19.6 16.7 9.8 - 25.6	SERO- PREVALENCE PATE (*) (95% C.I.) (3) TESTED POSITIV  0 0.0 1 2. 0 0 0.0 2 2. 0 0 0.0 4 2. 0 0 0.0 5 2. 0 0 0.0 5 2. 0 0 0.0 6. 7 1.1 - 28. 0 4 0.9 3.0 - 19.6 53 4 0.9 3.0 - 19.6 53 4 0.9 3.0 - 25.6 78 11
	OB	95% C.I.) (3)  0.4 - 12.3  3.1 - 12.5  2.0 - 8.8  2.0 - 10.2  5.7 - 11.7  6.8 - 14.3	NUMBER TESTED  0 7 7 23 56 96 117 90		NUMBER (2) POSITIVE 0 0 2 2 5 16 6 6	99	SERO- PREVALENCE RATE (%)  0.0 8.7 8.9 16.7 5.6 0.0	SERO- PREVALENCE RATE (*) (95% C.I.) (3)  8.7 1.1 - 28.0 8.9 3.0 - 19.6 16.7 9.8 - 25.6 5.1 1.9 - 10.8 5.6 1.8 - 12.5 0.0 12.5	SERO- SERO- PREVALENCE RATE (*) (95% C.I.)(3)  100  100  100  100  100  100  100  1
		SERO- PREVALENCE RATE (*)  0.0 5.9 7.1 6.7 17.2 14.9 0.0	SERO- PREVALENCE RATE (*) (95* C.  11.2 14.9 14.9 10.1 10.1 6.6	SERO- PREVALENCE (*) (95 ° C.I.) (3) TE RATE (*) (95 ° C.I.) (3) TE 10.0	B9 SURVEY  SERO- PREVALENCE  RATE (*) (95* C.I.) (3)  10.0  1.1  1.9  1.1  1.1  1.1  1.1  1.	SERO- SERO- PREVALENCE RATE (*) (95 C.I.) (3) TESTED POSITIVE  0.0 - 2.5   73   14   71.2   72.2   73   74.1   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.2   74.	SERO- PREVALENCE NUMBER NUMBER (2) PREVALENCE RATE (*) (95 ° C.I.) (3) TESTED POSITIVE RATE (*) 7.1 0.9 - 23.5 149 7 4.7 1.1.2 8.9 - 28.7 306 23 7.5 14.9 224 21 9.4 1.3 1.2 2.2 12 9.4 1.3 1.3 1.2 2.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1	SERO- PREVALENCE RATE (*) (95* C.I.)(3)  190 SURVEY  NUMBER (2) PREVALENCE RATE (*) (95* C.I.)(3)  10.0  10.0  10.1  10.1  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.0  10.	SERO-   NUMBER (2)   PREVALENCE   PREVALEN

HIV SEROPREVALENCE FOR INJECTION DRUG USERS (IDUS) AND NON-INJECTION DRUG USERS (NON-IDUS) ENTERING A DRUG-FREE DETOXIFICATION PROGRAM BY GENDER AND SEXUAL ORIENTATION, SAN FRANCISCO, 1990 - 1994 (1)

3.8 - 7.3	U. 44	38	708	6.0 - 9.1	7.4	85	1145	TOTAL
		0	0			0	0	MISSING GENDER
0.5 - 4.7	1.9	44	216	1.0 - 4.6	2.4	80	337	SUB-TOTAL FEMALE
0.6 - 5.6	0.20	040	180	1.1 - 5.3	2.6	0 7 1	268	Lespian/Bisexual Heterosexual Unknown Orientation
	,							FEMALE
4.8 - 9.5	6.9	ىن <u>4</u>	492	7.6 - 11.8	9.5	77	808	SUB-TOTAL MALE
34.8 - 67.6 1.3 - 4.5	51.3 2.5 15.8	20 111 3	434	23.1 - 40.5 4.0 - 7.7	31.4 5.7 10.5	37 38 2	118 671 19	Gay/Bisexual Heterosexual Unknown Orientation
								MALE
(95% C.I.) (3)	SERO- PREVALENCE RATE (%)	NUMBER (2) POSITIVE	NUMBER	SERO- REVALENCE RATE (%) (95% C.I.) (3)	SERO- PREVALENCE RATE (%)	NUMBER (2) POSITIVE	NUMBER	GENDER AND SEXUAL ORIENTATION
	NON-IDUS	NON-	,		ū	IDUs		

screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Sample includes both injection drug users (IDUs) who have a history of needle use since 1978, and non-injection drug users to treatment due to HIV/AIDS, and persons under alcohol treatment only. Excludes persons with a prior admission to treatment during the survey period, persons who were preferentially admitted who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment. Blood specimens were collected for syphilis

		IDUs	18			NON-IDUS	IDUs	
RACE/ETHNICITY	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
WHITE	734	47	6.4	4.7 - 8.4	241	: :	1.6	2.3 - 8.0
AFRICAN AMERICAN	TAA	0	1.2.1	3.0 - 13.7	220		:	0.0
LATINO	138	6	4.4	1.6 - 9.2	77		1.3	0.0 - 7.0
ASIAN/PACIFIC ISLANDER	43	N	4.7	0.6 - 15.8	50	0	0.0	0.0 - 5.8
NONE OF THE ABOVE (4)	31	N	6.5	0.8 - 21.4	15	ų	6.7	
TOTAL	1145	85	7.4	6.0 - 9.1	708	38	5.4	3.8 - 7.3

screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race. Sample includes both injection drug users (IDUs) who have a history of needle use since 1978, and non-injection drug users who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment Excludes persons with a prior admission to treatment during the survey period, persons who were preferentially admitted to treatment due to HTV/AIDS, and persons under alcohol treatment only. Blood specimens were collected for syphilis This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program.

HIV SEROPREVALENCE FOR INJECTION DRUG USERS (IDUs) AND NON-INJECTION DRUG USERS (NON-IDUS) ENTERING A DRUG-FREE DETOXIFICATION PROGRAM BY AGE-GROUP, SAN FRANCISCO, 1990 - 1994 (1)

3.8 - 7.3	5.4	38	708	6.0 - 9.1	7.4	85	1145	TOTAL
	0.0	0	ω		0.0	0	6	MISSING
0.6 - 15.5	4.5	ν	44	7.6 - 21.6	13.5	14	104	45 AND OVER
2.3 - 13.0	6.2	6	97	5.6 - 14.2	9.2	18	195	40 - 44
0.8 - 7.5	3.0	4.	134	4.2 - 10.9	7.0	18	256	35 - 39
4.5 - 13.9	8.4	13	155	5.7 - 13.9	9.2	20	217	30 - 34
3.1 - 10.8	6.2	11	178	2.6 - 9.0	5.1	11	214	25 - 29
	2.2	N	90	0.8 - 7.4	2.9	4.	136	20 - 24
	0.0	0	7		0.0	0	17	19 AND UNDER
SERO- PREVALENCE RATE (*) (95 * C.I.) (3)	SERO- PREVALENCE RATE (%)	NUMBER (2) POSITIVE	NUMBER	SERO- REVALENCE RATE (%) (95% C.I.)(3)	SERO- PREVALENCE RATE (%)	NUMBER (2) POSITIVE	NUMBER	AGE-GROUP (YEARS)
	1000	MOM-TOGO			ŭ	TDOS		
	TOITO	NON			ī	Thri		

⁽¹⁾ This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Sample includes both injection drug users (IDUs) who have a history of needle use since 1978, and non-injection drug users who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment Excludes persons with a prior admission to treatment during the survey period, persons who were preferentially admitted to treatment due to HIV/AIDS, and persons under alcohol treatment only. Blood specimens were collected for syphilis screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

3.8 - 7.3	5.4	38	708	6.0 - 9.1	7.4	85	TOTAL 1145
0.8 - 10.7 3.5 - 8.0 	3.8 5.4 0.0 2.24	4 8 0 0 3 3	79 425 0 0 3 22 179	2.5 - 5.3 2.4 - 20.4 5.6 - 25.8 5.1 - 29.9 14.1 - 29.9 8.8 - 20.5	3.7 8.5 13.5 13.9	29 4 7 0 21 21	PEROIN  TREATMENT OF THE PROPERTY OF THE PROPE
SERO- REVALENCE RATE (%) (95% C.I.)(3)	SERO- PREVALENCE RATE (%)	NUMBER (2) POSITIVE	NUMBER	SERO- REVALENCE RATE (%) (95% C.I.)(3)	SERO- PREVALENCE RATE (%)	NUMBER (2) POSITIVE	PRIMARY DRUG TESTED
	NON-IDUS	-NON			<b>6</b>	IDUs	

Excludes persons with a prior admission to treatment during the survey period, persons who were preferentially admitted to treatment due to HIVAIDS, and persons under alcohol treatment only. Blood specimens were collected for syphilis screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. Sample includes both injection drug users (IDUs) who have a history of needle use since 1978, and non-injection drug users who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment. This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program.

		198	1989 SURVEY			199	1990 SURVEY			199	1991 SURVEY	
TRANSMISSION CATEGORY	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95 <b>%</b> C.I.) (3)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)
Heterosexual IDU (4) Sex Partner at Risk for HIV Blood Recipient (5) Heterosexual (6) Unknown Risk (7)	1266	00004	0.32	0.09 - 0.81	20 24 11 1313 8	0+00+	0.00 0.00 0.00 0.00	0.13 -24.87 0.00 -11.73 0.00 - 0.42	9 11 4 1925 8	0000+	11.11 0.00 0.10 0.00	0.01 - 0.37
TOTAL	1266	44	0.32	0.09 - 0.81	1376	2	0.15	0.02 - 0.52	1957	ω	0.15	0.03 - 0.45
		199	1992 SURVEY						•			
TRANSMISSION CATEGORY	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)								
Heterosexual IDU (4) Sex Partner at Risk for HIV Blood Recipient (5) Heterosexual (6) Unknown Risk (7)	1293 0	0 0 0 0 0	0.00	0.00 - 0.43								
TOTAL	1297	1	0.08	0.00 - 0.43								
(1) This unlinked (blinded) survey was drawn from women seeking family planning services. Specimens were collected from initial and annual visits, and tested for HIV after all personal identifiers were removed.  (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (3) 954 Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. Includes persons with a history of injection drug use (IDU) since January 1978.  (4) Includes persons with a history of blood transfusions(s) between January 1977 and March 1985.  (5) Includes persons with a history of blood transfusions(s) between January 1977 and March 1985.  (6) Self-identified heterosexuals with no other identified risks.	rrey was can test and test can exact bind istory of istory of istory of interpretable with ralls with ralls with results of the results of th	irawn from the for HIV reactive mial. Condition displayed transplayed transpla	women seekir all parter all parter all parter all parter all parter and parte	g family planning ersonal identification of the property of th	y services ers were r a Western a nted for s 1978.	. Specimens emoved. blot assay. ample sizes rch 1985.	were colle	cted				

		ΣŁΤ	1989 SURVEY			19	1990 SURVEY			199	1991 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER (2)	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)
WHITE	122	ъ	0.82	0.02 - 4.48	126	, р	0.79	0.02 - 4.34	156	0	0.00	0.00 - 1.90
AFRICAN AMERICAN	154	, р	0.65	0.02 - 3.56	145	0	0.00	0.00 - 2.04	141	, µ	0.71	0.02 - 3.89
LATINA	810	o N	0.25	0.03 - 0.89	908	. 0	0.00	0.00 - 0.33	1441	o N	0.14	0.02 - 0.50
NONE OF THE ABOVE (4)	31	, o c	0.00	0.00 - 1.33	31	0 H	0.00	0.00 - 9.21	41	00	0.00	0.00 - 7.05
						¢.						
TOTAL	1266	44	0.32	0.09 - 0.81	1376	N	0.15	0.02 - 0.52	1957	ω	0.15	0.03 - 0.45
		199	1992 SURVEY									
RACE/ETHNICITY	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)								
WHITE	82	0	0.00	0.00 - 3.59	'							
AFRICAN AMERICAN	1001	- 0	0.00	0.00 - 2.81								
ASIAN/PACIFIC ISLANDER	94	0 1	0.00	0.00 - 3.14								
NONE OF THE ABOVE (4)	15	0	0.00		!							
TOTAL	1297	1	0.08	0.00 - 0.43	,							
(1) This unlinked (blinded) survey was drawn from women seeking family planning services. Specimens were collected	irvey was d	lrawn from v	Momen seekin	g family plannir	g services	. Specimen	s were colle	ected				

trom initial and annual visits, and tested for HTV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

		198	1989 SURVEY			199	1990 SURVEY			199	1991 SURVEY	
AGE-GROUP (YEARS)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95 <b>%</b> C.I.) (3)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (*)	(95 <b>%</b> C.I.) (3)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)
								- 1				
19 AND UNDER	73	0	0.00		93	, 0	0.00	0.00 - 3.17	107	, c	0.00	0.00 - 2.78
20 - 24	420	1	0.24	0.01 - 1.32	474	0	0.00	0.00 - 0.63	636	0	0.00	- 1
25 - 29	414	1	0.24		401	0	0.00		646	2	0.31	- 1
30 - 34	226	2	0.88	0.11 - 3.16	243	ם	0.41	0.01 - 2.27	334	0	0.00	1
35 - 39	105	0	0.00	1	97	0	0.00	1	175	1	0.57	0.01 - 3.14
40 - 44	18	0	0.00	ı	34	ב	2.94	0.07 -15.33	42	0	0.00	1
45 AND OVER	7	0	0.00		00	0	0.00		6	0	0.00	
UNKNOWN	ω.	0 (	0.00		26	0	0.00	0.00 -10.88	1	0	0.00	
Cartanonia												
TOTAL	1266	44	0.32	0.09 - 0.81	1376	2	0.15	0.02 - 0.52	1957	ω	0.15	0.03 - 0.45
		1992	2 SURVEY									
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	·							
19 AND INDER	ر م	Þ	0	0 00 - 4 87								
20 - 24	390	0 (	0.00	0.00 - 0.77								
25 - 29	427	1	0.23	0.01 - 1.30	_							
30 - 34	223	0	0.00	0.00 - 1.33								
35 - 39	138	0	0.00	0.00 - 2.15								
40 - 44	45	0	0.00	0.00 - 6.44								
UNKNOWN	<b>б</b> 0	00	0.00	: :								
TOTAL	1297	P	0.08	0.00 - 0.43								
								•				
from initial and annual visits, and tested for HIV after all personal identifiers were removed.  (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes	ere repeated , exact bind	ed for HIV lly reactive mial. Conf	after all pe by ELISA ar idence Inter	r HIV after all personal identifiers were removed. active by ELISA and confirmed by a Mestern blot assay. Confidence Intervals not calculated for sample sizes under 20 observations	ers were re a Western k ated for sa	emoved. olot assay. emple sizes	under 20 ob	servations.				

0.56 - 2.29	1.21	9	742	0.49 - 2.01	0.45	1.06	9	846	0.14 - 2.02	0.70	u	431	TOTAL
0.22 - 1.59	14.29 60.00 0.68	0 M W P	7 5 730	0.13 - 1.25	0.13	35.71 0.00 0.49 0.00	NO40	14 7 817	0.06 - 1.71	12.50 0.00 0.48 0.00	0 20 0 P	8 419 1	Heterosexual IDU (4) Sex Partner at Risk for HIV Heterosexual (5) Unknown Risk
SERO- PREVALENCE PATE (*) (95* C.I.) (3)	SERO- PREVALENCE RATE (%)	NUMBER(2) POSITIVE	NUMBER TESTED	SERO- PREVALENCE RATE (*) (95% C.I.) (3)	ICE (95%		NUMBER (2) POSITIVE	NUMBER TESTED	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	SERO- PREVALENCE RATE (%)	NUMBER (2) POSITIVE	NUMBER TESTED	TRANSMISSION CATEGORY
	1992 SURVEY	199			,	1991 SURVEY	19	,		1990 SURVEY	199		

 This unlinked (blinded) survey was drawn from women seeking induced abortions. Specimens were collected for evaluation purposes, and tested for HIV after all personal identifiers were removed.
 All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 Self Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.
 Includes persons with a history of injection drug use (IDU) since January 1978.
 Self-identified heterosexuals with no other identified risks. Specimens were collected for evaluation

		199	1990 SURVEY			19	1991 SURVEY			199	1992 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)
WHITE	50	1	2.00	0.05 -10.65	71	3	4.23	0.88 -11.86	50	N	4.00	0.49 -13.71
AFRICAN AMERICAN	106	2	1.89	0.23 - 6.65	206	w	1.46	0.30 - 4.20	172	6	3.49	1.29 - 7.44
LATINA	223	0	0.00	0.00 - 1.33	437	ω	0.69	0.14 - 1.99	393	0	0.00	0.00 - 0.76
ASIAN/PACIFIC ISLANDER	45	0	0.00	0.00 - 6.44	107	0	0.00	0.00 - 2.76	108	0	0.00	0.00 - 2.74
NONE OF THE ABOVE (4)	7	0	0.00		25	0	0.00	0.00 -11.29	19	1	5.26	
TOTAL	431	ω	0.70	0.14 - 2.02	846	9	1.06	0.49 - 2.01	742	9	1.21	0.56 - 2.29
(1) This unlinked (blinded) survey was drawn from women seeking induced abortions. Specimens were collected for evaluation purposes, and tested for HIV after all personal identifiers were removed.  (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.	urvey was cafter all per repeated exact bind	irawn from w personal ide ily reactive	vomen seekir entifiers we by ELISA a idence Inte	ng induced abortions or removed.  and confirmed by a calculation of calculations.	ons. Spec	imens were blot assay.	collected fo	r evaluation				
(3) 95% confidence intervals, exact pinomial. confidence intervals not carculated for sample significant (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race	can Indian	and Alaskar	Native and	cestry, other race	e, and unk	nown race.	miner 50 Or	SCIVACIOIS.				

TOTAL	19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 35 - 39 40 - 44 45 AND OVER UNKNOWN	AGE-GROUP (YEARS)	
431	68 1139 106 80 26 8	NUMBER TESTED	
ω	00000000	NUMBER (2) POSITIVE	199
0.70	0.00 0.72 0.00 2.50 0.00	SERO- PREVALENCE RATE (%)	1990 SURVEY
0.14 - 2.02	0.00 - 4.31 0.02 - 3.94 0.00 - 2.79 0.30 - 8.74 0.00 - 10.88	SERO- PREVALENCE RATE (%) (95% C.I.) (3)	
846	133 253 223 118 86 87 27	NUMBER	,
9	00011421	NUMBER (2) POSITIVE	199
1.06	0.75 0.79 1.79 1.85 1.16 0.00	SERO- PREVALENCE RATE (%)	1991 SURVEY
0.49 - 2.01	0.02 - 4.12 0.10 - 2.83 0.49 - 4.53 0.02 - 4.63 0.03 - 6.63 0.00 - 10.50	SERO- REVALENCE RATE (%) (95% C.I.)(3)	
742	1112 189 202 131 81 83 23	NUMBER	
v	1000130	NUMBER (2) POSITIVE	1992
1.21	0.00 1.06 1.49 0.76 0.47 0.00 0.00	SERO- PREVALENCE RATE (%)	32 SURVEY
0.56 - 2.29	0.00 - 2.64 0.13 - 3.77 0.31 - 4.28 0.02 - 4.18 0.30 - 8.64 0.00 - 12.21	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	

This unlinked (blinded) survey was drawn from women seeking induced abortions. Specimens were collected for evaluation purposes, and tested for HIV after all personal identifiers were removed.
 All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 Starting of the property of the personal identifiers were removed. Specimens were collected for evaluation

²⁴ 

HIV SEROPREVALENCE FOR NEWBORN INFANTS AND THEIR MOTHERS BY AGE GROUP AND RACE/ETHNICITY, 1989-1993 (1)

		198	1989 SURVEY			199	1990 SURVEY			199	1991 SURVEY	
	NUMBER TESTED	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95 <b>%</b> C.I.) (3)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)	NUMBER TESTED	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)
AGE-GROUP (YEARS)					:							
UNDER 20	219	٢	0.46	0.01 - 2.52	181	0	0.00	0.00 - 1.64	206	1	0.49	0.01 - 2.67
20 - 24	442	2	0.45	0.05 - 1.62	446	0	0.00	0.00 - 0.67	454	0	0.00	0.00 - 0.66
25 - 29	638	0	0.00	ı	618	-	0.16	1	653	4	0.61	1
30 - 34	625	0	0.00	0.00 - 0.48	625	۲	0.16		695	2	0.29	
35 AND OVER	485	0	0.00	0.00 - 0.62	451	0	0.00	0.00 - 0.66	429		0.23	1
UNKNOWN	138	н	0.72	0.02 - 3.97	117	0	0.00	0.00 - 2.53	72	٢	1.39	0.04 - 7.50
RACE/ETHNICITY												
WHITE	679	- 0	0.00	0.00 - 0.44	663	o µ	0.15	0.00 - 0.84	640	حد س	0.63	0.17 - 1.59 $0.20 - 2.74$
LATINO	564	. ب	0.18	0.00 - 0.98	608	۲	0.16	0.00 - 0.91	634	_	0.16	ı
ASIAN/PACIFIC IS.	636	0	0.00	1	633	0	0.00	1	454	0	0.00	- 1
OTHER	206		0.49	- 1	115	0	0.00	ı	367	. 0	0.00	-1
CNKNOWN	124	۰	0.78	0.02 - 4.28	y	c	0.00	0.00 - 3.10		۰	1.04	0.00
TOTAL - SAN FRANCISCO	2547	44	0.16	0.04 - 0.40	2438	2	0.08	0.01 - 0.30	2509	9	0.36	0.16 - 0.68
TOTAL - BAY AREA (4)	21217	25	0.12	0.08 - 0.17	21397	23	0.11	0.07 - 0.16	22103	31	0.14	0.10 - 0.20
TOTAL - STATEWIDE	144284	92	0.06	0.05 - 0.08	150494	106	0.07	0.06 - 0.09	154918	124	0.08	0.07 - 0.10
(1) Data courtesy of the California Department of Health Services Office of AIDS. Specimens from this survey of newborn infants (and women giving birth) are drawn from the genetic diseases screening program. Antibodies in a newborn infant reflect the infection status of the mother and not necessarily of the child. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes the counties of Alameda, Contra Costa, Marin, San Francisco, San Mateo, and Santa Clara.	fornia Depar ving birth) he infection re repeatedl exact binom Alameda, Con	rtment of H are drawn n status of ly reactive nial. Conf	fealth Servi from the ge the mother by ELISA a Eidence Inte	ices Office of Al enetic diseases a r and not necessa and confirmed by ervals not calcul	DS. Specimorerening property of the a Western by atted for say	ens from th ogram. Ant child. lot assay. imple sizes	Antibodies Antibodies ay. ay. tes under 20 ok	of Oservations.				

		199	1992 SURVEY		,	199	1993 SURVEY	
	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER (2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.) (3)
AGE-GROUP (YEARS)								
UNDER 20	165	0	0.00	0.00 - 1.80	170	ш	0.59	0.01 - 3.23
20 - 24	428	0	0.00	ı	446	0	0.00	0.00 - 0.67
25 - 29	639	2	0.31	1	662	-	0.15	0.00 - 0.84
30 - 34	628	N	0.32	1	677	2	0.30	0.04 - 1.06
35 AND OVER	446		0.22		466	۲	0.21	0.01 - 1.19
UNKNOWN	136	0	0.00	0.00 - 2.18	14	o	0.00	:
RACE/ETHNICITY								
WHITE	646	0	0.00	0.00 - 0.46	717	N	0.28	0.03 - 1.00
AFRICAN AMERICAN	312	ຫ	1.60		316		0.32	0.01 - 1.75
LATINO	610	0	0.00	0.00 - 0.49	590	2	0.34	0.04 - 1.22
ASIAN/PACIFIC IS.	135	<b>&gt;</b> 0	0.00	0.00 - 0.45	148	00	0.00	0.00 - 0.45
UNKNOWN	77	0	0.00	0.00 - 3.82	3	0	0.00	
TOTAL - SAN FRANCISCO	2442	σ	0.20	0.07 - 0.48	2435	տ	0.21	0.07 - 0.48
TOTAL - BAY AREA (4)	21565	31	0.14	0.10 - 0.20	21601	16	0.07	0.04 - 0.12
TOTAL - STATEWIDE	151033	101	0.07	0.05 - 0.08	150598	83	0.06	0.04 - 0.07

 ⁽¹⁾ Data courtesy of the California Department of Health Services Office of AIDS. Specimens from this survey of newborn infants (and women giving birth) are drawn from the genetic diseases screening program. Antibodies in a newborn infant reflect the infection status of the mother and not necessarily of the child.
 (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot asset of the child.
 (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.
 (4) Includes the counties of Alameda, Contra Costa, Marin, San Francisco, San Mateo, and Santa Clara.

TOTAL	Heterosexual (5) Unknown Risk SUB-TOTAL FEMALE	>	HALE HOMOSEXUAL/BiseXUAL HOMOSEXUAL/BiseXUAL, IDU (4) HeteroseXUAL/BiseXUAL, IDU (4) HeteroseXUAL (5) Unknown Risk	GENDER AND TRANSMISSION CATEGORY
446	13 112	334 16	62 29 31 196	NUMBER
94	5 0 1	ου 4s ι	46 22 7 12 2	NUMBER (2) POSITIVE
21.1	4.5	25.0	74.2 75.9 22.6 6.1 12.5	SERO- PREVALENCE RATE (%)
17.4 - 25.2	1 1	22.0 - 31.7	1 1 1 1 1	(95% C.I.) (3)

⁽¹⁾ This interview-based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and TB suspects (class 5). Data collected between the 1st quarter of 1989 and the 4th quarter of 1992.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons with a history of injection drug use (IDU) since January 1978.

(5) Includes persons with a sexual partner(s) at risk for HIV, persons with a history of blood transfusion(s) or with a

Includes persons with a history of injection drug use (IDU) since January 1978.

Includes persons with a sexual partner(s) at risk for HIV, persons with a history of blood transfusion(s) or with a bleeding disorder, and self-identified heterosexuals with no other identified risks.

TOTAL	BORN IN USA BORN OUTSIDE USA	ORIGIN OF BIRTH
446	229 217	NUMBER TESTED
94	82 12	NUMBER (2) POSITIVE
21.1	35.8 5.5	SERO- PREVALENCE RATE (%)
17.4 - 25.2	29.6 - 42.4 2.9 - 9.5	SERO- PREVALENCE RATE (%) (95% C.I.)(3)

This interview-based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and TB suspects (class 5). Data collected between the 1st quarter of 1999 and the 4th quarter of 1992.
 All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

TOTAL	AFRICAN AMERICAN LATINO LATINO ASIAN/PACIFIC ISLANDER NOME OF THE ABOVE (4)	RACE/ETHNICITY
446	93 112 94 136	NUMBER
94	39 30 19 2	NUMBER (2) POSITIVE
21.1	41.9 26.8 20.2 1.5 36.4	SERO- PREVALENCE RATE (%)
17.4 - 25.2	31.8 - 52.6 18.9 - 36.0 12.6 - 29.8 0.2 - 5.2	SERO- PREVALENCE RATE (*) (95% C.I.)(3)

⁽¹⁾ This interview-based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and TB suspects (class 5). Data collected between the lst quarter of 1999 and the 4th quarter of 1992.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TOTAL	19 AND UNDER 20 - 29 30 - 39 40 - 49 50 AND OVER UNKNOWN	AGE-GROUP (YEARS)
446	9 78 128 108 123 0	NUMBER
94	1 20 33 32 0	NUMBER (2) POSITIVE
21.1	29.6 6.5	SERO- PREVALENCE RATE (%)
17.4 - 25.2	16.4 - 36.8 18.5 - 34.3 21.2 - 34.3 2.1.2 - 39.2 2.8 - 12.4	(95% C.I.) (3)

This interview-based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and TB suspects (class 5). Data collected between the 1st quarter of 1999 and the 4th quarter of 1992.
 All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 Can all positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 Can all positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

TOTAL	MISSING GENDER	SUB-TOTAL FEMALE	Heterosexual IDU (4) Heterosexual (5) Unknown Risk	FEMALE	SUB-TOTAL MALE	Homosexual/Bisexual Heterosexual, IDU (4) Heterosexual (5) Unknown Risk	MALE	GENDER AND TRANSMISSION CATEGORY
2415	6	531	17 509 5		1878	19 23 1817 19		NUMBER
œ	0	(L)	0 0		5	4040		NUMBER (2) POSITIVE
0.3	0.0	0.6	000		0.3	0.005		SERO- PREVALENCE RATE (%)
0.1 - 0.7		0.1 - 1.6	0.1 - 1.7		0.1 - 0.6	0.0 - 12.2		(95% C.I.) (3)

(1) This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood specimens were collected for syphilis screening on inmates as part of the routine intake process. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95 Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons with a history of injection drug use (IDU) since January 1978.

TOTAL	HHITE APRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NOME OF THE ABOVE (4)	RACE/ETHNICITY
2415	205 1236 597 320 57	NUMBER
œ	01160	NUMBER(2) POSITIVE
0.3	0.5 0.5 0.3	SERO- PREVALENCE RATE (%)
0.1 - 0.7	0.0 - 1.5 0.2 - 1.1 0.2 - 0.9 0.0 - 1.7 0.0 - 5.1	SERO- PREVALENCE RATE (%) (95% C.I.)(3)

(1) This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood specimens were collected for syphilis screening on inmates as part of the routine intake process. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

AGE-GROUP (YEARS)	NUMBER	NUMBER (2) POSITIVE	PREVALENCE RATE (%)	PREVALENCE RATE (%) (95% C.I.)(3)
UNDER 15	445	H	0.2	0.0 - 1.2
15 - 19	1933	7	0.4	0.1 - 0.7
20 - 24	4	0	0.0	
25 - 29	0	0		
UNKNOWN	33	0	0.0	0.0 - 8.7
TOTAL	2415	œ	0.3	0.1 - 0.7

This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood specimens were collected for syphilis acreening on inmates as part of the routine intake process. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.
 All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 St Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

TOTAL	MISSING GENDER	SUB-TOTAL FEMALE	(5)	Heterosexual IDU (4)	FEMALE	SUB-TOTAL MALE		Heterogexual, IDU (4) Heterogexual (5)	 Gay/Bisexual	MALE	GENDER AND TRANSMISSION CATEGORY
2593	10	1522	1320	170		1061	23	78 591	369		NUMBER
195	2	18	٥٤	7		175	۳	o N	166		NUMBER (2) POSITIVE
7.5	20.0	1.2	0.0	<b>4</b> .1		16.5	4.3	2.6	45.0		SERO- PREVALENCE RATE (%)
6.5 - 8.6	2.5 - 55.6	0.7 - 1.9	0.4 - 1.5	1.7 - 8.3		14.3 - 18.9	•	0.3 - 8.9			(95% C.I.) (3)

⁽¹⁾ This unlinked (blinded) survey include adolescents seeking services at two homeless youth shelters. Blood specimens were collected for syphilis screening as part of the routine medical evaluation. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 915 Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons with a history of injection drug use (IDU) since January 1978.

TOTAL 2593	WHITE 1044 APRICAN AMERICAN 570 LATINO ASIAN/PACIFIC ISLANDER 257 NONE OF THE ABOVE (4) 106	RACE/ETHNICITY TESTED
195	122 24 32 11	NUMBER (2) POSITIVE
7.5	11.7 4.2 5.2 4.3	SERO- PREVALENCE RATE (%)
6.5 - 8.6	9.8 - 13.8 2.7 - 6.2 3.6 - 7.3 3.2 - 7.5 2.1 - 11.9	SERO- PREVALENCE RATE (%) (95% C.I.)(3)

(1) This unlinked (blinded) survey include adolescents seeking services at two homeless youth shelters. Blood specimens were collected for syphilis acreening as part of the routine medical evaluation. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.

(3) 95% Confidence Intervals, exact binomial. (Onlidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

TOTAL	UNDER 15 15 - 19 20 - 24 25 - 29 UNXVOWN	AGE-GROUP (YEARS)
2593	272 1874 415 5	NUMBER
195	2 59 131 1 2	NUMBER (2) POSITIVE
7.5	0.7 3.1 31.6 20.0 7.4	SERO- PREVALENCE RATE (%)
6.5 - 8.6	0.1 - 2.6 2.4 - 4.0 2.7.1 - 36.3 0.5 - 71.6 0.9 - 24.3	SERO- PREVALENCE RATE (%) (95% C.I.)(3)

This unlinked (blinded) survey include adolescents seeking services at two homeless youth shelters. Blood specimens were collected for syphilis screening as part of the routine medical evaluation. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.
 All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 Secure of the confidence of

HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENDER AND YEAR, 1985 - 1994 (1)

	The second second					
	6440 25 0.39	373 2 0.54	395 0 0.00	401 1 0.25	工 480 2 0.42	TOTAL
	5357 23 0.43 1083 2 0.18	300 2 0.67 73 0 0.00	322 0 0.00 73 0 0.00	315 1 0.32 86 0 0.00	. 407 2 0.49 LLE 73 0 0.00	MALE FEMALE
	N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	DER N(2) HIV+(3) %(4)	GENDER
	TOTAL	1994	1993	1992	1991	
	N					
625 0 0.00	835 3 0.36	937 2 0.21	1012 5 0.49	1124 10 0.89	AL 258 0 0.00	TOTAL
520 0 0.00 105 0 0.00	711 2 0.28 124 1 0.81	759 2 0.26 178 0 0.00	869 5 0.58 143 0 0.00	941 9 0.96 183 1 0.55	213 0 0.00 LLE 45 0 0.00	MALE FEMALE
N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	DER N(2) HIV+(3) %(4)	GENDER
1990	1989	1988	1987	1986	1985	

Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC). Data Collected between October 1984 and December 1994.
 Wumber of specimens tested.
 Number of specimens tested.
 All positive specimens were repeatedly reactive by EUISA and confirmed by a Western blot assay.
 Seroprevalence rate (%).

	6440 25 0.39	373 0 0.00	395 2 0.51	401 1 0.25	TOTAL 480 2 0.42
	2249 15 0.67 1167 7 0.59 716 2 0.28 2083 0 0.00 . 225 1 0.44	134 2 1.49 47 0 0.00 47 0 0.00 133 0 0.00 12 0 0.00	142 0 0.00 43 0 0.00 64 0 0.00 133 0 0.00	134 0 0.00 53 0 0.00 49 1 2.04 158 0 0.00 7 0 0.00	HHITE 160 2 1.25 BLACK 63 0 0.00 LATINO 68 0 0.00 ASIAN/P.I. 173 0 0.00 OTHER 16 0 0.00
	N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	RACE/ETHNICITY N(2) HIV+(3) %(4)
	TOTAL	1994	1993	1992	1991
625 0 0.00	835 3 0.36	937 2 0.21	1012 5 0.49	1124 10 0.89	TOTAL 258 0 0.00
210 0 0.00 85 0 0.00 78 0 0.00 232 0 0.00 20 0.00	286 1 0.35 178 1 0.56 102 1 0.98 253 0 0.00 16 0 0.00	334 1 0.30 193 1 0.52 115 0 0.00 267 0 0.00 28 0 0.00	346 2 0.58 212 3 1.42 1108 0 0.00 320 0 0.00 26 0 0.00	409 7 1.71 242 2 0.83 74 0 0.00 329 0 0.00 70 1 1.43	WHITE 94 0 0.00 BLACK 51 0 0.00 LATINO 11 0 0.00 ASIAN/P.I. 85 0 0.00 OTHER 17 0 0.00
N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	RACE/ETHNICITY N(2) HIV+(3) %(4)
1990	1989	1988	1987	1986	1985

Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC). Data Collected between October 1985 and December 1994.
 Wimber of specimens tested.
 Wimber of specimens tested.
 All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 Seroprevalence rate (*).

HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY AGE-GROUP AND YEAR, 1985 - 1994 (1)

	2862 3 0.10 1622 4 0.25	137 0 0.00 106 0 0.00	174 0 0.00 108 0 0.00	193 0 0.00 99 0 0.00	19 AND UNDER 227 1 0.44 20 - 24 110 0 0.00
	N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	AGE-GROUP N(2) HIV+(3) %(4)
	TOTAL	1994	1993	1992	1991
625 0 0.00	835 3 0.36	937 2 0.21	1012 5 0.49	1124 10 0.89	TOTAL 258 0 0.00
300 0 0.00 111 0 0.00 0 0 0.00	352 0 0.00 211 1 0.47 170 2 1.18 102 0 0.0 0 0 .	417 1 0.24 236 0 0.00 163 1 0.61 121 0 0.00 0 0 .	448 0 0.00 265 1 0.38 166 1 0.60 133 3 2.26	485 1 0.21 285 2 0.70 204 3 1.47 150 4 2.67 0 0 2.6	19 AND UNDER 129 0 0.00 20 - 24 48 0 0.00 25 - 29 45 0 0.00 30 AND OVER 36 0 0.00 UNKNOWN 0 0
N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	N(2) HIV+(3) %(4)	AGE-GROUP N(2) HIV+(3) %(4)
1990	1989	1988	1987	1986	1985

25 - 29 30 AND OVER UNKNOWN

76 67

004

1.32

65 44 0

001

0.00

45

000

0.00

76 54 0

0 10 0

3.70

1144 812 0

0.79

TOTAL

480

Ν

0.42

401

μ

0.25

395

0

0.00

373

N

0.54

6440

25

0.39

Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC). Data Collected between October 1985 and December 1994.
 Number of specimens tested.
 N11 positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 Seroprevalence rate (%).

TOTAL	1985 1986 1987 1988 1989 1990 1991 1991 1992 1993	YEAR OF DONATION
809457	72204 88168 91396 90192 87320 87320 87370 7787 778097 70545 69684	TOTAL
216	80 40 30 23 11 11 6 6	NUMBER (2) POSITIVE
0.027	0.111 0.045 0.033 0.033 0.026 0.011 0.013 0.010 0.000 0.000	SERO- PREVALENCE RATE (%)
0.023 - 0.031	0.088 - 0.139 0.033 - 0.662 0.023 - 0.047 0.017 - 0.039 0.006 - 0.022 0.007 - 0.024 0.005 - 0.018 0.001 - 0.014 0.003 - 0.018	(95% C.I.) (3)

 ⁽¹⁾ Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca.
 (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 (3) 95% Confidence Intervals, normal approximation.

HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY DONATION STATUS AND GENDER, JANUARY 1991 - DECEMBER 1994 (1)

i	1					i
	TOTAL	DONORS	REPEAT	DONORS	FIRST-TIME	DONATION
		Female	Male	Female	Male	GENDER
	295599	TORSOR	120810	33727	32754	TOTAL
	22		4. (	W	13	NUMBER (2) POSITIVE
	0.007	0.002	0.003	0.009	0.040	PREVALENCE RATE (%)
	0.005 - 0.011	0.000	0.001 - 0.009	0.002 - 0.028	0.022 - 0.070	(95 <b>%</b> C.I.) (3)


Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca.
 All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 95% Confidence Intervals, normal approximation.

TOTAL	WHITE AFRICAN AMERICAN ASSAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	RACE/ETHNICITY
295599	243645 11941 22218 17795	TOTAL
22	12 7 0	NUMBER (2) POSITIVE
0.007	0.005 0.059 0.000 0.017	SERO- PREVALENCE RATE (%)
0.005 - 0.011	0.003 - 0.009 0.026 - 0.127 0.000 - 0.016 0.004 - 0.054	(95% C.I.) (3)

Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca.
 All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 Spt Confidence Intervals, normal approximation.
 Includes Latinos, American Indians, Alaskan Natives, other race, and unknown race.

TOTAL	40 AND OVER	30 - 39	20 - 29	19 AND UNDER	AGE-GROUP (YEARS)
295599	144798	79409	51933	19459	TOTAL
22	ω	14	υī	0	NUMBER (2) POSITIVE
0.007	0.002	0.018	0.010	0.000	PREVALENCE RATE (*)
0.005 - 0.011	0.001 - 0.007	0.010 - 0.030	0.004 - 0.024	0.000 - 0.019	(95% C.I.) (3)

 ⁽¹⁾ Data provided by the Irvin Memorial Blood Centers, San Francisco, Ca.
 (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
 (3) 95% Confidence Intervals, normal approximation.





## **HIV Seroprevalence Report**

DOCUMENTS DEPT.

JUN 26 1996 SAN FRANCISCO PUBLIC LIBRARY

San Francisco Department of Public Health AIDS Office May, 1996 Volume 7, No. 1

## Contents

	Page
SURVEY OF CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC: 1989-94	
HIV Seroprevalence for Clients Attending a STD Clinic by Gender and Transmission Category HIV Seroprevalence for Clients Attending a STD Clinic by Race/Ethnicity HIV Seroprevalence for Clients Attending a STD Clinic by Age Group HIV Seroprevalence for Gay & Bisexual Men Attending a STD Clinic by Race/Ethnicity HIV Seroprevalence for Gay & Bisexual Men Attending a STD Clinic by Age Group HIV Seroprevalence for Heterosexual Males Attending a STD Clinic by Race/Ethnicity HIV Seroprevalence for Heterosexual Males Attending a STD Clinic by Age Group HIV Seroprevalence for Heterosexual Females Attending a STD Clinic by Race/Ethnicity	1 4 6 8 10 12 14
HIV Seroprevalence for Heterosexual Females Attending a STD Clinic by Age Group	18
SURVEY OF INJECTION DRUG USERS (IDUS) ENTERING METHADONE TREATMENT PROGRAMS	
HIV Seroprevalence for IDUs Entering Methadone Treatment by Gender & Sexual Orientation HIV Seroprevalence for IDUs Entering Methadone Treatment by Race/Ethnicity HIV Seroprevalence for IDUs Entering Methadone Treatment by Age Group	20 22 23
SURVEY OF DRUG USERS (IDUs & NON-IDUs) ENTERING A METHADONE-FREE DETOX PROGRAM	
HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Gender & Sexual Oriental	tion 24
HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Race/Ethnicity HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Age Group	25 26
HIV Seroprevalence for Clients Entering a Drug-Free Detox Program by Primary Drug	27
SURVEY OF WOMEN OF REPRODUCTIVE AGE: FAMILY PLANNING & ABORTION CLINIC CLIENTS	
HIV Seroprevalence for Women Attending a Family Planning Clinic by Transmission Category HIV Seroprevalence for Women Attending a Family Planning Clinic by Race/Ethnicity HIV Seroprevalence for Women Attending a Family Planning Clinic by Age Group HIV Seroprevalence for Women Attending an Abortion Clinic by Transmission Category HIV Seroprevalence for Women Attending an Abortion Clinic by Race/Ethnicity HIV Seroprevalence for Women Attending an Abortion Clinic by Age Group	28 29 30 31 32 33
SURVEY OF CHILDBEARING WOMEN IN SAN FRANCISCO: 1989-93	
HIV Seroprevalence for Newborn Infants and Their Mothers by Age Group and Race/Ethnicity	34
SURVEY OF PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A TB CLINIC	
HIV Seroprevalence for TB Patients by Gender and Transmission Category HIV Seroprevalence for TB Patients by Origin of Birth HIV Seroprevalence for TB Patients by Race/Ethnicity	36 37 38

## SURVEY OF ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER (JDC) AND HOMELESS YOUTH CENTERS (HYCs)

HIV Seroprevalence for Adolescents Entering a JDC by Gender & Transmission Category	40
HIV Seroprevalence for Adolescents Entering a JDC by Race/Ethnicity	41
HIV Seroprevalence for Adolescents Entering a JDC by Age Group	42
HIV Seroprevalence for Adolescents Entering HYCs by Gender & Transmission Category	43
HIV Seroprevalence for Adolescents Entering HYCs by Race/Ethnicity	44
HIV Seroprevalence for Adolescents Entering HYCs by Age Group	45
RESULTS OF HIV SCREENING OF CIVILIAN APPLICANTS FOR MILITARY SERVICE: 1985-1994	
HIV Seroprevalence for Civilian Applicants for Military Service by Gender & Year	46
HIV Seroprevalence for Civilian Applicants for Military Service by Race/Ethnicity & Year	47
HIV Seroprevalence for Civilian Applicants for Military Service by Age Group & Year	48
RESULTS OF HIV SCREENING OF BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA: 1985-1994	
HIV Seroprevalence for Blood Donors by Year of Donation	49
HIV Seroprevalence for Blooa Donors by Donation Status & Gender	50
HIV Seroprevalence for Blood Donors by Race/Ethnicity	51
HIV Seroprevalence for Blood Donors by Age Group	52
, oo.op.o. a.oo is. soop	

HIV SEROPREVALENCE REPORT is released on a semi-annual basis by the San Francisco Department of Public Health, AIDS Office, Seroepidemiology and Surveillance Branch, 25 Van Ness Avenue, Suite 500, San Francisco, CA 94102-6033. Phone (415) 554-9050. Director of Epidemiology, Disease Control, and AIDS, Mitch Katz, M.D. Seroepidemiology Section Branch Chief, Willi McFarland, M.D., Ph.D. Program Coordinator, Sean Nguyen. Epidemiologist/Data Manager, Tim Kellogg. Funding and technical support is provided by the Division of HIV/AIDS, Centers for Disease Control and Prevention. Additional support is provided by the California Department of Health Services, Office of AIDS.

SION CATEGORY,	
TRANSMISSION	
AND	
GENDER	
CL:NIC BY	
(STD)	
DISEASE	
ENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CL:NIC BY GENDER AND TRANSMISSI	
SEXUALLY	1995 (1)
ENDING A	1989 -
ENTS ATT	NANCI SCO,
R CLI	AN FR
F FC	ς, Υ
SEROPREVALENCE	AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995 (1)
HIV S	AND

1989 SURVEY

1991 SURVEY

1990 SURVEY

GENDER AND TRANSMISSION CATEGORY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	)(3)
HALE															
Gay/Bisexual Gay/Bisexual, IDU (4) Heterosexual IDU (4) Sex Partner at Risk for HIV Blood Recipient (5) Heterosexual (6)	440 114 104 1023 1023	224 81 13 3 14	50 71.7 72.7 7.7 7.7 7.7	61.8 6.8 0.9 0.1 0.8	25.7 20.4 12.0 21.9	626 90 101 103 1381	269 555 29 29 29 29	43.0 61.1 7.9 8.7 11.11	50.3 4.1 7.4	47.0 771.2 15.0 15.9	672 79 118 122 1663	255 377 9 4 10 15	46.8 4.6 3.7 5.5 5.5 7.5	35.5	41.6 58.4 14.0 8.2 3.3
SUB-TOTAL MALE	1788	338	18.9	17.1 -	20.8	2497	396	15.9		17.4	2713	360	13.3		- 14.6
FEMALE															
IDU (4) Sex Partner at Risk for HIV Lesbian/Bisexual (7) Blood Recipient (5) Heterosexual (6) Unknown Risk	55 58 11 380 5	v-o-wo	1.6 1.0 0.0	3.0	20.00	60 55 0 541 19	∾-o-£0	8.3 1.8 16.7 2.4 0.0	2.8 - 0.0 - 1.3	18.4	59 65 26 3 681 15	WW0084	6.000 - 6.000 - 7.2000 - 7.2000	1.1.	14.1 12.9 10.9 2.3
SUB-TOTAL FEMALE	209	10	2.0	- 6.0	3.6	681	20	5.9	1.8 -	4.5	849	15	1.8	1.0 -	2.9
MISSING GENDER	0	0		:	•	0	0		•	•	0	0		:	
TOTAL	2297	348	15.2	13.7 -	16.7	3178	416	13.1	11.9 -	- 14.3	3562	375	10.5	9.5 - 1	- 11.6
These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.  (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (3) ASK Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.  (4) Includes persons with a history of blood transfusions(s) between January 1978 and March 1985.  (5) Self-identified heterosexuals with no other identified risks.  (7) Includes women who have sex with women and women who have sex with both men and women. Lesbian or bisexual women who have are an history of injection drug use (IDU) since 1978 are included in the IDU category. Collection of female sexual orientation began in 1991.	rveys wer examinat IV after a repeate exact binc itory of b itory of b	e drawn from ill pon, and/or ill presonal Illy reactive Mmial. Conf njection dr lood transft o other ide o other ide en and wome	drawn from blood specimens collected for routine syphilis screening on and/or treatment for a NEW SID episode. Specimens were collected to personal identifiers were removed.  Y reactive by ELISA and confiniend by a Western blot assay. In the confidence Intervals not calculated for sample sizes under 20 obsidection drug use (IDU) since January 1978.  Odd transfusions(s) between January 1977 and March 1985.  Odd transfusions(s) between January 1977 and women. Lesbian or bisexual in and women who have sex with both men and women. Lesbian or bisexual in since 1978 are included in the IDU category. Collection of female	imens co or a NEW were re d confir vals not since J tween Ja S. ex with ded in t	ollected f 1 SID epis moved. med by calculat anuary 197 muary 197 he IDU ca	or routine ode. Spec Western bl ed for san 78 and Marc and women, tegory.	utine syphilis screening of Specimens were collected for the blot assay. r sample sizes under 20 on March 1985. March 1985. owen. Lesbian or bisexual y. Collection of female	collected collected mder 20 obs	rervation women wh	·					

	1994 SURVEY
LINIC BY GENDER AND TRANSMISSION CATEGORY,	1993 SURVEY
SEROPREVALENCE FOR CLIENTS ATTENDING A SETUALLY TRANSMITTED DISEASE (STD) CLINIC BY GENDER AND TRANSMISSION CATEGORY, YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995 (1)	1992 SURVEY

AND H

GENDER AND TRANSMISSION CATEGORY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	.)(3)	NUMBER N	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
MALE 														
Gay/Bisexual Gay/Bisexual, IDU (4) Heterosexual IDU (4) Sex Partner at Risk for HIV Blood Recipient (5) Heterosexual (6) Unknown Risk	650 50 104 66 66 7 1575 43	226 19 7 7 36 7	34.8 38.0 6.7 6.1 72.3 16.3	24.7 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 - 1.6 -	38.6 113.4 14.8 33.2	69 44 1771 65 65	23 22 40 12 12 12 13 13	34.2 47.8 8.0 6.3 7.7 18.5	30.7 32.9 3.0 2.1 1.6 9.9	37.8 63.1 14.0 3.1	69 105 1752 4	201 27 20 20 20 20 20 20 20 20 20 20 20 20 20	28.9 4.9.2 3.7.7 1.8 0.0	25.6 - 32.4 36.6 - 61.9 2.7 - 13.3 0.8 - 10.7 1.2 - 2.5
SUB-TOTAL MALE	2495	539	12.0	10.7 - 1	13.3	5749	325	11.8	10.6 -	13.1	2725	574	10.1	9.0 - 11.2
FEMALE														
IDU (4) Sex Partner at Risk for HIV Lesbian/Bisexual (7) Blood Recipient (5) Heterosexual (6) Unknown Risk	26 31 669 7	W-0040	3.8 3.8 0.0 0.0 0.0	0.00	1.5	44 43 698 23	m000 <b>∞</b> −	8000014 5000012	0.00	7.87 9.5 6.7 2.2 21.9	55 57 48 7 661 2	ooro	880080	0.0 - 9.4
SUB-TOTAL FEMALE	977	œ	1.0	- 7.0	2.0	846	12	1.4	- 2.0	2.5	830	2	8.0	0.3 - 1.7
MISSING GENDER	-	0	0.0		•	0	0		•		0	0		:
TOTAL	3272	707	9.4	8.4 - 1	- 10.4	3595	337	9.6	8.4 -	- 10.4	3555	281	6.7	7.0 - 3.8
(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for MIV after all personal identifiers were removed. (2) All positive specimens where repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 5% Confidence intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes persons with a history of injection drug use (IDU) since January 1978. (5) Self-identified heterosexuals with no other identified risks. (6) Self-identified heterosexuals with women and women who have a bistory of injection drug use (IDU) since 1978 are included in the IDU category. Collection of female sexual orientation began in 1991.	veys wer examinat / after a repeated act bino :ory of i :ory of i .ory of b .s with n with wom	trion, and/or treatment for a NEW SID all personal identifiers were removed. diy reactive by ELISA and confinmed by ominal. Confidence intervals not calculification drug use (IDI) since January ho other identified risks.  Dio other identified risks.  Mem and women who have sex with both must both must be since 1978 are included in the IDI)	n from blood specimens collected for routine syphilis screening on nd/or treatment for a NEW SID episode. Specimens were collected sonal identifiers were removed.  Civit by EliSA and confirmed by a Western blot assay.  Confidence Intervals not calculated for sample sizes under 20 observations. of any use (IDU) since January 1978.  Fansfusions(s) between January 1977 and March 1985.  I identified risks.  Women who have sex with both men and women. Lesbian or bisexual women who ce 1978 are included in the IDU category. Collection of female	imens co. or a NEW were red d confirr vals not since Ja tween Jar S. ex with h	Ilected for STD epison moved. The calculate anuary 1971 uary 1972 uary 1972 uary 1972 et 100 cat	or routine ode. Spec Mestern blu ed for sam 78. 7 and Marcl 3nd Women.	trine syphilis screening of Specimens were collected round to assay. r sample sizes under 20 ob March 1985. mann. Lesbian or bisexual y. Collection of female	collected collected nder 20 obs	ervation Women wh	i o				

	(95% C.1.)(3)	24.9 - 31.3 18.9 - 39.5 4.1 - 14.8 0.3 - 8.4 1.0 - 2.2 14.0 - 22.2	1.0 - 13.1 0.0 - 9.9 0.7 - 2.8 0.0 - 2.8 7.8 - 28.8 8.2 - 10 0
5 SURVEY	SERO- PREVALENCE RATE (%)	28.0 28.4 8.3 8.3 17.8	7:1
1995	NUMBER(2) POSITIVE	222 23 23 24 26 26 34 34	8 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
	NUMBER	793 81 120 83 0 1724 354	64 64 64 64 64 64 64 64 64 64 64 64 64 6
	GENDER AND TRANSMISSION CATEGORY	MALE  Gay/Bisexual Gay/Bisexual, IDU (4) Heterosexual IDU (4) Sex Partrer at Risk for HIV Blood Reipient (5) Heterosexual (6) Unknown Risk SUB-TOTAL MALE	FEMALE  1DU (4) Sex Partner at Risk for HIV Lesbian/Bisexual (7) Blood Recipient (5) Hererosexual (6) Unknown Risk SUB-TOTAL FEMALE MISSING GENDER

(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on

individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for NIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes persons with a history of bined of range of (10) since January 1978.

(5) Includes persons with a history of blood transfusions(s) between January 1977 and March 1985.

(6) Self-identified heterosexuals with no other identified risks.

(7) Includes women who have sex with women and women who have sex with both men and women. Lesbian or bisexual women who have an example of injection drug use (100) since 1978 are included in the IDU category. Collection of female sexual orientation began in 1991.

	1991 SURVEY
LINIC BY RACE/ETHNICIT",	1990 SURVEY
HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY RACE/ETHNICIT [*] AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995 (1)	1989 SURVEY

1991 SURVEY	SERO- NUMBER(2) PREVALENCE POSITIVE RATE (%) (95% C.I.)(3)	210 14.7 12.9 - 16.6 78 6.7 5.3 - 8.3 67 9.9 7.8 - 12.4 13 5.6 3.0 - 9.4 7 11.7 4.8 - 22.6	375 10.5 9.5 - 11.6	1994 SURVEY	SERO- NUMBER(2) PREVALENCE POSITIVE RATE (%) (95% C.I.)(3)	147 11.1 9.5 - 12.9 77 7.4 5.9 - 9.2 43 5.5 6.0 - 7.4 7 6.2 2.3 0.9 - 4.6 7 6.2 2.5 - 12.3	281 7.9 7.0 - 8.8	
	NUMBER NUN TESTED POS	1429 1165 675 233 60	3562		NUMBER NUN TESTED POS	1321 1038 776 307 113	3555	
	E (95% C.1.)(3)	7.8 - 11.2 7.8 - 11.2 9.8 - 15.0 3.8 - 15.0 3.9 - 25.1	11.9 - 14.3		E (95% C.1.)(3)	72.4 - 16.2 4.6 - 7.5 6.1 - 10.1 1.4 - 5.8 2.9 - 16.2	8.4 - 10.4	on bservations.
O SURVEY	SERO- PREVALENCE RATE (%)	7.2.1 7.2.1 7.1.6	13.1	33 SURVEY	SERO- PREVALENCE RATE (%)	7.2 6.0 7.9 3.1 7.8	9.6	screening e collected under 20 o
1990	NUMBER(2) POSITIVE	219 111 68 13	416	1993	NUMBER(2) POSITIVE	199 66 57 9 9	337	e syphilis cimens were olot assay. Imple sizes
	NUMBER	1210 1178 564 183 43	3178		NUMBER	1398 1109 719 292 77	3595	for routir isode. Spe a Western k ated for sa
	(95% C.1.)(3)	20.1 - 25.7 7.3 - 11.4 10.6 - 18.0 1.6 - 9.2 3.8 - 24.6	13.7 - 16.7		(95% C.1.)(3)	10.6 - 14.2 5.9 - 9.3 5.9 - 10.0 2.0 - 8.2 4.5 - 24.3	8.4 - 10.4	ere drawn from blood specimens collected for routine syphilis screening on ation, and/or treatment for a NEW STD episode. Specimens were collected all personal identifiers were removed. edgly reactive by ELISA and confirmed by a Western blot assay. nomial. Confidence Intervals not calculated for sample sizes under 20 observations. In and Alaskan Native ancestry, other race, and unknown race.
9 SURVEY	SERO- PREVALENCE RATE (%)	22.8 9.2 14.0 11.4	15.2	2 SURVEY	SERO- PREVALENCE RATE (%)	12.3 7.5 7.8 4.4 12.0	9.4	n blood sper treatment identifier by ELISA and
1989	NUMBER(2) POSITIVE	209 76 52 6	348	1992	NUMBER(2) POSITIVE	163 76 53 9 6	307	e drawn fro ion, and/or il personal ily reactive mial. Conf
	NUMBER	916 828 371 138 44	2297		NUMBER	1320 1016 683 203 50	3272	Surveys wer n, examinat HIV after a re repeated exact bino can Indian
	RACE/ETHNICITY	WHITE AREIGAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL		RACE/ETHNICITY	WHITE ARRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL	(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. (2) All posible specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence intervals not calculated for sample sizes under 20 obside the cloudes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

			1995 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
WHITE ARRICAN AMERICAN LA'INO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	1598 1123 835 300 190	791 79 79 9	12.3 7.0 8.0 8.0 8.4	10.8 - 14.0 5.6 - 8.7 6.3 - 10.1 1.4 - 5.6 4.9 - 13.3
TOTAL	4046	368	9.1	8.2 - 10.0

(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEB 181 episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

	1991 SURVEY	SERO- NUMBER NUMBER(2) PREVALENCE TESTED POSITIVE RATE (%) (95% C.1.)(3)	288 1 0.3 0.0 - 1.9
LINIC BY AGE-GROUP,	1990 SURVEY	SERO- NUMBER NUMBER(2) PREVALENCE TESTED POSITIVE RATE (%) (95% C.1.)(3) TE	274 6 2.2 0.8 - 4.7
'SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY AGE-GROUP, YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995 (1)	1989 SURVEY	SERO- NUMBER NUMBER(2) PREVALENCE GE-GROUP (YEARS) TESTED POSITIVE RATE (%) (95% C.1.)(3)	9 AND UNDER 223 3 1.3 0.3 - 3.9

2 ş

	į	ء ا	0=0=000
		5)(.1.	1.9 4.1 12.7 20.1 23.5 24.3
		(95% C.1.)(3)	0.0 8.5.5.7.8 6.5.5.7.8
	1 SURVEY	SERO- PREVALENCE RATE (%) (	0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	1991	NUMBER(2) POSITIVE	-888882 -8888882
		NUMBER	288 897 897 609 390 263 17
		(5)(7)	4.7 6.6 15.8 13.3 28.1 18.9
		(95% C.1.)(3)	2.3.3 1.0.1 1.0.4 1.0.4 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5 1.0.5
	O SURVEY	SERO- PREVALENCE RATE (%)	2.2 13.2 13.2 13.7 0.0
	1990	NUMBER(2) POSITIVE	0 338 0 338 0 0
		NUMBER	274 708 785 570 382 223 224 10
		.)(3)	20.3 20.3 23.5 23.9 26.1
	SURVEY	(95% C.1.)(3)	0.3 4.7 13.9 17.9 11.6 13.1
		SERO- PREVALENCE RATE (%) (	25.7. 21.8 27.7. 17.1. 19.0
	1989	NUMBER(2) POSITIVE	0 % 3 3 8 8 3 3 2 4
		NUMBER TESTED	223 526 550 633 158 0
		RS)	
		AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN

	Z F			
	(95% C.1.)(3)	0.8 - 4.7 3.3 - 6.6 111.0 - 15.8 19.4 - 23.3 19.4 - 22.1 12.3 - 22.6 9.5 - 18.9	11.9 - 14.3	
O SURVEY	SERO- PREVALENCE RATE (%)	2.2 4.8 13.2 19.8 23.6 17.0 13.7	13.1	
1990	BER(2)	6 34 113 90 38 31	416	

1990	NUMBER NUMBER(2) TESTED POSITIVE	274 6 708 34 708 34 570 113 570 113 570 113 223 38 223 38 10 0	3178 416	1993	NUMBER NUMBER(2) TESTED POSITIVE	244 1 790 9 883 65 65 65 65 65 65 65 65 65 65 65 65 65
	1.)(3)	26.2 26.2 23.2 23.9 26.2 34.2	16.7		1.)(3)	3.0 4.0 17.7 22.7 22.2 14.6

- 16.7

13.7

15.2

348

2297

TOTAL

		(95% C.1.	0.0 13.5.7 1.2.9 1.2.9 1.2.9 1.2.9
	3 SURVEY	SERO- PREVALENCE RATE (%)	0.4 17.7 17.5 12.8 3.8
	1993	NUMBER(2) POSITIVE	1085 9 1 139 459 1
		NUMBER	244 790 883 883 394 304 275 26

(95% C.1.)(3)

PREVALENCE RATE (%)

NUMBER(2) POSITIVE

NUMBER

AGE-GROUP (YEARS)

UNDER

SURVEY

1992

(95% C.1.)(3)

PREVALENCE RATE (%)

NUMBER(2) POSITIVE

NUMBER

33

SURVEY

766

0.0 4.0 7.7 8.7 7.0 8.7

40.25.25.00

08332447

225 833 833 258 258 294 294

12.0 13.0 13.0 13.0 13.0

241 252 253 253 253 253 253

19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 45 - 44 45 AND OVER UNKNOMN

8.8

7.0

7.9

281

3555

10.4

8.4

7.6

337

3595

- 10.4

8.4

9.4

307

3272

TOTAL

(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact vinomial. Confidence Intervals not calculated for sample siz:: under 20 observations.

	(95% C.1.	0.8 13.3 16.6 19.4 12.3 12.3 12.3 12.3 12.3	11.9 - 1		(95% C.1.	
ou survey	SERO- PREVALENCE RATE (%)	2.2 4.68 19.8 19.8 13.7 0.0	13.1	93 SURVEY	SERO- PREVALENCE RATE (%)	

- 11.6

9.5

0.5

375

	NUMBER	288 897 833 609 390 263 17	3562	
	95% C.1.)(3)	0.8 - 4.7 3.3 - 6.6 6.6 - 15.8 10.4 - 28.1 12.3 - 22.6 9.5 - 18.9	11.9 - 14.3	

	NUMBER	288 897 897 833 609 390 263 17	-
		72300378	
1991	NUMBER(2) P POSITIVE	103 103 103 103 103 103 103 103 103 103	
SURVEY	SERO- PREVALENCE RATE (%)	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	

HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED JISEASE (STD) CLINIC BY AGE-GROUP, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995 (1)

	(95% c.1.)(3)	0.4 - 4.0 1.5 - 3.8 4.3 - 7.2 12.7 - 17.4 12.7 - 19.5 11.6 - 19.5 8.8 - 16.2	8.2 - 10.0
1995 SURVEY	SERO- PREVALENCE RATE (%)	2.2 2.2 4.5 5.5 5.2 5.2 5.3 5.3	9.1
199	NUMBER(2) POSITIVE	20 28 106 81 40 8	368
	NUMBER TESTED	254 806 1033 725 725 515 335 329 49	9505
	AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 25 - 29 35 - 34 35 - 39 40 - 44 45 AND OVER UNKNOMN	TOTAL

(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence intervals not calculated for sample sizes under 20 observations.

EASE (STD) CLINIC BY RACE/ETHNICITY,	
HIV SEROPREVALENCE FOR GAY AND BISEXUAL MEN ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995 (1)	1000

		1989	9 SURVEY				1990	SURVEY			1991	SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
WHITE ARRICAN LATINO LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	372 84 78 14	194 54 48 4 5	52.2 64.3 61.5 28.6 83.3	46.9 - 5. 53.1 - 74 49.8 - 77	57.3 74.4 72.3	456 117 107 28 8	188 74 50 8 4	41.2 63.2 46.7 50.0	36.7 - 45.9 53.8 - 72.0 37.0 - 56.6 13.2 - 48.7	525 83 105 27 11	182 44 48 48 6	34.7 53.0 45.7 40.7 54.5	30.6 - 38.9 41.7 - 64.1 36.0 - 55.7 22.4 - 61.2
TOTAL	554	305	55.1	50.8 - 59	59.3	716	324	45.3	41.6 - 49.0	157	291	38.7	35.2 - 42.3
		1992	2 SURVEY				1993	SURVEY			1994	4 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
WHITE ARRICAN LATINO LATINO ASIAW/PACIFIC ISLANDER NONE OF THE ABOVE (4)	25 105 105 105 105 105 105 105 105 105 10	147 46 39 7 6	32.3 45.1 37.1 50.0	28.0 35.2 27.9 11.6 - 4	36.8 55.3 47.1	497 76 120 39 13	165 39 4 4 4 7 4	33.2 51.3 38.3 30.8	29.1 - 37.5 39.6 - 63.0 29.6 - 47.6 7.5 - 33.5	487 89 114 47 23	135 47 37 7	27.7 52.8 32.5 14.9 30.4	23.8 - 31.9 41.9 - 63.5 24.0 - 41.9 6.2 - 28.3 13.2 - 52.9
TOTAL	002	245	35.0	31.5 - 38.7	8.7	242	261	35.0	31.6 - 38.6	092	233	30.7	27.4 - 34.1
<ol> <li>These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for NIV after all personal identifiers were removed.</li> <li>All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.</li> <li>Spx Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.</li> <li>Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.</li> </ol>	urveys we cammina iv after e repeater exact bing	re drawn fro tion, and/or all personal dly reactive omial. Conf and Alaskan	m blood spec treatment identifiers by ELISA ar idence Inter Native ance	cimens col for a NEW S were rem nd confirm vals not	lected for STD episcoved. ed by a vergel by a vergel	or routine ode. Spec Western bl ed for sam and unkno	syphilis s imens were ot assay. ple sizes u	collected	ervations.				

		199	1995 SURVEY	
RACE/ETHNIC1TY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
WHITE	558	145	26.0	22.4 - 29.8
AFRICAN AMERICAN LATINO	\$ <u>12</u>	94 4	46.5 26.8	36.4 - 56.8 20.0 - 34.5
ASIAN/PACIFIC ISLANDER	39	80	20.5	9.3 - 36.5
NONE OF THE ABOVE (4)	52	in .	20.0	6.8 - 40.7
TOTAL	874	245	28.0	25.1 - 31.1

(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on addividuals seeking evaluation, examination, and/or treatment for a NEW TID episode. Specimens were collected consecutively and tested for NIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

		(95% C.1.)(3)	11.2 - 28.8 31.1 - 45.2 39.8 - 55.1 38.2 - 56.9 32.0 - 53.6	35.2 - 42.3
	1 SURVEY	SERO- PREVALENCE RATE (%) (	10.0 18.8 37.9 47.5 42.5 30.0	38.7
	1991	NUMBER(2) POSITIVE	116 747 833 37 0 0	291
		NUMBER	01 88 11 87 12 18 88 8 1 1 1 1 1 1 1 1 1 1 1 1 1 1	751
		(95% C.1.)(3)	53.7 59.7 59.5 60.3 61.4 64.3	41.6 - 49.0
		(95%	23.5.5 23.5.5 23.5.5 23.5.5	41.6
Town away	O SURVEY	SERO- PREVALENCE RATE (%)	14.3 33.3 46.0 53.8 53.5 48.4 33.3	45.3
	1990	NUMBER(2) POSITIVE	0 3 3 2 2 2 5 3 3 2 5 5 5 5 5 5 5 5 5 5 5	324
		NUMBER	728 128 128 128 128 128 128 128 128 128 1	216
		(95% c.1.)(3)	. 54.3 . 67.5 . 69.8 . 59.4 . 57.6	50.8 - 59.3
		c %5% c	37.0 37.0 37.0 37.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5	50.8
- 1995 (1)	9 SURVEY	SERO- PREVALENCE RATE (%)	0.0 41.0 62.7 58.9 45.7 44.3	55.1
	1989	NUMBER(2) POSITIVE	0 23 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	305
4CISCO, 1989		NUMBER TESTED	61 134 1129 112 55 61 0	554
AND YEAR OF SURVEY, SAN FRANCISCO, 1989		AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 25 - 29 35 - 34 35 - 34 40 - 44 45 AND OVER UNKNOWN	TOTAL

		1992	2 SURVEY			1993	3 SURVEY				1994	4 SURVEY	
AGE-GROUP (YEARS)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	
19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN	162 162 186 103 74 67	18342252	20.0 17.1 32.1 38.7 47.6 52.2 54.3 16.7	10.3 - 26.7 25.0 - 39.9 37.6 - 46.1 37.6 - 64.6 15.1 - 35.7	2 12 12 12 12 12 12 12 12 12 12 12 12 12	1130688960 1130688960	0.0 8.5 26.1 46.7 44.1 34.1 20.0	3.2. 19.9 37.4 37.5 24.7	33.0 55.77 56.70 56.70	12 77 181 182 137 75 95 0	0 28 38 8 4 0	221.0 231.0 355.2 30.8 30.8 30.5	
TOTAL	700	542	35.0	31.5 - 38.7	745	261	35.0	31.6 - 38.6	38.6	092	233	30.7	10
These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evoluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.  (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated or sample sizes under 20 obse	surveys we n, examina IIV after re repeate exact bin	re drawn fro tion, and/or all personal dly reactive omial. Conf	om blood spe treatment identifier by Ells a	ded) surveys were drawn from blood specimens collected for routine syphilis screening on lation, and/or treatment for a NEW STD episode. Specimens were collected for HIV after all personal identifiers were removed.  Is were repeatedly reactive by ELISA and confirmed by a Western blot assay.	for routir isode. Spe a Western k ated or sa	ne syphilis ecimens were olot assay.	screening or collected under 20 obs	Servation					

(95% C.1.)(3)

28.6 27.7 43.1 49.6 52.7

28.8 28.8 22.6 21.5

27.4 - 34.1

		199	1995 SURVEY		
AGE-GROUP (YEARS)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	,
19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN	98 206 197 150 109 106	0 2 3 3 5 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	16.0 18.0 39.6 37.3 25.4 25.5	8.8 - 24.0 13.0 - 23.9 32.7 - 46.8 21.0 - 38.9 17.5 - 34.9	
TOTAL	874	245	28.0	25.1 - 31.1	

(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected conscutively and tested for HIV after all personal identifiers were removed.
(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

		1989	19 SURVEY				1990	1990 SURVEY				1991	1 SURVEY		
RACE/ETHNICITY	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)	(4)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)	)(4)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)	.)(4)
WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (5)	316 471 209 78 19	N 0 - 1 - 0	0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	33.6	413 683 286 84 18	11 8 0	2.7 2.8 2.8 1.2 0.0	1.3 - 0.0	4.7. 6.5.	497 741 399 122 26	55500	49.09.0 0.09.0	#4.00 #4.00	4.2 4.0 5.2 5.8
TOTAL	1093	17	1.6	0.9 - 2	2.5	1484	38	2.6	1.8 -	3.5	1785	45	2.5	1.8 -	3.4
								ç							
		1992	2 SURVEY				1993	SURVEY				1994	4 SURVEY		
RACE/ETHNIC1TY	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)	(4)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)	. (4)(	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)	.)(4)
WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (5)	520 632 91 91	10 7 7 0	1.9 2.3 0.0	0.9 - 3 2.1 - 5 0.7 - 3 0.3 - 7	7.380	569 687 416 148 31	20 16 7 1	3.5 2.3 3.2 3.2	2.2 - 1.3 - 0.7 - 0.0 - 0.1 - 1	5.4 3.8 3.7 16.7	518 635 471 159 51	2,450	7.00 0.00 0.00	0.3 - 0.0 - 0.0 -	25.2 2.5 5.7

5.6

1.3

1:0

34

1834

1.8 - 3.2

2.4

45

1851

1.7 - 3.3

5.4

9

1641

TOTAL

(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.

(2) These unlinked (blinded) surveys where drann from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SIO episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(3) All postitive specimens where repeatedly readrive by ELISA and confirmed by a Western blot assay.

(4) Six Confidence Intervals, exact binomial. Confidence intervals not calculated for sample sizes under 20 observations.

(5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

RACE/ETHNICITY I ESTED POSITIVE RATE (%) (95% C.I.)(4) WHITE 560 7 1.3 0.5 - 2.6 AFRICAN AMERICAN 660 12 1.9 1.0 - 3.3 LATINO 7 1.3 0.5 - 2.6 ASIAN/PACIFIC ISLANDER 133 0 0.0 0.0 - 2.2 NONE OF THE ABOVE (5) 58 1			199	1995 SURVEY	
560 7 1.3 0.5 - 640 12 1.9 1.0 - 640 12 1.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	RACE/ETHNICITY	NUMBER		SERO- PREVALENCE RATE (%)	(95% C.1.)(4)
640 12 1.9 1.0 - 416 1 1.9 0.8 - 1.0 - 6.8 - 6.8 1 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0	HITE	260	7	1.3	
(5) 58 1 1.7 0.0 -	FRICAN AMERICAN	640 416	12ء	<u>.</u> .	
- 0.0 /.1 1.7 0.0 -	SIAN/PACIFIC ISLANDER	<u>E</u>	.0	0.0	
	ONE OF THE ABOVE (5)	, 20 20 20 20 20 20 20 20 20 20 20 20 20	-	١./	

(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.

(2) These uninked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(4) 5% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(5) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

		(95% C.1.)(4)	13.5 13.5 13.5 13.5 13.5
		%56)	0.000.00
	1 SURVEY	SERO- PREVALENCE RATE (%) (	0002442445 081-475800
	1991	NUMBER(3) POSITIVE	0405574-
		NUMBER	157 497 424 288 175 103 133
		1.)(4)	287.27.08.0 287.07.7.1
		(95% С.	0.01.000
BY AGE-GROUP	0 SURVEY	SERO- PREVALENCE RATE (%) (95% C.I.)(4)	
STD) CLINIC	1990	NUMBER(3) POSITIVE	04558W-0
DISEASE (		NUMBER	157 380 389 229 158 98 89
ISMITTE:		(-)(4)	2.42. 2.42. 3.42. 3.43. 4.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43. 5.43.
ILLY TRA		(95% C.)	0.001000
(1) ATTENDING A SEXUALLY TRANSMITTE: DISEASE (STD) CLINIC BY AGE-GROUP, 1995 (2)	39 SURVEY	SERO- PREVALENCE RATE (%) (95% C.I.)(4)	0-04w0w 8004v00
ES (1) ATTEN - 1995 (2)	1989	NUMBER(3) POSITIVE	-mommono
SEXUAL MAL 1SCO, 1989		NUMBER	126 2312 2655 181 93 0
HIV SEROPREVALENCE FOR HETEROSEXUAL MALES (AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - '		AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 30 - 34 35 - 39 40 - 44 45 AND OVER UNKNOAN
AND		AC	5.9988.24.2

	NUMBE	151 429 288 288 177 177 133	178		
	(95% C.1.)(4)	0.2 - 4.5 0.3 - 2.8 1.2 - 4.7 2.2 - 9.7 0.6 - 8.7	1.8 - 3.5		
0 SURVEY	SERO- PREVALENCE RATE (%)	2.23.4 2.23.4 2.00.0	2.6	3 SURVEY	
1990	NUMBER(3) POSITIVE	<b>7455</b> 8₩-0	38	1993	
	NUMBER	157 380 389 229 158 98 89 4	1484		

(95% C.1.)(4)

PREVALENCE RATE (%)

NUMBER(3) POSITIVE

NUMBER TESTED

(95% C.1.)(4)

PREVALENCE RATE (%)

NUMBER(3) POSITIVE

NUMBER

(95% C.1.)(4)

SERO-PREVALENCE RATE (%)

NUMBER(3) POSITIVE

AGE-GROUP (YEARS)

AND UNDER

SURVEY

992

SURVEY

1994

3.4 .

8.

2.5

5

2.5

%

1.6

1

1093

TOTAL

24.02.54

20.07

02287-20

4.5.0.5.0.5.0.4 4.5.0.5.0.4

0.174.0

0.502.70

0200000

**48883354** 

5.09-0.45

0.027.00

02004--

956538475

19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN

5.6

1.3

1.9

34

1834

3.2

1.8

2.4

45

1851

3.3

1.7

2.4

9

1641

(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.

(2) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NIH SID episode. Specimens were collected consecutively and rested for HIV after all personal identifiers were removed. Section to the sexted for HIV after all personal identifiers were removed. All toositive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(4) 95% Confidence Intervals, exact binomial. Confidence intervals not calculated for sample sizes under 20 observations.

HIV SERCYREVALENCE FOR HETEROSEXUAL MALES (1) ATTENDING A SEXUALLY TRAHISMITTED DISEASE (STD) CLINIC BY AGE-GROUP, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995 (2)

		1995	5 SURVEY	
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(4)
AND UNDER	105	-	1.0	0.0 - 5.2
- 23	412 519	04	0.0	0.0 - 0.7
- 34	318 206	<b>ο</b> α	2.8	1.3 - 5.3
40 - 44 45 AND OVER	119	104	7-2	0.2 - 5.9
KNOWN	0	.0		
TOTAL	1807	78	1.5	1.0 - 2.2

(1) includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.

These unfinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. Size of the size

HIV SEROPREVALENCE FOR HETEROSEXUAL FEMALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLIMIC BY RACE/ETHNICITY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995 (2)	D DISEASE (STD) CLINIC BY RACE/ETHNICITY,	
1989 SURVEY	1990 SURVEY	1991 SURVEY

		1989	19 SURVEY				1990	1990 SURVEY				1991	1 SURVEY		
RACE/ETHNIC1TY	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)		NUMBER N	NUMBER(3)   POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)	.)(4)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)	.)(4)
WHITE ARRICAN AMERICAN LATINA ASTAN/PACIFIC ISLANDER NONE OF THE ABOVE (5)	145 184 61 40 8	-m000	7.0 0.0 0.0 0.0	0.0 - 3	8.4.7.	171 263 101 53 8	w <i>o</i> 0	3.4 0.0 0.0	1.6	5.0	257 266 133 74 16	rv-00	0.00	9.00	4.5 4.1 4.0
TOTAL	438	4	0.0	0.2 - 2	2.3	296	14	2.3	1.3 -	3.9	97/2	11	1.5	- 2.0	2.6
		1992	2 SURVEY				1993	SURVEY				1994	4 SURVEY		
RACE/ETHNIC1TY	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)		NUMBER N	NUMBER(3) I	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)	.)(4)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)	.)(4)
WHITE ARRICAN AMERICAN LATINA ASIAN PACIFIC ISLANDER NONE OF THE ABOVE (5)	245 214 150 72 14	00000	0.01.4.00.00	0.00	2.07.1.	215 260 145 87 21	wenee	4.1. 4.1. 4.8	0.00	23.8	205 251 154 22 22	₩ <i>0</i> 1-00	0.00	0.00	23.6 23.6 7.7
TOTAL	969	2	0.7	0.2 - 1	1.7	728	8	1.1	0.5 -	2.2	718	9	0.8	0.3 -	1.8
(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.  (2) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.  (3) ALI Lositive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (4) 95% Confidence Intervals, exact binomial. Confidence Intervals, not calculated for sample sizes under 20 observations.	th a sex p surveys we on, examina HIV after re repeate exact bin can Indian	artner at ri re drawn fro tion, and/or all personal dly reactive omial. Conf and Alaskan	rther at risk for HIV and heterosexuals with no other identified risks drawn from blood specimens collected for routine syphilis screening ion, and/or treatment for a NEW SID episode. Specimens were collected til personal identifiers were removed.  HIV reactive by ELISA and confirmed by a Western blot assay.  Mial. Confidence Intervals not calculated for sample sizes under 20 of and Alaskan Native ancestry, other race, and unknown race.	and heteros simens coll for a NEW S were remo nd confirme vals not c	exuals with ected for TD episode ved. d by a Wes alculated r race, ark	h no oth routine . Speci tern blo for samp	ner identif syphilis s mens were t assay. tle sizes u n race.	ied risks. creening on collected nder 20 obs	ervation	<u>v</u>					

667 10 1.5 0.7 - 2.7	NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER STATION	1995 NUMBER(3) POSTITIVE 1 1 1 1	995 SURVEY SERO- S RATE (%) 0.5 3.3 0.0 2.9	SERO- PREVALENCE RATE (%) (95% C.I.)(4) 0.5 0.0 - 2.6 3.3 1.3 - 6.7 0.8 0.0 - 4.2 0.0 0.0 - 3.6 2.9 0.1 - 14.9
	299	10	1.5	0.7 - 2.7

(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.

(2) These uniniked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(4) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

		361	1989 SURVEY			199	1990 SURVEY				1991	1 SURVEY		
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%) (95% C.I.)(4)	(95% C.1.	)(4)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)	(4)
19 AND UNDER 20 - 24 35 - 29 35 - 34 35 - 34 45 - 44 45 AND OVER	20 20 20 20 20 20 20 20 20 20 20 20 20 2	N00000	2.3 1.0 0.0 0.0 0.0 0.0	0.3 - 8.1 0.0 - 4.6 0.0 - 5.4 0.0 - 7.4 0.0 - 13.9	194 137 137 137 43 43 44 44 45 47	0-w4w-00	20.02 2.02 2.00 0.00	0001-00 0004-00	8.0 2.25 17.0 1.7 1.7	116 258 160 86 42 42 48 32 48	0-000000	0.0 0.0 4.4 4.2 0.0 0.0 0.0	0.0000000000000000000000000000000000000	22.5 2.6.2 2.5.2 2.5.3 3.5.2 5.5.3
TOTAL	438	4	0.0	0.2 - 2.3	2965	14	2.3	1.3 - 3.9	3.9	746	Ξ	1.5	0.7 - 2.6	2.6
		199	1992 SURVEY			199.	1993 SURVEY		-		1994	4 SURVEY		

	<u>ي</u> ۳-	
SURVEY	SERO- PREVALENCE RATE (%)	0.00
1994	NUMBER(3) POSITIVE	220000
	NUMBER	98 217 164 93 58 46 46
	1.)(4)	5.6 3.1 4.5 7.7 22.8
	(95% C.I.)(4)	00000-0
3 SURVEY	SERO- PREVALENCE RATE (%) (	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
1993	NUMBER(3) POSITIVE	-00m00
	NUMBER	98 213 180 95 60 47 29
	1.)(4)	8.22.25 2.2.2.2 2.2.2.2 2.2.2.2
	(95% C.1.)(4)	000000
2 SURVEY	SERO- PREVALENCE RATE (%) (	000000000
1992	NUMBER(3) POSITIVE	00%000
	NUMBER	188 174 23 23 3

AGE-GROUP (YEARS)

AND UNDER

19 AND UNDER 20 - 24 25 - 29 35 - 34 35 - 34 45 AND OVER UNKNOWN

(95% C.1.)(4)

65.24.256

00000000

- 1.8

0.3

8.0

ø

718

2.2

0.5

7

æ

728

1.7 0.2 -

0.7

'n

695

TOTAL

(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.
(2) These unlinked klinded) surveys where drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NIH STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. Specimens were repeatedly reactive by ELISA and confirmed by a Western blot issay All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot issay (4) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

	SERO- PREVALENCE RATE (%) (95% C.I.)(4)	0.6 - 7.9 0.1 - 3.8 0.6 - 5.8 0.0 - 7.5 0.0 - 15.3 0.0 - 15.3	0.7 - 2.7
1995 SURVEY	1 1	81-00400	1.5
199	NUMBER(3) POSITIVE	m N M O = = 00	10
	NUMBER	108 190 147 147 72 72 73 33	199
	AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 34 40 - 44 45 AND OVER UNKNOWN	TOTAL

(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.

2) These unfilhed (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. Pisode specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) ALI positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

ORIENTATION,
KUAL
SE
R AN
GENDE
₩ 8
PROCRAM
TREATMENT
Ä.
ET HADO
5
ATER 4
RS EI 199
USE 89 -
DRUG ', 19
NOI I
INJECT
FOR
AL FNCE SURVEY,
ROPREVI
## 2.5
Ξ¥

		1989	39 SURVEY			1990	0 SURVEY			1991	1 SURVEY	
GENDER AND SEXUAL ORIENTATION	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
MALE												
Gay/Bisexual Heterosexual Unknown Orientation	143 3	2 ⁴ 0	33.3 9.8 0.0	5.5 - 15.9	25 716 7	57 1	32.0 8.0 14.3	14.9 - 53.5 6.1 - 10.2	28 11	50 2	25.0 7.3 18.2	10.7 - 44.9 5.4 - 9.5
SUB-TOTAL MALE	152	16	10.5	6.1 - 16.5	748	99	8.8	6.9 - 11.1	727	59	1.8	6.2 - 10.3
FEMALE												
Lesbian/Bisexual Heterosexual Unknown Orientation	4 L L	080	0.00	4.9 - 20.5	376 376 2	0 25 2	0.0 0.0 0.0	1.2 - 31.7 3.7 - 8.7	376 0	080	0.0	3.9 - 9.0
SUB-TOTAL FEMALE	82	ಹ	10.3	4.5 - 19.2	398	54	0.9	3.9 - 8.8	390	23	5.9	3.8 - 8.7
MISSING GENDER	7	0	0.0		12	0	0.0	:	15	2	13.3	:
TOTAL	237	54	10.1	6.6 - 14.7	1158	06	7.8	6.3 - 9.5	1132	84	7.4	6.0 - 9.1
(1) Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 1978.  Excludes persons with a prior admission to treatment during the survey period, and persons who were preferentially admitted to treatment due to HIV/AIDS. Blood specimens were collected for syphilis screening as part of th admission requirements, and tested for HIV after all personal identifiers were removed.  (2) Atl positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.  (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.	nethadone ndmission ntment due ements, a	treatment w to treatmen to HIV/AID nd tested for ly reactive	ho have a hi it during the S. Blood sp or HIV after by ELISA an	treatment who have a history of injection drug use (IDU) since 1978, to treatment during the survey period, and persons who were to HIV/AIDS. Blood specimens were collected for syphilis screening ind tested for HIV after all persons i identifiers were removed. It reactive by ELISA and confirmed by a Western blot assay, mial. Confidence Intervals not calculated for sample sizes under 28.	ion drug us and person (lected for dentifiers a Western b	ie (IDU) sinus who were syphilis so were removed lot assay.	ce 1978. creening d. under 20 obs	ervations.				

HIV SEROPREVALENCE FOR INJECTION DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS BY GENDER AND SEXUAL ORIFYTATION, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (1)

1992 SURVEY

1994 SURVEY

1993 SURVEY

GENDER AND SEXUAL ORIENTATION	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	(5)(1)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)
MALE													
Gay/Bisexual Heterosexual Unknown Orientation	26 849 40	825.	30.8 7.4 7.5	14.3 - 5 5.7 - 1.6 - 2	51.8 9.4 20.4	236	4 17 0	44.4	4.3 - 11.3	13 207 0	20000	15.4 9.7	6.0 - 14.5
SUB-TOTAL MALE	915	7.4	8.1	6.4 - 10.0	10.0	546	21	8.5	5.4 - 12.8	220	22	10.0	6.4 - 14.7
FEMALE													
Lesbian/Bisexual Heterosexual Unknown Orientation	21 432 5	282	6.00	1.2 - 4.0 -	30.4	130 1	2110	15.4 8.5 0.0	4.3 - 14.6	12 150 0	×20 0	16.7	5.7 - 16.0
SUB-TOTAL FEMALE	458	28	6.1	4.1 -	8.7	144	13	0.6	4.9 - 14.9	162	17	10.5	6.2 - 16.3
MISSING GENDER	14	-	7.1		•	-	0	0.0	:	-	0	0.0	:
TOTAL	1387	103	7.4	6.1 -	8.9	391	34	8.7	6.11 - 11.9	383	39	10.2	7.3 - 13.7
(1) Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 1978.  Excludes persons with a prior admission to treatment during the survey period, and persons who were preferentially admitted to treatment due to HIV/AIDS. Blood specimens were collected for syphilis screening as part of the admission requirements, and tisted for HIV after all personal identifiers were removed.  (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (3) 95% confidence intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.	methadone admission eatment due lirements, a re repeated exact bino	treatment with to treatment to treatment to HIV/AIDS and tasted fully reactive mial. Confi	treatment who have a history of injection drug use (IDU) sir to treatment during the survey period, and persons who were to HIV/AIDS. Blood specimens were collected for syphilis s nd t.sted for HIV after all personal identifiers were remove Ty exective by ELISA and confirmed by a Western blot assay. mial. Confidence Intervals not calculated for sample sizes	istory of e survey becimens r all per d confir	f injectic period, a were coll rsonal ide rmed by a t calculat	on drug us lected for Western b ted for sa	treatment who have a history of injection drug use (1DU) since 1978. to treatment during the survey period, and persons who were to HIV/AIDS. Blood specimens were collected for syphilis screening nd trated for HIV after all personal identifiers were removed. If y reactive by ELISA and confirmed by a Western blot assay.	ce 1978. creening d. under 20 obs	ervations.				

ENT PROGRAMS BY RACE/ETHNICITY	
DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS BY RACE/ETHNICITY ), 1989 - 1994 (1)	
HIV SEROPRIVALENCE FOR INJECTION DE AND YEAR OF SURVEY, SAN FRANCISCO,	

		1989	19 SURVEY			1990	0 SURVEY			1991	1 SURVEY		
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% c.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	9
WHITE ARECAN AMERICAN LATINO ASTAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	142 27 27 2	ν <b>4</b> νοο	3.5 18.5 0.0 0.0	1.2 - 8.0 13.2 - 35.5 6.3 - 38.1	722 256 135 29 16	525 447 447 447	23.3 5.2 6.3	2.1 - 4.9 16.3 - 26.6 2.1 - 10.4 3.9 - 31.7	699 267 118 28 20	24 53 7 0 0	3.4 19.9 5.9 0.0 0.0	2.2 - 5. 15.2 - 25. 0.0 - 10. 0.0 - 13.	5.1 11.8 13.9
TOTAL	237	54	10.1	6.6 - 14.7	1158	06	7.8	6.3 - 9.5	1132	. 84	7.4	6 - 0.9	9.1
		1992	2 SURVEY			1993	3 SURVEY			1994	4 SURVEY		İ
RACE/ETHNIC1TY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	9
WHITE ARRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	889 299 139 29 31	32 11 3 0	3.9 7.9 7.9 7.9	2.8 - 5.4 13.9 - 22.9 4.0 - 7.8 2.0 - 25.8	264 77 36 3	271200	73.9 0.0 0.0	5.0 - 11.9 7.2 - 23.5 0.7 - 18.7	240 81 48 12 2	2179	6.3 21.0 12.5 8.3 0.0	3.5 - 10.1 12.7 - 31.5 4.7 - 25.2	-ivid
TOTAL	1387	103	4.7	6.1 - 8.9	391	34	8.7	6.11 - 11.9	383	39	10.2	7.3 - 13	13.7
(1) Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 1978.  Excludes persons with a prior admission to treatment during the survey period, and persons who were preferentially admitted to treatment due to HIV/AIDS. Blood specimens were collected for syphilis screening as part of the admission requirements, and tested for HIV after all personal identifiers were removed.  (2) All positive speciens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (3) 95% confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.	methadone admission atment du rements, è e repeatec exact binc an Indian	treatment w to treatmen e to HIV/AID and tested f lly reactive mial. Conf and Alaskan	ho have a h it during thi S. Blood si or HIV aftel by ELISH idence Inter	treatment who have a history of injection drug use (10U) since 1978 to treatment during the survey period, and persons who were to HIV/AIDS. Blood specimens were collected for syphilis screening the tested for HIV after all personal identifiers were removed. If ye reactive by ELISA and confirmed by a Western blot assay. Milal. Confidence Intervals not calculated for sample sizes under 2 and Alaskan Native ancestry, other race, and unknown race.	ion drug u and persol llected fo dentifiers a Western l ated for si e, and unki	se (IDU) sin ns who were r syphilis s Were remove Hold assay. ample slizes nown race.	ce 1978. creening d. under 20 obs	iervations.					

	(95% C.1.)(3)	0.0 . 5.3 2.1 - 10.5 3.4 - 11.5 5.6 - 12.2 6.0 - 13.4 2.1 - 26.5	6.0 - 9.1		(95% C.1.)(3)	0.0 - 12.2 0.1 - 12.2 2.1 - 18.2 7.3 - 23.8 7.4 - 22.0 3.5 - 16.6	7.3 - 13.7	
1 SURVEY	SERO- PREVALENCE RATE (%)	0.0 0.0 5.5 8.5 7.7 0.0	7.4	4 SURVEY	SERO- PREVALENCE RATE (%) (	0.0 8.3 7.7 14.1 13.5 0.0	10.2	
1991	NUMBER(2) POSITIVE	00768368	78	1994	NUMBER(2) POSITIVE	00441250	39	
	NUMBER	7 134 183 307 261 155	1132		NUMBER	23 23 23 83 2	383	
	(95% C.1.)(3)	0.0 - 7.4 3.9 - 9.4 4.8 - 11.1 5.9 - 14.0 8.5 - 19.4	6.3 - 9.5	•	(95% C.1.)(3)	1.1 - 28.0 3.0 - 19.6 9.8 - 25.6 1.9 - 10.8 1.8 - 12.5	6.1 - 11.9	ervations.
) SURVEY	SERO- PREVALENCE RATE (%)	16.7 4.7 7.5 9.4 13.3 8.3	7.8	3 SURVEY	SERO- PREVALENCE RATE (%)	0.0 88.7 16.7 5.1 5.0	8.7	ce 1978. creening
1990	NUMBER(2) POSITIVE	1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	06	1993	NUMBER(2) POSITIVE	00005200	34	e (IDU) sin is who were syphilis s were remove itot assay.
	NUMBER	6 149 149 222 306 306 166 12	1158		NUMBER TESTED	23 23 56 56 117 90 2	391	ion drug us and persor lected for dentifiers a Western b
	(95% C.1.)(3)	0.9 - 23.5 10.9 - 23.5 8.9 - 28.7 6.2 - 28.3	6.6 - 14.7		(95% C.1.)(3)	0.4 - 12.3 3.1 - 12.5 4.6 - 10.2 5.7 - 11.7 6.8 - 14.3	6.1 - 8.9	story of injecti survey period, ecimens were col all personal id d confirmed by a
SURVEY	SERO- PREVALENCE RATE (%)	0.0 5.9 7.1 6.7 17.2 14.9	10.1	2 SURVEY	SERO- PREVALENCE RATE (%)	0.0 3.6 6.8 7.7 7.0 7.1 7.5	7.4	ho have a hi t during the S. Blood sp or HIV after by ELISA an
1989	NUMBER(2) POSITIVE	0138210	54	1992	NUMBER(2) POSITIVE	0 2 8 30 30 1	103	treatment W to treatmen to treatmen to HIV/AID and tested f Ily reactive mial. Conf
	NUMBER	217 217 444 644 644	237		NUMBER	6 56 133 · 175 367 277 22	1387	methadone admission eatment due lirements, a
	AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 25 - 29 35 - 34 35 - 39 45 - 44 45 AND OVER UNKNOWN	TOTAL		AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 25 - 29 35 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN	TOTAL	(1) Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 1978.  Excludes persons with a prior admission to treatment during the survey period, and persons who were preferentially admitted to treatment due to MIVANIDs. Bloods specimens were collected for syphilis screening as part of the admission requirements, and tested for HIV after all personal identifiers were removad.  (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.  (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

HIV SEROPREVALENCE FOR INJECTION DRIG OSERS (IDUS) AND NON-INJECTION DRUG USERS (NON-IDUS) ENTERI'G A DRUG-FREE DETOXIFICATION PROGRAM BY GENDER AND SEXUAL ORIENTATION, SAN FRANCISCO, 1990 - 1994 (1)

		IDUS	s			-NON	NON-IDUS	,
GENDER AND SEXUAL ORIENTATION	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
MALE								
Gay/Bisexual Heterosexual Unknown Orientation	118 671 19	37 38 2	31.4 5.7 10.5	23.1 - 40.5	434	20 11 3	51.3 2.5 15.8	34.8 - 67.6
SUB-TOTAL MALE	808	j E	9.5	7.6 - 11.8	765	, %	6.9	4.8 - 9.5
FEMALE								
Lesbian/Bisexual Heterosexual Unknown Orientation	60 268 9	-20	7.7 2.6 0.0	0.0 - 8.9	31 5	040	0.00	0.0 - 9.2
SUB-TOTAL FEMALE	337	, ⁶⁰	5.4	1.0 - 4.6	216	4	1.9	0.5 - 4.7
MISSING GENDER	0	0			0	0		
TOTAL	1145	85	7.4	6.0 - 9.1	708	38	5.4	3.8 -, 7.3

(1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Sample includes both injection drug users (10.8) who have a history of needle use since 1978, and non-injection drug users who have smoked, snorted, inhaled, or shallowed narcofics within the previous 12-months prior to admission to treatment. Excludes persons who were i-referentially admitted to reatment due to HIVAIDS, and persons under alcohol treatment only. Blood specimens were collected for syphilis screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed. (2) All possitive petimens were repeatedy; reactive by EliS and confirmed by a Western blot sample sizes under 20 observations. (3) %% confidence intervals, exact binomial. Confidence intervals, exact binomial.

HIV FTROPREVALENCE FOR INJECTION DRUG USERS (IDUS) AND NON-INJECTICH DRUG USERS (NON-IDUS) ENTERING A DRUG-FREE DETOXIFICATION PROGRAM BY RACE/ETHNICITY, SAN FRANCISCO, 1990 - 1994 (1)

		IDUs	sı			-NON	NON-1DUS		
RACE/ETHNICITY	NUMBER TESTED	NUMBER(2) POSITIVE		SERO- PREVALENCE RATE (%) (95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%) (95% C.1.)(3)	(95% C.1.	)(3)
LHITE	72.	27	7 7		24.1	11	7 7	1	α
AFRICAN AMERICAN	199	58	14.1	9.6 - 19.7	325	10	7.7	5.0 - 1	1:0
LATINO	138	9	4.3		22	-	.3		7.0
ASIAN/PACIFIC ISLANDER	643	7	4.7		20	0	0.0		5.8
NONE OF THE ABOVE (4)	31	~	6.5		15	-	2.9	٠.	•
TOTAL	1145	82	7.4	6.0 - 9.1	208	38	5.4	3.8 - 7.3	7.3
								}	

(1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Sample includes both injection drug users (IDUS) who have a history of needle use as ince 1978, and non-injection drug users who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment. Excludes persons with a prior admission to treatment during the survey period, persons who were preferentially admitted to treatment due to HIV/AIDS, and persons under alcohol treatment only. Blood specimens where collected for syphilis screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) Sex. Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

HIV SEROPREVALENCE FOR INJECTION PRUG USERS (IDUS) AND NON-INJECTION DRUG USERS (NON-IDUS) ENTFRING A DRUG-FREE DETOXIFICATION PROGRAM BY AGE-GROUP, SAN FRANCISCO, 1990 - 1994 (1)

AGE-GROUP (YEARS) 19 AND UNDER 20 - 24 25 - 29	NUMBER TESTED 17 136 214	NUMBER(2) POSITIVE 0 4 4 11	SERO- PREVALENCE RATE (%) 0.0 2.9 5.1		NUMBER TESTED 7 90 178	NUMBER(2) POSITIVE	SERO- C(2) PREVALENCE VE RATE (%) 0.0 2.2 2.2 6.2	
	217 256 195 104 6	20 84 7 0 83 83 83 83 83	7.2 13.5 13.5 7.4	5.7 - 13.9 4.2 - 10.9 5.6 - 21.6 	737 3 4 4 7 9 7 7 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	£44000 88	4.6.2.2.2.0. 4.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.	5.5 - 13.9 0.8 - 7.5 2.3 - 13.0 0.6 - 15.5 

(1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Sample includes both injection drug users (IDUS) who have a history of needle use a since 1978, and non-injection drug users who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment. Stackles persons who were preferentially admitted to treatment dering the survey period, persons who were preferentially admitted to treatment due to HIV/AIDS, and persons under alcohol treatment only. Blood specimens were collected for syphilis screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blotch assay. (3) 9% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

		IDUs	ø			-NON	NON-IDUS	
PRIMARY DRUG	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE		SERO- PREVALENCE RATE (%) (95% C.I.)(3)
HERDIN COCAINE/CRACK HERDIN AND COCAINE (SPEEDBALL) BARBITUGATES AMPHETAMINES/SPEED OTHER OR UNSPECIFIED DRUGS	782 47 52 113 151	55,0 7,5	3.7 8.5 13.5 13.9	2.5 - 5.3 2.4 - 20.4 5.6 - 25.8 14.1 - 29.9 8.8 - 20.5	79 425 0 3 22 179	53 0 0 0 0 0 0 0	3.8 5.4 36.4 2.2	3.5 - 8.0 
	1145	85	7.4	6.0 - 9.1	708	38	5.4	3.8 - 7.3

(1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Sample includes both injection drug users who have an istory of needle use since 1978, and non-injection drug users who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment. Excludes persons with a prior admission to treatment during the survey period, persons who were preferentially admitted to treatment due to HIV/AIDS, and persons under alcohol treatment only. Blood specimens were collected for syphilis screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY TRANSMISSION CATEGORY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1992 (1)

		1989	9 SURVEY			1990	0 SURVEY			1991	1 SURVEY	
TRANSMISSION CATEGORY	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
Heterosexual IDU (4) Sex Partner at Risk for HIV Blood Recipient (5) Heterosexual (6) Unknown Risk (7)	0 0 0 1266	.00004	0.32	0.09 - 0.81	20 24 11 1313 8	-00-0	5.00 0.00 0.00 0.00	0.13 -24.87	9 11 4 1925 8	-0000	0.00 0.00 0.10 0.00	0.01 - 0.37
TOTAL	1266	. 4	0.32	0.09 - 0.81	1376	2	0.15	0.02 - 0.52	1957	3	0.15	0.03 - 0.45

		199	1992 SURVEY	-
TRANSMISSION CATEGORY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3
Heterosexual IDU (4) Sex Partner at Risk for HIV Blood Recipient (5) Unknown Risk (7)	4 0 0 1293 0	000-0	0.00	0.00 - 0.43

(1) This unlinked (blinded) survey was drawn from women seeking family planning services. Specimens were collected from initial and annual visits, and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons with a history of injection drug use, (10b) since January 1978.

(5) Includes persons with a history of blood transfusions(s) between January 1977 and March 1985.

(6) Self-identified heterosexuals with no other identified eisks.

(7) The 1999 unlinked survey did not collect risk information.

0.00 - 0.43

0.08

1297

TOTAL

		1989	39 SURVEY				1990	0 SURVEY			1991	91 SURVEY	
RACE/ETHNIC1TY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%) (95% C.1.)(3)	(95% C.1	.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE		SERO- PREVALENCE RATE (%) (95% C.1.)(3)
WHITE AFRICAN AMERICAN LATINA ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	122 154 810 149 31	<del></del> 000	0.82 0.65 0.00 0.00	0.02 - 0.03 - 0.00 - 0.00 - 0.00	4.48 3.56 0.89 1.99 9.21	126 145 908 166 31	-00-0	00.00	0.02 - 4.34 0.00 - 2.04 0.00 - 0.33 0.02 - 3.31 0.00 - 9.21	156 1441 178 178 1 441	0-400	0.00	0.00 - 1.90 0.02 - 3.89 0.02 - 0.50 0.00 - 1.67 0.00 - 7.05
TOTAL	1266	7	0.32	0.09 - 0.81	0.81	1376	2	0.15	0.02 - 0.52	2   1957	ю	0.15	0.03 - 0.45

	(95% C.1.)(3)	0.00 - 3.59 0.00 - 2.81 0.00 - 3.14	0.00 - 0.43
1992 SURVEY	SERO- PREVALENCE RATE (%)	00000	0.08
199	NUMBER(2) POSITIVE	00-00	1
	NUMBER	82 105 1001 94 15	1297
	RACE/ETHNICITY	HHITE AFRICAN AMERICAN LATINA ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL

(1) This unlinked (blinded) survey was drawn from women seeking family planning services. Specimens were collected from initial and annual visits, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1992 (1)

1989 SURVEY 1990 SURVEY 1991 SURVEY	SERO- NUMBER NUMBER(2) PREVALENCE TESTED POSITIVE RATE (%) (95% C.1.)(3)  SERO- NUMBER NUMBER(2) PREVALENCE TESTED POSITIVE RATE (%) (95% C.1.)(3)  TESTED POSITIVE RATE (%) (95% C.1.)(3)	R         73         0         0.00         0.00         -0.00         0.00         -0.00         -0.05         636         636         0.00         0.00         -0.47         0         0.00         0.00         -0.63         636         0         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00	1266 4 0.32 0.09 - 0.81 1376 2 0.15 0.02 - 0.52 1957 3 0.15 0.03 - 0.45	1992 SURVEY	SERO- NUMBER NUMBER(2) PREVALENCE YEARS) TESTED POSITIVE RATE (%) (95% C.I.)(3)	8 60 0 0.00 -4.87 390 0.00 -4.87 427 1 0.00 0.00 -4.87 523 0 0.00 0.00 -1.33 523 0 0.00 0.00 -1.33 523 0 0.00 0.00 -1.33 523 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
	AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 25 - 29 25 - 34 35 - 39 40 - 44 45 AND OVER	TOTAL		AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 30 - 34 35 - 39 35 - 34 45 AND OVER UNKNOWN

(1) This unlinked (blinded) survey was drawn from women seeking family planning services. Specimens were collected from initial and amunal Visits, and tested for HIV after all personal identifiers were removed.
All positive specimens were repeatedly reactive by ELISA and confirmed by a Hestern blot assay.
(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

0.00 - 0.43

0.08

1297

TOTAL

HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY TRANSMISSION CATEGORY AND YEAR OF SURVEY, SAN FRANCISCO, 1990 - 1992 (1)

1992 SURVEY	SERO- NUMBER NUMBER(2) PREVALENCE TESTED POSITIVE RATE (%) (95% C.1.)(3)	7 1 14.29	742 9 1.21 0.56 - 2.29	
		55 .		
	SERO- REVALENCE RATE (%) (95% C.1.)(3)	0.13 - 1.25	0.49 - 2.01	drawn from women seeking induced abortions. Specimens were collected for evaluation personal identifiers were removed.  ddy reactive by ELISA and confirmed by a Western blot assay.  maint. Confidence Intervals not calculated for sample sizes under 20 observations. injection drug use (IDU) since January 1978.
1991 SURVEY		35.71 0.00 0.49 0.00	1.06	collected fo
195	NUMBER(2) POSITIVE	NO40	6	imens were colot assay.
	NUMBER	14 7 817 8	846	ons. Speci Western k sted for sa 1978.
	.1.)(3)	0.06 - 1.71	0.14 - 2.02	ed abortionved. irmed by and calcula
	(95% 0	00.0	0.14	g inducre remond conf
1990 SURVEY	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	12.50 0.00 0.48 0.00	0.70	omen seekin ntifiers we by ELISA a idence Inte ug use (IDU ntified ris
199	NUMBER(2) POSITIVE	T020	м	Irawn from w wersonal ide Ily reactive mial. Conf njection dr
	NUMBER	419	431	vey was creall presented act bind tory of its with r
	TRANSMISSION CATEGORY	Heterosexual IDU (4) Sex Partner at Risk for HIV Heterosexual (5) Unknown Risk	TOTAL	(1) This unlinked (blinded) survey was drawn from women seeking induced abortions. Specimens were collected for evaluation purposes, and tested for MIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes persons with a history of injection drug use (10U) since January 1978.

HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1990 - 1992 (1)

		1990	O SURVEY			1991	11 SURVEY			1992	72 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE		SERO- PREVALENCE RATE (%) (95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
WHITE AFRICAN AMERICAN LATINA ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	50 106 223 45 7	-2000	2.00 1.89 0.00 0.00	0.05 -10.65 0.23 - 6.65 0.00 - 1.33 0.00 - 6.44	71 206 437 107 25	mmm00	4.23 1.46 0.69 0.00 0.00	0.88 -11.86 0.30 - 4.20 0.14 - 1.99 0.00 - 2.76 0.00 -11.29	50 172 393 108 19	N 900+	4.00 3.49 0.00 5.26	0.49 -13.71 1.29 - 7.44 0.00 - 0.76 0.00 - 2.74
TOTAL	431	3	0.70	0.14 - 2.02	846	6	1.06	0.49 - 2.01	742	6	1.21	0.56 - 2.29

(1) This unlinked (blinded) survey was drawn from women seeking induced abortions. Specimens were collected for evaluation purposes, and tested for HIV after all personal identifiers were removed.

(3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 55% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

HIV SEROPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY AGE-GROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1990 - 1992 (1)

ା ଛୀ	27.888322	8 1
6.1.3		0.56 - 2.29
(95%	0.00 0.31 0.32 0.30 0.00 0.00	0.56
SERO- PREVALENCE RATE (%)	0.00 1.06 1.49 0.76 2.47 0.00 33.33	1.21
NUMBER(2) POSITIVE	008-000-	٥
NUMBER TESTED	112 189 202 131 23 1 23	74.2
)(3)	50	.01
, c.1.		0.49 - 2.01
.E (955	000000	0.0
SERO- PREVALENC RATE (%)	0.00 0.05 0.08 0.00 0.00	1.06
NUMBER(2) POSITIVE	-24000	6
NUMBER	133 253 223 223 118 86 27 27 6	846
.)(3)	2.94 2.79 3.74 3.74 	20.2
5% C.1.	200000000000000000000000000000000000000	0.14 - 2.02
CE (95	66666	0
SERO- PREVALEN RATE (%	0.00 0.72 0.00 0.00 0.00	0.70
NUMBER(2) POSITIVE	0-00000	м
NUMBER	68 106 106 80 80 8 0	431
E-GROUP (YEARS)	AND UNDER - 24 - 29 - 34 - 34 - 44 AND OVER	TOTAL
	SERO- NUMBER(2) PREVALENCE POSITIVE RATE (%) (95% C.1.)(3) TESTED  SERO- NUMBER TESTED  RESTED	NUMBER (2)   PREVALENCE   TESTED   POSITIVE   RATE (%) (95% C.I.)(3)   TESTED   POSITIVE   RATE (%) (95% C.I.

(1) This unlinked (blinded) survey was drawn from women seeking induced abortions. Specimens were collected for evaluation purposes, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confinmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

HIV SEROPREVALENCE FOR NEWBORN INFANTS AND THEIR MOTHERS BY AGE GROUP AND RACE/ETHNICITY, 1989-1993 (1)

-		1989	39 SURVEY				1990	) SURVEY				1991	1 SURVEY	
	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
AGE-GROUP (YEARS)	219 442 638 625 485 138	-4000-	0.45 0.45 0.00 0.00 0.00	0.00	2.52 1.62 0.47 0.62 3.97	181 446 618 625 451	0000	0.0.0.0 0.0.0.0 0.0.0.0 0.0.0.0 0.0.0.0 0.0.0.0 0.0.0.0 0.0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0.0 0.0 0.0.0 0.0.0 0.0 0.0.0 0.0.0 0.0 0.0.0 0.0 0.0.0 0.0.0 0.0.0 0.0	8888888	1.64 - 0.67 - 0.90 - 0.89 - 2.53	72 454 429 429 429	-040	0.49 0.00 0.61 0.29 1.39	0.01 - 2.67 0.00 - 0.66 0.17 - 1.56 0.03 - 1.04 0.01 - 1.29
RACE/ETHNICITY WHITE ARICAN AMERICAN LATINO ASIAN/PACIFIC IS. OTHER	679 334 564 564 128	00	0.00 0.30 0.18 0.00 0.49	0.00 - 0.44 0.01 - 1.66 0.00 - 0.98 0.00 - 0.47 0.01 - 2.67	0.44 1.66 0.98 0.47 4.28	663 608 633 115	-0-000	.0.0.0.0 .0.00.00 .0.000	8888888	. 0.84 . 0.92 . 0.91 . 2.57 . 3.10	640 317 634 654 767 967	4M-00-	0.00 0.00 0.00 0.00 0.00	0.17 - 1.59 0.20 - 2.74 0.00 - 0.88 0.00 - 0.66 0.00 - 0.81
TOTAL - SAN FRANCISCO	2547		0.16	0.04 - 0.40	07.0	2438	2	0.08	0.01 -	- 0.30	2509	٥	0.36	0.16 - 0.68
TOTAL - BAY AREA (4) TOTAL - STATEWIDE	21217	52 52	0.12	0.08 - 0.17	0.08	21397	106	0.11	0.07 - 0.16 0.06 - 0.09	0.09	22103	124	0.14	0.10 - 0.20
	fornia Depering birth; The infection of the repeater exact bincular languages.	artment of H ) are drawn )n status of 11y reactive >mial. Conf	rtment of Health Services Office of AIDS. Specimens from this surva en drawn from the genetic diseases screening program. Antibodies n status of the mother and not necessarily of the Child. If ye reactive by ELISA and confirmed by a Mestern blot assay. mial. Confidence Intervals not calculated for sample sizes under 2! ntra Costa, Marin, San Francisco, San Mateo, and Santa Clara.	ces Offices and not and confirmation reals not reals not reals not reals not reals not reals not reals not reals not reals not reals not reals not reals not reals not reals not reals not reals not reals not reals not real section reals not real section real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not real not re	ce of AIDS seases scr necessari rmed by a t calculat	S. Specime reening pro 1ly of the Western bl ted for sam iteo, and S	ens from the sgram. Antichild. ot assay. uple sizes uanta Clara.	Specimens from this survey of ning program. Antibodies of the child. Stern blot assay. for sample sizes under 20 obs. o, and Santa Clara.	ervation	. st				

HIV SEROPREVALENCE FOR NEWBORP INFANTS AND THEIR MOTHERS BY AGE GROUP AND RACE/ETHNICITY, 1939-1993(1)

	1.)(3)	3.23 0.67 0.84 1.19	1.22	7 - 0.48 4 - 0.12 0.07
· '	(95% C.1.)(3)	200000	0.000.000.00000000000000000000000000000	0.07 - 0.48
1993 SURVEY	SERO- PREVALENCE RATE (%)	0.59 0.00 0.15 0.21 0.00	0.28 0.32 0.34 0.00 0.00	0.21
199	NUMBER(2) POSITIVE	-0-2-0	0000	5 16 83
	NUMBER	170 446 662 667 466	717 316 590 661 148	2435 21601 150598
	.)(3)	1.80 0.70 1.13 1.24 2.18	3.70 3.70 0.49 0.45 3.82	3.48 3.20 3.08
	(95% C.1.)(3)	0.00000	0.0000000000000000000000000000000000000	0.07 - 0.48
2 SURVEY	SERO- PREVALENCE RATE (%)	0.00 0.33 0.32 0.02 0.02	0.0000	0.20
1992	NUMBER(2) POSITIVE	0-000-0	010000	31
	NUMBER	165 428 628 628 446 136	646 312 610 662 135	2442 21565 151033
		AGE-GROUP (YEARS)	RACE/ETHNICITY WHITE WHITE ARRICAN AMERICAN LATINO SASAM/PACIFIC IS. OTHER	TOTAL - SAN FRANCISCO TOTAL - BAY AREA (4) TOTAL - STATEWIDE

(1) Data courtesy of the California Department of Health Services Office of AlDS. Specimens from this survey of meaborn infants (and women giving birth) are drawn from the genetic diseases screening program. Antibodies in a newborn infant reflect the infection status of the mother and not necessarily of the child.

(2) All positive specimens were repeatedly reactive by ElISA and confirmed by a Western blot assay.

(3) SSX Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes the counties of Alameda, Contra Costa, Marin, San Francisco, San Mateo, and Santa Clara.

HIV SEROPREVALENC: FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A MUNICIPAL TB CLINIC BY GENDER AND TRANSMISSION CATEGORY, SAM FRANCISCO, 1989 - 1992 (1)

	(95% C.1.)(3)		61.5 - 84.5 56.5 - 89.7 9.6 - 41.1 3.2 - 10.5	22.0 - 31.7		0.0 - 6.5	1.5 - 10.1	
CATEGORY,	SERO- PREVALENCE RATE (%)		74.2 75.9 22.6 6.1	56.6		25.0 1.2 0.0	4.5	
TRANSMISSION CATEGORY,	NUMBER(2) POSITIVE		22 Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	) &		4-0	, °	- Contraction
GENDER AND T	NUMBER		62 239 196 16	) # <u></u>		16 83 13	112	
IV SEKORKOWLEKT, THE FAILERIS ONDER INEAIMENI THE LOGEROLICASIS (192) AM MINICIPEL TB CLINIC BY GENDER AND TRANSMISSION CATEGORY, AM FRANCISCO, 1989 - 1992 (1)	I CATEGORY		1 100 (4) 1 100 (4) (5)	IALE		DE (5)	EMALE	
IV SEKOPREVAL T A MUNICIPAL AN FRANCISCO,	GENDER AND TRANSMISSION CATEGORY	MALE 	Gay/Bisexual Gay/Bisexual Heterosexual Heterosexual Unknown Risk	SUB-TOTAL MALE	FEMALE	Heterosexual Heterosexual Unknown Risk	SUB-TOTAL FEMALE	The second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second secon

(1) This interview based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and TB suspects (class 5). Data collected between the 1st quarter of 1989 and the 4th quarter of 1992.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence intervals, exact binomial. Confidence intervals not calculated for sample sizes under 20 observations.

(4) Includes persons with a history of injection drug use (IDU) since January 978.

(5) Includes persons with a sixtery of injection drug use (IDU) since January 978.

(6) Includes persons with a sexual partner(s) at risk for HIV, persons with a history of blood transfusion(s) or with a bleeding disorder, and self-identified heterosexuals with no other identified risks.

17.4 - 25.2

21.1

8

955

TOTAL

SERO- NUMBER(2) PREVALENCE POSITIVE RATE (%) (95% C.1.)(3)	29.6 - 42.4	17.4 - 25.2
SERO- PREVALENCE RATE (%)	35.8 5.5	21.1
NUMBER(2) POSITIVE	82 12	76
NUMBER	229	977
ORIGIN OF BIRTH	BORN IN USA BORN OUTSIDE USA	TOTAL

(1) This interview based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and TB suspects (class 5). Data collected between the 1st quarter of 1989 and the 4th quarter of 1992. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals, exact binomial.

HIV SEROPREVALENCE FOR PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB) AT A MUNICIPAL TB CLINIC BY RACE/ETHNICITY, SAN FRANCISCO, 1989 - 1992 (1)

SERO- PREVALENCE RATE (%) (95% C.I.)(3)	31.8 - 52.6 18.9 - 36.0 12.6 - 29.8 0.2 - 5.2
SERO- PREVALENCE RATE (%)	41.9 26.8 20.2 1.5 36.4
NUMBER(2) POSITIVE	39 30 4 2 4
NUMBER	93 112 94 136
RACE/ETHNICITY	WHITE AFRICAN AMERICAN LATINO ASTAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)

17.4 - 25.2

21.1

8

446

TOTAL

(1) This interview based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and TB suspects (class 5). Data collected between the 1st quarter of 1989 and the 4th quarter of 1992.
(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blots assay.
(3) \$9\$\$, Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

(95% c.1.)(3)	16.4 - 36.8 18.5 - 34.3 21.2 - 39.2 2.8 - 12.4	17.4 - 25.2
SERO- PREVALENCE RATE (%) (	25.6 25.8 29.6 6.5	21.1
NUMBER(2) POSITIVE	20 33 32 8 0	76
NUMBER TESTED	9 78 128 108 123	977
AGE-GROUP (YEARS)	19 AND UNDER 20 - 29 30 - 39 40 - 49 50 AND OVER UNKNOWN	TOTAL

(1) This interview based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and TB suspects (class 5). Data collected between the 1st quarter of 1989 and the 4th quarter of 1992. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence presents, exact binomial. Confidence intervals, exact binomial. Confidence intervals not calculated for sample sizes under 20 observations.

•	(95% C.1.)(3)	0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00	0.1 - 0.6
	SERO- PREVALENCE RATE (%)	2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.3
	NUMBER(2) POSITIVE	-040 \ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ω
	NUMBER	2008 2008 2008 28 28 28 28 2173 2173 2173 575 509	2779
	GENDER AND TRANSMISSION CATEGORY	MALE Homosexual/Bisexual Heterosexual, 1DU (4) Heterosexual (5) Unknown Risk SUB-TOTAL MALE FEMALE Heterosexual IDU (4) Heterosexual (5) Unknown Risk SUB-TOTAL FEMALE MISSING GENDER	TOTAL

(1) This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood specimens were collected for syphilis screening on inmates as part of the routine intake process. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. Specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (2) 95% Confidence Intervals for Confidence Intervals to Confidence Intervals to Confidence Intervals to Confidence Intervals of injection drug use (IDU) since January 1978. (4) Includes persons with a history of injection drug use (IDU) since January 1978.

(1) This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood specimens were collected consclucted for sphilit's screening on immates as part of the routine intake process. Specimens were collected conscluvely and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

HIV SEROPREVALENCE FOR ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER BY AGE-GROUP, SAN FRANCISCO, 1990 - 1995 (1)

SERO- PREVALENCE RATE (%) (95% C.I.)(3)	0.0 - 1.1	0.1 - 0.6
SERO- PREVALENCE RATE (%)	0.00	0.3
NUMBER(2) POSITIVE	-2000	80
NUMBER	503 2231 4 0 41	2779
AGE-GROUP (YEARS)	UNDER 15 15 - 19 20 - 24 25 - 29 UNKNOWN	TOTAL

(1) This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood specimens were collected for syphilis screening on inmates as part of the routine intake process. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(95% C.1.)(3)	42.4 - 51.5 0.6 - 8.9 0.5 - 2.1 0.1 - 21.9 15.7 - 19.9	0.5 - 7.6 0.5 - 1.6 0.0 - 7.6 0.8 - 1.9	
SERO- PREVALENCE RATE (%)	46.9 3.1 4.3 17.7	3.9 1.0 0.0 1.3	
NUMBER(2) POSITIVE	223 3 1 1 8 235	24   0 18	
NUMBER	475 473 732 1326	203 1667 38 38  1908	
GENDER AND TRANSMISSION CATEGORY	MALE Gay/Bisexual Heterosexual, IDU (4) Heterosexual (5) Unknown Risk SUB-TOTAL MALE FEMALE	Heterosexual IDU (4) Heterosexual (5) Unknown Risk SUB-TOTAL FEMALE MISSING GENDER	

(1) This unlinked (blinded) survey include adolescents seeking services at two homeless youth shelters. Blood specimens were collected for syphilis screening as part of the routine medical evaluation. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomic., Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons with a history of injection drug use (IDU) since January 1978.

7.1 - 9.0

261

3244

TOTAL

HIV SEROPREV. ENCE FOR ADOLESCENTS ENTERING HOMELESS YOUTH CENTERS BY RACE/ETHNICITY, SAN FRANCISCO, 1990 - 1995 (1)

SERO- (2) PREVALENCE VE RATE (%) (95% C.1.)(3)	10.8 - 14.5 3.4 - 6.7 3.4 - 6.6 3.1 - 8.2 2.9 - 11.7	7.1 - 9.0
SERO- PREVALENCE RATE (%)	12.6 4.9 4.8 5.2 6.3	8.0
NUMBER(2) POSITIVE	164 34 37 17 9	261
NUMBER	1306 701 768 327 142	3244
RACE/ETHN1C1TY	HITE ATINO AZINO SSIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	COTAL

(1) This unlinked (blinded) survey include adolescents seeking services at two homeless youth shelters. Blood specimens were collected for syphilis screening as part of the routine medical evaluation. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 59% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

AGE-GROUP (YEARS)	TESTED	POSITIVE	RATE (%)	RATE (%) (95% C.I.)(3)
UNDER 15 15 - 19 20 - 24	333 2300 577	184 184	31.9	0.5 - 3.5 2.3 - 3.7 28.1 - 35.9
× ×	58 o	77	7.1	0.9 - 23.5

Blood specimens were (1) This unlinked (blinded) survey include adolescents seeking services at two homeless youth shelters. Blood specimens worlected for syphilis screening as part of the routine medical evaluation. Specimens were collected conscentively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENDER AND YEAR, 1985 - 1995 (1)

1990	N(2) HIV+(3) %(4)	520 0 0.00 105 0 0.00	625 0 0.00	TOTAL	N(2) HIV+(3) %(4)	5616 23 0.41 1142 2 0.18	6758 25 0.37
1989	N(2) HIV+(3) %(4)	711 2 0.28 124 1 0.81	835 3 0.36	5661	N(2) HIV+(3) %(4)	257 0 0.00 58 0 0.00	315 0 0.00
1988	N(2) HIV+(3) %(4)	759 2 0.26 178 0 0.00	937 2 0.21	7661	N(2) HIV+(3) %(4)	302 2 0.66 74 0 0.00	376 2 0.53
1987	N(2) HIV+(3) %(4)	869 5 0.58 143 0 0.00	1012 5 0.49	1993	N(2) HIV+(3) %(4)	322 0 0.00 73 0 0.00	395 0 0.00
1986	N(2) HIV+(3) %(4)	941 9 0.96 183 1 0.55	1124 10 0.89	1992	N(2) HIV+(3) %(4)	315 1 0.32 86 0 0.00	401 1 0.25
1985	N(2) HIV+(3) %(4)	213 0 0.00 45 0 0.00	258 0 0.00	1991	N(2) HIV+(3) %(4)	407 2 0.49 73 0 0.00	480 2 0.42
	GENDER	MALE FEMALE	TOTAL		GENDER	MALE FEMALE	TOTAL

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC). Data Collected between October 1985 and December 1995. (2) Number of specimens tested. (3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (4) Seroprevalence rate (%).

HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY ANY COUNTY OF SAN FRANCISCO BY RACE AND ETHNICITY AND YEAR, 1985 - 1995 (1)

1989 1990	N(2) HIV+(3) %(4) N(2) HIV+(3) %(4)	286 1 0.35 210 0 0.00 178 1 0.56 85 0 0.00 102 1 0.08 78 0 0.00 253 0 0.00 237 0 0.00 16 0.00 20 20 0 0.00	835 3 0.36 625 0 0.00	1995 TOTAL	N(2) HIV+(3) %(4) N(2) HIV+(3) %(4)	104 0 0.00 2353 15 0.64 41 0 0.00 1210 7 0.58 50 0 0.00 766 2 0.26 118 0 0.00 2202 0 0.00 2 0 0.00 2277 1 0.44	315 0 0.00 6750 25 0.37
1988	N(2) HIV+(3) %(4)	334 1 0.30 193 1 0.52 115 0 0.00 267 0 0.00	937 2 0.21	1994	N(2) HIV+(3) %(4)	134 2 1.49 49 0 0.00 47 0 0.00 134 0 0.00	376 2 0.53
1987	N(2) HIV+(3) %(4)	346 2 0.58 212 3 1.42 108 0 0.00 320 0 0.00 26 0 0.00	1012 5 0.49	1993	N(2) HIV+(3) %(4)	142 0 0.00 64 0 0.00 133 0 0.00	395 0 3,00
1986	N(2) HIV+(3) %(4)	409 7 1.71 242 2 0.83 74 0 0.00 329 0 0.00 70 1 1.43	1124 10 0.89	1992	N(2) HIV+(3) %(4)	134 0 0.00 53 0 0.00 49 1 2.04 158 0 0.00 7 0 0.00	401 1 0.25
1985	N(2) HIV+(3) %(4)	94, 0 0.00 51, 0 0.00 111 0 0.00 85 0 0.00 17 0 0.00	258 0 0.00	1991	N(2) HIV+(3) %(4)	160 2 1.25 63 0 0.00 68 0 0.00 173 0 0.00 16 0 0.00	480 2 0.42
	RACE/ETHNICITY	WHITE BLACK HISPANIC ASIAN/P.I. OTHER	TOTAL		RACE/ETHNICITY	WHITE BLACK LATINO ASIAN/P.I. OTHER	TOTAL

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC). Data Collected between October 1985 and December 1995.
(2) Number of specimens tested.
(3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
(4) Seroprevalence rate (%).

HIV SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY AGE-GROUP AND YEAR, 1985 - 1995 (1)

					<b>.</b>		f	,
	N(2) HIV+(3) %(4)	8886	00.00	7	N(2) HIV+(3) %(4)	0.10	0.37	
1990	HIV+(	00000	0	TOTAL	H1V+(	W4000	Я	
	N(2)	300 154 111 60 0	625		N(2)	2992 1701 1203 862 0	8529	
	(4)	0.00 0.47 1.18 0.00	0.36		(4)%	00000	0.00	
1989	۷+(3	0-400	ъ	1995	V+(3	00000	0	
	N(2) HIV+(3) %(4)	352 211 170 102 0	835	1	N(2) HIV+(3) %(4)	131 79 57 57 48 0	315	
	%(4)	0.24	0.21		%(4)	3.57	0.53	
1988	N(2) HIV+(3) %(4)	-0-00	5	1994	N(2) HIV+(3) %(4)	00000	2	
-	2) HI	417 236 163 121 0	937	-	2) HI	35 88 50 0	376	
	N	4844			N	## · · ·		
	(4)	0.00 0.38 0.60 2.26	0.49		(4)%	00000	0.00	
1987	+(3)	04-1-0	2	1993	(3)	00000		
19	N(2) HIV+(3) %(4)	448 265 166 133		19	N(2) HIV+(3) %(4)	174 108 68 45 0	395	
	NC2	26 13 13	1012		NC2	17	33	
	(4)	0.21 0.70 1.47 2.67	0.89		(4)%	0.00 0.00 1.54 0.00	0.25	
1986	+(3)	-0W40	10	1992	+(3)	00-00	_	
19	N(2) HIV+(3) %(4)			19	N(2) HIV+(3) %(4)	193 99 65 0	_	
	N(2	485 285 204 150 0	1124		N(2	99	401	
	(4)	0.00	0.00		(4)	0.44 0.00 1.32 0.00	0.42	
1985	N(2) HIV+(3) %(4)	00000		16	N(2) HIV+(3) %(4)	-0-00	2 (	
198	HIV.			1991	HIV-			
	N(2	129 48 45 36 0	258		N(2	227 110 76 67 0	480	
	AGE-GROUP	19 AND UNDER 20 - 24 25 - 29 30 AND OVER UNKNOWN	TOTAL		AGE-GROUP	19 AND UNDER 20 - 24 25 - 29 35 - 29 30 AND OVER UNKNOWN	TOTAL	

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC). Data Collected between October 1985 and December 1995. (2) Number of specimens tested. (2) Number of specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (4) Seroprevalence rate (%).

(95% c.1.)(3)	0.088 - 0.139 0.033 - 0.062 0.023 - 0.067 0.017 - 0.039 0.007 - 0.024 0.007 - 0.024 0.003 - 0.018 0.003 - 0.014	0.023 - 0.031
SERO- PREVALENCE RATE (%)	0.111 0.045 0.033 0.036 0.013 0.013 0.010 0.006	0.027
NUMBER(2) POSITIVE	480 30 30 11 11 5 3	216
TOTAL	72204 88168 88168 91366 90192 87320 77277 78197 70545 69684	809457
YEAR OF DONATION	1985 1986 1988 1988 1990 1991 1992 1993	TOTAL

(1) Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, normal approximation.

HIV SEROPREVALENCE FOR BLOOD DOWORS FROM THE SAN FRANCISCO BAY AREA BY DONATION STATUS AND GENDER, JANUARY 1991 - DECEMBER 1994 (1)

(95% C.1.)(3)	0.022 - 0.070 0.002 - 0.028	0.001 - 0.009	0.005 - 0.011
SERO- PREVALENCE RATE (%)	0.040	0.003	0.007
NUMBER(2) POSITIVE	13 3.	40	25
TOTAL	32754 33727	120810 108308	295599
GENDER	Male Female	Male Female	
DONATION	FIRST-TIME DONORS	REPEAT DONORS	TOTAL

(1) Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, normal approximation.

(95% C.I.)(3)	0.003 - 0.009 0.026 - 0.127 0.000 - 0.016 0.004 - 0.054	0.005 - 0.011
SERO- PREVALENCE RATE (%)	0.005 0.059 0.000 0.017	0.007
NUMBER(2) POSITIVE	12 7 7 0 3 0	52
TOTAL	243645 11941 22218 17795	295599
RACE/ETHNICITY	WHITE AFRICAN AMERICAN ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL

(1) Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca. (2) All positive specimens where repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, normal approximation. (4) Includes Latinos, American Indians, Alaskan Natives, other race, and unknown race.

HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA BY AGE-GROUP, JANUARY 1991 - DECEMBER 1994 (1)

			assay
			'n blot
(95% C.1.)(3)	0.000 - 0.019 0.004 - 0.024 0.010 - 0.030 0.001 - 0.007	0.005 - 0.011	d by a Wester
(95% c	0.000	0.005	co, Ca. onfirme
SERU- PREVALENCE RATE (%)	0.000 0.010 0.018 0.002	0.007	s, San Francis by ELISA and c
NUMBER(2) POSITIVE	0 N 7 W	22	l Blood Centers edly reactive b pproximation.
TOTAL	19459 51933 79409 144798	295599	Irwin Memoria ns were repeat vals, normal a
AGE-GROUP (YEARS)	19 AND UNDER 20 - 29 30 - 39 40 AND OVER	TOTAL	(1) Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay (3) 95% Confidence Intervals, normal approximation.

070 # 58 Nov 1996 17:2 c 2

## HIV Seroprevalence Report

MAR 2 6 1998

SAN FRANCISCO
PUBLIC LIBRARY

San Francisco Department of Public Health AIDS Office November, 1996 Volume 7, No. 2

## Contents

Comonio		
		<u>Page</u>
SURVEY OF CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISE	EASE (STD) CLINIC: 1989-95	
HIV Seroprevalence for Clients Attending a STD Clinic by Gen HIV Seroprevalence for Clients Attending a STD Clinic by Race HIV Seroprevalence for Clients Attending a STD Clinic by Age HIV Seroprevalence for Gay & Bisexual Men Attending a STD C HIV Seroprevalence for Gay & Bisexual Men Attending a STD C HIV Seroprevalence for Heterosexual Males Attending a STD C HIV Seroprevalence for Heterosexual Males Attending a STD C HIV Seroprevalence for Heterosexual Females Attending a STD C HIV Seroprevalence for Heterosexual Females Attending a STD	e/Ethnicity Group Clinic by Race/Ethnicity Clinic by Age Group Clinic by Race/Ethnicity Clinic by Age Group D Clinic by Age Group D Clinic by Race/Ethnicity	1 4 6 8 10 12 14 16
SURVEY OF INJECTION DRUG USERS (IDUs) ENTERING METHADO	ONE TREATMENT PROGRAMS	
HIV Seroprevalence for IDUs Entering Methadone Treatment b HIV Seroprevalence for IDUs Entering Methadone Treatment b HIV Seroprevalence for IDUs Entering Methadone Treatment b	by Race/Ethnicity	20 22 23
SURVEY OF DRUG USERS (IDUS & NON-IDUS) ENTERING A METHA	ADONE-FREE DETOX PROGRAM	
HIV Seroprevalence for Clients Entering a Drug-Free Detox Pro	ogram by Gender & Sexual Orienta	
HIV Seroprevalence for Clients Entering a Drug-Free Detox Pro HIV Seroprevalence for Clients Entering a Drug-Free Detox Pro HIV Seroprevalence for Clients Entering a Drug-Free Detox Pro	gram by Age Group	24 25 26 27
SURVEY OF WOMEN OF REPRODUCTIVE AGE: FAMILY PLANNING	G & ABORTION CLINIC CLIENTS	
HIV Seroprevalence for Women Attending a Family Planning O HIV Seroprevalence for Women Attending a Family Planning O HIV Seroprevalence for Women Attending a Family Planning O HIV Seroprevalence for Women Attending an Abortion Clinic to HIV Seroprevalence for Women Attending an Abortion Clinic to HIV Seroprevalence for Women Attending an Abortion Clinic to	Clinic by Race/Ethnicity Clinic by Age Group by Transmission Category by Race/Ethnicity	28 29 30 31 32 33
SURVEY OF CHILDBEARING WOMEN IN SAN FRANCISCO: 1989-0	94	
HIV Seroprevalence for Newborn Infants and Their Mothers by	Age Group and Race/Ethnicity	34
SURVEY OF PATIENTS UNDER TREATMENT FOR TUBERCULOSIS (TB	) AT A TB CLINIC	
HIV Seroprevalence for TB Patients by Gender and Transmission HIV Seroprevalence for TB Patients by Origin of Birth HIV Seroprevalence for TB Patients by Race/Ethnicity HIV Seroprevalence for TB Patients by Age Group	DOCUMENTS DEPT. MAR 2 5 1998	36 37 38 39
	SAN FRANCISCO PUBLIC LIBRARY	

## SURVEY OF ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER (JDC) AND HOMELESS YOUTH CENTERS (HYCs)

HIV Seroprevalence for Adolescents Entering a JDC by Gender & Transmission Category HIV Seroprevalence for Adolescents Entering a JDC by Race/Ethnicity HIV Seroprevalence for Adolescents Entering a JDC by Age Group HIV Seroprevalence for Adolescents Entering HYCs by Gender & Transmission Category HIV Seroprevalence for Adolescents Entering HYCs by Race/Ethnicity	40 41 42 43 44
HIV Seroprevalence for Adolescents Entering HYCs by Age Group  RESULTS OF HIV SCREENING OF CIVILIAN APPLICANTS FOR MILITARY SERVICE: 1985-1995	45
HIV Seroprevalence for Civilian Applicants for Military Service by Gender & Year HIV Seroprevalence for Civilian Applicants for Military Service by Race/Ethnicity & Year HIV Seroprevalence for Civilian Applicants for Military Service by Age Group & Year	46 47 48
RESULTS OF HIV SCREENING OF BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA: 1985-1995	
HIV Seroprevalence for Blood Donors by Year of Donation HIV Seroprevalence for Blood Donors by Donation Status & Gender HIV Seroprevalence for Blood Donors by Race/Ethnicity HIV Seroprevalence for Blood Donors by Age Group	49 50 51 52

HIV SEROPREVALENCE REPORT is released on a semi-annual basis by the San Francisco Department of Public Health, AIDS Office, Seroepidemiology and Surveillance Branch, 25 Van Ness Avenue, Suite 500, San Francisco, CA 94102-6033. Phone (415) 554-9050. Director of Epidemiology, Disease Control, and AIDS, Mitch Katz, M.D. Seroepidemiology Section Branch Chief, Willi McFarland, M.D., Ph.D. Program Coordinator, Sean Nguyen. Epidemiologist/Data Manager, Tim Kellogg, Funding and technical support is provided by the Division of HIV/AIDS, Centers for Disease Control and Prevention. Additional support is provided by the California Department of Health Services. Office of AIDS.

HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED PISEASE (STD) CLINIC BY GENDER AND TRANSMISSION CATEGORY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995 (1)

1991 SURVEY	SERO- HUMBER NUMBER(2) PREVALENCE TESTED POSITIVE RATE (%) (95% C.I.)(3)		672 254 37.8 34.1 41.6 79 37 46.8 35.5 - 58.4 118 9 7.6 3.5 - 14.0 122 4 3.3 0.9 - 8.2 1653 41 2.5 1.8 - 3.3	360 13.3 12.0 -		59 3 5.1 1.1 14.1 65 3 4.6 1.0 12.9 26 0 0.0 0.0 10.9 3 0 0.0 0.0 10.9 681 8 1.2 0.5 2.3 15 1 6.7	849 15 1.8 1.0 - 2.9		3562 375 10.5 9.5 - 11.6	
	(95% C.1.)(3)		39.1 - 47.0 50.3 - 71.2 3.5 - 15.0 4.1 - 15.9	- 17.4		2.8 - 18.4 0.0 - 9.7 	1.8 - 4.5	· :	11.9 - 14.3	vations. men who
SURVEY	SERO- PREVALENCE RATE (%) (95		61.1 67.9 8.7 11.1			16.7 16.7 1.0 1.0	5.9		13.1 1.	collected collected inder 20 observ r bisexual wor
1990	NUMBER(2) POSITIVE		269 55 88 29 1 9 8	3%		2-0-E0	50	0	416	re syphilis s cimens were lot assay. mmple sizes u ch 1985. L. Lesbian o
	NUMBER		626 90 101 103 9 1381	167		55 0 0 541 19	189	0	3178	for routir isode. Spe specification of the 1978. 977 and Mar and womer
	(95% C.1.)(3)		46.1 - 55.7 61.8 - 79.2 6.8 - 20.4 0.9 - 12.0 0.1 - 21.9 0.8 - 2.3	17.1 - 20.8		3.0 - 20.0	0.9 - 3.6	:	13.7 - 16.7	imens collected or a NEW SID ear enemoved. d confirmed by a do confirmed by a vals not calculus since January 11 s. ex with both mended in the IDU.
SURVEY	SERO- PREVALENCE RATE (%)		50.9 71.1 72.5 74.3 7.4	18.9		9.1 9.1 0.0	2.0		15.2	blood spec treatment f identifiers by ELISA an dence Inter guse (IDU) sions(s) be tified risk who have s
1989	NUMBER(2) POSITIVE		224 81 13 3 14	338		v-0-w0	10	0	348	e drawn from ion, and/or Il personal Iy reactive mial. Confi mial. Confi mial. Lonfi o other iden o other iden en and women
	NUMBER		440 114 104 70 70 1023	1788		55 58 0 11 380 5	509	0	2297	urveys wer examinat 1V after a er repeated exact binon story of i story of a als with mom ug use (ID)
	GENDER AND TRANSMISSION CATEGORY	MALE 	Gay/Bisexual, IDU (4) Gay/Bisexual, IDU (4) Heterosexual IDU (4) Sex Partner at Risk for HIV Blood Recipient (5) Heterosexual (6)	SUB-TOTAL MALE	FEMALE 	IDU (4) Sex Partner at Risk for HIV Lesbian/Bisexual (7) Blood Recipient (5) Heterosexual (6) Unknown Risk	SUB-TOTAL FEMALE	MISSING GENDER	TOTAL	(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.  30 MI positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  31 SM, Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.  43 Includes persons with a history of injection drug use (IDU) since January 1978.  53 Self-identified heterosexuals with no other identified risks.  54 Includes women who have sex with women and women who have sex with women and women who have sex with women and women who have sex with women and women who have sex history of injection drug use (IDU) since 1978 are included in the IDU category. Collection of female sexual orientation began in 1991.

HIV SEROPREVALENCE FOR CLIENTS FTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY GENDER AND TRANSMISSION CATEGORY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995 (1)

	(95% 0.11.)(3)		25.6 - 32.4 36.6 - 61.9 2.7 - 13.3 0.0 - 12.7 1.2 - 2.5	9.0 - 11.2		0.0 - 9.7 0.0 - 9.4 0.0 - 6.1 0.2 - 1.8	0.3 - 1.7		7.0 - 8.8	
4 SURVEY	SERO- PREVALENCE RATE (%) (		28.9 49.2 6.7 3.7 1.8 0.0	10.1		0.00 0.00 0.08 0.08	0.8		6.7	
1994	NUMBER(2) POSITIVE		201 32 7 3 0 0	574		00w0	7	0	281	
	NUMBER TESTED		695 65 105 82 22 1752	2725		55 57 48 7 661	830	0	3555	
	(95% C.1.)(3)		30.7 - 37.8 32.9 - 63.1 3.0 - 16.6 2.1 - 14.0 1.6 - 3.1 9.9 - 30.0	10.6 - 13.1		1.4 - 18.7 0.0 - 9.5 0.0 - 6.7 0.5 - 2.2 0.1 - 21.9	0.7 - 2.5	:	8.4 - 10.4	ervations.
3 SURVEY	SERO- PREVALENCE RATE (%) (		34.2 47.8 8.0 6.3 7.7 18.5	11.8		6.8 0.0 0.0 4.1	1.4		9.4	screening on collected under 20 observations or bisexual women who
1993	NUMBER(2) POSITIVE		23 22 22 6 6 40 12	325		M0008←	12	0	£:	te syphilis scimens were scimens were slot assay. Imple sizes to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the size to the
	NUMBER		699 46 75 1771 65	5749		44 330 43 698 23	948	0	3595	for routificacies. Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Special Spe
	(95% C.1.)(3)		24.7 - 58.6 24.7 - 52.8 2.7 - 13.4 1.7 - 14.8 1.6 - 3.2 6.8 - 30.7	10.7 - 13.3		1.5 - 19.1 0.1 - 19.6 0.0 - 9.2 0.2 - 1.5	0.4 - 2.0	:	8.4 - 10.4	The drawn from blood specimens collected for routine syphilis scration, and/or treatment for a NEW STD episode. Specimens were coall personal identifiers were removed.  all personal identifiers were removed.  all personal identifiers were removed.  omial. Confidence intervals not calculated for sample sizes und injection drug use (10U) since January 1978.  blood transfusions(s) between January 1977 and March 1985.  no other identified risks, with both men and women. Lesbian or DDU) since 1978 are included in the IDU category. Collection of
2 SURVEY	SERO- PREVALENCE RATE (%)		38.4.8 58.0 6.1.7 7.2.3 6.13	12.0		7.0 0.0 0.0 0.0	1.0	0.0	9.4	re drawn from blood specime tion, and/or treatment for all personal identifiers we dly reactive by ELISA and omial. Confidence Interval injection drug use (IDU) si blood transfusions(s) betw no other identified risks. men and women who have sex. men and women who have sex.
1992	NUMBER(2) POSITIVE		226 19 7 4 36 7	599		w-0040	80	0	307	e drawn from ion, and/or 11 personal Ily reactive mial. Conf njection dr lood transfi o other ide en and women
	NUMBER		650 104 66 7 1575 43	5495		26 31 669 7	776	-	3272	urveys wer examinat iv after a exact bino story of i story of b story of b ats with nor auguse (ID
	GENDER AND TRANSMISSION CATEGORY	MALE 	Gay/Bisexual DD (4) Gay/Bisexual, DD (4) Heterosexual IDU (4) Sex Partner at Risk for HIV Blood Recipient (5) Heterosexual (6) Unknown Risk	SUB-TOTAL MALE	FEMALE	IDU (4) Sex Partner at Risk for HIV Lesbian/Bisexual (7) Blood Recipient (5) Heterosexual (6) Unknown Risk	SUB-TOTAL FEMALE	MISSING GENDER	TOTAL	(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.  (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.  (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.  (4) Includes persons with a history of injection drug use (IDU) since annuary 1978.  (5) Includes persons with a history of blood transfusions(s) between January 1978.  (6) Self-identified heterosexuals with no other identified risks.  (7) Includes women who have sex with women and women who have sex with both men and women. Lesbian or bisexual women who sexual orientation began in 1991.

H:V SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED JISEASE (STD) CLINIC BY GENDER AND TRANSMISSION CATEGORY, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995 (1)

,	. ——			
	(95% C.1.)(3)	24.9 - 31.3 18.9 - 39.5 4.1 - 14.8 0.3 - 8.4 1.0 - 2.2	9.9 - 12.1 1.0 - 13.1 0.0 - 9.9 	0.8 - 2.6 7.8 - 28.8 3.2 - 10.0
SURVEY	SERO- PREVALENCE RATE (%) (	28.4 28.4 8.3 2.4 1.5	11.0 6.1 5.1 0.0	1.6
1995	NUMBER(2) POSITIVE	. 222 23 23 10 2 63 63	% K-0060	368
	NUMBER	793 81 120 83 0 1724 354	3155 64 54 0 0 613 105	836
	GENDER AND TRANSHISSION CATEGORY	MALE Gay/Bisexual, IDU (4) Heterosexual, IDU (4) Elood Recipient (5) Heterosexual (6) Uknown Risk	SUB-TOTAL MALE	SUB-TOTAL FEMALE MISSING GENDER TOTAL

(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on andividuals seeking evaluation, examination, and/or treatment for a NEW TID episode. Specimens were collected consecutively and tested for MIV after all personal identifiers were removed. STD episode seeking ever repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 55% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (5) Includes persons with a history of injection drug use (10U) since January 1978. (6) Self-identified heterosexuals with no other identified risks. (6) Self-identified heterosexuals with women and women who have sex with both men and women. Lesbian or bisexual women who sexual orientation began in 1991.

HNICITY	
RACE:'ET	
INIC BY	
STD) CL	
SEASE (	
ITTED DI	
TRANSM	
EXUALLY	95 (1)
ING A S	89 - 19
? ATTENO	1800, 19
CLIENT	N FRANC
INCE FOR	₹VEY, SA
HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY RACE-ETHNICITY,	R OF SU
HIV SER	AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995 (1)

	(95% C.1.)(3)	12.9 - 16.6 5.3 - 8.3 7.8 - 12.4 3.0 - 9.4 4.8 - 22.6	9.5 - 11.6		(95% C.1.)(3)	9.5 - 12.9 5.9 - 9.2 4.0 - 7.4 0.9 - 4.6 2.5 - 12.3	7.0 - 8.8	
1 SURVEY	SERO- PREVALENCE RATE (%)	7.7. 6.9.9 5.6 7.11	10.5	4 SURVEY	SERO- PREVALENCE RATE (%)	7.4 7.4 5.5 6.2	6-2	
1991	NUMBER(2) POSITIVE	210 78 67 67 13	375	1994	NUMBER(2) POSITIVE	147 77 43 7	281	
	. NUMBER TESTED	1429 1165 675 233 60	3562		NUMBER	1321 1038 776 307 113	3555	
	(95% C.1.)(3)	16.0 - 20.4 7.8 - 11.2 9.8 - 15.0 3.8 - 11.8 3.9 - 25.1	11.9 - 14.3		(95% C.1.)(3)	12.4 - 16.2 4.6 - 7.5 4.1 - 10.1 1.4 - 5.8 2.9 - 16.2	8.4 - 10.4	ervations.
O SURVEY	SERO- PREVALENCE RATE (%)	18.1 9.4 12.1 7.1 11.6	13.1	3 SURVEY	SERO- PREVALENCE RATE (%)	14.2 6.0 7.9 3.1 7.8	4.6	screening on collected under 20 obs
1990	NUMBER(2) POSITIVE	219 111 68 13	416	1993	NUMBER(2) POSITIVE	961 66 77 9	337	e syphilis cimens were lot assay. mple sizes
	NUMBER	1210 1178 564 183 43	3178		NUMBER	1398 1109 719 292 77	3595	for routir isode. Spe Western k ated for sa
	(95% C.1.)(3)	20.1 - 25.7 7.3 - 11.4 10.6 - 18.0 1.6 - 9.2 3.8 - 24.6	13.7 - 16.7		(95% c.1.)(3)	10.6 - 14.2 5.9 - 9.3 5.9 - 10.0 2.0 - 8.2 4.5 - 24.3	8.4 - 10.4	reatment for a NEW STD epidential state of treatment for a NEW STD epidentifiers were removed.  By ELISA and confirmed by indence Intervals not calcul. Native ancestry, other rac-
9 SURVEY	SERO- PREVALENCE RATE (%)	22.8 9.2 14.0 4.3	15.2	2 SURVEY	SERO- PREVALENCE RATE (%)	12.3 7.5 7.8 4.4 12.0	9.4	n blood spec treatment f identifiers by ELISA an idence Inter Native ance
1989	NUMBER(2) POSITIVE	209 76 52 6 5	348	1992	NUMBER(2) POSITIVE	163 76 53 9 6	307	e drawn from ion, and/or ll personal ly reactive mial. Confand and Alaskan
	NUMBER TESTED	916 828 371 138 44	2297		NUMBER	1320 1016 683 203 50	3272	surveys wer 7, examinat 11V after a re repeated exact bino can Indian
	RACE/ETHNICITY	WHITE ARRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL		RACE/ETHNICITY	WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL	(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for IIV after all personal identifiers were removed. (2) ALL lossitive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals, not calculated for sample sizes under 20 observations. (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

		198	1995 SURVEY	
RACE/ETHNIC1TY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
WHITE ARRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	1598 1123 835 300 190	797 79 97 9	72.3 7.0 8.0 8.4 8.4	10.8 - 14.0 5.6 - 8.7 6.3 - 10.1 1.4 - 5.6 4.9 - 13.3
TOTAL	9707	368	9.1	8.2 - 10.0

(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.
(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.
(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

1989 SURVEY	1990 SURVEY	1991 SURVEY

		1989	99 SURVEY			1990	0 SURVEY			15	1991 SURVEY		
AGE-GROUP (YEARS)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%) (	(95% C.1.)(3:	NUMBER TESTED	ER NUMBER(2)	SERO- PREVALENCE RATE (%)	(95% C.I.)(3)	)(3)
19 AND UNDER 20 - 24 30 - 29 35 - 34 35 - 34 45 - 44 45 AND OVER	223 526 526 530 403 158 158	0 0 0 0	1.3 16.7 16.9 21.8 25.7 17.1 19.0	0.3 - 3.9 4.7 - 20.3 17.9 - 26.2 20.7 - 31.2 11.1 - 26.1	274 708 708 785 770 570 570 526 223 10	0 1133 1133 1133 1133 1133 1133 1133 11	2.2 4.8 19.8 13.2 17.0 0.0	0.8 - 4.7 3.3 - 6.6 11.0 - 15.8 16.6 - 23.3 19.4 - 28.1 12.3 - 28.1 12.3 - 28.1	7 288 6 897 8 833 3 609 6 263 0 265 17	103 25 25 25 25 25 25 25 25 25 25 25 25 25	0.2.0 2.6.0 2.0.0 2.0.0 2.0.0 3.0 3.0	0.0 1.8 1.8 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	1.9 4.1 20.1 23.5 24.3 17.0

ITTED DISEASE (STD) CLINIC BY FRE-GROUP,	1990 SURVEY
(STD)	
DISEASE	
ITTED	<u></u>

ROUP,		-

URVEY	

1989 SURVEY	1990 SURVEY	1991 SURVEY
SERO-	SERO-	SERO-

9

(95% C.1.)(3)

PREVALENCE RATE (%)

NUMBER(2) POSITIVE

NUMBER

(95% C.1.)(3)

PREVALENCE RATE (%)

NUMBER(2) POSITIVE

NUMBER

(95% C.1.)(3)

PREVALENCE RATE (%) SERO-

NUMBER(2) POSITIVE

NUMBER TESTED

AGE-GROUP (YEARS)

SURVEY

766

SURVEY

1993

992

11.6

9.5

S

ë:

375

- 14.3

11.9

13.1

416

3178

16.7

13.7

15.2

348

2297

TOTAL

0.0 4.0 8.7 7.0 8.7

4000000000

083307477

225 833 879 879 438 294 294

2.3 2.18 2.18 2.1.3 17.1.3 17.1.3

0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.

4.01 4.7.5 4.8 8.8 8.8 8.8

39 45 68 67 9 1

244 283 394 394 264 304 304

3.0 17.7 22.2 14.6 31.7

0.12.0 12.0 12.0 12.0 12.0

0.8 8.6 7.7 16.9 10.0

22422222222

241 776 775 775 621 374 243 202 202

9 AND UNDER 0 - 24 5 - 29 0 - 34 0 - 39 0 - 44 1 AND OVER 19 AND (20 - 24 25 - 29 30 - 34 40 - 44 45 AND OUNKNOWN 8.8

7.0

7.9

281

3555

- 10.4

8.4

7.6

337

3595

307

HIV SEROPREVALENCE FOR CLIENTS ATTENDING A SEXUALLY TPANSMITTED DISEASE (STD) CLINIC BY AGE-GROUP, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995 (1)

	(95% C.1.)(3)	0.4 - 4.0 1.5 - 3.8 4.3 - 7.2 112.7 - 17.4 11.6 - 19.5 8.8 - 16.2 7.3 - 29.7	8.2 - 10.0
5 SURVEY	SERO- PREVALENCE RATE (%)	6.5.2.2.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.	9.1
1995	NUMBER(2) POSITIVE	20 20 10 8 10 8 40 8	368
	NUMBER TESTED	254 806 1033 725 515 329 49	9505
	AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 30 - 29 35 - 34 35 - 39 40 - 44 5 AND OVER UNKNOWN	TOTAL

(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected sometively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

) CLINIC BY RACE/ETHNICITY,
(STI
DISEASE (STD) CI
TRANSMITTED
\ SEXUALLY
TTENDING A
195
INCE FOR GAY AND BISEXUAL MEN ATTENDI RVEY, SAN FRANCISCO, 1989 - 1995 (1)
BIS SCO,
AND
GAY N FR
FOR
V SEROPREVALENCE FOR ID YEAR OF SURVEY, SAN
EAR
HIV S

(5)(1)

38.9 64.1 55.7 61.2 45.3

	(95% C.1.	30.6 - 3 41.7 - 6 36.0 - 5 22.4 - 6	35.2 - 4			(95% C.1.	23.8 - 3 41.9 - 6 24.0 - 4 6.2 - 2 13.2 - 5	27.4 - 3	
SURVEY	SERO- PREVALENCE RATE (%) (9	34.7 53.0 45.7 40.7 54.5	38.7		SURVEY	SERO- PREVALENCE RATE (%) (1	27.7 52.8 32.5 14.9 30.4	30.7	
1991	NUMBER(2) POSITIVE	182 44 48 11 6	291		1994	NUMBER(2) POSITIVE	135 47 37 7	233	
	NUMBER	525 83 105 27 11	151			NUMBER	487 89 114 47 23	260	
	(95% C.1.)(3)	36.7 - 45.9 53.8 - 72.0 37.0 - 56.6 13.2 - 48.7	41.6 - 49.0			(95% c.1.)(3)	29.1 - 37.5 39.6 - 63.0 29.6 - 47.6 7.5 - 33.5	31.6 - 38.6	ervations.
) SURVEY	SERO- PREVALENCE RATE (%)	41.2 63.2 46.7 28.6 50.0	45.3		3 SURVEY	SERO- PREVALENCE RATE (%)	33.2 51.3 38.3 30.8	35.0	screening on collected under 20 obs
1990	NUMBER(2) POSITIVE	188 74 74 50 8 4	324	1993	NUMBER(2) POSITIVE	165 39 46 7 4	261	e syphilis cimens were to assay.	
	NUMBER	456 117 107 28 8	716			NUMBER	497 76 120 39 13	745	for routin sode. Spe Western b ited for sa i, and unkn
	(95% c.1.)(3)	46.9 - 57.3 53.1 - 74.4 49.8 - 72.3	50.8 - 59.3			(95% C.1.)(3)	28.0 - 36.8 35.2 - 55.3 27.9 - 47.1 11.6 - 47.8	31.5 - 38.7	mens collected br a NEW STD epi were removed. I confirmed by a /als not calcula
SURVEY	SERO- PREVALENCE RATE (%)	52.2 64.3 61.5 28.6 83.3	55.1		1992 SURVEY	SERO- PREVALENCE RATE (%)	32.3 45.1 37.1 26.9 50.0	35.0	blood spectreatment for identifiers by ELISA and dence Interventer
1989	NUMBER(2) POSITIVE	794 54 48 48 5	305		195	NUMBER(2) POSITIVE	147 46 39 7 6	245	e drawn from ion, and/or il personal ly reactive mial. Confi
	NUMBER	372 84 78 78 6	554			NUMBER	455 102 105 126 12	200	urveys wer 1, examinat 11V after a 1e repeated exact binom 2an Indian
	RACE/ETHNICITY	WHITE AFRICAN AMERICAN LATINO SATAN/PACFFC ISLANDER NONE OF THE ABOVE (4)	TOTAL			RACE/ETHNICITY	WHITE AFRICAN AMERICAN LATINO SASAM/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL	(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. Secimens were collected (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

1.)(3)

31.9 63.5 41.9 52.9 34.1

		199	1995 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE		SERO- PREVALENCE RATE (%) (95% C.I.)(3)
WHITE	558	145	26.0	22.4 - 29.8
AFRICAN AMERICAN	99	94,	46.5	36.4 - 56.8
ASIAN/PACIFIC ISLANDER	38	± ∞	20.5	9.3 - 36.5
NONE OF THE ABOVE (4)	S	7	20.0	6.8 - 40.7
TOTAL	876	276	28.0	25.1 - 31.1
		ì	2	

(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.
(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.
(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

HIV SEROPREVALENCE FOR GAY AND BISEXUAL AND YEAR OF SURVEY, SAN FRANCISCO, 1989			NG A SEXUAL	MEN ATTENDING A SEXUALLY TRANSMITTED DISEACE (STD) CLINIC BY AGE-GROUP, - 1995 (1)	DISEASE (STI	D) CLINIC BY	AGE-GROUP,					
		1989	99 SURVEY			1990	O SURVEY			1991	1 SURVEY	
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- ITIVE RATE (%) (95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- ER(2) PREVALENCE TIVE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- BER(2) PREVALENCE ITIVE RATE (%) (95% C.I.)(3)
19 AND UNDER 20 - 24 25 - 29 30 - 34 55 - 39	134 129 1129	68 2 4 8 5 0 0 8 4 8 4 8 4 8 4 8 4 8 4 8 4 8 4 8 4	0.0 41.0 62.7 58.9 60.7	28.6 - 54.3 53.9 - 70.9 49.9 - 67.5 51.0 - 69.8	174 174 168 129	2 27 80 87 87	14.3 33.3 46.0 51.8 53.5	23.2 - 44.7 38.4 - 53.7 44.0 - 59.5 44.5 - 62.3	01 8 5 7 1 8 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	- 55 × 52 × 52 × 52 × 53 × 54 × 54 × 54 × 54 × 54 × 54 × 54	10.0 18.8 37.9 47.4 47.5	11.2 - 28.8 31.1 - 45.2 39.8 - 55.1 38.2 - 56.9

(8)(1.1.) %(8)	11.2 - 28.8 31.1 - 45.2 39.8 - 55.9 38.2 - 56.9 32.0 - 53.6	35.2 - 42.3		(95% C.1.)(3)	10.3 - 28.6 15.3 - 27.7 28.8 - 43.7 32.6 - 49.6 29.6 - 52.7 21.5 - 40.8	27.4 - 34.1	
KAIE (%) (9	10.0 378.8 47.4 47.5 42.5 30.0 0.0	38.7 3	SURVEY	SERO- PREVALENCE RATE (%) (9	18.2 21.0 21.0 35.7 40.9 30.5 20.5	30.7 2	
PUSTITVE	24 24 24 24 24 24 24	291	1994	NUMBER(2) P	0 2 3 4 5 6 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	233	
IESIED	01 852 118 871 108 108	151		NUMBER	21 77 181 137 75 75 0	760	
(5)(.1.5 %(5)	23.2 - 44.7 38.4 - 53.7 44.5 - 62.3 35.5 - 61.4 23.6 - 44.3	41.6 - 49.0		(95% C.1.)(3)	3.2 - 17.5 19.9 - 33.0 37.4 - 54.0 37.5 - 56.0 32.1 - 56.7 24.7 - 45.2	31.6 - 38.6	ervations.
WALE (M)	14, 33,3 46,0 483,3 483,5 0,0	45.3	SURVEY	SERO- PREVALENCE RATE (%)	0.0 8.5 26.1 44.4 44.1 20.0	35.0	screening on collected under 20 obs
1001111	2 2 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	324	1993	NUMBER(2) POSITIVE	7330 330 330 11	261	Specimens were collected specimens were collected in blot assay.
153156	14 174 168 168 62 62 87	716		NUMBER TESTED	7 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	242	for routin isode. Spe a Western b
(6)(	28.6 - 54.3 53.9 - 70.9 49.9 - 67.5 51.0 - 69.8 33.0 - 59.4 31.5 - 57.6	50.8 - 59.3		(95% c.1.)(3)	10.3 - 26.7 25.0 - 39.9 31.7 - 46.1 37.6 - 57.6 39.7 - 64.6	31.5 - 38.7	i were drawn from blood specimens collected for routine syphilis screening on ination, and/or treatment for a NEW SID episode. Specimens were collected er all personal identifiers were removed.  astedly reactive by ELISA and confirmed by a Western blot assay. binomial. Confidence Intervals not calculated for sample sizes under 20 observations.
, , , , , , , , , , , , , , , , , , , ,	0.0 41.0 62.7 58.9 60.7 45.5 44.3	55.1	2 SURVEY	SERO- PREVALENCE RATE (%) (	20.0 17.4 32.1 38.7 57.6 57.6 16.7	35.0	n blood speci treatment fo identifiers by ELISA and idence Interv
	. \$3.58 . 27.53 . 27.53 . 27.53	305	1992	NUMBER(2) POSITIVE	252 252 18 18 18 18	245	e drawn froi ion, and/or il personal ly reactive mial. Conf
	2 13 4 12 9 13 4 12 9 12 9 12 9 12 9 12 9 12 9 12 9 12	554		NUMBER	10 162 186 133 103 77 6	700	surveys wer on, examinat HIV after a ere repeated exact bino
	19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 45 - 44 45 AND OVER UNKNOWN	TOTAL	-	AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 39 40 - 44 45 AND OVER UNKNOMN	TOTAL	<ol> <li>These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens wer consecutively and tested for HIV after all personal identifiers were removed.</li> <li>All positive specimens were repeatedly reactive by ELISA and confirmed by a Wastern blot assay.</li> <li>55% Confidence intervals, exact binomial. Confidence Intervals not calculated for sample sizes</li> </ol>

	<u> </u>		_
	(95% C.1.)(3)	8.8 - 24.0 13.0 - 23.9 32.7 - 46.8 29.6 - 45.6 21.0 - 38.8	25.1 - 31.1
5 SURVEY	SERO- PREVALENCE RATE (%) (9	0.0 15.3 18.0 39.6 37.3 29.4 25.5	28.0
1995	NUMBER(2) POSITIVE	110 347 347 358 322 322 0	545
	NUMBER TESTED	208 208 1197 1150 1109 106	874
	AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 25 - 29 35 - 34 35 - 39 40 - 44 45 AND OVER UNKNOMN	TOTAL

(1) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

HIV SEROPREVALENCF FOR HETEROSEXUAL MALES (1) ATTENDING A SEXUALLY TRANSMITTED C∶SEASE ( AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995 (2)	ITTED C:SEASE (STD) CLINIC BY RACE/ETHNICITY,
ATTENDING A SEXUALLY TRANSM (2)	:ASE
ATTENDING A SEXUALLY TRANSM (2)	L'SE
HIV SEROPREVALENCE FOR HETEROSEXUAL MALES (1) ATTENDING A SEXUALLY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995 (2)	TRANSMITTED
HIV SEROPREVALENCF FOR HETEROSEXUAL MALES (1) ATTENDING A AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995 (2)	SEXUALLY
HIV SEROPREVALENCT FOR HETEROSEXUAL MALES (1) ATTEND AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995 (2)	ING A
HIV SEROPREVALENCF FOR HETEROSEXUAL MALES (1) A AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995	TTEND (2)
HIV SEROPREVALENCT FOR HETEROSEXUAL MALES AND YEAR OF SURVEY, SAN FRANCISCO, 1989 -	(1) A
HIV SEROPREVALENCF FOR HETEROSEXUAL AND YEAR OF SURVEY, SAN FRANCISCO, 1	MALES 989 -
HIV SEROPREVALENCE FOR HETEROSE AND YEAR OF SURVEY, SAN FRANCIS	XUAL CO, 1
HIV SEROPREVALENCE FOR HETAND YEAR OF SURVEY, SAN FI	TEROSE RANCIS
HIV SEROPREVALENCE FO	OR HE
HIV SEROPREVALEN	Ę,
HIV SEROPRE	VALEN
IS VIN	EROPRE EAR OF
	IS AND

	.)(4)	4.0 2.2 2.8 9.0	3.4			(+)(-)	5.25.2	2.6			
	(95% C.1.)(4)	1.8 - 1.6 - 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	1.8			(95% C.1.)(4)	2.4 0.3 0.0 0.0	1.3 -			
1 SURVEY	SERO- PREVALENCE RATE (%)	22.6 32.6 0.0 0.0	2.5		1994 SURVEY		SERO- PREVALENCE RATE (%)	0.00 0.00 0.00	1.9		
1991	NUMBER(3) POSITIVE	55500	45				NUMBER(3) POSITIVE	n 42 n 0 0	34		
	NUMBER	497 741 399 122 26	1785			NUMBER	518 635 471 159 51	1834			
	.)(4)	5.4	3.5			.)(4)	3.7	3.2	<u>.</u>		
	(95% C.1.)(4)	1.3	1.8 -			(95% C.1.)(4)	2.2 1.3 0.7 0.0	1.8 -	ervation		
SURVEY	SERO- PREVALENCE RATE (%)	2.7 2.8 2.8 1.2	2.6		3 SURVEY	SERO- PREVALENCE RATE (%)	3.2	2.4	fied risks. screening on collected under 20 obs		
1990	NUMBER(3) POSITIVE	11888	38		1993	NUMBER(3) POSITIVE	20 16 7	45	ther identi e syphilis cimens were clot assay. mple sizes		
	NUMBER	413 683 286 84 18	1484			NUMBER	569 687 416 148 31	1851	with no o for routin isode. Spe a Western b ated for sa		
	.)(4)	6.9	2.5	·				.)(4)	3.8	3.3	osexual lected stock smoved. med by calcul
	(95% C.1.)(4)	0.0	- 6.0			(95% C.1.)(4)	0.9 - 2.1 - 0.7 - 0.3 -	1.7 -	nd heter imens co or a NEV were re d confir vals not		
19 SURVEY	SERO- PREVALENCE RATE (%)	6.1.0 0.0 0.0 0.0 0.0	1.6		2 SURVEY	SERO- PREVALENCE RATE (%)	3.3 1.8 0.0	2.4	x partner at risk for HIV and heterosexuals with no other identified risks. Were drawn from blood specimens collected for routine syphilis screening on ination, and/or treatment for a NEW SID episode. Specimens were collected at la personal identifiers were removed. atedly reactive by EIRA and confirmed by a Western blot assay. binomial. Confidence Intervals not calculated for sample sizes under 20 observations.		
1989	NUMBER(3) POSITIVE	0-15-60	17		1992	NUMBER(3) POSITIVE	10 21 7 0	70	rtner at ri e drawn fro ion, and/or ill personal lly reactive mial. Conf		
	NUMBER	316 471 209 78 19	1093			NUMBER	520 632 379 91 19	1641	th a sex pa surveys wer n, examinat HIV after a re repeatec exact binc		
	RACE/ETHNIC1TY	WHITE ARRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (5)	TOTAL			RACE/ETHNICITY	WHITE ARRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (5)	TOTAL	<ol> <li>Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.</li> <li>These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected conscentively and tested for HIV after all personal identifiers were removed.</li> <li>All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.</li> <li>95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 obsection locations of American Indian and Alaskan Native ancestry, other race, and unknown race.</li> </ol>		

	SERO- PREVALENCE RATE (%) (95% C.I.)(4)	0.5 - 2.6 0.8 - 3.3 0.0 - 9.2	1.0 - 2.2
5 SURVEY	SERO- PREVALENCE RATE (%)	1.9	1.5
1995	NUMBER(3) POSITIVE	7218001	28
	NUMBER	560 640 416 133 58	1807
	RACE/ETHNICITY	WHITE ARICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (5)	TOTAL

(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.

To These uninked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

AS ALL positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

AS Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

	SURVEY	SERO- PREVALENCE RATE (%) (95% C.1.)(4)	0.0 0.8 0.8 3.5 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
	1991	NUMBER(3) F POSITIVE	04055646
		NUMBER	157 497 424 288 175 103 133
		SERO- PREVALENCE RATE (%) (95% C.I.)(4)	0.3 - 4.5 0.3 - 4.5 2.1 - 7.9 0.6 - 8.7
Y AGE-GROUP	SURVEY	SERO- PREVALENCE RATE (%)	
(1) ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD) CLINIC BY AGE-GROUP, 1995 (2)	1989 SURVEY 1990	NUMBER(3) POSITIVE	04 <u>5</u> 5888-0
		NUMBER	157 380 389 229 158 98 89
		SERO- PREVALENCE RATE (%) (95% C.I.)(4)	0.0 - 4.3 0.0 - 1.1 1.9 - 8.5 0.0 - 7 - 9.1 0.4 - 12.3
JING A SEXUAL		SERO- PREVALENCE RATE (%) (	3.5 3.0 3.0 3.0 3.0 3.0
:S (1) ATTENI - 1995 (2)		NUMBER(3) POSITIVE	-mommono
SEXUAL MALE		NUMBER	126 312 265 281 93 93 60 56
HIV SEROPREVALE™E FOR HETEROSEXUAL MALES AND YEAR OF SURVEY, SAN FRANCISCO, 1989 -		AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 25 - 29 35 - 34 35 - 34 45 - 30 OVER UNKNOWN

A P

NUMBER (3 POSITIVE	0405574-	57	
NUMBER	157 497 424 288 175 103 133	1785	
(95% C.1.)(4)	0.2 - 4.5 0.3 - 2.8 1.2 - 4.7 2.1 - 7.9 2.2 - 8.7 0.6 - 8.7	1.8 - 3.5	
SERO- PREVALENCE RATE (%)	2.1.3 2.4.2.0 0.0	2.6	
NUMBER(3) POSITIVE	24008WL0	38	

3.4

1.8

2.5

1484

2.5

6.0

9:

1

1093

TOTAL

(95%	0.1.1.00	1.8	ervat
SERO- PREVALENCE RATE (%)	0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%	2.4	fied risks. screening on collected under 20 obs
NUMBER(3) POSITIVE	ow5550wo	45	other identine syphilis ecimens were
NUMBER	125 454 459 333 126 128 158	1851	s with no for routing isode. Spi Western Bated for si
SERO- REVALENCE RATE (%) (95% C.I.)(4)	0.0 - 2.3 0.1 - 2.0 1.2 - 4.6 1.2 - 8.1 1.4 - 8.0 1.0 - 9.4	1.7 - 3.3	nd heterosexual; imens collected or a NEW SID ep Were removed. d confirmed by a
SERO- PREVALENCE RATE (%)	0.00 7.00 7.00 7.00 1.00	2.4	sk for HIV s m blood spec treatment f identifiers by ELISA ar
NUMBER(3) POSITIVE	ow57v4	40	artner at ri re drawn fro tion, and/or all personal dly reactive omial. Conf
NUMBER	127 441 330 300 159 106 106	1641	with a sex p cd) surveys we ntion, examina or HIV after were repeater is, exact bin
AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 30 - 29 35 - 29 35 - 34 40 - 44 40 - 44 45 AND OVER UNKNOWN	TOTAL	<ol> <li>Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.</li> <li>These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.</li> <li>All positive specimens were repeatedly reactive by ELISA and confirmed by i Western blot assay.</li> <li>SX Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observat</li> </ol>

(95% C.1.)(4)

SERO-PREVALENCE RATE (%)

NUMBER(3) POSITIVE

NUMBER TESTED

95% C.1.)(4)

SURVEY

1994

SURVEY

1993

SURVEY

1992

2.6 1.4 5.0 5.0 1.3

2.07

07587-20

112 496 470 3309 309 117 124

7.50 7.50 7.50 7.50 7.50

0.00

ŝ	
ations.	
at	

5.6

1.3

.9

34

1834

3.2

1.8

	(4)		
	(95% C.1.)(4)	0.00	1.0 - 2.2
1995 SURVEY	SERO- PREVALENCE RATE (%)	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	1.5
1995	NUMBER(3) POSITIVE	-0408040	82
	NUMBER	105 412 318 318 128 128 0	1807
	AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 25 - 29 30 - 34 40 - 44 5 AND OVER UNKNOWN	TOTAL

(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.

C) These unfinked (binded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID especimens were collected consecutively and tested for HIV after all personal identifiers were removed. Specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) ALI positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

LINIC BY RACE/ETHNICITY,
STD) (
KANSMITTED DISEASE (
HETEROSEXUAL FEM ^e les (1) attending a sexually transmitted disease (std) clinic by race/e Francisco, 1989 - 1995 (2)
FEM ^c LES (1) AT
R HETEROSEXUAL
IV SEROPREVALENCE FOR HETEROSEXUAL FI ND YEAR OF SURVEY, SAN FRANCISCO, 197
HIV

		1989	9 SURVEY				1990	0 SURVEY				1991	SURVEY		
RACE/ETHNICITY	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)	(+)((+)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)	)(4)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)	(4)
WHITE AFRICAN AMERICAN LATINA ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (5)	145 184 61 40 8	- 8000	7.000 0.000 0.000	0.00	3.8	171 263 101 53 8	x o − − 0	8.7.0 8.4.0 8.0 8.0 8.0 8.0 8.0 8.0 8.0 8.0 8.0 8	0.4 - 1.6 - 0.0 - 1 - 0.0 -	5.0 6.4 10.1	257 266 133 74 16	WW-00	6.00 0.00 0.00	444	4.5
TOTAL	438	4	0.9	0.2 -	2.3	296	14	2.3	1.3 -	3.9	97/2	11	1.5	0.7 - 2	2.6
			-												İ
		1992	2 SURVEY				1993	3 SURVEY				1994	SURVEY		
RACE/ETHNIC1TY	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)	(+)((-)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)	)(4)	NUMBER	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(4)	(4)
WHITE AFRICAN AMERICAN LATINA ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (5)	245 214 150 72 14	00000	0.1.0 4.0.0 0.03	0.00	202.4	215 260 145 87 21	w-0	4.0 4.1 4.1 6.8	0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0.0 - 0	4.0 2.1 4.9 6.2 23.8	205 251 154 86 22	mα−00		0.3 - 4 0.0 - 3 0.0 - 3 0.0 - 12	4.2 3.6 3.4
TOTAL	695	5	7.0	0.2 -	1.7	728	8	1.1	0.5 -	2.2	718	9	9.0	0.3 - 1	1.8
<ol> <li>Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.</li> <li>These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW SID episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.</li> <li>It lositive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.</li> <li>SEX Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.</li> <li>Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.</li> </ol>	n a sex pa Irveys wer examinat V after a Prepeated xact bino In Indian	rrtner at ris e drawn from ion, and/or ll personal lly reactive mial. Confi	sk for HIV a n blood spec treatment f identifiers by ELISA an idence Inter Native ance	ind heter imens co or a NEL were re id confir vals not stry, ot	rosexuals ollected 1 A SID epis emoved. med by a t calculat	with no of for routine sode. Spec Western bl ted for sam	ther identifies cimens were lot assay. mple sizes comm race.	fied risks. screening or collected under 20 obs	ervations						1

	SERO- PREVALENCE RATE (%) (95% C.1.)(4)	0.0 - 2.6 1.3 - 6.7 0.0 - 4.2 0.0 - 14.9	0.7 - 2.7
1995 SURVEY	SERO- PREVALENCE RATE (%)	3.3 0.0 2.9	1.5
199	NUMBER(3) POSITIVE	-7-0-	10
	NUMBER	211 211 129 81 35	299
	RACE/ETHNICITY	WHITE AFRICAN AMERICAN LA'INA ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (5)	TOTAL

(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.

(2) These unifixed (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.

(4) 5% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

		( <del>1</del> )	rizoonini.
		(95% C.1.)	0.0 - 2.5 0.0 - 3.4 0.0 - 1.9 0.7 - 9.9 0.5 - 14.2 0.5 - 14.3
	1 SURVEY	SERO- PREVALENCE RATE (%) (95% C.I.)(4)	0.4.4.0.0
	1991	NUMBER(3) POSITIVE	0,000000
		NUMBER	116 258 160 86 42 42 32 4
		.)(4)	8.0 2.8 12.5 19.0 1.7
νD,		(95% C.1	0.00
C BY AGE-GRO	1990 SURVEY	SERO- PREVALENCE RATE (%) (95% C.1.)(4)	2.2 2.2 3.7 0.0 0.0
(STO; CLINI	199	NUMBER(3) POSITIVE	N←W4W←00
0 01SEASE		NUMBER TESTEO	194 137 79 79 27 24
RANSMITTE		(4)(-1	13.755.6 13.9 13.9 13.9 13.9
KUALLY TR		(95% C.1	m000000
ENOING A SE)	9 SURVEY	SERO- PREVALENCE RATE (%) (95% C.I.)(4)	0.00000
ALES (1) ATT - 1995 (2)	1989	NUMBER(3) POSITIVE	N00000
27.1AL FEM.		NUMBER TESTEO	119 101 20 20 20 0
HETEROSE N FRANCIS			
ALENCE FOR SURVEY, SA		(YEARS)	<u>س</u> «
HIV SEROPREVALENCE FOR HETEROSEX:AL FEMALES (1) ATTENDING A SEXUALLY TRANSMITTED DISEASE (STD; CLINIC BY AGE-GROUP, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1995 (2)		AGE-GROUP (YEARS)	19 AND UNDER 20 - 24 25 - 29 30 - 34 35 - 34 40 - 44 45 AND OVER UNKNOWN

	NUMBER NUMBER(5)(4)		1.4 217 1 5.7 93 2 7.5 93 2 7.5 42 0 7.5 42 0 7.5 46 0	717 93 93 45 64 0 0
	SERO- PREVALENCE RATE (%) (95% C.1.)(4)	0.0 - 5	0.5 - 2.2	.6
		0.0 0.0 0.0 0.0 6.4 0.0 0.0	1:1	tified risks s screening e collected
	NUMBER(3) POSITIVE	-00MN0	80	other ident ine syphilis pecimens wer
	NUMBER TESTEO	213 213 180 95 60 67 77 60 60 60 60 60 60 60 60 60 60 60 60 60	728	als with no ed for rout episode. S
	SERO- REVALENCE RATE (%) (95% C.I.)(4)	0.0 - 3.0 0.0 - 3.2 0.0 - 3.2 0.0 - 3.2 0.0 - 11.0 0.0 - 12.2	0.2 - 1.7	and heterosexu scimens collect for a NEW STO s were removed
	۵.	0.000.0000	0.7	isk for HIV om blood spe or treatment identifier
	NUMBER(3) POSITIVE	00m000	22	partner at reere drawn fration, and/call personal
	NUMBER S) TESTEO	97 1188 1174 77 73 233 33	569	(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.  (2) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on individuals seeking evaluation, examination, and/or treatment for a NEW STO episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.
-	AGE-GROUP (YEARS)	19 ANO UNDER 20 - 24 30 - 29 35 - 29 35 - 34 46 - 44 40 - 44 UNKNOWN	TOTAL	(1) Includes heter (2) These unlinker individuals seekir consecutively and

(95% C.1.)(4)

PREVALENCE RATE (%)

S W

SERO-

SURVEY

766

SURVEY

993

SURVEY

1992

5.6

0.7

1.5

Ξ

942

3.9

1.3

2.3

7

596

2.3

0.2

6.0

TOTAL

5.50 5.00 5.00 5.00 5.00 5.00

0.012000

1.8

0.3

8.0

18

		199	1995 SURVEY	
AGE-GROUP (YEARS)	NUMBER TESTED	NUMBER(3) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(4)
19 AND UNDER 20 - 24 25 - 29 36 - 34 35 - 39 40 - 44 45 AND OVER UNKNOWN	108 190 147 147 72 34 33	MUM0++00	21-20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0	0.6 - 7.9 0.1 - 3.8 0.0 - 3.5 0.0 - 7.5 0.1 - 16.7
TOTAL	299	10	1.5	0.7 - 2.7

(1) Includes heterosexuals with a sex partner at risk for HIV and heterosexuals with no other identified risks.

(2) These unlinked (blinded) surveys were drawn from blood specimens collected for routine syphilis screening on anyioviduals seeking evaluation, examination, and/or treatment for a NEW STD episode. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(4) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

RIENTATION,
SEXUAL 0
SENDER AND
PROGRAMS BY C
TREATMENT
METHADONE
UG USERS ENTERING 1989 - 1994 (1)
ECTION DRUG U
FOR INJ
OPREVALENCE R OF SURVEY,
HIV SER

SURVEY	SERO- PREVALENCE RATE (%) (95% C.I.)(3)		25.0 10.7 - 44.9 7.3 5.4 - 9.5 18.2	8.1 6.2 - 10.3		0.0 6.1 3.9 5 9.0	5.9 3.8 - 8.7	13.3	7.4 6.0 - 9.1	
1991 SURVEY	NUMBER(2) PRE POSITIVE RA		202	59		020	82	~	84	
	NUMBER		28 688 11	727		14 376 0	390	15	1132	
	(95% C.1.)(3)		14.9 - 53.5 6.1 - 10.2	6.9 - 11.1		1.2 - 31.7 3.7 - 8.7	3.9 - 8.8	:	6.3 - 9.5	
SURVEY	SERO- PREVALENCE RATE (%)		32.0 8.0 14.3	8.8		10.0 5.9 0.0	0.9	0.0	7.8	e 1978. reening
1990	NUMBER(2) POSITIVE		8 1	99		0 52 %	54	0	06	(IDU) sinc who were syphilis sc ere removed ot assay.
	NUMBER	·	25 716 7	248		20 376 2	398	12	1158	on drug use and persons lected for entifiers w
-	(95% C.1.)(3)		5.5 - 15.9	6.1 - 16.5		4.9 - 20.5	4.5 - 19.2	:	6.6 - 14.7	one treatment who have a history of injection drug use (IDU) since 1978. ion to treatment during the survey period, and persons who were due to HIVARIDS. Blood specimens were collected for syphilis screening s, and tested for HIV after all personal identifiers were removed. atedly reactive by ELISA and confirmed by a Western blot assay.
SURVEY	SERO- PREVALENCE RATE (%)		33.3 9.8 0.0	10.5		0.00	10.3	0.0	10.1	o have a hi during the Blood sp r HIV after by ELISA an
1989	NUMBER(2) POSITIVE		2 ⁴ 0	. 91		೦ಐ೦	∞	0	24	reatment who treatment to HIV/AIDS d tested fo
	NUMBER		143	152		4 E C	82	۷	237	methadone t admission t atment due rements, an
	GENDER AND SEXUAL ORIENTATION	MALE	Gay/Bisexual Heterosexual Unknown Orientation	SUB-TOTAL MALE	FEMALE	Lesbian/Bisexual Heterosexual Unknown Orientation	SUB-TOTAL FEMALE	MISSING GENDER	TOTAL	(1) Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 1978. Excludes persons with a prior admission to treatment during the survey period, and persons who were preferentially admitted to treatment due to HIV/AIDS. Blood specimens were collected for syphilis screening as part of the admission requirements, and tested for HIV after all personal Identifiers were removed.

HIV SEROPREVALENCE FOR INJECTION DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS BY GENDER AND SEXUAL ORIENTATION, AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (1)

		1992	2 SURVEY			1993	3 SURVEY			1994	4 SURVEY	
GENDER AND SEXUAL ORIENTATION	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
MALE												
Gay/Bisexual Heterosexual Unknown Orientation	70 846 70	825	30.8 7.4 7.5	14.3 - 51.8 5.7 - 9.4 1.6 - 20.4	236	4 17 0	44.4	4.3 - 11.3	13 207 0	50 S	15.4 9.7	6.0 - 14.5
SUB-TOTAL MALE	915	72	8.1	6.4 - 10.0	546	21	8.5	5.4 - 12.8	220	22	10.0	6.4 - 14.7
FEMALE												
Lesbian/Bisexual Heterosexual Unknown Orientation	432 5	28 0 0	6.0	1.2 - 30.4	13 130	2110	15.4 8.5 0.0	4.3 - 14.6	150 150	2 <del>1</del> 50	16.7	5.7 - 16.0
SUB-TOTAL FEMALE	458	28	6.1	4.1 - 8.7	144	13	0.6	4.9 - 14.9	162	17	10.5	6.2 - 16.3
MISSING GENDER	14	-	7.1	· :	-	0	0.0	:	-	0	0.0	
TOTAL	1387	103	7.4	6.1 - 8.9	391	34	8.7	6.1 - 11.9	383	39	10.2	7.3 - 13.7

(1) Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 1978. Studies persons with a prior admission to treatment during the survey period, and persons who were preferentially admitted to treatment due to HIV/AIDS. Blood specimens were collected for syphilis screening as part c' the admission requirements, and tested for HIV after all persinal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

BY RACE/ETHNICITY
MENT PROGRAMS
TREATMENT
METHADONE
ENTERING 194 (1)
DRUG USERS , 1989 - 19
OR INJECTION DRUG USERS ENTERING M SAN FRANCISCO, 1989 - 1994 (1)
A N
SEROPREVALENCE FO
HIV

		1989	9 SURVEY			195	1990 SURVEY			1991	1 SURVEY		
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER TESTED	R NUMBER(2)	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	)(3)
WHITE ARRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	245 272 272 2	v4v00	3.5 23.0 18.5 0.0	1.2 - 8.0 13.2 - 35.5 6.3 - 38.1	722 725 5256 735 735 74	25 24 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	23.2 5.2 6.3 6.3	2.1 - 4.9 16.3 - 26.6 2.1 - 10.4 3.9 - 31.7	699 267 118 28 20	24 53 7 0	3.4 5.9 0.0 0.0	2.2 - 251 2.4 - 121 0.0 - 101 111 - 101	5.1 11.8 10.1 13.9
TOTAL	237	54	10.1	6.6 - 14.7	1158	06	7.8	6.3 - 9.5	1132	84	7.4	6.0 - 8	9.1
													İ
		1992	2 SURVEY			1993	3 SURVEY			1994	4 SURVEY		
RACE/ETHNIC1TY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER TESTED	R NUMBER(2)	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	)(3)
WHITE ARRICAN AMERICAN LATIAN ASIAN/PACFEC ISLANDER NONE OF THE ABOVE (4)	299 299 139 31	327	3.9 7.9 7.9 7.9	2.8 - 5.4 13.9 - 22.9 4.0 - 13.7 0.0 - 9.8 2.0 - 25.8	264	21 11 0 0	8.0 13.9 5.6 0.0	5.0 - 11.9 7.2 - 23.5 0.7 - 18.7	240 81 48 12 2	2/2	6.3 21.0 12.5 8.3 0.0	12.7 - 3.5 - 10.	10.1 31.5 25.2
TOTAL	1387	103	7.4	6.1 - 8.9	391	34	8.7	6.1 - 11.9	383	39	10.2	7.3 - 1	13.7
(1) Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 1978. Excludes persons with a prior admission to treatment during the survey period, and persons who were preferentially admitted to treatment due to HIV/AIDS. Blood specimens were collected for syphilis screening as part of the admission requirements, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assaw (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.	methadone admission atment due rements, a e repeatec exact binc	treatment w to treatmen e to HV/AID and tested for ally reactive waiel. Conf	ho have a hi t during the S. Blood sp or HIV after by ELISA an idence Inter Native ance	story of in) survey peripecimens were all persons d confirmed vals not cal	lection drug od, and per collected il identifie by a Wester culated for race, and ur	treatment who have a history of injection drug use (1DU) since 1978. to treatment during the survey period, and persons who where it to MIV/AIDS. Blood specimens were collected for syphilis screening and tested for HIV after all personal identifiers were removed. If y reactive by ELISA and confirmed by a Western blot assay. Minal. Confidence Intervals not calculated for sample sizes under 20 and Alaskan Native ancestry, other race, and unknown race.	ice 1978. creening d. under 20 obs	servations.					

GE - GROUP	
3¥ A	ŀ
PROGRAMS	
TREATMENT	10000
METHADONE	
SEROPPEVALENCE FOR INJECTION DRUG USERS ENTERING METHADONE TREATMENT PROGRAMS BY AGE-GROUP YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (1)	
, 198	l
INJECTION ( FRANCISCO,	
SAN	
SEROPPEVALENCE FOR INJECTION DRUG USERS ENTERIY YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1994 (1)	THE RESERVE THE PARTY OF PERSONS ASSESSED.
	ı

AND AND

		1989	19 SURVEY			1990	) SURVEY			1991	1 SURVEY	
AGE-GROUP (YEARS)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- REVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- IER(2) PREVALENCE TIVE RATE (%) (95% C.I.)(3)
19 AND UNDER 20 - 24 20 - 29 30 - 34 35 - 39 45 - 44 45 AND OVER UNKNOWN	2 17 28 28 45 47 47 47	0-0WEr00	0.0 7.7 7.7 17.2 14.9 0.0	0.9 - 23.5 1.4 - 18.3 8.9 - 28.7 6.2 - 28.3	6 73 149 222 306 224 166	1223347	7.7-4 7.7-4 7.5-5 7.5-5 8.3-3-6 8.3	0.0 - 7.4 1.9 - 9.4 3.5 - 10.4 5.8 - 11.1 5.9 - 14.0	55 134 183 307 261 155 30	252 2 4 2 0 0 0 3 2 5 2 5 2 5 2 5 5 5 5 5 5 5 5 5 5 5 5	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	2.1 - 26.5 5.6 - 12.2 5.6 - 12.2 6.6 - 13.4 6.1 - 13.4 2.1 - 26.5

•	6.3 -	
8.3	7.8	
-	06	
12	1158	
	6.6 - 14.7	
0.0	10.1	
0	54	
o	237	

TOTAL

9	
7.8	
06	
28	

6.3 - 9.5	
7.8	1993 SURVEY
	1993

9.1

0.9

(95% C.1.)(3)

PREVALENCE RATE (%)

NUMBER(2) POSITIVE

NUMBER TESTED

PREVALENCE RATE (%) (95% C.1.)(3)

SERO-

NUMBER(2) POSITIVE

NUMBER TESTED

PREVALENCE RATE (%) (95% C.1.)(3)

NUMBER(2) POSITIVE

NUMBER TESTED

AGE-GROUP (YEARS)

SERO-

1992 SURVEY

SERO-

SURVEY

766

12.2 20.0 18.2 23.8 22.0 16.6

22.3

0.0 8.3 7.5 13.5 0.0

0 0 4 4 1 1 2 4 0 0

288833

28.0 19.6 25.6 10.8

.0.0 8.9 7.5 1.0 0.0

00005000

0 - 23 8 5 6 9 2

12.3 17.5 10.2 11.7 14.3

02082080

6 56 133 175 175 227 227 227

19 AND UNDER 20 - 24 25 25 - 29 34 35 - 39 40 - 44 45 AND OVER

UNKNOWN

13.7

7.3

10.2

33

383

- 11.9

6.1

8.7

34

391

8.9

6.1

7.4

103

387

TOTAL

PREVALEN RATE (%	0.00 5.2 8.6 7.7 0.01	7.4	
NUMBER(2) POSITIVE	0 0 7 7 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	84	
NUMBER	7 55 134 183 307 261 155 30	1132	
c.1.)(3)	7.4.9.4	- 9.5	

⁽¹⁾ Includes persons entering methadone treatment who have a history of injection drug use (IDU) since 1978.

Excludes persons with a prior admission to treatment during the survey period, and persons who were preferentially admitted to treatment due to HIVAIDS. Blood specimens were collected for syphilis screening as part of the admission requirements, and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

HIV SEYOPREVALENCE FOR INJECTION DRUG USERS (IDUS) AND NON-INJECTION PRUG USERS (NON-IDUS) ENTERING A DRUG-FREE DETOXIFICATION PROGRAM BY GENDER AND SEXUAL ORIENTATION, SAN FRANCISCO, 1990 - 1994 (1)

		1						
		IDUS	<u>so</u>			-NON	NON-IDUS	
GENDER AND SEXUAL ORIENTATION	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% c.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- NEVALENCE RATE (%) (95% C.1.)(3)
MALE 								
Gay/Bisexual Heterosexual Unknown Orientation	118 671 19	37 38 2	31.4 5.7 10.5	23.1 - 40.5	39 434 19	20 11	51.3 2.5 15.8	34.8 - 67.6
SUB-TOTAL MALE	808	1 =	9.5	7.6 - 11.8	492	34	6.9	4.8 - 9.5
FEMALE								
Lesbian/Bisexual Heterosexual Jhknown Orientation	60 268 9	1 6 0	1.7 2.6 0.0	0.0 - 8.9	180 180 5	040	0.00	0.0 - 9.2
SUB-TOTAL FEMALE	37.	ļ [∞]	2.4	1.0 - 4.6	216	· *	1.9	0.5 - 4.7
MISSING GENDER	0	0		:	0	0		· :
TOTAL	1145	85	4.7	6.0 - 9.1	208	38	5.4	3.8 - 7.3

(1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Sample includes both injection drug users (1018) who have a history of needle use since 1978, and non-injection drug users who have smoked, snorted, inhaled, or swallowed narotics within the previous 12-months prior to admission to treatment. Excluding the survey period, persons who were preferentially admitted to treatment due to HIVARIDS, and persons under alcohol treatment only. Blood specimens were collected for syphilis screening as part of the routine admission requirements, and tested for HIV after all personsul identifiers were removed. (2) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

NON-1DUS	SERO- 2) PREVALENCE E RATE (%) (95% C.1.)(3)	4.6 2.3 8.0 7.7 5.0 - 11.1 1.3 0.0 7.0 0.0 0.0 5.8	5.4 3.8 - 7.3
2	NUMBER(2) POSITIVE	252 1 0	38
	NUMBER	241 325 77 50 15	708
	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	4.7 - 8.4 9.6 - 19.7 1.6 - 15.8 0.6 - 15.8	6.0 - 9.1
S	SERO- PREVALENCE RATE (%)	6.4 4.3 6.5	7.4
IDUs	NUMBER(2) POSITIVE	47 28 6 2	85
	NUMBER	734 199 138 43 31	1145
	RACE/ETHNIC1TY	WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL

(1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Sample includes both injection drug users (IDUS) who have a history of needle use since 1978, and non-injection drug users who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment. Excludes persons with a prior admission to treatment during the survey period, persons who were preferentially admitted screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were remeatedly reactive by ELISA and confinmed by a Western blot assay.

(3) 55% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

HIV SEROPREVALENCE FOR INJECTION DRUG USERS (IDUS) AND NON-INJECTION DRUG USERS (NON-IDUS) ENTERING A DRUG-FREE DETOXIFICATION PROGRAM BY AGE-GROUP, SAN FRANCISCO, 1990 - 1994 (1)

	. IDUs			NON - IDUS	snai	
NUMBER NUMBER(2) TESTED POSITIVE		SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
	0.0		7	0	0.0	
	2.9		8	~;	2.2	
	9.5		155	- τ.	2.6 8.4	
	7.0		134	4.	3.0	
	13.5		<b>7</b> 7	٥٨	2.9	2.3 - 13.0
	0.0	:	M	0	0.0	1
	7 7	10.04	200	20	, ,	1.0
	:		00.7	8	4.	5.0 - 0.0
1 7 1 7 7 1	256 18 195 18 104 14 6 0	A	85 0 28 85	18 7.0 4.2 1.8 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	18 7.0 4.2 - 10.9 18 9.2 5.6 - 14.2 14 13.5 7.6 - 21.6 0.0 0.0	18 7.0 4.2 10.9 134 18 7.0 5.6 - 14.2 97 14 13.5 7.6 - 21.6 44 0 0.0

(1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Sample includes both injection drug users (IDUS) who have a history of needle use since 1978, and non-injection drug users who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment. Excludes persons with a prior admission to treatment during the survey period, persons who were preferentially admitted to treatment due to HIV/AIDS, and persons under alcohol treatment only. Blood specimens were collected for syphilis screening as part of the routine admission requirements, and tested for HIV after all persons under repeatedly reactive by ELISA and confirmed by a Mestern blot assay.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.

HIV SEROPREVALENCE FOR INJECTION DRUG USERS (IDUS) AND NON-INJECTION DRUG USERS (NON-IDUS) ENTERING A DRUG-FREE DETOXIFICATION PROGRAM BY PRIMARY DRUG, SAN FRANCISCO, 1990 - 1994 (1)

		IDUS	S			NON	NON-IDUS	
PRIMARY DRUG	NUMBER	NUMBER(2) POSITIVE		SERO- PREVALENCE RATE (%) (95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE		SERO- PREVALENCE RATE (%) (95% C.1.)(3)
HEROIN COCAINE/CRACK HEROIN AND COCAINE (SPEEDBALL	782 47	7 4 7 4 7 4 7 4 7 4 7 4 7 4 7 4 7 4 7 4	3.7 8.5 13.5	2.5 - 5.3 2.4 - 20.4 5.6 - 25.8	425 0	23.3	3.8	3.5 - 8.0
BARBITURATES AMPHETAMINES/SPEED OTHER OR UNSPECIFIED DRUGS	113	24.0	21.ż 13.9	14.1 - 29.9 8.8 - 20.5	22 179	084	36.4	17.2 - 59.3 0.6 - 5.6
TOTAL	1145	85	7.4	6.0 - 9.1	708	38	5.4	3.8 - 7.3

(1) This unlinked (blinded) survey monitors prevalence of HIV in a non-profit, drug-free outpatient treatment program. Sample includes both injection drug users (IDUS) who have a history of needle use since 1978, and non-injection drug users who have smoked, snorted, inhaled, or swallowed narcotics within the previous 12-months prior to admission to treatment. Excludes persons with a prior admission to treatment during the survey period, persons who were preferentially admitted to treatment due to HIVANDS, and persons under alcohol treatment only. Blood specimens were collected for syphilis screening as part of the routine admission requirements, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

HIV SEROPRIVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY TRANSMISSION CATEGORY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1992 (1)	
SION	
Skrs	
TRAN	
Β¥	
INIC	
5	
NNI	
₹8	
HIV SEROPRIVALENCE FOR WOMEN ATTENDING A FAMILY PLA AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1992 (1)	
A 289	
ND 15	
ATTE	
RANC	
AN W	
Α.Υ. Σ.Ν.	
NLENC	
OF S	
SEROF	
AND	

		1985	1989 SURVEY			1990	1990 SURVEY			1991	1 SURVEY	
TRANSMISSION CATEGORY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% 0.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
Heterosexual IDU (4) Sex Partner at Risk for HIV Blood Recipient (5) Heterosexual (6) Unknown Risk (7)	0 0 0 1266	.00004	0.32	0.09 - 0.81	20 24 11 1313 8	-00-0	5.00 0.00 0.08 0.08	0.13 -24.87 0.00 -11.73 0.00 - 0.42	9 11 4 1925 8	-0080	0.00 0.00 0.10 0.00	0.01 - 0.37
TOTAL	1266	4	0.32	0.09 - 0.81	1376	2	0.15	0.02 - 0.52	1957	м	0.15	0.03 - 0.45
		1992	2 SURVEY									
TRANSHISSION CATEGORY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)								
Heterosexual IDU (4) Sex Partner at Risk for HIV Blood Recipient (5) Heterosexual (6) Unknown Risk (7)	4 0 1293 0	000-0	0.00	0.00 - 0.43								
TOTAL	1297	-	0.08	0.00 - 0.43								
(1) This unlinked (blinded) survey was drawn from women seeking family planning services. Specimens were collected from initial and annual visits, and tested for Hilv after all personal identifiers were removed. (2) ALL loositive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes persons with a history of injection drug use (IDU) since January 1978. (5) Includes persons with a history of blood transfusions(s) between January 1977 and March 1985. (6) Self-identified heterosexuals with no other identified risks. (7) The 1989 unlinked survey did not collect risk information.	vey was c and test repeated xact bino tory of i tory of b ls with n	drawn from we ted for HIV selly reactive ominiection drugs also transfu to other identice.	omen seeking after all pe by ELISA an idence Inter- ug use (IDU) usions(s) be trified risk	family planning rsonal identifie d confirmed by a vals not calcula since January 1 tween January 19	services. Framere reverse western by the for sa 978.	Specimens moved. Not assay. mple sizes u	were collec under 20 obs	ited				

HIV SEROPREVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY RACE/ETHNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1992 (1)

		198	1989 SURVEY				1990	SURVEY				1991	1 SURVEY	
RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	(95% C.1.	)(3)	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	(95% C.1.	(5)(.	NUMBER TESTED	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
WHITE ARRICAN AMERICAN LATINA ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	122 154 154 810 149 31	400	0.82 0.65 0.25 0.00	0.02 - 4 0.02 - 3 0.03 - 0 0.00 - 1 0.00 - 9	4.48 3.56 0.89 1.99 9.21	126 145 908 166 31	-00-0	0.00	0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.00 - 0.0	4.34 2.04 0.33 3.31 9.21	156 141 1441 178 41	0-000	0.00 0.71 0.14 0.00	0.00 - 1.90 0.02 - 3.89 0.02 - 0.50 0.00 - 1.67 0.00 - 7.05
TOTAL	1266	7	0.32	0.09 - 0.81	1.81	1376	2	0.15	0.02 - 0.52	0.52	1957	3	0.15	0.03 - 0.45
		199	1992 SURVEY											

RACE/ETHNIC1TY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
WHITE AFRICAN AMERICAN LATINA ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	82 105 1001 94 15	00-00	000000	0.00 - 3.59 0.00 - 2.81 0.00 - 0.56 0.00 - 3.14
TOTAL	1297	-	0.08	0.00 - 0.43

⁽¹⁾ This unlinked (blinded) survey was drawn from women seeking family planning services. Specimens were collected from initial and annual visits, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confinmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

		1989	19 SURVEY			1990	) SURVEY			1991	1 SURVEY		
AGE-GROUP (YEARS)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	<u> </u>
19 AND UNDER 20 - 24 25 - 20 34 35 - 39 40 - 44 45 AND OVER UNKNOWN	73 420 414 226 105 18 3	00000	0.00 0.00 0.00 0.00 0.00 0.00	0.00 - 4.02 0.01 - 1.32 0.01 - 1.34 0.11 - 3.16 0.00 - 2.81	93 474 401 243 97 34 8 8	000-0-00	0.00 0.00 0.00 0.00 0.00 0.00	0.00 - 3.17 0.00 - 0.63 0.01 - 0.74 0.01 - 2.27 0.00 - 3.04 0.07 - 15.33	111 112 112 112 112 112 112	0000-000	0.00 0.00 0.03 0.00 0.00 0.00	0.00 - 2.76 0.00 - 0.47 0.00 - 1.11 0.00 - 3.14 0.00 - 6.88	76 11 11 14 14 14 14
TOTAL	1266	4	0.32	0.09 - 0.81	1376	2	0.15	0.02 - 0.52	1957	ы	0.15	0.03 - 0.45	1 5
		1992	2 SURVEY										
AGE-GROUP (YEARS)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)									
19 AND UNDER 20 - 24 25 - 29 35 - 29 35 - 34 40 - 44 45 AND OVER UNKNOWN	390 390 427 223 138 45 6	00-0000	000000000000000000000000000000000000000	0.00 - 4.87 0.00 - 0.77 0.01 - 1.30 0.00 - 2.15 0.00 - 6.44									
ТОТАL	1297	-	0.08	0.00 - 0.43									

HIV SEROPGEVALENCE FOR WOMEN ATTENDING A FAMILY PLANNING CLINIC BY AGE-TROUP AND YEAR OF SURVEY, SAN FRANCISCO, 1989 - 1992 (1)

(1) This unlinked (blinded) survey was drawn from women seeking family planning services. Specimens were collected from initial and annual visits, and tested for HIV after all personal identifiers were removed. All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

		1990	O SURVEY			1991	1 SURVEY			1992	2 SURVEY	
TRANSMISSION CATEGORY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- PREVALENCE RATE (%) (95% C.I.)(3)
Heterosexual IDU (4) Sex Partner at Risk for HIV Heterosexual (5) Unknown Risk	8 3 419 1	050	12.50 0.00 0.48 0.00	0.06 - 1.71	14 7 817 8	NO40	35.71 0.00 0.49 0.00	0.13 - 1.25	730	-mv0	14.29 60.00 0.68	0.22 - 1.59
TOTAL	431	м	0.70	0.14 - 2.02	846	6	1.06	0.49 - 2.01	742	٥	1.21	0.56 - 2.29

(1) This unlinked (blinded) survey was drawn from women seeking induced abortions. Specimens were collected for evaluation surposes, and tested for HIV after all personal identifiers were removed.

All positive specimens were repeatedfy reactive by ELISA and confirmed by a Western blot assay.

Sys. Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

Includes persons with a history of injection drug use (IDU) since January 1978.

HIV SETOPREVALENCE FOR WOMEN ATTENDING AN ABORTION CLINIC BY RACE/ETWNICITY AND YEAR OF SURVEY, SAN FRANCISCO, 1990 - 1992 (1)

1	.)(3)	3.71 7.44 0.76 2.74	2.29
	(95% 0.11.)(3)	0.49 -13.71 1.29 - 7.44 0.00 - 0.76 0.00 - 2.74	0.56 - 2.29
2 SURVEY	SERO- PREVALENCE RATE (%) (	7.00 0.00 0.00 5.26	1.21
1992	NUMBER(2) POSITIVE	N 900 F	٥
	NUMBER	50 172 393 108 19	242
	c.1.)(3)	-11.86 - 4.20 - 1.99 - 2.76 -11.29	0.49 - 2.01
	(95%	0.88 0.30 0.14 0.00	0.49
1 SURVEY	SERO- PREVALENCE RATE (%) (95% C.1.)(3)	4.23 1.46 0.69 0.00 0.00	1.06
1991	NUMBER(2) POSITIVE	mmm00	6
	NUMBER	71 206 437 107 25	846
	:.1.)(3)	0.05 -10.65 0.03 - 6.65 0.00 - 1.33 0.00 - 6.44	0.14 - 2.02
	(95% (	0.00	0.14
O SURVEY	SERO- PREVALENCE RATE (%) (95% C.1.)(3)	2.00 1.89 0.00 0.00	0.70
1990	NUMBER(2) POSITIVE	<del>-</del> 2000	ъ
	NUMBER	50 106 223 45 7	431
	RACE/ETHNIC1TY	WHITE AFRICAN AMERICAN LATINA ASIAM/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL

(1) This unlinked (blinded) survey was drawn from women seeking induced abortions. Specimens were collected for evaluation purposes, and tested for HIV after all personal identifiers were removed.
(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.
(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

		1990	O SURVEY			1991	1 SURVEY			1992	2 SURVEY		1
AGE-GROUP (YEARS)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%) (	(95% C.1.)(3)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%) (95% C.1.)(3)	(95% C.1	.)(3)
19 AND UNDER 20 - 24 35 - 29 35 - 34 40 - 44 4 - 44 UNKNOWN	268 806 806 806 806 806 806 806 806 806 8		0.00	0.00 - 4.31 0.02 - 3.94 0.00 - 2.79 0.00 - 10.88 0.00 - 10.88	133 253 223 223 118 86 27 27 6	- N4 000	0.00 0.00 0.00	0.02 - 4.12 0.10 - 4.53 0.49 - 4.53 0.02 - 4.63 0.03 - 6.31 0.00 - 10.50	112 202 202 131 131 23 3	008-400-	0.00 1.06 1.49 0.76 0.00 33.33	0.00 0.13 0.02 0.30 0.00	2.64 3.77 4.28 4.18 8.64 12.21
TOTAL	431	м	0.70	0.14 - 2.02	846	٥	1.06	0.49 - 2.01	742	6	1.21	0.56 - 2.29	2.29

(1) This unlinked (blinded) survey was drawn from women seeking induced abortions. Specimens were collected for evaluation surposes, and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

E HIV SEROPREVALENCE FOR NEWBORN INFANTS AND THEIR MOTHERS BY AGE GROUP AND RACE/ETHNICITY, 1989-1994

1	1	1	
	.5(3)		2.67 1.56 1.29 7.50
	0.1.		
	(95%		0.00
ÆY	%) (%)		00-0M0
SURVEY	SERO- PREVALENCE RATE (%) (95% C.1.)(3)		0.00 0.00 0.23 0.23
1991			
	NUMBER(2) POSITIVE		-048
			206 454 653 695 72
	NUMBER		255627
	2 -		
	)(3)		1.64 0.67 0.90 0.89 0.66
	c. 1.		
	SERO- PREVALENCE RATE (%) (95% C.I.)(3)		000000
ÆΥ	0- ENCE (%)		22222
SURVEY	SEF REVAI		0.00 0.16 0.00 0.00
1990			
	NUMBER(2) POSITIVE		0000
			138617
	UMBER TESTED		181 446 618 625 451 117
	Z F		
	)(3)		2.52 1.62 0.47 0.62 3.97
	C.1.3		
	(95% C.1.)(3)		0.00
EY	SERO- PREVALENCE RATE (%)		
SURVEY	SER REVALI		0.46 0.00 0.00 0.72
6861			
	NUMBER(2) POSITIVE		-4000-
	POS		
	NUMBER		219 442 638 625 485 138
	3.5		
		ARS)	
		P (YE	VER
		GE-GROUP (YEARS)	UNDER 20 20 - 24 25 - 29 30 - 34 35 AND OVER UNKNOWN
		AGE	288888 28888

-0-000	23 106
663 324 608 633 115 95	2438 21397 150494
0.00 - 0.44 0.01 - 1.66 0.00 - 0.98 0.00 - 0.47 0.01 - 2.67	0.04 - 0.40 0.08 - 0.17 0.05 - 0.08
0.00 0.30 0.18 0.49 0.78	0.16
00	25 92
679 334 564 636 128	2547
WHITE AFRICAN AMERICAN LATINO ASTANPAGIFIC IS. OTHER UNKNOMN	TOTAL - SAN FRANCISCO TOTAL - BAY AREA (4) TOTAL - STATEWIDE

RACE/ETHNICITY

0.20 0.10

0.10

0.07

90.0

154918

22103

0.07 90.0

0.68

0.16

0.36

0 31 124

0.30 0.16 0.09

0.01

0.08 0.11 0.07

1.59 2.74 0.88 0.66 0.81 5.67

. . . . . .

0.063

4M-00-

640 317 634 454 367 96

0.84 0.92 0.91 2.57 3.10

. . . . . .

888888

0000000

(1) Data courtesy of the California Department of Health Services Office of AIDS. Specimens from this survey of memborn infants tand women giving birth) are drawn from the genetic diseases screening program. Antibodies in a newborn infant reflect the infection status of the mother and not necessarity of the child.
(2) All positive specimens where repeatedly in-civity by ELISA and confirmed by a Western blot assay.
(3) St. Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.
(4) Includes the counties of Alameda, Contra Costa, Marin, San Francisco, San Mateo, and Santa Clara.

HIV SEROPREVALENCE FOR NEWBORN LMFANTS AND THEIR MOTHERS BY AGE GROUP AND RACE/ETHNICITY, 1989 1994(1)

SURVEY	SERO- RATE (%) (95% C.I.)(3)	00 0.00 - 1.60 00 0.00 - 0.75 44 0.04 - 1.21 00 0.00 - 0.43 00 0.06 - 1.72	6 0.00 - 0.91 8 0.22 - 3.11 0.00 - 0.51 0.00 - 0.54 0.00 - 1.46 0.00 - 1.46	7 0.05 - 0.45	19 0.06 - 0.14	60.0 - 90.0 41
1994 SUR	SE	0.00 0.34 0.00 0.08	6.00 0.00 0.00 0.00	0.17	0.0	0.07
19	POSITIVE	000000	-m0000	4	22	105
	TESTED	186 397 593 689 417	611 279 591 652 159	2293	24141	143095
	.1.)(3)	. 3.23 - 0.67 - 0.84 - 1.06 - 1.19	1.75	0.07 - 0.48	0.04 - 0.12	- 0.07
	E (95% C	0.00 0.00 0.00 10.00 10.00	0.00 0.00 0.00 0.00	0.07	0.04	•
3 SURVEY	SERO- PRATE (%)E (95% C.1.)(3)	0.59 0.15 0.21 0.00	0.28 0.32 0.00 0.00	0.21	0.07	90.0
1993	POSITIVE)	-0-0-0	2-2000	5	16	83
	TESTED	170 446 662 677 677 146	717 316 590 661 148 3	2435	21601	150598
	(5)(3)	1.80 0.70 1.13 1.15 1.24 2.18	0.46 3.70 0.49 0.45 3.82	0.48	0.20	0.08
	(95% C.	0.00	0.0000000000000000000000000000000000000	0.07 - 0.48	0.10 - 0.20	0.05 - 0.08
2 SURVEY	SERO- PRATE (%)E (95% C.1.)(3)	0.00 0.31 0.32 0.02 0.00	0.0000000000000000000000000000000000000	0.20	0.14	0.07
1992	POSITIVE)	0-1000	00000	2	31	101
	TESTED	165 428 639 628 446 136	646 312 610 640 135 77	2442	21565	151033
		AGE-GROUP (YEARS)	RACE/ETHNICITY WHITE AFRICAN AMERICAN LATINO ASIAN/PACIFIC IS. UNKNOWN	TOTAL - SAN FRANCISCO	TOTAL - BAY AREA (4)	TOTAL - STATEWIDE

⁽¹⁾ Data courtesy of the California Department of Health Services Office of AIDS. Specimens from this survey of newborn infant verifiect the infection status of the mother and not necessarity of the child.
In a newborn infant reflect the infection status of the mother and not necessarity of the child.
(2) AIL positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
(3) 95% Confidence Intervals, when thomals. Confidence Intervals not calculated for sample ≥ zes under 20 observations.
(4) Includes the counties of Alameda, Contra Costa, Marin, San Francisco, San Mateo, and Santa Clara.

(95% 0.1.)(3)		61.5 - 84.5 56.5 - 89.7 9.6 - 41.1 3.2 - 10.5	22.0 - 31.7	0.0 - 6.5	17.4 - 25.2
SERO- PREVALENCE RATE (%)		74.2 75.9 22.6 6.1	26.6	25.0 1.2 0.0 4.5	21.1
NUMBER(2) POSITIVE		46 22 22 12 12	88	410   10	76
NUMBER		62 239 31 196 16	334	13 112	944
GENDER AND TRANSMISSION CATEGORY	MALE	Gay/Bisexual, IDU (4) Heterosexual IDU (4) Heterosexual (5) Unknown Risk	SUB-TOTAL MALE FEMALE	Heterosexual IDU Heterosexual (5) Unknown Risk SUB-TOTAL FEMALE	TOTAL

(1) This interview based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and TB suspects (class 5). Data collected between the 1st quarter of 1992 and the 4th quarter of 1992.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Hestern blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons with a Nistory of injection drug use (IDU) since January 1978.

(5) Includes persons with a sexual partner(s) at risk for HIV, persons with a history of blood transfusion(s) or with a bleeding disorder, and self-identified heterosexuals with no other identified risks.

SERO- NUMBER(2) PREVALENCE POSITIVE RATE (%) (95% C.I.)(3)	29.6 - 42.4 2.9 - 9.5	17.4 - 25.2
SERO- PREVALENCE RATE (%)	35.8	21.1
NUMBER(2) POSITIVE	82 12	76
NUMBER	229	944
ORIGIN OF BIRTH	BORN IN USA BORN OUTSIDE USA	TOTAL

(1) This interview based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and TB Suspects (class 5). Data collected between the 1st quarter of 1989 and the 4th quarter of 1992. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(1) This interview based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and TB suspects (class 5). Data collected between the 1st quarter of 1999 and the 4th quarter of 1992.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Mestern blot assay.

(3) 95% Confidence intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

SERO- PREVALENCE RATE (%) (95% C.1.)(3)	16.4 - 36.8 18.5 - 34.3 21.2 - 39.2 2.8 - 12.4	17.4 - 25.2
SERO- PREVALENCE RATE (%)	25.8 25.8 29.6 6.5	21.1
NUMBER(2) POSITIVE	0 8 33 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	76
NUMBER	9 78 128 108 123 0	944
AGE-GROUP (YEARS)	19 AND UNDER 20 - 29 30 - 39 40 - 49 50 AND OVER UNKNOM	TOTAL

(1) This interview based survey of risk behaviors includes persons with newly diagnosed tuberculosis (TB) (class 3) and 1B suspects (class 5). Data collected between the 1st quarter of 1999 and the 4th quarter of 1992. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assument were repeatedly reactive by ELISA and confirmed by a Western blot assumer 20 observations. (3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(1)	(95% C.1.)(3)		0.1 - 23.8 0.0 - 11.3 0.1 - 0.5 0.0 - 10.1	0.1 - 0.5	0.1 - 1.5	0.1 - 1.5	
1990 - 1995	SERO- PREVALENCE RATE (%)		8.7 0.0 0.0 0.0	0.5	0.0	0.5	0.0
ING A JUVEN FRANCISCO,	NUMBER(2) POSITIVE		-040	ļ <u>v</u>	080	m c	-
ESCENTS ENTER CATEGORY, SAN	NUMBER		21 2099 28	2173	18 575 6	599	
HIV SEROPREVALENCE FOR ADOLESCENTS ENTERING A JUVENILE DETENTION CENTER BY GENDER AND TRANSMISSION CATEGORY, SAN FRANCISCO, 1990 - 1995 (1)	GENDER AND TRANSMISSION CATEGORY	MALE	Homosexual/Bisexual Heterosexual, IDU (4) Heterosexual (5) Unknown Risk	SUB-TOTAL MALE FEMALE	Heterosexual 10U (4) Heterosexual (5) Unknown Risk	SUB-TOTAL FEMALE	אוססומת תבאסבא

(1) This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood specimens were collected for syphilis screening on immates as part of the routine intake process. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.
(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
(3) 95% Confidence intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.
(4) Includes persons with a history of injection drug use (10U) since January 1978.

9.0 0.1 -

0.3

æ

2779

TOTAL

RACE/ETHNICITY	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%) (95% C.I.)(3)	(95% C.1.	)(3)	
WHITE ARRICAN AMERICAN LATINO ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	226 1422 690 370 71	0.40	0.000.000.00000000000000000000000000000	0.0 - 1.3 0.0 - 0.9 0.0 - 0.8 0.0 - 1.5	1.3 0.9 1.5 4.1	
TOTAL	2779	ω	0.3	0.1 - 0.6	0.6	
I) This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood spollected for syphilis screening on innates as part of the routine intek process. Specimens were coll backering and tested for MIV of the coll contact of the routine interpretations.	vey include on inma	ides adolesc	ents enterir	ng a juver tine intak	ile detention cent	er. Blood sp ens were coll

(1) This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood specimens were collected or sphilis screening on immates as part of the routine intake process. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(4) Includes persons of American Indian and Alaskan Native ancestry, other race, and unknown race.

AGE-GROUP (YEARS)	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%)	SERO- 2) PREVALENCE E RATE (%) (95% C.I.)(3)
UNDER 15 15 - 19 20 - 24 25 - 29 UNKNOWN	503 2231 4 4 0 0	-2000	0.2	0.0 - 1.1
TOTAL	2779	8	0.3	0.1 - 0.6

(1) This unlinked (blinded) survey includes adolescents entering a juvenile detention center. Blood specimens were collected for syphilis screening on immates as part of the routine intake process. Specimens were collected consecutively and tested for HIV after all personal identifiers were ramoved.
(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

(95% c.1.)(3)	42.4 - 51.5	0.6 - 8.9 0.5 - 2.1 0.1 - 21.9	15.7 - 19.9		1.7 - 7.6 0.5 - 1.6 0.0 - 7.6	0.8 - 1.9		
SERO- PREVALENCE RATE (%)	6.94	4.3	17.7		3.9	1.3	20.0	
NUMBER(2) POSITIVE	223		235		8 5 0	5%	2	
NUMBER	475	732	1326		203 1667 38	1908	10	
GENDER AND TRANSMISSION CATEGORY	MALE  Gay/Bisexual	Heterosexual, IDU (4) Heterosexual (5) Unknown Risk	SUB-TOTAL MALE	FEMALE	Heterosexual IDU (4) Heterosexual (5) Unknown Risk	SUB-TOTAL FEMALE	MISSING GENDER	Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction of the Contraction o

(1) This unlinked (blinded) survey include adolescents seeking services at two homeless youth shelters. Blood specimens were collected for syphilis screening as part of the routine medical evaluation. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 9% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations. (4) Includes persons with a history of injection drug use (10U) since January 1978.

9.0 7.1 -

8.0

261

TOTAL

	NUMBER	NUMBER(2) POSITIVE	SERO- PREVALENCE RATE (%) (	(95% C.1.)(3)
WHITE AFRICAN ARRICAN ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	1306 701 768 327 142	164 37 17 9	12.6 4.9 5.2 5.3	10.8 - 14.5 3.4 - 6.7 3.4 - 6.6 3.1 - 8.2 2.9 - 11.7
	3244	261	8.0	7.1 - 9.0

(1) This unlinked (blinded) survey include adolescents seeking services at two homeless youth shelters. Blood specimens were collected for sphilis screening as part of the routine medical evaluation. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.
(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.
(3) 59% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.
(4) Includes persons of American Indian and Alaskan Mative ancestry, other race, and unknown race.

(95% C.1.)(3)	0.5 - 3.5 2.3 - 3.7 28.1 - 35.9 0.9 - 23.5	7.1 - 9.0
SERO- PREVALENCE RATE (%) (	3.0 3.1.9 33.3 7.1	8.0
NUMBER(2) POSITIVE	284 22 22	261
NUMBER	333 2300 577 6 28	3244
AGE-GROUP (YEARS)	UNDER 15 15 - 19 20 - 24 25 - 29 UNKNOHN	TOTAL

(1) This unlinked (blinded) survey include adolescents seeking services at two homeless youth shelters. Blood specimens were collected for syphilis screening as part of the routine medical evaluation. Specimens were collected consecutively and tested for HIV after all personal identifiers were removed.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(3) 95% Confidence Intervals, exact binomial. Confidence Intervals not calculated for sample sizes under 20 observations.

P:V SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY GENDER AND YEAR, 1985 - 1995 (1)

·			ě						
	(4)%	0.00	0.00	Ì		(4)%	0.40	0.37	
1990	10+(3)	00	0		TOTAL	10+(3)	23	25	
	N(2) HIV+(3) %(4)	520 105	625			N(2) HIV+(3) %(4)	5618 1142	0929	
	(4)%	0.28	0.36			(4)%	0.00	0.00	
1989	1V+(3)	2-	m		1995	10+(3)	00	0	
	N(2) HIV+(3) %(4)	711	835			N(2) HIV+(3) %(4)	259 58	317	
	(4)%	0.26	0.21			(4)%	0.66	0.53	
1988	N(2) HIV+(3) %(4)	0.0	2		1994	N(2) HIV+(3) %(4)	0 0	7	
	(2) HI	759 178	937		-	(2) HI	302	376	
	Ż					Z			
,	(4)	0.58	67.0			(4)	0.00	0.00	
1987	+(3) %	50	5		1993	+(3) %	00	0	
19	N(2) HIV+(3) %(4)	143	1012		19	N(2) HIV+(3) %(4)	322 73	395	
	N	8-	10			N		- E	
	%(4)	0.96	0.89			(4)%	0.32	0.25	
1986	۷+(3)	٥-	5		1992	۷+(3)	-0		
	N(2) HIV+(3) %(4)	941	1124		1	N(2) HIV+(3) %(4)	315 86	401 1	
	z					Z			
	%(4)	0.00	0.00			%(4)	00.0	0.42	
1985	N(2) HIV+(3) %(4)	00	0		1991	N(2) HIV+(3) %(4)	20	2	
-	(2) HI	213	258		-	(2) HI	407	087	
	ž	, ,	, 7			ž	7	4	
	GENDER	MALE FEMALE	TOTAL			GENDER	MALE FEMALE	TOTAL	

(1) Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC). Data Collected between October 1985 and December 1995. When the Comber 1985 and December 1995 are sested.

(2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(4) Seroprevalence rate (%).

HIV SEROPREVALENCE FOR CIVIL'AN APPLICANTS FOR MILITARY SERVICE FROM THE CITY AND COUNTY OF SAN FRANCISCO BY RACE AND ETHNICITY AND YEAR, 1985 - 1995 (1)

	N(2) HIV+(3) %(4)	000000	0.00		(4)% (	0.64 0.58 0.26 0.00 0.44	C.37	
1990	11/4(3	00000	0	TOTAL	10+(3	27 20 1	52	
	N(2) F	210 85 78 232 20	625		N(2) HIV+(3)	2353 1210 766 2204 227	0929	
	%(4)	0.00	0.36		%(4)	00000	0.00	
1989	1,4+(3)	00	m	1995	10+(3)	00000	0	
	N(2) HIV+(3) %(4)	286 178 102 253 16	835		N(2) HIV+(3)	104 41 120 2	317	
	%(4)	0.30 0.00 0.00 0.00	0.21		%(4)	0.00	0.53	
1988	17+(3)	000	2	1994	10+(3)	N0000	2	
	N(2) HIV+(3) %(4)	334 193 115 267 28	937		N(2) HIV+(3) %(4)	134 49 47 134	376	1000
	(7)%	0.58 1.42 0.00 0.00	67.0		%(4)	00000	00.0	
1987	۷+(3)	NM000	2	1993	V+(3)	00000	0	
_	N(2) HIV+(3) %(4)	346 212 108 320 26	1012	-	N(2) HIV+(3) %(4)	142 43 133 133	395	,
	(7)%	1.71 0.83 0.00 1.43	0.89		%(4)	0.00	0.25	the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the part of the pa
1986	V+(3)	~~00F	₽	1992	۷+(3)	00-00	-	
-	N(2) HIV+(3) %(4)	409 242 74 329 70	1124	1	N(2) HIV+(3) %(4)	134 53 49 158	401	Department of Defence
	%(4)	0.00	0.00		%(4)	1.25 0.00 0.00 0.00	0.42	1000
1985	HIV+(3) %(4)	00000	0	1991	HIV+(3) %(4)	70000	(c)	0
	N(2) HI	94 51 11 85 17	258		N(2) HI	160 63 68 173 16	480	
	RACE/ETHNICITY	1. P.1.			RACE/ETHNICITY	.1.		1) Data provided by the
	RACE/E	WHITE BLACK HISPANIC ASIAN/P.I. OTHER	TOTAL		RACE/E	WHITE BLACK LATINO ASIAN/P.I. OTHER	TOTAL	1) Data

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC). Data Collected between October 1985 and December 1995.

(2) Number of specimens tested.
(3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(4) Scroprevalence rate (%).

41V SEROPREVALENCE FOR CIVILIAN APPLICANTS FOR MILITARY SERVICF FROM THE CITY AND COUNTY OF SAN FRANCISCO BY AGE-GROUP AND YEAR, 1985 - 1995 (1)

1990	N(2) H1V+(3) %(4)	300 154 111 10 60 0 0 0 0 0	625 0 0.00	TOTAL	N(2) H1V+(3) %(4)	2994 3 0.10 1702 4 0.23 1202 9 0.75 862 9 1.04	6760 25 0.37	
1989	N(2) H1V+(3) %(4)	352 0 0.00 211 1 0.47 170 2 1.18 102 0 0.00 0 0 0	835 3 0.36	1995	N(2) H1V+(3) %(4)	133 0 0.00 80 0 0.00 56 0 0.00 48 0 0.00	317 : 0.00	
1988	N(2) H1V+(3) %(4)	417 1 0.24 236 0 000 163 1 0.61 121 0 0.00	937 2 0.21	1994	N(2) H1V+(3) %(4)	136 0 0.00 106 0 0.00 78 0 0.00 56 2 3.57 0 0	376 2 0.53	
1987	N(2) HIV+(3) %(4)	448 0 0.00 265 1 0.38 166 1 0.60 133 3 2.26 0 0 .	1012 5 0.49	1993	N(2) HIV+(3) %(4)	174 0 0.00 108 0 0.00 68 0 0.00 45 0 0.00 0 0 .00	395 0 0.00	
1986	N(2) HIV+(3) %(4)	485 1 0.21 285 2 0.70 204 3 1.47 150 4 2.67 0 0	1124 10 0.89	1992	N(2) HIV+(3) %(4)	193 0 0.00 99 0 0.00 65 1 1.54 44 0 0.00 0 0	401 1 0.25	
1985	N(2) HIV+(3) %(4)	129 0 0.00 48 0 0.00 45 0 0.00 36 0 0.00	258 0 0.00	1991	N(2) HIV+(3) %(4)	227 1 0.44 110 0 0.00 76 1 1.32 67 0 0.00	480 2 0.42	
	AGE-GROUP	19 AND UNDER 20 - 24 25 - 29 30 AND OVER UNKNOWN	TOTAL		AGE-GROUP	19 AND UNDER 20 - 24 25 - 29 30 AND OVER UNKNOWN	TOTAL	

⁽¹⁾ Data provided by the U.S. Department of Defense, and the Centers for Disease Control (CDC). Data Collected between Dotober 1985 and December 1995.

(2) Number of specimens tested.

(3) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay.

(4) Seroprevalence rate (%).

	1	i i
(95% C.1.)(3)	0.062 0.067 0.067 0.022 0.022 0.024 0.018	0.022 - 0.029
(95% C.	0.088 0.033 0.017 0.007 0.007 0.005 0.003 0.001	0.022
SERO- PREVALENCE RATE (%)	0.005 0.0033 0.0033 0.0011 0.0000 0.0007	0.025
NUMBER(2) POSITIVE	88 233 233 233 24 25 25 25 25 25 25 25 25 25 25 25 25 25	219
TOTAL DONORS	72204 88168 91396 90192 87320 84578 77273 78097 70545 69684	875480
YEAR OF DONATION	1985 1986 1988 1988 1989 1992 1993 1994	TOTAL

(1) Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, normal approximation.

	TOTAL NUMBER(2) DONORS POSITIVE	SERO- PREVALENCE RATE (%)	(95% C.1.)(3)
FIRST-TIME Male 4 DONORS Female 4	40015 14 41046 4	0.035	0.020 - 0.060
REPEAT Male 14 DONORS Female 13	147890 4 132671 3	0.003	0.001 - 0.007

(1) Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, normal approximation.

		,
(95% C.1.)(3)	0.002 - 0.008 0.026 - 0.114 0.000 - 0.013 0.006 - 0.050	0.005 - 0.010
SERO- PREVALENCE RATE (%)	0.004 0.055 0.000 0.018	0.007
NUMBER(2) POSITIVE	13 8 0 4	52
TOTAL	297711 14425 27508 21978	361622
RACE/ETHNICITY	WHITE AFRICAN AMERICAN ASIAN/PACIFIC ISLANDER NONE OF THE ABOVE (4)	TOTAL

(1) Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca. (2) All positive specimens were repeatedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, normal approximation. (4) Includes Latinos, American Indians, Alaskan Natives, other race, and unknown race.

HIV SEROPREVALENCE FOR BLOOD DONORS FROM THE SAN FRANCISCO BAY AREA

(95% C.1.)(3)	0.000 - 0.015 0.003 - 0.020 0.009 - 0.026 0.001 - 0.007	0.005 - 0.010
SERO- PREVALENCE RATE (%)	0.000 0.008 0.016 0.003	0.007
NUMBER(2) POSITIVE	0 2 2 2	22
TOTAL	24373 62512 96062 178675	361622
AGE-GROUP (YEARS)	19 AND UNDER 20 - 29 30 - 39 40 AND OVER	TOTAL
	SERO- TOTAL NUMBER(2) PREVALENCE DONORS POSITIVE RATE (%)	ARS) DONORS POSITIVE RATE (%)  24.373 0 0.000 6.2512 5 0.008 9.6062 15 0.006 178675 5 0.003

(1) Data provided by the Irwin Memorial Blood Centers, San Francisco, Ca. (2) Atl positive specimens were repestedly reactive by ELISA and confirmed by a Western blot assay. (3) 95% Confidence Intervals, normal approximation.







